



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C01D 1/32, 3/16, 7/26, C22B 26/10,</b> <b>C07K 14/705, A61K 39/00, 39/12, 39/385</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 99/16710</b> <b>(43) International Publication Date:</b> 8 April 1999 (08.04.99)
<b>(21) International Application Number:</b> PCT/US98/20681 <b>(22) International Filing Date:</b> 29 September 1998 (29.09.98)  <b>(30) Priority Data:</b> 60/060,422                      30 September 1997 (30.09.97)      US  <b>(71) Applicants (for all designated States except US):</b> CEL-SCI CORPORATION [US/US]; Suite 802, 8229 Bone Boulevard, Vienna, VA 22182 (US). NORTHEASTERN OHIO UNIVERSITIES COLLEGE OF MEDICINE [US/US]; 4209 State Route 44, Rootstown, OH 44272 (US).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> ZIMMERMAN, Daniel, H. [US/US]; 5527 Oakmont Avenue, Bethesda, MD 20817 (US). ROSENTHAL, Kenneth, S. [US/US]; 320 Harvest Drive, Akron, OH 44333 (US).  <b>(74) Agent:</b> STEINBERG, Richard, A.; Sherman & Shalloway, 413 North Washington Street, Alexandria, VA 22314 (US).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, HR, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
<b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>		
<b>(54) Title:</b> IMMUNOGENIC CONJUGATED POLYPEPTIDE FOR TREATMENT OF HERPES SIMPLEX VIRUS		
<b>(57) Abstract</b>		
<p>Peptide constructs chemically synthesized to contain a Herpes Simplex Virus specific antigenic peptide, such as, the 322-332 peptide (H1) from the ICP27 protein of Herpes Simplex Virus (HSV-1) and a peptide from a T cell binding ligand (TCBL), such as <math>\beta</math>-2M (aa 35-50), which elicits a TH1-like response <i>in vitro</i> tests in mice, were protective against challenge with HSV.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		



## IMMUNOGENIC CONJUGATED POLYPEPTIDE FOR TREATMENT OF HERPES SIMPLEX VIRUS

(1) Field of the Invention

This invention relates to peptide conjugates which can be used to form an immunogenic composition useful to activate the immune system of a patient exposed to or at  
5 risk of infection by Herpes Simplex Virus (HSV). More particularly, this invention relates to immunogenic conjugated peptides which contain both a herpes simplex virus specific peptide and an immunomodulatory peptide covalently linked directly or via a linking group and to  
10 compositions and diagnostic products containing and methods using such peptide conjugates in the treatment, prevention, or diagnosis of herpes simplex virus.

(2) Background of the Invention

Herpes simplex virus type 1 (HSV-1) and its close  
15 cousin, herpes simplex virus type 2 (HSV-2), cause various benign diseases, such as the common cold sore found near the lips and also genital herpes. Herpes simplex virus can also cause serious disease upon infection of the eye (e.g., keratoconjunctivitis, with  
20 the potential to lead to blindness), the brain (e.g., encephalitis). Individuals who are immunosuppressed, such as a newborn baby, AIDS patient or transplant patient, are especially vulnerable. HSV infections of immunocompromised individuals and neonates can lead to  
25 disseminated and life-threatening disease. Unlike many

viruses, once an individual is infected with HSV, the virus remains latent in neurons and can be reactivated by stress or immunosuppression and cause recurrent disease.

A herpes simplex virus vaccine has the potential for use as both a prophylactic to prevent initial infection as well as a treatment to prevent or ameliorate recurrent disease. No vaccine is currently available for prevention or treatment of HSV. Live vaccine development has been hampered because HSV has the capacity to establish latent infection and potentially, to promote neoplastic transformation of cells. The efficacy of live attenuated killed and subunit vaccines has been questioned due to difficulties in eliciting protective cell mediated immune responses.

Cellular immunity and specifically, cytotoxic T lymphocyte cell (CTL) and delayed type hypersensitivity (DTH) responses, are important for the control of HSV. These responses are included in the TH1-type of immune response initiated by CD4 and CD8 T cells following appropriate activation. CD 8 T cells recognize 8-9 amino acid peptides presented by an MHC I molecule and become the target for CTL killing of infected cells. However, immunization with these and other CTL epitope-containing peptides rarely elicits protective immunity because the peptides are too small to be recognized and presented to the immune system. In order to use such a peptide as a vaccine, the peptide must be modified or presented in a

manner which will make it more visible to the immune system. Ideally, the modification or manner of presentation should itself be invisible to the immune response and should facilitate the development of the appropriate T cell and overall immune response to the peptide.

T cell responses can be classified by the cytokine profile produced in response to activation. T1 (TH1:CD4 T cells and TC1:CD8 T cells) responses are associated with production of interferon gamma, interleukin-2, lymphotoxin alpha, preferential stimulation of IgG2a production in the mouse, and induction of DTH reactions. T2 (TH2 and TC2) responses are associated with production of interleukin-4, interleukin-10, preferential stimulation of humoral responses, IgG1 production and inhibition of T1 responses. Stimulation of a T2 response may exacerbate infectious diseases which are controlled by protective T1 responses.

Traditionally, small peptides must be attached to carrier proteins in order to elicit immune responses. Often a large protein such as KLH is used. However, it has been observed that heterogenous (impure) KLH yields a better immune response than a more homogenous preparation. Nevertheless, these conjugates tend to promote the production of T2 associated responses and antibody is developed to both the peptide and the carrier.

It would be desirable to find other methods to direct the response primarily or substantially to murine IgG2a or human IgG3, a TH1 associated pathway. It has previously been proposed by one of the present inventors  
5 that the carrier should not be directing the response in an undesired direction and since the KLH molecule seems to be predominantly directing the response in the TH2 direction it was concluded that another carrier should be considered. Likewise, other factors such as costs, ease  
10 of manufacture, and stability need to be taken into account.

Previous serological studies with *M. tuberculosis* peptides conjugated to a T cell binding ligand (TCBL) derived from the  $\beta$ -2-microglobulin protein of the Major  
15 Histocompatibility Complex (MHC) Class I (specifically, at amino acid positions aa 38-50, hereinafter referred to as " $\beta$ -2M 38-50" or, alternatively, as "Peptide J") induced a TH1-like response whereas similar peptide constructs but using a TCBL, such as MHCII $\beta$ 2 135-149  
20 (Peptide G) induced a TH2-like response (Zimmerman, et al., Vacc. Res. 5:103-118, 1995).

Generally, incorporation of an antigenic peptide into a conjugated polypeptide with the appropriate T cell ligand will elicit a defined T cell response. The T cell  
25 binding ligand incorporated into the construct will determine whether the response is a TH1 or a TH2 response or mixed or predominantly one or the other of these responses. For any particular disease causing

microorganism either or both types of responses may be desirable or preferred. However, elicitation of a TH1 (DTH) type response would be expected to be especially useful against infectious agents which are normally  
5 successfully resolved by TH1 (e.g., DTH) responses rather than TH2 responses, associated with mature antibody responses. The conjugated polypeptide technology is effective in allowing small peptides to elicit appropriate TH1 responses (or/and TH2 responses, in  
10 appropriate cases) without large protein carriers.

One of the present inventors previously reported that addition of a T cell binding ligand to a peptide epitope could alter the nature of the immune response (i.e., TH1 or TH2). Antibodies derived from certain  
15 conjugated polypeptides were better able to recognize the native molecule than were the antibodies prepared by using a conventional peptide-KLH conjugate.

It was shown that the antibodies induced by the heteroconjugate had a broader specificity, so that they  
20 recognized the peptide epitope not only in the linear form, but also in the native molecule. In some cases the use of the peptide conjugated to KLH was not able to recognize the epitope in the native molecule.

Accordingly, it would be highly desirable to provide a  
25 vaccine for HSV which would be effective to prevent initial infection as well as a treatment for individuals who suffer from frequent recurrent disease associated with HSV.

SUMMARY OF THE INVENTION

The present invention relates to certain conjugated polypeptides comprising at least two T cell specific binding peptides covalently linked together, wherein the first peptide binds to a specific class or subclass of T cells and elicits a predominantly T1 or T2 type response and a second peptide is an herpes simplex virus specific antigenic peptide, and wherein the polypeptide is capable of eliciting TH1 associated antibodies when administered to a human in need thereof.

The peptide used as T cell specific binding molecule in the conjugated peptides of this invention are peptides which are portions of molecules or analogues of such portions which bind specifically or at least preferentially to specific class or subclass of T cells, such as helper T cells (TH), suppressor T cells (TS), cytotoxic T lymphocytes (CTL), and the like, and which directs the immune system to a predominantly T1 type immune response against the HSV specific antigenic peptide. These conjugated polypeptides offer the advantages previously seen with other conjugated peptides, such as those more generally disclosed by one of the present inventors in U.S. Patent No. 5,652,342 (referred to therein as "heterofunctional cellular immunological reagent), of inducing broad spectrum antibodies but, additionally providing a desired T1 specificity.

In particular, the invention provides an immunogenic conjugated polypeptide effective as immunogen in a vaccine for treatment or prevention of infection by herpes simplex virus, said polypeptide represented by the  
5 formula  $P_1 - x - P_2$  or  $P_2 - x - P_1$  where  $P_1$  represents a herpes simplex virus specific antigenic peptide from a herpes simplex virus type 1 or type 2, selected from the group consisting of the ICP27 protein, glycoprotein B, ribonucleotide reductase, ICP4, ICP34.5, glycoprotein E  
10 and glycoprotein F;  $P_2$  represents an immunodulatory peptide which is a portion of an immunoprotein which promotes binding to a class or subclass of T cells and which direct a predominantly TH1 type immune response to the peptide  $P_1$ ; and  $x$  represents a covalent bond or a  
15 divalent peptide linking group, which may be cleavable or non-cleavable.

The present invention also relates to pharmaceutically effective compositions containing such conjugated polypeptide for eliciting immunization to  
20 infection against Herpes Simplex Virus, HSV, type 1 or type 2, in a human subject. Such compositions, in addition to the conjugated polypeptides of this invention may also, and preferably will, include suitable immunological adjuvant.

25 Similarly, the invention relates to the use of such conjugated polypeptide and the pharmaceutically effective composition containing same for treating or preventing HSV infection by administering to a human patient in need

thereof, a therapeutically or prophylactically effective amount of the conjugated polypeptide as defined above.

The invention also relates to a diagnostic assay for diagnosing the presence of infection (active or latent) in an individual by HSV wherein T cells from the individual to be diagnosed is mixed with the conjugated polypeptide to the above formula  $P_1-x-P_2$  or  $P_2-x-P_1$ , and thereafter detecting a reaction between previously HSV primed T cells and conjugated polypeptide. The conjugated polypeptide may be labelled to facilitate detection of the reaction.

The invention will now be described in further detail by way of the following explanations and preferred embodiments and with the aid of the accompanying drawings.

It is expected that HSV immune T cells would behave in differently or otherwise be different in the presence of the conjugated polypeptide compared to naive or non-immune T cells.

#### BRIEF DESCRIPTION OF DRAWINGS

Fig. 1 is a graph plotting the results of Symptomatic Conditions after viral challenge (average symptomatic score versus days post challenge) of non-vaccinated and vaccinated mice (using conjugated polypeptides based on antigenic peptide from ICP27 of HSV-1 or antigenic peptide alone) after intraperitoneal challenge with HSV-1.



Fig. 2 is a graph plotting the results of survival after viral challenge (% survivors versus days post challenge) of the same vaccinated and non-vaccinated mice as used in the study shown in Fig. 1.

5        Fig. 3 is a graph plotting the results of Delayed type Hypersensitivity (DTH response as swelling after 48 hours) for three surviving non-vaccinated mice and three each of the vaccinated unchallenged mice as used in the study shown in Fig. 1.

10       Fig. 4 is a graph similar to Fig. 1 but in a second test procedure following challenge of vaccinated and non-vaccinated mice with an LD<sub>50</sub> of HSV-1.

Fig. 5 is a graph similar to Fig. 2 but for the survival of the mice used to prepare Fig. 4.

15       Fig. 6 is a graph of the delayed hypersensitivity response (DTH) as swelling (%) for non-vaccinated and vaccinated mice used to prepare Fig. 4 (using either a conjugated polypeptide or antigenic HSV peptide alone).

20       Fig. 7 is a graph of percent survival versus time (days post challenge) for non-vaccinated and vaccinated mice (using conjugated polypeptides based on antigenic peptide from glycoprotein B of HSV-1 or the antigenic peptide alone).

DETAILED DESCRIPTION OF THE INVENTION AND PREFERREDEMBODIMENTS

For the peptides disclosed above and below and as employed in the experimentation described herein, the amino acid sequences thereof, are set forth by the single  
 5 identification letter or three-letter identification symbol as follows:

	<u>Amino Acid</u>	<u>Three-letter abbreviation</u>	<u>One-letter symbol</u>
10	Alanine	Ala	A
	Arginine	Arg	R
	Asparagine	Asn	N
	Aspartic Acid	Asp	D
	Cysteine	Cys	C
15	Glutamine	Gln	Q
	Glutamic Acid	Glu	E
	Glycine	Gly	G
	Histidine	His	H
	Isoleucine	Ile	I
20	Leucine	Leu	L
	Lysine	Lys	K
	Methionine	Met	M
	Phenylalanine	Phe	F
	Proline	Pro	P
25	Serine	Ser	S
	Threonine	Thr	T
	Tryptophan	Trp	W
	Tyrosine	Tyr	Y
	Valin	Val	V

It should be understood that in any of the amino acid sequences specified herein variations of specific amino acids which do not adversely effect the desired biological activity are contemplated and fall within the scope of the invention. Although the regions of interest of the preferred antigenic peptides are highly conserved, natural and spontaneously occurring amino acid variations are specifically contemplated. In some cases, it may be advantageous to use mixtures of peptides, the sequences of which, within the guidelines given above, and discussed in more detail below, correspond to two or more natural and spontaneously occurring variants of HSV.

Still further, as well recognized in the art, it is often advantageous to make specific amino acid substitutions in order, for example, to provide specific binding sites or for purpose of introducing radioactive or radiisotope or fluorescent tagging of the peptide. Tagging with other types of identifying labels, as well known in the art, such as, for example, toxins and drugs, may also advantageously be included in or with the conjugated peptides of this invention. Such "designed" amino acid sequences are also within the scope of the antigenic peptides of this invention.

In addition, it is also recognized that the amino acids at the N-terminal and C-terminal may be present as the free acid (amino or carboxyl groups) or as the salts, esters, ethers, or amides thereof. In particular amide end groups at th C-terminal and ac tylation, .g.,

myristyl, etc. at the N- or C-terminal, are often useful without effecting the immunological properties of the peptide.

The peptides  $P_1$  and  $P_2$  (as hereinafter defined) of the conjugated polypeptides of the present invention can be prepared by conventional processes for synthesizing proteins, such as, for example, solid phase peptide synthesis, as described by Merrifield, R. B., 1963, J. of Am. Chem. Soc., 85:2149-2154. It is also within the scope of the invention and within the skill in the art to produce the novel conjugated peptides of this invention or the peptide components thereof by genetic engineering technology.

The conjugated polypeptides of this invention may be represented by the formula



In the above formulas,  $P_1$  represents an herpes simplex virus specific antigenic peptide from a herpes simplex viral protein. The antigenic peptide is preferably one selected from one of the following herpes simplex viral proteins ICP27, glycoprotein B, ribonucleotide reductase, ICP4, ICP34.5, glycoprotein E and glycoprotein F. The ICP27 protein of herpes simplex virus type 1 or type 2, and glycoprotein B (gB) of herpes simplex virus type 1 are especially preferred.

P<sub>2</sub> represents an immunomodulatory peptide which is a portion of an immunoprotein which promotes binding to a class or subclass of T cells and which will direct a predominantly TH1 type immune response to the peptide P<sub>1</sub>.

5       x represents a covalent bond or a cleavable or non-cleavable divalent peptide linking group.

Preferred antigenic peptides P<sub>1</sub> include a peptide comprising amino acid residues 322 to 332 (LYRTFAGNPRA) (SEQ ID NO:1) (hereinafter may be referred to as Peptide H1) of the ICP27 protein of herpes simplex virus type 1 (HSV-1), a peptide comprising amino acid residues AEIDYATLGVG (SEQ ID NO:2) (hereinafter may be referred to as Peptide H2) of the ICP27 protein of HSV-1; a peptide comprising amino acid residues 448 to 456 (DYATLGVG) (SEQ ID NO: 3) of the ICP27 protein of HSV-1; a peptide comprising amino acid residues 498 to 505 (SSIEFARL) (SEQ ID NO:4) (hereinafter may be referred to as Peptide B1) from glycoprotein B of HSV-1, a peptide comprising amino acid residues 128 to 139 (DRRDPLARYGSR) (SEQ ID NO:5) from glycoprotein C of HSV-1.

20       In addition, a peptide comprising from about 10 to about 30 consecutive amino acid residues taken from residues 1 to 30 of SEQ ID NO:6, such as, for example, residues 9 to 21 (LKMADPNRFRGKD) (SEQ ID NO:7), residues 8 to 23 (SLKMADPNRFRGKDLP) (SEQ ID NO: 8) or amino acid residues 1 to 30 (KRALADASLKMADPNRFRGKDLPLDQLTD) (SEQ ID NO: 6) from glycoprotein D of HSV-2 (see Bosch, et al.,

J. Virol. 61:3607, 1987); Weijer, et al., J. Virol. 62:501, 1988), may also be effectively used as the peptide P<sub>1</sub>.

The HSV specific antigenic peptide may be chosen  
5 from any of the HSV type 1 or type 2 proteins which has been found to elicit a protective T cell response. Of particular interest is the ICP27 protein, found in both type 1 and type 2.

ICP27 is an early, nuclear protein of HSV which  
10 elicits a protective T cell response but does not elicit a protective antibody response. Rouse, et al. have shown that up to 25% of the T cell response is directed toward ICP27 during natural infection. The ICP27 protein elicits predominantly a TH1 response (Manickan E, et al.  
15 and Rouse B. 1995, J. Virol. 69:4711-4716). As a nuclear protein of HSV, the ICP27 protein is also advantageous in that it should not be under immunological selection to undergo mutation. In particular, the aa 322-332 peptid is recognized by cytotoxic T cells from Balb/c mice (H2d  
20 major histocompatibility group). (Banks, et al., J. Virol. 67:613-616, 1993). As a nuclear antigen, the ICP27 protein and its peptides will not elicit a protective antibody response.

However, the ICP27 aa 322-332 peptide (H1) is  
25 insufficient in and of itself to induce an immune response.

The ICP27 protein peptide at amino acid residues aa 448 to 456 was also identified by these authors, e.g., Rouse, et al. as CTL peptide containing a T cell epitope, and can be used as peptide P<sub>1</sub>.

5        Another HSV specific antigenic peptide of interest is the peptide at aa 498 to 505 of glycoprotein B (gB) from HSV-1. This peptide has been identified as a cytotoxic T cell lymphocyte (CTL) target by testing a library of nested, overlapping synthetic peptides for  
10 conversion of uninfected cells into target cells (Hanke, et al., J. Virol. 65:1177-1186, 1991). Cells were incubated with the peptides and then challenged with CTLs present in mice immunized by infection with HSV-1.

      The peptide 498-505 has the following sequence (SEQ  
15 ID NO:4)

Ser Ser Ile Glu Phe Ala Arg Leu.

A longer peptide 497-507 which is also immunogenic but less potent may also be used:

Thr Ser Ser Ile Glu Phe Ala Arg Leu Glu Phe  
20 (SEQ ID NO:8)

The gB peptides differ from the ICP27 peptides in that the former peptide elicits immunological response in H-2K<sup>b</sup> mice (e.g., C57Bl/6) whereas the latter elicits a response in Balb-C mice.

25        More generally, peptides from the glycoproteins gB and gD as described in the literature, e.g., Koelle, et al., J. Virol. 68:2803-2810, 1994; Cose, et al., J. Virol. 69:5844-5852, 1995; Heiligenhause, et al., Eye,

9:89-95, 1995; Damhof, et al., Arch. Virol. 130:187-193, 1993; Wachsmann, et al., Vaccine, 10:447-454, 1992, the disclosures of which are incorporated herein in their entireties, may elicit CTL and protective response. Even  
5 where such T cell epitope-containing peptides, P<sub>1</sub>, do not elicit protective antibody response, the antibodies which are produced should be able to bind to virion and infected cell surfaces and, therefore, would be useful in the conjugated polypeptides of this invention not only  
10 for therapeutic and immunological activity but also for immunological diagnostic assays.

In the present invention, the antigenic peptide P<sub>1</sub> is conjugated to a T cell binding peptide P<sub>2</sub>. Any T cell binding peptide which is associated with predominantly a  
15 TH1 type immune response may be used as peptide P<sub>2</sub> in this invention. More particularly, peptide P<sub>2</sub> is preferably chosen from the portion of an immunoprotein which promotes its binding to T-cells. A preferred example is peptide J from  $\beta$ -2-microglobulin ( $\beta$ -2M 35-50) (Parham, et  
20 al., 1983, J Biol Chem. 258:6179; Zimmerman, et al.). Other related  $\beta$ -2M peptides include amino acid residues 24 to 58 and amino acid residues 58 to 84, as described more fully in U.S. 5,652,342. Examples of other peptides which may be used as peptide P<sub>2</sub> of the conjugated  
25 polypeptides of the invention may be found in commonly assigned U.S. Patent No. 5,652,342, the disclosure of which is incorporated herein in its entirety by reference thereto. Guidelines for selection of these or other



suitable T cell binding peptides are discussed therein as well as in the Zimmerman, et al. article. Mention may be made of, for example, the molecules known as B7 (Freeman, et al., Science 262:909); B70 (Azuma, et al., 1993, Nature 366:76); GL1 (Hathcock, et al., 1993, Science 262:905); CD58 (Arulanandam, et al., 1993, Proc. Nat. Acad. Sci. 90:11613), CD40 (van Essen, et al., 1995, Nature 378:620); and ICAM-1 (Becker, et al., 1993, J. Immunol. 151:7224). Other potentially useful immunogenic peptides as P<sub>2</sub> include, for example, MHC class Ia3 domain comprising a.a. residues 223-229 or 223-230 (Peptide E, Salter, et al., Nature, 345:41, 1990); Interleukin I $\beta$ , residues 163-171 (Nenconi, et al., J. Immunol. 139:800, 1987); MHC class II  $\beta$ 2 domain, a.a. 135-149 (Konig, et al., Nature 356:796, 1992); Cammarota, et al., Nature 356:799, 1992). The reader is referred to these literature articles for further details.

Conjugated polypeptides according to the invention may be prepared by directly bonding an antigenic specific peptide P<sub>1</sub> to a T cell binding peptide P<sub>2</sub>, or by bonding the peptides P<sub>1</sub> and P<sub>2</sub> via a linking group, by conventional techniques, or as more particularly described in detail in the aforementioned U.S. 5,652,342, the disclosure of which is incorporated herein in its entirety by reference thereto. When x represents the divalent linking group, it may be comprised of one or more amino acids, such as, for example, glycine-glycine, or a bifunctional chemical linking group, such as, for

example, N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP), m-maleimidobenzoyl-N-hydroxy-succinimide ester (MBS), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), or any other reagent commonly employed to link  
5 peptides. Again, reference is made to the disclosure of U.S. 5,652,342 for further details.

The linking group will generally be non-cleavable under the conditions of use, however, cleavable groups may also be used where it is desired to separate peptide  
10  $P_1$  or peptide  $P_2$  after the conjugated peptide bonds to its target T cell. For example, the linking group x may be one which is enzymatically cleavable or cleavage may be induced, such as by photoactivation, including for example, exposure to UV radiation.

15 The immunogenic conjugated peptides of this invention can elicit an immune response to HSV (as shown in the examples to follow) that can be directed toward the desired TH1 as evidenced by the numerous examples of the TH1 characteristic antibody IgG2a (mouse) or IgG3  
20 (man), and/or by a DTH response.

The order of the antigenic peptide  $P_1$  and T cell binding peptide  $P_2$  is not usually critical and may be reversed. For example, if first peptide =  $P_1$  and second peptide =  $P_2$ , then the conjugated peptide may have the  
25 sequence  $P_1$ -x- $P_2$  or  $P_2$ -x- $P_1$ . Also, while the peptide  $P_1$  and peptide  $P_2$  may be directly coupled to each other, (i.e., x is a direct peptide bond) in some cases a small linker sequence or a larger heterolinker molecule may be

advantageously used to couple the two peptides. For example, as the spacer, one or a few, up to about 5, preferably, up to about 3, neutral amino acids, such as glycine, may be used to link the peptides. A preferred  
5 spacer peptide is GGG, however, the spacer may be made larger or smaller and altered to include other molecules besides the amino acid glycine. As examples of heterolinkers mention may be made of, for example, N-succinimidyl-3-(2-pyridylthio)propionate (SPDP), m-  
10 maleimidobenzoyl-N-hydroxy-succinimide (MBS) as well as any of the other reagents employed to link peptides, including without limitation those disclosed in the aforementioned U.S. Patent No. 5,652,342. When the peptides P1 and P2 are not directly bonded the linking  
15 group will generally and preferably be any divalent linking group. The linking group may be cleavable or non-cleavable under physiological conditions or by appropriate inducement.

Although the total number of amino acids in the  
20 conjugated polypeptide is not particularly critical, from a practical aspect, the minimum number of amino acids, including any amino acid spacers or linkers, will generally be at least about 15 or 16, preferably at least about 20, to obtain adequate antigen presentation and  
25 immunogenicity. Moreover, from practical considerations of ease of manufacture by synthetic techniques, the maximum number of amino acids will often be less than about 100, preferably, no more than about 70, especially,

no more than about 50. However, where the conjugated polypeptide may be manufactured by genetic engineering techniques, much larger molecules may be useful.

The conjugated polypeptide of this invention, e.g.,  
5 Peptide J ( $\beta$ -2M, 38-50) as  $P_1$  and the peptide H1 as  $P_2$ ,  
may be used to direct the immune response as a  
prophylactic vaccine for a TH1 directed immune response  
to prevent the infection by HSV, or to direct the immune  
response as a therapeutic vaccine for a TH1 directed  
10 immune response in HSV infected persons perhaps in  
conjunction with other therapies, to reduce viral load  
and to control or cure the infection by HSV. The  
conjugated polypeptides may also be used to direct the  
immune response as a prophylactic vaccine to induce a  
15 TH1, TH2 or mixed TH1/TH2 directed immune response to  
prevent the infection by HSV, or to direct the immune  
response as a therapeutic vaccine to induce a TH1, TH2 or  
mixed TH1/TH2 directed immune response against the HSV  
virus, perhaps in conjunction with other therapies to  
20 reduce the viral load and to control or cure the  
infection by HSV.

The conjugated polypeptides of this invention may be  
used as a vaccine either prophylactically or  
therapeutically. When provided prophylactically the  
25 vaccine is provided in advance of any evidence of HSV.  
The prophylactic administration of the invention vaccine  
should serve to prevent or attenuate HSV disease in a  
mammal. In a preferred embodiment a human, at high risk

for HSV is prophylactically treated with a vaccine of this invention. When provided therapeutically, the vaccine is provided to enhance the patient's own immune response to the HSV antigen and, hence, control of  
5 disease.

While it is possible for the immunogenic conjugated polypeptide to be administered in a pure or substantially pure form, it is preferable to present it as a pharmaceutical composition, formulation or preparation.  
10 The formulations of the present invention, both for clinical and for human use, comprise a conjugated polypeptide as described above, together with one or more pharmaceutically acceptable carriers and, optionally, other therapeutic ingredients. The carrier(s) must be  
15 "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. The formulations may conveniently be presented in unit dosage form and may be prepared by any method well-known in the pharmaceutical  
20 art.

In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping  
25 the product into the desired formulation.

Formulations suitable for any route of administration may be used, such as, for example, intravenous, intramuscular, subcutaneous, intraperitoneal, nasal, oral, rectal, vaginal, etc.

5 Generally, the formulations will comprise sterile aqueous solutions of the active ingredient with solutions which are preferably isotonic with the blood of the recipient. Such formulations may be conveniently prepared by dissolving solid active ingredient in water containing  
10 physiologically compatible substances such as sodium chloride (e.g. 0.1-2.0M), glycine, and the like, and having a buffered pH compatible with physiological conditions to produce an aqueous solution, and rendering the solution sterile. These may be present in unit or  
15 multi-dose containers, for example, sealed ampoules or vials.

The formulations of the present invention may incorporate a stabilizer. Illustrative stabilizers include polyethylene glycol, proteins, saccharides, amino  
20 acids, inorganic acids, and organic acids which may be used either on their own or as admixtures. These stabilizers, when used, are preferably incorporated in an amount of about 0.1 to about 10,000 parts by weight per part by weight of immunogen. If two or more stabilizers  
25 are to be used, their total amount is preferably within the range specified above. These stabilizers are used in aqueous solutions at the appropriate concentration and pH. The specific osmotic pressure of such aqueous

solutions is generally in the range of about 0.1 to about 3.0 osmoles, preferably in the range of about 0.3 to about 1.2. The pH of the aqueous solution is adjusted to be within the range of about 5.0 to about 9.0, preferably within the range of 6-8. In formulating the immunogen of the present invention, anti-adsorption agent may be used.

Additional pharmaceutical methods may be employed to control the duration of action. Controlled release preparations may be achieved through the use of polymer to complex or absorb the conjugated polypeptide. The controlled delivery may be exercised by selecting appropriate macromolecules (for example polyester, polyamino acids, polyvinyl, pyrrolidone, ethylenevinylacetate, methylcellulose, carboxymethylcellulose, or protamine sulfate) and the concentration of macromolecules as well as the methods of incorporation in order to control release. Another possible method to control the duration of action by controlled-release preparations is to incorporate the conjugated polypeptide into particles of a polymeric material such as polyesters, polyamino acids, hydrogels, poly(lactic acid) or ethylene vinylacetate copolymers. Alternatively, instead of incorporating these agents into polymeric particles, it is possible to entrap these materials in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxy-methylcellulose or gelatin-microcapsules and poly(methylmethacrylate) microcapsules,

respectively, or in colloidal drug delivery systems, for example, liposomes, albumin microspheres, microemulsions, nanoparticles, and nanocapsules or in macroemulsions.

When oral preparations are desired, the compositions  
5 may be combined with typical carriers, such as lactose, sucrose, starch, talc, magnesium stearate, crystalline cellulose, methyl cellulose, carboxymethyl cellulose, glycerin, sodium alginate or gum arabic among others. These carriers may likewise be used for preparing to be  
10 administered via other cavities, e.g., nasal, rectal, etc.

The conjugated polypeptides of the present invention may be supplied in the form of a kit, alone, or in the form of a pharmaceutical composition as described above.

15 Vaccination can be conducted by conventional methods. For example, the immunogenic polypeptide can be used in a suitable diluent such as saline or water, or complete or incomplete adjuvants. The immunogen can be administered by any route appropriate for antibody  
20 production such as intravenous, intraperitoneal, intramuscular, subcutaneous, and the like. The immunogen may be administered once or at periodic intervals until, for example, a significant titer of CD4<sup>+</sup> or CD8<sup>+</sup> T cell and/or antibodies directed against the HSV antigen is  
25 obtained. In particular, the antigenic polypeptides of the invention elicit TH1 associated antibodies and other aspects of a TH1 immune response. The presence of immune cells versus non-immune cells may be assessed in vitro by



measuring cytokine secretion, lymphoproliferation, cell activation markers, cytotoxicity, or altered metabolism, in response to T cells pulsed with the immunogen or by DTH using the conjugated polypeptide in vivo. The  
5 antibody may be detected in the serum using conventional immunoassays.

As noted above, the administration of the vaccine of the present invention may be for either a prophylactic or therapeutic purpose. When provided prophylactically, the  
10 immunogen is provided in advance of any evidence or in advance of any symptom due to HSV, especially in patients at significant risk for occurrence. The prophylactic administration of the immunogen serves to prevent or attenuate disease HSV in a human. When provided  
15 therapeutically, the immunogen is provided at (or after) the onset of the disease or at the onset of any symptom of the disease. The therapeutic administration of the immunogen serves to attenuate the disease.

The invention also concerns a method for treating or  
20 preventing herpes simplex virus (HSV) by administering to a human patient in need thereof a therapeutically effective amount of the conjugated polypeptide of this invention, such as the polypeptide of formula (I).

According to this invention the immune response is  
25 at least predominantly directed toward at least the desired TH1 response as evidenced by the examples of the TH1 characteristic antibody IgG2a (mouse) and presumably thereby IgG3 (man). These peptides may, however, in

addition to the TH1 elicited immune response, elicit a TH2 immune response, and in particular, a mixed TH1/TH2 immune response.

The present invention, therefore, provides antigenic  
5 conjugated polypeptides, which provide powerful vaccines for eliciting immune response for neutralizing HSV and killing HSV infected cells. Therefore, the vaccines of this invention can be used to immunize patients at risk for HSV or exposed to HSV including HSV-1 and HSV-2.

10 The conjugated polypeptides, which may be prepared by conventional solid phase peptide synthesis or other conventional means for peptide synthesis, however, the peptides may also be prepared by genetic engineering techniques. The DNA sequences coding for the peptides of  
15 this invention can be prepared by any of the well known techniques for recombinant gene technology. For example, reference can be made to the disclosure of recombinant proteins and peptides in U.S. 5,142,024 and the body of literature mentioned therein, the disclosures of which  
20 are incorporated herein by reference thereto.

Thus, this invention also provides a recombinant DNA molecule comprising all or part of the nucleic acid sequence encoding the antigenic peptide or the immunomodulatory peptide for subsequent direct linking or  
25 linking via a linking group, as previously described, or, more preferably, encoding the conjugated polypeptide of formula  $P_1-x-P_2$  or  $P_2-x-P_1$ , as described above, and a  
v ctor. Expression vectors suitable for use in the

present invention comprise at least one expression control element operationally linked to the nucleic acid sequence. The expression control elements are inserted in the vector to control and regulate the expression of

5 the nucleic acid sequence. Examples of expression control elements include, but are not limited to, lac system, operator and promoter regions of phage lambda, yeast promoters and promoters derived from polyoma, adenovirus, retrovirus or SV40. Additional preferred or

10 required operational elements include, but are not limited to, leader sequence, termination codons, polyadenylation signals and any other sequences necessary or preferred for the appropriate transcription and subsequent translation of the nucleic acid sequence in

15 the host system. It will be understood by one skilled in the art that the correct combination of required or preferred expression control elements will depend on the host system chosen. It will further be understood that the expression vector should contain additional elements

20 necessary for the transfer and subsequent replication of the expression vector containing the nucleic acid sequence in the host system. Examples of such elements include, but are not limited to, origins of replication and selectable markers. It will further be understood by

25 one skilled in the art that such vectors are easily constructed using conventional methods (see, e.g.,

Ausubel, et al., (1987) in "Current Protocols in Molecular Biology", John Wiley and Sons, New York, New York) or are commercially available.

Another aspect of this invention relates to a host  
5 organism into which a recombinant expression vector containing all or part of the nucleic acid sequence encoding for the immunogenic conjugated polypeptide as described above, has been inserted. The host cells transformed with the nucleic acid sequences encompassed  
10 by this invention include eukaryotes, such as animal, plant, insect and yeast cells and prokaryotes, such as E. coli. The means by which the vector carrying the gene may be introduced into the cell include, but are not limited to, microinjection, electroporation,  
15 transduction, or transfection using DEAE-dextran, lipofection, calcium phosphate or other procedures known to one skilled in the art (see, e.g., Sambrook, et al. (1989) in "Molecular Cloning. A Laboratory Manual", Cold Spring Harbor Press, Plainview, New York).

20 In a preferred embodiment, eukaryotic expression vectors that function in eukaryotic cells are used. Examples of such vectors include, but are not limited to, retroviral vectors, vaccinia virus vectors, adenovirus vectors, herpes virus vector, fowl pox virus vector,  
25 plasmids, such as pCDNA3 (Invitrogen, San Diego, CA) or the baculovirus transfer vectors. Preferred eukaryotic cell lines include, but are not limited to, COS cells, CHO c lls, HeLa c lls, NIH/3T3 cells, 293 cells (ATCC#

CRL1573), T2 cells, dendritic cells, monocytes or Epstein-Barr Virus transformed B cells. Mammalian cells, such as NIH/3T3, COS-7, CHO, 293 cells (ATCC #CRL 1573), T2 cells, dendritic cells, or monocytes are generally  
5 preferred to ensure proper processing and modification of the protein.

The recombinant protein expressed by the host cells can be obtained as a crude lysate or can be purified by standard protein purification procedures known in the art  
10 which may include differential precipitation, molecular sieve chromatography, ion-exchange chromatography, isoelectric focusing, gel electrophoresis, affinity, and immunoaffinity chromatography and the like. (see, e.g., Ausubel, et al., (1987) in "Current Protocols in  
15 Molecular Biology" John Wiley and Sons, New York, New York). In the case of immunoaffinity chromatography, the recombinant protein may be purified by passage through a column containing a resin which has bound thereto antibodies specific for the antigenic peptide (Ausubel,  
20 et al., (1987) in "Current Protocols in Molecular Biology" John Wiley and Sons, New York, New York).

By way of example, a vaccine prepared using recombinant expression vectors may be used. To provide a vaccine to an individual a genetic sequence which encodes  
25 for all or part of the immunogenic conjugated polypeptid is inserted into an expression vector, as described above, and introduced into the mammal to be immunized. Examples of vectors that may be used in th

aforementioned vaccines include, but are not limited to, defective retroviral vectors, andenoviral vectors, vaccinia viral vectors, fowl pox viral vectors, or other viral vectors (Mulligan, R.C., (1993) Science 260:926-  
5 932). The viral vectors carrying the nucleic sequence can be introduced into a mammal either prior to any evidence of HSV or to mediate progression of the disease in a mammal afflicted with HSV.

Examples of methods for administering the viral  
10 vector into the mammals include, but are not limited to, exposure of cells to the virus *ex vivo*, or injection of the retrovirus or a producer cell line of the virus into the affected tissue or intravenous administration of the virus. The quantity of viral vector, carrying the  
15 appropriate nucleic acid sequence encoding for the immunogenic conjugated polypeptide to be administered is based on the titer of virus particles. By way of example, a range of the immunogen to be administered may be about  $10^6$  to about  $10^{11}$  virus particles per mammal,  
20 preferably a human. After immunization the efficacy of the vaccine can be assessed by production of antibodies or immune cells that recognize the antigen, as assessed by specific cytokine production or by disease regression. One skilled in the art would know the conventional  
25 methods to assess the aforementioned parameters, such as CTL lymphoproliferation, etc.

Moreover, the conjugated polypeptides of this invention and DNA sequences encoding same may be used in a genetic immunization technique, such as disclosed in U.S. 5,593,972, the disclosure of which is incorporated  
5 herein in its entirety by reference thereto. According to the genetic immunization technique, the nucleotide sequence is operatively linked to regulatory sequences to enable expression in cells of an individual to which the nucleic acid molecule is administered. The resulting  
10 cells may then be used for prophylactic or therapeutic immunization.

When used as a vaccine in the method of this invention, the vaccine can be introduced into the host most conveniently by injection, intramuscularly,  
15 intradermally, parenterally, orally or subcutaneously. Any of the common liquid or solid vehicles may be employed, which are acceptable to the host and which do not have any adverse side effects on the host or any detrimental effects on the vaccine. Phosphate buffered  
20 saline (PBS), at physiological pH, e.g. pH 6.8 to 7.4, preferably pH 7, may be used as a carrier, alone or with a suitable adjuvant. The concentration of immunogenic polypeptide may vary from about 0.1 to 200  $\mu\text{g}/\text{kg}$ , such as about 25  $\mu\text{g}/\text{kg}$  per injection, in a volume of clinical  
25 solvent generally from about 0.1 to 1 ml, such as about 0.2 ml, preclinical studies in animals, and from about 0.5 ml to about 2 ml, such as about 1 ml in humans. Multiple injections may be required after the initial

injections and may be given at intervals of from about 2 to 4 weeks, for example, about 2 weeks in animals and about 8 weeks in humans, when multiple injections are given.

- 5           A preferred concentration of immunogenic polypeptid in the vaccines of the present invention may be in the range of from 10 to 25  $\mu\text{g/kg}$ , however, a higher dose may be administered as needed.

          The following are exemplary of applications for  
10 various embodiments of the conjugated polypeptides of the invention but, it is understood that the invention is not restricted to the following described examples.

Examples

I.   Peptides

- 15           One T cell binding peptide  $P_2$  of the conjugated polypeptide used in these studies includes a region of  $\beta$ -2 microglobulin, aa 35-47, Peptide J (shown underlined) and modified to include a spacer, for a MHC Class I-like action

20   PEPTIDE J   DLL KNG ERI EKV EGG C-amide   (SEQ ID NO:9)

          The conjugate with the antigenic peptide  $P_1$  and the Peptide J contained a spacer of one additional glycine substituted for the C-terminal cysteine for a total of three glycine residues. Accordingly, the conjugated  
25 polypeptide

(J-H1) had the following formula

DLL KN   GER IEK VEG

GGL YRT FAG NPR A

(SEQ ID NO:10)



wherein the underlined portion represents peptide H1.

Similarly polypeptide (J-H2) is prepared with the formula

DLL KN GER IEK VEG

GGA EID YAT LGV GV (SEQ ID NO:11)

- 5 Other representative polypeptides which can be prepared according to this invention or as controls are shown in the following Table 1.

Table 1

	NGQ EEK AGV VST GLI GGG LYR TFA GNP RA	(G-H1)
10	(SEQ ID NO:12)	
	LHG PEI LDV PST GGG LYR TFA GNP RA	(L-H1)
	(SEQ ID NO:13)	
	LHG PEI LDV PST GGG AEI DYA TLG VGY	(L-H2)
	(SEQ ID NO:14)	
15	NGQ EEK AGV VST GLI GGG AEI DYA TLG VGY	(G-H2)
	(SEQ ID NO:15)	
	DLL KNG ERI EKV EGG GSS IEF ARL	(J-B1)
	(SEQ ID NO:16)	
	NGQ EEK AGV VST GLI GGG SSI EFA RL	(G-B1)
20	(SEQ ID NO:17)	
	LHG PEI LDV PST GGG SSI EFA RL	(L-B1)
	(SEQ ID NO:18)	

- The peptides may be synthesized using the FMOC procedure and a double coupling protocol for the first  
25 8 residues. Usually the peptide is prepared with the carboxyl terminus as an amide form. The peptides may be purified using preparative HPLC, and analyzed by an analytical HPLC, amino acid analysis and mass

spectrophotometer. The peptides should be greater than 95%, usually greater than 98%, pure by HPLC criteria. The dry peptides are stored in glass vials with desiccant at -20°C.

5 II. Preparation of Conjugated Polypeptides

The conjugated polypeptide may be synthesized as a single peptide without any conjugation step or by conjugation of the peptide P<sub>1</sub> and the peptide P<sub>2</sub> by using the thioether method or by any other conjugation method  
10 known to the skilled practitioner.

Formulations for the following tests are adjusted to contain about 1000 µg/ml of peptide, and stored frozen (-20°C) in aliquots ready for thawing and may be administered in combination with an adjuvant (e.g., alum,  
15 MPL, ICFA, QS21, SF59, SAF-1) and/or carrier (e.g., liposomes or Novasomes). In particular, the peptides may be emulsified in Novasome adjuvants. Other adjuvants, such as, for example, Hunter's TiterMax (CYTRX) may also be used.

20 III. Immunization, Anti-sera Collection and Processing

An intraperitoneal challenge model using mice test animal was selected although the predominant presentation of HSV disease is not intraperitoneal since a reproducible course of disease occurs following viral  
25 challenge; since the viral challenge dose can be well defined and readily delivered by intraperitoneal injection since the symptoms are readily detected and the course of disease can be qualitatively evaluated; and

since the relevant parameter of survival may be readily evaluated. Immune function studies may also be conducted in vitro to further characterize the responses to the test vaccines.

5 Procedure A for Peptide H1 of ICP27

In a series of experiments, groups (12 per group) of 3 week old Balb/c female mice (Taconic Farms, Germantown, NY) are immunized and test bled according to the following schedule. Schedule A: immunizations on day 0 and day 14, and two weeks later nine mice of each group are challenged moderately with a lethal dose ( $< LD_{50}$ ) of HSV (H129 clinical strain) administered intraperitoneally. In this regard, young Balb/c mice show a defined course of disease which progresses from abdominal swelling, lethargy, paraplegia, to death within 1 to 2 weeks. Therefore, the effectiveness of the vaccinations may be readily determined.

The following Table 2 identifies each group with respect to the peptide which was tested.

Table 2

Immunization and Challenge Schedule

Group*	Immunization	Challenge	Unchallenged Immune Studies; Blood, DTH and Spleen
cells			
A NoVac	0	9	**
B H1	12	9	3
C G-H1	12	9	3
D L-H1	12	9	3
E J-H1	12	9	3

\*The group of 12 mice were divided into the two groups as indicated.

The dose of peptide was determined on a molar basis using 100  $\mu\text{g}$  of JH1 as the basis (0.033  $\mu$  moles/animal)

5   \*\*Three infected but surviving mice were available for DTH or naturally immunized antisera.

Each immunization consisted of 33 nmoles of conjugated polypeptide or non-conjugated antigenic peptide H1 (equivalent to 100  $\mu\text{g}$  of the JH1 vaccine). The peptide

10   was mixed with the Novasome liposomal adjuvant (50% v/v).

The mice were immunized twice with a two week interval between inoculations. After an additional two weeks, most of the mice received an intraperitoneal challenge

with the EKN clinical strain of HSV-1. The mice were  
15   evaluated daily for symptoms. DTH evaluation was performed 6 weeks after the initial vaccination on 3 mice that did not receive HSV-1 challenge. Blood was obtained from selected mice for ELISA studies prior to immunization and prior to virus challenge. The results  
20   are shown in Fig. 1 for symptom (on a daily basis) and in Fig. 2 for survival following vaccination and sub-lethal challenge.

In Fig. 1 symptoms were scored daily as:

- 1- non-specific mild symptoms
- 25   2- mild swelling of the abdomen
- 3- significant swelling of the abdomen and malais
- 4- incapacitation
- 5- death

From Fig. 1 the following conclusions may be drawn:

1. Unvaccinated (NO VAC) mice exhibited mild symptoms until the tenth day after the challenge at which time they suffered significant swelling of the abdomen and malaise. All but one mouse recovered.

2. JH1 vaccinated mice were protected from disease and only two mice showed significant symptoms, one of these mice died.

3. Mice vaccinated with the H1 peptide, GH1 or LH1 conjugated peptides exhibited more severe symptoms throughout the course of infection and death.

4. Vaccination with the H1 peptide, GH1 or LH1 conjugated polypeptide seemed to exacerbate the disease symptoms.

From Fig. 2 it is seen that maximal survival was observed for unvaccinated and JH1 vaccinated mice. Vaccination with the H1 peptide, GH1 or LH1 conjugates seemed to exacerbate the disease symptoms.

DTH response was evaluated 4 weeks after the last immunization for the vaccinated mice and three unvaccinated HSV challenged mice which had recovered from disease (C). Swelling of the right ear pinna was measured at 48 hours following injection of ultraviolet inactivated HSV and compared to the left ear pinna which had been injected with buffer. The results are shown in Fig. 3.

In another series of parallel experiments Balb/c female mice (n=9) were vaccinated with the H1 peptide or the JH1, GH1 or LH1 conjugated polypeptides according to the same protocol as for the HSV-1 challenge experiment described above. As seen from Fig. 3 DTH was observed qualitatively by redness induced by inflammation and measured quantitatively for the unvaccinated, HSV-1 challenged mice (C) and the JH1 vaccinated mice but not for mice vaccinated with the GH1, LH1 or H1 peptides.

10 Similar tests as described above were carried out. Balb/c mice (4 wk old) (n=6) were unvaccinated (NO VAC) or vaccinated and revaccinated two weeks later with the H1 peptide or the indicated conjugated polypeptide. The mice were then challenged two weeks later with an LD<sub>50</sub> of

15 HSV-1. Symptoms were scored daily as:

- 1- non-specific mild symptoms
- 2- mild swelling of the abdomen
- 3- significant swelling of the abdomen and malaise
- 4- incapacitation
- 20 5- death

The results are shown in Fig. 4 for symptoms, in Fig. 5 for survival and in Fig. 6 for DTH.

Unvaccinated mice and mice vaccinated with the H1 peptide, GH1 or LH1 heteroconjugates exhibited severe symptoms and death. However, JH1 vaccinated mice were protected from disease symptoms and death (see Figs. 4 and 5).

DTH response was evaluated 4 weeks after the last immunization for the vaccinated mice and three unvaccinated HSV challenged mice which had recovered from disease (Ctrl).

5       The protocol used in this experiment differed slightly from that of Fig. 3. Swelling in the right ear pinna was measured by micrometer prior to and at 24, 48 and 96 hours following injection of ultraviolet inactivated HSV and compared to the left ear pinna which  
10       had been injected with an uninfected Vero cell extract. The results are shown in Fig. 6.

From Fig. 6, it is seen that DTH was observed on each day, qualitatively by redness induced by inflammation and quantitatively for all of the mice in  
15       the unvaccinated, HSV-1 challenged (C) and the JH1 vaccinated groups. Some swelling but no redness was observed for some but not all of the mice vaccinated with the GH1, LH1 or H1 peptides.

From the above results it is understood that  
20       immunization with the conjugated polypeptide wherein a T cell binding peptide elicits predominantly a Th1 type immune response, e.g. Peptide J, provides protection from disease and death following intraperitoneal infection with HSV-1.

25       Antibody responses to the antigenic peptide, e.g. peptide H1 are undetectable by ELISA.

Mice immunized with the conjugated polypeptide of this invention develop capacity for a DTH response to HSV-1.

Neither the antigenic peptide alone nor the LH1  
5 conjugated polypeptides (the T cell binding peptide L being characterized by eliciting primarily a TH2 type response) nor the GH1 conjugated polypeptide elicited protection and may, in fact, have exacerbated disease and mortality following HSV challenge. These polypeptides  
10 did not elicit DTH responses.

Elicitation of protection and DTH responses indicate that immunization with the conjugated polypeptide of the invention stimulates TH1 T cell responses and that T cell responses are sufficient for protection.

15 These studies, therefore, confirm that covalently binding or conjugating a T cell specific binding peptide which elicits a TH1 type immune response to an antigenic peptide for HSV may enhance and promote the generation of a TH1 type T cell response. These studies are believed  
20 to be the first to show that this immune response can be sufficient to elicit protection from infectious challenge.

Procedure B for Peptide B1 of glycoprotein B

In order to further establish the effectiveness of  
25 conjugated peptides according to this invention as effective vaccines for treatment of herpes simplex virus, the HSV epitope B1, which is a T cell epitope (aa 498-505, SSIEFARL) of glycoprotein B found in both HSV-1 or



HSV-2 (see Hanke, et al, J. Virol. 65:1177-86; and  
Bonneau, et al, Virology 195:62-70) was selected and  
evaluated with either peptide J or peptide G or peptide L  
as described above. Namely, the conjugated peptides GB1,  
5 JB1 and LB1, as described in Table 1 above, were tested  
under the same conditions as previously described except  
that in place of the Balb/c mice, C57BI6 mice were  
vaccinated with the B1 conjugated peptides or non-  
conjugated B1 peptide (SEQ ID NO:4). The survival  
10 results are shown in Fig. 7. The mice immunized with the  
B1 peptide or with the conjugated peptide LB1 were not  
protected from HSV-1 challenge (0 of 9 or 1 of 9  
survival, respectively, after day 8) and, in fact the B1  
and LB1 immunized mice fared worse than the control  
15 (unvaccinated) mice (2 of 9 survival after day 8).

In contrast, the mice vaccinated with conjugated  
peptide GB1 or JB1 had survivals of 55.5% (5 of 9) and  
44.4% (4 of 9) respectively, indicative of partial  
protection.

20 In DTH tests carried out on 3 unchallenged immunized  
mice as previously described in connection with Fig.6,  
only the mice immunized with the JB1 conjugated peptide  
vaccine and the HSV challenged, surviving mice exhibited  
a DTH response. The GB vaccinated mice and the B peptide  
25 vaccinated mice did not exhibit a DTH response.

The antibody responses of vaccinated and unchallenged mice, vaccinated and challenged mice and unvaccinated and challenged mice were measured by ELISA assay. Serum was obtained 7 weeks after the initial immunization or 2 weeks after the virus challenge. B1 peptide or infected cell extracts were bound to the ELISA plate as antigen. Results are shown in Table 3 and were taken from pooled serum taken from 2 or 3 mice. The results were corrected for non-specific responses by subtracting the absorbance obtained towards an unrelated antigen.

TABLE 3

ELISA ASSAY OF ANTIBODY RESPONSES  
FOLLOWING B1 PEPTIDE VACCINATIONS

TREATMENT	B1 PEPTIDE RESPONSE	ANTIVIRUS RESPONSE
B1 Peptide	0.031	not tested
LB1 polypeptide	0.031	not tested
GB1 polypeptide	0.035	not tested
JB1 polypeptide	0.025	not tested
Normal mouse serum	0.043	0.059
HSV-1 challenged	0.045	0.447
GB1 and challenge	0.017	not tested
JB1 and challenge	0.19	0.445

From the results reported in Table 3 it is seen that no specific antibody was detected following immunization with the conjugated peptide vaccines. Also, no significant difference in response towards whole virus antigen was observed for unimmunized mice.

The large response towards the B1 peptide for mice preimmunized with the JB1 vaccine upon viral challenge is consistent with a prime-boost mechanism of immunization, i.e., antibody production.

5           When the results of the tests with polypeptides JH1 and GH1 are compared to the results with polypeptides JB1 and GB1, it is presumed that the protection afforded by the GB1 polypeptide compared to the lack of protection with the GH1 polypeptide, whereas both of the Peptide J  
10 conjugated polypeptides conferred protection, may be the result of Peptide G eliciting both a B cell (Th2) and a T cell (Th1) response. Similarly, the B1 peptide is believed to exhibit both a CTL epitope and a B cell epitope.

15           Accordingly, one of ordinary skill in the art will, in view of the above results, be able to determine, based on the nature of the epitopes of the HSV antigenic peptide, the expression of the target cell, and the nature of the response to which the TCBL is directed, the  
20 type of protective immunity and, therefore, the most appropriate combinations of the TCBL and the antigenic peptide for forming the conjugated polypeptides of this invention and the vaccines for HSV based thereon.

WHAT IS CLAIMED IS:

1        Claim 1. An immunogenic conjugated polypeptide  
2 effective as immunogen in a vaccine for treatment or  
3 prevention of infection by herpes simplex virus, said  
4 polypeptide represented by the formula  $P_1 - x - P_2$  or  
5  $P_2 - x - P_1$

6           where P<sub>1</sub> represents a herpes simplex virus specific  
7 antigenic peptide from a protein of herpes simplex virus  
8 type 1 or type 2, selected from the group consisting of  
9 ICP27, glycoprotein B, ribonucleotide reductase, ICP4,  
10 ICP34.5, glycoprotein E and glycoprotein F;

11 P<sub>2</sub> represents an immunomodulatory peptide which is a  
12 portion of an immunoprotein which promotes binding to a  
13 class or subclass of T cells and which direct a  
14 predominantly TH1 type immune response to the peptide P<sub>1</sub>;  
15 and

16        x represents a covalent bond or a cleavable or non-  
17 cleavable peptide linking group.

1            Claim 2. A conjugated polypeptide according to  
2 claim 1 wherein peptide P<sub>1</sub> is selected from the group  
3 consisting of

4 LYR TFA GNP RA (SEQ ID NO:1)

5 AEI DYA TLG VGV (SEQ ID NO:2)

6           DYA TLG VGV                                 (SEQ ID NO:3)

7 and

8 SSI EFA RL (SEQ ID NO:4) .

1           Claim 3. A conjugated polypeptide according to  
2 claim 1 wherein peptide P<sub>2</sub> is selected from the group  
3 consisting of

4           DLL KNG ERI EKV E                               (SEQ ID NO:19)  
5 and NGQ EEK AGV VST GLI                               (SEQ ID NO:20).

1           Claim 4. A conjugated polypeptide according to  
2 claim 1 which is selected from the group consisting of  
3 DLL KNE GER IEK VEG GGL YRT FAG NPR A       (J-H1)  
4 (SEQ ID NO:10)

5 DLL KNG ERI EKV EGG GSS IEF ARL                       (J-B1)  
6 (SEQ ID NO:16) and  
7 NGQ EEK AGV VST GLI GGG SSI EFA RL                       (G-B1)  
8 (SEQ ID NO:17).

1           Claim 5. A composition effective in the treatment  
2 or prevention of herpes simplex virus comprising a  
3 conjugated polypeptide according to claim 1 and a  
4 pharmaceutically effective carrier.

1           Claim 6. A method for the treatment or prevention  
2 of herpes simplex virus comprising administering to a  
3 patient in need thereof a therapeutically effective  
4 amount of a conjugated polypeptide according to claim 1.

1           Claim 7. A method for diagnosing the presence of  
2 infection active or latent in an individual by herpes  
3 simplex virus which comprises mixing T cells from the  
4 individual with conjugated polypeptide represented by th  
5 formula P<sub>1</sub>-x-P<sub>2</sub> or P<sub>2</sub>-x-P<sub>1</sub> as defined in claim 1 and  
6 detecting a reaction between T cells and conjugated  
7 p ptide.

- 1           Claim 8. The method of claim 1 wher in th
- 2   conjugated polypeptide is labelled with a detectable
- 3   species to facilate detection of said reaction.

1 / 7




FIG. 1

2 / 7





FIG. 2



3 / 7






FIG. 3

4 / 7



5 / 7



6 / 7




FIG. 6

7/7




FIG. 7

Raw Sequence List  
International Patent Application

Sequence Listing

(1) GENERAL INFORMATION:

- (i) APPLICANT: NORTHEASTERN OHIO UNIVERSITIES COLLEGE OF MEDICINE
- (ii) TITLE OF INVENTION: CONJUGATED POLYPEPTIDES FOR TREATING HERPES SIMPLEX VIRUS, COMPOSITIONS AND VACCINES CONTAINING SAME AND USES THEREOF FOR TREATMENT OR PREVENTION OF HERPES SIMPLEX VIRUS AND AS DIAGNOSTIC TOOL AND IN DIAGNOSTIC KIT
- (iii) NUMBER OF SEQUENCES: 20
- (iv) CORRESPONDENCE ADDRESS:
  - (A) ADDRESSEE: Law Office of Sherman and Shalloway
  - (B) STREET: 413 N. Washington Street
  - (C) CITY: Alexandria
  - (D) STATE: Virginia
  - (E) COUNTRY: USA
  - (F) ZIP: 22313
- (v) COMPUTER READABLE FORM:
  - (A) MEDIUM TYPE: Diskette, 5.25 inch, 360 kb storage
  - (B) COMPUTER: Dell System 210; Intel 80 286 Microprocessor
  - (C) OPERATING SYSTEM: MS DOS 6.2
  - (D) SOFTWARE: Word Perfect, Version 5.1
- (vi) CURRENT APPLICATION DATA:
  - (A) APPLICATION NUMBER: Unassigned
  - (B) FILING DATE: Concurrently herewith
  - (C) CLASSIFICATION:
- (vii) ATTORNEY/AGENT INFORMATION:
  - (A) NAME: Richard A. Steinberg
  - (B) REGISTRATION NUMBER: 26,588
  - (C) REFERENCE/DOCKET NUMBER: CELL-104/PCT
- (ix) TELECOMMUNICATION INFORMATION:
  - (A) TELEPHONE: (703) 549-2282
  - (B) TELEFAX: (703) 836-0106

2

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:11 amino acids

(B) TYPE:amino acids

(C) TOPOLOGY:linear

(ii) MOLECULE TYPE:

(iii) HYPOTHETICAL:

(v) FRAGMENT TYPE:internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM:HSV1

(ix) FEATURE:

(A) NAME/KEY:Peptide H1 of ICP27

(B) LOCATION:322 to 332

(C) IDENTIFICATION METHOD:

(D) OTHER INFORMATION:

(xi) SEQUENCE DESCRIPTION:SEQ ID NO:1:

Leu Tyr Arg Thr Phe Ala Gly Asn Pro Arg Ala  
5 10

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:12 amino acids

(B) TYPE:amino acids

(C) TOPOLOGY:linear

(ii) MOLECULE TYPE:

(iii) HYPOTHETICAL:

(v) FRAGMENT TYPE:internal

(vi) ORIGINAL SOURCE:HSV1

(A) ORGANISM:

(ix) FEATURE:

(A) NAME/KEY:Peptide H2 of ICP27

(B) LOCATION:

(C) IDENTIFICATION METHOD:

(xi) SEQUENCE DESCRIPTION:SEQ ID NO: 2:

Ala Glu Ile Asp Tyr Ala Thr Leu Gly Val Gly Val  
5 10

3

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:9 amino acids

(B) TYPE:amino acids

(C) TOPOLOGY:linear

(ii) MOLECULE TYPE:

(iii) HYPOTHETICAL:

(v) FRAGMENT TYPE:internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM:HSV1

(ix) FEATURE:

(A) NAME/KEY:ICP27

(B) LOCATION:448 to 456

(C) IDENTIFICATION METHOD:

(D) OTHER INFORMATION:

(xi) SEQUENCE DESCRIPTION:SEQ ID NO:3:

Asp Tyr Ala Thr Leu Gly Val Gly Val

5

(2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:8 amino acids

(B) TYPE:amino acids

(C) TOPOLOGY:linear

(ii) MOLECULE TYPE:

(iii) HYPOTHETICAL:

(v) FRAGMENT TYPE:internal

(vi) ORIGINAL SOURCE:HSV1

(A) ORGANISM:

(ix) FEATURE:

(A) NAME/KEY:Peptide B1 of glycoprotein B

(B) LOCATION:498 to 505

(C) IDENTIFICATION METHOD:

(xi) SEQUENCE DESCRIPTION:SEQ ID NO: 4:

Ser Ser Ile Glu Phe Ala Arg Leu

5



4

(2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:12 amino acids

(B) TYPE:amino acids

(C) TOPOLOGY:linear

(ii) MOLECULE TYPE:

(iii) HYPOTHETICAL:

(v) FRAGMENT TYPE:internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM:HSV1

(ix) FEATURE:

(A) NAME/KEY:glycoprotein C

(B) LOCATION:128 to 139

(C) IDENTIFICATION METHOD:

(D) OTHER INFORMATION:

(xi) SEQUENCE DESCRIPTION:SEQ ID NO:5:

Asp Arg Arg Asp Pro Leu Ala Arg Tyr Gly Ser Arg  
                                   5                                  10

(2) INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:30 amino acids

(B) TYPE:amino acids

(C) TOPOLOGY:linear

(ii) MOLECULE TYPE:

(iii) HYPOTHETICAL:

(v) FRAGMENT TYPE:internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM:HSV1

(ix) FEATURE:

(A) NAME/KEY:glycoprotein D

(B) LOCATION:

(C) IDENTIFICATION METHOD:

(xi) SEQUENCE DESCRIPTION:SEQ ID NO: 6:

Lys Arg Ala Leu Ala Asp Ala Ser Leu Lys Met Ala Asp Pro Asn Arg  
                                   5                                  10                                  15

Phe Arg Gly Lys Asp Leu Pro Val Leu Asp Glu Leu Asp Thr  
                                   20                                  25

5

## (2) INFORMATION FOR SEQ ID NO: 7:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:13 amino acids

(B) TYPE:amino acids

(C) TOPOLOGY:linear

## (ii) MOLECULE TYPE:

## (iii) HYPOTHETICAL:

## (v) FRAGMENT TYPE:internal

## (vi) ORIGINAL SOURCE:

(A) ORGANISM:HSV1

## (ix) FEATURE:

(A) NAME/KEY:glycoprotein D

(B) LOCATION:

(C) IDENTIFICATION METHOD:

(D) OTHER INFORMATION:

## (xi) SEQUENCE DESCRIPTION:SEQ ID NO:7:

Leu Lys Met Ala Asp Pro Asn Arg Phe Arg Gly Lys Asp  
5 10

## (2) INFORMATION FOR SEQ ID NO: 8:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:17 amino acids

(B) TYPE:amino acids

(C) TOPOLOGY:linear

## (ii) MOLECULE TYPE:

## (iii) HYPOTHETICAL:

## (v) FRAGMENT TYPE:internal

## (vi) ORIGINAL SOURCE:

(A) ORGANISM:HSV1

## (ix) FEATURE:

(A) NAME/KEY:glycoprotein D

(B) LOCATION:

(C) IDENTIFICATION METHOD:

## (xi) SEQUENCE DESCRIPTION:SEQ ID NO: 8:

Ser Leu Lys Met Ala Asp Pro Arg Asn Arg Phe Arg Gly Lys Asp Leu  
5 10 15

Pro

(2) INFORMATION FOR SEQ ID NO: 9:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:15 amino acids

(B) TYPE:amino acids

(C) TOPOLOGY: linear

(ii) MOLECULE TYPE:

(iii) HYPOTHETICAL:

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM:

(ix) **FEATURE:**

(A) NAME/KEY:  $\beta$ -2 microglobulin, Peptide J

(B) LOCATION: 35 to 47

(C) IDENTIFICATION METHOD:

(D) OTHER INFORMATION:

(xi) SEQUENCE DESCRIPTION:SEQ ID NO:9:

Asp Leu Leu Lys Asn Gly Glu Arg Ile Gly Lys Val Glu Gly Gly  
5 10 15

(2) INFORMATION FOR SEQ ID NO: 10:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:27 amino acids

(B) TYPE:amino acids

(C) TOPOLOGY: linear

## (ii) MOLECULE TYPE:

(iii) HYPOTHETICAL:

(vi) ORIGINAL SOURCE:

(A) ORGANISM:

(ix) **FEATURE:**

(A) NAME/KEY:

(B) LOCATION:

(C) IDENTIFICATION METHOD:

(xi) SEQUENCE DESCRIPTION:SEQ ID NO: 10:

Asp Leu Leu Lys Asn Gly Glu Arg Ile Glu Lys Val Glu Gly Gly Gly  
5 10 15

Leu Tyr Arg Thr Phe Ala Gly Asn Pro Arg Ala  
20 25

7

## (2) INFORMATION FOR SEQ ID NO: 11:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:28 amino acids

(B) TYPE:amino acids

(C) TOPOLOGY:linear

## (ii) MOLECULE TYPE:

## (iii) HYPOTHETICAL:

## (vi) ORIGINAL SOURCE:

(A) ORGANISM:

## (ix) FEATURE:

(A) NAME/KEY:

(B) LOCATION:

(C) IDENTIFICATION METHOD:

(D) OTHER INFORMATION:

## (xi) SEQUENCE DESCRIPTION:SEQ ID NO:11:

Asp Leu Leu Lys Asn Gly Glu Arg Ile Glu Lys Val Glu Gly Gly Gly  
5 10 15

Ala Glu Ile Asp Tyr Ala Thr Leu Gly Val Gly Val  
20 25

## (2) INFORMATION FOR SEQ ID NO: 12:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:29 amino acids

(B) TYPE:amino acids

(C) TOPOLOGY:linear

## (ii) MOLECULE TYPE:

## (iii) HYPOTHETICAL:

## (vi) ORIGINAL SOURCE:

(A) ORGANISM:

## (ix) FEATURE:

(A) NAME/KEY:

(B) LOCATION:

(C) IDENTIFICATION METHOD:

## (xi) SEQUENCE DESCRIPTION:SEQ ID NO: 12:

Asn Gly Gln Glu Glu Lys Ala Gly Val Val Ser Thr Gly Leu Ile Gly  
5 10 15

Gly Gly Leu Tyr Arg Thr Phe Ala Gly Asn Pro Arg Ala  
20 25

8

## (2) INFORMATION FOR SEQ ID NO: 13:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:26 amino acids

(B) TYPE:amino acids

(C) TOPOLOGY:linear

## (ii) MOLECULE TYPE:

## (iii) HYPOTHETICAL:

## (vi) ORIGINAL SOURCE:

(A) ORGANISM:

## (ix) FEATURE:

(A) NAME/KEY:

(B) LOCATION:

(C) IDENTIFICATION METHOD:

(D) OTHER INFORMATION:

## (xi) SEQUENCE DESCRIPTION:SEQ ID NO:13:

Leu His Gly Pro Glu Ile Leu Asp Val Pro Ser Thr Gly Gly Gly Leu  
                    5                    10                    15

Tyr Arg Thr Phe Ala Gly Asn Pro Arg Ala  
                    20                    25

## (2) INFORMATION FOR SEQ ID NO: 14:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:27 amino acids

(B) TYPE:amino acids

(C) TOPOLOGY:linear

## (ii) MOLECULE TYPE:

## (iii) HYPOTHETICAL:

## (vi) ORIGINAL SOURCE:

(A) ORGANISM:

## (ix) FEATURE:

(A) NAME/KEY:

(B) LOCATION:

(C) IDENTIFICATION METHOD:

## (xi) SEQUENCE DESCRIPTION:SEQ ID NO: 14:

Leu His Gly Pro Glu Ile Leu Asp Val Pro Ser Thr Gly Gly Gly Ala  
                    5                    10                    15

Glu Ile Asp Tyr Ala Thr Leu Gly Val Gly Ala  
                    20                    25

9

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH:30 amino acids  
(B) TYPE:amino acids  
(C) TOPOLOGY:linear

(iii) HYPOTHETICAL:

(A) ORGANISM:

(A) NAME/KEY:

(B) LOCATION:

(C) IDENTIFICATION METHOD:

(D) OTHER INFORMATION:

(xi) SEQUENCE DESCRIPTION:SEQ ID NO:15:

Asn Gly Gln Glu Glu Lys Ala Gly Val Val Ser Thr Gly Leu Ile Gly  
5 10 15

Gly Gly Ala Glu Ile Asp Tyr Ala Thr Leu Gly Val Gly Tyr  
20 25 30

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH:27 amino acids  
(B) TYPE:amino acids  
(C) TOPOLOGY:linear

(iii) HYPOTHETICAL:

(A) ORGANISM:

(A) NAME/KEY:

(B) LOCATION:

(C) IDENTIFICATION METHOD:

(xi) SEQUENCE DESCRIPTION:SEQ ID NO: 16:

Asp Leu Leu Lys Asn Gly Glu Arg Ile Glu Lys Val Glu Gly Gly Gly  
5 10 15

Ser Ser Gly Ser Ser Ile Glu Phe Ala Arg Leu  
20 25

10

(2) INFORMATION FOR SEQ ID NO: 17:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:26 amino acids

(B) TYPE:amino acids

(C) TOPOLOGY:linear

(ii) MOLECULE TYPE:

(iii) HYPOTHETICAL:

(vi) ORIGINAL SOURCE:

(A) ORGANISM:

(ix) FEATURE:

(A) NAME/KEY:

(B) LOCATION:

(C) IDENTIFICATION METHOD:

(D) OTHER INFORMATION:

(xi) SEQUENCE DESCRIPTION:SEQ ID NO:17:

Asn Gly Gln Glu Glu Lys Ala Gly Val Val Ser Thr Gly Leu Ile Gly  
                                  5                                  10                                  15

Gly Gly Ser Ser Ile Glu Phe Ala Arg Leu  
                                  20                                  25

(2) INFORMATION FOR SEQ ID NO: 18:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:23 amino acids

(B) TYPE:amino acids

(C) TOPOLOGY:linear

(ii) MOLECULE TYPE:

(iii) HYPOTHETICAL:

(vi) ORIGINAL SOURCE:

(A) ORGANISM:

(ix) FEATURE:

(A) NAME/KEY:

(B) LOCATION:

(C) IDENTIFICATION METHOD:

(xi) SEQUENCE DESCRIPTION:SEQ ID NO: 18:

Leu His Gly Pro Glu Ile Leu Asp Val Pro Ser Thr Gly Gly Gly Ser  
                                  5                                  10                                  15

Ser Ile Glu Phe Ala Arg Leu  
                                  20

11

(2) INFORMATION FOR SEQ ID NO: 19:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:13 amino acids

(B) TYPE:amino acids

(C) TOPOLOGY:linear

(ii) MOLECULE TYPE:

(iii) HYPOTHETICAL:

(vi) ORIGINAL SOURCE:

(A) ORGANISM:

(ix) FEATURE:

(A) NAME/KEY:

(B) LOCATION:

(C) IDENTIFICATION METHOD:

(D) OTHER INFORMATION:

(xi) SEQUENCE DESCRIPTION:SEQ ID NO:19:

Asp Leu Leu Lys Asn Gly Glu Arg Ile Glu Lys Val Glu  
5 10

(2) INFORMATION FOR SEQ ID NO: 20:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:15 amino acids

(B) TYPE:amino acids

(C) TOPOLOGY:linear

(ii) MOLECULE TYPE:

(iii) HYPOTHETICAL:

(vi) ORIGINAL SOURCE:

(A) ORGANISM:

(ix) FEATURE:

(A) NAME/KEY:

(B) LOCATION:

(C) IDENTIFICATION METHOD:

(xi) SEQUENCE DESCRIPTION:SEQ ID NO: 20:

Asn Gly Gln Glu Glu Lys Ala Gly Val Val Ser Thr Gly Leu Ile  
5 10 15



## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US98/20681

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC(6) : Please See Extra Sheet. US CL : 424/ 184.1, 185.1, 192.1, 193.1, 204.1, 231.1; 530/403, 300 According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) U.S. : 424/ 184.1, 185.1, 192.1, 193.1, 204.1, 231.1; 530/403, 300  Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) APS, STN ONLINE, MEDLINE, EMBASE, BIOSIS, INPADOC search terms: HSV-1, HSV-2 fusion proteins, Th1, Th2, immunogenic peptide, conjugate		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5,652,342 A (ZIMMERMAN et al.) 29 July 1997, see abstract.	1-8
Y	HINUMA, S. et al. A novel strategy for converting recombinant viral protein into high immunogenic antigen. Federation of European Biochemical Societies. August 1991, Vol. 288, No. 1,2, pages 138-142, see abstract.	1-8
Y	NAKAO, M. et al. Immunotherapy of Acute and Recurrent Herpes Simplex Virus Type 2 Infection with an Adjuvant-Free Form of Recombinant Glycoprotein D-Interleukin-2 Fusion Protein. The Journal of Infectious Diseases. 1994, Vol. 169, pages 787-791, see abstract.	1-8
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
*A*	Special categories of cited documents: document defining the general state of the art which is not considered to be of particular relevance	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*E*	earlier document published on or after the international filing date	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*L*	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*O*	document referring to an oral disclosure, use, exhibition or other means	*G* document member of the same patent family
*P*	document published prior to the international filing date but later than the priority date claimed	
Date of the actual completion of the international search 21 DECEMBER 1998		Date of mailing of the international search report 08 MAR 1999
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer <i>J. Williams</i> JAY WILLIAMS Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992)\*

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US98/20681

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	BANKS, T. et al. Recognition by and In Vitro Induction of Cytotoxic T Lymphocytes against Predicted Epitopes of the Immediate-Early Protein ICP27 of Herpes Simplex Virus. Journal of Virology. January 1993, Vol. 67, No. 1, pages 613-616, see abstract.	1-8
Y	NENCIONI, L. et al. In Vivo Immunostimulating Activity of the 163-171 Peptide of Human IL-1B. The Journal of Immunology. 1 August 1987, Vol. 139, No. 3, pages 800-804, see abstract.	1-8
Y	CAMMAROTA, G. et al. Identification of a CD-4 binding site on the Beta2 domain of HIL-DR molecules. Nature, 30 April 1992, Vol. 356, pages 799-801, see abstract.	1-8

Form PCT/ISA/210 (continuation of second sheet)(July 1992)★

INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US98/20681

A. CLASSIFICATION OF SUBJECT MATTER:  
IPC (6):

C01D 1/32, 3/16, 7/26; C22B 26/10; C07K 14/705; A61K 39/00, 39/12, 39/385



routine recombinant DNA techniques, one or more of the CDRs may be inserted within framework regions, e.g., into human framework regions to humanize a non-human antibody, as described supra. The framework regions may be naturally occurring or consensus framework regions, and preferably human framework regions (see, e.g., Chothia et al., J. Mol. Biol. 278: 457-479 (1998) for a listing of human framework regions). Preferably, the polynucleotide generated by the combination of the framework regions and CDRs encodes an antibody that specifically binds a polypeptide of the invention. Preferably, as discussed supra, one or more amino acid substitutions may be made within the framework regions, and, preferably, the amino acid substitutions improve binding of the antibody to its antigen. Additionally, such methods may be used to make amino acid substitutions or deletions of one or more variable region cysteine residues participating in an intrachain disulfide bond to generate antibody molecules lacking one or more intrachain disulfide bonds. Other alterations to the polynucleotide are encompassed by the present invention and within the skill of the art.

In addition, techniques developed for the production of "chimeric antibodies" (Morrison et al., Proc. Natl. Acad. Sci. 81:851-855 (1984); Neuberger et al., Nature 312:604-608 (1984); Takeda et al., Nature 314:452-454 (1985)) by splicing genes from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity can be used. As described supra, a chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine mAb and a human immunoglobulin constant region, e.g., humanized antibodies.

Alternatively, techniques described for the production of single chain antibodies (U.S. Patent No. 4,946,778; Bird, Science 242:423-42 (1988); Huston et al., Proc. Natl. Acad. Sci. USA 85:5879-5883 (1988); and Ward et al., Nature 334:544-54 (1989)) can be adapted to produce single chain antibodies. Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a single chain polypeptide. Techniques for the assembly of functional Fv fragments in E. coli may also be used (Skerra et al., Science 242:1038-1041 (1988)).

### Methods of Producing Antibodies

The antibodies of the invention can be produced by any method known in the art for the synthesis of antibodies, in particular, by chemical synthesis or preferably,  
5 by recombinant expression techniques.

Recombinant expression of an antibody of the invention, or fragment, derivative or analog thereof, (e.g., a heavy or light chain of an antibody of the invention or a single chain antibody of the invention), requires construction of an expression vector containing a polynucleotide that encodes the antibody. Once a  
10 polynucleotide encoding an antibody molecule or a heavy or light chain of an antibody, or portion thereof (preferably containing the heavy or light chain variable domain), of the invention has been obtained, the vector for the production of the antibody molecule may be produced by recombinant DNA technology using techniques well known in the art. Thus, methods for preparing a protein by  
15 expressing a polynucleotide containing an antibody encoding nucleotide sequence are described herein. Methods which are well known to those skilled in the art can be used to construct expression vectors containing antibody coding sequences and appropriate transcriptional and translational control signals. These methods include, for example, in vitro recombinant DNA techniques, synthetic techniques, and in vivo  
20 genetic recombination. The invention, thus, provides replicable vectors comprising a nucleotide sequence encoding an antibody molecule of the invention, or a heavy or light chain thereof, or a heavy or light chain variable domain, operably linked to a promoter. Such vectors may include the nucleotide sequence encoding the constant region of the antibody molecule (see, e.g., PCT Publication WO 86/05807; PCT  
25 Publication WO 89/01036; and U.S. Patent No. 5,122,464) and the variable domain of the antibody may be cloned into such a vector for expression of the entire heavy or light chain.

The expression vector is transferred to a host cell by conventional techniques and the transfected cells are then cultured by conventional techniques to produce an  
30 antibody of the invention. Thus, the invention includes host cells containing a polynucleotide encoding an antibody of the invention, or a heavy or light chain thereof, or a single chain antibody of the invention, operably linked to a heterologous

promoter. In preferred embodiments for the expression of double-chained antibodies, vectors encoding both the heavy and light chains may be co-expressed in the host cell for expression of the entire immunoglobulin molecule, as detailed below.

A variety of host-expression vector systems may be utilized to express the antibody molecules of the invention. Such host-expression systems represent vehicles by which the coding sequences of interest may be produced and subsequently purified, but also represent cells which may, when transformed or transfected with the appropriate nucleotide coding sequences, express an antibody molecule of the invention in situ. These include but are not limited to microorganisms such as bacteria (e.g., *E. coli*, *B. subtilis*) transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing antibody coding sequences; yeast (e.g., *Saccharomyces*, *Pichia*) transformed with recombinant yeast expression vectors containing antibody coding sequences; insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) containing antibody coding sequences; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing antibody coding sequences; or mammalian cell systems (e.g., COS, CHO, BHK, 293, 3T3 cells) harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the adenovirus late promoter; the vaccinia virus 7.5K promoter). Preferably, bacterial cells such as *Escherichia coli*, and more preferably, eukaryotic cells, especially for the expression of whole recombinant antibody molecule, are used for the expression of a recombinant antibody molecule. For example, mammalian cells such as Chinese hamster ovary cells (CHO), in conjunction with a vector such as the major intermediate early gene promoter element from human cytomegalovirus is an effective expression system for antibodies (Foecking et al., *Gene* 45:101 (1986); Cockett et al., *Bio/Technology* 8:2 (1990)).

In bacterial systems, a number of expression vectors may be advantageously selected depending upon the use intended for the antibody molecule being expressed. For example, when a large quantity of such a protein is to be produced, for the

generation of pharmaceutical compositions of an antibody molecule, vectors which direct the expression of high levels of fusion protein products that are readily purified may be desirable. Such vectors include, but are not limited, to the *E. coli* expression vector pUR278 (Ruther et al., EMBO J. 2:1791 (1983)), in which the antibody coding  
5 sequence may be ligated individually into the vector in frame with the lac Z coding region so that a fusion protein is produced; pIN vectors (Inouye & Inouye, Nucleic Acids Res. 13:3101-3109 (1985); Van Heeke & Schuster, J. Biol. Chem. 24:5503-5509 (1989)); and the like. pGEX vectors may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such  
10 fusion proteins are soluble and can easily be purified from lysed cells by adsorption and binding to matrix glutathione-agarose beads followed by elution in the presence of free glutathione. The pGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned target gene product can be released from the GST moiety.

15 In an insect system, *Autographa californica* nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes. The virus grows in *Spodoptera frugiperda* cells. The antibody coding sequence may be cloned individually into non-essential regions (for example the polyhedrin gene) of the virus and placed under control of an AcNPV promoter (for example the polyhedrin  
20 promoter).

In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, the antibody coding sequence of interest may be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric  
25 gene may then be inserted in the adenovirus genome by in vitro or in vivo recombination. Insertion in a non-essential region of the viral genome (e.g., region E1 or E3) will result in a recombinant virus that is viable and capable of expressing the antibody molecule in infected hosts. (e.g., see Logan & Shenk, Proc. Natl. Acad. Sci. USA 81:355-359 (1984)). Specific initiation signals may also be required for  
30 efficient translation of inserted antibody coding sequences. These signals include the ATG initiation codon and adjacent sequences. Furthermore, the initiation codon must be in phase with the reading frame of the desired coding sequence to ensure



translation of the entire insert. These exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements, transcription terminators, etc. (see Bittner et al.,  
5 Methods in Enzymol. 153:51-544 (1987)).

In addition, a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (e.g., glycosylation) and processing (e.g., cleavage) of protein products may be important for the function of the protein.

10 Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins and gene products. Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed. To this end, eukaryotic host cells which possess the cellular machinery for proper processing of the primary transcript,  
15 glycosylation, and phosphorylation of the gene product may be used. Such mammalian host cells include but are not limited to CHO, VERO, BHK, HeLa, COS, MDCK, 293, 3T3, WI38, and in particular, breast cancer cell lines such as, for example, BT483, Hs578T, HTB2, BT20 and T47D, and normal mammary gland cell line such as, for example, CRL7030 and Hs578Bst.

20 For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express the antibody molecule may be engineered. Rather than using expression vectors which contain viral origins of replication, host cells can be transformed with DNA controlled by appropriate expression control elements (e.g., promoter, enhancer, sequences,  
25 transcription terminators, polyadenylation sites, etc.), and a selectable marker. Following the introduction of the foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to  
30 form foci which in turn can be cloned and expanded into cell lines. This method may advantageously be used to engineer cell lines which express the antibody molecule.

Such engineered cell lines may be particularly useful in screening and evaluation of compounds that interact directly or indirectly with the antibody molecule.

- A number of selection systems may be used, including but not limited to the herpes simplex virus thymidine kinase (Wigler et al., Cell 11:223 (1977)),
- 5 hypoxanthine-guanine phosphoribosyltransferase (Szybalska & Szybalski, Proc. Natl. Acad. Sci. USA 48:202 (1992)), and adenine phosphoribosyltransferase (Lowy et al., Cell 22:817 (1980)) genes can be employed in tk-, hgp<sup>r</sup>t- or ap<sup>r</sup>t- cells, respectively. Also, antimetabolite resistance can be used as the basis of selection for the following genes: dhfr, which confers resistance to methotrexate (Wigler et al., Natl. Acad. Sci. USA 77:357 (1980); O'Hare et al., Proc. Natl. Acad. Sci. USA 78:1527 (1981)); gpt, which confers resistance to mycophenolic acid (Mulligan & Berg, Proc. Natl. Acad. Sci. USA 78:2072 (1981)); neo, which confers resistance to the aminoglycoside G-418 Clinical Pharmacy 12:488-505; Wu and Wu, Biotherapy 3:87-95 (1991); Tolstoshev, Ann. Rev. Pharmacol. Toxicol. 32:573-596 (1993); Mulligan, Science 15 260:926-932 (1993); and Morgan and Anderson, Ann. Rev. Biochem. 62:191-217 (1993); May, 1993, TIB TECH 11(5):155-215); and hyg<sup>r</sup>, which confers resistance to hygromycin (Santerre et al., Gene 30:147 (1984)). Methods commonly known in the art of recombinant DNA technology may be routinely applied to select the desired recombinant clone, and such methods are described, for example, in Ausubel et al. 20 (eds.), Current Protocols in Molecular Biology, John Wiley & Sons, NY (1993); Kriegler, Gene Transfer and Expression, A Laboratory Manual, Stockton Press, NY (1990); and in Chapters 12 and 13, Dracopoli et al. (eds), Current Protocols in Human Genetics, John Wiley & Sons, NY (1994); Colberre-Garapin et al., J. Mol. Biol. 150:1 (1981), which are incorporated by reference herein in their entireties.
- 25 The expression levels of an antibody molecule can be increased by vector amplification (for a review, see Bebbington and Hentschel, The use of vectors based on gene amplification for the expression of cloned genes in mammalian cells in DNA cloning, Vol.3. (Academic Press, New York, 1987)). When a marker in the vector system expressing antibody is amplifiable, increase in the level of inhibitor present in 30 culture of host cell will increase the number of copies of the marker gene. Since the amplified region is associated with the antibody gene, production of the antibody will also increase (Crouse et al., Mol. Cell. Biol. 3:257 (1983)).

The host cell may be co-transfected with two expression vectors of the invention, the first vector encoding a heavy chain derived polypeptide and the second vector encoding a light chain derived polypeptide. The two vectors may contain identical selectable markers which enable equal expression of heavy and light chain polypeptides. Alternatively, a single vector may be used which encodes, and is capable of expressing, both heavy and light chain polypeptides. In such situations, the light chain should be placed before the heavy chain to avoid an excess of toxic free heavy chain (Proudfoot, Nature 322:52 (1986); Kohler, Proc. Natl. Acad. Sci. USA 77:2197 (1980)). The coding sequences for the heavy and light chains may comprise cDNA or genomic DNA.

Once an antibody molecule of the invention has been produced by an animal, chemically synthesized, or recombinantly expressed, it may be purified by any method known in the art for purification of an immunoglobulin molecule, for example, by chromatography (e.g., ion exchange, affinity, particularly by affinity for the specific antigen after Protein A, and sizing column chromatography), centrifugation, differential solubility, or by any other standard technique for the purification of proteins. In addition, the antibodies of the present invention or fragments thereof can be fused to heterologous polypeptide sequences described herein or otherwise known in the art, to facilitate purification.

The present invention encompasses antibodies recombinantly fused or chemically conjugated (including both covalently and non-covalently conjugations) to a polypeptide (or portion thereof, preferably at least 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 amino acids of the polypeptide) of the present invention to generate fusion proteins. The fusion does not necessarily need to be direct, but may occur through linker sequences. The antibodies may be specific for antigens other than polypeptides (or portion thereof, preferably at least 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 amino acids of the polypeptide) of the present invention. For example, antibodies may be used to target the polypeptides of the present invention to particular cell types, either in vitro or in vivo, by fusing or conjugating the polypeptides of the present invention to antibodies specific for particular cell surface receptors. Antibodies fused or conjugated to the polypeptides of the present invention may also be used in in vitro immunoassays and purification methods using methods known in the art. See e.g.,

Harbor et al., supra, and PCT publication WO 93/21232; EP 439,095; Naramura et al., Immunol. Lett. 39:91-99 (1994); U.S. Patent 5,474,981; Gillies et al., PNAS 89:1428-1432 (1992); Fell et al., J. Immunol. 146:2446-2452(1991), which are incorporated by reference in their entireties.

5           The present invention further includes compositions comprising the polypeptides of the present invention fused or conjugated to antibody domains other than the variable regions. For example, the polypeptides of the present invention may be fused or conjugated to an antibody Fc region, or portion thereof. The antibody portion fused to a polypeptide of the present invention may comprise the constant  
10   region, hinge region, CH1 domain, CH2 domain, and CH3 domain or any combination of whole domains or portions thereof. The polypeptides may also be fused or conjugated to the above antibody portions to form multimers. For example, Fc portions fused to the polypeptides of the present invention can form dimers through disulfide bonding between the Fc portions. Higher multimeric forms can be  
15   made by fusing the polypeptides to portions of IgA and IgM. Methods for fusing or conjugating the polypeptides of the present invention to antibody portions are known in the art. See, e.g., U.S. Patent Nos. 5,336,603; 5,622,929; 5,359,046; 5,349,053; 5,447,851; 5,112,946; EP 307,434; EP 367,166; PCT publications WO 96/04388; WO 91/06570; Ashkenazi et al., Proc. Natl. Acad. Sci. USA 88:10535-10539 (1991);  
20   Zheng et al., J. Immunol. 154:5590-5600 (1995); and Vil et al., Proc. Natl. Acad. Sci. USA 89:11337-11341(1992) (said references incorporated by reference in their entireties).

          As discussed, supra, the polypeptides corresponding to a polypeptide, polypeptide fragment, or a variant of SEQ ID NO:Y may be fused or conjugated to  
25   the above antibody portions to increase the in vivo half life of the polypeptides or for use in immunoassays using methods known in the art. Further, the polypeptides corresponding to SEQ ID NO:Y may be fused or conjugated to the above antibody portions to facilitate purification. One reported example describes chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various  
30   domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. (EP 394,827; Traunecker et al., Nature 331:84-86 (1988). The polypeptides of the present invention fused or conjugated to an antibody having

disulfide- linked dimeric structures (due to the IgG) may also be more efficient in binding and neutralizing other molecules, than the monomeric secreted protein or protein fragment alone. (Fountoulakis et al., J. Biochem. 270:3958-3964 (1995)). In many cases, the Fc part in a fusion protein is beneficial in therapy and diagnosis, and thus can result in, for example, improved pharmacokinetic properties. (EP A 232,262). Alternatively, deleting the Fc part after the fusion protein has been expressed, detected, and purified, would be desired. For example, the Fc portion may hinder therapy and diagnosis if the fusion protein is used as an antigen for immunizations. In drug discovery, for example, human proteins, such as hIL-5, have been fused with Fc portions for the purpose of high-throughput screening assays to identify antagonists of hIL-5. (See, Bennett et al., J. Molecular Recognition 8:52-58 (1995); Johanson et al., J. Biol. Chem. 270:9459-9471 (1995)).

Moreover, the antibodies or fragments thereof of the present invention can be fused to marker sequences, such as a peptide to facilitate purification. In preferred embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311), among others, many of which are commercially available. As described in Gentz et al., Proc. Natl. Acad. Sci. USA 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. Other peptide tags useful for purification include, but are not limited to, the "HA" tag, which corresponds to an epitope derived from the influenza hemagglutinin protein (Wilson et al., Cell 37:767 (1984)) and the "flag" tag.

The present invention further encompasses antibodies or fragments thereof conjugated to a diagnostic or therapeutic agent. The antibodies can be used diagnostically to, for example, monitor the development or progression of a tumor as part of a clinical testing procedure to, e.g., determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, radioactive materials, positron emitting metals using various positron emission tomographies, and nonradioactive paramagnetic metal ions. The detectable substance may be coupled or conjugated either directly to the antibody (or fragment

thereof) or indirectly, through an intermediate (such as, for example, a linker known in the art) using techniques known in the art. See, for example, U.S. Patent No. 4,741,900 for metal ions which can be conjugated to antibodies for use as diagnostics according to the present invention. Examples of suitable enzymes include horseradish  
5 peroxidase, alkaline phosphatase, beta-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material  
10 includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin; and examples of suitable radioactive material include  $^{125}\text{I}$ ,  $^{131}\text{I}$ ,  $^{111}\text{In}$  or  $^{99}\text{Tc}$ .

Further, an antibody or fragment thereof may be conjugated to a therapeutic moiety such as a cytotoxin, e.g., a cytostatic or cytotoxic agent, a therapeutic agent or  
15 a radioactive metal ion, e.g., alpha-emitters such as, for example,  $^{213}\text{Bi}$ . A cytotoxin or cytotoxic agent includes any agent that is detrimental to cells. Examples include paclitaxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-  
20 dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin and analogs or homologs thereof. Therapeutic agents include, but are not limited to, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating agents (e.g., mechlorethamine, thioepa chlorambucil, melphalan, carmustine (BSNU) and lomustine (CCNU),  
25 cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC)), and anti-mitotic agents (e.g., vincristine and vinblastine).

30 The conjugates of the invention can be used for modifying a given biological response, the therapeutic agent or drug moiety is not to be construed as limited to classical chemical therapeutic agents. For example, the drug moiety may be a protein

or polypeptide possessing a desired biological activity. Such proteins may include, for example, a toxin such as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin; a protein such as tumor necrosis factor,  $\alpha$ -interferon,  $\beta$ -interferon, nerve growth factor, platelet derived growth factor, tissue plasminogen activator, an apoptotic agent, e.g., TNF- $\alpha$ , TNF- $\beta$ , AIM I (See, International Publication No. WO 97/33899), AIM II (See, International Publication No. WO 97/34911), Fas Ligand (Takahashi *et al.*, *Int. Immunol.*, 6:1567-1574 (1994)), VEGI (See, International Publication No. WO 99/23105), a thrombotic agent or an anti-angiogenic agent, e.g., angiostatin or endostatin; or, biological response modifiers such as, for example, lymphokines, interleukin-1 ("IL-1"), interleukin-2 ("IL-2"), interleukin-6 ("IL-6"), granulocyte macrophage colony stimulating factor ("GM-CSF"), granulocyte colony stimulating factor ("G-CSF"), or other growth factors.

Antibodies may also be attached to solid supports, which are particularly useful for immunoassays or purification of the target antigen. Such solid supports include, but are not limited to, glass, cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene.

Techniques for conjugating such therapeutic moiety to antibodies are well known, see, e.g., Arnon *et al.*, "Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy", in *Monoclonal Antibodies And Cancer Therapy*, Reisfeld *et al.* (eds.), pp. 243-56 (Alan R. Liss, Inc. 1985); Hellstrom *et al.*, "Antibodies For Drug Delivery", in *Controlled Drug Delivery* (2nd Ed.), Robinson *et al.* (eds.), pp. 623-53 (Marcel Dekker, Inc. 1987); Thorpe, "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review", in *Monoclonal Antibodies '84: Biological And Clinical Applications*, Pinchera *et al.* (eds.), pp. 475-506 (1985); "Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy", in *Monoclonal Antibodies For Cancer Detection And Therapy*, Baldwin *et al.* (eds.), pp. 303-16 (Academic Press 1985), and Thorpe *et al.*, "The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates", *Immunol. Rev.* 62:119-58 (1982).

Alternatively, an antibody can be conjugated to a second antibody to form an antibody heteroconjugate as described by Segal in U.S. Patent No. 4,676,980, which is incorporated herein by reference in its entirety.

An antibody, with or without a therapeutic moiety conjugated to it, administered alone or in combination with cytotoxic factor(s) and/or cytokine(s) can be used as a therapeutic.

## 5 Immunophenotyping

The antibodies of the invention may be utilized for immunophenotyping of cell lines and biological samples. The translation product of the gene of the present invention may be useful as a cell specific marker, or more specifically as a cellular marker that is differentially expressed at various stages of differentiation and/or  
10 maturation of particular cell types. Monoclonal antibodies directed against a specific epitope, or combination of epitopes, will allow for the screening of cellular populations expressing the marker. Various techniques can be utilized using monoclonal antibodies to screen for cellular populations expressing the marker(s), and include magnetic separation using antibody-coated magnetic beads, "panning" with  
15 antibody attached to a solid matrix (i.e., plate), and flow cytometry (See, e.g., U.S. Patent 5,985,660; and Morrison *et al.*, *Cell*, 96:737-49 (1999)).

These techniques allow for the screening of particular populations of cells, such as might be found with hematological malignancies (i.e. minimal residual disease (MRD) in acute leukemic patients) and "non-self" cells in transplantations to  
20 prevent Graft-versus-Host Disease (GVHD). Alternatively, these techniques allow for the screening of hematopoietic stem and progenitor cells capable of undergoing proliferation and/or differentiation, as might be found in human umbilical cord blood.

## Assays For Antibody Binding

25 The antibodies of the invention may be assayed for immunospecific binding by any method known in the art. The immunoassays which can be used include but are not limited to competitive and non-competitive assay systems using techniques such as western blots, radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich" immunoassays, immunoprecipitation assays, precipitin reactions,  
30 gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, complement-fixation assays, immunoradiometric assays, fluorescent immunoassays, protein A immunoassays, to name but a few. Such assays are routine and well



known in the art (see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York, which is incorporated by reference herein in its entirety). Exemplary immunoassays are described briefly below (but are not intended by way of limitation).

5           Immunoprecipitation protocols generally comprise lysing a population of cells in a lysis buffer such as RIPA buffer (1% NP-40 or Triton X- 100, 1% sodium deoxycholate, 0.1% SDS, 0.15 M NaCl, 0.01 M sodium phosphate at pH 7.2, 1% Trasylol) supplemented with protein phosphatase and/or protease inhibitors (e.g., EDTA, PMSF, aprotinin, sodium vanadate), adding the antibody of interest to the cell  
10   lysate, incubating for a period of time (e.g., 1-4 hours) at 4° C, adding protein A and/or protein G sepharose beads to the cell lysate, incubating for about an hour or more at 4° C, washing the beads in lysis buffer and resuspending the beads in SDS/sample buffer. The ability of the antibody of interest to immunoprecipitate a particular antigen can be assessed by, e.g., western blot analysis. One of skill in the  
15   art would be knowledgeable as to the parameters that can be modified to increase the binding of the antibody to an antigen and decrease the background (e.g., pre-clearing the cell lysate with sepharose beads). For further discussion regarding immunoprecipitation protocols see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at 10.16.1.

20           Western blot analysis generally comprises preparing protein samples, electrophoresis of the protein samples in a polyacrylamide gel (e.g., 8%- 20% SDS-PAGE depending on the molecular weight of the antigen), transferring the protein sample from the polyacrylamide gel to a membrane such as nitrocellulose, PVDF or nylon, blocking the membrane in blocking solution (e.g., PBS with 3% BSA or non-fat milk), washing the membrane in washing buffer (e.g., PBS-Tween 20), blocking  
25   the membrane with primary antibody (the antibody of interest) diluted in blocking buffer, washing the membrane in washing buffer, blocking the membrane with a secondary antibody (which recognizes the primary antibody, e.g., an anti-human antibody) conjugated to an enzymatic substrate (e.g., horseradish peroxidase or  
30   alkaline phosphatase) or radioactive molecule (e.g., 32P or 125I) diluted in blocking buffer, washing the membrane in wash buffer, and detecting the presence of the antigen. One of skill in the art would be knowledgeable as to the parameters that can

be modified to increase the signal detected and to reduce the background noise. For further discussion regarding western blot protocols see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at 10.8.1.

5           ELISAs comprise preparing antigen, coating the well of a 96 well microtiter plate with the antigen, adding the antibody of interest conjugated to a detectable compound such as an enzymatic substrate (e.g., horseradish peroxidase or alkaline phosphatase) to the well and incubating for a period of time, and detecting the presence of the antigen. In ELISAs the antibody of interest does not have to be  
10           conjugated to a detectable compound; instead, a second antibody (which recognizes the antibody of interest) conjugated to a detectable compound may be added to the well. Further, instead of coating the well with the antigen, the antibody may be coated to the well. In this case, a second antibody conjugated to a detectable compound may be added following the addition of the antigen of interest to the  
15           coated well. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the signal detected as well as other variations of ELISAs known in the art. For further discussion regarding ELISAs see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at 11.2.1.

20           The binding affinity of an antibody to an antigen and the off-rate of an antibody-antigen interaction can be determined by competitive binding assays. One example of a competitive binding assay is a radioimmunoassay comprising the incubation of labeled antigen (e.g., <sup>3</sup>H or <sup>125</sup>I) with the antibody of interest in the presence of increasing amounts of unlabeled antigen, and the detection of the  
25           antibody bound to the labeled antigen. The affinity of the antibody of interest for a particular antigen and the binding off-rates can be determined from the data by scatchard plot analysis. Competition with a second antibody can also be determined using radioimmunoassays. In this case, the antigen is incubated with antibody of interest conjugated to a labeled compound (e.g., <sup>3</sup>H or <sup>125</sup>I) in the presence of  
30           increasing amounts of an unlabeled second antibody.

### Therapeutic Uses

The present invention is further directed to antibody-based therapies which involve administering antibodies of the invention to an animal, preferably a mammal, and most preferably a human, patient for treating one or more of the disclosed diseases, disorders, or conditions. Therapeutic compounds of the invention include, but are not limited to, antibodies of the invention (including fragments, analogs and derivatives thereof as described herein) and nucleic acids encoding antibodies of the invention (including fragments, analogs and derivatives thereof and anti-idiotypic antibodies as described herein). The antibodies of the invention can be used to treat, inhibit or prevent diseases, disorders or conditions associated with aberrant expression and/or activity of a polypeptide of the invention, including, but not limited to, any one or more of the diseases, disorders, or conditions described herein. The treatment and/or prevention of diseases, disorders, or conditions associated with aberrant expression and/or activity of a polypeptide of the invention includes, but is not limited to, alleviating symptoms associated with those diseases, disorders or conditions. Antibodies of the invention may be provided in pharmaceutically acceptable compositions as known in the art or as described herein.

A summary of the ways in which the antibodies of the present invention may be used therapeutically includes binding polynucleotides or polypeptides of the present invention locally or systemically in the body or by direct cytotoxicity of the antibody, e.g. as mediated by complement (CDC) or by effector cells (ADCC). Some of these approaches are described in more detail below. Armed with the teachings provided herein, one of ordinary skill in the art will know how to use the antibodies of the present invention for diagnostic, monitoring or therapeutic purposes without undue experimentation.

The antibodies of this invention may be advantageously utilized in combination with other monoclonal or chimeric antibodies, or with lymphokines or hematopoietic growth factors (such as, e.g., IL-2, IL-3 and IL-7), for example, which serve to increase the number or activity of effector cells which interact with the antibodies.

The antibodies of the invention may be administered alone or in combination with other types of treatments (e.g., radiation therapy, chemotherapy, hormonal therapy, immunotherapy and anti-tumor agents). Generally, administration of

products of a species origin or species reactivity (in the case of antibodies) that is the same species as that of the patient is preferred. Thus, in a preferred embodiment, human antibodies, fragments derivatives, analogs, or nucleic acids, are administered to a human patient for therapy or prophylaxis.

5 It is preferred to use high affinity and/or potent in vivo inhibiting and/or neutralizing antibodies against polypeptides or polynucleotides of the present invention, fragments or regions thereof, for both immunoassays directed to and therapy of disorders related to polynucleotides or polypeptides, including fragments thereof, of the present invention. Such antibodies, fragments, or regions, will  
10 preferably have an affinity for polynucleotides or polypeptides of the invention, including fragments thereof. Preferred binding affinities include those with a dissociation constant or  $K_d$  less than  $5 \times 10^{-2}$  M,  $10^{-2}$  M,  $5 \times 10^{-3}$  M,  $10^{-3}$  M,  $5 \times 10^{-4}$  M,  $10^{-4}$  M,  $5 \times 10^{-5}$  M,  $10^{-5}$  M,  $5 \times 10^{-6}$  M,  $10^{-6}$  M,  $5 \times 10^{-7}$  M,  $10^{-7}$  M,  $5 \times 10^{-8}$  M,  $10^{-8}$  M,  $5 \times 10^{-9}$  M,  $10^{-9}$  M,  $5 \times 10^{-10}$  M,  $10^{-10}$  M,  $5 \times 10^{-11}$  M,  $10^{-11}$  M,  $5 \times 10^{-12}$  M,  $10^{-12}$  M,  $5 \times 10^{-13}$  M,  $10^{-13}$  M,  $5 \times 10^{-14}$  M,  $10^{-14}$  M,  $5 \times 10^{-15}$  M, and  $10^{-15}$  M.  
15

#### Gene Therapy

In a specific embodiment, nucleic acids comprising sequences encoding antibodies or functional derivatives thereof, are administered to treat, inhibit or  
20 prevent a disease or disorder associated with aberrant expression and/or activity of a polypeptide of the invention, by way of gene therapy. Gene therapy refers to therapy performed by the administration to a subject of an expressed or expressible nucleic acid. In this embodiment of the invention, the nucleic acids produce their encoded protein that mediates a therapeutic effect.

25 Any of the methods for gene therapy available in the art can be used according to the present invention. Exemplary methods are described below.

For general reviews of the methods of gene therapy, see Goldspiel et al., Clinical Pharmacy 12:488-505 (1993); Wu and Wu, Biotherapy 3:87-95 (1991); Tolstoshev, Ann. Rev. Pharmacol. Toxicol. 32:573-596 (1993); Mulligan, Science  
30 260:926-932 (1993); and Morgan and Anderson, Ann. Rev. Biochem. 62:191-217 (1993); May, TIBTECH 11(5):155-215 (1993). Methods commonly known in the art of recombinant DNA technology which can be used are described in Ausubel et al.

(eds.), Current Protocols in Molecular Biology, John Wiley & Sons, NY (1993); and Kriegler, Gene Transfer and Expression, A Laboratory Manual, Stockton Press, NY (1990).

In a preferred aspect, the compound comprises nucleic acid sequences  
5 encoding an antibody, said nucleic acid sequences being part of expression vectors that express the antibody or fragments or chimeric proteins or heavy or light chains thereof in a suitable host. In particular, such nucleic acid sequences have promoters operably linked to the antibody coding region, said promoter being inducible or constitutive, and, optionally, tissue-specific. In another particular embodiment,  
10 nucleic acid molecules are used in which the antibody coding sequences and any other desired sequences are flanked by regions that promote homologous recombination at a desired site in the genome, thus providing for intrachromosomal expression of the antibody encoding nucleic acids (Koller and Smithies, Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); Zijlstra et al., Nature 342:435-438 (1989). In specific  
15 embodiments, the expressed antibody molecule is a single chain antibody; alternatively, the nucleic acid sequences include sequences encoding both the heavy and light chains, or fragments thereof, of the antibody.

Delivery of the nucleic acids into a patient may be either direct, in which case the patient is directly exposed to the nucleic acid or nucleic acid-carrying vectors, or  
20 indirect, in which case, cells are first transformed with the nucleic acids in vitro, then transplanted into the patient. These two approaches are known, respectively, as in vivo or ex vivo gene therapy.

In a specific embodiment, the nucleic acid sequences are directly administered in vivo, where it is expressed to produce the encoded product. This can be  
25 accomplished by any of numerous methods known in the art, e.g., by constructing them as part of an appropriate nucleic acid expression vector and administering it so that they become intracellular, e.g., by infection using defective or attenuated retrovirals or other viral vectors (see U.S. Patent No. 4,980,286), or by direct injection of naked DNA, or by use of microparticle bombardment (e.g., a gene gun;  
30 Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, encapsulation in liposomes, microparticles, or microcapsules, or by administering them in linkage to a peptide which is known to enter the nucleus, by

administering it in linkage to a ligand subject to receptor-mediated endocytosis (see, e.g., Wu and Wu, J. Biol. Chem. 262:4429-4432 (1987)) (which can be used to target cell types specifically expressing the receptors), etc. In another embodiment, nucleic acid-ligand complexes can be formed in which the ligand comprises a fusogenic viral peptide to disrupt endosomes, allowing the nucleic acid to avoid lysosomal degradation. In yet another embodiment, the nucleic acid can be targeted in vivo for cell specific uptake and expression, by targeting a specific receptor (see, e.g., PCT Publications WO 92/06180; WO 92/22635; WO92/20316; WO93/14188, WO 93/20221). Alternatively, the nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination (Koller and Smithies, Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); Zijlstra et al., Nature 342:435-438 (1989)).

In a specific embodiment, viral vectors that contains nucleic acid sequences encoding an antibody of the invention are used. For example, a retroviral vector can be used (see Miller et al., Meth. Enzymol. 217:581-599 (1993)). These retroviral vectors contain the components necessary for the correct packaging of the viral genome and integration into the host cell DNA. The nucleic acid sequences encoding the antibody to be used in gene therapy are cloned into one or more vectors, which facilitates delivery of the gene into a patient. More detail about retroviral vectors can be found in Boesen et al., Biotherapy 6:291-302 (1994), which describes the use of a retroviral vector to deliver the *mdr1* gene to hematopoietic stem cells in order to make the stem cells more resistant to chemotherapy. Other references illustrating the use of retroviral vectors in gene therapy are: Clowes et al., J. Clin. Invest. 93:644-651 (1994); Kiem et al., Blood 83:1467-1473 (1994); Salmons and Gunzberg, Human Gene Therapy 4:129-141 (1993); and Grossman and Wilson, Curr. Opin. in Genetics and Devel. 3:110-114 (1993).

Adenoviruses are other viral vectors that can be used in gene therapy. Adenoviruses are especially attractive vehicles for delivering genes to respiratory epithelia. Adenoviruses naturally infect respiratory epithelia where they cause a mild disease. Other targets for adenovirus-based delivery systems are liver, the central nervous system, endothelial cells, and muscle. Adenoviruses have the advantage of being capable of infecting non-dividing cells. Kozarsky and Wilson, Current

Opinion in Genetics and Development 3:499-503 (1993) present a review of adenovirus-based gene therapy. Bout et al., Human Gene Therapy 5:3-10 (1994) demonstrated the use of adenovirus vectors to transfer genes to the respiratory epithelia of rhesus monkeys. Other instances of the use of adenoviruses in gene therapy can be found in Rosenfeld et al., Science 252:431-434 (1991); Rosenfeld et al., Cell 68:143-155 (1992); Mastrangeli et al., J. Clin. Invest. 91:225-234 (1993); PCT Publication WO94/12649; and Wang, et al., Gene Therapy 2:775-783 (1995). In a preferred embodiment, adenovirus vectors are used.

Adeno-associated virus (AAV) has also been proposed for use in gene therapy (Walsh et al., Proc. Soc. Exp. Biol. Med. 204:289-300 (1993); U.S. Patent No. 5,436,146).

Another approach to gene therapy involves transferring a gene to cells in tissue culture by such methods as electroporation, lipofection, calcium phosphate mediated transfection, or viral infection. Usually, the method of transfer includes the transfer of a selectable marker to the cells. The cells are then placed under selection to isolate those cells that have taken up and are expressing the transferred gene. Those cells are then delivered to a patient.

In this embodiment, the nucleic acid is introduced into a cell prior to administration in vivo of the resulting recombinant cell. Such introduction can be carried out by any method known in the art, including but not limited to transfection, electroporation, microinjection, infection with a viral or bacteriophage vector containing the nucleic acid sequences, cell fusion, chromosome-mediated gene transfer, microcell-mediated gene transfer, spheroplast fusion, etc. Numerous techniques are known in the art for the introduction of foreign genes into cells (see, e.g., Loeffler and Behr, Meth. Enzymol. 217:599-618 (1993); Cohen et al., Meth. Enzymol. 217:618-644 (1993); Cline, Pharmac. Ther. 29:69-92m (1985) and may be used in accordance with the present invention, provided that the necessary developmental and physiological functions of the recipient cells are not disrupted. The technique should provide for the stable transfer of the nucleic acid to the cell, so that the nucleic acid is expressible by the cell and preferably heritable and expressible by its cell progeny.

The resulting recombinant cells can be delivered to a patient by various methods known in the art. Recombinant blood cells (e.g., hematopoietic stem or progenitor cells) are preferably administered intravenously. The amount of cells envisioned for use depends on the desired effect, patient state, etc., and can be  
5 determined by one skilled in the art.

Cells into which a nucleic acid can be introduced for purposes of gene therapy encompass any desired, available cell type, and include but are not limited to epithelial cells, endothelial cells, keratinocytes, fibroblasts, muscle cells, hepatocytes; blood cells such as Tlymphocytes, Blymphocytes, monocytes, macrophages,  
10 neutrophils, eosinophils, megakaryocytes, granulocytes; various stem or progenitor cells, in particular hematopoietic stem or progenitor cells, e.g., as obtained from bone marrow, umbilical cord blood, peripheral blood, fetal liver, etc.

In a preferred embodiment, the cell used for gene therapy is autologous to the patient.

15 In an embodiment in which recombinant cells are used in gene therapy, nucleic acid sequences encoding an antibody are introduced into the cells such that they are expressible by the cells or their progeny, and the recombinant cells are then administered in vivo for therapeutic effect. In a specific embodiment, stem or progenitor cells are used. Any stem and/or progenitor cells which can be isolated and  
20 maintained in vitro can potentially be used in accordance with this embodiment of the present invention (see e.g. PCT Publication WO 94/08598; Stemple and Anderson, Cell 71:973-985 (1992); Rheinwald, Meth. Cell Bio. 21A:229 (1980); and Pittelkow and Scott, Mayo Clinic Proc. 61:771 (1986)).

In a specific embodiment, the nucleic acid to be introduced for purposes of  
25 gene therapy comprises an inducible promoter operably linked to the coding region, such that expression of the nucleic acid is controllable by controlling the presence or absence of the appropriate inducer of transcription. Demonstration of Therapeutic or Prophylactic Activity

The compounds or pharmaceutical compositions of the invention are  
30 preferably tested in vitro, and then in vivo for the desired therapeutic or prophylactic activity, prior to use in humans. For example, in vitro assays to demonstrate the therapeutic or prophylactic utility of a compound or pharmaceutical composition



include, the effect of a compound on a cell line or a patient tissue sample. The effect of the compound or composition on the cell line and/or tissue sample can be determined utilizing techniques known to those of skill in the art including, but not limited to, rosette formation assays and cell lysis assays. In accordance with the invention, in vitro assays which can be used to determine whether administration of a specific compound is indicated, include in vitro cell culture assays in which a patient tissue sample is grown in culture, and exposed to or otherwise administered a compound, and the effect of such compound upon the tissue sample is observed.

#### 10 Therapeutic/Prophylactic Administration and Composition

The invention provides methods of treatment, inhibition and prophylaxis by administration to a subject of an effective amount of a compound or pharmaceutical composition of the invention, preferably an antibody of the invention. In a preferred aspect, the compound is substantially purified (e.g., substantially free from substances that limit its effect or produce undesired side-effects). The subject is preferably an animal, including but not limited to animals such as cows, pigs, horses, chickens, cats, dogs, etc., and is preferably a mammal, and most preferably human.

Formulations and methods of administration that can be employed when the compound comprises a nucleic acid or an immunoglobulin are described above; additional appropriate formulations and routes of administration can be selected from among those described herein below.

Various delivery systems are known and can be used to administer a compound of the invention, e.g., encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the compound, receptor-mediated endocytosis (see, e.g., Wu and Wu, J. Biol. Chem. 262:4429-4432 (1987)), construction of a nucleic acid as part of a retroviral or other vector, etc. Methods of introduction include but are not limited to intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The compounds or compositions may be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents. Administration can be systemic or local. In

addition, it may be desirable to introduce the pharmaceutical compounds or compositions of the invention into the central nervous system by any suitable route, including intraventricular and intrathecal injection; intraventricular injection may be facilitated by an intraventricular catheter, for example, attached to a reservoir, such as an Ommaya reservoir. Pulmonary administration can also be employed, e.g., by use of an inhaler or nebulizer, and formulation with an aerosolizing agent.

In a specific embodiment, it may be desirable to administer the pharmaceutical compounds or compositions of the invention locally to the area in need of treatment; this may be achieved by, for example, and not by way of limitation, local infusion during surgery, topical application, e.g., in conjunction with a wound dressing after surgery, by injection, by means of a catheter, by means of a suppository, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers. Preferably, when administering a protein, including an antibody, of the invention, care must be taken to use materials to which the protein does not absorb.

In another embodiment, the compound or composition can be delivered in a vesicle, in particular a liposome (see Langer, *Science* 249:1527-1533 (1990); Treat et al., in *Liposomes in the Therapy of Infectious Disease and Cancer*, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 353- 365 (1989); Lopez-Berestein, *ibid.*, pp. 317-327; see generally *ibid.*)

In yet another embodiment, the compound or composition can be delivered in a controlled release system. In one embodiment, a pump may be used (see Langer, *supra*; Sefton, *CRC Crit. Ref. Biomed. Eng.* 14:201 (1987); Buchwald et al., *Surgery* 88:507 (1980); Saudek et al., *N. Engl. J. Med.* 321:574 (1989)). In another embodiment, polymeric materials can be used (see *Medical Applications of Controlled Release*, Langer and Wise (eds.), CRC Pres., Boca Raton, Florida (1974); *Controlled Drug Bioavailability, Drug Product Design and Performance*, Smolen and Ball (eds.), Wiley, New York (1984); Ranger and Peppas, J., *Macromol. Sci. Rev. Macromol. Chem.* 23:61 (1983); see also Levy et al., *Science* 228:190 (1985); During et al., *Ann. Neurol.* 25:351 (1989); Howard et al., *J. Neurosurg.* 71:105 (1989)). In yet another embodiment, a controlled release system can be placed in proximity of the therapeutic target, i.e., the brain, thus requiring only a fraction of the systemic dose

(see, e.g., Goodson, in Medical Applications of Controlled Release, supra, vol. 2, pp. 115-138 (1984)).

Other controlled release systems are discussed in the review by Langer (Science 249:1527-1533 (1990)).

5           In a specific embodiment where the compound of the invention is a nucleic acid encoding a protein, the nucleic acid can be administered in vivo to promote expression of its encoded protein, by constructing it as part of an appropriate nucleic acid expression vector and administering it so that it becomes intracellular, e.g., by use of a retroviral vector (see U.S. Patent No. 4,980,286), or by direct injection, or by  
10 use of microparticle bombardment (e.g., a gene gun; Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, or by administering it in linkage to a homeobox-like peptide which is known to enter the nucleus (see e.g., Joliot et al., Proc. Natl. Acad. Sci. USA 88:1864-1868 (1991)), etc. Alternatively, a nucleic acid can be introduced intracellularly and incorporated within host cell DNA  
15 for expression, by homologous recombination.

The present invention also provides pharmaceutical compositions. Such compositions comprise a therapeutically effective amount of a compound, and a pharmaceutically acceptable carrier. In a specific embodiment, the term  
20 "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic is administered. Such pharmaceutical carriers can be sterile liquids, such as water  
25 and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel,  
30 sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering

agents. These compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained-release formulations and the like. The composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides. Oral formulation can include standard carriers such as

5 pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Examples of suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E.W. Martin. Such compositions will contain a therapeutically effective amount of the compound, preferably in purified form, together with a suitable amount of carrier

10 so as to provide the form for proper administration to the patient. The formulation should suit the mode of administration.

In a preferred embodiment, the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to human beings. Typically, compositions for intravenous

15 administration are solutions in sterile isotonic aqueous buffer. Where necessary, the composition may also include a solubilizing agent and a local anesthetic such as lignocaine to ease pain at the site of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such

20 as an ampoule or sachette indicating the quantity of active agent. Where the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the composition is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.

25 The compounds of the invention can be formulated as neutral or salt forms. Pharmaceutically acceptable salts include those formed with anions such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those formed with cations such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol,

30 histidine, procaine, etc.

The amount of the compound of the invention which will be effective in the treatment, inhibition and prevention of a disease or disorder associated with aberrant

expression and/or activity of a polypeptide of the invention can be determined by standard clinical techniques. In addition, in vitro assays may optionally be employed to help identify optimal dosage ranges. The precise dose to be employed in the formulation will also depend on the route of administration, and the seriousness of the disease or disorder, and should be decided according to the judgment of the practitioner and each patient's circumstances. Effective doses may be extrapolated from dose-response curves derived from in vitro or animal model test systems.

For antibodies, the dosage administered to a patient is typically 0.1 mg/kg to 100 mg/kg of the patient's body weight. Preferably, the dosage administered to a patient is between 0.1 mg/kg and 20 mg/kg of the patient's body weight, more preferably 1 mg/kg to 10 mg/kg of the patient's body weight. Generally, human antibodies have a longer half-life within the human body than antibodies from other species due to the immune response to the foreign polypeptides. Thus, lower dosages of human antibodies and less frequent administration is often possible. Further, the dosage and frequency of administration of antibodies of the invention may be reduced by enhancing uptake and tissue penetration (e.g., into the brain) of the antibodies by modifications such as, for example, lipidation.

The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. **Diagnosis and Imaging**

Labeled antibodies, and derivatives and analogs thereof, which specifically bind to a polypeptide of interest can be used for diagnostic purposes to detect, diagnose, or monitor diseases and/or disorders associated with the aberrant expression and/or activity of a polypeptide of the invention. The invention provides for the detection of aberrant expression of a polypeptide of interest, comprising (a) assaying the expression of the polypeptide of interest in cells or body fluid of an individual using one or more antibodies specific to the polypeptide interest and (b) comparing the level of gene expression with a standard gene expression level, whereby an

increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of aberrant expression.

The invention provides a diagnostic assay for diagnosing a disorder, comprising (a) assaying the expression of the polypeptide of interest in cells or body fluid of an individual using one or more antibodies specific to the polypeptide interest and (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of a particular disorder. With respect to cancer, the presence of a relatively high amount of transcript in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

Antibodies of the invention can be used to assay protein levels in a biological sample using classical immunohistological methods known to those of skill in the art (e.g., see Jalkanen, et al., J. Cell. Biol. 101:976-985 (1985); Jalkanen, et al., J. Cell Biol. 105:3087-3096 (1987)). Other antibody-based methods useful for detecting protein gene expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA). Suitable antibody assay labels are known in the art and include enzyme labels, such as, glucose oxidase; radioisotopes, such as iodine (125I, 121I), carbon (14C), sulfur (35S), tritium (3H), indium (112In), and technetium (99Tc); luminescent labels, such as luminol; and fluorescent labels, such as fluorescein and rhodamine, and biotin.

One aspect of the invention is the detection and diagnosis of a disease or disorder associated with aberrant expression of a polypeptide of interest in an animal, preferably a mammal and most preferably a human. In one embodiment, diagnosis comprises: a) administering (for example, parenterally, subcutaneously, or intraperitoneally) to a subject an effective amount of a labeled molecule which specifically binds to the polypeptide of interest; b) waiting for a time interval following the administering for permitting the labeled molecule to preferentially concentrate at sites in the subject where the polypeptide is expressed (and for

unbound labeled molecule to be cleared to background level); c) determining background level; and d) detecting the labeled molecule in the subject, such that detection of labeled molecule above the background level indicates that the subject has a particular disease or disorder associated with aberrant expression of the polypeptide of interest. Background level can be determined by various methods including, comparing the amount of labeled molecule detected to a standard value previously determined for a particular system.

It will be understood in the art that the size of the subject and the imaging system used will determine the quantity of imaging moiety needed to produce diagnostic images. In the case of a radioisotope moiety, for a human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of <sup>99m</sup>Tc. The labeled antibody or antibody fragment will then preferentially accumulate at the location of cells which contain the specific protein. In vivo tumor imaging is described in S.W. Burchiel et al., "Immunopharmacokinetics of Radiolabeled Antibodies and Their Fragments." (Chapter 13 in Tumor Imaging: The Radiochemical Detection of Cancer, S.W. Burchiel and B. A. Rhodes, eds., Masson Publishing Inc. (1982).

Depending on several variables, including the type of label used and the mode of administration, the time interval following the administration for permitting the labeled molecule to preferentially concentrate at sites in the subject and for unbound labeled molecule to be cleared to background level is 6 to 48 hours or 6 to 24 hours or 6 to 12 hours. In another embodiment the time interval following administration is 5 to 20 days or 5 to 10 days.

In an embodiment, monitoring of the disease or disorder is carried out by repeating the method for diagnosing the disease or disease, for example, one month after initial diagnosis, six months after initial diagnosis, one year after initial diagnosis, etc.

Presence of the labeled molecule can be detected in the patient using methods known in the art for in vivo scanning. These methods depend upon the type of label used. Skilled artisans will be able to determine the appropriate method for detecting a particular label. Methods and devices that may be used in the diagnostic methods of the invention include, but are not limited to, computed tomography (CT), whole body

scan such as position emission tomography (PET), magnetic resonance imaging (MRI), and sonography.

In a specific embodiment, the molecule is labeled with a radioisotope and is detected in the patient using a radiation responsive surgical instrument (Thurston et al., U.S. Patent No. 5,441,050). In another embodiment, the molecule is labeled with a fluorescent compound and is detected in the patient using a fluorescence responsive scanning instrument. In another embodiment, the molecule is labeled with a positron emitting metal and is detected in the patient using positron emission-tomography. In yet another embodiment, the molecule is labeled with a paramagnetic label and is detected in a patient using magnetic resonance imaging (MRI). Kits

The present invention provides kits that can be used in the above methods. In one embodiment, a kit comprises an antibody of the invention, preferably a purified antibody, in one or more containers. In a specific embodiment, the kits of the present invention contain a substantially isolated polypeptide comprising an epitope which is specifically immunoreactive with an antibody included in the kit. Preferably, the kits of the present invention further comprise a control antibody which does not react with the polypeptide of interest. In another specific embodiment, the kits of the present invention contain a means for detecting the binding of an antibody to a polypeptide of interest (e.g., the antibody may be conjugated to a detectable substrate such as a fluorescent compound, an enzymatic substrate, a radioactive compound or a luminescent compound, or a second antibody which recognizes the first antibody may be conjugated to a detectable substrate).

In another specific embodiment of the present invention, the kit is a diagnostic kit for use in screening serum containing antibodies specific against proliferative and/or cancerous polynucleotides and polypeptides. Such a kit may include a control antibody that does not react with the polypeptide of interest. Such a kit may include a substantially isolated polypeptide antigen comprising an epitope which is specifically immunoreactive with at least one anti-polypeptide antigen antibody. Further, such a kit includes means for detecting the binding of said antibody to the antigen (e.g., the antibody may be conjugated to a fluorescent compound such as fluorescein or rhodamine which can be detected by flow cytometry). In specific embodiments, the



kit may include a recombinantly produced or chemically synthesized polypeptide antigen. The polypeptide antigen of the kit may also be attached to a solid support.

In a more specific embodiment the detecting means of the above-described kit includes a solid support to which said polypeptide antigen is attached. Such a kit may  
5 also include a non-attached reporter-labeled anti-human antibody. In this embodiment, binding of the antibody to the polypeptide antigen can be detected by binding of the said reporter-labeled antibody.

In an additional embodiment, the invention includes a diagnostic kit for use in screening serum containing antigens of the polypeptide of the invention. The  
10 diagnostic kit includes a substantially isolated antibody specifically immunoreactive with polypeptide or polynucleotide antigens, and means for detecting the binding of the polynucleotide or polypeptide antigen to the antibody. In one embodiment, the antibody is attached to a solid support. In a specific embodiment, the antibody may be a monoclonal antibody. The detecting means of the kit may include a second, labeled  
15 monoclonal antibody. Alternatively, or in addition, the detecting means may include a labeled, competing antigen.

In one diagnostic configuration, test serum is reacted with a solid phase reagent having a surface-bound antigen obtained by the methods of the present invention. After binding with specific antigen antibody to the reagent and removing  
20 unbound serum components by washing, the reagent is reacted with reporter-labeled anti-human antibody to bind reporter to the reagent in proportion to the amount of bound anti-antigen antibody on the solid support. The reagent is again washed to remove unbound labeled antibody, and the amount of reporter associated with the reagent is determined. Typically, the reporter is an enzyme which is detected by  
25 incubating the solid phase in the presence of a suitable fluorometric, luminescent or colorimetric substrate (Sigma, St. Louis, MO).

The solid surface reagent in the above assay is prepared by known techniques for attaching protein material to solid support material, such as polymeric beads, dip sticks, 96-well plate or filter material. These attachment methods generally include  
30 non-specific adsorption of the protein to the support or covalent attachment of the protein, typically through a free amine group, to a chemically reactive group on the solid support, such as an activated carboxyl, hydroxyl, or aldehyde group.

Alternatively, streptavidin coated plates can be used in conjunction with biotinylated antigen(s).

Thus, the invention provides an assay system or kit for carrying out this diagnostic method. The kit generally includes a support with surface- bound  
5 recombinant antigens, and a reporter-labeled anti-human antibody for detecting surface-bound anti-antigen antibody.

### **Fusion Proteins**

10 Any polypeptide of the present invention can be used to generate fusion proteins. For example, the polypeptide of the present invention, when fused to a second protein, can be used as an antigenic tag. Antibodies raised against the polypeptide of the present invention can be used to indirectly detect the second  
15 protein by binding to the polypeptide. Moreover, because secreted proteins target cellular locations based on trafficking signals, the polypeptides of the present invention can be used as targeting molecules once fused to other proteins.

Examples of domains that can be fused to polypeptides of the present invention include not only heterologous signal sequences, but also other heterologous functional regions. The fusion does not necessarily need to be direct, but may occur  
20 through linker sequences.

Moreover, fusion proteins may also be engineered to improve characteristics of the polypeptide of the present invention. For instance, a region of additional amino acids, particularly charged amino acids, may be added to the N-terminus of the polypeptide to improve stability and persistence during purification from the host cell  
25 or subsequent handling and storage. Also, peptide moieties may be added to the polypeptide to facilitate purification. Such regions may be removed prior to final preparation of the polypeptide. The addition of peptide moieties to facilitate handling of polypeptides are familiar and routine techniques in the art.

Moreover, polypeptides of the present invention, including fragments, and  
30 specifically epitopes, can be combined with parts of the constant domain of immunoglobulins (IgA, IgE, IgG, IgM) or portions thereof (CH1, CH2, CH3, and any combination thereof, including both entire domains and portions thereof), resulting in

chimeric polypeptides. These fusion proteins facilitate purification and show an increased half-life in vivo. One reported example describes chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. (EP A 394,827; Traunecker et al., Nature 331:84-86 (1988).)

5 Fusion proteins having disulfide-linked dimeric structures (due to the IgG) can also be more efficient in binding and neutralizing other molecules, than the monomeric secreted protein or protein fragment alone. (Fountoulakis et al., J. Biochem. 270:3958-3964 (1995).)

10 Similarly, EP-A-O 464 533 (Canadian counterpart 2045869) discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, the Fc part in a fusion protein is beneficial in therapy and diagnosis, and thus can result in, for example, improved pharmacokinetic properties. (EP-A 0232 262.) Alternatively, deleting the Fc part after the fusion protein has been expressed, detected, and purified, would be desired. For example, the Fc portion may hinder therapy and diagnosis if the fusion protein is used as an antigen for immunizations. In drug discovery, for example, human proteins, such as hIL-5, have been fused with Fc portions for the purpose of high-throughput screening assays to identify antagonists of hIL-5. (See, 15 D. Bennett et al., J. Molecular Recognition 8:52-58 (1995); K. Johanson et al., J. Biol. Chem. 270:9459-9471 (1995).)

Moreover, the polypeptides of the present invention can be fused to marker sequences, such as a peptide which facilitates purification of the fused polypeptide. In preferred embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, 25 Chatsworth, CA, 91311), among others, many of which are commercially available. As described in Gentz et al., Proc. Natl. Acad. Sci. USA 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. Another peptide tag useful for purification, the "HA" tag, corresponds to an epitope derived from the influenza hemagglutinin protein. (Wilson et al., Cell 37:767 30 (1984).)

Thus, any of these above fusions can be engineered using the polynucleotides or the polypeptides of the present invention.

### **Vectors, Host Cells, and Protein Production**

5           The present invention also relates to vectors containing the polynucleotide of the present invention, host cells, and the production of polypeptides by recombinant techniques. The vector may be, for example, a phage, plasmid, viral, or retroviral vector. Retroviral vectors may be replication competent or replication defective. In the latter case, viral propagation generally will occur only in complementing host  
10       cells.

          The polynucleotides may be joined to a vector containing a selectable marker for propagation in a host. Generally, a plasmid vector is introduced in a precipitate, such as a calcium phosphate precipitate, or in a complex with a charged lipid. If the vector is a virus, it may be packaged in vitro using an appropriate packaging cell line  
15       and then transduced into host cells.

          The polynucleotide insert should be operatively linked to an appropriate promoter, such as the phage lambda PL promoter, the E. coli lac, trp, phoA and tac promoters, the SV40 early and late promoters and promoters of retroviral LTRs, to name a few. Other suitable promoters will be known to the skilled artisan. The  
20       expression constructs will further contain sites for transcription initiation, termination, and, in the transcribed region, a ribosome binding site for translation. The coding portion of the transcripts expressed by the constructs will preferably include a translation initiating codon at the beginning and a termination codon (UAA, UGA or UAG) appropriately positioned at the end of the polypeptide to be translated.

25           As indicated, the expression vectors will preferably include at least one selectable marker. Such markers include dihydrofolate reductase, G418 or neomycin resistance for eukaryotic cell culture and tetracycline, kanamycin or ampicillin resistance genes for culturing in E. coli and other bacteria. Representative examples of appropriate hosts include, but are not limited to, bacterial cells, such as E. coli,  
30       Streptomyces and Salmonella typhimurium cells; fungal cells, such as yeast cells; insect cells such as Drosophila S2 and Spodoptera Sf9 cells; animal cells such as

CHO, COS, 293, and Bowes melanoma cells; and plant cells. Appropriate culture mediums and conditions for the above-described host cells are known in the art.

Among vectors preferred for use in bacteria include pQE70, pQE60 and pQE-9, available from QIAGEN, Inc.; pBluescript vectors, Phagescript vectors, pNH8A, pNH16a, pNH18A, pNH46A, available from Stratagene Cloning Systems, Inc.; and ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 available from Pharmacia Biotech, Inc. Among preferred eukaryotic vectors are pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; and pSVK3, pBPV, pMSG and pSVL available from Pharmacia. Other suitable vectors will be readily apparent to the skilled artisan.

Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection, or other methods. Such methods are described in many standard laboratory manuals, such as Davis et al., Basic Methods In Molecular Biology (1986). It is specifically contemplated that the polypeptides of the present invention may in fact be expressed by a host cell lacking a recombinant vector.

A polypeptide of this invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography ("HPLC") is employed for purification.

Polypeptides of the present invention, and preferably the secreted form, can also be recovered from: products purified from natural sources, including bodily fluids, tissues and cells, whether directly isolated or cultured; products of chemical synthetic procedures; and products produced by recombinant techniques from a prokaryotic or eukaryotic host, including, for example, bacterial, yeast, higher plant, insect, and mammalian cells. Depending upon the host employed in a recombinant production procedure, the polypeptides of the present invention may be glycosylated or may be non-glycosylated. In addition, polypeptides of the invention may also include an initial modified methionine residue, in some cases as a result of host-

mediated processes. Thus, it is well known in the art that the N-terminal methionine encoded by the translation initiation codon generally is removed with high efficiency from any protein after translation in all eukaryotic cells. While the N-terminal methionine on most proteins also is efficiently removed in most prokaryotes, for some  
5 proteins, this prokaryotic removal process is inefficient, depending on the nature of the amino acid to which the N-terminal methionine is covalently linked.

In addition to encompassing host cells containing the vector constructs discussed herein, the invention also encompasses primary, secondary, and immortalized host cells of vertebrate origin, particularly mammalian origin, that have  
10 been engineered to delete or replace endogenous genetic material (e.g., coding sequence), and/or to include genetic material (e.g., heterologous polynucleotide sequences) that is operably associated with the polynucleotides of the invention, and which activates, alters, and/or amplifies endogenous polynucleotides. For example, techniques known in the art may be used to operably associate heterologous control  
15 regions (e.g., promoter and/or enhancer) and endogenous polynucleotide sequences via homologous recombination, resulting in the formation of a new transcription unit (see, e.g., U.S. Patent No. 5,641,670, issued June 24, 1997; U.S. Patent No. 5,733,761, issued March 31, 1998; International Publication No. WO 96/29411, published September 26, 1996; International Publication No. WO 94/12650,  
20 published August 4, 1994; Koller et al., Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); and Zijlstra et al., Nature 342:435-438 (1989), the disclosures of each of which are incorporated by reference in their entireties).

In addition, polypeptides of the invention can be chemically synthesized using techniques known in the art (e.g., see Creighton, 1983, *Proteins: Structures and*  
25 *Molecular Principles*, W.H. Freeman & Co., N.Y., and Hunkapiller et al., *Nature*, 310:105-111 (1984)). For example, a polypeptide corresponding to a fragment of a polypeptide sequence of the invention can be synthesized by use of a peptide synthesizer. Furthermore, if desired, nonclassical amino acids or chemical amino acid analogs can be introduced as a substitution or addition into the polypeptide sequence.  
30 Non-classical amino acids include, but are not limited to, to the D-isomers of the common amino acids, 2,4-diaminobutyric acid,  $\alpha$ -amino isobutyric acid, 4-aminobutyric acid, Abu, 2-amino butyric acid, g-Abu, e-Ahx, 6-amino hexanoic acid,

Aib, 2-amino isobutyric acid, 3-amino propionic acid, ornithine, norleucine, norvaline, hydroxyproline, sarcosine, citrulline, homocitrulline, cysteic acid, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine, b-alanine, fluoro-amino acids, designer amino acids such as b-methyl amino acids, Ca-methyl amino acids, Na-methyl amino acids, and amino acid analogs in general. Furthermore, the amino acid can be D (dextrorotary) or L (levorotary).

The invention encompasses polypeptides which are differentially modified during or after translation, *e.g.*, by glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to an antibody molecule or other cellular ligand, etc. Any of numerous chemical modifications may be carried out by known techniques, including but not limited, to specific chemical cleavage by cyanogen bromide, trypsin, chymotrypsin, papain, V8 protease, NaBH<sub>4</sub>; acetylation, formylation, oxidation, reduction; metabolic synthesis in the presence of tunicamycin; etc.

Additional post-translational modifications encompassed by the invention include, for example, *e.g.*, N-linked or O-linked carbohydrate chains, processing of N-terminal or C-terminal ends), attachment of chemical moieties to the amino acid backbone, chemical modifications of N-linked or O-linked carbohydrate chains, and addition or deletion of an N-terminal methionine residue as a result of procaryotic host cell expression. The polypeptides may also be modified with a detectable label, such as an enzymatic, fluorescent, isotopic or affinity label to allow for detection and isolation of the protein.

Also provided by the invention are chemically modified derivatives of the polypeptides of the invention which may provide additional advantages such as increased solubility, stability and circulating time of the polypeptide, or decreased immunogenicity (see U.S. Patent NO: 4,179,337). The chemical moieties for derivitization may be selected from water soluble polymers such as polyethylene glycol, ethylene glycol/propylene glycol copolymers, carboxymethylcellulose, dextran, polyvinyl alcohol and the like. The polypeptides may be modified at random positions within the molecule, or at predetermined positions within the molecule and may include one, two, three or more attached chemical moieties.

The polymer may be of any molecular weight, and may be branched or unbranched. For polyethylene glycol, the preferred molecular weight is between about 1 kDa and about 100 kDa (the term "about" indicating that in preparations of polyethylene glycol, some molecules will weigh more, some less, than the stated molecular weight) for ease in handling and manufacturing. Other sizes may be used, depending on the desired therapeutic profile (e.g., the duration of sustained release desired, the effects, if any on biological activity, the ease in handling, the degree or lack of antigenicity and other known effects of the polyethylene glycol to a therapeutic protein or analog).

The polyethylene glycol molecules (or other chemical moieties) should be attached to the protein with consideration of effects on functional or antigenic domains of the protein. There are a number of attachment methods available to those skilled in the art, e.g., EP 0 401 384, herein incorporated by reference (coupling PEG to G-CSF), see also Malik et al., Exp. Hematol. 20:1028-1035 (1992) (reporting pegylation of GM-CSF using tresyl chloride). For example, polyethylene glycol may be covalently bound through amino acid residues via a reactive group, such as, a free amino or carboxyl group. Reactive groups are those to which an activated polyethylene glycol molecule may be bound. The amino acid residues having a free amino group may include lysine residues and the N-terminal amino acid residues; those having a free carboxyl group may include aspartic acid residues glutamic acid residues and the C-terminal amino acid residue. Sulfhydryl groups may also be used as a reactive group for attaching the polyethylene glycol molecules. Preferred for therapeutic purposes is attachment at an amino group, such as attachment at the N-terminus or lysine group.

One may specifically desire proteins chemically modified at the N-terminus. Using polyethylene glycol as an illustration of the present composition, one may select from a variety of polyethylene glycol molecules (by molecular weight, branching, etc.), the proportion of polyethylene glycol molecules to protein (polypeptide) molecules in the reaction mix, the type of pegylation reaction to be performed, and the method of obtaining the selected N-terminally pegylated protein. The method of obtaining the N-terminally pegylated preparation (i.e., separating this moiety from other monopegylated moieties if necessary) may be by purification of the



N-terminally pegylated material from a population of pegylated protein molecules. Selective proteins chemically modified at the N-terminus modification may be accomplished by reductive alkylation which exploits differential reactivity of different types of primary amino groups (lysine versus the N-terminal) available for derivatization in a particular protein. Under the appropriate reaction conditions, substantially selective derivatization of the protein at the N-terminus with a carbonyl group containing polymer is achieved.

The polypeptides of the invention may be in monomers or multimers (i.e., dimers, trimers, tetramers and higher multimers). Accordingly, the present invention relates to monomers and multimers of the polypeptides of the invention, their preparation, and compositions (preferably, *Therapeutics*) containing them. In specific embodiments, the polypeptides of the invention are monomers, dimers, trimers or tetramers. In additional embodiments, the multimers of the invention are at least dimers, at least trimers, or at least tetramers.

Multimers encompassed by the invention may be homomers or heteromers. As used herein, the term homomer, refers to a multimer containing only polypeptides corresponding to the amino acid sequence of SEQ ID NO:Y or encoded by the cDNA contained in a deposited clone (including fragments, variants, splice variants, and fusion proteins, corresponding to these polypeptides as described herein). These homomers may contain polypeptides having identical or different amino acid sequences. In a specific embodiment, a homomer of the invention is a multimer containing only polypeptides having an identical amino acid sequence. In another specific embodiment, a homomer of the invention is a multimer containing polypeptides having different amino acid sequences. In specific embodiments, the multimer of the invention is a homodimer (e.g., containing polypeptides having identical or different amino acid sequences) or a homotrimer (e.g., containing polypeptides having identical and/or different amino acid sequences). In additional embodiments, the homomeric multimer of the invention is at least a homodimer, at least a homotrimer, or at least a homotetramer.

As used herein, the term heteromer refers to a multimer containing one or more heterologous polypeptides (i.e., polypeptides of different proteins) in addition to the polypeptides of the invention. In a specific embodiment, the multimer of the

invention is a heterodimer, a heterotrimer, or a heterotetramer. In additional embodiments, the heteromeric multimer of the invention is at least a heterodimer, at least a heterotrimer, or at least a heterotetramer.

Multimers of the invention may be the result of hydrophobic, hydrophilic, 5 ionic and/or covalent associations and/or may be indirectly linked, by for example, liposome formation. Thus, in one embodiment, multimers of the invention, such as, for example, homodimers or homotrimers, are formed when polypeptides of the invention contact one another in solution. In another embodiment, heteromultimers of the invention, such as, for example, heterotrimers or heterotetramers, are formed 10 when polypeptides of the invention contact antibodies to the polypeptides of the invention (including antibodies to the heterologous polypeptide sequence in a fusion protein of the invention) in solution. In other embodiments, multimers of the invention are formed by covalent associations with and/or between the polypeptides of the invention. Such covalent associations may involve one or more amino acid 15 residues contained in the polypeptide sequence ( e.g., that recited in the sequence listing, or contained in the polypeptide encoded by a deposited clone). In one instance, the covalent associations are cross-linking between cysteine residues located within the polypeptide sequences which interact in the native (i.e., naturally occurring) polypeptide. In another instance, the covalent associations are the 20 consequence of chemical or recombinant manipulation. Alternatively, such covalent associations may involve one or more amino acid residues contained in the heterologous polypeptide sequence in a fusion protein of the invention.

In one example, covalent associations are between the heterologous sequence contained in a fusion protein of the invention (see, e.g., US Patent Number 25 5,478,925). In a specific example, the covalent associations are between the heterologous sequence contained in an Fc fusion protein of the invention (as described herein). In another specific example, covalent associations of fusion proteins of the invention are between heterologous polypeptide sequence from another protein that is capable of forming covalently associated multimers, such as for 30 example, osteoprotegerin (see, e.g., International Publication NO: WO 98/49305, the contents of which are herein incorporated by reference in its entirety). In another embodiment, two or more polypeptides of the invention are joined through peptide

linkers. Examples include those peptide linkers described in U.S. Pat. No. 5,073,627 (hereby incorporated by reference). Proteins comprising multiple polypeptides of the invention separated by peptide linkers may be produced using conventional recombinant DNA technology.

5           Another method for preparing multimer polypeptides of the invention involves use of polypeptides of the invention fused to a leucine zipper or isoleucine zipper polypeptide sequence. Leucine zipper and isoleucine zipper domains are polypeptides that promote multimerization of the proteins in which they are found. Leucine  
10           zipper were originally identified in several DNA-binding proteins (Landschulz et al., Science 240:1759, (1988)), and have since been found in a variety of different proteins. Among the known leucine zippers are naturally occurring peptides and derivatives thereof that dimerize or trimerize. Examples of leucine zipper domains  
15           suitable for producing soluble multimeric proteins of the invention are those described in PCT application WO 94/10308, hereby incorporated by reference. Recombinant fusion proteins comprising a polypeptide of the invention fused to a polypeptide  
sequence that dimerizes or trimerizes in solution are expressed in suitable host cells, and the resulting soluble multimeric fusion protein is recovered from the culture  
supernatant using techniques known in the art.

            Trimeric polypeptides of the invention may offer the advantage of enhanced  
20           biological activity. Preferred leucine zipper moieties and isoleucine moieties are those that preferentially form trimers. One example is a leucine zipper derived from lung surfactant protein D (SPD), as described in Hoppe et al. (FEBS Letters 344:191, (1994)) and in U.S. patent application Ser. No. 08/446,922, hereby incorporated by  
reference. Other peptides derived from naturally occurring trimeric proteins may be  
25           employed in preparing trimeric polypeptides of the invention.

            In another example, proteins of the invention are associated by interactions between Flag® polypeptide sequence contained in fusion proteins of the invention containing Flag® polypeptide sequence. In a further embodiment, associations  
30           proteins of the invention are associated by interactions between heterologous polypeptide sequence contained in Flag® fusion proteins of the invention and anti-Flag® antibody.

The multimers of the invention may be generated using chemical techniques known in the art. For example, polypeptides desired to be contained in the multimers of the invention may be chemically cross-linked using linker molecules and linker molecule length optimization techniques known in the art (see, e.g., US Patent  
5 Number 5,478,925, which is herein incorporated by reference in its entirety). Additionally, multimers of the invention may be generated using techniques known in the art to form one or more inter-molecule cross-links between the cysteine residues located within the sequence of the polypeptides desired to be contained in the multimer (see, e.g., US Patent Number 5,478,925, which is herein incorporated by  
10 reference in its entirety). Further, polypeptides of the invention may be routinely modified by the addition of cysteine or biotin to the C terminus or N-terminus of the polypeptide and techniques known in the art may be applied to generate multimers containing one or more of these modified polypeptides (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). Additionally,  
15 techniques known in the art may be applied to generate liposomes containing the polypeptide components desired to be contained in the multimer of the invention (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety).

Alternatively, multimers of the invention may be generated using genetic  
20 engineering techniques known in the art. In one embodiment, polypeptides contained in multimers of the invention are produced recombinantly using fusion protein technology described herein or otherwise known in the art (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). In a specific embodiment, polynucleotides coding for a homodimer of the invention are  
25 generated by ligating a polynucleotide sequence encoding a polypeptide of the invention to a sequence encoding a linker polypeptide and then further to a synthetic polynucleotide encoding the translated product of the polypeptide in the reverse orientation from the original C-terminus to the N-terminus (lacking the leader sequence) (see, e.g., US Patent Number 5,478,925, which is herein incorporated by  
30 reference in its entirety). In another embodiment, recombinant techniques described herein or otherwise known in the art are applied to generate recombinant polypeptides of the invention which contain a transmembrane domain (or hydrophobic or signal

peptide) and which can be incorporated by membrane reconstitution techniques into liposomes (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety).

## 5 **Uses of the Polynucleotides**

Each of the polynucleotides identified herein can be used in numerous ways as reagents. The following description should be considered exemplary and utilizes known techniques.

The polynucleotides of the present invention are useful for chromosome  
10 identification. There exists an ongoing need to identify new chromosome markers, since few chromosome marking reagents, based on actual sequence data (repeat polymorphisms), are presently available. Each polynucleotide of the present invention can be used as a chromosome marker.

Briefly, sequences can be mapped to chromosomes by preparing PCR primers  
15 (preferably 15-25 bp) from the sequences shown in SEQ ID NO:X. Primers can be selected using computer analysis so that primers do not span more than one predicted exon in the genomic DNA. These primers are then used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the SEQ ID NO:X will yield an  
20 amplified fragment.

Similarly, somatic hybrids provide a rapid method of PCR mapping the polynucleotides to particular chromosomes. Three or more clones can be assigned per day using a single thermal cycler. Moreover, sublocalization of the polynucleotides can be achieved with panels of specific chromosome fragments. Other gene mapping  
25 strategies that can be used include in situ hybridization, prescreening with labeled flow-sorted chromosomes, and preselection by hybridization to construct chromosome specific-cDNA libraries.

Precise chromosomal location of the polynucleotides can also be achieved using fluorescence in situ hybridization (FISH) of a metaphase chromosomal spread.  
30 This technique uses polynucleotides as short as 500 or 600 bases; however, polynucleotides 2,000-4,000 bp are preferred. For a review of this technique, see

Verma et al., "Human Chromosomes: a Manual of Basic Techniques," Pergamon Press, New York (1988).

For chromosome mapping, the polynucleotides can be used individually (to mark a single chromosome or a single site on that chromosome) or in panels (for marking multiple sites and/or multiple chromosomes). Preferred polynucleotides correspond to the noncoding regions of the cDNAs because the coding sequences are more likely conserved within gene families, thus increasing the chance of cross hybridization during chromosomal mapping.

Once a polynucleotide has been mapped to a precise chromosomal location, the physical position of the polynucleotide can be used in linkage analysis. Linkage analysis establishes coinheritance between a chromosomal location and presentation of a particular disease. (Disease mapping data are found, for example, in V. McKusick, Mendelian Inheritance in Man (available on line through Johns Hopkins University Welch Medical Library) .) Assuming 1 megabase mapping resolution and one gene per 20 kb, a cDNA precisely localized to a chromosomal region associated with the disease could be one of 50-500 potential causative genes.

Thus, once coinheritance is established, differences in the polynucleotide and the corresponding gene between affected and unaffected individuals can be examined. First, visible structural alterations in the chromosomes, such as deletions or translocations, are examined in chromosome spreads or by PCR. If no structural alterations exist, the presence of point mutations are ascertained. Mutations observed in some or all affected individuals, but not in normal individuals, indicates that the mutation may cause the disease. However, complete sequencing of the polypeptide and the corresponding gene from several normal individuals is required to distinguish the mutation from a polymorphism. If a new polymorphism is identified, this polymorphic polypeptide can be used for further linkage analysis.

Furthermore, increased or decreased expression of the gene in affected individuals as compared to unaffected individuals can be assessed using polynucleotides of the present invention. Any of these alterations (altered expression, chromosomal rearrangement, or mutation) can be used as a diagnostic or prognostic marker.

Thus, the invention also provides a diagnostic method useful during diagnosis of a disorder, involving measuring the expression level of polynucleotides of the present invention in cells or body fluid from an individual and comparing the measured gene expression level with a standard level of polynucleotide expression level, whereby an increase or decrease in the gene expression level compared to the  
5 level, whereby an increase or decrease in the gene expression level compared to the standard is indicative of a disorder.

In still another embodiment, the invention includes a kit for analyzing samples for the presence of proliferative and/or cancerous polynucleotides derived from a test subject. In a general embodiment, the kit includes at least one polynucleotide probe  
10 containing a nucleotide sequence that will specifically hybridize with a polynucleotide of the present invention and a suitable container. In a specific embodiment, the kit includes two polynucleotide probes defining an internal region of the polynucleotide of the present invention, where each probe has one strand containing a 31'mer-end internal to the region. In a further embodiment, the probes  
15 may be useful as primers for polymerase chain reaction amplification.

Where a diagnosis of a disorder, has already been made according to conventional methods, the present invention is useful as a prognostic indicator, whereby patients exhibiting enhanced or depressed polynucleotide of the present invention expression will experience a worse clinical outcome relative to patients  
20 expressing the gene at a level nearer the standard level.

By "measuring the expression level of polynucleotide of the present invention" is intended qualitatively or quantitatively measuring or estimating the level of the polypeptide of the present invention or the level of the mRNA encoding the polypeptide in a first biological sample either directly (e.g., by determining or  
25 estimating absolute protein level or mRNA level) or relatively (e.g., by comparing to the polypeptide level or mRNA level in a second biological sample). Preferably, the polypeptide level or mRNA level in the first biological sample is measured or estimated and compared to a standard polypeptide level or mRNA level, the standard being taken from a second biological sample obtained from an individual not having  
30 the disorder or being determined by averaging levels from a population of individuals not having a disorder. As will be appreciated in the art, once a standard polypeptide

level or mRNA level is known, it can be used repeatedly as a standard for comparison.

By "biological sample" is intended any biological sample obtained from an individual, body fluid, cell line, tissue culture, or other source which contains the polypeptide of the present invention or mRNA. As indicated, biological samples include body fluids (such as semen, lymph, sera, plasma, urine, synovial fluid and spinal fluid) which contain the polypeptide of the present invention, and other tissue sources found to express the polypeptide of the present invention. Methods for obtaining tissue biopsies and body fluids from mammals are well known in the art. Where the biological sample is to include mRNA, a tissue biopsy is the preferred source.

The method(s) provided above may preferably be applied in a diagnostic method and/or kits in which polynucleotides and/or polypeptides are attached to a solid support. In one exemplary method, the support may be a "gene chip" or a "biological chip" as described in US Patents 5,837,832, 5,874,219, and 5,856,174. Further, such a gene chip with polynucleotides of the present invention attached may be used to identify polymorphisms between the polynucleotide sequences, with polynucleotides isolated from a test subject. The knowledge of such polymorphisms (i.e. their location, as well as, their existence) would be beneficial in identifying disease loci for many disorders, including cancerous diseases and conditions. Such a method is described in US Patents 5,858,659 and 5,856,104. The US Patents referenced supra are hereby incorporated by reference in their entirety herein.

The present invention encompasses polynucleotides of the present invention that are chemically synthesized, or reproduced as peptide nucleic acids (PNA), or according to other methods known in the art. The use of PNAs would serve as the preferred form if the polynucleotides are incorporated onto a solid support, or gene chip. For the purposes of the present invention, a peptide nucleic acid (PNA) is a polyamide type of DNA analog and the monomeric units for adenine, guanine, thymine and cytosine are available commercially (Perceptive Biosystems). Certain components of DNA, such as phosphorus, phosphorus oxides, or deoxyribose derivatives, are not present in PNAs. As disclosed by P. E. Nielsen, M. Egholm, R. H. Berg and O. Buchardt, Science 254, 1497 (1991); and M. Egholm, O. Buchardt,



L.Christensen, C. Behrens, S. M. Freier, D. A. Driver, R. H. Berg, S. K. Kim, B. Norden, and P. E. Nielsen, *Nature* 365, 666 (1993), PNAs bind specifically and tightly to complementary DNA strands and are not degraded by nucleases. In fact, PNA binds more strongly to DNA than DNA itself does. This is probably because  
5 there is no electrostatic repulsion between the two strands, and also the polyamide backbone is more flexible. Because of this, PNA/DNA duplexes bind under a wider range of stringency conditions than DNA/DNA duplexes, making it easier to perform multiplex hybridization. Smaller probes can be used than with DNA due to the strong binding. In addition, it is more likely that single base mismatches can be determined  
10 with PNA/DNA hybridization because a single mismatch in a PNA/DNA 15-mer lowers the melting point ( $T_{sub.m}$ ) by 8°-20° C, vs. 4°-16° C for the DNA/DNA 15-mer duplex. Also, the absence of charge groups in PNA means that hybridization can be done at low ionic strengths and reduce possible interference by salt during the analysis.

15 The present invention is useful for detecting cancer in mammals. In particular the invention is useful during diagnosis of pathological cell proliferative neoplasias which include, but are not limited to: acute myelogenous leukemias including acute monocytic leukemia, acute myeloblastic leukemia, acute promyelocytic leukemia, acute myelomonocytic leukemia, acute erythroleukemia, acute megakaryocytic  
20 leukemia, and acute undifferentiated leukemia, etc.; and chronic myelogenous leukemias including chronic myelomonocytic leukemia, chronic granulocytic leukemia, etc. Preferred mammals include monkeys, apes, cats, dogs, cows, pigs, horses, rabbits and humans. Particularly preferred are humans.

Pathological cell proliferative disorders are often associated with inappropriate  
25 activation of proto-oncogenes. (Germann, E. P. et al., "The Etiology of Acute Leukemia: Molecular Genetics and Viral Oncology," in *Neoplastic Diseases of the Blood*, Vol 1., Wiernik, P. H. et al. eds., 161-182 (1985)). Neoplasias are now believed to result from the qualitative alteration of a normal cellular gene product, or from the quantitative modification of gene expression by insertion into the  
30 chromosome of a viral sequence, by chromosomal translocation of a gene to a more actively transcribed region, or by some other mechanism. (Germann et al., *supra*) It is likely that mutated or altered expression of specific genes is involved in the

pathogenesis of some leukemias, among other tissues and cell types. (Germann et al., supra) Indeed, the human counterparts of the oncogenes involved in some animal neoplasias have been amplified or translocated in some cases of human leukemia and carcinoma. (Germann et al., supra)

- 5 For example, c-myc expression is highly amplified in the non-lymphocytic leukemia cell line HL-60. When HL-60 cells are chemically induced to stop proliferation, the level of c-myc is found to be downregulated. (International Publication Number WO 91/15580) However, it has been shown that exposure of HL-60 cells to a DNA  
10 construct that is complementary to the 5' end of c-myc or c-myb blocks translation of the corresponding mRNAs which downregulates expression of the c-myc or c-myb proteins and causes arrest of cell proliferation and differentiation of the treated cells. (International Publication Number WO 91/15580; Wickstrom et al., Proc. Natl. Acad. Sci. 85:1028 (1988); Anfossi et al., Proc. Natl. Acad. Sci. 86:3379 (1989)). However, the skilled artisan would appreciate the present invention's usefulness would not be  
15 limited to treatment of proliferative disorders of hematopoietic cells and tissues, in light of the numerous cells and cell types of varying origins which are known to exhibit proliferative phenotypes.

- In addition to the foregoing, a polynucleotide can be used to control gene expression through triple helix formation or antisense DNA or RNA. Antisense  
20 techniques are discussed, for example, in Okano, J. Neurochem. 56: 560 (1991); "Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988). Triple helix formation is discussed in, for instance Lee et al., Nucleic Acids Research 6: 3073 (1979); Cooney et al., Science 241: 456 (1988); and Dervan et al., Science 251: 1360 (1991). Both methods rely on binding of the  
25 polynucleotide to a complementary DNA or RNA. For these techniques, preferred polynucleotides are usually oligonucleotides 20 to 40 bases in length and complementary to either the region of the gene involved in transcription (triple helix - see Lee et al., Nucl. Acids Res. 6:3073 (1979); Cooney et al., Science 241:456 (1988); and Dervan et al., Science 251:1360 (1991) ) or to the mRNA itself (antisense  
30 - Okano, J. Neurochem. 56:560 (1991); Oligodeoxy-nucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988).) Triple helix formation optimally results in a shut-off of RNA transcription from DNA, while

antisense RNA hybridization blocks translation of an mRNA molecule into polypeptide. Both techniques are effective in model systems, and the information disclosed herein can be used to design antisense or triple helix polynucleotides in an effort to treat disease.

5           Polynucleotides of the present invention are also useful in gene therapy. One goal of gene therapy is to insert a normal gene into an organism having a defective gene, in an effort to correct the genetic defect. The polynucleotides disclosed in the present invention offer a means of targeting such genetic defects in a highly accurate manner. Another goal is to insert a new gene that was not present in the host genome,  
10           thereby producing a new trait in the host cell.

          The polynucleotides are also useful for identifying individuals from minute biological samples. The United States military, for example, is considering the use of restriction fragment length polymorphism (RFLP) for identification of its personnel. In this technique, an individual's genomic DNA is digested with one or more  
15           restriction enzymes, and probed on a Southern blot to yield unique bands for identifying personnel. This method does not suffer from the current limitations of "Dog Tags" which can be lost, switched, or stolen, making positive identification difficult. The polynucleotides of the present invention can be used as additional DNA  
20           markers for RFLP.

          The polynucleotides of the present invention can also be used as an alternative to RFLP, by determining the actual base-by-base DNA sequence of selected portions of an individual's genome. These sequences can be used to prepare PCR primers for amplifying and isolating such selected DNA, which can then be sequenced. Using  
25           this technique, individuals can be identified because each individual will have a unique set of DNA sequences. Once an unique ID database is established for an individual, positive identification of that individual, living or dead, can be made from extremely small tissue samples.

          Forensic biology also benefits from using DNA-based identification techniques as disclosed herein. DNA sequences taken from very small biological  
30           samples such as tissues, e.g., hair or skin, or body fluids, e.g., blood, saliva, semen, synovial fluid, amniotic fluid, breast milk, lymph, pulmonary sputum or surfactant, urine, fecal matter, etc., can be amplified using PCR. In one prior art

technique, gene sequences amplified from polymorphic loci, such as DQa class II HLA gene, are used in forensic biology to identify individuals. (Erlich, H., PCR Technology, Freeman and Co. (1992).) Once these specific polymorphic loci are amplified, they are digested with one or more restriction enzymes, yielding an  
5 identifying set of bands on a Southern blot probed with DNA corresponding to the DQa class II HLA gene. Similarly, polynucleotides of the present invention can be used as polymorphic markers for forensic purposes.

There is also a need for reagents capable of identifying the source of a particular tissue. Such need arises, for example, in forensics when presented with  
10 tissue of unknown origin. Appropriate reagents can comprise, for example, DNA probes or primers specific to particular tissue prepared from the sequences of the present invention. Panels of such reagents can identify tissue by species and/or by organ type. In a similar fashion, these reagents can be used to screen tissue cultures for contamination.

15 In the very least, the polynucleotides of the present invention can be used as molecular weight markers on Southern gels, as diagnostic probes for the presence of a specific mRNA in a particular cell type, as a probe to "subtract-out" known sequences in the process of discovering novel polynucleotides, for selecting and making oligomers for attachment to a "gene chip" or other support, to raise anti-DNA  
20 antibodies using DNA immunization techniques, and as an antigen to elicit an immune response.

### **Uses of the Polypeptides**

Each of the polypeptides identified herein can be used in numerous ways. The  
25 following description should be considered exemplary and utilizes known techniques.

A polypeptide of the present invention can be used to assay protein levels in a biological sample using antibody-based techniques. For example, protein expression in tissues can be studied with classical immunohistological methods. (Jalkanen, M., et al., J. Cell. Biol. 101:976-985 (1985); Jalkanen, M., et al., J. Cell . Biol. 105:3087-  
30 3096 (1987).) Other antibody-based methods useful for detecting protein gene expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA). Suitable antibody assay labels are known

in the art and include enzyme labels, such as, glucose oxidase, and radioisotopes, such as iodine ( $^{125}\text{I}$ ,  $^{121}\text{I}$ ), carbon ( $^{14}\text{C}$ ), sulfur ( $^{35}\text{S}$ ), tritium ( $^3\text{H}$ ), indium ( $^{112}\text{In}$ ), and technetium ( $^{99\text{m}}\text{Tc}$ ), and fluorescent labels, such as fluorescein and rhodamine, and biotin.

5           In addition to assaying secreted protein levels in a biological sample, proteins can also be detected in vivo by imaging. Antibody labels or markers for in vivo imaging of protein include those detectable by X-radiography, NMR or ESR. For X-radiography, suitable labels include radioisotopes such as barium or cesium, which emit detectable radiation but are not overtly harmful to the subject. Suitable markers  
10       for NMR and ESR include those with a detectable characteristic spin, such as deuterium, which may be incorporated into the antibody by labeling of nutrients for the relevant hybridoma.

          A protein-specific antibody or antibody fragment which has been labeled with an appropriate detectable imaging moiety, such as a radioisotope (for example,  $^{131}\text{I}$ ,  
15        $^{112}\text{In}$ ,  $^{99\text{m}}\text{Tc}$ ), a radio-opaque substance, or a material detectable by nuclear magnetic resonance, is introduced (for example, parenterally, subcutaneously, or intraperitoneally) into the mammal. It will be understood in the art that the size of the subject and the imaging system used will determine the quantity of imaging moiety needed to produce diagnostic images. In the case of a radioisotope moiety, for a  
20       human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of  $^{99\text{m}}\text{Tc}$ . The labeled antibody or antibody fragment will then preferentially accumulate at the location of cells which contain the specific protein. In vivo tumor imaging is described in S.W. Burchiel et al., "Immunopharmacokinetics of Radiolabeled Antibodies and Their Fragments." (Chapter 13 in Tumor Imaging:  
25       The Radiochemical Detection of Cancer, S.W. Burchiel and B. A. Rhodes, eds., Masson Publishing Inc. (1982).)

          Thus, the invention provides a diagnostic method of a disorder, which involves (a) assaying the expression of a polypeptide of the present invention in cells or body fluid of an individual; (b) comparing the level of gene expression with a  
30       standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of a disorder. With respect to cancer, the presence of a relatively high

amount of transcript in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ  
5 preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

Moreover, polypeptides of the present invention can be used to treat disease. For example, patients can be administered a polypeptide of the present invention in an effort to replace absent or decreased levels of the polypeptide (e.g., insulin), to  
10 supplement absent or decreased levels of a different polypeptide (e.g., hemoglobin S for hemoglobin B, SOD, catalase, DNA repair proteins), to inhibit the activity of a polypeptide (e.g., an oncogene or tumor suppressor), to activate the activity of a polypeptide (e.g., by binding to a receptor), to reduce the activity of a membrane bound receptor by competing with it for free ligand (e.g., soluble TNF receptors used  
15 in reducing inflammation), or to bring about a desired response (e.g., blood vessel growth inhibition, enhancement of the immune response to proliferative cells or tissues).

Similarly, antibodies directed to a polypeptide of the present invention can also be used to treat disease. For example, administration of an antibody directed to a  
20 polypeptide of the present invention can bind and reduce overproduction of the polypeptide. Similarly, administration of an antibody can activate the polypeptide, such as by binding to a polypeptide bound to a membrane (receptor).

At the very least, the polypeptides of the present invention can be used as molecular weight markers on SDS-PAGE gels or on molecular sieve gel filtration  
25 columns using methods well known to those of skill in the art. Polypeptides can also be used to raise antibodies, which in turn are used to measure protein expression from a recombinant cell, as a way of assessing transformation of the host cell. Moreover, the polypeptides of the present invention can be used to test the following biological activities.

30

### Gene Therapy Methods

Another aspect of the present invention is to gene therapy methods for treating disorders, diseases and conditions. The gene therapy methods relate to the introduction of nucleic acid (DNA, RNA and antisense DNA or RNA) sequences into an animal to achieve expression of a polypeptide of the present invention. This method requires a polynucleotide which codes for a polypeptide of the invention that operatively linked to a promoter and any other genetic elements necessary for the expression of the polypeptide by the target tissue. Such gene therapy and delivery techniques are known in the art, see, for example, WO90/11092, which is herein incorporated by reference.

Thus, for example, cells from a patient may be engineered with a polynucleotide (DNA or RNA) comprising a promoter operably linked to a polynucleotide of the invention *ex vivo*, with the engineered cells then being provided to a patient to be treated with the polypeptide. Such methods are well-known in the art. For example, see Beldegrun et al., J. Natl. Cancer Inst., 85:207-216 (1993); Ferrantini et al., Cancer Research, 53:107-1112 (1993); Ferrantini et al., J. Immunology 153: 4604-4615 (1994); Kaido, T., et al., Int. J. Cancer 60: 221-229 (1995); Ogura et al., Cancer Research 50: 5102-5106 (1990); Santodonato, et al., Human Gene Therapy 7:1-10 (1996); Santodonato, et al., Gene Therapy 4:1246-1255 (1997); and Zhang, et al., Cancer Gene Therapy 3: 31-38 (1996)), which are herein incorporated by reference. In one embodiment, the cells which are engineered are arterial cells. The arterial cells may be reintroduced into the patient through direct injection to the artery, the tissues surrounding the artery, or through catheter injection.

As discussed in more detail below, the polynucleotide constructs can be delivered by any method that delivers injectable materials to the cells of an animal, such as, injection into the interstitial space of tissues (heart, muscle, skin, lung, liver, and the like). The polynucleotide constructs may be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

In one embodiment, the polynucleotide of the invention is delivered as a naked polynucleotide. The term "naked" polynucleotide, DNA or RNA refers to sequences that are free from any delivery vehicle that acts to assist, promote or facilitate entry into the cell, including viral sequences, viral particles, liposome formulations,

lipofectin or precipitating agents and the like. However, the polynucleotides of the invention can also be delivered in liposome formulations and lipofectin formulations and the like can be prepared by methods well known to those skilled in the art. Such methods are described, for example, in U.S. Patent Nos. 5,593,972, 5,589,466, and  
5 5,580,859, which are herein incorporated by reference.

The polynucleotide vector constructs of the invention used in the gene therapy method are preferably constructs that will not integrate into the host genome nor will they contain sequences that allow for replication. Appropriate vectors include pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene;  
10 pSVK3, pBPV, pMSG and pSVL available from Pharmacia; and pEF1/V5, pcDNA3.1, and pRc/CMV2 available from Invitrogen. Other suitable vectors will be readily apparent to the skilled artisan.

Any strong promoter known to those skilled in the art can be used for driving the expression of polynucleotide sequence of the invention. Suitable promoters  
15 include adenoviral promoters, such as the adenoviral major late promoter; or heterologous promoters, such as the cytomegalovirus (CMV) promoter; the respiratory syncytial virus (RSV) promoter; inducible promoters, such as the MMT promoter, the metallothionein promoter; heat shock promoters; the albumin promoter; the ApoAI promoter; human globin promoters; viral thymidine kinase promoters,  
20 such as the Herpes Simplex thymidine kinase promoter; retroviral LTRs; the b-actin promoter; and human growth hormone promoters. The promoter also may be the native promoter for the polynucleotides of the invention.

Unlike other gene therapy techniques, one major advantage of introducing naked nucleic acid sequences into target cells is the transitory nature of the  
25 polynucleotide synthesis in the cells. Studies have shown that non-replicating DNA sequences can be introduced into cells to provide production of the desired polypeptide for periods of up to six months.

The polynucleotide construct of the invention can be delivered to the interstitial space of tissues within the an animal, including of muscle, skin, brain, lung, liver,  
30 spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, and connective tissue. Interstitial space of the tissues comprises the intercellular,



fluid, mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue ensheathing muscle cells or in the lacunae of bone. It is similarly the space occupied by the plasma of the circulation and the lymph  
5 fluid of the lymphatic channels. Delivery to the interstitial space of muscle tissue is preferred for the reasons discussed below. They may be conveniently delivered by injection into the tissues comprising these cells. They are preferably delivered to and expressed in persistent, non-dividing cells which are differentiated, although delivery and expression may be achieved in non-differentiated or less completely differentiated  
10 cells, such as, for example, stem cells of blood or skin fibroblasts. *In vivo* muscle cells are particularly competent in their ability to take up and express polynucleotides.

For the naked *nucleic acid* sequence injection, an effective dosage amount of DNA or RNA will be in the range of from about 0.05 mg/kg body weight to about 50 mg/kg body weight. Preferably the dosage will be from about 0.005 mg/kg to about 20  
15 mg/kg and more preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as the artisan of ordinary skill will appreciate, this dosage will vary according to the tissue site of injection. The appropriate and effective dosage of nucleic acid sequence can readily be determined by those of ordinary skill in the art and may depend on the condition being treated and the route of administration.

20 The preferred route of administration is by the parenteral route of injection into the interstitial space of tissues. However, other parenteral routes may also be used, such as, inhalation of an aerosol formulation particularly for delivery to lungs or bronchial tissues, throat or mucous membranes of the nose. In addition, naked DNA constructs can be delivered to arteries during angioplasty by the catheter used in the  
25 procedure.

The naked polynucleotides are delivered by any method known in the art, including, but not limited to, direct needle injection at the delivery site, intravenous injection, topical administration, catheter infusion, and so-called "gene guns". These delivery methods are known in the art.

30 The constructs may also be delivered with delivery vehicles such as viral sequences, viral particles, liposome formulations, lipofectin, precipitating agents, etc. Such methods of delivery are known in the art.

In certain embodiments, the polynucleotide constructs of the invention are complexed in a liposome preparation. Liposomal preparations for use in the instant invention include cationic (positively charged), anionic (negatively charged) and neutral preparations. However, cationic liposomes are particularly preferred because a  
5 tight charge complex can be formed between the cationic liposome and the polyanionic nucleic acid. Cationic liposomes have been shown to mediate intracellular delivery of plasmid DNA (Felgner et al., Proc. Natl. Acad. Sci. USA , 84:7413-7416 (1987), which is herein incorporated by reference); mRNA (Malone et al., Proc. Natl. Acad. Sci. USA , 86:6077-6081 (1989), which is herein incorporated  
10 by reference); and purified transcription factors (Debs et al., J. Biol. Chem., 265:10189-10192 (1990), which is herein incorporated by reference), in functional form.

Cationic liposomes are readily available. For example, N[1-2,3-dioleoyloxy)propyl]-N,N,N-triethylammonium (DOTMA) liposomes are  
15 particularly useful and are available under the trademark Lipofectin, from GIBCO BRL, Grand Island, N.Y. (See, also, Felgner et al., Proc. Natl Acad. Sci. USA , 84:7413-7416 (1987), which is herein incorporated by reference). Other commercially available liposomes include transfectace (DDAB/DOPE) and DOTAP/DOPE (Boehringer).

20 Other cationic liposomes can be prepared from readily available materials using techniques well known in the art. See, e.g. PCT Publication NO: WO 90/11092 (which is herein incorporated by reference) for a description of the synthesis of DOTAP (1,2-bis(oleoyloxy)-3-(trimethylammonio)propane) liposomes. Preparation of DOTMA liposomes is explained in the literature, see, e.g., Felgner et al., Proc.  
25 Natl. Acad. Sci. USA, 84:7413-7417, which is herein incorporated by reference. Similar methods can be used to prepare liposomes from other cationic lipid materials.

Similarly, anionic and neutral liposomes are readily available, such as from Avanti Polar Lipids (Birmingham, Ala.), or can be easily prepared using readily available materials. Such materials include phosphatidyl, choline, cholesterol,  
30 phosphatidyl ethanolamine, dioleoylphosphatidyl choline (DOPC), dioleoylphosphatidyl glycerol (DOPG), dioleoylphosphatidyl ethanolamine (DOPE), among others. These materials can also be mixed with the DOTMA and DOTAP

starting materials in appropriate ratios. Methods for making liposomes using these materials are well known in the art.

For example, commercially dioleoylphosphatidyl choline (DOPC),  
dioleoylphosphatidyl glycerol (DOPG), and dioleoylphosphatidyl ethanolamine  
5 (DOPE) can be used in various combinations to make conventional liposomes, with or  
without the addition of cholesterol. Thus, for example, DOPG/DOPC vesicles can be  
prepared by drying 50 mg each of DOPG and DOPC under a stream of nitrogen gas  
into a sonication vial. The sample is placed under a vacuum pump overnight and is  
hydrated the following day with deionized water. The sample is then sonicated for 2  
10 hours in a capped vial, using a Heat Systems model 350 sonicator equipped with an  
inverted cup (bath type) probe at the maximum setting while the bath is circulated at  
15EC. Alternatively, negatively charged vesicles can be prepared without sonication  
to produce multilamellar vesicles or by extrusion through nucleopore membranes to  
produce unilamellar vesicles of discrete size. Other methods are known and available  
15 to those of skill in the art.

The liposomes can comprise multilamellar vesicles (MLVs), small unilamellar  
vesicles (SUVs), or large unilamellar vesicles (LUVs), with SUVs being preferred.  
The various liposome-nucleic acid complexes are prepared using methods well known  
in the art. See, e.g., Straubinger et al., *Methods of Immunology*, 101:512-527 (1983),  
20 which is herein incorporated by reference. For example, MLVs containing nucleic  
acid can be prepared by depositing a thin film of phospholipid on the walls of a glass  
tube and subsequently hydrating with a solution of the material to be encapsulated.  
SUVs are prepared by extended sonication of MLVs to produce a homogeneous  
population of unilamellar liposomes. The material to be entrapped is added to a  
25 suspension of preformed MLVs and then sonicated. When using liposomes containing  
cationic lipids, the dried lipid film is resuspended in an appropriate solution such as  
sterile water or an isotonic buffer solution such as 10 mM Tris/NaCl, sonicated, and  
then the preformed liposomes are mixed directly with the DNA. The liposome and  
DNA form a very stable complex due to binding of the positively charged liposomes  
30 to the cationic DNA. SUVs find use with small nucleic acid fragments. LUVs are  
prepared by a number of methods, well known in the art. Commonly used methods  
include  $\text{Ca}^{2+}$ -EDTA chelation (Papahadjopoulos et al., *Biochim. Biophys. Acta*,

394:483 (1975); Wilson et al., Cell , 17:77 (1979)); ether injection (Deamer et al., Biochim. Biophys. Acta, 443:629 (1976); Ostro et al., Biochem. Biophys. Res. Commun., 76:836 (1977); Fraley et al., Proc. Natl. Acad. Sci. USA, 76:3348 (1979)); detergent dialysis (Enoch et al., Proc. Natl. Acad. Sci. USA , 76:145 (1979)); and  
5 reverse-phase evaporation (REV) (Fraley et al., J. Biol. Chem., 255:10431 (1980); Szoka et al., Proc. Natl. Acad. Sci. USA , 75:145 (1978); Schaefer-Ridder et al., Science, 215:166 (1982)), which are herein incorporated by reference.

Generally, the ratio of DNA to liposomes will be from about 10:1 to about 1:10. Preferably, the ration will be from about 5:1 to about 1:5. More preferably, the  
10 ration will be about 3:1 to about 1:3. Still more preferably, the ratio will be about 1:1.

U.S. Patent NO: 5,676,954 (which is herein incorporated by reference) reports on the injection of genetic material, complexed with cationic liposomes carriers, into mice. U.S. Patent Nos. 4,897,355, 4,946,787, 5,049,386, 5,459,127, 5,589,466, 5,693,622, 5,580,859, 5,703,055, and international publication NO: WO 94/9469  
15 (which are herein incorporated by reference) provide cationic lipids for use in transfecting DNA into cells and mammals. U.S. Patent Nos. 5,589,466, 5,693,622, 5,580,859, 5,703,055, and international publication NO: WO 94/9469 (which are herein incorporated by reference) provide methods for delivering DNA-cationic lipid complexes to mammals.

20 In certain embodiments, cells are engineered, *ex vivo* or *in vivo*, using a retroviral particle containing RNA which comprises a sequence encoding polypeptides of the invention. Retroviruses from which the retroviral plasmid vectors may be derived include, but are not limited to, Moloney Murine Leukemia Virus, spleen necrosis virus, Rous sarcoma Virus, Harvey Sarcoma Virus, avian leukosis  
25 virus, gibbon ape leukemia virus, human immunodeficiency virus, Myeloproliferative Sarcoma Virus, and mammary tumor virus.

The retroviral plasmid vector is employed to transduce packaging cell lines to form producer cell lines. Examples of packaging cells which may be transfected include, but are not limited to, the PE501, PA317, R-2, R-AM, PA12, T19-14X, VT-  
30 19-17-H2, RCRE, RCRIP, GP+E-86, GP+envAm12, and DAN cell lines as described in Miller, Human Gene Therapy , 1:5-14 (1990), which is incorporated herein by reference in its entirety. The vector may transduce the packaging cells through any

means known in the art. Such means include, but are not limited to, electroporation, the use of liposomes, and  $\text{CaPO}_4$  precipitation. In one alternative, the retroviral plasmid vector may be encapsulated into a liposome, or coupled to a lipid, and then administered to a host.

5           The producer cell line generates infectious retroviral vector particles which include polynucleotide encoding polypeptides of the invention. Such retroviral vector particles then may be employed, to transduce eukaryotic cells, either *in vitro* or *in vivo*. The transduced eukaryotic cells will express polypeptides of the invention.

          In certain other embodiments, cells are engineered, *ex vivo* or *in vivo*, with  
10   polynucleotides of the invention contained in an adenovirus vector. Adenovirus can be manipulated such that it encodes and expresses polypeptides of the invention, and at the same time is inactivated in terms of its ability to replicate in a normal lytic viral life cycle. Adenovirus expression is achieved without integration of the viral DNA  
15   into the host cell chromosome, thereby alleviating concerns about insertional mutagenesis. Furthermore, adenoviruses have been used as live enteric vaccines for many years with an excellent safety profile (Schwartz et al., Am. Rev. Respir. Dis., 109:233-238 (1974)). Finally, adenovirus mediated gene transfer has been  
20   demonstrated in a number of instances including transfer of alpha-1-antitrypsin and CFTR to the lungs of cotton rats (Rosenfeld et al., Science, 252:431-434 (1991); Rosenfeld et al., Cell, 68:143-155 (1992)). Furthermore, extensive studies to attempt to establish adenovirus as a causative agent in human cancer were uniformly negative (Green et al. Proc. Natl. Acad. Sci. USA, 76:6606 (1979)).

          Suitable adenoviral vectors useful in the present invention are described, for example, in Kozarsky and Wilson, Curr. Opin. Genet. Devel., 3:499-503 (1993);  
25   Rosenfeld et al., Cell, 68:143-155 (1992); Engelhardt et al., Human Genet. Ther., 4:759-769 (1993); Yang et al., Nature Genet., 7:362-369 (1994); Wilson et al., Nature, 365:691-692 (1993); and U.S. Patent NO: 5,652,224, which are herein incorporated by reference. For example, the adenovirus vector Ad2 is useful and can be grown in human 293 cells. These cells contain the E1 region of adenovirus and  
30   constitutively express Ela and Elb, which complement the defective adenoviruses by providing the products of the genes deleted from the vector. In addition to Ad2, other

varieties of adenovirus (e.g., Ad3, Ad5, and Ad7) are also useful in the present invention.

Preferably, the adenoviruses used in the present invention are replication deficient. Replication deficient adenoviruses require the aid of a helper virus and/or packaging cell line to form infectious particles. The resulting virus is capable of infecting cells and can express a polynucleotide of interest which is operably linked to a promoter, but cannot replicate in most cells. Replication deficient adenoviruses may be deleted in one or more of all or a portion of the following genes: E1a, E1b, E3, E4, E2a, or L1 through L5.

In certain other embodiments, the cells are engineered, *ex vivo* or *in vivo*, using an adeno-associated virus (AAV). AAVs are naturally occurring defective viruses that require helper viruses to produce infectious particles (Muzyczka, Curr. Topics in Microbiol. Immunol., 158:97 (1992)). It is also one of the few viruses that may integrate its DNA into non-dividing cells. Vectors containing as little as 300 base pairs of AAV can be packaged and can integrate, but space for exogenous DNA is limited to about 4.5 kb. Methods for producing and using such AAVs are known in the art. See, for example, U.S. Patent Nos. 5,139,941, 5,173,414, 5,354,678, 5,436,146, 5,474,935, 5,478,745, and 5,589,377.

For example, an appropriate AAV vector for use in the present invention will include all the sequences necessary for DNA replication, encapsidation, and host-cell integration. The polynucleotide construct containing polynucleotides of the invention is inserted into the AAV vector using standard cloning methods, such as those found in Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press (1989). The recombinant AAV vector is then transfected into packaging cells which are infected with a helper virus, using any standard technique, including lipofection, electroporation, calcium phosphate precipitation, etc. Appropriate helper viruses include adenoviruses, cytomegaloviruses, vaccinia viruses, or herpes viruses. Once the packaging cells are transfected and infected, they will produce infectious AAV viral particles which contain the polynucleotide construct of the invention.

These viral particles are then used to transduce eukaryotic cells, either *ex vivo* or *in vivo*. The transduced cells will contain the polynucleotide construct integrated into its genome, and will express the desired gene product.

Another method of gene therapy involves operably associating heterologous control regions and endogenous polynucleotide sequences (e.g. encoding the polypeptide sequence of interest) via homologous recombination (see, e.g., U.S. Patent NO: 5,641,670, issued June 24, 1997; International Publication NO: WO 96/29411, published September 26, 1996; International Publication NO: WO 94/12650, published August 4, 1994; Koller et al., Proc. Natl. Acad. Sci. USA, 86:8932-8935 (1989); and Zijlstra et al., Nature, 342:435-438 (1989). This method involves the activation of a gene which is present in the target cells, but which is not normally expressed in the cells, or is expressed at a lower level than desired.

Polynucleotide constructs are made, using standard techniques known in the art, which contain the promoter with targeting sequences flanking the promoter. Suitable promoters are described herein. The targeting sequence is sufficiently complementary to an endogenous sequence to permit homologous recombination of the promoter-targeting sequence with the endogenous sequence. The targeting sequence will be sufficiently near the 5' end of the desired endogenous polynucleotide sequence so the promoter will be operably linked to the endogenous sequence upon homologous recombination.

The promoter and the targeting sequences can be amplified using PCR. Preferably, the amplified promoter contains distinct restriction enzyme sites on the 5' and 3' ends. Preferably, the 3' end of the first targeting sequence contains the same restriction enzyme site as the 5' end of the amplified promoter and the 5' end of the second targeting sequence contains the same restriction site as the 3' end of the amplified promoter. The amplified promoter and targeting sequences are digested and ligated together.

The promoter-targeting sequence construct is delivered to the cells, either as naked polynucleotide, or in conjunction with transfection-facilitating agents, such as liposomes, viral sequences, viral particles, whole viruses, lipofection, precipitating agents, etc., described in more detail above. The P promoter-targeting sequence can be delivered by any method, included direct needle injection, intravenous injection, topical administration, catheter infusion, particle accelerators, etc. The methods are described in more detail below.

The promoter-targeting sequence construct is taken up by cells. Homologous recombination between the construct and the endogenous sequence takes place, such that an endogenous sequence is placed under the control of the promoter. The promoter then drives the expression of the endogenous sequence.

5           The polynucleotides encoding polypeptides of the present invention may be administered along with other polynucleotides encoding other angiogenic proteins. Angiogenic proteins include, but are not limited to, acidic and basic fibroblast growth factors, VEGF-1, VEGF-2 (VEGF-C), VEGF-3 (VEGF-B), epidermal growth factor alpha and beta, platelet-derived endothelial cell growth factor, platelet-derived growth  
10 factor, tumor necrosis factor alpha, hepatocyte growth factor, insulin like growth factor, colony stimulating factor, macrophage colony stimulating factor, granulocyte/macrophage colony stimulating factor, and nitric oxide synthase.

          Preferably, the polynucleotide encoding a polypeptide of the invention contains a secretory signal sequence that facilitates secretion of the protein.  
15       Typically, the signal sequence is positioned in the coding region of the polynucleotide to be expressed towards or at the 5' end of the coding region. The signal sequence may be homologous or heterologous to the polynucleotide of interest and may be homologous or heterologous to the cells to be transfected. Additionally, the signal sequence may be chemically synthesized using methods known in the art.

20           Any mode of administration of any of the above-described polynucleotides constructs can be used so long as the mode results in the expression of one or more molecules in an amount sufficient to provide a therapeutic effect. This includes direct needle injection, systemic injection, catheter infusion, biolistic injectors, particle accelerators (i.e., "gene guns"), gelfoam sponge depots, other commercially available  
25 depot materials, osmotic pumps (e.g., Alza minipumps), oral or suppositorial solid (tablet or pill) pharmaceutical formulations, and decanting or topical applications during surgery. For example, direct injection of naked calcium phosphate-precipitated plasmid into rat liver and rat spleen or a protein-coated plasmid into the portal vein has resulted in gene expression of the foreign gene in the  
30 rat livers. (Kaneda et al., Science, 243:375 (1989)).

          A preferred method of local administration is by direct injection. Preferably, a recombinant molecule of the present invention complexed with a delivery vehicle is



administered by direct injection into or locally within the area of arteries.

Administration of a composition locally within the area of arteries refers to injecting the composition centimeters and preferably, millimeters within arteries.

Another method of local administration is to contact a polynucleotide  
5 construct of the present invention in or around a surgical wound. For example, a patient can undergo surgery and the polynucleotide construct can be coated on the surface of tissue inside the wound or the construct can be injected into areas of tissue inside the wound.

Therapeutic compositions useful in systemic administration, include  
10 recombinant molecules of the present invention complexed to a targeted delivery vehicle of the present invention. Suitable delivery vehicles for use with systemic administration comprise liposomes comprising ligands for targeting the vehicle to a particular site.

Preferred methods of systemic administration, include intravenous injection,  
15 aerosol, oral and percutaneous (topical) delivery. Intravenous injections can be performed using methods standard in the art. Aerosol delivery can also be performed using methods standard in the art (see, for example, Stribling et al., Proc. Natl. Acad. Sci. USA, 189:11277-11281 (1992), which is incorporated herein by reference). Oral delivery can be performed by complexing a polynucleotide construct of the present  
20 invention to a carrier capable of withstanding degradation by digestive enzymes in the gut of an animal. Examples of such carriers, include plastic capsules or tablets, such as those known in the art. Topical delivery can be performed by mixing a polynucleotide construct of the present invention with a lipophilic reagent (e.g., DMSO) that is capable of passing into the skin.

25 Determining an effective amount of substance to be delivered can depend upon a number of factors including, for example, the chemical structure and biological activity of the substance, the age and weight of the animal, the precise condition requiring treatment and its severity, and the route of administration. The frequency of treatments depends upon a number of factors, such as the amount of  
30 polynucleotide constructs administered per dose, as well as the health and history of the subject. The precise amount, number of doses, and timing of doses will be determined by the attending physician or veterinarian. Therapeutic compositions of

the present invention can be administered to any animal, preferably to mammals and birds. Preferred mammals include humans, dogs, cats, mice, rats, rabbits sheep, cattle, horses and pigs, with humans being particularly

## 5 **Biological Activities**

The polynucleotides or polypeptides, or agonists or antagonists of the present invention can be used in assays to test for one or more biological activities. If these polynucleotides and polypeptides do exhibit activity in a particular assay, it is likely that these molecules may be involved in the diseases associated with the biological  
10 activity. Thus, the polynucleotides or polypeptides, or agonists or antagonists could be used to treat the associated disease.

## **Immune Activity**

The polynucleotides or polypeptides, or agonists or antagonists of the present  
15 invention may be useful in treating deficiencies or disorders of the immune system, by activating or inhibiting the proliferation, differentiation, or mobilization (chemotaxis) of immune cells. Immune cells develop through a process called hematopoiesis, producing myeloid (platelets, red blood cells, neutrophils, and macrophages) and lymphoid (B and T lymphocytes) cells from pluripotent stem cells.  
20 The etiology of these immune deficiencies or disorders may be genetic, somatic, such as cancer or some autoimmune disorders, acquired (e.g., by chemotherapy or toxins), or infectious. Moreover, a polynucleotides or polypeptides, or agonists or antagonists of the present invention can be used as a marker or detector of a particular immune system disease or disorder.

25 A polynucleotides or polypeptides, or agonists or antagonists of the present invention may be useful in treating or detecting deficiencies or disorders of hematopoietic cells. A polynucleotides or polypeptides, or agonists or antagonists of the present invention could be used to increase differentiation and proliferation of hematopoietic cells, including the pluripotent stem cells, in an effort to treat those  
30 disorders associated with a decrease in certain (or many) types hematopoietic cells. Examples of immunologic deficiency syndromes include, but are not limited to: blood protein disorders (e.g. agammaglobulinemia, dysgammaglobulinemia), ataxia

telangiectasia, common variable immunodeficiency, Digeorge Syndrome, HIV infection, HTLV-BLV infection, leukocyte adhesion deficiency syndrome, lymphopenia, phagocyte bactericidal dysfunction, severe combined immunodeficiency (SCIDs), Wiskott-Aldrich Disorder, anemia, thrombocytopenia, or hemoglobinuria.

Moreover, a polynucleotides or polypeptides, or agonists or antagonists of the present invention could also be used to modulate hemostatic (the stopping of bleeding) or thrombolytic activity (clot formation). For example, by increasing hemostatic or thrombolytic activity, a polynucleotides or polypeptides, or agonists or antagonists of the present invention could be used to treat blood coagulation disorders (e.g., afibrinogenemia, factor deficiencies), blood platelet disorders (e.g. thrombocytopenia), or wounds resulting from trauma, surgery, or other causes. Alternatively, a polynucleotides or polypeptides, or agonists or antagonists of the present invention that can decrease hemostatic or thrombolytic activity could be used to inhibit or dissolve clotting. These molecules could be important in the treatment of heart attacks (infarction), strokes, or scarring.

A polynucleotides or polypeptides, or agonists or antagonists of the present invention may also be useful in treating or detecting autoimmune disorders. Many autoimmune disorders result from inappropriate recognition of self as foreign material by immune cells. This inappropriate recognition results in an immune response leading to the destruction of the host tissue. Therefore, the administration of a polynucleotides or polypeptides, or agonists or antagonists of the present invention that inhibits an immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing autoimmune disorders.

Examples of autoimmune disorders that can be treated or detected by the present invention include, but are not limited to: Addison's Disease, hemolytic anemia, antiphospholipid syndrome, rheumatoid arthritis, dermatitis, allergic encephalomyelitis, glomerulonephritis, Goodpasture's Syndrome, Graves' Disease, Multiple Sclerosis, Myasthenia Gravis, Neuritis, Ophthalmia, Bullous Pemphigoid, Pemphigus, Polyendocrinopathies, Purpura, Reiter's Disease, Stiff-Man Syndrome, Autoimmune Thyroiditis, Systemic Lupus Erythematosus, Autoimmune Pulmonary

Inflammation, Guillain-Barre Syndrome, insulin dependent diabetes mellitus, and autoimmune inflammatory eye disease.

Similarly, allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems, may also be treated by a  
5 polynucleotides or polypeptides, or agonists or antagonists of the present invention. Moreover, these molecules can be used to treat anaphylaxis, hypersensitivity to an antigenic molecule, or blood group incompatibility.

A polynucleotides or polypeptides, or agonists or antagonists of the present invention may also be used to treat and/or prevent organ rejection or graft-versus-host  
10 disease (GVHD). Organ rejection occurs by host immune cell destruction of the transplanted tissue through an immune response. Similarly, an immune response is also involved in GVHD, but, in this case, the foreign transplanted immune cells destroy the host tissues. The administration of a polynucleotides or polypeptides, or agonists or antagonists of the present invention that inhibits an immune response,  
15 particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing organ rejection or GVHD.

Similarly, a polynucleotides or polypeptides, or agonists or antagonists of the present invention may also be used to modulate inflammation. For example, the polypeptide or polynucleotide or agonists  
20 or antagonist may inhibit the proliferation and differentiation of cells involved in an inflammatory response. These molecules can be used to treat inflammatory conditions, both chronic and acute conditions, including inflammation associated with infection (e.g., septic shock, sepsis, or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-  
25 mediated hyperacute rejection, nephritis, cytokine or chemokine induced lung injury, inflammatory bowel disease, Crohn's disease, or resulting from over production of cytokines (e.g., TNF or IL-1.)

### **Hyperproliferative Disorders**

30 A polynucleotides or polypeptides, or agonists or antagonists of the invention can be used to treat or detect hyperproliferative disorders, including neoplasms. A polynucleotides or polypeptides, or agonists or antagonists of the present invention

may inhibit the proliferation of the disorder through direct or indirect interactions. Alternatively, a polynucleotides or polypeptides, or agonists or antagonists of the present invention may proliferate other cells which can inhibit the hyperproliferative disorder.

5           For example, by increasing an immune response, particularly increasing antigenic qualities of the hyperproliferative disorder or by proliferating, differentiating, or mobilizing T-cells, hyperproliferative disorders can be treated. This immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, decreasing an  
10   immune response may also be a method of treating hyperproliferative disorders, such as a chemotherapeutic agent.

          Examples of hyperproliferative disorders that can be treated or detected by a polynucleotides or polypeptides, or agonists or antagonists of the present invention include, but are not limited to neoplasms located in the: abdomen, bone, breast,  
15   digestive system, liver, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), eye, head and neck, nervous (central and peripheral), lymphatic system, pelvic, skin, soft tissue, spleen, thoracic, and urogenital.

          Similarly, other hyperproliferative disorders can also be treated or detected by  
20   a polynucleotides or polypeptides, or agonists or antagonists of the present invention. Examples of such hyperproliferative disorders include, but are not limited to: hypergammaglobulinemia, lymphoproliferative disorders, paraproteinemias, purpura, sarcoidosis, Sezary Syndrome, Waldenstrom's Macroglobulinemia, Gaucher's Disease, histiocytosis, and any other hyperproliferative disease, besides neoplasia,  
25   located in an organ system listed above.

          One preferred embodiment utilizes polynucleotides of the present invention to inhibit aberrant cellular division, by gene therapy using the present invention, and/or protein fusions or fragments thereof.

          Thus, the present invention provides a method for treating cell proliferative  
30   disorders by inserting into an abnormally proliferating cell a polynucleotide of the present invention, wherein said polynucleotide represses said expression.

Another embodiment of the present invention provides a method of treating cell-proliferative disorders in individuals comprising administration of one or more active gene copies of the present invention to an abnormally proliferating cell or cells. In a preferred embodiment, polynucleotides of the present invention is a DNA construct comprising a recombinant expression vector effective in expressing a DNA sequence encoding said polynucleotides. In another preferred embodiment of the present invention, the DNA construct encoding the polynucleotides of the present invention is inserted into cells to be treated utilizing a retrovirus, or more preferably an adenoviral vector (See G J. Nabel, et. al., PNAS 1999 96: 324-326, which is hereby incorporated by reference). In a most preferred embodiment, the viral vector is defective and will not transform non-proliferating cells, only proliferating cells. Moreover, in a preferred embodiment, the polynucleotides of the present invention inserted into proliferating cells either alone, or in combination with or fused to other polynucleotides, can then be modulated via an external stimulus (i.e. magnetic, specific small molecule, chemical, or drug administration, etc.), which acts upon the promoter upstream of said polynucleotides to induce expression of the encoded protein product. As such the beneficial therapeutic affect of the present invention may be expressly modulated (i.e. to increase, decrease, or inhibit expression of the present invention) based upon said external stimulus.

Polynucleotides of the present invention may be useful in repressing expression of oncogenic genes or antigens. By "repressing expression of the oncogenic genes " is intended the suppression of the transcription of the gene, the degradation of the gene transcript (pre-message RNA), the inhibition of splicing, the destruction of the messenger RNA, the prevention of the post-translational modifications of the protein, the destruction of the protein, or the inhibition of the normal function of the protein.

For local administration to abnormally proliferating cells, polynucleotides of the present invention may be administered by any method known to those of skill in the art including, but not limited to transfection, electroporation, microinjection of cells, or in vehicles such as liposomes, lipofectin, or as naked polynucleotides, or any other method described throughout the specification. The polynucleotide of the present invention may be delivered by known gene delivery systems such as, but not

limited to, retroviral vectors (Gilboa, J. Virology 44:845 (1982); Hocke, Nature 320:275 (1986); Wilson, et al., Proc. Natl. Acad. Sci. U.S.A. 85:3014), vaccinia virus system (Chakrabarty et al., Mol. Cell Biol. 5:3403 (1985) or other efficient DNA delivery systems (Yates et al., Nature 313:812 (1985)) known to those skilled in the art. These references are exemplary only and are hereby incorporated by reference. In order to specifically deliver or transfect cells which are abnormally proliferating and spare non-dividing cells, it is preferable to utilize a retrovirus, or adenoviral (as described in the art and elsewhere herein) delivery system known to those of skill in the art. Since host DNA replication is required for retroviral DNA to integrate and the retrovirus will be unable to self replicate due to the lack of the retrovirus genes needed for its life cycle. Utilizing such a retroviral delivery system for polynucleotides of the present invention will target said gene and constructs to abnormally proliferating cells and will spare the non-dividing normal cells.

The polynucleotides of the present invention may be delivered directly to cell proliferative disorder/disease sites in internal organs, body cavities and the like by use of imaging devices used to guide an injecting needle directly to the disease site. The polynucleotides of the present invention may also be administered to disease sites at the time of surgical intervention.

By "cell proliferative disease" is meant any human or animal disease or disorder, affecting any one or any combination of organs, cavities, or body parts, which is characterized by single or multiple local abnormal proliferations of cells, groups of cells, or tissues, whether benign or malignant.

Any amount of the polynucleotides of the present invention may be administered as long as it has a biologically inhibiting effect on the proliferation of the treated cells. Moreover, it is possible to administer more than one of the polynucleotide of the present invention simultaneously to the same site. By "biologically inhibiting" is meant partial or total growth inhibition as well as decreases in the rate of proliferation or growth of the cells. The biologically inhibitory dose may be determined by assessing the effects of the polynucleotides of the present invention on target malignant or abnormally proliferating cell growth in tissue culture, tumor growth in animals and cell cultures, or any other method known to one of ordinary skill in the art.

The present invention is further directed to antibody-based therapies which involve administering of anti-polypeptides and anti-polynucleotide antibodies to a mammalian, preferably human, patient for treating one or more of the described disorders. Methods for producing anti-polypeptides and anti-polynucleotide antibodies polyclonal and monoclonal antibodies are described in detail elsewhere  
5      herein. Such antibodies may be provided in pharmaceutically acceptable compositions as known in the art or as described herein.

A summary of the ways in which the antibodies of the present invention may be used therapeutically includes binding polynucleotides or polypeptides of the present invention locally or systemically in the body or by direct cytotoxicity of the  
10     antibody, e.g. as mediated by complement (CDC) or by effector cells (ADCC). Some of these approaches are described in more detail below. Armed with the teachings provided herein, one of ordinary skill in the art will know how to use the antibodies of the present invention for diagnostic, monitoring or therapeutic purposes without  
15     undue experimentation.

In particular, the antibodies, fragments and derivatives of the present invention are useful for treating a subject having or developing cell proliferative and/or differentiation disorders as described herein. Such treatment comprises administering a single or multiple doses of the antibody, or a fragment, derivative, or a conjugate  
20     thereof.

The antibodies of this invention may be advantageously utilized in combination with other monoclonal or chimeric antibodies, or with lymphokines or hematopoietic growth factors, for example, which serve to increase the number or activity of effector cells which interact with the antibodies.

It is preferred to use high affinity and/or potent in vivo inhibiting and/or neutralizing antibodies against polypeptides or polynucleotides of the present invention, fragments or regions thereof, for both immunoassays directed to and therapy of disorders related to polynucleotides or polypeptides, including fragments thereof, of the present invention. Such antibodies, fragments, or regions, will  
25     preferably have an affinity for polynucleotides or polypeptides, including fragments thereof. Preferred binding affinities include those with a dissociation constant or  $K_d$  less than  $5 \times 10^{-6}M$ ,  $10^{-6}M$ ,  $5 \times 10^{-7}M$ ,  $10^{-7}M$ ,  $5 \times 10^{-8}M$ ,  $10^{-8}M$ ,  $5 \times 10^{-9}M$ ,  $10^{-9}M$ ,  $5 \times 10^{-10}M$ ,  $10^{-10}M$ ,  $5 \times 10^{-11}M$ ,  $10^{-11}M$ ,  $5 \times 10^{-12}M$ ,  $10^{-12}M$ ,  $5 \times 10^{-13}M$ ,  $10^{-13}M$ ,  $5 \times 10^{-14}M$ ,  $10^{-14}M$ ,  $5 \times 10^{-15}M$ ,  $10^{-15}M$ ,  $5 \times 10^{-16}M$ ,  $10^{-16}M$ ,  $5 \times 10^{-17}M$ ,  $10^{-17}M$ ,  $5 \times 10^{-18}M$ ,  $10^{-18}M$ ,  $5 \times 10^{-19}M$ ,  $10^{-19}M$ ,  $5 \times 10^{-20}M$ ,  $10^{-20}M$ ,  $5 \times 10^{-21}M$ ,  $10^{-21}M$ ,  $5 \times 10^{-22}M$ ,  $10^{-22}M$ ,  $5 \times 10^{-23}M$ ,  $10^{-23}M$ ,  $5 \times 10^{-24}M$ ,  $10^{-24}M$ ,  $5 \times 10^{-25}M$ ,  $10^{-25}M$ ,  $5 \times 10^{-26}M$ ,  $10^{-26}M$ ,  $5 \times 10^{-27}M$ ,  $10^{-27}M$ ,  $5 \times 10^{-28}M$ ,  $10^{-28}M$ ,  $5 \times 10^{-29}M$ ,  $10^{-29}M$ ,  $5 \times 10^{-30}M$ ,  $10^{-30}M$ ,  $5 \times 10^{-31}M$ ,  $10^{-31}M$ ,  $5 \times 10^{-32}M$ ,  $10^{-32}M$ ,  $5 \times 10^{-33}M$ ,  $10^{-33}M$ ,  $5 \times 10^{-34}M$ ,  $10^{-34}M$ ,  $5 \times 10^{-35}M$ ,  $10^{-35}M$ ,  $5 \times 10^{-36}M$ ,  $10^{-36}M$ ,  $5 \times 10^{-37}M$ ,  $10^{-37}M$ ,  $5 \times 10^{-38}M$ ,  $10^{-38}M$ ,  $5 \times 10^{-39}M$ ,  $10^{-39}M$ ,  $5 \times 10^{-40}M$ ,  $10^{-40}M$ ,  $5 \times 10^{-41}M$ ,  $10^{-41}M$ ,  $5 \times 10^{-42}M$ ,  $10^{-42}M$ ,  $5 \times 10^{-43}M$ ,  $10^{-43}M$ ,  $5 \times 10^{-44}M$ ,  $10^{-44}M$ ,  $5 \times 10^{-45}M$ ,  $10^{-45}M$ ,  $5 \times 10^{-46}M$ ,  $10^{-46}M$ ,  $5 \times 10^{-47}M$ ,  $10^{-47}M$ ,  $5 \times 10^{-48}M$ ,  $10^{-48}M$ ,  $5 \times 10^{-49}M$ ,  $10^{-49}M$ ,  $5 \times 10^{-50}M$ ,  $10^{-50}M$ ,  $5 \times 10^{-51}M$ ,  $10^{-51}M$ ,  $5 \times 10^{-52}M$ ,  $10^{-52}M$ ,  $5 \times 10^{-53}M$ ,  $10^{-53}M$ ,  $5 \times 10^{-54}M$ ,  $10^{-54}M$ ,  $5 \times 10^{-55}M$ ,  $10^{-55}M$ ,  $5 \times 10^{-56}M$ ,  $10^{-56}M$ ,  $5 \times 10^{-57}M$ ,  $10^{-57}M$ ,  $5 \times 10^{-58}M$ ,  $10^{-58}M$ ,  $5 \times 10^{-59}M$ ,  $10^{-59}M$ ,  $5 \times 10^{-60}M$ ,  $10^{-60}M$ ,  $5 \times 10^{-61}M$ ,  $10^{-61}M$ ,  $5 \times 10^{-62}M$ ,  $10^{-62}M$ ,  $5 \times 10^{-63}M$ ,  $10^{-63}M$ ,  $5 \times 10^{-64}M$ ,  $10^{-64}M$ ,  $5 \times 10^{-65}M$ ,  $10^{-65}M$ ,  $5 \times 10^{-66}M$ ,  $10^{-66}M$ ,  $5 \times 10^{-67}M$ ,  $10^{-67}M$ ,  $5 \times 10^{-68}M$ ,  $10^{-68}M$ ,  $5 \times 10^{-69}M$ ,  $10^{-69}M$ ,  $5 \times 10^{-70}M$ ,  $10^{-70}M$ ,  $5 \times 10^{-71}M$ ,  $10^{-71}M$ ,  $5 \times 10^{-72}M$ ,  $10^{-72}M$ ,  $5 \times 10^{-73}M$ ,  $10^{-73}M$ ,  $5 \times 10^{-74}M$ ,  $10^{-74}M$ ,  $5 \times 10^{-75}M$ ,  $10^{-75}M$ ,  $5 \times 10^{-76}M$ ,  $10^{-76}M$ ,  $5 \times 10^{-77}M$ ,  $10^{-77}M$ ,  $5 \times 10^{-78}M$ ,  $10^{-78}M$ ,  $5 \times 10^{-79}M$ ,  $10^{-79}M$ ,  $5 \times 10^{-80}M$ ,  $10^{-80}M$ ,  $5 \times 10^{-81}M$ ,  $10^{-81}M$ ,  $5 \times 10^{-82}M$ ,  $10^{-82}M$ ,  $5 \times 10^{-83}M$ ,  $10^{-83}M$ ,  $5 \times 10^{-84}M$ ,  $10^{-84}M$ ,  $5 \times 10^{-85}M$ ,  $10^{-85}M$ ,  $5 \times 10^{-86}M$ ,  $10^{-86}M$ ,  $5 \times 10^{-87}M$ ,  $10^{-87}M$ ,  $5 \times 10^{-88}M$ ,  $10^{-88}M$ ,  $5 \times 10^{-89}M$ ,  $10^{-89}M$ ,  $5 \times 10^{-90}M$ ,  $10^{-90}M$ ,  $5 \times 10^{-91}M$ ,  $10^{-91}M$ ,  $5 \times 10^{-92}M$ ,  $10^{-92}M$ ,  $5 \times 10^{-93}M$ ,  $10^{-93}M$ ,  $5 \times 10^{-94}M$ ,  $10^{-94}M$ ,  $5 \times 10^{-95}M$ ,  $10^{-95}M$ ,  $5 \times 10^{-96}M$ ,  $10^{-96}M$ ,  $5 \times 10^{-97}M$ ,  $10^{-97}M$ ,  $5 \times 10^{-98}M$ ,  $10^{-98}M$ ,  $5 \times 10^{-99}M$ ,  $10^{-99}M$ ,  $5 \times 10^{-100}M$ ,  $10^{-100}M$ ,  $5 \times 10^{-101}M$ ,  $10^{-101}M$ ,  $5 \times 10^{-102}M$ ,  $10^{-102}M$ ,  $5 \times 10^{-103}M$ ,  $10^{-103}M$ ,  $5 \times 10^{-104}M$ ,  $10^{-104}M$ ,  $5 \times 10^{-105}M$ ,  $10^{-105}M$ ,  $5 \times 10^{-106}M$ ,  $10^{-106}M$ ,  $5 \times 10^{-107}M$ ,  $10^{-107}M$ ,  $5 \times 10^{-108}M$ ,  $10^{-108}M$ ,  $5 \times 10^{-109}M$ ,  $10^{-109}M$ ,  $5 \times 10^{-110}M$ ,  $10^{-110}M$ ,  $5 \times 10^{-111}M$ ,  $10^{-111}M$ ,  $5 \times 10^{-112}M$ ,  $10^{-112}M$ ,  $5 \times 10^{-113}M$ ,  $10^{-113}M$ ,  $5 \times 10^{-114}M$ ,  $10^{-114}M$ ,  $5 \times 10^{-115}M$ ,  $10^{-115}M$ ,  $5 \times 10^{-116}M$ ,  $10^{-116}M$ ,  $5 \times 10^{-117}M$ ,  $10^{-117}M$ ,  $5 \times 10^{-118}M$ ,  $10^{-118}M$ ,  $5 \times 10^{-119}M$ ,  $10^{-119}M$ ,  $5 \times 10^{-120}M$ ,  $10^{-120}M$ ,  $5 \times 10^{-121}M$ ,  $10^{-121}M$ ,  $5 \times 10^{-122}M$ ,  $10^{-122}M$ ,  $5 \times 10^{-123}M$ ,  $10^{-123}M$ ,  $5 \times 10^{-124}M$ ,  $10^{-124}M$ ,  $5 \times 10^{-125}M$ ,  $10^{-125}M$ ,  $5 \times 10^{-126}M$ ,  $10^{-126}M$ ,  $5 \times 10^{-127}M$ ,  $10^{-127}M$ ,  $5 \times 10^{-128}M$ ,  $10^{-128}M$ ,  $5 \times 10^{-129}M$ ,  $10^{-129}M$ ,  $5 \times 10^{-130}M$ ,  $10^{-130}M$ ,  $5 \times 10^{-131}M$ ,  $10^{-131}M$ ,  $5 \times 10^{-132}M$ ,  $10^{-132}M$ ,  $5 \times 10^{-133}M$ ,  $10^{-133}M$ ,  $5 \times 10^{-134}M$ ,  $10^{-134}M$ ,  $5 \times 10^{-135}M$ ,  $10^{-135}M$ ,  $5 \times 10^{-136}M$ ,  $10^{-136}M$ ,  $5 \times 10^{-137}M$ ,  $10^{-137}M$ ,  $5 \times 10^{-138}M$ ,  $10^{-138}M$ ,  $5 \times 10^{-139}M$ ,  $10^{-139}M$ ,  $5 \times 10^{-140}M$ ,  $10^{-140}M$ ,  $5 \times 10^{-141}M$ ,  $10^{-141}M$ ,  $5 \times 10^{-142}M$ ,  $10^{-142}M$ ,  $5 \times 10^{-143}M$ ,  $10^{-143}M$ ,  $5 \times 10^{-144}M$ ,  $10^{-144}M$ ,  $5 \times 10^{-145}M$ ,  $10^{-145}M$ ,  $5 \times 10^{-146}M$ ,  $10^{-146}M$ ,  $5 \times 10^{-147}M$ ,  $10^{-147}M$ ,  $5 \times 10^{-148}M$ ,  $10^{-148}M$ ,  $5 \times 10^{-149}M$ ,  $10^{-149}M$ ,  $5 \times 10^{-150}M$ ,  $10^{-150}M$ ,  $5 \times 10^{-151}M$ ,  $10^{-151}M$ ,  $5 \times 10^{-152}M$ ,  $10^{-152}M$ ,  $5 \times 10^{-153}M$ ,  $10^{-153}M$ ,  $5 \times 10^{-154}M$ ,  $10^{-154}M$ ,  $5 \times 10^{-155}M$ ,  $10^{-155}M$ ,  $5 \times 10^{-156}M$ ,  $10^{-156}M$ ,  $5 \times 10^{-157}M$ ,  $10^{-157}M$ ,  $5 \times 10^{-158}M$ ,  $10^{-158}M$ ,  $5 \times 10^{-159}M$ ,  $10^{-159}M$ ,  $5 \times 10^{-160}M$ ,  $10^{-160}M$ ,  $5 \times 10^{-161}M$ ,  $10^{-161}M$ ,  $5 \times 10^{-162}M$ ,  $10^{-162}M$ ,  $5 \times 10^{-163}M$ ,  $10^{-163}M$ ,  $5 \times 10^{-164}M$ ,  $10^{-164}M$ ,  $5 \times 10^{-165}M$ ,  $10^{-165}M$ ,  $5 \times 10^{-166}M$ ,  $10^{-166}M$ ,  $5 \times 10^{-167}M$ ,  $10^{-167}M$ ,  $5 \times 10^{-168}M$ ,  $10^{-168}M$ ,  $5 \times 10^{-169}M$ ,  $10^{-169}M$ ,  $5 \times 10^{-170}M$ ,  $10^{-170}M$ ,  $5 \times 10^{-171}M$ ,  $10^{-171}M$ ,  $5 \times 10^{-172}M$ ,  $10^{-172}M$ ,  $5 \times 10^{-173}M$ ,  $10^{-173}M$ ,  $5 \times 10^{-174}M$ ,  $10^{-174}M$ ,  $5 \times 10^{-175}M$ ,  $10^{-175}M$ ,  $5 \times 10^{-176}M$ ,  $10^{-176}M$ ,  $5 \times 10^{-177}M$ ,  $10^{-177}M$ ,  $5 \times 10^{-178}M$ ,  $10^{-178}M$ ,  $5 \times 10^{-179}M$ ,  $10^{-179}M$ ,  $5 \times 10^{-180}M$ ,  $10^{-180}M$ ,  $5 \times 10^{-181}M$ ,  $10^{-181}M$ ,  $5 \times 10^{-182}M$ ,  $10^{-182}M$ ,  $5 \times 10^{-183}M$ ,  $10^{-183}M$ ,  $5 \times 10^{-184}M$ ,  $10^{-184}M$ ,  $5 \times 10^{-185}M$ ,  $10^{-185}M$ ,  $5 \times 10^{-186}M$ ,  $10^{-186}M$ ,  $5 \times 10^{-187}M$ ,  $10^{-187}M$ ,  $5 \times 10^{-188}M$ ,  $10^{-188}M$ ,  $5 \times 10^{-189}M$ ,  $10^{-189}M$ ,  $5 \times 10^{-190}M$ ,  $10^{-190}M$ ,  $5 \times 10^{-191}M$ ,  $10^{-191}M$ ,  $5 \times 10^{-192}M$ ,  $10^{-192}M$ ,  $5 \times 10^{-193}M$ ,  $10^{-193}M$ ,  $5 \times 10^{-194}M$ ,  $10^{-194}M$ ,  $5 \times 10^{-195}M$ ,  $10^{-195}M$ ,  $5 \times 10^{-196}M$ ,  $10^{-196}M$ ,  $5 \times 10^{-197}M$ ,  $10^{-197}M$ ,  $5 \times 10^{-198}M$ ,  $10^{-198}M$ ,  $5 \times 10^{-199}M$ ,  $10^{-199}M$ ,  $5 \times 10^{-200}M$ ,  $10^{-200}M$ ,  $5 \times 10^{-201}M$ ,  $10^{-201}M$ ,  $5 \times 10^{-202}M$ ,  $10^{-202}M$ ,  $5 \times 10^{-203}M$ ,  $10^{-203}M$ ,  $5 \times 10^{-204}M$ ,  $10^{-204}M$ ,  $5 \times 10^{-205}M$ ,  $10^{-205}M$ ,  $5 \times 10^{-206}M$ ,  $10^{-206}M$ ,  $5 \times 10^{-207}M$ ,  $10^{-207}M$ ,  $5 \times 10^{-208}M$ ,  $10^{-208}M$ ,  $5 \times 10^{-209}M$ ,  $10^{-209}M$ ,  $5 \times 10^{-210}M$ ,  $10^{-210}M$ ,  $5 \times 10^{-211}M$ ,  $10^{-211}M$ ,  $5 \times 10^{-212}M$ ,  $10^{-212}M$ ,  $5 \times 10^{-213}M$ ,  $10^{-213}M$ ,  $5 \times 10^{-214}M$ ,  $10^{-214}M$ ,  $5 \times 10^{-215}M$ ,  $10^{-215}M$ ,  $5 \times 10^{-216}M$ ,  $10^{-216}M$ ,  $5 \times 10^{-217}M$ ,  $10^{-217}M$ ,  $5 \times 10^{-218}M$ ,  $10^{-218}M$ ,  $5 \times 10^{-219}M$ ,  $10^{-219}M$ ,  $5 \times 10^{-220}M$ ,  $10^{-220}M$ ,  $5 \times 10^{-221}M$ ,  $10^{-221}M$ ,  $5 \times 10^{-222}M$ ,  $10^{-222}M$ ,  $5 \times 10^{-223}M$ ,  $10^{-223}M$ ,  $5 \times 10^{-224}M$ ,  $10^{-224}M$ ,  $5 \times 10^{-225}M$ ,  $10^{-225}M$ ,  $5 \times 10^{-226}M$ ,  $10^{-226}M$ ,  $5 \times 10^{-227}M$ ,  $10^{-227}M$ ,  $5 \times 10^{-228}M$ ,  $10^{-228}M$ ,  $5 \times 10^{-229}M$ ,  $10^{-229}M$ ,  $5 \times 10^{-230}M$ ,  $10^{-230}M$ ,  $5 \times 10^{-231}M$ ,  $10^{-231}M$ ,  $5 \times 10^{-232}M$ ,  $10^{-232}M$ ,  $5 \times 10^{-233}M$ ,  $10^{-233}M$ ,  $5 \times 10^{-234}M$ ,  $10^{-234}M$ ,  $5 \times 10^{-235}M$ ,  $10^{-235}M$ ,  $5 \times 10^{-236}M$ ,  $10^{-236}M$ ,  $5 \times 10^{-237}M$ ,  $10^{-237}M$ ,  $5 \times 10^{-238}M$ ,  $10^{-238}M$ ,  $5 \times 10^{-239}M$ ,  $10^{-239}M$ ,  $5 \times 10^{-240}M$ ,  $10^{-240}M$ ,  $5 \times 10^{-241}M$ ,  $10^{-241}M$ ,  $5 \times 10^{-242}M$ ,  $10^{-242}M$ ,  $5 \times 10^{-243}M$ ,  $10^{-243}M$ ,  $5 \times 10^{-244}M$ ,  $10^{-244}M$ ,  $5 \times 10^{-245}M$ ,  $10^{-245}M$ ,  $5 \times 10^{-246}M$ ,  $10^{-246}M$ ,  $5 \times 10^{-247}M$ ,  $10^{-247}M$ ,  $5 \times 10^{-248}M$ ,  $10^{-248}M$ ,  $5 \times 10^{-249}M$ ,  $10^{-249}M$ ,  $5 \times 10^{-250}M$ ,  $10^{-250}M$ ,  $5 \times 10^{-251}M$ ,  $10^{-251}M$ ,  $5 \times 10^{-252}M$ ,  $10^{-252}M$ ,  $5 \times 10^{-253}M$ ,  $10^{-253}M$ ,  $5 \times 10^{-254}M$ ,  $10^{-254}M$ ,  $5 \times 10^{-255}M$ ,  $10^{-255}M$ ,  $5 \times 10^{-256}M$ ,  $10^{-256}M$ ,  $5 \times 10^{-257}M$ ,  $10^{-257}M$ ,  $5 \times 10^{-258}M$ ,  $10^{-258}M$ ,  $5 \times 10^{-259}M$ ,  $10^{-259}M$ ,  $5 \times 10^{-260}M$ ,  $10^{-260}M$ ,  $5 \times 10^{-261}M$ ,  $10^{-261}M$ ,  $5 \times 10^{-262}M$ ,  $10^{-262}M$ ,  $5 \times 10^{-263}M$ ,  $10^{-263}M$ ,  $5 \times 10^{-264}M$ ,  $10^{-264}M$ ,  $5 \times 10^{-265}M$ ,  $10^{-265}M$ ,  $5 \times 10^{-266}M$ ,  $10^{-266}M$ ,  $5 \times 10^{-267}M$ ,  $10^{-267}M$ ,  $5 \times 10^{-268}M$ ,  $10^{-268}M$ ,  $5 \times 10^{-269}M$ ,  $10^{-269}M$ ,  $5 \times 10^{-270}M$ ,  $10^{-270}M$ ,  $5 \times 10^{-271}M$ ,  $10^{-271}M$ ,  $5 \times 10^{-272}M$ ,  $10^{-272}M$ ,  $5 \times 10^{-273}M$ ,  $10^{-273}M$ ,  $5 \times 10^{-274}M$ ,  $10^{-274}M$ ,  $5 \times 10^{-275}M$ ,  $10^{-275}M$ ,  $5 \times 10^{-276}M$ ,  $10^{-276}M$ ,  $5 \times 10^{-277}M$ ,  $10^{-277}M$ ,  $5 \times 10^{-278}M$ ,  $10^{-278}M$ ,  $5 \times 10^{-279}M$ ,  $10^{-279}M$ ,  $5 \times 10^{-280}M$ ,  $10^{-280}M$ ,  $5 \times 10^{-281}M$ ,  $10^{-281}M$ ,  $5 \times 10^{-282}M$ ,  $10^{-282}M$ ,  $5 \times 10^{-283}M$ ,  $10^{-283}M$ ,  $5 \times 10^{-284}M$ ,  $10^{-284}M$ ,  $5 \times 10^{-285}M$ ,  $10^{-285}M$ ,  $5 \times 10^{-286}M$ ,  $10^{-286}M$ ,  $5 \times 10^{-287}M$ ,  $10^{-287}M$ ,  $5 \times 10^{-288}M$ ,  $10^{-288}M$ ,  $5 \times 10^{-289}M$ ,  $10^{-289}M$ ,  $5 \times 10^{-290}M$ ,  $10^{-290}M$ ,  $5 \times 10^{-291}M$ ,  $10^{-291}M$ ,  $5 \times 10^{-292}M$ ,  $10^{-292}M$ ,  $5 \times 10^{-293}M$ ,  $10^{-293}M$ ,  $5 \times 10^{-294}M$ ,  $10^{-294}M$ ,  $5 \times 10^{-295}M$ ,  $10^{-295}M$ ,  $5 \times 10^{-296}M$ ,  $10^{-296}M$ ,  $5 \times 10^{-297}M$ ,  $10^{-297}M$ ,  $5 \times 10^{-298}M$ ,  $10^{-298}M$ ,  $5 \times 10^{-299}M$ ,  $10^{-299}M$ ,  $5 \times 10^{-300}M$ ,  $10^{-300}M$ ,  $5 \times 10^{-301}M$ ,  $10^{-301}M$ ,  $5 \times 10^{-302}M$ ,  $10^{-302}M$ ,  $5 \times 10^{-303}M$ ,  $10^{-303}M$ ,  $5 \times 10^{-304}M$ ,  $10^{-304}M$ ,  $5 \times 10^{-305}M$ ,  $10^{-305}M$ ,  $5 \times 10^{-306}M$ ,  $10^{-306}M$ ,  $5 \times 10^{-307}M$ ,  $10^{-307}M$ ,  $5 \times 10^{-308}M$ ,  $10^{-308}M$ ,  $5 \times 10^{-309}M$ ,  $10^{-309}M$ ,  $5 \times 10^{-310}M$ ,  $10^{-310}M$ ,  $5 \times 10^{-311}M$ ,  $10^{-311}M$ ,  $5 \times 10^{-312}M$ ,  $10^{-312}M$ ,  $5 \times 10^{-313}M$ ,  $10^{-313}M$ ,  $5 \times 10^{-314}M$ ,  $10^{-314}M$ ,  $5 \times 10^{-315}M$ ,  $10^{-315}M$ ,  $5 \times 10^{-316}M$ ,  $10^{-316}M$ ,  $5 \times 10^{-317}M$ ,  $10^{-317}M$ ,  $5 \times 10^{-318}M$ ,  $10^{-318}M$ ,  $5 \times 10^{-319}M$ ,  $10^{-319}M$ ,  $5 \times 10^{-320}M$ ,  $10^{-320}M$ ,  $5 \times 10^{-321}M$ ,  $10^{-321}M$ ,  $5 \times 10^{-322}M$ ,  $10^{-322}M$ ,  $5 \times 10^{-323}M$ ,  $10^{-323}M$ ,  $5 \times 10^{-324}M$ ,  $10^{-324}M$ ,  $5 \times 10^{-325}M$ ,  $10^{-325}M$ ,  $5 \times 10^{-326}M$ ,  $10^{-326}M$ ,  $5 \times 10^{-327}M$ ,  $10^{-327}M$ ,  $5 \times 10^{-328}M$ ,  $10^{-328}M$ ,  $5 \times 10^{-329}M$ ,  $10^{-329}M$ ,  $5 \times 10^{-330}M$ ,  $10^{-330}M$ ,  $5 \times 10^{-331}M$ ,  $10^{-331}M$ ,  $5 \times 10^{-332}M$ ,  $10^{-332}M$ ,  $5 \times 10^{-333}M$ ,  $10^{-333}M$ ,  $5 \times 10^{-334}M$ ,  $10^{-334}M$ ,  $5 \times 10^{-335}M$ ,  $10^{-335}M$ ,  $5 \times 10^{-336}M$ ,  $10^{-336}M$ ,  $5 \times 10^{-337}M$ ,  $10^{-337}M$ ,  $5 \times 10^{-338}M$ ,  $10^{-338}M$ ,  $5 \times 10^{-339}M$ ,  $10^{-339}M$ ,  $5 \times 10^{-340}M$ ,  $10^{-340}M$ ,  $5 \times 10^{-341}M$ ,  $10^{-341}M$ ,  $5 \times 10^{-342}M$ ,  $10^{-342}M$ ,  $5 \times 10^{-343}M$ ,  $10^{-343}M$ ,  $5 \times 10^{-344}M$ ,  $10^{-344}M$ ,  $5 \times 10^{-345}M$ ,  $10^{-345}M$ ,  $5 \times 10^{-346}M$ ,  $10^{-346}M$ ,  $5 \times 10^{-347}M$ ,  $10^{-347}M$ ,  $5 \times 10^{-348}M$ ,  $10^{-348}M$ ,  $5 \times 10^{-349}M$ ,  $10^{-349}M$ ,  $5 \times 10^{-350}M$ ,  $10^{-350}M$ ,  $5 \times 10^{-351}M$ ,  $10^{-351}M$ ,  $5 \times 10^{-352}M$ ,  $10^{-352}M$ ,  $5 \times 10^{-353}M$ ,  $10^{-353}M$ ,  $5 \times 10^{-354}M$ ,  $10^{-354}M$ ,  $5 \times 10^{-355}M$ ,  $10^{-355}M$ ,  $5 \times 10^{-356}M$ ,  $10^{-356}M$ ,  $5 \times 10^{-357}M$ ,  $10^{-357}M$ ,  $5 \times 10^{-358}M$ ,  $10^{-358}M$ ,  $5 \times 10^{-359}M$ ,  $10^{-359}M$ ,  $5 \times 10^{-360}M$ ,  $10^{-360}M$ ,  $5 \times 10^{-361}M$ ,  $10^{-361}M$ ,  $5 \times 10^{-362}M$ ,  $10^{-362}M$ ,  $5 \times 10^{-363}M$ ,  $10^{-363}M$ ,  $5 \times 10^{-364}M$ ,  $10^{-364}M$ ,  $5 \times 10^{-365}M$ ,  $10^{-365}M$ ,  $5 \times 10^{-366}M$ ,  $10^{-366}M$ ,  $5 \times 10^{-367}M$ ,  $10^{-367}M$ ,  $5 \times 10^{-368}M$ ,  $10^{-368}M$ ,  $5 \times 10^{-369}M$ ,  $10^{-369}M$ ,  $5 \times 10^{-370}M$ ,  $10^{-370}M$ ,  $5 \times 10^{-371}M$ ,  $10^{-371}M$ ,  $5 \times 10^{-372}M$ ,  $10^{-372}M$ ,  $5 \times 10^{-373}M$ ,  $10^{-373}M$ ,  $5 \times 10^{-374}M$ ,  $10^{-374}M$ ,  $5 \times 10^{-375}M$ ,  $10^{-375}M$



$10^{-10}$ M,  $10^{-10}$ M,  $5 \times 10^{-11}$ M,  $10^{-11}$ M,  $5 \times 10^{-12}$ M,  $10^{-12}$ M,  $5 \times 10^{-13}$ M,  $10^{-13}$ M,  $5 \times 10^{-14}$ M,  $10^{-14}$ M,  $5 \times 10^{-15}$ M, and  $10^{-15}$ M.

Moreover, polypeptides of the present invention are useful in inhibiting the angiogenesis of proliferative cells or tissues, either alone, as a protein fusion, or in combination with other polypeptides directly or indirectly, as described elsewhere herein. In a most preferred embodiment, said anti-angiogenesis effect may be achieved indirectly, for example, through the inhibition of hematopoietic, tumor-specific cells, such as tumor-associated macrophages (See Joseph IB, et al. J Natl Cancer Inst, 90(21):1648-53 (1998), which is hereby incorporated by reference). Antibodies directed to polypeptides or polynucleotides of the present invention may also result in inhibition of angiogenesis directly, or indirectly (See Witte L, et al., Cancer Metastasis Rev. 17(2):155-61 (1998), which is hereby incorporated by reference)).

Polypeptides, including protein fusions, of the present invention, or fragments thereof may be useful in inhibiting proliferative cells or tissues through the induction of apoptosis. Said polypeptides may act either directly, or indirectly to induce apoptosis of proliferative cells and tissues, for example in the activation of a death-domain receptor, such as tumor necrosis factor (TNF) receptor-1, CD95 (Fas/APO-1), TNF-receptor-related apoptosis-mediated protein (TRAMP) and TNF-related apoptosis-inducing ligand (TRAIL) receptor-1 and -2 (See Schulze-Osthoff K, et.al., Eur J Biochem 254(3):439-59 (1998), which is hereby incorporated by reference). Moreover, in another preferred embodiment of the present invention, said polypeptides may induce apoptosis through other mechanisms, such as in the activation of other proteins which will activate apoptosis, or through stimulating the expression of said proteins, either alone or in combination with small molecule drugs or adjuvants, such as apoptonin, galectins, thioredoxins, antiinflammatory proteins (See for example, Mutat Res 400(1-2):447-55 (1998), Med Hypotheses.50(5):423-33 (1998), Chem Biol Interact. Apr 24;111-112:23-34 (1998), J Mol Med.76(6):402-12 (1998), Int J Tissue React;20(1):3-15 (1998), which are all hereby incorporated by reference).

Polypeptides, including protein fusions to, or fragments thereof, of the present invention are useful in inhibiting the metastasis of proliferative cells or tissues.

Inhibition may occur as a direct result of administering polypeptides, or antibodies directed to said polypeptides as described elsewhere herein, or indirectly, such as activating the expression of proteins known to inhibit metastasis, for example alpha 4 integrins, (See, e.g., Curr Top Microbiol Immunol 1998;231:125-41, which is hereby  
5 incorporated by reference). Such therapeutic affects of the present invention may be achieved either alone, or in combination with small molecule drugs or adjuvants.

In another embodiment, the invention provides a method of delivering compositions containing the polypeptides of the invention (e.g., compositions containing polypeptides or polypeptide antibodies associated with heterologous  
10 polypeptides, heterologous nucleic acids, toxins, or prodrugs) to targeted cells expressing the polypeptide of the present invention. Polypeptides or polypeptide antibodies of the invention may be associated with with heterologous polypeptides, heterologous nucleic acids, toxins, or prodrugs via hydrophobic, hydrophilic, ionic and/or covalent interactions.

15 Polypeptides, protein fusions to, or fragments thereof, of the present invention are useful in enhancing the immunogenicity and/or antigenicity of proliferating cells or tissues, either directly, such as would occur if the polypeptides of the present invention 'vaccinated' the immune response to respond to proliferative antigens and immunogens, or indirectly, such as in activating the expression of proteins known to  
20 enhance the immune response (e.g. chemokines), to said antigens and immunogens.

### **Cardiovascular Disorders**

Polynucleotides or polypeptides, or agonists or antagonists of the invention may be used to treat cardiovascular disorders, including peripheral artery disease,  
25 such as limb ischemia.

Cardiovascular disorders include cardiovascular abnormalities, such as arterio-arterial fistula, arteriovenous fistula, cerebral arteriovenous malformations, congenital heart defects, pulmonary atresia, and Scimitar Syndrome. Congenital heart defects include aortic coarctation, cor triatriatum, coronary vessel anomalies, crisscross heart,  
30 dextrocardia, patent ductus arteriosus, Ebstein's anomaly, Eisenmenger complex, hypoplastic left heart syndrome, levocardia, tetralogy of fallot, transposition of great vessels, double outlet right ventricle, tricuspid atresia, persistent truncus arteriosus,

and heart septal defects, such as aortopulmonary septal defect, endocardial cushion defects, Lutembacher's Syndrome, trilogy of Fallot, ventricular heart septal defects.

Cardiovascular disorders also include heart disease, such as arrhythmias, carcinoid heart disease, high cardiac output, low cardiac output, cardiac tamponade, endocarditis (including bacterial), heart aneurysm, cardiac arrest, congestive heart failure, congestive cardiomyopathy, paroxysmal dyspnea, cardiac edema, heart hypertrophy, congestive cardiomyopathy, left ventricular hypertrophy, right ventricular hypertrophy, post-infarction heart rupture, ventricular septal rupture, heart valve diseases, myocardial diseases, myocardial ischemia, pericardial effusion, pericarditis (including constrictive and tuberculous), pneumopericardium, postpericardiotomy syndrome, pulmonary heart disease, rheumatic heart disease, ventricular dysfunction, hyperemia, cardiovascular pregnancy complications, Scimitar Syndrome, cardiovascular syphilis, and cardiovascular tuberculosis.

Arrhythmias include sinus arrhythmia, atrial fibrillation, atrial flutter, bradycardia, extrasystole, Adams-Stokes Syndrome, bundle-branch block, sinoatrial block, long QT syndrome, parasystole, Lown-Ganong-Levine Syndrome, Mahaim-type pre-excitation syndrome, Wolff-Parkinson-White syndrome, sick sinus syndrome, tachycardias, and ventricular fibrillation. Tachycardias include paroxysmal tachycardia, supraventricular tachycardia, accelerated idioventricular rhythm, atrioventricular nodal reentry tachycardia, ectopic atrial tachycardia, ectopic junctional tachycardia, sinoatrial nodal reentry tachycardia, sinus tachycardia, Torsades de Pointes, and ventricular tachycardia.

Heart valve disease include aortic valve insufficiency, aortic valve stenosis, hear murmurs, aortic valve prolapse, mitral valve prolapse, tricuspid valve prolapse, mitral valve insufficiency, mitral valve stenosis, pulmonary atresia, pulmonary valve insufficiency, pulmonary valve stenosis, tricuspid atresia, tricuspid valve insufficiency, and tricuspid valve stenosis.

Myocardial diseases include alcoholic cardiomyopathy, congestive cardiomyopathy, hypertrophic cardiomyopathy, aortic subvalvular stenosis, pulmonary subvalvular stenosis, restrictive cardiomyopathy, Chagas cardiomyopathy, endocardial fibroelastosis, endomyocardial fibrosis, Kearns Syndrome, myocardial reperfusion injury, and myocarditis.

Myocardial ischemias include coronary disease, such as angina pectoris, coronary aneurysm, coronary arteriosclerosis, coronary thrombosis, coronary vasospasm, myocardial infarction and myocardial stunning.

Cardiovascular diseases also include vascular diseases such as aneurysms, angiodyplasia, angiomatosis, bacillary angiomatosis, Hippel-Lindau Disease, Klippel-Trenaunay-Weber Syndrome, Sturge-Weber Syndrome, angioneurotic edema, aortic diseases, Takayasu's Arteritis, aortitis, Leriche's Syndrome, arterial occlusive diseases, arteritis, enarteritis, polyarteritis nodosa, cerebrovascular disorders, diabetic angiopathies, diabetic retinopathy, embolisms, thrombosis, erythromelalgia, hemorrhoids, hepatic veno-occlusive disease, hypertension, hypotension, ischemia, peripheral vascular diseases, phlebitis, pulmonary veno-occlusive disease, Raynaud's disease, CREST syndrome, retinal vein occlusion, Scimitar syndrome, superior vena cava syndrome, telangiectasia, atacia telangiectasia, hereditary hemorrhagic telangiectasia, varicocele, varicose veins, varicose ulcer, vasculitis, and venous insufficiency.

Aneurysms include dissecting aneurysms, false aneurysms, infected aneurysms, ruptured aneurysms, aortic aneurysms, cerebral aneurysms, coronary aneurysms, heart aneurysms, and iliac aneurysms.

Arterial occlusive diseases include arteriosclerosis, intermittent claudication, carotid stenosis, fibromuscular dysplasias, mesenteric vascular occlusion, Moyamoya disease, renal artery obstruction, retinal artery occlusion, and thromboangiitis obliterans.

Cerebrovascular disorders include carotid artery diseases, cerebral amyloid angiopathy, cerebral aneurysm, cerebral anoxia, cerebral arteriosclerosis, cerebral arteriovenous malformation, cerebral artery diseases, cerebral embolism and thrombosis, carotid artery thrombosis, sinus thrombosis, Wallenberg's syndrome, cerebral hemorrhage, epidural hematoma, subdural hematoma, subaraxhnoid hemorrhage, cerebral infarction, cerebral ischemia (including transient), subclavian steal syndrome, periventricular leukomalacia, vascular headache, cluster headache, migraine, and vertebrobasilar insufficiency.

Embolisms include air embolisms, amniotic fluid embolisms, cholesterol embolisms, blue toe syndrome, fat embolisms, pulmonary embolisms, and

thromboembolisms. Thrombosis include coronary thrombosis, hepatic vein thrombosis, retinal vein occlusion, carotid artery thrombosis, sinus thrombosis, Wallenberg's syndrome, and thrombophlebitis.

Ischemia includes cerebral ischemia, ischemic colitis, compartment  
5 syndromes, anterior compartment syndrome, myocardial ischemia, reperfusion injuries, and peripheral limb ischemia. Vasculitis includes aortitis, arteritis, Behcet's Syndrome, Churg-Strauss Syndrome, mucocutaneous lymph node syndrome, thromboangiitis obliterans, hypersensitivity vasculitis, Schoenlein-Henoch purpura, allergic cutaneous vasculitis, and Wegener's granulomatosis.

10 Polynucleotides or polypeptides, or agonists or antagonists of the invention, are especially effective for the treatment of critical limb ischemia and coronary disease.

Polypeptides may be administered using any method known in the art, including, but not limited to, direct needle injection at the delivery site, intravenous  
15 injection, topical administration, catheter infusion, biolistic injectors, particle accelerators, gelfoam sponge depots, other commercially available depot materials, osmotic pumps, oral or suppository solid pharmaceutical formulations, decanting or topical applications during surgery, aerosol delivery. Such methods are known in the art. Polypeptides of the invention may be administered as part of a *Therapeutic*,  
20 described in more detail below. Methods of delivering polynucleotides of the invention are described in more detail herein.

#### **Anti-Angiogenesis Activity**

The naturally occurring balance between endogenous stimulators and  
25 inhibitors of angiogenesis is one in which inhibitory influences predominate. Rastinejad *et al.*, *Cell* 56:345-355 (1989). In those rare instances in which neovascularization occurs under normal physiological conditions, such as wound healing, organ regeneration, embryonic development, and female reproductive processes, angiogenesis is stringently regulated and spatially and temporally  
30 delimited. Under conditions of pathological angiogenesis such as that characterizing solid tumor growth, these regulatory controls fail. Unregulated angiogenesis becomes pathologic and sustains progression of many neoplastic and non-neoplastic diseases.

A number of serious diseases are dominated by abnormal neovascularization including solid tumor growth and metastases, arthritis, some types of eye disorders, and psoriasis. See, e.g., reviews by Moses *et al.*, *Biotech.* 9:630-634 (1991); Folkman *et al.*, *N. Engl. J. Med.*, 333:1757-1763 (1995); Auerbach *et al.*, *J. Microvasc. Res.* 29:401-411 (1985); Folkman, *Advances in Cancer Research*, eds. Klein and Weinhouse, Academic Press, New York, pp. 175-203 (1985); Patz, *Am. J. Ophthalmol.* 94:715-743 (1982); and Folkman *et al.*, *Science* 221:719-725 (1983). In a number of pathological conditions, the process of angiogenesis contributes to the disease state. For example, significant data have accumulated which suggest that the growth of solid tumors is dependent on angiogenesis. Folkman and Klagsbrun, *Science* 235:442-447 (1987).

The present invention provides for treatment of diseases or disorders associated with neovascularization by administration of the polynucleotides and/or polypeptides of the invention, as well as agonists or antagonists of the present invention. Malignant and metastatic conditions which can be treated with the polynucleotides and polypeptides, or agonists or antagonists of the invention include, but are not limited to, malignancies, solid tumors, and cancers described herein and otherwise known in the art (for a review of such disorders, see Fishman *et al.*, *Medicine*, 2d Ed., J. B. Lippincott Co., Philadelphia (1985)). Thus, the present invention provides a method of treating an angiogenesis-related disease and/or disorder, comprising administering to an individual in need thereof a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist of the invention. For example, polynucleotides, polypeptides, antagonists and/or agonists may be utilized in a variety of additional methods in order to therapeutically treat a cancer or tumor. Cancers which may be treated with polynucleotides, polypeptides, antagonists and/or agonists include, but are not limited to solid tumors, including prostate, lung, breast, ovarian, stomach, pancreas, larynx, esophagus, testes, liver, parotid, biliary tract, colon, rectum, cervix, uterus, endometrium, kidney, bladder, thyroid cancer; primary tumors and metastases; melanomas; glioblastoma; Kaposi's sarcoma; leiomyosarcoma; non-small cell lung cancer; colorectal cancer; advanced malignancies; and blood born tumors such as leukemias. For example, polynucleotides, polypeptides, antagonists and/or agonists may be delivered topically,

in order to treat cancers such as skin cancer, head and neck tumors, breast tumors, and Kaposi's sarcoma.

Within yet other aspects, polynucleotides, polypeptides, antagonists and/or agonists may be utilized to treat superficial forms of bladder cancer by, for example, intravesical administration. Polynucleotides, polypeptides, antagonists and/or agonists may be delivered directly into the tumor, or near the tumor site, via injection or a catheter. Of course, as the artisan of ordinary skill will appreciate, the appropriate mode of administration will vary according to the cancer to be treated. Other modes of delivery are discussed herein.

Polynucleotides, polypeptides, antagonists and/or agonists may be useful in treating other disorders, besides cancers, which involve angiogenesis. These disorders include, but are not limited to: benign tumors, for example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas; arteriosclerotic plaques; ocular angiogenic diseases, for example, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, retinoblastoma, uveitis and Pterygia (abnormal blood vessel growth) of the eye; rheumatoid arthritis; psoriasis; delayed wound healing; endometriosis; vasculogenesis; granulations; hypertrophic scars (keloids); nonunion fractures; scleroderma; trachoma; vascular adhesions; myocardial angiogenesis; coronary collaterals; cerebral collaterals; arteriovenous malformations; ischemic limb angiogenesis; Osler-Webber Syndrome; plaque neovascularization; telangiectasia; hemophilic joints; angiofibroma; fibromuscular dysplasia; wound granulation; Crohn's disease; and atherosclerosis.

For example, within one aspect of the present invention methods are provided for treating hypertrophic scars and keloids, comprising the step of administering a polynucleotide, polypeptide, antagonist and/or agonist of the invention to a hypertrophic scar or keloid.

Within one embodiment of the present invention polynucleotides, polypeptides, antagonists and/or agonists are directly injected into a hypertrophic scar or keloid, in order to prevent the progression of these lesions. This therapy is of particular value in the prophylactic treatment of conditions which are known to result in the development of hypertrophic scars and keloids (e.g., burns), and is preferably

initiated after the proliferative phase has had time to progress (approximately 14 days after the initial injury), but before hypertrophic scar or keloid development. As noted above, the present invention also provides methods for treating neovascular diseases of the eye, including for example, corneal neovascularization, neovascular glaucoma, proliferative diabetic retinopathy, retrolental fibroplasia and macular degeneration.

Moreover, Ocular disorders associated with neovascularization which can be treated with the polynucleotides and polypeptides of the present invention (including agonists and/or antagonists) include, but are not limited to: neovascular glaucoma, diabetic retinopathy, retinoblastoma, retrolental fibroplasia, uveitis, retinopathy of prematurity macular degeneration, corneal graft neovascularization, as well as other eye inflammatory diseases, ocular tumors and diseases associated with choroidal or iris neovascularization. See, e.g., reviews by Waltman *et al.*, *Am. J. Ophthalmol.* 85:704-710 (1978) and Gartner *et al.*, *Surv. Ophthalmol.* 22:291-312 (1978).

Thus, within one aspect of the present invention methods are provided for treating neovascular diseases of the eye such as corneal neovascularization (including corneal graft neovascularization), comprising the step of administering to a patient a therapeutically effective amount of a compound (as described above) to the cornea, such that the formation of blood vessels is inhibited. Briefly, the cornea is a tissue which normally lacks blood vessels. In certain pathological conditions however, capillaries may extend into the cornea from the pericorneal vascular plexus of the limbus. When the cornea becomes vascularized, it also becomes clouded, resulting in a decline in the patient's visual acuity. Visual loss may become complete if the cornea completely opacitates. A wide variety of disorders can result in corneal neovascularization, including for example, corneal infections (e.g., trachoma, herpes simplex keratitis, leishmaniasis and onchocerciasis), immunological processes (e.g., graft rejection and Stevens-Johnson's syndrome), alkali burns, trauma, inflammation (of any cause), toxic and nutritional deficiency states, and as a complication of wearing contact lenses.

Within particularly preferred embodiments of the invention, may be prepared for topical administration in saline (combined with any of the preservatives and antimicrobial agents commonly used in ocular preparations), and administered in eyedrop form. The solution or suspension may be prepared in its pure form and



administered several times daily. Alternatively, anti-angiogenic compositions, prepared as described above, may also be administered directly to the cornea. Within preferred embodiments, the anti-angiogenic composition is prepared with a muco-adhesive polymer which binds to cornea. Within further embodiments, the anti-angiogenic factors or anti-angiogenic compositions may be utilized as an adjunct to conventional steroid therapy. Topical therapy may also be useful prophylactically in corneal lesions which are known to have a high probability of inducing an angiogenic response (such as chemical burns). In these instances the treatment, likely in combination with steroids, may be instituted immediately to help prevent subsequent complications.

Within other embodiments, the compounds described above may be injected directly into the corneal stroma by an ophthalmologist under microscopic guidance. The preferred site of injection may vary with the morphology of the individual lesion, but the goal of the administration would be to place the composition at the advancing front of the vasculature (i.e., interspersed between the blood vessels and the normal cornea). In most cases this would involve perilimbic corneal injection to "protect" the cornea from the advancing blood vessels. This method may also be utilized shortly after a corneal insult in order to prophylactically prevent corneal neovascularization. In this situation the material could be injected in the perilimbic cornea interspersed between the corneal lesion and its undesired potential limbic blood supply. Such methods may also be utilized in a similar fashion to prevent capillary invasion of transplanted corneas. In a sustained-release form injections might only be required 2-3 times per year. A steroid could also be added to the injection solution to reduce inflammation resulting from the injection itself.

Within another aspect of the present invention, methods are provided for treating neovascular glaucoma, comprising the step of administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eye, such that the formation of blood vessels is inhibited. In one embodiment, the compound may be administered topically to the eye in order to treat early forms of neovascular glaucoma. Within other embodiments, the compound may be implanted by injection into the region of the anterior chamber angle. Within other embodiments, the compound may also be placed in any location such that the

compound is continuously released into the aqueous humor. Within another aspect of the present invention, methods are provided for treating proliferative diabetic retinopathy, comprising the step of administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eyes, such that the formation of blood vessels is inhibited.

Within particularly preferred embodiments of the invention, proliferative diabetic retinopathy may be treated by injection into the aqueous humor or the vitreous, in order to increase the local concentration of the polynucleotide, polypeptide, antagonist and/or agonist in the retina. Preferably, this treatment should be initiated prior to the acquisition of severe disease requiring photocoagulation.

Within another aspect of the present invention, methods are provided for treating retrolental fibroplasia, comprising the step of administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eye, such that the formation of blood vessels is inhibited. The compound may be administered topically, via intravitreal injection and/or via intraocular implants.

Additionally, disorders which can be treated with the polynucleotides, polypeptides, agonists and/or antagonists include, but are not limited to, hemangioma, arthritis, psoriasis, angiofibroma, atherosclerotic plaques, delayed wound healing, granulations, hemophilic joints, hypertrophic scars, nonunion fractures, Osler-Weber syndrome, pyogenic granuloma, scleroderma, trachoma, and vascular adhesions.

Moreover, disorders and/or states, which can be treated with the polynucleotides, polypeptides, agonists and/or antagonists include, but are not limited to, solid tumors, blood born tumors such as leukemias, tumor metastasis, Kaposi's sarcoma, benign tumors, for example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas, rheumatoid arthritis, psoriasis, ocular angiogenic diseases, for example, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, retinoblastoma, and uveitis, delayed wound healing, endometriosis, vasculogenesis, granulations, hypertrophic scars (keloids), nonunion fractures, scleroderma, trachoma, vascular adhesions, myocardial angiogenesis, coronary collaterals, cerebral collaterals, arteriovenous malformations, ischemic limb

angiogenesis, Osler-Webber Syndrome, plaque neovascularization, telangiectasia, hemophiliac joints, angiofibroma fibromuscular dysplasia, wound granulation, Crohn's disease, atherosclerosis, birth control agent by preventing vascularization required for embryo implantation controlling menstruation, diseases that have  
5 angiogenesis as a pathologic consequence such as cat scratch disease (Rochele minalia quintosa), ulcers (*Helicobacter pylori*), Bartonellosis and bacillary angiomatosis.

In one aspect of the birth control method, an amount of the compound sufficient to block embryo implantation is administered before or after intercourse and  
10 fertilization have occurred, thus providing an effective method of birth control, possibly a "morning after" method. Polynucleotides, polypeptides, agonists and/or agonists may also be used in controlling menstruation or administered as either a peritoneal lavage fluid or for peritoneal implantation in the treatment of endometriosis.

15 Polynucleotides, polypeptides, agonists and/or agonists of the present invention may be incorporated into surgical sutures in order to prevent stitch granulomas.

Polynucleotides, polypeptides, agonists and/or agonists may be utilized in a wide variety of surgical procedures. For example, within one aspect of the present  
20 invention a compositions (in the form of, for example, a spray or film) may be utilized to coat or spray an area prior to removal of a tumor, in order to isolate normal surrounding tissues from malignant tissue, and/or to prevent the spread of disease to surrounding tissues. Within other aspects of the present invention, compositions (e.g., in the form of a spray) may be delivered via endoscopic procedures in order to coat  
25 tumors, or inhibit angiogenesis in a desired locale. Within yet other aspects of the present invention, surgical meshes which have been coated with anti- angiogenic compositions of the present invention may be utilized in any procedure wherein a surgical mesh might be utilized. For example, within one embodiment of the invention a surgical mesh laden with an anti-angiogenic composition may be utilized  
30 during abdominal cancer resection surgery (e.g., subsequent to colon resection) in order to provide support to the structure, and to release an amount of the anti-angiogenic factor.

Within further aspects of the present invention, methods are provided for treating tumor excision sites, comprising administering a polynucleotide, polypeptide, agonist and/or agonist to the resection margins of a tumor subsequent to excision, such that the local recurrence of cancer and the formation of new blood vessels at the site is inhibited. Within one embodiment of the invention, the anti-angiogenic compound is administered directly to the tumor excision site (e.g., applied by swabbing, brushing or otherwise coating the resection margins of the tumor with the anti-angiogenic compound). Alternatively, the anti-angiogenic compounds may be incorporated into known surgical pastes prior to administration. Within particularly preferred embodiments of the invention, the anti-angiogenic compounds are applied after hepatic resections for malignancy, and after neurosurgical operations.

Within one aspect of the present invention, polynucleotides, polypeptides, agonists and/or agonists may be administered to the resection margin of a wide variety of tumors, including for example, breast, colon, brain and hepatic tumors. For example, within one embodiment of the invention, anti-angiogenic compounds may be administered to the site of a neurological tumor subsequent to excision, such that the formation of new blood vessels at the site are inhibited.

The polynucleotides, polypeptides, agonists and/or agonists of the present invention may also be administered along with other anti-angiogenic factors. Representative examples of other anti-angiogenic factors include: Anti-Invasive Factor, retinoic acid and derivatives thereof, paclitaxel, Suramin, Tissue Inhibitor of Metalloproteinase-1, Tissue Inhibitor of Metalloproteinase-2, Plasminogen Activator Inhibitor-1, Plasminogen Activator Inhibitor-2, and various forms of the lighter "d group" transition metals.

Lighter "d group" transition metals include, for example, vanadium, molybdenum, tungsten, titanium, niobium, and tantalum species. Such transition metal species may form transition metal complexes. Suitable complexes of the above-mentioned transition metal species include oxo transition metal complexes.

Representative examples of vanadium complexes include oxo vanadium complexes such as vanadate and vanadyl complexes. Suitable vanadate complexes include metavanadate and orthovanadate complexes such as, for example, ammonium metavanadate, sodium metavanadate, and sodium orthovanadate. Suitable vanadyl

complexes include, for example, vanadyl acetylacetonate and vanadyl sulfate including vanadyl sulfate hydrates such as vanadyl sulfate mono- and trihydrates.

Representative examples of tungsten and molybdenum complexes also include oxo complexes. Suitable oxo tungsten complexes include tungstate and tungsten  
5 oxide complexes. Suitable tungstate complexes include ammonium tungstate, calcium tungstate, sodium tungstate dihydrate, and tungstic acid. Suitable tungsten oxides include tungsten (IV) oxide and tungsten (VI) oxide. Suitable oxo molybdenum complexes include molybdate, molybdenum oxide, and molybdenyl complexes. Suitable molybdate complexes include ammonium molybdate and its  
10 hydrates, sodium molybdate and its hydrates, and potassium molybdate and its hydrates. Suitable molybdenum oxides include molybdenum (VI) oxide, molybdenum (VI) oxide, and molybdic acid. Suitable molybdenyl complexes include, for example, molybdenyl acetylacetonate. Other suitable tungsten and molybdenum complexes include hydroxo derivatives derived from, for example, glycerol, tartaric acid, and  
15 sugars.

A wide variety of other anti-angiogenic factors may also be utilized within the context of the present invention. Representative examples include platelet factor 4; protamine sulphate; sulphated chitin derivatives (prepared from queen crab shells), (Murata et al., Cancer Res. 51:22-26, 1991); Sulphated Polysaccharide Peptidoglycan  
20 Complex (SP- PG) (the function of this compound may be enhanced by the presence of steroids such as estrogen, and tamoxifen citrate); Staurosporine; modulators of matrix metabolism, including for example, proline analogs, cishydroxyproline, d,L-3,4-dehydroproline, Thiaproline, alpha,alpha-dipyridyl, aminopropionitrile fumarate; 4-propyl-5-(4-pyridinyl)-2(3H)-oxazolone; Methotrexate; Mitoxantrone; Heparin;  
25 Interferons; 2 Macroglobulin-serum; ChIMP-3 (Pavloff et al., J. Bio. Chem. 267:17321-17326, 1992); Chymostatin (Tomkinson et al., Biochem J. 286:475-480, 1992); Cyclodextrin Tetradasulfate; Eponemycin; Camptothecin; Fumagillin (Ingber et al., Nature 348:555-557, 1990); Gold Sodium Thiomalate ("GST"; Matsubara and Ziff, J. Clin. Invest. 79:1440-1446, 1987); anticollagenase-serum;  
30 alpha2-antiplasmin (Holmes et al., J. Biol. Chem. 262(4):1659-1664, 1987); Bisantrene (National Cancer Institute); Lobenzarit disodium (N-(2)-carboxyphenyl-4-chloroanthronilic acid disodium or "CCA"; Takeuchi et al., Agents Actions 36:312-

316, 1992); Thalidomide; Angostatic steroid; AGM-1470; carboxynaminolimidazole; and metalloproteinase inhibitors such as BB94.

### **Diseases at the Cellular Level**

5 Diseases associated with increased cell survival or the inhibition of apoptosis that could be treated or detected by the polynucleotides or polypeptides and/or antagonists or agonists of the invention, include cancers (such as follicular lymphomas, carcinomas with p53 mutations, and hormone-dependent tumors, including, but not limited to colon cancer, cardiac tumors, pancreatic cancer,  
10 melanoma, retinoblastoma, glioblastoma, lung cancer, intestinal cancer, testicular cancer, stomach cancer, neuroblastoma, myxoma, myoma, lymphoma, endothelioma, osteoblastoma, osteoclastoma, osteosarcoma, chondrosarcoma, adenoma, breast cancer, prostate cancer, Kaposi's sarcoma and ovarian cancer); autoimmune disorders (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary  
15 cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis and rheumatoid arthritis) and viral infections (such as herpes viruses, pox viruses and adenoviruses), inflammation, graft v. host disease, acute graft rejection, and chronic graft rejection. In preferred embodiments, the polynucleotides or polypeptides, and/or agonists or antagonists of  
20 the invention are used to inhibit growth, progression, and/or metasis of cancers, in particular those listed above.

Additional diseases or conditions associated with increased cell survival that could be treated or detected by the polynucleotides or polypeptides, or agonists or antagonists of the invention, include, but are not limited to, progression, and/or  
25 metastases of malignancies and related disorders such as leukemia (including acute leukemias (e.g., acute lymphocytic leukemia, acute myelocytic leukemia (including myeloblastic, promyelocytic, myelomonocytic, monocytic, and erythroleukemia)) and chronic leukemias (e.g., chronic myelocytic (granulocytic) leukemia and chronic  
30 lymphocytic leukemia)), polycythemia vera, lymphomas (e.g., Hodgkin's disease and non-Hodgkin's disease), multiple myeloma, Waldenstrom's macroglobulinemia, heavy chain disease, and solid tumors including, but not limited to, sarcomas and carcinomas such as fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma,

osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal  
5 cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder  
10 carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, menangioma, melanoma, neuroblastoma, and retinoblastoma.

Diseases associated with increased apoptosis that could be treated or detected by the polynucleotides or polypeptides, and/or agonists or antagonists of the  
15 invention, include AIDS; neurodegenerative disorders (such as Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis, Retinitis pigmentosa, Cerebellar degeneration and brain tumor or prior associated disease); autoimmune disorders (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus  
20 erythematosus and immune-related glomerulonephritis and rheumatoid arthritis) myelodysplastic syndromes (such as aplastic anemia), graft v. host disease, ischemic injury (such as that caused by myocardial infarction, stroke and reperfusion injury), liver injury (e.g., hepatitis related liver injury, ischemia/reperfusion injury, cholestasis (bile duct injury) and liver cancer); toxin-induced liver disease (such as that caused by  
25 alcohol), septic shock, cachexia and anorexia.

### **Wound Healing and Epithelial Cell Proliferation**

In accordance with yet a further aspect of the present invention, there is provided a process for utilizing the polynucleotides or polypeptides, and/or agonists  
30 or antagonists of the invention, for therapeutic purposes, for example, to stimulate epithelial cell proliferation and basal keratinocytes for the purpose of wound healing, and to stimulate hair follicle production and healing of dermal wounds.

Polynucleotides or polypeptides, as well as agonists or antagonists of the invention, may be clinically useful in stimulating wound healing including surgical wounds, excisional wounds, deep wounds involving damage of the dermis and epidermis, eye tissue wounds, dental tissue wounds, oral cavity wounds, diabetic ulcers, dermal  
5 ulcers, cubitus ulcers, arterial ulcers, venous stasis ulcers, burns resulting from heat exposure or chemicals, and other abnormal wound healing conditions such as uremia, malnutrition, vitamin deficiencies and complications associated with systemic treatment with steroids, radiation therapy and antineoplastic drugs and antimetabolites. Polynucleotides or polypeptides, and/or agonists or antagonists of  
10 the invention, could be used to promote dermal reestablishment subsequent to dermal loss

The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to increase the adherence of skin grafts to a wound bed and to stimulate re-epithelialization from the wound bed. The following are a non-  
15 exhaustive list of grafts that polynucleotides or polypeptides, agonists or antagonists of the invention, could be used to increase adherence to a wound bed: autografts, artificial skin, allografts, autodermic graft, autoepdermic grafts, avacular grafts, Blair-Brown grafts, bone graft, brephoplastic grafts, cutis graft, delayed graft, dermic graft, epidermic graft, fascia graft, full thickness graft, heterologous graft, xenograft,  
20 homologous graft, hyperplastic graft, lamellar graft, mesh graft, mucosal graft, Ollier-Thiersch graft, omenpal graft, patch graft, pedicle graft, penetrating graft, split skin graft, thick split graft. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, can be used to promote skin strength and to improve the appearance of aged skin.

25 It is believed that the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, will also produce changes in hepatocyte proliferation, and epithelial cell proliferation in the lung, breast, pancreas, stomach, small intestine, and large intestine. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could promote proliferation of epithelial cells such as  
30 sebocytes, hair follicles, hepatocytes, type II pneumocytes, mucin-producing goblet cells, and other epithelial cells and their progenitors contained within the skin, lung, liver, and gastrointestinal tract. The polynucleotides or polypeptides, and/or agonists



or antagonists of the invention, may promote proliferation of endothelial cells, keratinocytes, and basal keratinocytes.

The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could also be used to reduce the side effects of gut toxicity that result from radiation, chemotherapy treatments or viral infections. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, may have a cytoprotective effect on the small intestine mucosa. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, may also stimulate healing of mucositis (mouth ulcers) that result from chemotherapy and viral infections.

The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could further be used in full regeneration of skin in full and partial thickness skin defects, including burns, (i.e., repopulation of hair follicles, sweat glands, and sebaceous glands), treatment of other skin defects such as psoriasis. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to treat epidermolysis bullosa, a defect in adherence of the epidermis to the underlying dermis which results in frequent, open and painful blisters by accelerating reepithelialization of these lesions. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could also be used to treat gastric and duodenal ulcers and help heal by scar formation of the mucosal lining and regeneration of glandular mucosa and duodenal mucosal lining more rapidly. Inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis, are diseases which result in destruction of the mucosal surface of the small or large intestine, respectively. Thus, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to promote the resurfacing of the mucosal surface to aid more rapid healing and to prevent progression of inflammatory bowel disease. Treatment with the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, is expected to have a significant effect on the production of mucus throughout the gastrointestinal tract and could be used to protect the intestinal mucosa from injurious substances that are ingested or following surgery. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention,

could be used to treat diseases associate with the under expression of the polynucleotides of the invention.

Moreover, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to prevent and heal damage to the lungs due to various pathological states. A growth factor such as the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, which could stimulate proliferation and differentiation and promote the repair of alveoli and bronchiolar epithelium to prevent or treat acute or chronic lung damage. For example, emphysema, which results in the progressive loss of aveoli, and inhalation injuries, i.e., resulting from smoke inhalation and burns, that cause necrosis of the bronchiolar epithelium and alveoli could be effectively treated using the polynucleotides or polypeptides, and/or agonists or antagonists of the invention. Also, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to stimulate the proliferation of and differentiation of type II pneumocytes, which may help treat or prevent disease such as hyaline membrane diseases, such as infant respiratory distress syndrome and bronchopulmonary dysplasia, in premature infants.

The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could stimulate the proliferation and differentiation of hepatocytes and, thus, could be used to alleviate or treat liver diseases and pathologies such as fulminant liver failure caused by cirrhosis, liver damage caused by viral hepatitis and toxic substances (i.e., acetaminophen, carbon tetrachloride and other hepatotoxins known in the art).

In addition, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used treat or prevent the onset of diabetes mellitus. In patients with newly diagnosed Types I and II diabetes, where some islet cell function remains, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to maintain the islet function so as to alleviate, delay or prevent permanent manifestation of the disease. Also, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used as an auxiliary in islet cell transplantation to improve or promote islet cell function.

### **Neurological Diseases**

Nervous system disorders, which can be treated with the compositions of the invention (e.g., polypeptides, polynucleotides, and/or agonists or antagonists), include, but are not limited to, nervous system injuries, and diseases or disorders which result in either a disconnection of axons, a diminution or degeneration of neurons, or demyelination. Nervous system lesions which may be treated in a patient (including human and non-human mammalian patients) according to the invention, include but are not limited to, the following lesions of either the central (including spinal cord, brain) or peripheral nervous systems: (1) ischemic lesions, in which a lack of oxygen in a portion of the nervous system results in neuronal injury or death, including cerebral infarction or ischemia, or spinal cord infarction or ischemia; (2) traumatic lesions, including lesions caused by physical injury or associated with surgery, for example, lesions which sever a portion of the nervous system, or compression injuries; (3) malignant lesions, in which a portion of the nervous system is destroyed or injured by malignant tissue which is either a nervous system associated malignancy or a malignancy derived from non-nervous system tissue; (4) infectious lesions, in which a portion of the nervous system is destroyed or injured as a result of infection, for example, by an abscess or associated with infection by human immunodeficiency virus, herpes zoster, or herpes simplex virus or with Lyme disease, tuberculosis, syphilis; (5) degenerative lesions, in which a portion of the nervous system is destroyed or injured as a result of a degenerative process including but not limited to degeneration associated with Parkinson's disease, Alzheimer's disease, Huntington's chorea, or amyotrophic lateral sclerosis (ALS); (6) lesions associated with nutritional diseases or disorders, in which a portion of the nervous system is destroyed or injured by a nutritional disorder or disorder of metabolism including but not limited to, vitamin B12 deficiency, folic acid deficiency, Wernicke disease, tobacco-alcohol amblyopia, Marchiafava-Bignami disease (primary degeneration of the corpus callosum), and alcoholic cerebellar degeneration; (7) neurological lesions associated with systemic diseases including, but not limited to, diabetes (diabetic neuropathy, Bell's palsy), systemic lupus erythematosus, carcinoma, or sarcoidosis; (8) lesions caused by toxic substances including alcohol, lead, or particular neurotoxins; and (9) demyelinated lesions in which a portion of the nervous system is destroyed or injured by a demyelinating disease including, but not limited to,

multiple sclerosis, human immunodeficiency virus-associated myelopathy, transverse myelopathy or various etiologies, progressive multifocal leukoencephalopathy, and central pontine myelinolysis.

In a preferred embodiment, the polypeptides, polynucleotides, or agonists or  
5 antagonists of the invention are used to protect neural cells from the damaging effects of cerebral hypoxia. According to this embodiment, the compositions of the invention are used to treat or prevent neural cell injury associated with cerebral hypoxia. In one aspect of this embodiment, the polypeptides, polynucleotides, or  
10 agonists or antagonists of the invention are used to treat or prevent neural cell injury associated with cerebral ischemia. In another aspect of this embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat or prevent neural cell injury associated with cerebral infarction. In another aspect of this embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat or prevent neural cell injury associated with a stroke.  
15 In a further aspect of this embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat or prevent neural cell injury associated with a heart attack.

The compositions of the invention which are useful for treating or preventing a nervous system disorder may be selected by testing for biological activity in  
20 promoting the survival or differentiation of neurons. For example, and not by way of limitation, compositions of the invention which elicit any of the following effects may be useful according to the invention: (1) increased survival time of neurons in culture; (2) increased sprouting of neurons in culture or *in vivo*; (3) increased production of a neuron-associated molecule in culture or *in vivo*, *e.g.*, choline acetyltransferase or  
25 acetylcholinesterase with respect to motor neurons; or (4) decreased symptoms of neuron dysfunction *in vivo*. Such effects may be measured by any method known in the art. In preferred, non-limiting embodiments, increased survival of neurons may routinely be measured using a method set forth herein or otherwise known in the art, such as, for example, the method set forth in Arakawa et al. (J. Neurosci.  
30 10:3507-3515 (1990)); increased sprouting of neurons may be detected by methods known in the art, such as, for example, the methods set forth in Pestronk et al. (Exp. Neurol. 70:65-82 (1980)) or Brown et al. (Ann. Rev. Neurosci. 4:17-42 (1981));

increased production of neuron-associated molecules may be measured by bioassay, enzymatic assay, antibody binding, Northern blot assay, etc., using techniques known in the art and depending on the molecule to be measured; and motor neuron dysfunction may be measured by assessing the physical manifestation of motor neuron disorder, e.g., weakness, motor neuron conduction velocity, or functional disability.

In specific embodiments, motor neuron disorders that may be treated according to the invention include, but are not limited to, disorders such as infarction, infection, exposure to toxin, trauma, surgical damage, degenerative disease or malignancy that may affect motor neurons as well as other components of the nervous system, as well as disorders that selectively affect neurons such as amyotrophic lateral sclerosis, and including, but not limited to, progressive spinal muscular atrophy, progressive bulbar palsy, primary lateral sclerosis, infantile and juvenile muscular atrophy, progressive bulbar paralysis of childhood (Fazio-Londe syndrome), poliomyelitis and the post polio syndrome, and Hereditary Motorsensory Neuropathy (Charcot-Marie-Tooth Disease).

### **Infectious Disease**

A polypeptide or polynucleotide and/or agonist or antagonist of the present invention can be used to treat or detect infectious agents. For example, by increasing the immune response, particularly increasing the proliferation and differentiation of B and/or T cells, infectious diseases may be treated. The immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, polypeptide or polynucleotide and/or agonist or antagonist of the present invention may also directly inhibit the infectious agent, without necessarily eliciting an immune response.

Viruses are one example of an infectious agent that can cause disease or symptoms that can be treated or detected by a polynucleotide or polypeptide and/or agonist or antagonist of the present invention. Examples of viruses, include, but are not limited to Examples of viruses, include, but are not limited to the following DNA and RNA viruses and viral families: Arbovirus, Adenoviridae, Arenaviridae, Arterivirus, Birnaviridae, Bunyaviridae, Caliciviridae, Circoviridae, Coronaviridae,

Dengue, EBV, HIV, Flaviviridae, Hepadnaviridae (Hepatitis), Herpesviridae (such as, Cytomegalovirus, Herpes Simplex, Herpes Zoster), Mononegavirus (e.g., Paramyxoviridae, Morbillivirus, Rhabdoviridae), Orthomyxoviridae (e.g., Influenza A, Influenza B, and parainfluenza), Papiloma virus, Papovaviridae, Parvoviridae, 5 Picornaviridae, Poxviridae (such as Smallpox or Vaccinia), Reoviridae (e.g., Rotavirus), Retroviridae (HTLV-I, HTLV-II, Lentivirus), and Togaviridae (e.g., Rubivirus). Viruses falling within these families can cause a variety of diseases or symptoms, including, but not limited to: arthritis, bronchiolitis, respiratory syncytial virus, encephalitis, eye infections (e.g., conjunctivitis, keratitis), chronic fatigue 10 syndrome, hepatitis (A, B, C, E, Chronic Active, Delta), Japanese B encephalitis, Junin, Chikungunya, Rift Valley fever, yellow fever, meningitis, opportunistic infections (e.g., AIDS), pneumonia, Burkitt's Lymphoma, chickenpox, hemorrhagic fever, Measles, Mumps, Parainfluenza, Rabies, the common cold, Polio, leukemia, Rubella, sexually transmitted diseases, skin diseases (e.g., Kaposi's, warts), and 15 viremia. polynucleotides or polypeptides, or agonists or antagonists of the invention, can be used to treat or detect any of these symptoms or diseases. In specific embodiments, polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat: meningitis, Dengue, EBV, and/or hepatitis (e.g., hepatitis B). In an additional specific embodiment polynucleotides, polypeptides, or agonists 20 or antagonists of the invention are used to treat patients nonresponsive to one or more other commercially available hepatitis vaccines. In a further specific embodiment polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat AIDS.

Similarly, bacterial or fungal agents that can cause disease or symptoms and 25 that can be treated or detected by a polynucleotide or polypeptide and/or agonist or antagonist of the present invention include, but not limited to, include, but not limited to, the following Gram-Negative and Gram-positive bacteria and bacterial families and fungi: Actinomycetales (e.g., Corynebacterium, Mycobacterium, Norcardia), Cryptococcus neoformans, Aspergillosis, Bacillaceae (e.g., Anthrax, Clostridium), 30 Bacteroidaceae, Blastomycosis, Bordetella, Borrelia (e.g., Borrelia burgdorferi), Brucellosis, Candidiasis, Campylobacter, Coccidioidomycosis, Cryptococcosis, Dermatocycoses, E. coli (e.g., Enterotoxigenic E. coli and Enterohemorrhagic E.

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>C07K 14/47, C12N 5/10, 5/16, 15/12, 15/63, 15/64</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/55198</b> <b>(43) International Publication Date:</b> 21 September 2000 (21.09.00)
<b>(21) International Application Number:</b> PCT/US00/06012 <b>(22) International Filing Date:</b> 9 March 2000 (09.03.00)  <b>(30) Priority Data:</b> 60/124,093 12 March 1999 (12.03.99) US 60/166,989 23 November 1999 (23.11.99) US  <b>(71) Applicant (for all designated States except US):</b> HUMAN GENOME SCIENCES, INC. [US/US]; 9410 Key West Avenue, Rockville, MD 20850 (US).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> ROSEN, Craig, A. [US/US]; 22400 Rolling Hill Road, Laytonsville, MD 20882 (US). RUBEN, Steven, M. [US/US]; 18528 Heritage Hills Drive, Laytonsville, MD 20882 (US). KOMAT-SOULIS, George [US/US]; 9518 Garwood Street, Silver Spring, MD 20901 (US).  <b>(74) Agents:</b> HOOVER, Kenley, K. et al.; Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850 (US).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> 50 HUMAN SECRETED PROTEINS  <b>(57) Abstract</b>  The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LJ	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		



## 50 Human Secreted Proteins

### *Field of the Invention*

This invention relates to newly identified polynucleotides and the polypeptides encoded by these polynucleotides, uses of such polynucleotides and polypeptides, and  
5 their production.

### *Background of the Invention*

Unlike bacterium, which exist as a single compartment surrounded by a membrane, human cells and other eucaryotes are subdivided by membranes into many functionally distinct compartments. Each membrane-bounded compartment, or  
10 organelle, contains different proteins essential for the function of the organelle. The cell uses "sorting signals," which are amino acid motifs located within the protein, to target proteins to particular cellular organelles.

One type of sorting signal, called a signal sequence, a signal peptide, or a leader sequence, directs a class of proteins to an organelle called the endoplasmic  
15 reticulum (ER). The ER separates the membrane-bounded proteins from all other types of proteins. Once localized to the ER, both groups of proteins can be further directed to another organelle called the Golgi apparatus. Here, the Golgi distributes the proteins to vesicles, including secretory vesicles, the cell membrane, lysosomes, and the other organelles.

20 Proteins targeted to the ER by a signal sequence can be released into the extracellular space as a secreted protein. For example, vesicles containing secreted proteins can fuse with the cell membrane and release their contents into the extracellular space - a process called exocytosis. Exocytosis can occur constitutively or after receipt of a triggering signal. In the latter case, the proteins are stored in  
25 secretory vesicles (or secretory granules) until exocytosis is triggered. Similarly, proteins residing on the cell membrane can also be secreted into the extracellular space by proteolytic cleavage of a "linker" holding the protein to the membrane.

Despite the great progress made in recent years, only a small number of genes encoding human secreted proteins have been identified. These secreted proteins  
30 include the commercially valuable human insulin, interferon, Factor VIII, human growth hormone, tissue plasminogen activator, and erythropoietin. Thus, in light of

the pervasive role of secreted proteins in human physiology, a need exists for identifying and characterizing novel human secreted proteins and the genes that encode them. This knowledge will allow one to detect, to treat, and to prevent medical disorders by using secreted proteins or the genes that encode them.

5

### ***Summary of the Invention***

The present invention relates to novel polynucleotides and the encoded polypeptides. Moreover, the present invention relates to vectors, host cells, antibodies, and recombinant and synthetic methods for producing the polypeptides and polynucleotides. Also provided are diagnostic methods for detecting disorders and conditions related to the polypeptides and polynucleotides, and therapeutic methods for treating such disorders and conditions. The invention further relates to screening methods for identifying binding partners of the polypeptides.

15

### ***Detailed Description***

#### **Definitions**

The following definitions are provided to facilitate understanding of certain terms used throughout this specification.

In the present invention, "isolated" refers to material removed from its original environment (e.g., the natural environment if it is naturally occurring), and thus is altered "by the hand of man" from its natural state. For example, an isolated polynucleotide could be part of a vector or a composition of matter, or could be contained within a cell, and still be "isolated" because that vector, composition of matter, or particular cell is not the original environment of the polynucleotide. The term "isolated" does not refer to genomic or cDNA libraries, whole cell total or mRNA preparations, genomic DNA preparations (including those separated by electrophoresis and transferred onto blots), sheared whole cell genomic DNA preparations or other compositions where the art demonstrates no distinguishing features of the polynucleotide/sequences of the present invention.

30

In the present invention, a "secreted" protein refers to those proteins capable of being directed to the ER, secretory vesicles, or the extracellular space as a result of a signal sequence, as well as those proteins released into the extracellular space without necessarily containing a signal sequence. If the secreted protein is released  
5 into the extracellular space, the secreted protein can undergo extracellular processing to produce a "mature" protein. Release into the extracellular space can occur by many mechanisms, including exocytosis and proteolytic cleavage.

In specific embodiments, the polynucleotides of the invention are at least 15, at least 30, at least 50, at least 100, at least 125, at least 500, or at least 1000  
10 continuous nucleotides but are less than or equal to 300 kb, 200 kb, 100 kb, 50 kb, 15 kb, 10 kb, 7.5 kb, 5 kb, 2.5 kb, 2.0 kb, or 1 kb, in length. In a further embodiment, polynucleotides of the invention comprise a portion of the coding sequences, as disclosed herein, but do not comprise all or a portion of any intron. In another embodiment, the polynucleotides comprising coding sequences do not contain coding  
15 sequences of a genomic flanking gene (i.e., 5' or 3' to the gene of interest in the genome). In other embodiments, the polynucleotides of the invention do not contain the coding sequence of more than 1000, 500, 250, 100, 50, 25, 20, 15, 10, 5, 4, 3, 2, or 1 genomic flanking gene(s).

As used herein, a "polynucleotide" refers to a molecule having a nucleic acid  
20 sequence contained in SEQ ID NO:X or the cDNA contained within the clone deposited with the ATCC. For example, the polynucleotide can contain the nucleotide sequence of the full length cDNA sequence, including the 5' and 3' untranslated sequences, the coding region, with or without the signal sequence, the secreted protein coding region, as well as fragments, epitopes, domains, and variants  
25 of the nucleic acid sequence. Moreover, as used herein, a "polypeptide" refers to a molecule having the translated amino acid sequence generated from the polynucleotide as broadly defined.

In the present invention, the full length sequence identified as SEQ ID NO:X was often generated by overlapping sequences contained in multiple clones (contig  
30 analysis). A representative clone containing all or most of the sequence for SEQ ID NO:X was deposited with the American Type Culture Collection ("ATCC"). As shown in Table 1, each clone is identified by a cDNA Clone ID (Identifier) and the

ATCC Deposit Number. The ATCC is located at 10801 University Boulevard, Manassas, Virginia 20110-2209, USA. The ATCC deposit was made pursuant to the terms of the Budapest Treaty on the international recognition of the deposit of microorganisms for purposes of patent procedure.

- 5           A "polynucleotide" of the present invention also includes those polynucleotides capable of hybridizing, under stringent hybridization conditions, to sequences contained in SEQ ID NO:X, the complement thereof, or the cDNA within the clone deposited with the ATCC. "Stringent hybridization conditions" refers to an overnight incubation at 42 degree C in a solution comprising 50% formamide, 5x SSC  
10 (750 mM NaCl, 75 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 µg/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1x SSC at about 65 degree C.

- Also contemplated are nucleic acid molecules that hybridize to the polynucleotides of the present invention at lower stringency hybridization conditions.  
15 Changes in the stringency of hybridization and signal detection are primarily accomplished through the manipulation of formamide concentration (lower percentages of formamide result in lowered stringency); salt conditions, or temperature. For example, lower stringency conditions include an overnight incubation at 37 degree C in a solution comprising 6X SSPE (20X SSPE = 3M NaCl;  
20 0.2M NaH<sub>2</sub>PO<sub>4</sub>; 0.02M EDTA, pH 7.4), 0.5% SDS, 30% formamide, 100 ug/ml salmon sperm blocking DNA; followed by washes at 50 degree C with 1XSSPE, 0.1% SDS. In addition, to achieve even lower stringency, washes performed following stringent hybridization can be done at higher salt concentrations (e.g. 5X SSC).

- 25           Note that variations in the above conditions may be accomplished through the inclusion and/or substitution of alternate blocking reagents used to suppress background in hybridization experiments. Typical blocking reagents include Denhardt's reagent, BLOTTO, heparin, denatured salmon sperm DNA, and commercially available proprietary formulations. The inclusion of specific blocking  
30 reagents may require modification of the hybridization conditions described above, due to problems with compatibility.

Of course, a polynucleotide which hybridizes only to polyA<sup>+</sup> sequences (such as any 3' terminal polyA<sup>+</sup> tract of a cDNA shown in the sequence listing), or to a complementary stretch of T (or U) residues, would not be included in the definition of "polynucleotide," since such a polynucleotide would hybridize to any nucleic acid molecule containing a poly (A) stretch or the complement thereof (e.g., practically any double-stranded cDNA clone generated using oligo dT as a primer).

The polynucleotide of the present invention can be composed of any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. For example, polynucleotides can be composed of single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, the polynucleotide can be composed of triple-stranded regions comprising RNA or DNA or both RNA and DNA. A polynucleotide may also contain one or more modified bases or DNA or RNA backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications can be made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically, or metabolically modified forms.

The polypeptide of the present invention can be composed of amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres, and may contain amino acids other than the 20 gene-encoded amino acids. The polypeptides may be modified by either natural processes, such as posttranslational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched, for example, as a result of

ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched, and branched cyclic polypeptides may result from posttranslation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. (See, for instance, PROTEINS - STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York (1993); POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B. C. Johnson, Ed., Academic Press, New York, pgs. 1-12 (1983); Seifter et al., Meth Enzymol 182:626-646 (1990); Rattan et al., Ann NY Acad Sci 663:48-62 (1992).)

"SEQ ID NO:X" refers to a polynucleotide sequence while "SEQ ID NO:Y" refers to a polypeptide sequence, both sequences identified by an integer specified in Table 1.

"A polypeptide having biological activity" refers to polypeptides exhibiting activity similar, but not necessarily identical to, an activity of a polypeptide of the present invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. In the case where dose dependency does exist, it need not be identical to that of the polypeptide, but rather substantially similar to the dose-dependence in a given activity as compared to the polypeptide of the present invention (i.e., the candidate polypeptide will exhibit greater activity or not more than about 25-fold less and, preferably, not more than about tenfold less activity, and most preferably, not more than about three-fold less activity relative to the polypeptide of the present invention.)

Many proteins (and translated DNA sequences) contain regions where the amino acid composition is highly biased toward a small subset of the available

residues. For example, membrane spanning domains and signal peptides (which are also membrane spanning) typically contain long stretches where Leucine (L), Valine (V), Alanine (A), and Isoleucine (I) predominate. Poly-Adenosine tracts (polyA) at the end of cDNAs appear in forward translations as poly-Lysine (poly-K) and poly-  
5 Phenylalanine (poly-F) when the reverse complement is translated. These regions are often referred to as “low complexity” regions.

Such regions can cause database similarity search programs such as BLAST to find high-scoring sequence matches that do not imply true homology. The problem is exacerbated by the fact that most weight matrices (used to score the alignments  
10 generated by BLAST) give a match between any of a group of hydrophobic amino acids (L,V and I) that are commonly found in certain low complexity regions almost as high a score as for exact matches.

In order to compensate for this, BLASTX.2 (version 2.0a5MP-WashU) employs two filters (“seg” and “xnu”) which “mask” the low complexity regions in a  
15 particular sequence. These filters parse the sequence for such regions, and create a new sequence in which the amino acids in the low complexity region have been replaced with the character “X”. This is then used as the input sequence (sometimes referred to herein as “Query” and/or “Q”) to the BLASTX program. While this regime helps to ensure that high-scoring matches represent true homology, there is a  
20 negative consequence in that the BLASTX program uses the query sequence that has been masked by the filters to draw alignments.

Thus, a stretch of “X”s in an alignment shown in the following application does not necessarily indicate that either the underlying DNA sequence or the translated protein sequence is unknown or uncertain. Nor is the presence of such  
25 stretches meant to indicate that the sequence is identical or not identical to the sequence disclosed in the alignment of the present invention. Such stretches may simply indicate that the BLASTX program masked amino acids in that region due to the detection of a low complexity region, as defined above. In all cases, the reference sequence(s) (sometimes referred to herein as “Subject”, “Sbjct”, and/or “S”) indicated  
30 in the specification, sequence table (Table 1), and/or the deposited clone is (are) the definitive embodiment(s) of the present invention, and should not be construed as

limiting the present invention to the partial sequence shown in an alignment, unless specifically noted otherwise herein.

### **Polynucleotides and Polypeptides of the Invention**

5

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 1**

It has been discovered that this gene is expressed primarily in Human Adipose tissue.

Many polynucleotide sequences, such as EST sequences, are publicly  
10 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:11 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention  
15 are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2304 of SEQ ID NO:11, b is an integer of 15 to 2318, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:11, and where b is greater than or equal to a + 14.

20

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 2**

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares fetal liver spleen 1NFLS and to a lesser extent in Human Colon Cancer;re-excision, wilm's tumor,

25 Soares\_fetal\_liver\_spleen\_1NFLS\_S1, Human Adipose, and H. Frontal cortex,epileptic;re-excision.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:12 and may have been publicly available prior to conception of  
30 the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention



are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 606 of SEQ ID NO:12, b is an integer of 15 to 620, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:12, and where b is greater than or equal to a + 14.

### FEATURES OF PROTEIN ENCODED BY GENE NO: 3

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gil439877 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "reverse transcriptase". A partial alignment demonstrating the observed homology is shown immediately below.

```

15      >gi|439877 reverse transcriptase [Homo sapiens]
          Length = 361

          Plus Strand HSPs:

20      Score = 104 (36.6 bits), Expect = 1.1e-18, Sum P(4) = 1.1e-18
          Identities = 22/53 (41%), Positives = 31/53 (58%), Frame = +2

25      Query:      23 FCSVKDTVKRLKMQATAWQKIFTKHISDKGLIS-----RTYPNSQNSTIRK 160
                   FC+ K T R+ QAT W+KIF ++SDKGL+S          + Y      N+ I+K
          Sbjct:    105 FCTAKQTTIRVNRQATEWEKIFATYLSDKGLLSGICNELKQIYKKKTNNPIKK 157

```

The segment of gil439877 that is shown as "Sbjct" above is set out as SEQ ID NO. 111. Based on the structural similarity these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art and described elsewhere herein. Assays for determining such activities are also known in the art some of which have been described elsewhere herein.

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out as SEQ ID NO. 112 which corresponds to the Query sequence in the alignment shown above (gaps introduced in the sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following tissues: Human Adipose.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:13 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 816 of SEQ ID NO:13, b is an integer of 15 to 830, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:13, and where b is greater than or equal to a + 14.

#### 15           **FEATURES OF PROTEIN ENCODED BY GENE NO: 4**

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gil1777577 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "WW-domain binding protein 1". A partial alignment demonstrating the observed homology is shown immediately below.

```

25           >gi|1777577 WW-domain binding protein 1 [Mus musculus]
              Length = 305

              Plus Strand HSPs:

              Score = 336 (118.3 bits), Expect = 7.8e-34, Sum P(2) = 7.8e-34
30           Identities = 53/85 (62%), Positives = 64/85 (75%), Frame = +2

              Query:     113 KEACVGTNNQSYICDTGHCCGQSQCCNYYYELWWFWLVWTIIIIILSCCCVCHHRRAKHRL
                          292           +E C G N Q Y+C+TGHCCG++ CC YYYELWWFWL+WT++I+ SCCC   HRRAK RL
35           Sbjct:     60 RELCPGVNTQPYLCETGHCCGETGCCTYYYELWWFWLLWTVLILFSCCCAFRHHRAKLRL
                          119

              Query:     293 QAQQRQHEINLIAYREA-HNYSALP 364
                          Q QQRQ EINL+AY   A H       +P
40           Sbjct:     120 QQQRQREINLLAYHGACHGAGPVP 144

```

The segment of gill777577 that is shown as "Sbjct" above is set out in the sequence listing as SEQ ID NO. 113. Based on the structural similarity these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art and described elsewhere herein. Assays for determining such activities are also known in the art some of which have been described elsewhere herein.

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 114 which corresponds to the Query sequence in the alignment shown above (gaps introduced in the sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares fetal liver spleen 1NFLS, Soares infant brain 1NIB and to a lesser extent in Jurkat T-cell G1 phase, Human Adipose, Synovial Fibroblasts (control), Hodgkin's Lymphoma II, Pancreatic Islet, Soares\_fetal\_heart\_NbHH19W, Synovial hypoxia-RSF subtracted, Human Chronic Synovitis, Soares\_pregnant\_uterus\_NbHPU, Stratagene endothelial cell 937223, Stratagene lung (#937210), Smooth muscle, serum treated, Human Fetal Kidney, LNCAP + 30nM R1881, H. Adipose Tissue, Dermatofibrosarcoma Protuberance, Human Primary Breast Cancer, Human Tonsils, Lib 2, Alzheimers, spongy change, Soares\_total\_fetus\_Nb2HF8\_9w, Human Umbilical Vein, Endo. remake, Human Fetal Epithelium (Skin), Soares\_NhHMPu\_S1, Human Manic Depression Tissue, Human Fetal Kidney, Human Umbilical Vein Endothelial Cells, uninduced, Soares breast 2NbHBst, Human Adrenal Gland Tumor, Colon Normal II, Soares breast 3NbHBst, Human Testes Tumor, Human Synovial Sarcoma, Human Fetal Lung III, Bone marrow, human tonsils, Activated T-Cell (12hs)/Thiouridine labelledEco, CD34 depleted Buffy Coat (Cord Blood), re-excision, HUMAN B CELL LYMPHOMA, Keratinocyte, Nine Week Old Early Stage Human, and Human Cerebellum.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 64 as residues: Met-1 to Trp-8.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:14 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 4040 of SEQ ID NO:14, b is an integer of 15 to 4054, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:14, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 5**

It has been discovered that this gene is expressed primarily in the following tissues: Human Adipose.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 65 as residues: Gly-22 to Val-29.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:15 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 438 of SEQ ID NO:15, b is an integer of 15 to 452, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:15, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 6**

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Human Adipose and to a lesser extent in Human Fetal Brain, normalized A5002F, Hodgkin's Lymphoma I, Merkel Cells, and Human Amygdala.

Many polynucleotide sequences, such as EST sequences, are publicly  
5 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:16 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention  
10 are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1179 of SEQ ID NO:16, b is an integer of 15 to 1193, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:16, and where b is greater than or equal to a + 14.

15

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 7**

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares\_total\_fetus\_Nb2HF8\_9w, Human Adipose and to a lesser extent in H. Frontal cortex,epileptic;re-excision, Soares ovary tumor NbHOT,  
20 Human Amygdala Depression, re-excision, H. Striatum Depression, subtracted, Smooth muscle, control; re-excision, Human aorta polyA+ (TFujiwara), NCI\_CGAP\_GCB1, NCI\_CGAP\_Brn23, Soares\_parathyroid\_tumor\_NbHPA, Soares\_senescent\_fibroblasts\_NbHSF, Soares\_placenta\_8to9weeks\_2NbHP8to9W, Synovial IL-1/TNF stimulated, Human Osteoclastoma, re-excision, Human Prostate,  
25 Soares\_senescent\_fibroblasts\_NbHSF, Apoptotic T-cell, Hemangiopericytoma, Human Adrenal Gland Tumor, Human Adult Pulmonary;re-excision, Human 8 Week Whole Embryo, and Soares placenta Nb2HP.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 67 as residues: Ala-17 to Trp-23, Ser-46 to Thr-51.

30 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:17 and may have been publicly available prior to conception of

the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the  
5 general formula of a-b, where a is any integer between 1 to 1580 of SEQ ID NO:17, b is an integer of 15 to 1594, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:17, and where b is greater than or equal to a + 14.

## 10 FEATURES OF PROTEIN ENCODED BY GENE NO: 8

It has been discovered that this gene is expressed primarily in Human Adipose.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are  
15 related to SEQ ID NO:18 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the  
20 general formula of a-b, where a is any integer between 1 to 1028 of SEQ ID NO:18, b is an integer of 15 to 1042, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:18, and where b is greater than or equal to a + 14.

25

## FEATURES OF PROTEIN ENCODED BY GENE NO: 9

It has been discovered that this gene is expressed primarily in the following tissues: Human Pineal Gland, Human Adipose and to a lesser extent in H. Adipose Tissue, Human Hypothalamus, schizophrenia, re-excision, Human  
30 Hypothalamus, Schizophrenia.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are

related to SEQ ID NO:19 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 841 of SEQ ID NO:19, b is an integer of 15 to 855, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:19, and where b is greater than or equal to a + 14.

10

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 10**

It has been discovered that this gene is expressed primarily in Human Adipose.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:20 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1106 of SEQ ID NO:20, b is an integer of 15 to 1120, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:20, and where b is greater than or equal to a + 14.

25

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 11**

It has been discovered that this gene is expressed primarily in Human Adipose.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 71 as residues: Lys-21 to Thr-26.

30

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are

related to SEQ ID NO:21 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1264 of SEQ ID NO:21, b is an integer of 15 to 1278, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:21, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 12**

It has been discovered that this gene is expressed primarily in Human Adipose.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 72 as residues: Thr-24 to Glu-29.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:22 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 728 of SEQ ID NO:22, b is an integer of 15 to 742, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:22, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 13**

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Stratagene lung (#937210), Human Adipose, Human umbilical vein endothelial cells, IL-4 induced.



Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:23 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1019 of SEQ ID NO:23, b is an integer of 15 to 1033, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:23, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 14**

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares infant brain 1NIB and to a lesser extent in Soares retina N2b4HR, Stratagene lung (#937210), H. Adipose, subtracted, Soares\_NhHMPu\_S1, H. Kidney Cortex, subtracted, Soares breast 3NbHBst, Soares\_multiple\_sclerosis\_2NbHMSP, Soares fetal liver spleen 1NFLS, Human Old Ovary, Human Amygdala Depression, re-excision, Human Fetal Lung, Soares retina N2b5HR, H. Atrophic Endometrium, Human Pineal Gland, Human Amygdala;re-excision, B Cell lymphoma, Human Colon; re-excision, Human Manic Depression Tissue, Soares\_fetal\_lung\_NbHL19W, Human Synovial Sarcoma, Human Fetal Lung III, Human Amygdala, and Nine Week Old Early Stage Human.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:24 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1899 of SEQ ID NO:24, b is an integer of 15 to 1913, where both a and b correspond to the positions of

nucleotide residues shown in SEQ ID NO:24, and where b is greater than or equal to a + 14.

## FEATURES OF PROTEIN ENCODED BY GENE NO: 15

5           The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gnllPIDle311534 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "phosphate cyclase."

10       A partial alignment demonstrating the observed homology is shown immediately below.

```

>gnl|PID|e311534 phosphate cyclase [Homo sapiens] >gnl|PID|e311729
phosphate
15         cyclase [Homo sapiens] {SUB 1-48}
           Length = 366

           Plus Strand HSPs:

20       Score = 687 (241.8 bits), Expect = 5.7e-67, P = 5.7e-67
       Identities = 137/147 (93%), Positives = 138/147 (93%), Frame = +3

       Query:      6 EEIRDLYVNIQPVQEPKDQAFXXXXXXXXXAETSTGCLFAGSSLGKRGVNADKVGIEAAE
185
25       +EIRDLYVNIQPVQEPKDQAF                      AETSTGCLFAGSSLGKRGVNADKVGIEAAE
       Sbjct:      220 KEIRDLYVNIQPVQEPKDQAFGNGNGIIIIAETSTGCLFAGSSLGKRGVNADKVGIEAAE
279

       Query:      186 MLLANLRHGGTVDEYLQDQLIVFMALANGVSRIKTGPVTLHTQTAIHF AEQIAKAKFIVK
30       365
       MLLANLRHGGTVDEYLQDQLIVFMALANGVSRIKTGPVTLHTQTAIHF AEQIAKAKFIVK
       Sbjct:      280 MLLANLRHGGTVDEYLQDQLIVFMALANGVSRIKTGPVTLHTQTAIHF AEQIAKAKFIVK
339

       Query:      366 KSEDEEDA AKDTYII ECQGIGMTNPNL 446
       KSEDEEDA AKDTYII ECQGIGMTNPNL
       Sbjct:      340 KSEDEEDA AKDTYII ECQGIGMTNPNL 366

40

```

The segment of gnllPIDle311534 that is shown as "Sbjct" above is set out in the sequence listing as SEQ ID NO. 121. Based on the structural similarity these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art and described elsewhere herein. Assays for

determining such activities are also known in the art some of which have been described elsewhere herein.

Preferred polypeptides of the invention comprise polypeptides having the amino acid sequence set out in the sequence listing as SEQ ID NO. 122 which  
5 corresponds to the Query sequence in the alignment shown above (gaps introduced in the sequence by the computer are, of course, removed, and residues shown as "X" do to use of a low complexity filter in the BLAST routine can be resolved by reference to other sequences provided for Gene 15 in the sequence listing).

It has been discovered that this gene is expressed primarily in the following  
10 tissues/cDNA libraries: NCI\_CGAP\_GCB1, NCI\_CGAP\_Pr22, Primary Dendritic Cells, lib 1 and to a lesser extent in Activated T-Cells, 4 hrs., ligation 2, Aorta endothelial cells + TNF-a, Spleen metastatic melanoma, Human Adult Small Intestine, 12 Week Old Early Stage Human, II, Stratagene endothelial cell 937223, Human Umbilical Vein Endothelial Cells, uninduced, Stromal cell TF274, Spinal cord, Soares  
15 melanocyte 2NbHM, Soares\_multiple\_sclerosis\_2NbHMSP, T cell helper II, Human Cerebellum, and NCI\_CGAP\_Lu5, NCI\_CGAP\_Ov2, NCI\_CGAP\_Co10, NCI\_CGAP\_Kid5.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 75 as residues: Lys-61 to Lys-70.

20 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:25 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence  
25 would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1719 of SEQ ID NO:25, b is an integer of 15 to 1733, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:25, and where b is greater than or equal to a  
30 + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 16

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares infant brain 1NIB and to a lesser extent in Colon Normal III, Human Cerebellum, Stratagene neuroepithelium NT2RAMI 937234, Human fetal brain (TFujiwara), Soares\_fetal\_heart\_NbHH19W, Whole brain, HUMAN STOMACH, Aorta endothelial cells + TNF-a, Stratagene colon (#937204), Smooth Muscle- HASTE normalized, Human Colon Cancer;re-excision, Human Whole Brain #2 - Oligo dT > 1.5Kb, Stratagene HeLa cell s3 937216, Spinal Cord, re-excision, Merkel Cells, Human umbilical vein endothelial cells, IL-4 induced, Human Adrenal Gland Tumor, NCI\_CGAP\_Co10, NCI\_CGAP\_GCB1, Human Osteoclastoma, Human Amygdala, Human Bone Marrow, treated, and Human Testes.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:26 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2708 of SEQ ID NO:26, b is an integer of 15 to 2722, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:26, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 17**

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Human Amygdala and Soares infant brain 1NIB.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 77 as residues: Ser-11 to Gly-19.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:27 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence

would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1080 of SEQ ID NO:27, b is an integer of 15 to 1094, where both a and b correspond to the positions of  
5 nucleotide residues shown in SEQ ID NO:27, and where b is greater than or equal to a + 14.

### **FEATURES OF PROTEIN ENCODED BY GENE NO: 18**

It has been discovered that this gene is expressed primarily in Human  
10 Amygdala.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:28 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically  
15 excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1825 of SEQ ID NO:28, b is an integer of 15 to 1839, where both a and b correspond to the positions of  
20 nucleotide residues shown in SEQ ID NO:28, and where b is greater than or equal to a + 14.

### **FEATURES OF PROTEIN ENCODED BY GENE NO: 19**

It has been discovered that this gene is expressed primarily in the following  
25 tissues/cDNA libraries: Soares\_multiple\_sclerosis\_2NbHMSP and to a lesser extent in Pharynx Carcinoma, Soares\_fetal\_heart\_NbHH19W, Soares\_pregnant\_uterus\_NbHPU, H. Meningioma, M1, wilm's tumor, Human Amygdala, and Soares placenta Nb2HP.

When tested against U937 Myeloid cell lines, supernatants removed from cells  
30 containing this gene activated the GAS assay. Thus, it is likely that this gene activates myeloid cells through the Jak-STAT signal transduction pathway. The gamma activating sequence (GAS) is a promoter element found upstream of many genes

which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 79 as residues: Met-1 to Trp-7, and Arg-40 to Ser-55.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:29 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1316 of SEQ ID NO:29, b is an integer of 15 to 1330, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:29, and where b is greater than or equal to a + 14.

## 20 FEATURES OF PROTEIN ENCODED BY GENE NO: 20

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Human Amygdala;re-excision, Human Osteosarcoma, wilm's tumor, Adipocytes, CD34 depleted Buffy Coat (Cord Blood), re-excision, and Human Amygdala.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:30 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1490 of SEQ ID NO:30, b

is an integer of 15 to 1504, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:30, and where b is greater than or equal to a + 14.

## 5 FEATURES OF PROTEIN ENCODED BY GENE NO: 21

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gnl|PID|e314281 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "Pro-Pol-dUTPase polyprotein" A partial alignment demonstrating the observed homology is shown immediately below.

```

15  >gnl|PID|e314281 Pro-Pol-dUTPase polyprotein [Mus musculus] >bbs|132484
    fibulin
        gene homolog [mice, Peptide Partial, 78 aa] [Mus sp.] (SUB
        380-457)
        Length = 1182

20  Minus Strand HSPs:

    Score = 221 (77.8 bits), Expect = 1.1e-20, Sum P(3) = 1.1e-20
    Identities = 68/193 (35%), Positives = 93/193 (48%), Frame = -1

25  Query:   572 VDYIELLPKWKG*HFVLTRTDPR--YRFA-----SSYKILPKLSSMVSW-NALPIVIFH
    420
        VDY+  LPSWKG  FVLT  D    Y FA      S+   +  L+   + + + +P  I
    Sbjct:   837 VDYVGPLPSWKGQRFVLTGVDYSGYGFAFPARNASAKTTIHGLTECLIYRHGIPHSIAS
    896

30  Query:   419 TTLLXIKXXSQKNFSMSH-CSWNSLVYVPYHAKEAGLIG*WDGLLKIXXXXXXXXXXXXX
    243
        + + ++  H   W+   +VP+H +  AGLI  W+GLLK+
    Sbjct:   897 DQGTHF-TAREVRQWAHDHGIHWS--YHVPHHPEAAGLIERWNGLLKMLQHQGLGGSLE
    35  953

    Query:   242 XXXSSPEGIYALNQHPINGTFFPSI----ARNQGVETKVAPCIINPGDPLAKFILPVLI
    75
        +  +YALNQ  I GT  P      +RNQGE  + P  I   DPL KF+LPV  I
    Sbjct:   954 GWGRVLQKAVYALNQRSIYGTVSPARIHGSRNQGEKGIVPLTITHSDPLGKFLLPVPI
    40  1013

    Query:    74 ILCPTGLEVLVPKGEI 27
        L   GLEVL P+  +
    Sbjct:  1014 TLGSAGLEVLAPAEAGV 1029
45

```

The segment of gnlIPIDle314281 that is shown as "Sbjct" above is set out as sequence(s) SEQ ID NO. 123 Based on the structural similarity these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art and described elsewhere herein. Assays for determining such activities are also known in the art some of which have been described elsewhere herein. Preferred polypeptides of the invention comprise polypeptides having the amino acid sequence(s) set out as SEQ ID NO. 124 which correspond to the Query sequence in the alignment shown above (gaps introduced in the sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in Human Amygdala.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:31 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1266 of SEQ ID NO:31, b is an integer of 15 to 1280, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:31, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 22**

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: T-Cell PHA 16 hrs, Human Osteoclastoma, Soares infant brain 1NIB and to a lesser extent in Morton Fetal Cochlea, 12 Week Old Early Stage Human, II, Human T-Cell Lymphoma, Soares melanocyte 2NbHM, Soares\_pregnant\_uterus\_NbHPU, CD34 positive cells (Cord Blood), Spleen, Chronic lymphocytic leukemia, Soares placenta Nb2HP, Primary Dendritic Cells, lib 1, Thyroid Thyroiditis, Osteoclastoma-normalized A, Normal Prostate, Thymus, Human Adult Liver, subtracted, Human Gall Bladder, fraction II, Ovarian Tumor 10-3-95,



Morton Fetal, Soares\_pineal\_gland\_N3HPG, Human Colon Cancer;re-excision,  
NTERA2 + retinoic acid, 14 days, H. Kidney Cortex, subtracted, Jurkat T-cell G1  
phase, Human Primary Breast Cancer Reexcision, Stromal cell TF274, Human  
umbilical vein endothelial cells, IL-4 induced, Liver, Hepatoma, Stratagene lung  
5 carcinoma 937218, Stratagene NT2 neuronal precursor 937230, Ulcerative Colitis,  
Human Adrenal Gland Tumor, Soares\_placenta\_8to9weeks\_2NbHP8to9W, Human  
Placenta, Activated T-Cell (12hs)/Thiouridine labelledEco, CD34 depleted Buffy  
Coat (Cord Blood), re-excision, Human Amygdala, HUMAN B CELL LYMPHOMA,  
Soares\_fetal\_heart\_NbHH19W, Human Testes, T cell helper II, and Hodgkin's  
10 Lymphoma II.

Many polynucleotide sequences, such as EST sequences, are publicly  
available and accessible through sequence databases. Some of these sequences are  
related to SEQ ID NO:32 and may have been publicly available prior to conception of  
the present invention. Preferably, such related polynucleotides are specifically  
15 excluded from the scope of the present invention. To list every related sequence  
would be cumbersome. Accordingly, preferably excluded from the present invention  
are one or more polynucleotides comprising a nucleotide sequence described by the  
general formula of a-b, where a is any integer between 1 to 1514 of SEQ ID NO:32, b  
is an integer of 15 to 1528, where both a and b correspond to the positions of  
20 nucleotide residues shown in SEQ ID NO:32, and where b is greater than or equal to a  
+ 14.

### FEATURES OF PROTEIN ENCODED BY GENE NO: 23

The computer algorithm BLASTX has been used to determine that the  
25 translation product of this gene shares sequence homology with, as a non-limiting  
example, the sequence accessible through the following database accession no.  
gill142706 (all information available through the recited accession number is  
incorporated herein by reference) which is described therein as "hORC2L." A partial  
alignment demonstrating the observed homology is shown immediately below.

30

```
>gi|1142706 hORC2L [Homo sapiens]  
Length = 577
```

Minus Strand HSPs:

Score = 171 (60.2 bits), Expect = 5.1e-09, P = 5.1e-09  
Identities = 33/34 (97%), Positives = 34/34 (100%), Frame = -2

5

Query: 950 KQTLRNLLSKVSPSFSaelKQLNQYEkLFHKWM 849  
+QTLRNLLSKVSPSFSaelKQLNQYEkLFHKWM  
Sbjct: 269 QQTLRNLLSKVSPSFSaelKQLNQYEkLFHKWM 302

10

The segment of gill142706 that is shown as "Sbjct" above is set out as SEQ ID NO. 125. Based on the structural similarity these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art and described elsewhere herein. Assays for determining such activities are also known in the art some of which have been described elsewhere herein.

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 126 which corresponds to the Query sequence in the alignment shown above (gaps introduced in the sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in Human Amygdala.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:33 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1444 of SEQ ID NO:33, b is an integer of 15 to 1458, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:33, and where b is greater than or equal to a + 14.

**35 FEATURES OF PROTEIN ENCODED BY GENE NO: 24**

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: NCI\_CGAP\_Co3 and to a lesser extent in Soares retina N2b5HR, Human colon carcinoma (HCC) cell line, remake, Soares retina N2b4HR, Soares\_fetal\_liver\_spleen\_1NFLS\_S1, Soares\_pregnant\_uterus\_NbHPU, HEL cell  
5 line, Human Adult Small Intestine, Soares adult brain N2b5HB55Y, and Anergetic T-cell.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 84 as residues: Met-1 to Lys-12.

Many polynucleotide sequences, such as EST sequences, are publicly  
10 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:34 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention  
15 are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1746 of SEQ ID NO:34, b is an integer of 15 to 1760, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:34, and where b is greater than or equal to a + 14.

20

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 25**

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares\_multiple\_sclerosis\_2NbHMSP, Soares melanocyte 2NbHM and to a lesser extent in Weizmann Olfactory Epithelium, Human  
25 Hypothalmus, Schizophrenia, and Human Amygdala.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:35 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically  
30 excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the

general formula of a-b, where a is any integer between 1 to 1554 of SEQ ID NO:35, b is an integer of 15 to 1568, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:35, and where b is greater than or equal to a + 14.

5

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 26**

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares placenta Nb2HP and to a lesser extent in Human Fetal Kidney, and Human Amygdala.

10 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:36 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence  
15 would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 729 of SEQ ID NO:36, b is an integer of 15 to 743, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:36, and where b is greater than or equal to a  
20 + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 27**

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares infant brain 1NIB and to a lesser extent in Soares  
25 melanocyte 2NbHM, Soares fetal liver spleen 1NFLS, Human Testes, Stratagene fetal spleen (#937205), Soares\_fetal\_heart\_NbHH19W, Human Testes Tumor, Human Skin Tumor, Human Fetal Heart, Spleen, Chronic lymphocytic leukemia, Human Fetal Spleen, Jurkat T-cell G1 phase, Soares\_pregnant\_uterus\_NbHPU, Human Adipose, Soares adult brain N2b5HB55Y, Human adult testis, large inserts, Human  
30 Gall Bladder, Soares\_placenta\_8to9weeks\_2NbHP8to9W, Soares\_NhHMPu\_S1, Stratagene NT2 neuronal precursor 937230, T cell helper II, Stratagene colon (#937204), Primary Dendritic Cells, lib 1, Soares ovary tumor NbHOT, CD34+ cell,

I, CD34+cells, II, FRACTION 2, Human Adult Liver, subtracted, Human Primary Breast Cancer;re-excision, Human Neutrophils, Activated, re-excision, Human T-cell lymphoma;re-excision, Human Soleus, Human Adult Heart;re-excision, B Cell lymphoma, Human Colon Cancer;re-excision, Synovial hypoxia, H. Meningima, M1, Human Neutrophil, Apoptotic T-cell, human ovarian cancer, Human Uterine Cancer, Human Pancreas Tumor, Human Heart, Stratagene colon (#937204), Stratagene NT2 neuronal precursor 937230, Human umbilical vein endothelial cells, IL-4 induced, Spinal cord, Soares\_fetal\_liver\_spleen\_1NFLS\_S1, Epithelial-TNF $\alpha$  and INF induced, Human T-Cell Lymphoma, Soares\_NhHMPu\_S1, Stratagene neuroepithelium (#937231), Human Placenta, Bone marrow, Human Amygdala, HUMAN B CELL LYMPHOMA, Bone Marrow Cell Line (RS4;11), and Stratagene pancreas (#937208).

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:37 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1701 of SEQ ID NO:37, b is an integer of 15 to 1715, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:37, and where b is greater than or equal to a + 14.

## 25 **FEATURES OF PROTEIN ENCODED BY GENE NO: 28**

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gil2911265 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "Unknown gene product." A partial alignment demonstrating the observed homology is shown immediately below.

```

5      >gi|2911265 (AC002550) Unknown gene product [Homo sapiens]
      >sp|O43329|O43329
      HYPOTHETICAL 23.8 KD PROTEIN.
      Length = 206

      Plus Strand HSPs:

10     Score = 1070 (376.7 bits), Expect = 1.5e-107, P = 1.5e-107
      Identities = 206/206 (100%), Positives = 206/206 (100%), Frame = +1

      Query: 1027 MINIDGKMRPSESFLLEFLCNFFSTLLIVPDHPEHGVFLVRELLNVIQDYTWEDNSDEK
1206
      Sbjct: 1 MINIDGKMRPSESFLLEFLCNFFSTLLIVPDHPEHGVFLVRELLNVIQDYTWEDNSDEK
15 60

      Query: 1207 IRIYTCVLHLLSAMSQETYLYHIDKVDSNDSLYGGDSKFLAENNKLCETVMAQILEHLKT
1386
      Sbjct: 61 IRIYTCVLHLLSAMSQETYLYHIDKVDSNDSLYGGDSKFLAENNKLCETVMAQILEHLKT
20 120

      Query: 1387 LAKDEALKRQSSLGLSFFNSILAHGDLRNNKLNQLSVNLWHLAQRHGCADTRTMVKTLEY
25 1566
      Sbjct: 121 LAKDEALKRQSSLGLSFFNSILAHGDLRNNKLNQLSVNLWHLAQRHGCADTRTMVKTLEY
180

      Query: 1567 IKKQSKQPDMTHTLTELALRLPLQTRT 1644
30      IKKQSKQPDMTHTLTELALRLPLQTRT
      Sbjct: 181 IKKQSKQPDMTHTLTELALRLPLQTRT 206

35

```

The segment of gi2911265 that is shown as "Sbjct" above is set out in the sequence listing as SEQ ID NO. 127.

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out as SEQ ID NO. 128 which corresponds to the Query sequence in the alignment shown above (gaps introduced in the sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Human retina cDNA randomly primed sublibrary, Soares\_multiple\_sclerosis\_2NbHMSP, Human Testes and to a lesser extent in NCI\_CGAP\_Pr2, Human Synovial Sarcoma, Primary Dendritic cells, frac 2, Soares\_fetal\_heart\_NbHH19W, Human Pancreatic Carcinoma, HUMAN STOMACH, Stratagene ovary (#937217), Human fetal heart, Lambda ZAP Express, NCI\_CGAP\_Pr11, Human Adult Testes, Large Inserts, Reexcision, Liver, Hepatoma,

Synovial Fibroblasts (control), Rejected Kidney, lib 4, Human Amygdala, Hodgkin's Lymphoma II, Soares fetal liver spleen 1NFLS, and Primary Dendritic Cells, lib 1.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are  
5 related to SEQ ID NO:38 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the  
10 general formula of a-b, where a is any integer between 1 to 1882 of SEQ ID NO:38, b is an integer of 15 to 1896, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:38, and where b is greater than or equal to a + 14.

## 15 **FEATURES OF PROTEIN ENCODED BY GENE NO: 29**

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Human Amygdala, Activated T-Cell (12hs)/Thiouridine labelledEco.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO.  
20 89 as residues: Pro-57 to Phe-65.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:39 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically  
25 excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2061 of SEQ ID NO:39, b is an integer of 15 to 2075, where both a and b correspond to the positions of  
30 nucleotide residues shown in SEQ ID NO:39, and where b is greater than or equal to a + 14.

**FEATURES OF PROTEIN ENCODED BY GENE NO: 30**

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares infant brain 1N1B, Human Amygdala and to a lesser extent in Human Infant Brain, and Soares\_multiple\_sclerosis\_2NbHMSP.

5 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:40 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence  
10 would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1578 of SEQ ID NO:40, b is an integer of 15 to 1592, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:40, and where b is greater than or equal to a  
15 + 14.

**FEATURES OF PROTEIN ENCODED BY GENE NO: 31**

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares retina N2b4HR, Human Amygdala.

20 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:41 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence  
25 would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1310 of SEQ ID NO:41, b is an integer of 15 to 1324, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:41, and where b is greater than or equal to a  
30 + 14.

**FEATURES OF PROTEIN ENCODED BY GENE NO: 32**



It has been discovered that this gene is expressed primarily in Human Amygdala.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 92 as residues: Asn-39 to Lys-44.

5 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:42 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence  
10 would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1200 of SEQ ID NO:42, b is an integer of 15 to 1214, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:42, and where b is greater than or equal to a  
15 + 14.

### FEATURES OF PROTEIN ENCODED BY GENE NO: 33

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting  
20 example, the sequence accessible through the following database accession no. gnllPIDld1026388 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "KIAA0532 protein." A partial alignment demonstrating the observed homology is shown immediately  
below.

25

```
>gnl|PID|dl026388 (AB011104) KIAA0532 protein [Homo sapiens]
>sp|D1026388|D1026388 KIAA0532 PROTEIN (FRAGMENT).
Length = 1637
```

30

Plus Strand HSPs:

```
Score = 395 (139.0 bits), Expect = 1.0e-51, Sum P(2) = 1.0e-51
Identities = 80/84 (95%), Positives = 80/84 (95%), Frame = +2
```

35

```
Query: 857 KMLQSLGRPEVHMALDVVLVRGSGQEHEGCLLLTSEVLFVVSSED TQQQAXPVTEIDCA
1036
KMLQSLGRPEVHMALDVVLVRGSGQEHEGCLLLTSEVLFVVSSED TQQQA PVTEIDCA
Sbjct: 1473 KMLQSLGRPEVHMALDVVLVRGSGQEHEGCLLLTSEVLFVVSSED TQQQAFPVTEIDCA
1532
```

Query: 1037 QDXKQNNLLTVQXKQPRVAXDVEV 1108  
 QD KQNNLLTVQ KQPRVA DVEV  
 Sbjet: 1533 QDSKQNNLLTVQLKQPRVACDVEV 1556

Score = 194 (68.3 bits), Expect = 1.0e-51, Sum P(2) = 1.0e-51  
 Identities = 35/35 (100%), Positives = 35/35 (100%), Frame = +3

Query: 192 GILHGAGLSQLPKQRHQPSDLHADQAPNSHVKYVW 296  
 GILHGAGLSQLPKQRHQPSDLHADQAPNSHVKYVW  
 Sbjet: 1438 GILHGAGLSQLPKQRHQPSDLHADQAPNSHVKYVW 1472

15 The segments of gnlIPIDld1026388 that are shown as "Sbjet" above are set out as  
 SEQ ID NO. 129 and SEQ ID NO. 131 in the sequence listing.

Preferred polypeptides of the invention comprise a polypeptide having the  
 amino acid sequence set out as SEQ ID NO. 130 or SEQ ID NO. 132 in the sequence  
 listing which correspond to the Query sequence in the alignment shown above (gaps  
 20 introduced in the sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following  
 tissues: Human Amygdala, Human 8 Week Whole Embryo.

Many polynucleotide sequences, such as EST sequences, are publicly  
 available and accessible through sequence databases. Some of these sequences are  
 25 related to SEQ ID NO:43 and may have been publicly available prior to conception of  
 the present invention. Preferably, such related polynucleotides are specifically  
 excluded from the scope of the present invention. To list every related sequence  
 would be cumbersome. Accordingly, preferably excluded from the present invention  
 are one or more polynucleotides comprising a nucleotide sequence described by the  
 30 general formula of a-b, where a is any integer between 1 to 1324 of SEQ ID NO:43, b  
 is an integer of 15 to 1338, where both a and b correspond to the positions of  
 nucleotide residues shown in SEQ ID NO:43, and where b is greater than or equal to a  
 + 14.

### 35 **FEATURES OF PROTEIN ENCODED BY GENE NO: 34**

It has been discovered that this gene is expressed primarily in the following  
 tissues/cDNA libraries: Human Amygdala, Stratagene lung (#937210).

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:44 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1672 of SEQ ID NO:44, b is an integer of 15 to 1686, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:44, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 35**

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Stratagene HeLa cell s3 937216, Soares infant brain 1NIB and to a lesser extent in Human Prostate, Soares\_total\_fetus\_Nb2HF8\_9w, Human Testes, Human Infant Brain, NTERA2, control, Human Testes Tumor, Stratagene neuroepithelium (#937231), Human Synovial Sarcoma, Anergic T-cell, and Human Amygdala.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:45 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1620 of SEQ ID NO:45, b is an integer of 15 to 1634, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:45, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 36**

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares placenta Nb2HP and to a lesser extent in T-Cell PHA 24 hrs, T Cell helper I, and Human Amygdala.

Many polynucleotide sequences, such as EST sequences, are publicly  
5 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:46 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence  
10 would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1998 of SEQ ID NO:46, b is an integer of 15 to 2012, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:46, and where b is greater than or equal to a + 14.

15

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 37**

It has been discovered that this gene is expressed primarily in Human Amygdala.

Many polynucleotide sequences, such as EST sequences, are publicly  
20 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:47 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention  
25 are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1308 of SEQ ID NO:47, b is an integer of 15 to 1322, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:47, and where b is greater than or equal to a + 14.

30

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 38**

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares infant brain 1N1B and to a lesser extent in Hypothalamus, Human Fetal Brain, Soares retina N2b4HR, wilm's tumor, Human Hippocampus, Soares\_multiple\_sclerosis\_2NbHMSP, and Human Amygdala.

5 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:48 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence  
10 would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 927 of SEQ ID NO:48, b is an integer of 15 to 941, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:48, and where b is greater than or equal to a  
15 + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 39**

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: CD34 positive cells (Cord Blood) and to a lesser extent in  
20 Human Lung Cancer, subtracted, Human Osteoblasts II, Human Amygdala, and Primary Dendritic Cells, lib 1.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 99 as residues: Gly-20 to His-33.

25 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:49 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention  
30 are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1860 of SEQ ID NO:49, b is an integer of 15 to 1874, where both a and b correspond to the positions of

nucleotide residues shown in SEQ ID NO:49, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 40**

5 It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Human Cerebellum and to a lesser extent in Human Pituitary, re-excision, Human Adult Heart;re-excision, Soares adult brain N2b4HB55Y, and Human Amygdala.

Many polynucleotide sequences, such as EST sequences, are publicly  
10 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:50 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence  
15 would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 629 of SEQ ID NO:50, b is an integer of 15 to 643, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:50, and where b is greater than or equal to a + 14.

20

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 41**

It has been discovered that this gene is expressed primarily in the following tissues: Synovial hypoxia-RSF subtracted, Human Amygdala, Spleen, and Chronic lymphocytic leukemia.

25 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:51 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence  
30 would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1655 of SEQ ID NO:51, b

is an integer of 15 to 1669, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:51, and where b is greater than or equal to a + 14.

## 5 FEATURES OF PROTEIN ENCODED BY GENE NO: 42

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gnl|PID|d1010352 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "platelet activating factor acetylhydrolase." A partial alignment demonstrating the observed homology is shown immediately below.

```

15  >gnl|PID|d1010352 platelet activating factor acetylhydrolase IB gamma-
    subunit
        [Homo sapiens] >pir|JC4246|JC4246 platelet-activating factor
        acetylhydrolase (EC 3.1.1.-) gamma chain - human
        >sp|Q15102|PA1G_HUMAN PLATELET-ACTIVATING FACTOR
20  ACETYLHYDROLASE IB
        GAMMA SUBUNIT (EC 3.1.1.47) (PAF ACETYLHYDROLASE 29 KD
        SUBUNIT)
        (PAF-AH 29 KD SUBUNIT) (PAF-AH GAMMA SUBUNIT).
        Length = 231

25  Plus Strand HSPs:

        Score = 1176 (414.0 bits), Expect = 8.2e-119, P = 8.2e-119
        Identities = 219/231 (94%), Positives = 219/231 (94%), Frame = +2

30  Query:   185 MSGEENPASKPTPVQDVQGDGRWMSLHHRFVADSKDKEPEVVFIGDSLVLQMHQCEIWRE
        364
        MSGEENPASKPTPVQDVQGDGRWMSLHHRFVADSKDKEPEVVFIGDSLVLQMHQCEIWRE
        Sbjct:   1 MSGEENPASKPTPVQDVQGDGRWMSLHHRFVADSKDKEPEVVFIGDSLVLQMHQCEIWRE
        60

35  Query:   365 LFSPLHALNFGIGGDGTQHVLWRLNGELEHIRPKIVVVWVGTTNNHGHTAEQVTGGIKAI
        544
        LFSPLHALNFGIGGDGTQHVLWRLNGELEHIRPKIVVVWVGTTNNHGHTAEQVTGGIKAI
        Sbjct:   61 LFSPLHALNFGIGGDGTQHVLWRLNGELEHIRPKIVVVWVGTTNNHGHTAEQVTGGIKAI
40  120

        Query:   545 VQLVNERQPQARVVVLGLLPRGQHPNPLREKNRQVNELVRAALAGHPRAHFLDADPGFVH
        724
        VQLVNERQPQARVVVLGLLPRGQHPNPLREKNRQVNELVRAALAGHPRAHFLDADPGFVH
45  Sbjct:   121 VQLVNERQPQARVVVLGLLPRGQHPNPLREKNRQVNELVRAALAGHPRAHFLDADPGFVH
        180

        Query:   725 SDGTISHHDMYDYLHLSRLGYTPVCXXXXXXXXXXXXXQDQGQGAPLLEPAP 877
        SDGTISHHDMYDYLHLSRLGYTPVC QDQGQGAPLLEPAP
50  Sbjct:   181 SDGTISHHDMYDYLHLSRLGYTPVCRAHLSLLRLLAQDQGQGAPLLEPAP 231

```

The segment of gnlIPIDd1010352 that is shown as "Sbjct" above is set out in the sequence listing as SEQ ID NO. 133. Based on the structural similarity these homologous polypeptides are expected to share at least some biological activities.

- 5 Such activities are known in the art and described elsewhere herein. Assays for determining such activities are also known in the art some of which have been described elsewhere herein.

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 134 which  
10 corresponds to the Query sequence in the alignment shown above (gaps introduced in the sequence by the computer are, of course, removed, and residues shown as "X" do to use of a low complexity filter in the BLAST routine can be resolved by reference to other sequences provided for Gene 15 in the sequence listing).

- It has been discovered that this gene is expressed primarily in the following  
15 tissues/cDNA libraries: Nine Week Old Early Stage Human and to a lesser extent in Human Pituitary, subt IX, Jurkat Cells, cyclohexamide treated, dif, Soares ovary tumor NbHOT, Human Fetal Brain, Breast Cancer Cell line, angiogenic, Human Fetal Kidney, HUMAN JURKAT MEMBRANE BOUND POLYSOMES, Human Primary Breast Cancer Reexcision, Soares\_fetal\_heart\_NbHH19W, Human Fetal Brain, Early  
20 Stage Human Brain, Soares melanocyte 2NbHM, Soares\_fetal\_heart\_NbHH19W, Hodgkin's Lymphoma II, Soares infant brain 1NIB, CAMA1Ee Cell Line, Human Lung Cancer, subtracted, 7 Week Old Early Stage Human, subtracted, Human Aortic Endothelium, Human Colon Carcinoma (HCC) cell line, Human Pituitary, subtracted, Human Primary Breast Cancer, Human Thyroid, Breast Cancer cell line, MDA 36, H.  
25 Kidney Cortex, subtracted, Jurkat T-cell G1 phase, Jurkat T-Cell, S phase, wilm's tumor, Soares\_testis\_NHT, Human Fetal Dura Mater, Human Adult Testes, Large Inserts, Reexcision, T-Cell PHA 24 hrs, Spinal cord, Epithelial-TNF $\alpha$  and INF induced, Hemangiopericytoma, Human Synovial Sarcoma, human tonsils, Activated T-Cell (12hs)/Thiouridine labelledEco, Human Amygdala, Human Testes, and Soares  
30 fetal liver spleen 1NFLS.



Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 102 as residues: Asn-74 to Gln-79, and Pro-89 to Val-104.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:52 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 934 of SEQ ID NO:52, b is an integer of 15 to 948, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:52, and where b is greater than or equal to a + 14.

## 15 FEATURES OF PROTEIN ENCODED BY GENE NO: 43

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gil1255373 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "coded for by C. elegans cDNA yk34a10.3." A partial alignment demonstrating the observed homology is shown immediately below.

```

25  >gi|1255373 coded for by C. elegans cDNA yk34a10.3; coded for by C.
    elegans
        cDNA CEESU74F; coded for by C. elegans cDNA yk34a10.5; coded
    for by
        C. elegans cDNA yk61d6.5; similar to regulator of chromosome
    30  condensation BJ1 [Caenorhabditis elegans]
        Length = 3766

    Plus Strand HSPs:

    Score = 144 (50.7 bits), Expect = 2.9e-08, Sum P(3) = 2.9e-08
    35  Identities = 33/72 (45%), Positives = 45/72 (62%), Frame = +3

    Query:  1362 PKKEKS-SFLFKG----DGSKPLEPAK----QAMSPSVAECARAVFASFLWHEGIVHDAM
    1514
            P E S S F   G   D +P+E K   A++PSVA+C RAVFA+F+WHE +V D M
    40  Sbjct:  2351 PSSETLSFSFSTNGNDEEDLERPIERKKTRLPNALTPSVADCIRAVFAAFVWHEHLVKDLM
    2410
  
```

Query: 1515 ACSSFLKFHPEL 1550  
A +++L+FH L  
Sbjct: 2411 AAAAYLRFHQNL 2422

5

The segment of gil1255373 that is shown as "Sbjct" above is set out in the sequence listing as SEQ ID NO. 135. Based on the structural similarity these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art and described elsewhere herein. Assays for determining such activities are also known in the art some of which have been described elsewhere herein.

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 136 which corresponds to the Query sequence in the alignment shown above (gaps introduced in the sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares fetal liver spleen 1NFLS and to a lesser extent in Human Amygdala, Soares\_NhHMPu\_S1, L428, Rejected Kidney, lib 4, NCI\_CGAP\_GCB1, Morton Fetal Cochlea, Soares\_parathyroid\_tumor\_NbHPA, KMH2, Human Umbilical Vein Endothelial Cells, uninduced, Human Adrenal Gland Tumor, human tonsils, Soares\_multiple\_sclerosis\_2NbHMSP, and T cell helper II.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:53 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1993 of SEQ ID NO:53, b is an integer of 15 to 2007, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:53, and where b is greater than or equal to a + 14.

**FEATURES OF PROTEIN ENCODED BY GENE NO: 44**

It has been discovered that this gene is expressed primarily in the following tissues: Human Testes, Reexcision, and Human Amygdala.

When tested against Jurkat E cell lines, supernatants removed from cells  
5 containing this gene activated the GAS assay. Thus, it is likely that this gene activates T-cells through the Jak-STAT signal transduction pathway. The gamma activating sequence (GAS) is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells.  
10 Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are  
15 related to SEQ ID NO:54 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the  
20 general formula of a-b, where a is any integer between 1 to 1270 of SEQ ID NO:54, b is an integer of 15 to 1284, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:54, and where b is greater than or equal to a + 14.

**25 FEATURES OF PROTEIN ENCODED BY GENE NO: 45**

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gil3080665 (all information available through the recited accession number is  
30 incorporated herein by reference) which is described therein as "neurexophilin." A partial alignment demonstrating the observed homology is shown immediately below.

5 >gi|3080665 (AC004613) neurexophilin; secreted glycoprotein and possible  
neurexin ligand; similar to Q28145 (PID:g2498669) and Q61200  
(PID:g2498667) [Homo sapiens] >gi|1336015 neurexophilin 1 [Mus  
musculus] >sp|Q61200|NPH1\_MOUSE NEUREXOPHILIN 1 (FRAGMENT).  
COMPLETE >sp|G3080665|G3080665 PAC CLONE DJ0651K02 FROM 7P21-P22,  
SEQUENCE (FRAGMENT).  
Length = 253

10 Plus Strand HSPs:

Score = 683 (240.4 bits), Expect = 2.9e-81, Sum P(2) = 2.9e-81  
Identities = 127/128 (99%), Positives = 127/128 (99%), Frame = +2

15 Query: 2 FKKMFGWGDFHSNIKTVKLNLLITGKIVDHGNGTFSVYFRHNSTGQGNVSVSLVPPTKIV  
181  
Sbjct: 97 FKKMFGWGDFHSNIKTVKLNLLITGKIVDHGNGTFSVYFRHNSTGQGNVSVSLVPPTKIV  
156

20 Query: 182 EFDLAQQTVIDAKDSKSFNCRIEYEKVDKATKNTLCNYDPSKTCYQEQTQSHVSWLCSKP  
361  
Sbjct: 157 EFDLAQQTVIDAKDSKSFNCRIEYEKVDKATKNTLCNYDPSKTCYQEQTQSHVSWLCSKP  
216

25 Query: 362 FKVICIXI 385  
FKVICI I  
Sbjct: 217 FKVICIYI 224

30 Score = 158 (55.6 bits), Expect = 2.9e-81, Sum P(2) = 2.9e-81  
Identities = 27/27 (100%), Positives = 27/27 (100%), Frame = +3

35 Query: 390 YSTDYKLVQKVC PDYNYHSDTPYFPSG 470  
YSTDYKLVQKVC PDYNYHSDTPYFPSG  
Sbjct: 227 YSTDYKLVQKVC PDYNYHSDTPYFPSG 253

40 The segments of gil3080665 that are shown as "Sbjct" above are set out in the  
sequence listing as SEQ ID NO. 137 and SEQ ID NO. 139. Based on the structural  
similarity these homologous polypeptides are expected to share at least some  
biological activities. Such activities are known in the art and described elsewhere  
herein. Assays for determining such activities are also known in the art some of which  
45 have been described elsewhere herein. Preferred polypeptides of the invention  
comprise a polypeptide having the amino acid sequence set out in the sequence listing  
as SEQ ID NO. 138 or SEQ ID NO. 140 which correspond to the Query sequence in  
the alignment shown above (gaps introduced in the sequence by the computer are, of  
course, removed).

It has been discovered that this gene is expressed primarily in the following tissue/cDNA libraries: Soares\_multiple\_sclerosis\_2NbHMSP and to a lesser extent in Human Adrenal Gland Tumor, NCI\_CGAP\_Br3, and Human Amygdala.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 105 as residues: Thr-34 to Pro-39.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:55 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1673 of SEQ ID NO:55, b is an integer of 15 to 1687, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:55, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 46**

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares fetal liver spleen 1NFLS and to a lesser extent in Thyroid Thyroiditis, Human Soleus, Resting T-Cell; re-excision, Macrophage (GM-CSF treated), Human Placenta, Bone marrow, Endothelial cells-control, Soares\_NhHMPu\_S1, Human Fetal Brain, HE6W, H. Umbilical Vein endothelial cells, uninduced, Human Liver, normal adult, Human Brain, Human Thymus Tumor, subtracted, Human Pituitary, re-excision, Human Fetal Brain, Human Aortic Endothelium, Human Pituitary, subtracted, human corpus colosum, Healing groin wound; 7.5 hours post incision, Human Fetal Epithelium (Skin), Human Ovary, wilm's tumor, Human Neutrophil, H. Kidney Medulla, re-excision, Human Dermal Endothelial Cells,untreated, Human Brain, Striatum, Human Fetal Kidney, Spinal cord, Human Thymus, Human Adrenal Gland Tumor, Smooth muscle, serum treated, H Macrophage (GM-CSF treated), re-excision, Human Adult Pulmonary;re-excision,

Human Amygdala, Spleen, Chronic lymphocytic leukemia, Bone Marrow Cell Line (RS4;11), Hodgkin's Lymphoma II, and Osteoblasts.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:56 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 938 of SEQ ID NO:56, b is an integer of 15 to 952, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:56, and where b is greater than or equal to a + 14.

#### 15 **FEATURES OF PROTEIN ENCODED BY GENE NO: 47**

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares fetal liver spleen 1NFLS and to a lesser extent in Soares\_fetal\_heart\_NbHH19W, Soares melanocyte 2NbHM, Stratagene lung (#937210), NCI\_CGAP\_GCB1, Soares\_fetal\_heart\_NbHH19W, Soares placenta Nb2HP, Soares retina N2b4HR, Soares\_fetal\_heart\_NbHH19W, Stratagene ovarian cancer (#937219), Human 8 Week Whole Embryo, 12 Week Old Early Stage Human, Human Placenta, Soares\_fetal\_heart\_NbHH19W, Spleen, Chronic lymphocytic leukemia, Hodgkin's Lymphoma II, Nine Week Old Early Stage Human, Soares infant brain 1NIB, H Umbilical Vein Endothelial Cells, frac A, re-excision, Soares retina N2b5HR, Stratagene colon (#937204), Soares\_senescent\_fibroblasts\_NbHSF, Human Adult Small Intestine, Apoptotic T-cell, Human Osteoblasts II, HUMAN JURKAT MEMBRANE BOUND POLYSOMES, T-Cell PHA 24 hrs, Human Chondrosarcoma, Synovial Fibroblasts (control), Soares\_testis\_NHT, Rejected Kidney, lib 4, Stratagene liver (#937224), Soares\_pregnant\_uterus\_NbHPU, Stratagene lung carcinoma 937218, Stratagene ovarian cancer (#937219), Human T-Cell Lymphoma, Human Microvascular Endothelial Cells, fract. A, Stratagene HeLa cell s3 937216, Activated T-cell(12h)/Thiouridine-re-excision, Human Testes,

Keratinocyte, Soares\_fetal\_liver\_spleen\_1NFLS\_S1, Primary Dendritic Cells, lib 1, H. Striatum Depression, subt II, Kidney medulla, Rectum tumour, Human Infant Adrenal Gland, Raji cells, cyclohexamide treated, subtracted, Thymus, Human Uterus, normal, Human Adult Spleen, stomach cancer (human), Human Adult Pulmonary, Healing Abdomen wound;70&90 min post incision, Frontal lobe,dementia;re-excision, Human Fetal Bone, Human T-cell lymphoma;re-excision, Human Skin Tumor, NTERA2 teratocarcinoma cell line+retinoic acid (14 days), Raji Cells, cyclohexamide treated, Human Tonsils, Lib 2, H. Whole Brain #2, re-excision, Ovarian Tumor 10-3-95, HEL cell line, Human Synovium, Healing groin wound; 7.5 hours post incision, NTERA2 + retinoic acid, 14 days, H. Kidney Cortex, subtracted, Healing groin wound, 6.5 hours post incision, Human Osteoclastoma, re-excision, Synovial hypoxia, Human Bone Marrow, re-excision, Human Thymus, Human Uterine Cancer, Stratagene fibroblast (#937212), Merkel Cells, Human Hypothalamus,Schizophrenia, Ulcerative Colitis, Human Thymus Stromal Cells, Epithelial-TNF $\alpha$  and INF induced, Hemangiopericytoma, Human Whole Six Week Old Embryo, NTERA2, control, Human Gall Bladder, Stratagene colon (#937204), Stratagene hNT neuron (#937233), T Cell helper I, Colon Carcinoma, Human Testes Tumor, Soares\_multiple\_sclerosis\_2NbHMSP, Human Testes, Reexcision, Human Placenta, Bone marrow, Human Adult Pulmonary;re-excision, CD34 depleted Buffy Coat (Cord Blood), re-excision, Human Amygdala, CD34 positive cells (Cord Blood), HUMAN B CELL LYMPHOMA, and T cell helper II.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:57 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 5670 of SEQ ID NO:57, b is an integer of 15 to 5684, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:57, and where b is greater than or equal to a + 14.

**FEATURES OF PROTEIN ENCODED BY GENE NO: 48**

It has been discovered that this gene is expressed primarily in Human Amygdala.

- 5 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:58 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence
- 10 would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 543 of SEQ ID NO:58, b is an integer of 15 to 557, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:58, and where b is greater than or equal to a
- 15 + 14.

**FEATURES OF PROTEIN ENCODED BY GENE NO: 49**

- It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares placenta Nb2HP and to a lesser extent in Soares fetal
- 20 liver spleen 1NFLS, Soares infant brain 1NIB, Soares\_pregnant\_uterus\_NbHPU, Stratagene ovarian cancer (#937219), human corpus colosum, Human Adult Small Intestine, Human Amygdala, Soares\_fetal\_lung\_NbHL19W, Human Whole 6 Week Old Embryo (II), CAMA1Ee Cell Line, Human Fetal Brain, random primed, Human Neutrophils, Activated, re-excision, B Cell lymphoma, pBMC stimulated w/ poly I/C,
- 25 Healing groin wound, 6.5 hours post incision, Human Colon; re-excision, KMH2, Human Fetal Dura Mater, Human Hippocampus, Colon Tumor, Human T-Cell Lymphoma, Human Placenta, Human Fetal Lung III, Neutrophils control; re-excision, Bone marrow, Human Neutrophil, Activated, Soares\_multiple\_sclerosis\_2NbHMSP, and Human Endometrial Tumor.
- 30 Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 109 as residues: Met-1 to Phe-6.



Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:59 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1396 of SEQ ID NO:59, b is an integer of 15 to 1410, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:59, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 50

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gi|2665836 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "dynein light intermediate chain 2." A partial alignment demonstrating the observed homology is shown immediately below.

```

>gi|2665836 (AF035812) dynein light intermediate chain 2 [Homo sapiens]
      Length = 492

25      Plus Strand HSPs:

      Score = 815 (286.9 bits), Expect = 1.4e-80, P = 1.4e-80
      Identities = 163/184 (88%), Positives = 163/184 (88%), Frame = +1

30      Query:   1066 FRPAGWDNEKKIAILHENFTTVKPEDAYEDFIVKPPVRKLVHDKELAAEDEQVFLMKQQS
1245
                  F PAGWDNEKKIAILHENFTTVKPEDAYEDFIVKPPVRKLVHDKELAAEDEQVFLMKQQS
      Sbjct:   309 FIPAGWDNEKKIAILHENFTTVKPEDAYEDFIVKPPVRKLVHDKELAAEDEQVFLMKQQS
368

35      Query:   1246 LLAQQPATPTRVFEPARGPSGSPRTQGRXXXXXXXXXXXXXXXXXVKNPDPNIKNNAASEGV
1425
                  LLAQQPATPTR  E PARGPSGSPRTQGR                               VK PDPNIKNNAASEGV
      Sbjct:   369 LLAQQPATPTRASESPARGPSGSPRTQGRGGPASVPSSSPGTSVKKPDPNIKNNAASEGV
40      428

      Query:   1426 LPSFFNSLLSKKT VSPGSPGAGGVQSTAKKSGQKT VLSNVQEELDRMTRKPDSMVTNSST
1605
                  L SFFNSLLSKKT SPGSPGAGGVQSTAKKSGQKT VLSNVQEELDRMTRKPDSMVTNSST

```

Sbjct: 429 LASFFNSLLSKKTGSPGSPGAGGVQSTAKKSGQKTVLSNVQEELDRMTRKPDMSMTNSSST  
488

5 Query: 1606 ENEA 1617  
          ENE  
Sbjct: 489 ENEA 492

- 10 The segment of gil2665836 that is shown as "Sbjct" above is set out in the sequence listing as SEQ ID NO. 141. Based on the structural similarity these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art and described elsewhere herein. Assays for determining such activities are also known in the art some of which have been described elsewhere  
15 herein.

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out as SEQ ID NO. 142 which corresponds to the Query sequence in the alignment shown above (gaps introduced in the sequence by the computer are, of course, removed, and residues shown as "X" do to use of a low  
20 complexity filter in the BLAST routine can be resolved by reference to other sequences provided for Gene 50 in the sequence listing).

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Activated T-Cells, 12 hrs, re-excision and to a lesser extent in Soares melanocyte 2NbHM, neutrophils control, Soares\_fetal\_heart\_NbHH19W,  
25 Human Amygdala, Stratagene colon (#937204), Kidney Pyramids, Soares\_total\_fetus\_Nb2HF8\_9w, Normal trachea, stomach cancer (human), Soares retina N2b4HR, Stratagene colon (#937204), Human Whole Brain, re-excision, Soares adult brain N2b4HB55Y, Soares\_fetal\_heart\_NbHH19W, Human Ovary, Human Neutrophil, Human Pancreas Tumor, Spinal cord, H. Frontal  
30 cortex, epileptic; re-excision, Human Placenta, Human Testes, Reexcision, Human Placenta, Colon Normal III, Soares\_pregnant\_uterus\_NbHPU, Keratinocyte, Nine Week Old Early Stage Human, and Soares placenta Nb2HP.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are  
35 related to SEQ ID NO:60 and may have been publicly available prior to conception of

the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the

5 general formula of a-b, where a is any integer between 1 to 1745 of SEQ ID NO:60, b is an integer of 15 to 1759, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:60, and where b is greater than or equal to a + 14.

Table 1

Gene No.	cDNA Clone ID	ATCC Deposit NO:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
1	HADDJ13	203917 4/8/99	pSport1	11	2318	1	2318	347	347	61	1	20	21	30
2	HADDR24	203917 4/8/99	pSport1	12	620	1	620	230	230	62	1	31	32	35
3	HADET62	203917 4/8/99	pSport1	13	830	1	830	154	154	63	1	18	19	31
4	HADEY08	203917 4/8/99	pSport1	14	4054	1	4054	201	201	64	1			15
5	HADEY22	203917 4/8/99	pSport1	15	452	1	452	169	169	65	1	18	19	32
6	HADFB84	203917 4/8/99	pSport1	16	1193	1	1193	94	94	66	1	28	29	46
7	HADFD01	203917 4/8/99	pSport1	17	1594	1	1594	377	377	67	1	19	20	66
8	HADFK11	203917 4/8/99	pSport1	18	1042	1	1042	24	24	68	1	19	20	57
9	HADFT44	203917 4/8/99	pSport1	19	855	15	852	147	147	69	1	26	27	55
10	HADFW20	203917 4/8/99	pSport1	20	1120	1	1120	223	223	70	1	20	21	27

Gene No.	cDNA Clone ID	ATCC Deposit NO:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
11	HADFX10	203917 4/8/99	pSport1	21	1278	1	1278	187	187	71	1	18	19	36
12	HADFY80	203917 4/8/99	pSport1	22	742	1	742	83	83	72	1	23	24	34
13	HADGD93	203917 4/8/99	pSport1	23	1033	1	899	47	47	73	1	25	26	45
14	HADMA77	203917 4/8/99	pBluescript	24	1913	763	1913		992	74	1	16	17	23
15	HAFBB15	203917 4/8/99	pBluescript SK-	25	1733	1	1733	186	186	75	1	50	51	87
16	HAFBL14	203917 4/8/99	pBluescript SK-	26	2722	364	2722	542	542	76	1	17	18	31
17	HAGAB62	203917 4/8/99	Uni-ZAP XR	27	1094	1	1094	82	82	77	1	35	36	41
18	HAGAB83	203917 4/8/99	Uni-ZAP XR	28	1839	1	1839	35	35	78	1	22	23	35
19	HAGAF75	203917 4/8/99	Uni-ZAP XR	29	1330	1	1330	106	106	79	1	26	27	58
20	HAGAK40	203917 4/8/99	Uni-ZAP XR	30	1504	1	1504		187	80	1	19	20	19
21	HAGAZ36	203917 4/8/99	Uni-ZAP XR	31	1280	1	1280	128	128	81	1	16	17	65

Gene No.	cDNA Clone ID	ATCC Deposit NO:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
22	HAGBC57	203917 4/8/99	Uni-ZAP XR	32	1528	1	1528	358	358	82	1	15	16	18
23	HAGBL31	203917 4/8/99	Uni-ZAP XR	33	1458	1	1458	27	27	83	1	27	28	30
24	H2CBH91	203917 4/8/99	pBluescript SK-	34	1760	225	1760	309	309	84	1	36	37	40
25	HAGBO51	203917 4/8/99	Uni-ZAP XR	35	1568	1	1568	132	132	85	1	29	30	37
26	HAGBQ12	203917 4/8/99	Uni-ZAP XR	36	743	1	743	171	171	86	1	20	21	21
27	HAGBV06	203917 4/8/99	Uni-ZAP XR	37	1715	1	1715	98	98	87	1	22	23	25
28	HAGBV25	203917 4/8/99	Uni-ZAP XR	38	1896	456	1846	725	725	88	1			17
29	HAGBV29	203917 4/8/99	Uni-ZAP XR	39	2075	8	2075	16	16	89	1	21	22	65
30	HAGCC87	203917 4/8/99	Uni-ZAP XR	40	1592	479	1592	509	509	90	1			9
31	HAGCH67	203917 4/8/99	Uni-ZAP XR	41	1324	1	1324	150	150	91	1	30	31	41
32	HAGCI69	203917 4/8/99	Uni-ZAP XR	42	1214	1	1214		31	92	1	17	18	66

Gene No.	cDNA Clone ID	ATCC Deposit NO:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
33	HAGCT33	203917 4/8/99	Uni-ZAP XR	43	1338	1	1338	42	42	93	1	26	27	39
34	HAGCZ70	203917 4/8/99	Uni-ZAP XR	44	1686	54	1686	91	91	94	1	18	19	35
35	HAGDC73	203917 4/8/99	Uni-ZAP XR	45	1634	577	1634	744	744	95	1	16	17	30
36	HAGDG84	203917 4/8/99	Uni-ZAP XR	46	2012	1	2012	297	297	96	1	18	19	39
37	HAGDH85	203917 4/8/99	Uni-ZAP XR	47	1322	1	1322	45	45	97	1			33
38	HAGDI69	203917 4/8/99	Uni-ZAP XR	48	941	1	941	110	110	98	1			3
39	HAGDJ53	203917 4/8/99	Uni-ZAP XR	49	1874	2	1874	130	130	99	1	18	19	33
40	HAGDJ56	203917 4/8/99	Uni-ZAP XR	50	643	1	643	81	81	100	1	24	25	34
41	HAGDL51	203917 4/8/99	Uni-ZAP XR	51	1669	1	1669	218	218	101	1	21	22	33
42	HAGDO70	203917 4/8/99	Uni-ZAP XR	52	948	144	945	338	338	102	1	27	28	180
43	HAGDT30	203917 4/8/99	Uni-ZAP XR	53	2007	1	2007	198	198	103	1	22	23	35

Gene No.	cDNA Clone ID	ATCC Deposit NO:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
44	HAGDW20	203917 4/8/99	Uni-ZAP XR	54	1284	1	1284	238	238	104	1	17	18	17
45	HAGDW68	203917 4/8/99	Uni-ZAP XR	55	1687	1	1687	90	90	105	1	18	19	39
46	HAGDX84	203917 4/8/99	Uni-ZAP XR	56	952	1	952	223	223	106	1			5
47	HAGEG10	203917 4/8/99	Uni-ZAP XR	57	5684	100	2890	146	146	107	1	29	30	55
48	HAGBO12	203917 4/8/99	Uni-ZAP XR	58	557	1	557	54	54	108	1	18	19	32
49	HAGEK37	203917 4/8/99	Uni-ZAP XR	59	1410	744	1388	932	932	109	1	23	24	39
50	HAGEK86	203917 4/8/99	Uni-ZAP XR	60	1759	1	1759	165	165	110	1	24	25	31



Table 1 summarizes the information corresponding to each "Gene No." described above. The nucleotide sequence identified as "NT SEQ ID NO:X" was assembled from partially homologous ("overlapping") sequences obtained from the "cDNA clone ID" identified in Table 1 and, in some cases, from additional related DNA clones. The overlapping sequences were assembled into a single contiguous sequence of high redundancy (usually three to five overlapping sequences at each nucleotide position), resulting in a final sequence identified as SEQ ID NO:X.

The cDNA Clone ID was deposited on the date and given the corresponding deposit number listed in "ATCC Deposit No:Z and Date." Some of the deposits contain multiple different clones corresponding to the same gene. "Vector" refers to the type of vector contained in the cDNA Clone ID.

"Total NT Seq." refers to the total number of nucleotides in the contig identified by "Gene No." The deposited clone may contain all or most of these sequences, reflected by the nucleotide position indicated as "5' NT of Clone Seq." and the "3' NT of Clone Seq." of SEQ ID NO:X. The nucleotide position of SEQ ID NO:X of the putative start codon (methionine) is identified as "5' NT of Start Codon." Similarly, the nucleotide position of SEQ ID NO:X of the predicted signal sequence is identified as "5' NT of First AA of Signal Pep."

The translated amino acid sequence, beginning with the methionine, is identified as "AA SEQ ID NO:Y," although other reading frames can also be easily translated using known molecular biology techniques. The polypeptides produced by these alternative open reading frames are specifically contemplated by the present invention.

The first and last amino acid position of SEQ ID NO:Y of the predicted signal peptide is identified as "First AA of Sig Pep" and "Last AA of Sig Pep." The predicted first amino acid position of SEQ ID NO:Y of the secreted portion is identified as "Predicted First AA of Secreted Portion." Finally, the amino acid position of SEQ ID NO:Y of the last amino acid in the open reading frame is identified as "Last AA of ORF."

SEQ ID NO:X (where X may be any of the polynucleotide sequences disclosed in the sequence listing) and the translated SEQ ID NO:Y (where Y may be any of the polypeptide sequences disclosed in the sequence listing) are sufficiently

accurate and otherwise suitable for a variety of uses well known in the art and described further below. For instance, SEQ ID NO:X is useful for designing nucleic acid hybridization probes that will detect nucleic acid sequences contained in SEQ ID NO:X or the cDNA contained in the deposited clone. These probes will also  
5 hybridize to nucleic acid molecules in biological samples, thereby enabling a variety of forensic and diagnostic methods of the invention. Similarly, polypeptides identified from SEQ ID NO:Y may be used, for example, to generate antibodies which bind specifically to proteins containing the polypeptides and the secreted proteins encoded by the cDNA clones identified in Table 1.

10 Nevertheless, DNA sequences generated by sequencing reactions can contain sequencing errors. The errors exist as misidentified nucleotides, or as insertions or deletions of nucleotides in the generated DNA sequence. The erroneously inserted or deleted nucleotides cause frame shifts in the reading frames of the predicted amino acid sequence. In these cases, the predicted amino acid sequence diverges from the  
15 actual amino acid sequence, even though the generated DNA sequence may be greater than 99.9% identical to the actual DNA sequence (for example, one base insertion or deletion in an open reading frame of over 1000 bases).

Accordingly, for those applications requiring precision in the nucleotide sequence or the amino acid sequence, the present invention provides not only the  
20 generated nucleotide sequence identified as SEQ ID NO:X and the predicted translated amino acid sequence identified as SEQ ID NO:Y, but also a sample of plasmid DNA containing a human cDNA of the invention deposited with the ATCC, as set forth in Table 1. The nucleotide sequence of each deposited clone can readily be determined by sequencing the deposited clone in accordance with known methods.  
25 The predicted amino acid sequence can then be verified from such deposits. Moreover, the amino acid sequence of the protein encoded by a particular clone can also be directly determined by peptide sequencing or by expressing the protein in a suitable host cell containing the deposited human cDNA, collecting the protein, and determining its sequence.

30 The present invention also relates to the genes corresponding to SEQ ID NO:X, SEQ ID NO:Y, or the deposited clone. The corresponding gene can be isolated in accordance with known methods using the sequence information disclosed

herein. Such methods include preparing probes or primers from the disclosed sequence and identifying or amplifying the corresponding gene from appropriate sources of genomic material.

Also provided in the present invention are allelic variants, orthologs, and/or species homologs. Procedures known in the art can be used to obtain full-length genes, allelic variants, splice variants, full-length coding portions, orthologs, and/or species homologs of genes corresponding to SEQ ID NO:X, SEQ ID NO:Y, or a deposited clone, using information from the sequences disclosed herein or the clones deposited with the ATCC. For example, allelic variants and/or species homologs may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source for allelic variants and/or the desired homologue.

The polypeptides of the invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.

The polypeptides may be in the form of the secreted protein, including the mature form, or may be a part of a larger protein, such as a fusion protein (see below). It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification, such as multiple histidine residues, or an additional sequence for stability during recombinant production.

The polypeptides of the present invention are preferably provided in an isolated form, and preferably are substantially purified. A recombinantly produced version of a polypeptide, including the secreted polypeptide, can be substantially purified using techniques described herein or otherwise known in the art, such as, for example, by the one-step method described in Smith and Johnson, Gene 67:31-40 (1988). Polypeptides of the invention also can be purified from natural, synthetic or recombinant sources using techniques described herein or otherwise known in the art, such as, for example, antibodies of the invention raised against the secreted protein.

The present invention provides a polynucleotide comprising, or alternatively consisting of, the nucleic acid sequence of SEQ ID NO:X, and/or a cDNA contained in ATCC deposit Z. The present invention also provides a polypeptide comprising, or alternatively, consisting of, the polypeptide sequence of SEQ ID NO:Y and/or a polypeptide encoded by the cDNA contained in ATCC deposit Z. Polynucleotides encoding a polypeptide comprising, or alternatively consisting of the polypeptide sequence of SEQ ID NO:Y and/or a polypeptide sequence encoded by the cDNA contained in ATCC deposit Z are also encompassed by the invention.

### Signal Sequences

The present invention also encompasses mature forms of the polypeptide having the polypeptide sequence of SEQ ID NO:Y and/or the polypeptide sequence encoded by the cDNA in a deposited clone. Polynucleotides encoding the mature forms (such as, for example, the polynucleotide sequence in SEQ ID NO:X and/or the polynucleotide sequence contained in the cDNA of a deposited clone) are also encompassed by the invention. According to the signal hypothesis, proteins secreted by mammalian cells have a signal or secretory leader sequence which is cleaved from the mature protein once export of the growing protein chain across the rough endoplasmic reticulum has been initiated. Most mammalian cells and even insect cells cleave secreted proteins with the same specificity. However, in some cases, cleavage of a secreted protein is not entirely uniform, which results in two or more mature species of the protein. Further, it has long been known that cleavage specificity of a secreted protein is ultimately determined by the primary structure of the complete protein, that is, it is inherent in the amino acid sequence of the polypeptide.

Methods for predicting whether a protein has a signal sequence, as well as the cleavage point for that sequence, are available. For instance, the method of McGeoch, Virus Res. 3:271-286 (1985), uses the information from a short N-terminal charged region and a subsequent uncharged region of the complete (uncleaved) protein. The method of von Heinje, Nucleic Acids Res. 14:4683-4690 (1986) uses the information from the residues surrounding the cleavage site, typically residues -13 to +2, where +1 indicates the amino terminus of the secreted protein. The accuracy of predicting the cleavage points of known mammalian secretory proteins for each of

these methods is in the range of 75-80%. (von Heinje, supra.) However, the two methods do not always produce the same predicted cleavage point(s) for a given protein.

In the present case, the deduced amino acid sequence of the secreted polypeptide was analyzed by a computer program called SignalP (Henrik Nielsen et al., Protein Engineering 10:1-6 (1997)), which predicts the cellular location of a protein based on the amino acid sequence. As part of this computational prediction of localization, the methods of McGeoch and von Heinje are incorporated. The analysis of the amino acid sequences of the secreted proteins described herein by this program provided the results shown in Table 1.

As one of ordinary skill would appreciate, however, cleavage sites sometimes vary from organism to organism and cannot be predicted with absolute certainty. Accordingly, the present invention provides secreted polypeptides having a sequence shown in SEQ ID NO:Y which have an N-terminus beginning within 5 residues (i.e., + or - 5 residues) of the predicted cleavage point. Similarly, it is also recognized that in some cases, cleavage of the signal sequence from a secreted protein is not entirely uniform, resulting in more than one secreted species. These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present invention.

Moreover, the signal sequence identified by the above analysis may not necessarily predict the naturally occurring signal sequence. For example, the naturally occurring signal sequence may be further upstream from the predicted signal sequence. However, it is likely that the predicted signal sequence will be capable of directing the secreted protein to the ER. Nonetheless, the present invention provides the mature protein produced by expression of the polynucleotide sequence of SEQ ID NO:X and/or the polynucleotide sequence contained in the cDNA of a deposited clone, in a mammalian cell (e.g., COS cells, as described below). These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present invention.

### **Polynucleotide and Polypeptide Variants**

The present invention is directed to variants of the polynucleotide sequence disclosed in SEQ ID NO:X, the complementary strand thereto, and/or the cDNA sequence contained in a deposited clone.

The present invention also encompasses variants of the polypeptide sequence  
5 disclosed in SEQ ID NO:Y and/or encoded by a deposited clone.

"Variant" refers to a polynucleotide or polypeptide differing from the polynucleotide or polypeptide of the present invention, but retaining essential properties thereof. Generally, variants are overall closely similar, and, in many regions, identical to the polynucleotide or polypeptide of the present invention.

10 The present invention is also directed to nucleic acid molecules which comprise, or alternatively consist of, a nucleotide sequence which is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to, for example, the nucleotide coding sequence in SEQ ID NO:X or the complementary strand thereto, the nucleotide coding sequence contained in a deposited cDNA clone or the  
15 complementary strand thereto, a nucleotide sequence encoding the polypeptide of SEQ ID NO:Y, a nucleotide sequence encoding the polypeptide encoded by the cDNA contained in a deposited clone, and/or polynucleotide fragments of any of these nucleic acid molecules (e.g., those fragments described herein).  
Polynucleotides which hybridize to these nucleic acid molecules under stringent  
20 hybridization conditions or lower stringency conditions are also encompassed by the invention, as are polypeptides encoded by these polynucleotides.

The present invention is also directed to polypeptides which comprise, or alternatively consist of, an amino acid sequence which is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to, for example, the polypeptide sequence  
25 shown in SEQ ID NO:Y, the polypeptide sequence encoded by the cDNA contained in a deposited clone, and/or polypeptide fragments of any of these polypeptides (e.g., those fragments described herein).

By a nucleic acid having a nucleotide sequence at least, for example, 95% "identical" to a reference nucleotide sequence of the present invention, it is intended  
30 that the nucleotide sequence of the nucleic acid is identical to the reference sequence except that the nucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence encoding the polypeptide. In

other words, to obtain a nucleic acid having a nucleotide sequence at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. The query sequence may be an entire sequence shown in Table 1, the ORF (open reading frame), or any fragment specified as described herein.

As a practical matter, whether any particular nucleic acid molecule or polypeptide is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to a nucleotide sequence of the present invention can be determined conventionally using known computer programs. A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci. 6:237-245(1990)). In a sequence alignment the query and subject sequences are both DNA sequences. An RNA sequence can be compared by converting U's to T's. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB alignment of DNA sequences to calculate percent identity are: Matrix=Unitary, k-tuple=4, Mismatch Penalty=1, Joining Penalty=30, Randomization Group Length=0, Cutoff Score=1, Gap Penalty=5, Gap Size Penalty 0.05, Window Size=500 or the length of the subject nucleotide sequence, whichever is shorter.

If the subject sequence is shorter than the query sequence because of 5' or 3' deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for 5' and 3' truncations of the subject sequence when calculating percent identity. For subject sequences truncated at the 5' or 3' ends, relative to the query sequence, the percent identity is corrected by calculating the number of bases of the query sequence that are 5' and 3' of the subject sequence, which are not matched/aligned, as a percent of the total bases of the query sequence. Whether a nucleotide is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using

the specified parameters, to arrive at a final percent identity score. This corrected score is what is used for the purposes of the present invention. Only bases outside the 5' and 3' bases of the subject sequence, as displayed by the FASTDB alignment, which are not matched/aligned with the query sequence, are calculated for the purposes of manually adjusting the percent identity score.

For example, a 90 base subject sequence is aligned to a 100 base query sequence to determine percent identity. The deletions occur at the 5' end of the subject sequence and therefore, the FASTDB alignment does not show a matched/alignment of the first 10 bases at 5' end. The 10 unpaired bases represent 10% of the sequence (number of bases at the 5' and 3' ends not matched/total number of bases in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 bases were perfectly matched the final percent identity would be 90%. In another example, a 90 base subject sequence is compared with a 100 base query sequence. This time the deletions are internal deletions so that there are no bases on the 5' or 3' of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only bases 5' and 3' of the subject sequence which are not matched/aligned with the query sequence are manually corrected for. No other manual corrections are to made for the purposes of the present invention.

By a polypeptide having an amino acid sequence at least, for example, 95% "identical" to a query amino acid sequence of the present invention, it is intended that the amino acid sequence of the subject polypeptide is identical to the query sequence except that the subject polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the query amino acid sequence. In other words, to obtain a polypeptide having an amino acid sequence at least 95% identical to a query amino acid sequence, up to 5% of the amino acid residues in the subject sequence may be inserted, deleted, (indels) or substituted with another amino acid. These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.



As a practical matter, whether any particular polypeptide is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to, for instance, an amino acid sequences shown in Table 1 (SEQ ID NO:Y) or to the amino acid sequence encoded by cDNA contained in a deposited clone can be determined conventionally using known computer programs. A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci. 6:237-245(1990)). In a sequence alignment the query and subject sequences are either both nucleotide sequences or both amino acid sequences. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB amino acid alignment are: Matrix=PAM 0, k-tuple=2, Mismatch Penalty=1, Joining Penalty=20, Randomization Group Length=0, Cutoff Score=1, Window Size=sequence length, Gap Penalty=5, Gap Size Penalty=0.05, Window Size=500 or the length of the subject amino acid sequence, whichever is shorter.

If the subject sequence is shorter than the query sequence due to N- or C-terminal deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for N- and C-terminal truncations of the subject sequence when calculating global percent identity. For subject sequences truncated at the N- and C-termini, relative to the query sequence, the percent identity is corrected by calculating the number of residues of the query sequence that are N- and C-terminal of the subject sequence, which are not matched/aligned with a corresponding subject residue, as a percent of the total bases of the query sequence. Whether a residue is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This final percent identity score is what is used for the purposes of the present invention. Only residues to the N- and C-termini of the subject sequence, which are not matched/aligned with the query sequence, are considered for the purposes of manually adjusting the percent identity score. That is, only query residue positions outside the farthest N- and C-terminal residues of the subject sequence.

For example, a 90 amino acid residue subject sequence is aligned with a 100 residue query sequence to determine percent identity. The deletion occurs at the N-terminus of the subject sequence and therefore, the FASTDB alignment does not show a matching/alignment of the first 10 residues at the N-terminus. The 10  
5 unpaired residues represent 10% of the sequence (number of residues at the N- and C-termini not matched/total number of residues in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 residues were perfectly matched the final percent identity would be 90%. In another example, a 90 residue subject sequence is compared with a 100  
10 residue query sequence. This time the deletions are internal deletions so there are no residues at the N- or C-termini of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only residue positions outside the N- and C-terminal ends of the subject sequence, as displayed in the FASTDB alignment, which are not  
15 matched/aligned with the query sequence are manually corrected for. No other manual corrections are to be made for the purposes of the present invention.

The variants may contain alterations in the coding regions, non-coding regions, or both. Especially preferred are polynucleotide variants containing alterations which produce silent substitutions, additions, or deletions, but do not alter  
20 the properties or activities of the encoded polypeptide. Nucleotide variants produced by silent substitutions due to the degeneracy of the genetic code are preferred. Moreover, variants in which 5-10, 1-5, or 1-2 amino acids are substituted, deleted, or added in any combination are also preferred. Polynucleotide variants can be produced for a variety of reasons, e.g., to optimize codon expression for a particular host  
25 (change codons in the human mRNA to those preferred by a bacterial host such as *E. coli*).

Naturally occurring variants are called "allelic variants," and refer to one of several alternate forms of a gene occupying a given locus on a chromosome of an organism. (Genes II, Lewin, B., ed., John Wiley & Sons, New York (1985).) These  
30 allelic variants can vary at either the polynucleotide and/or polypeptide level and are included in the present invention. Alternatively, non-naturally occurring variants may be produced by mutagenesis techniques or by direct synthesis.

Using known methods of protein engineering and recombinant DNA technology, variants may be generated to improve or alter the characteristics of the polypeptides of the present invention. For instance, one or more amino acids can be deleted from the N-terminus or C-terminus of the secreted protein without substantial loss of biological function. The authors of Ron et al., J. Biol. Chem. 268: 2984-2988 (1993), reported variant KGF proteins having heparin binding activity even after deleting 3, 8, or 27 amino-terminal amino acid residues. Similarly, Interferon gamma exhibited up to ten times higher activity after deleting 8-10 amino acid residues from the carboxy terminus of this protein. (Dobeli et al., J. Biotechnology 7:199-216 (1988).)

Moreover, ample evidence demonstrates that variants often retain a biological activity similar to that of the naturally occurring protein. For example, Gayle and coworkers (J. Biol. Chem 268:22105-22111 (1993)) conducted extensive mutational analysis of human cytokine IL-1a. They used random mutagenesis to generate over 3,500 individual IL-1a mutants that averaged 2.5 amino acid changes per variant over the entire length of the molecule. Multiple mutations were examined at every possible amino acid position. The investigators found that "[m]ost of the molecule could be altered with little effect on either [binding or biological activity]." (See, Abstract.) In fact, only 23 unique amino acid sequences, out of more than 3,500 nucleotide sequences examined, produced a protein that significantly differed in activity from wild-type.

Furthermore, even if deleting one or more amino acids from the N-terminus or C-terminus of a polypeptide results in modification or loss of one or more biological functions, other biological activities may still be retained. For example, the ability of a deletion variant to induce and/or to bind antibodies which recognize the secreted form will likely be retained when less than the majority of the residues of the secreted form are removed from the N-terminus or C-terminus. Whether a particular polypeptide lacking N- or C-terminal residues of a protein retains such immunogenic activities can readily be determined by routine methods described herein and otherwise known in the art.

Thus, the invention further includes polypeptide variants which show substantial biological activity. Such variants include deletions, insertions,

inversions, repeats, and substitutions selected according to general rules known in the art so as have little effect on activity. For example, guidance concerning how to make phenotypically silent amino acid substitutions is provided in Bowie et al., Science 247:1306-1310 (1990), wherein the authors indicate that there are two main strategies  
5 for studying the tolerance of an amino acid sequence to change.

The first strategy exploits the tolerance of amino acid substitutions by natural selection during the process of evolution. By comparing amino acid sequences in different species, conserved amino acids can be identified. These conserved amino acids are likely important for protein function. In contrast, the amino acid positions  
10 where substitutions have been tolerated by natural selection indicates that these positions are not critical for protein function. Thus, positions tolerating amino acid substitution could be modified while still maintaining biological activity of the protein.

The second strategy uses genetic engineering to introduce amino acid changes at specific positions of a cloned gene to identify regions critical for protein function.  
15 For example, site directed mutagenesis or alanine-scanning mutagenesis (introduction of single alanine mutations at every residue in the molecule) can be used. (Cunningham and Wells, Science 244:1081-1085 (1989).) The resulting mutant molecules can then be tested for biological activity.

20 As the authors state, these two strategies have revealed that proteins are surprisingly tolerant of amino acid substitutions. The authors further indicate which amino acid changes are likely to be permissive at certain amino acid positions in the protein. For example, most buried (within the tertiary structure of the protein) amino acid residues require nonpolar side chains, whereas few features of surface side chains  
25 are generally conserved. Moreover, tolerated conservative amino acid substitutions involve replacement of the aliphatic or hydrophobic amino acids Ala, Val, Leu and Ile; replacement of the hydroxyl residues Ser and Thr; replacement of the acidic residues Asp and Glu; replacement of the amide residues Asn and Gln, replacement of the basic residues Lys, Arg, and His; replacement of the aromatic residues Phe, Tyr,  
30 and Trp, and replacement of the small-sized amino acids Ala, Ser, Thr, Met, and Gly.

Besides conservative amino acid substitution, variants of the present invention include (i) substitutions with one or more of the non-conserved amino acid residues,

where the substituted amino acid residues may or may not be one encoded by the genetic code, or (ii) substitution with one or more of amino acid residues having a substituent group, or (iii) fusion of the mature polypeptide with another compound, such as a compound to increase the stability and/or solubility of the polypeptide (for example, polyethylene glycol), or (iv) fusion of the polypeptide with additional amino acids, such as, for example, an IgG Fc fusion region peptide, or leader or secretory sequence, or a sequence facilitating purification. Such variant polypeptides are deemed to be within the scope of those skilled in the art from the teachings herein.

For example, polypeptide variants containing amino acid substitutions of charged amino acids with other charged or neutral amino acids may produce proteins with improved characteristics, such as less aggregation. Aggregation of pharmaceutical formulations both reduces activity and increases clearance due to the aggregate's immunogenic activity. (Pinckard et al., Clin. Exp. Immunol. 2:331-340 (1967); Robbins et al., Diabetes 36: 838-845 (1987); Cleland et al., Crit. Rev. Therapeutic Drug Carrier Systems 10:307-377 (1993).)

A further embodiment of the invention relates to a polypeptide which comprises the amino acid sequence of the present invention having an amino acid sequence which contains at least one amino acid substitution, but not more than 50 amino acid substitutions, even more preferably, not more than 40 amino acid substitutions, still more preferably, not more than 30 amino acid substitutions, and still even more preferably, not more than 20 amino acid substitutions. Of course, in order of ever-increasing preference, it is highly preferable for a peptide or polypeptide to have an amino acid sequence which comprises the amino acid sequence of the present invention, which contains at least one, but not more than 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 amino acid substitutions. In specific embodiments, the number of additions, substitutions, and/or deletions in the amino acid sequence of the present invention or fragments thereof (e.g., the mature form and/or other fragments described herein), is 1-5, 5-10, 5-25, 5-50, 10-50 or 50-150, conservative amino acid substitutions are preferable.

### **Polynucleotide and Polypeptide Fragments**

The present invention is also directed to polynucleotide fragments of the polynucleotides of the invention.

In the present invention, a "polynucleotide fragment" refers to a short polynucleotide having a nucleic acid sequence which: is a portion of that contained in a deposited clone, or encoding the polypeptide encoded by the cDNA in a deposited clone; is a portion of that shown in SEQ ID NO:X or the complementary strand thereto, or is a portion of a polynucleotide sequence encoding the polypeptide of SEQ ID NO:Y. The nucleotide fragments of the invention are preferably at least about 15 nt, and more preferably at least about 20 nt, still more preferably at least about 30 nt, and even more preferably, at least about 40 nt, at least about 50 nt, at least about 75 nt, or at least about 150 nt in length. A fragment "at least 20 nt in length," for example, is intended to include 20 or more contiguous bases from the cDNA sequence contained in a deposited clone or the nucleotide sequence shown in SEQ ID NO:X. In this context "about" includes the particularly recited value, a value larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini. These nucleotide fragments have uses that include, but are not limited to, as diagnostic probes and primers as discussed herein. Of course, larger fragments (e.g., 50, 150, 500, 600, 2000 nucleotides) are preferred.

Moreover, representative examples of polynucleotide fragments of the invention, include, for example, fragments comprising, or alternatively consisting of, a sequence from about nucleotide number 1-50, 51-100, 101-150, 151-200, 201-250, 251-300, 301-350, 351-400, 401-450, 451-500, 501-550, 551-600, 651-700, 701-750, 751-800, 800-850, 851-900, 901-950, 951-1000, 1001-1050, 1051-1100, 1101-1150, 1151-1200, 1201-1250, 1251-1300, 1301-1350, 1351-1400, 1401-1450, 1451-1500, 1501-1550, 1551-1600, 1601-1650, 1651-1700, 1701-1750, 1751-1800, 1801-1850, 1851-1900, 1901-1950, 1951-2000, or 2001 to the end of SEQ ID NO:X, or the complementary strand thereto, or the cDNA contained in a deposited clone. In this context "about" includes the particularly recited ranges, and ranges larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini. Preferably, these fragments encode a polypeptide which has biological activity. More preferably, these polynucleotides can be used as probes or primers as discussed herein. Polynucleotides which hybridize to these nucleic acid molecules under

stringent hybridization conditions or lower stringency conditions are also encompassed by the invention, as are polypeptides encoded by these polynucleotides.

In the present invention, a "polypeptide fragment" refers to an amino acid sequence which is a portion of that contained in SEQ ID NO:Y or encoded by the cDNA contained in a deposited clone. Protein (polypeptide) fragments may be "free-standing," or comprised within a larger polypeptide of which the fragment forms a part or region, most preferably as a single continuous region. Representative examples of polypeptide fragments of the invention, include, for example, fragments comprising, or alternatively consisting of, from about amino acid number 1-20, 21-40, 41-60, 61-80, 81-100, 102-120, 121-140, 141-160, or 161 to the end of the coding region. Moreover, polypeptide fragments can be about 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, or 150 amino acids in length. In this context "about" includes the particularly recited ranges or values, and ranges or values larger or smaller by several (5, 4, 3, 2, or 1) amino acids, at either extreme or at both extremes. Polynucleotides encoding these polypeptides are also encompassed by the invention.

Preferred polypeptide fragments include the secreted protein as well as the mature form. Further preferred polypeptide fragments include the secreted protein or the mature form having a continuous series of deleted residues from the amino or the carboxy terminus, or both. For example, any number of amino acids, ranging from 1-60, can be deleted from the amino terminus of either the secreted polypeptide or the mature form. Similarly, any number of amino acids, ranging from 1-30, can be deleted from the carboxy terminus of the secreted protein or mature form. Furthermore, any combination of the above amino and carboxy terminus deletions are preferred. Similarly, polynucleotides encoding these polypeptide fragments are also preferred.

Also preferred are polypeptide and polynucleotide fragments characterized by structural or functional domains, such as fragments that comprise alpha-helix and alpha-helix forming regions, beta-sheet and beta-sheet-forming regions, turn and turn-forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-forming regions, substrate binding region, and high antigenic index regions. Polypeptide fragments of SEQ ID NO:Y falling within conserved domains are

specifically contemplated by the present invention. Moreover, polynucleotides encoding these domains are also contemplated.

Other preferred polypeptide fragments are biologically active fragments. Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an activity of the polypeptide of the present invention. The biological  
5 activity of the fragments may include an improved desired activity, or a decreased undesirable activity. Polynucleotides encoding these polypeptide fragments are also encompassed by the invention.

Preferably, the polynucleotide fragments of the invention encode a  
10 polypeptide which demonstrates a functional activity. By a polypeptide demonstrating a "functional activity" is meant, a polypeptide capable of displaying one or more known functional activities associated with a full-length (complete) polypeptide of invention protein. Such functional activities include, but are not limited to, biological activity, antigenicity [ability to bind (or compete with a  
15 polypeptide of the invention for binding) to an antibody to the polypeptide of the invention], immunogenicity (ability to generate antibody which binds to a polypeptide of the invention), ability to form multimers with polypeptides of the invention, and ability to bind to a receptor or ligand for a polypeptide of the invention.

The functional activity of polypeptides of the invention, and fragments, variants derivatives, and analogs thereof, can be assayed by various methods.  
20

For example, in one embodiment where one is assaying for the ability to bind or compete with full-length polypeptide of the invention for binding to an antibody of the polypeptide of the invention, various immunoassays known in the art can be used, including but not limited to, competitive and non-competitive assay systems using  
25 techniques such as radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich" immunoassays, immunoradiometric assays, gel diffusion precipitation reactions, immunodiffusion assays, in situ immunoassays (using colloidal gold, enzyme or radioisotope labels, for example), western blots, precipitation reactions, agglutination assays (e.g., gel agglutination assays, hemagglutination assays), complement fixation assays, immunofluorescence assays,  
30 protein A assays, and immunoelectrophoresis assays, etc. In one embodiment, antibody binding is detected by detecting a label on the primary antibody. In another



embodiment, the primary antibody is detected by detecting binding of a secondary antibody or reagent to the primary antibody. In a further embodiment, the secondary antibody is labeled. Many means are known in the art for detecting binding in an immunoassay and are within the scope of the present invention.

5 In another embodiment, where a ligand for a polypeptide of the invention identified, or the ability of a polypeptide fragment, variant or derivative of the invention to multimerize is being evaluated, binding can be assayed, e.g., by means well-known in the art, such as, for example, reducing and non-reducing gel chromatography, protein affinity chromatography, and affinity blotting. See  
10 generally, Phizicky, E., et al., 1995, Microbiol. Rev. 59:94-123. In another embodiment, physiological correlates of binding of a polypeptide of the invention to its substrates (signal transduction) can be assayed.

In addition, assays described herein (see Examples) and otherwise known in the art may routinely be applied to measure the ability of polypeptides of the  
15 invention and fragments, variants derivatives and analogs thereof to elicit related biological activity related to that of the polypeptide of the invention (either in vitro or in vivo). Other methods will be known to the skilled artisan and are within the scope of the invention.

## 20 **Epitopes and Antibodies**

The present invention encompasses polypeptides comprising, or alternatively consisting of, an epitope of the polypeptide having an amino acid sequence of SEQ ID NO:Y, or an epitope of the polypeptide sequence encoded by a polynucleotide sequence contained in ATCC deposit No. Z or encoded by a polynucleotide that  
25 hybridizes to the complement of the sequence of SEQ ID NO:X or contained in ATCC deposit No. Z under stringent hybridization conditions or lower stringency hybridization conditions as defined supra. The present invention further encompasses polynucleotide sequences encoding an epitope of a polypeptide sequence of the invention (such as, for example, the sequence disclosed in SEQ ID NO:X),  
30 polynucleotide sequences of the complementary strand of a polynucleotide sequence encoding an epitope of the invention, and polynucleotide sequences which hybridize

to the complementary strand under stringent hybridization conditions or lower stringency hybridization conditions defined supra.

The term "epitopes," as used herein, refers to portions of a polypeptide having antigenic or immunogenic activity in an animal, preferably a mammal, and most preferably in a human. In a preferred embodiment, the present invention encompasses a polypeptide comprising an epitope, as well as the polynucleotide encoding this polypeptide. An "immunogenic epitope," as used herein, is defined as a portion of a protein that elicits an antibody response in an animal, as determined by any method known in the art, for example, by the methods for generating antibodies described infra. (See, for example, Geysen et al., Proc. Natl. Acad. Sci. USA 81:3998- 4002 (1983)). The term "antigenic epitope," as used herein, is defined as a portion of a protein to which an antibody can immunospecifically bind its antigen as determined by any method well known in the art, for example, by the immunoassays described herein. Immunospecific binding excludes non-specific binding but does not necessarily exclude cross- reactivity with other antigens. Antigenic epitopes need not necessarily be immunogenic.

Fragments which function as epitopes may be produced by any conventional means. (See, e.g., Houghten, Proc. Natl. Acad. Sci. USA 82:5131-5135 (1985), further described in U.S. Patent No. 4,631,211).

In the present invention, antigenic epitopes preferably contain a sequence of at least 4, at least 5, at least 6, at least 7, more preferably at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 20, at least 25, at least 30, at least 40, at least 50, and, most preferably, between about 15 to about 30 amino acids. Preferred polypeptides comprising immunogenic or antigenic epitopes are at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 amino acid residues in length. Additional non-exclusive preferred antigenic epitopes include the antigenic epitopes disclosed herein, as well as portions thereof. Antigenic epitopes are useful, for example, to raise antibodies, including monoclonal antibodies, that specifically bind the epitope. Preferred antigenic epitopes include the antigenic epitopes disclosed herein, as well as any combination of two, three, four, five or more of these antigenic epitopes. Antigenic epitopes can be used as the target molecules in

immunoassays. (See, for instance, Wilson et al., Cell 37:767-778 (1984); Sutcliffe et al., Science 219:660-666 (1983)).

Similarly, immunogenic epitopes can be used, for example, to induce antibodies according to methods well known in the art. (See, for instance, Sutcliffe et al., supra; Wilson et al., supra; Chow et al., Proc. Natl. Acad. Sci. USA 82:910-914; and Bittle et al., J. Gen. Virol. 66:2347-2354 (1985). Preferred immunogenic epitopes include the immunogenic epitopes disclosed herein, as well as any combination of two, three, four, five or more of these immunogenic epitopes. The polypeptides comprising one or more immunogenic epitopes may be presented for eliciting an antibody response together with a carrier protein, such as an albumin, to an animal system (such as rabbit or mouse), or, if the polypeptide is of sufficient length (at least about 25 amino acids), the polypeptide may be presented without a carrier. However, immunogenic epitopes comprising as few as 8 to 10 amino acids have been shown to be sufficient to raise antibodies capable of binding to, at the very least, linear epitopes in a denatured polypeptide (e.g., in Western blotting).

Epitope-bearing polypeptides of the present invention may be used to induce antibodies according to methods well known in the art including, but not limited to, in vivo immunization, in vitro immunization, and phage display methods. See, e.g., Sutcliffe et al., supra; Wilson et al., supra, and Bittle et al., J. Gen. Virol., 66:2347-2354 (1985). If in vivo immunization is used, animals may be immunized with free peptide; however, anti-peptide antibody titer may be boosted by coupling the peptide to a macromolecular carrier, such as keyhole limpet hemacyanin (KLH) or tetanus toxoid. For instance, peptides containing cysteine residues may be coupled to a carrier using a linker such as maleimidobenzoyl- N-hydroxysuccinimide ester (MBS), while other peptides may be coupled to carriers using a more general linking agent such as glutaraldehyde. Animals such as rabbits, rats and mice are immunized with either free or carrier- coupled peptides, for instance, by intraperitoneal and/or intradermal injection of emulsions containing about 100 µg of peptide or carrier protein and Freund's adjuvant or any other adjuvant known for stimulating an immune response. Several booster injections may be needed, for instance, at intervals of about two weeks, to provide a useful titer of anti-peptide antibody which can be detected, for example, by ELISA assay using free peptide adsorbed to a solid

surface. The titer of anti-peptide antibodies in serum from an immunized animal may be increased by selection of anti-peptide antibodies, for instance, by adsorption to the peptide on a solid support and elution of the selected antibodies according to methods well known in the art.

5           As one of skill in the art will appreciate, and as discussed above, the polypeptides of the present invention comprising an immunogenic or antigenic epitope can be fused to other polypeptide sequences. For example, the polypeptides of the present invention may be fused with the constant domain of immunoglobulins (IgA, IgE, IgG, IgM), or portions thereof (CH1, CH2, CH3, or any combination  
10 thereof and portions thereof) resulting in chimeric polypeptides. Such fusion proteins may facilitate purification and may increase half-life in vivo. This has been shown for chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. See, e.g., EP 394,827; Traunecker et al., Nature,  
15 331:84-86 (1988). Enhanced delivery of an antigen across the epithelial barrier to the immune system has been demonstrated for antigens (e.g., insulin) conjugated to an FcRn binding partner such as IgG or Fc fragments (see, e.g., PCT Publications WO 96/22024 and WO 99/04813). IgG Fusion proteins that have a disulfide-linked dimeric structure due to the IgG portion desulfide bonds have also been found to be  
20 more efficient in binding and neutralizing other molecules than monomeric polypeptides or fragments thereof alone. See, e.g., Fountoulakis et al., J. Biochem., 270:3958-3964 (1995). Nucleic acids encoding the above epitopes can also be recombined with a gene of interest as an epitope tag (e.g., the hemagglutinin ("HA") tag or flag tag) to aid in detection and purification of the expressed polypeptide. For  
25 example, a system described by Janknecht et al. allows for the ready purification of non-denatured fusion proteins expressed in human cell lines (Janknecht et al., 1991, Proc. Natl. Acad. Sci. USA 88:8972- 897). In this system, the gene of interest is subcloned into a vaccinia recombination plasmid such that the open reading frame of the gene is translationally fused to an amino-terminal tag consisting of six histidine  
30 residues. The tag serves as a matrix binding domain for the fusion protein. Extracts from cells infected with the recombinant vaccinia virus are loaded onto Ni2+

nitriloacetic acid-agarose column and histidine-tagged proteins can be selectively eluted with imidazole-containing buffers.

Additional fusion proteins of the invention may be generated through the techniques of gene-shuffling, motif-shuffling, exon-shuffling, and/or codon-shuffling (collectively referred to as "DNA shuffling"). DNA shuffling may be employed to modulate the activities of polypeptides of the invention, such methods can be used to generate polypeptides with altered activity, as well as agonists and antagonists of the polypeptides. See, generally, U.S. Patent Nos. 5,605,793; 5,811,238; 5,830,721; 5,834,252; and 5,837,458, and Patten et al., Curr. Opinion Biotechnol. 8:724-33 (1997); Harayama, Trends Biotechnol. 16(2):76-82 (1998); Hansson, et al., J. Mol. Biol. 287:265-76 (1999); and Lorenzo and Blasco, Biotechniques 24(2):308- 13 (1998) (each of these patents and publications are hereby incorporated by reference in its entirety). In one embodiment, alteration of polynucleotides corresponding to SEQ ID NO:X and the polypeptides encoded by these polynucleotides may be achieved by DNA shuffling. DNA shuffling involves the assembly of two or more DNA segments by homologous or site-specific recombination to generate variation in the polynucleotide sequence. In another embodiment, polynucleotides of the invention, or the encoded polypeptides, may be altered by being subjected to random mutagenesis by error-prone PCR, random nucleotide insertion or other methods prior to recombination. In another embodiment, one or more components, motifs, sections, parts, domains, fragments, etc., of a polynucleotide encoding a polypeptide of the invention may be recombined with one or more components, motifs, sections, parts, domains, fragments, etc. of one or more heterologous molecules.

## 25 Antibodies

Further polypeptides of the invention relate to antibodies and T-cell antigen receptors (TCR) which immunospecifically bind a polypeptide, polypeptide fragment, or variant of SEQ ID NO:Y, and/or an epitope, of the present invention (as determined by immunoassays well known in the art for assaying specific antibody-antigen binding). Antibodies of the invention include, but are not limited to, polyclonal, monoclonal, multispecific, human, humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab') fragments, fragments produced by a

Fab expression library, anti-idiotypic (anti-Id) antibodies (including, e.g., anti-Id antibodies to antibodies of the invention), and epitope-binding fragments of any of the above. The term "antibody," as used herein, refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules  
5 that contain an antigen binding site that immunospecifically binds an antigen. The immunoglobulin molecules of the invention can be of any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) or subclass of immunoglobulin molecule.

Most preferably the antibodies are human antigen-binding antibody fragments  
10 of the present invention and include, but are not limited to, Fab, Fab' and F(ab')<sub>2</sub>, Fd, single-chain Fvs (scFv), single-chain antibodies, disulfide-linked Fvs (sdFv) and fragments comprising either a VL or VH domain. Antigen-binding antibody fragments, including single-chain antibodies, may comprise the variable region(s) alone or in combination with the entirety or a portion of the following: hinge region,  
15 CH1, CH2, and CH3 domains. Also included in the invention are antigen-binding fragments also comprising any combination of variable region(s) with a hinge region, CH1, CH2, and CH3 domains. The antibodies of the invention may be from any animal origin including birds and mammals. Preferably, the antibodies are human, murine (e.g., mouse and rat), donkey, ship rabbit, goat, guinea pig, camel, horse, or  
20 chicken. As used herein, "human" antibodies include antibodies having the amino acid sequence of a human immunoglobulin and include antibodies isolated from human immunoglobulin libraries or from animals transgenic for one or more human immunoglobulin and that do not express endogenous immunoglobulins, as described infra and, for example in, U.S. Patent No. 5,939,598 by Kucherlapati et al.

25 The antibodies of the present invention may be monospecific, bispecific, trispecific or of greater multispecificity. Multispecific antibodies may be specific for different epitopes of a polypeptide of the present invention or may be specific for both a polypeptide of the present invention as well as for a heterologous epitope, such as a heterologous polypeptide or solid support material. See, e.g., PCT publications WO  
30 93/17715; WO 92/08802; WO 91/00360; WO 92/05793; Tutt, et al., J. Immunol. 147:60-69 (1991); U.S. Patent Nos. 4,474,893; 4,714,681; 4,925,648; 5,573,920; 5,601,819; Kostelny et al., J. Immunol. 148:1547-1553 (1992).

Antibodies of the present invention may be described or specified in terms of the epitope(s) or portion(s) of a polypeptide of the present invention which they recognize or specifically bind. The epitope(s) or polypeptide portion(s) may be specified as described herein, e.g., by N-terminal and C-terminal positions, by size in  
5 contiguous amino acid residues, or listed in the Tables and Figures. Antibodies which specifically bind any epitope or polypeptide of the present invention may also be excluded. Therefore, the present invention includes antibodies that specifically bind polypeptides of the present invention, and allows for the exclusion of the same.

Antibodies of the present invention may also be described or specified in  
10 terms of their cross-reactivity. Antibodies that do not bind any other analog, ortholog, or homolog of a polypeptide of the present invention are included. Antibodies that bind polypeptides with at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 65%, at least 60%, at least 55%, and at least 50% identity (as calculated using methods known in the art and described  
15 herein) to a polypeptide of the present invention are also included in the present invention. In specific embodiments, antibodies of the present invention cross-react with murine, rat and/or rabbit homologs of human proteins and the corresponding epitopes thereof. Antibodies that do not bind polypeptides with less than 95%, less than 90%, less than 85%, less than 80%, less than 75%, less than 70%, less than 65%,  
20 less than 60%, less than 55%, and less than 50% identity (as calculated using methods known in the art and described herein) to a polypeptide of the present invention are also included in the present invention. In a specific embodiment, the above-described cross-reactivity is with respect to any single specific antigenic or immunogenic polypeptide, or combination(s) of 2, 3, 4, 5, or more of the specific  
25 antigenic and/or immunogenic polypeptides disclosed herein. Further included in the present invention are antibodies which bind polypeptides encoded by polynucleotides which hybridize to a polynucleotide of the present invention under stringent hybridization conditions (as described herein). Antibodies of the present invention may also be described or specified in terms of their binding affinity to a polypeptide  
30 of the invention. Preferred binding affinities include those with a dissociation constant or  $K_d$  less than  $5 \times 10^{-2}$  M,  $10^{-2}$  M,  $5 \times 10^{-3}$  M,  $10^{-3}$  M,  $5 \times 10^{-4}$  M,  $10^{-4}$  M,  $5 \times 10^{-5}$  M,  $10^{-5}$  M,  $5 \times 10^{-6}$  M,  $10^{-6}$  M,  $5 \times 10^{-7}$  M,  $10^{-7}$  M,  $5 \times 10^{-8}$  M,  $10^{-8}$  M,  $5 \times 10^{-9}$

M,  $10^{-9}$  M,  $5 \times 10^{-10}$  M,  $10^{-10}$  M,  $5 \times 10^{-11}$  M,  $10^{-11}$  M,  $5 \times 10^{-12}$  M,  $10^{-12}$  M,  $5 \times 10^{-13}$  M,  $10^{-13}$  M,  $5 \times 10^{-14}$  M,  $10^{-14}$  M,  $5 \times 10^{-15}$  M, or  $10^{-15}$  M.

The invention also provides antibodies that competitively inhibit binding of an antibody to an epitope of the invention as determined by any method known in the art for determining competitive binding, for example, the immunoassays described herein. In preferred embodiments, the antibody competitively inhibits binding to the epitope by at least 95%, at least 90%, at least 85 %, at least 80%, at least 75%, at least 70%, at least 60%, or at least 50%.

Antibodies of the present invention may act as agonists or antagonists of the polypeptides of the present invention. For example, the present invention includes antibodies which disrupt the receptor/ligand interactions with the polypeptides of the invention either partially or fully. Preferably, antibodies of the present invention bind an antigenic epitope disclosed herein, or a portion thereof. The invention features both receptor-specific antibodies and ligand-specific antibodies. The invention also features receptor-specific antibodies which do not prevent ligand binding but prevent receptor activation. Receptor activation (i.e., signaling) may be determined by techniques described herein or otherwise known in the art. For example, receptor activation can be determined by detecting the phosphorylation (e.g., tyrosine or serine/threonine) of the receptor or its substrate by immunoprecipitation followed by western blot analysis (for example, as described supra). In specific embodiments, antibodies are provided that inhibit ligand activity or receptor activity by at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 60%, or at least 50% of the activity in absence of the antibody.

The invention also features receptor-specific antibodies which both prevent ligand binding and receptor activation as well as antibodies that recognize the receptor-ligand complex, and, preferably, do not specifically recognize the unbound receptor or the unbound ligand. Likewise, included in the invention are neutralizing antibodies which bind the ligand and prevent binding of the ligand to the receptor, as well as antibodies which bind the ligand, thereby preventing receptor activation, but do not prevent the ligand from binding the receptor. Further included in the invention are antibodies which activate the receptor. These antibodies may act as receptor



agonists, i.e., potentiate or activate either all or a subset of the biological activities of the ligand-mediated receptor activation, for example, by inducing dimerization of the receptor. The antibodies may be specified as agonists, antagonists or inverse agonists for biological activities comprising the specific biological activities of the peptides of the invention disclosed herein. The above antibody agonists can be made using methods known in the art. See, e.g., PCT publication WO 96/40281; U.S. Patent No. 5,811,097; Deng et al., *Blood* 92(6):1981-1988 (1998); Chen et al., *Cancer Res.* 58(16):3668-3678 (1998); Harrop et al., *J. Immunol.* 161(4):1786-1794 (1998); Zhu et al., *Cancer Res.* 58(15):3209-3214 (1998); Yoon et al., *J. Immunol.* 160(7):3170-3179 (1998); Prat et al., *J. Cell. Sci.* 111(Pt2):237-247 (1998); Pitard et al., *J. Immunol. Methods* 205(2):177-190 (1997); Liautard et al., *Cytokine* 9(4):233-241 (1997); Carlson et al., *J. Biol. Chem.* 272(17):11295-11301 (1997); Taryman et al., *Neuron* 14(4):755-762 (1995); Muller et al., *Structure* 6(9):1153-1167 (1998); Bartunek et al., *Cytokine* 8(1):14-20 (1996) (which are all incorporated by reference herein in their entireties).

Antibodies of the present invention may be used, for example, but not limited to, to purify, detect, and target the polypeptides of the present invention, including both in vitro and in vivo diagnostic and therapeutic methods. For example, the antibodies have use in immunoassays for qualitatively and quantitatively measuring levels of the polypeptides of the present invention in biological samples. See, e.g., Harlow et al., *Antibodies: A Laboratory Manual*, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988) (incorporated by reference herein in its entirety).

As discussed in more detail below, the antibodies of the present invention may be used either alone or in combination with other compositions. The antibodies may further be recombinantly fused to a heterologous polypeptide at the N- or C-terminus or chemically conjugated (including covalently and non-covalently conjugations) to polypeptides or other compositions. For example, antibodies of the present invention may be recombinantly fused or conjugated to molecules useful as labels in detection assays and effector molecules such as heterologous polypeptides, drugs, radionuclides, or toxins. See, e.g., PCT publications WO 92/08495; WO 91/14438; WO 89/12624; U.S. Patent No. 5,314,995; and EP 396,387.

The antibodies of the invention include derivatives that are modified, i.e., by the covalent attachment of any type of molecule to the antibody such that covalent attachment does not prevent the antibody from generating an anti-idiotypic response. For example, but not by way of limitation, the antibody derivatives include

5 antibodies that have been modified, e.g., by glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to a cellular ligand or other protein, etc. Any of numerous chemical modifications may be carried out by known techniques, including, but not limited to specific chemical cleavage, acetylation, formylation,

10 metabolic synthesis of tunicamycin, etc. Additionally, the derivative may contain one or more non-classical amino acids.

The antibodies of the present invention may be generated by any suitable method known in the art. Polyclonal antibodies to an antigen-of-interest can be produced by various procedures well known in the art. For example, a polypeptide of

15 the invention can be administered to various host animals including, but not limited to, rabbits, mice, rats, etc. to induce the production of sera containing polyclonal antibodies specific for the antigen. Various adjuvants may be used to increase the immunological response, depending on the host species, and include but are not limited to, Freund's (complete and incomplete), mineral gels such as aluminum

20 hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and corynebacterium parvum. Such adjuvants are also well known in the art.

Monoclonal antibodies can be prepared using a wide variety of techniques

25 known in the art including the use of hybridoma, recombinant, and phage display technologies, or a combination thereof. For example, monoclonal antibodies can be produced using hybridoma techniques including those known in the art and taught, for example, in Harlow et al., *Antibodies: A Laboratory Manual*, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988); Hammerling, et al., in: *Monoclonal Antibodies and*

30 *T-Cell Hybridomas* 563-681 (Elsevier, N.Y., 1981) (said references incorporated by reference in their entireties). The term "monoclonal antibody" as used herein is not limited to antibodies produced through hybridoma technology. The term

“monoclonal antibody” refers to an antibody that is derived from a single clone, including any eukaryotic, prokaryotic, or phage clone, and not the method by which it is produced.

Methods for producing and screening for specific antibodies using hybridoma  
5 technology are routine and well known in the art and are discussed in detail in the Examples (e.g., Example 16). In a non-limiting example, mice can be immunized with a polypeptide of the invention or a cell expressing such peptide. Once an immune response is detected, e.g., antibodies specific for the antigen are detected in the mouse serum, the mouse spleen is harvested and splenocytes isolated. The  
10 splenocytes are then fused by well known techniques to any suitable myeloma cells, for example cells from cell line SP20 available from the ATCC. Hybridomas are selected and cloned by limited dilution. The hybridoma clones are then assayed by methods known in the art for cells that secrete antibodies capable of binding a polypeptide of the invention. Ascites fluid, which generally contains high levels of  
15 antibodies, can be generated by immunizing mice with positive hybridoma clones.

Accordingly, the present invention provides methods of generating monoclonal antibodies as well as antibodies produced by the method comprising culturing a hybridoma cell secreting an antibody of the invention wherein, preferably, the hybridoma is generated by fusing splenocytes isolated from a mouse immunized  
20 with an antigen of the invention with myeloma cells and then screening the hybridomas resulting from the fusion for hybridoma clones that secrete an antibody able to bind a polypeptide of the invention.

Antibody fragments which recognize specific epitopes may be generated by known techniques. For example, Fab and F(ab')<sub>2</sub> fragments of the invention may be  
25 produced by proteolytic cleavage of immunoglobulin molecules, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')<sub>2</sub> fragments). F(ab')<sub>2</sub> fragments contain the variable region, the light chain constant region and the CH1 domain of the heavy chain.

For example, the antibodies of the present invention can also be generated  
30 using various phage display methods known in the art. In phage display methods, functional antibody domains are displayed on the surface of phage particles which carry the polynucleotide sequences encoding them. In a particular embodiment, such

phage can be utilized to display antigen binding domains expressed from a repertoire or combinatorial antibody library (e.g., human or murine). Phage expressing an antigen binding domain that binds the antigen of interest can be selected or identified with antigen, e.g., using labeled antigen or antigen bound or captured to a solid surface or bead. Phage used in these methods are typically filamentous phage including fd and M13 binding domains expressed from phage with Fab, Fv or disulfide stabilized Fv antibody domains recombinantly fused to either the phage gene III or gene VIII protein. Examples of phage display methods that can be used to make the antibodies of the present invention include those disclosed in Brinkman et al., J. Immunol. Methods 182:41-50 (1995); Ames et al., J. Immunol. Methods 184:177-186 (1995); Kettleborough et al., Eur. J. Immunol. 24:952-958 (1994); Persic et al., Gene 187 9-18 (1997); Burton et al., Advances in Immunology 57:191-280 (1994); PCT application No. PCT/GB91/01134; PCT publications WO 90/02809; WO 91/10737; WO 92/01047; WO 92/18619; WO 93/11236; WO 95/15982; WO 95/20401; and U.S. Patent Nos. 5,698,426; 5,223,409; 5,403,484; 5,580,717; 5,427,908; 5,750,753; 5,821,047; 5,571,698; 5,427,908; 5,516,637; 5,780,225; 5,658,727; 5,733,743 and 5,969,108; each of which is incorporated herein by reference in its entirety.

As described in the above references, after phage selection, the antibody coding regions from the phage can be isolated and used to generate whole antibodies, including human antibodies, or any other desired antigen binding fragment, and expressed in any desired host, including mammalian cells, insect cells, plant cells, yeast, and bacteria, e.g., as described in detail below. For example, techniques to recombinantly produce Fab, Fab' and F(ab')<sub>2</sub> fragments can also be employed using methods known in the art such as those disclosed in PCT publication WO 92/22324; Mullinax et al., BioTechniques 12(6):864-869 (1992); and Sawai et al., AJRI 34:26-34 (1995); and Better et al., Science 240:1041-1043 (1988) (said references incorporated by reference in their entireties).

Examples of techniques which can be used to produce single-chain Fvs and antibodies include those described in U.S. Patents 4,946,778 and 5,258,498; Huston et al., Methods in Enzymology 203:46-88 (1991); Shu et al., PNAS 90:7995-7999 (1993); and Skerra et al., Science 240:1038-1040 (1988). For some uses, including

in vivo use of antibodies in humans and in vitro detection assays, it may be preferable to use chimeric, humanized, or human antibodies. A chimeric antibody is a molecule in which different portions of the antibody are derived from different animal species, such as antibodies having a variable region derived from a murine monoclonal antibody and a human immunoglobulin constant region. Methods for producing chimeric antibodies are known in the art. See e.g., Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Gillies et al., (1989) J. Immunol. Methods 125:191-202; U.S. Patent Nos. 5,807,715; 4,816,567; and 4,816,397, which are incorporated herein by reference in their entirety. Humanized antibodies are antibody molecules from non-human species antibody that binds the desired antigen having one or more complementarity determining regions (CDRs) from the non-human species and a framework regions from a human immunoglobulin molecule. Often, framework residues in the human framework regions will be substituted with the corresponding residue from the CDR donor antibody to alter, preferably improve, antigen binding. These framework substitutions are identified by methods well known in the art, e.g., by modeling of the interactions of the CDR and framework residues to identify framework residues important for antigen binding and sequence comparison to identify unusual framework residues at particular positions. (See, e.g., Queen et al., U.S. Patent No. 5,585,089; Riechmann et al., Nature 332:323 (1988), which are incorporated herein by reference in their entirety.) Antibodies can be humanized using a variety of techniques known in the art including, for example, CDR-grafting (EP 239,400; PCT publication WO 91/09967; U.S. Patent Nos. 5,225,539; 5,530,101; and 5,585,089), veneering or resurfacing (EP 592,106; EP 519,596; Padlan, Molecular Immunology 28(4/5):489-498 (1991); Studnicka et al., Protein Engineering 7(6):805-814 (1994); Roguska. et al., PNAS 91:969-973 (1994)), and chain shuffling (U.S. Patent No. 5,565,332).

Completely human antibodies are particularly desirable for therapeutic treatment of human patients. Human antibodies can be made by a variety of methods known in the art including phage display methods described above using antibody libraries derived from human immunoglobulin sequences. See also, U.S. Patent Nos. 4,444,887 and 4,716,111; and PCT publications WO 98/46645, WO 98/50433, WO

98/24893, WO 98/16654, WO 96/34096, WO 96/33735, and WO 91/10741; each of which is incorporated herein by reference in its entirety.

Human antibodies can also be produced using transgenic mice which are incapable of expressing functional endogenous immunoglobulins, but which can  
5 express human immunoglobulin genes. For example, the human heavy and light chain immunoglobulin gene complexes may be introduced randomly or by homologous recombination into mouse embryonic stem cells. Alternatively, the human variable region, constant region, and diversity region may be introduced into mouse embryonic stem cells in addition to the human heavy and light chain genes.  
10 The mouse heavy and light chain immunoglobulin genes may be rendered non-functional separately or simultaneously with the introduction of human immunoglobulin loci by homologous recombination. In particular, homozygous deletion of the JH region prevents endogenous antibody production. The modified embryonic stem cells are expanded and microinjected into blastocysts to produce  
15 chimeric mice. The chimeric mice are then bred to produce homozygous offspring which express human antibodies. The transgenic mice are immunized in the normal fashion with a selected antigen, e.g., all or a portion of a polypeptide of the invention. Monoclonal antibodies directed against the antigen can be obtained from the immunized, transgenic mice using conventional hybridoma technology. The human  
20 immunoglobulin transgenes harbored by the transgenic mice rearrange during B cell differentiation, and subsequently undergo class switching and somatic mutation. Thus, using such a technique, it is possible to produce therapeutically useful IgG, IgA, IgM and IgE antibodies. For an overview of this technology for producing human antibodies, see Lonberg and Huszar, Int. Rev. Immunol. 13:65-93 (1995). For a  
25 detailed discussion of this technology for producing human antibodies and human monoclonal antibodies and protocols for producing such antibodies, see, e.g., PCT publications WO 98/24893; WO 92/01047; WO 96/34096; WO 96/33735; European Patent No. 0 598 877; U.S. Patent Nos. 5,413,923; 5,625,126; 5,633,425; 5,569,825; 5,661,016; 5,545,806; 5,814,318; 5,885,793; 5,916,771; and 5,939,598, which are  
30 incorporated by reference herein in their entirety. In addition, companies such as Abgenix, Inc. (Freemont, CA) and Genpharm (San Jose, CA) can be engaged to

provide human antibodies directed against a selected antigen using technology similar to that described above.

Completely human antibodies which recognize a selected epitope can be generated using a technique referred to as "guided selection." In this approach a  
5 selected non-human monoclonal antibody, e.g., a mouse antibody, is used to guide the selection of a completely human antibody recognizing the same epitope. (Jespers et al., Bio/technology 12:899-903 (1988)).

Further, antibodies to the polypeptides of the invention can, in turn, be utilized to generate anti-idiotypic antibodies that "mimic" polypeptides of the invention using  
10 techniques well known to those skilled in the art. (See, e.g., Greenspan & Bona, FASEB J. 7(5):437-444; (1989) and Nissinoff, J. Immunol. 147(8):2429-2438 (1991)). For example, antibodies which bind to and competitively inhibit polypeptide multimerization and/or binding of a polypeptide of the invention to a ligand can be used to generate anti-idiotypes that "mimic" the polypeptide multimerization and/or  
15 binding domain and, as a consequence, bind to and neutralize polypeptide and/or its ligand. Such neutralizing anti-idiotypes or Fab fragments of such anti-idiotypes can be used in therapeutic regimens to neutralize polypeptide ligand. For example, such anti-idiotypic antibodies can be used to bind a polypeptide of the invention and/or to bind its ligands/receptors, and thereby block its biological activity.

20

#### Polynucleotides Encoding Antibodies

The invention further provides polynucleotides comprising a nucleotide sequence encoding an antibody of the invention and fragments thereof. The invention also encompasses polynucleotides that hybridize under stringent or lower  
25 stringency hybridization conditions, e.g., as defined supra, to polynucleotides that encode an antibody, preferably, that specifically binds to a polypeptide of the invention, preferably, an antibody that binds to a polypeptide having the amino acid sequence of SEQ ID NO:Y.

The polynucleotides may be obtained, and the nucleotide sequence of the  
30 polynucleotides determined, by any method known in the art. For example, if the nucleotide sequence of the antibody is known, a polynucleotide encoding the antibody may be assembled from chemically synthesized oligonucleotides (e.g., as described

in Kutmeier et al., BioTechniques 17:242 (1994)), which, briefly, involves the synthesis of overlapping oligonucleotides containing portions of the sequence encoding the antibody, annealing and ligating of those oligonucleotides, and then amplification of the ligated oligonucleotides by PCR.

5           Alternatively, a polynucleotide encoding an antibody may be generated from nucleic acid from a suitable source. If a clone containing a nucleic acid encoding a particular antibody is not available, but the sequence of the antibody molecule is known, a nucleic acid encoding the immunoglobulin may be chemically synthesized or obtained from a suitable source (e.g., an antibody cDNA library, or a cDNA library  
10           generated from, or nucleic acid, preferably poly A+ RNA, isolated from, any tissue or cells expressing the antibody, such as hybridoma cells selected to express an antibody of the invention) by PCR amplification using synthetic primers hybridizable to the 3' and 5' ends of the sequence or by cloning using an oligonucleotide probe specific for the particular gene sequence to identify, e.g., a cDNA clone from a  
15           cDNA library that encodes the antibody. Amplified nucleic acids generated by PCR may then be cloned into replicable cloning vectors using any method well known in the art.

          Once the nucleotide sequence and corresponding amino acid sequence of the antibody is determined, the nucleotide sequence of the antibody may be manipulated  
20           using methods well known in the art for the manipulation of nucleotide sequences, e.g., recombinant DNA techniques, site directed mutagenesis, PCR, etc. (see, for example, the techniques described in Sambrook et al., 1990, Molecular Cloning, A Laboratory Manual, 2d Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY and Ausubel et al., eds., 1998, Current Protocols in Molecular Biology, John  
25           Wiley & Sons, NY, which are both incorporated by reference herein in their entireties ), to generate antibodies having a different amino acid sequence, for example to create amino acid substitutions, deletions, and/or insertions.

          In a specific embodiment, the amino acid sequence of the heavy and/or light chain variable domains may be inspected to identify the sequences of the  
30           complementarity determining regions (CDRs) by methods that are well know in the art, e.g., by comparison to known amino acid sequences of other heavy and light chain variable regions to determine the regions of sequence hypervariability. Using



coli), Enterobacteriaceae (Klebsiella, Salmonella (e.g., Salmonella typhi, and Salmonella paratyphi), Serratia, Yersinia), Erysipelothrix, Helicobacter, Legionellosis, Leptospirosis, Listeria, Mycoplasmatales, Mycobacterium leprae, Vibrio cholerae, Neisseriaceae (e.g., Acinetobacter, Gonorrhea, Meningococcal),

5 Meisseria meningitidis, Pasteurellacea Infections (e.g., Actinobacillus, Heamophilus (e.g., Heamophilus influenza type B), Pasteurella), Pseudomonas, Rickettsiaceae, Chlamydiaceae, Syphilis, Shigella spp., Staphylococcal, Meningiococcal, Pneumococcal and Streptococcal (e.g., Streptococcus pneumoniae and Group B Streptococcus). These bacterial or fungal families can cause the following diseases or

10 symptoms, including, but not limited to: bacteremia, endocarditis, eye infections (conjunctivitis, tuberculosis, uveitis), gingivitis, opportunistic infections (e.g., AIDS related infections), paronychia, prosthesis-related infections, Reiter's Disease, respiratory tract infections, such as Whooping Cough or Empyema, sepsis, Lyme Disease, Cat-Scratch Disease, Dysentery, Paratyphoid Fever, food poisoning,

15 Typhoid, pneumonia, Gonorrhea, meningitis (e.g., mengitis types A and B), Chlamydia, Syphilis, Diphtheria, Leprosy, Paratuberculosis, Tuberculosis, Lupus, Botulism, gangrene, tetanus, impetigo, Rheumatic Fever, Scarlet Fever, sexually transmitted diseases, skin diseases (e.g., cellulitis, dermatocycoses), toxemia, urinary tract infections, wound infections. Polynucleotides or polypeptides, agonists or

20 antagonists of the invention, can be used to treat or detect any of these symptoms or diseases. In specific embodiments, Ppolynucleotides, polypeptides, agonists or antagonists of the invention are used to treat: tetanus, Diphtheria, botulism, and/or meningitis type B.

Moreover, parasitic agents causing disease or symptoms that can be treated or

25 detected by a polynucleotide or polypeptide and/or agonist or antagonist of the present invention include, but not limited to, the following families or class: Amebiasis, Babesiosis, Coccidiosis, Cryptosporidiosis, Dientamoebiasis, Dourine, Ectoparasitic, Giardiasis, Helminthiasis, Leishmaniasis, Theileriasis, Toxoplasmosis, Trypanosomiasis, and Trichomonas and Sporozoans (e.g., Plasmodium virax,

30 Plasmodium falciparum, Plasmodium malariae and Plasmodium ovale). These parasites can cause a variety of diseases or symptoms, including, but not limited to: Scabies, Trombiculiasis, eye infections, intestinal disease (e.g., dysentery, giardiasis),

liver disease, lung disease, opportunistic infections (e.g., AIDS related), malaria, pregnancy complications, and toxoplasmosis. polynucleotides or polypeptides, or agonists or antagonists of the invention, can be used to treat or detect any of these symptoms or diseases. In specific embodiments, polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat malaria.

Preferably, treatment using a polypeptide or polynucleotide and/or agonist or antagonist of the present invention could either be by administering an effective amount of a polypeptide to the patient, or by removing cells from the patient, supplying the cells with a polynucleotide of the present invention, and returning the engineered cells to the patient (ex vivo therapy). Moreover, the polypeptide or polynucleotide of the present invention can be used as an antigen in a vaccine to raise an immune response against infectious disease.

### **Regeneration**

A polynucleotide or polypeptide and/or agonist or antagonist of the present invention can be used to differentiate, proliferate, and attract cells, leading to the regeneration of tissues. (See, Science 276:59-87 (1997).) The regeneration of tissues could be used to repair, replace, or protect tissue damaged by congenital defects, trauma (wounds, burns, incisions, or ulcers), age, disease (e.g. osteoporosis, osteoarthritis, periodontal disease, liver failure), surgery, including cosmetic plastic surgery, fibrosis, reperfusion injury, or systemic cytokine damage.

Tissues that could be regenerated using the present invention include organs (e.g., pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac), vasculature (including vascular and lymphatics), nervous, hematopoietic, and skeletal (bone, cartilage, tendon, and ligament) tissue. Preferably, regeneration occurs without or decreased scarring. Regeneration also may include angiogenesis.

Moreover, a polynucleotide or polypeptide and/or agonist or antagonist of the present invention may increase regeneration of tissues difficult to heal. For example, increased tendon/ligament regeneration would quicken recovery time after damage. A polynucleotide or polypeptide and/or agonist or antagonist of the present invention could also be used prophylactically in an effort to avoid damage. Specific diseases that could be treated include of tendinitis, carpal tunnel syndrome, and other tendon or

ligament defects. A further example of tissue regeneration of non-healing wounds includes pressure ulcers, ulcers associated with vascular insufficiency, surgical, and traumatic wounds.

Similarly, nerve and brain tissue could also be regenerated by using a polynucleotide or polypeptide and/or agonist or antagonist of the present invention to proliferate and differentiate nerve cells. Diseases that could be treated using this method include central and peripheral nervous system diseases, neuropathies, or mechanical and traumatic disorders (e.g., spinal cord disorders, head trauma, cerebrovascular disease, and stroke). Specifically, diseases associated with peripheral nerve injuries, peripheral neuropathy (e.g., resulting from chemotherapy or other medical therapies), localized neuropathies, and central nervous system diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome), could all be treated using the polynucleotide or polypeptide and/or agonist or antagonist of the present invention.

### **Chemotaxis**

A polynucleotide or polypeptide and/or agonist or antagonist of the present invention may have chemotaxis activity. A chemotaxic molecule attracts or mobilizes cells (e.g., monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells) to a particular site in the body, such as inflammation, infection, or site of hyperproliferation. The mobilized cells can then fight off and/or heal the particular trauma or abnormality.

A polynucleotide or polypeptide and/or agonist or antagonist of the present invention may increase chemotaxic activity of particular cells. These chemotactic molecules can then be used to treat inflammation, infection, hyperproliferative disorders, or any immune system disorder by increasing the number of cells targeted to a particular location in the body. For example, chemotaxic molecules can be used to treat wounds and other trauma to tissues by attracting immune cells to the injured location. Chemotactic molecules of the present invention can also attract fibroblasts, which can be used to treat wounds.

It is also contemplated that a polynucleotide or polypeptide and/or agonist or antagonist of the present invention may inhibit chemotactic activity. These molecules

could also be used to treat disorders. Thus, a polynucleotide or polypeptide and/or agonist or antagonist of the present invention could be used as an inhibitor of chemotaxis.

5

### **Binding Activity**

A polypeptide of the present invention may be used to screen for molecules that bind to the polypeptide or for molecules to which the polypeptide binds. The binding of the polypeptide and the molecule may activate (agonist), increase, inhibit  
10 (antagonist), or decrease activity of the polypeptide or the molecule bound. Examples of such molecules include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.

Preferably, the molecule is closely related to the natural ligand of the polypeptide, e.g., a fragment of the ligand, or a natural substrate, a ligand, a structural  
15 or functional mimetic. (See, Coligan et al., Current Protocols in Immunology 1(2):Chapter 5 (1991).) Similarly, the molecule can be closely related to the natural receptor to which the polypeptide binds, or at least, a fragment of the receptor capable of being bound by the polypeptide (e.g., active site). In either case, the molecule can be rationally designed using known techniques.

20 Preferably, the screening for these molecules involves producing appropriate cells which express the polypeptide, either as a secreted protein or on the cell membrane. Preferred cells include cells from mammals, yeast, *Drosophila*, or *E. coli*. Cells expressing the polypeptide (or cell membrane containing the expressed polypeptide) are then preferably contacted with a test compound potentially  
25 containing the molecule to observe binding, stimulation, or inhibition of activity of either the polypeptide or the molecule.

The assay may simply test binding of a candidate compound to the polypeptide, wherein binding is detected by a label, or in an assay involving competition with a labeled competitor. Further, the assay may test whether the  
30 candidate compound results in a signal generated by binding to the polypeptide.

Alternatively, the assay can be carried out using cell-free preparations, polypeptide/molecule affixed to a solid support, chemical libraries, or natural product

mixtures. The assay may also simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide, measuring polypeptide/molecule activity or binding, and comparing the polypeptide/molecule activity or binding to a standard.

- 5            Preferably, an ELISA assay can measure polypeptide level or activity in a sample (e.g., biological sample) using a monoclonal or polyclonal antibody. The antibody can measure polypeptide level or activity by either binding, directly or indirectly, to the polypeptide or by competing with the polypeptide for a substrate.

            Additionally, the receptor to which a polypeptide of the invention binds can be  
10 identified by numerous methods known to those of skill in the art, for example, ligand panning and FACS sorting (Coligan, et al., Current Protocols in Immun., 1(2), Chapter 5, (1991)). For example, expression cloning is employed wherein polyadenylated RNA is prepared from a cell responsive to the polypeptides, for example, NIH3T3 cells which are known to contain multiple receptors for the FGF  
15 family proteins, and SC-3 cells, and a cDNA library created from this RNA is divided into pools and used to transfect COS cells or other cells that are not responsive to the polypeptides. Transfected cells which are grown on glass slides are exposed to the polypeptide of the present invention, after they have been labelled. The polypeptides can be labeled by a variety of means including iodination or inclusion of a recognition  
20 site for a site-specific protein kinase.

            Following fixation and incubation, the slides are subjected to autoradiographic analysis. Positive pools are identified and sub-pools are prepared and re-transfected using an iterative sub-pooling and re-screening process, eventually yielding a single clones that encodes the putative receptor.

- 25            As an alternative approach for receptor identification, the labeled polypeptides can be photoaffinity linked with cell membrane or extract preparations that express the receptor molecule. Cross-linked material is resolved by PAGE analysis and exposed to X-ray film. The labeled complex containing the receptors of the polypeptides can be excised, resolved into peptide fragments, and subjected to protein  
30 microsequencing. The amino acid sequence obtained from microsequencing would be used to design a set of degenerate oligonucleotide probes to screen a cDNA library to identify the genes encoding the putative receptors.

Moreover, the techniques of gene-shuffling, motif-shuffling, exon-shuffling, and/or codon-shuffling (collectively referred to as "DNA shuffling") may be employed to modulate the activities of polypeptides of the invention thereby effectively generating agonists and antagonists of polypeptides of the invention. See  
5 generally, U.S. Patent Nos. 5,605,793, 5,811,238, 5,830,721, 5,834,252, and 5,837,458, and Patten, P. A., et al., Curr. Opinion Biotechnol. 8:724-33 (1997); Harayama, S. Trends Biotechnol. 16(2):76-82 (1998); Hansson, L. O., et al., J. Mol. Biol. 287:265-76 (1999); and Lorenzo, M. M. and Blasco, R. Biotechniques 24(2):308-13 (1998) (each of these patents and publications are hereby incorporated  
10 by reference). In one embodiment, alteration of polynucleotides and corresponding polypeptides of the invention may be achieved by DNA shuffling. DNA shuffling involves the assembly of two or more DNA segments into a desired polynucleotide sequence of the invention molecule by homologous, or site-specific, recombination. In another embodiment, polynucleotides and corresponding polypeptides of the  
15 invention may be altered by being subjected to random mutagenesis by error-prone PCR, random nucleotide insertion or other methods prior to recombination. In another embodiment, one or more components, motifs, sections, parts, domains, fragments, etc., of the polypeptides of the invention may be recombined with one or more components, motifs, sections, parts, domains, fragments, etc. of one or more  
20 heterologous molecules. In preferred embodiments, the heterologous molecules are family members. In further preferred embodiments, the heterologous molecule is a growth factor such as, for example, platelet-derived growth factor (PDGF), insulin-like growth factor (IGF-I), transforming growth factor (TGF)-alpha, epidermal growth factor (EGF), fibroblast growth factor (FGF), TGF-beta, bone morphogenetic protein (BMP)-2, BMP-4, BMP-5, BMP-6, BMP-7, activins A and B,  
25 decapentaplegic(dpp), 60A, OP-2, dorsalin, growth differentiation factors (GDFs), nodal, MIS, inhibin-alpha, TGF-beta1, TGF-beta2, TGF-beta3, TGF-beta5, and glial-derived neurotrophic factor (GDNF).

Other preferred fragments are biologically active fragments of the  
30 polypeptides of the invention. Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an activity of the polypeptide. The

biological activity of the fragments may include an improved desired activity, or a decreased undesirable activity.

Additionally, this invention provides a method of screening compounds to identify those which modulate the action of the polypeptide of the present invention.

5 An example of such an assay comprises combining a mammalian fibroblast cell, a the polypeptide of the present invention, the compound to be screened and 3[H] thymidine under cell culture conditions where the fibroblast cell would normally proliferate. A control assay may be performed in the absence of the compound to be screened and compared to the amount of fibroblast proliferation in the presence of the  
10 compound to determine if the compound stimulates proliferation by determining the uptake of 3[H] thymidine in each case. The amount of fibroblast cell proliferation is measured by liquid scintillation chromatography which measures the incorporation of 3[H] thymidine. Both agonist and antagonist compounds may be identified by this procedure.

15 In another method, a mammalian cell or membrane preparation expressing a receptor for a polypeptide of the present invention is incubated with a labeled polypeptide of the present invention in the presence of the compound. The ability of the compound to enhance or block this interaction could then be measured. Alternatively, the response of a known second messenger system following  
20 interaction of a compound to be screened and the receptor is measured and the ability of the compound to bind to the receptor and elicit a second messenger response is measured to determine if the compound is a potential agonist or antagonist. Such second messenger systems include but are not limited to, cAMP guanylate cyclase, ion channels or phosphoinositide hydrolysis.

25 All of these above assays can be used as diagnostic or prognostic markers. The molecules discovered using these assays can be used to treat disease or to bring about a particular result in a patient (e.g., blood vessel growth) by activating or inhibiting the polypeptide/molecule. Moreover, the assays can discover agents which may inhibit or enhance the production of the polypeptides of the invention from  
30 suitably manipulated cells or tissues. Therefore, the invention includes a method of identifying compounds which bind to the polypeptides of the invention comprising the steps of: (a) incubating a candidate binding compound with the polypeptide; and

(b) determining if binding has occurred. Moreover, the invention includes a method of identifying agonists/antagonists comprising the steps of: (a) incubating a candidate compound with the polypeptide, (b) assaying a biological activity, and (b) determining if a biological activity of the polypeptide has been altered.

5           Also, one could identify molecules bind a polypeptide of the invention experimentally by using the beta-pleated sheet regions contained in the polypeptide sequence of the protein. Accordingly, specific embodiments of the invention are directed to polynucleotides encoding polypeptides which comprise, or alternatively consist of, the amino acid sequence of each beta pleated sheet regions in a disclosed  
10   polypeptide sequence. Additional embodiments of the invention are directed to polynucleotides encoding polypeptides which comprise, or alternatively consist of, any combination or all of contained in the polypeptide sequences of the invention. Additional preferred embodiments of the invention are directed to polypeptides which comprise, or alternatively consist of, the amino acid sequence of each of the beta  
15   pleated sheet regions in one of the polypeptide sequences of the invention. Additional embodiments of the invention are directed to polypeptides which comprise, or alternatively consist of, any combination or all of the beta pleated sheet regions in one of the polypeptide sequences of the invention.

## 20   Targeted Delivery

          In another embodiment, the invention provides a method of delivering compositions to targeted cells expressing a receptor for a polypeptide of the invention, or cells expressing a cell bound form of a polypeptide of the invention.

          As discussed herein, polypeptides or antibodies of the invention may be  
25   associated with heterologous polypeptides, heterologous nucleic acids, toxins, or prodrugs via hydrophobic, hydrophilic, ionic and/or covalent interactions. In one embodiment, the invention provides a method for the specific delivery of compositions of the invention to cells by administering polypeptides of the invention (including antibodies) that are associated with heterologous polypeptides or nucleic  
30   acids. In one example, the invention provides a method for delivering a therapeutic protein into the targeted cell. In another example, the invention provides a method for delivering a single stranded nucleic acid (e.g., antisense or ribozymes) or double



stranded nucleic acid (e.g., DNA that can integrate into the cell's genome or replicate episomally and that can be transcribed) into the targeted cell.

In another embodiment, the invention provides a method for the specific destruction of cells (e.g., the destruction of tumor cells) by administering polypeptides of the invention (e.g., polypeptides of the invention or antibodies of the invention) in association with toxins or cytotoxic prodrugs.

By "toxin" is meant compounds that bind and activate endogenous cytotoxic effector systems, radioisotopes, holotoxins, modified toxins, catalytic subunits of toxins, or any molecules or enzymes not normally present in or on the surface of a cell that under defined conditions cause the cell's death. Toxins that may be used according to the methods of the invention include, but are not limited to, radioisotopes known in the art, compounds such as, for example, antibodies (or complement fixing containing portions thereof) that bind an inherent or induced endogenous cytotoxic effector system, thymidine kinase, endonuclease, RNase, alpha toxin, ricin, abrin, *Pseudomonas* exotoxin A, diphtheria toxin, saporin, momordin, gelonin, pokeweed antiviral protein, alpha-sarcin and cholera toxin. By "cytotoxic prodrug" is meant a non-toxic compound that is converted by an enzyme, normally present in the cell, into a cytotoxic compound. Cytotoxic prodrugs that may be used according to the methods of the invention include, but are not limited to, glutamyl derivatives of benzoic acid mustard alkylating agent, phosphate derivatives of etoposide or mitomycin C, cytosine arabinoside, daunorubisin, and phenoxyacetamide derivatives of doxorubicin.

### **Drug Screening**

Further contemplated is the use of the polypeptides of the present invention, or the polynucleotides encoding these polypeptides, to screen for molecules which modify the activities of the polypeptides of the present invention. Such a method would include contacting the polypeptide of the present invention with a selected compound(s) suspected of having antagonist or agonist activity, and assaying the activity of these polypeptides following binding.

This invention is particularly useful for screening therapeutic compounds by using the polypeptides of the present invention, or binding fragments thereof, in any

of a variety of drug screening techniques. The polypeptide or fragment employed in such a test may be affixed to a solid support, expressed on a cell surface, free in solution, or located intracellularly. One method of drug screening utilizes eukaryotic or prokaryotic host cells which are stably transformed with recombinant nucleic acids expressing the polypeptide or fragment. Drugs are screened against such transformed cells in competitive binding assays. One may measure, for example, the formulation of complexes between the agent being tested and a polypeptide of the present invention.

Thus, the present invention provides methods of screening for drugs or any other agents which affect activities mediated by the polypeptides of the present invention. These methods comprise contacting such an agent with a polypeptide of the present invention or a fragment thereof and assaying for the presence of a complex between the agent and the polypeptide or a fragment thereof, by methods well known in the art. In such a competitive binding assay, the agents to screen are typically labeled. Following incubation, free agent is separated from that present in bound form, and the amount of free or uncomplexed label is a measure of the ability of a particular agent to bind to the polypeptides of the present invention.

Another technique for drug screening provides high throughput screening for compounds having suitable binding affinity to the polypeptides of the present invention, and is described in great detail in European Patent Application 84/03564, published on September 13, 1984, which is incorporated herein by reference herein. Briefly stated, large numbers of different small peptide test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The peptide test compounds are reacted with polypeptides of the present invention and washed. Bound polypeptides are then detected by methods well known in the art. Purified polypeptides are coated directly onto plates for use in the aforementioned drug screening techniques. In addition, non-neutralizing antibodies may be used to capture the peptide and immobilize it on the solid support.

This invention also contemplates the use of competitive drug screening assays in which neutralizing antibodies capable of binding polypeptides of the present invention specifically compete with a test compound for binding to the polypeptides or fragments thereof. In this manner, the antibodies are used to detect the presence of

any peptide which shares one or more antigenic epitopes with a polypeptide of the invention.

### **Antisense And Ribozyme (Antagonists)**

5           In specific embodiments, antagonists according to the present invention are nucleic acids corresponding to the sequences contained in SEQ ID NO:X, or the complementary strand thereof, and/or to nucleotide sequences contained a deposited clone. In one embodiment, antisense sequence is generated internally by the organism, in another embodiment, the antisense sequence is separately administered  
10           (see, for example, O'Connor, *Neurochem.*, 56:560 (1991). *Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression*, CRC Press, Boca Raton, FL (1988). Antisense technology can be used to control gene expression through antisense DNA or RNA, or through triple-helix formation. Antisense techniques are discussed for example, in Okano, *Neurochem.*, 56:560 (1991); *Oligodeoxynucleotides as Antisense*  
15           *Inhibitors of Gene Expression*, CRC Press, Boca Raton, FL (1988). Triple helix formation is discussed in, for instance, Lee et al., *Nucleic Acids Research*, 6:3073 (1979); Cooney et al., *Science*, 241:456 (1988); and Dervan et al., *Science*, 251:1300 (1991). The methods are based on binding of a polynucleotide to a complementary DNA or RNA.

20           For example, the use of c-myc and c-myb antisense RNA constructs to inhibit the growth of the non-lymphocytic leukemia cell line HL-60 and other cell lines was previously described. (Wickstrom et al. (1988); Anfossi et al. (1989)). These experiments were performed in vitro by incubating cells with the oligoribonucleotide. A similar procedure for in vivo use is described in WO 91/15580. Briefly, a pair of  
25           oligonucleotides for a given antisense RNA is produced as follows: A sequence complimentary to the first 15 bases of the open reading frame is flanked by an EcoRI site on the 5' end and a HindIII site on the 3' end. Next, the pair of oligonucleotides is heated at 90°C for one minute and then annealed in 2X ligation buffer (20mM TRIS HCl pH 7.5, 10mM MgCl<sub>2</sub>, 10mM dithiothreitol (DTT) and 0.2 mM ATP) and then  
30           ligated to the EcoRI/Hind III site of the retroviral vector PMV7 (WO 91/15580).

For example, the 5' coding portion of a polynucleotide that encodes the mature polypeptide of the present invention may be used to design an antisense RNA

oligonucleotide of from about 10 to 40 base pairs in length. A DNA oligonucleotide is designed to be complementary to a region of the gene involved in transcription thereby preventing transcription and the production of the receptor. The antisense RNA oligonucleotide hybridizes to the mRNA in vivo and blocks translation of the mRNA molecule into receptor polypeptide.

In one embodiment, the antisense nucleic acid of the invention is produced intracellularly by transcription from an exogenous sequence. For example, a vector or a portion thereof, is transcribed, producing an antisense nucleic acid (RNA) of the invention. Such a vector would contain a sequence encoding the antisense nucleic acid of the invention. Such a vector can remain episomal or become chromosomally integrated, as long as it can be transcribed to produce the desired antisense RNA. Such vectors can be constructed by recombinant DNA technology methods standard in the art. Vectors can be plasmid, viral, or others known in the art, used for replication and expression in vertebrate cells. Expression of the sequence encoding a polypeptide of the invention, or fragments thereof, can be by any promoter known in the art to act in vertebrate, preferably human cells. Such promoters can be inducible or constitutive. Such promoters include, but are not limited to, the SV40 early promoter region (Bernoist and Chambon, *Nature*, 29:304-310 (1981), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto et al., *Cell*, 22:787-797 (1980), the herpes thymidine promoter (Wagner et al., *Proc. Natl. Acad. Sci. U.S.A.*, 78:1441-1445 (1981), the regulatory sequences of the metallothionein gene (Brinster et al., *Nature*, 296:39-42 (1982)), etc.

The antisense nucleic acids of the invention comprise a sequence complementary to at least a portion of an RNA transcript of a gene of interest. However, absolute complementarity, although preferred, is not required. A sequence "complementary to at least a portion of an RNA," referred to herein, means a sequence having sufficient complementarity to be able to hybridize with the RNA, forming a stable duplex; in the case of double stranded antisense nucleic acids of the invention, a single strand of the duplex DNA may thus be tested, or triplex formation may be assayed. The ability to hybridize will depend on both the degree of complementarity and the length of the antisense nucleic acid. Generally, the larger the hybridizing nucleic acid, the more base mismatches with a RNA sequence of the

invention it may contain and still form a stable duplex (or triplex as the case may be). One skilled in the art can ascertain a tolerable degree of mismatch by use of standard procedures to determine the melting point of the hybridized complex.

Oligonucleotides that are complementary to the 5' end of the message, *e.g.*,  
5 the 5' untranslated sequence up to and including the AUG initiation codon, should work most efficiently at inhibiting translation. However, sequences complementary to the 3' untranslated sequences of mRNAs have been shown to be effective at inhibiting translation of mRNAs as well. See generally, Wagner, R., *Nature*, 372:333-335 (1994). Thus, oligonucleotides complementary to either the 5' - or 3' -  
10 non- translated, non-coding regions of a polynucleotide sequence of the invention could be used in an antisense approach to inhibit translation of endogenous mRNA. Oligonucleotides complementary to the 5' untranslated region of the mRNA should include the complement of the AUG start codon. Antisense oligonucleotides complementary to mRNA coding regions are less efficient inhibitors of translation but  
15 could be used in accordance with the invention. Whether designed to hybridize to the 5' -, 3' - or coding region of mRNA, antisense nucleic acids should be at least six nucleotides in length, and are preferably oligonucleotides ranging from 6 to about 50 nucleotides in length. In specific aspects the oligonucleotide is at least 10 nucleotides, at least 17 nucleotides, at least 25 nucleotides or at least 50 nucleotides.

20 The polynucleotides of the invention can be DNA or RNA or chimeric mixtures or derivatives or modified versions thereof, single-stranded or double-stranded. The oligonucleotide can be modified at the base moiety, sugar moiety, or phosphate backbone, for example, to improve stability of the molecule, hybridization, etc. The oligonucleotide may include other appended groups such as peptides (*e.g.*,  
25 for targeting host cell receptors *in vivo*), or agents facilitating transport across the cell membrane (see, *e.g.*, Letsinger et al., *Proc. Natl. Acad. Sci. U.S.A.* 86:6553-6556 (1989); Lemaitre et al., *Proc. Natl. Acad. Sci.*, 84:648-652 (1987); PCT Publication NO: WO88/09810, published December 15, 1988) or the blood-brain barrier (see, *e.g.*, PCT Publication NO: WO89/10134, published April 25, 1988), hybridization-  
30 triggered cleavage agents. (See, *e.g.*, Krol et al., *BioTechniques*, 6:958-976 (1988)) or intercalating agents. (See, *e.g.*, Zon, *Pharm. Res.*, 5:539-549 (1988)). To this end, the oligonucleotide may be conjugated to another molecule, *e.g.*, a peptide,

hybridization triggered cross-linking agent, transport agent, hybridization-triggered cleavage agent, etc.

The antisense oligonucleotide may comprise at least one modified base moiety which is selected from the group including, but not limited to, 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xantine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine.

The antisense oligonucleotide may also comprise at least one modified sugar moiety selected from the group including, but not limited to, arabinose, 2-fluoroarabinose, xylulose, and hexose.

In yet another embodiment, the antisense oligonucleotide comprises at least one modified phosphate backbone selected from the group including, but not limited to, a phosphorothioate, a phosphorodithioate, a phosphoramidothioate, a phosphoramidate, a phosphordiamidate, a methylphosphonate, an alkyl phosphotriester, and a formacetal or analog thereof.

In yet another embodiment, the antisense oligonucleotide is an a-anomeric oligonucleotide. An a-anomeric oligonucleotide forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual b-units, the strands run parallel to each other (Gautier et al., Nucl. Acids Res., 15:6625-6641 (1987)). The oligonucleotide is a 2'-O-methylribonucleotide (Inoue et al., Nucl. Acids Res., 15:6131-6148 (1987)), or a chimeric RNA-DNA analogue (Inoue et al., FEBS Lett. 215:327-330 (1987)).

Polynucleotides of the invention may be synthesized by standard methods known in the art, e.g. by use of an automated DNA synthesizer (such as are commercially available from Biosearch, Applied Biosystems, etc.). As examples, phosphorothioate oligonucleotides may be synthesized by the method of Stein et al. (Nucl. Acids Res., 16:3209 (1988)), methylphosphonate oligonucleotides can be prepared by use of controlled pore glass polymer supports (Sarin et al., Proc. Natl. Acad. Sci. U.S.A., 85:7448-7451 (1988)), etc.

While antisense nucleotides complementary to the coding region sequence of the invention could be used, those complementary to the transcribed untranslated region are most preferred.

Potential antagonists according to the invention also include catalytic RNA, or a ribozyme (See, e.g., PCT International Publication WO 90/11364, published October 4, 1990; Sarver et al, Science, 247:1222-1225 (1990). While ribozymes that cleave mRNA at site specific recognition sequences can be used to destroy mRNAs corresponding to the polynucleotides of the invention, the use of hammerhead ribozymes is preferred. Hammerhead ribozymes cleave mRNAs at locations dictated by flanking regions that form complementary base pairs with the target mRNA. The sole requirement is that the target mRNA have the following sequence of two bases: 5' -UG-3'. The construction and production of hammerhead ribozymes is well known in the art and is described more fully in Haseloff and Gerlach, Nature, 334:585-591 (1988). There are numerous potential hammerhead ribozyme cleavage sites within each nucleotide sequence disclosed in the sequence listing. Preferably, the ribozyme is engineered so that the cleavage recognition site is located near the 5' end of the mRNA corresponding to the polynucleotides of the invention; i.e., to increase efficiency and minimize the intracellular accumulation of non-functional mRNA transcripts.

As in the antisense approach, the ribozymes of the invention can be composed of modified oligonucleotides (e.g. for improved stability, targeting, etc.) and should be delivered to cells which express the polynucleotides of the invention in vivo. DNA constructs encoding the ribozyme may be introduced into the cell in the same manner as described above for the introduction of antisense encoding DNA. A preferred method of delivery involves using a DNA construct "encoding" the

ribozyme under the control of a strong constitutive promoter, such as, for example, pol III or pol II promoter, so that transfected cells will produce sufficient quantities of the ribozyme to destroy endogenous messages and inhibit translation. Since ribozymes unlike antisense molecules, are catalytic, a lower intracellular  
5 concentration is required for efficiency.

Antagonist/agonist compounds may be employed to inhibit the cell growth and proliferation effects of the polypeptides of the present invention on neoplastic cells and tissues, i.e. stimulation of angiogenesis of tumors, and, therefore, retard or prevent abnormal cellular growth and proliferation, for example, in tumor formation  
10 or growth.

The antagonist/agonist may also be employed to prevent hyper-vascular diseases, and prevent the proliferation of epithelial lens cells after extracapsular cataract surgery. Prevention of the mitogenic activity of the polypeptides of the present invention may also be desirous in cases such as restenosis after balloon  
15 angioplasty.

The antagonist/agonist may also be employed to prevent the growth of scar tissue during wound healing.

The antagonist/agonist may also be employed to treat the diseases described herein.

20 Thus, the invention provides a method of treating disorders or diseases, including but not limited to the disorders or diseases listed throughout this application, associated with overexpression of a polynucleotide of the present invention by administering to a patient (a) an antisense molecule directed to the polynucleotide of the present invention, and/or (b) a ribozyme directed to the polynucleotide of the present  
25 invention

#### **Other Activities**

The polypeptide of the present invention, as a result of the ability to stimulate vascular endothelial cell growth, may be employed in treatment for stimulating re-vascularization of ischemic tissues due to various disease conditions such as  
30 thrombosis, arteriosclerosis, and other cardiovascular conditions. These polypeptide may also be employed to stimulate angiogenesis and limb regeneration, as discussed above.



The polypeptide may also be employed for treating wounds due to injuries, burns, post-operative tissue repair, and ulcers since they are mitogenic to various cells of different origins, such as fibroblast cells and skeletal muscle cells, and therefore, facilitate the repair or replacement of damaged or diseased tissue.

5       The polypeptide of the present invention may also be employed stimulate neuronal growth and to treat and prevent neuronal damage which occurs in certain neuronal disorders or neuro-degenerative conditions such as Alzheimer's disease, Parkinson's disease, and AIDS-related complex. The polypeptide of the invention may have the ability to stimulate chondrocyte growth, therefore, they may be  
10       employed to enhance bone and periodontal regeneration and aid in tissue transplants or bone grafts.

The polypeptide of the present invention may be also be employed to prevent skin aging due to sunburn by stimulating keratinocyte growth.

The polypeptide of the invention may also be employed for preventing hair  
15       loss, since FGF family members activate hair-forming cells and promotes melanocyte growth. Along the same lines, the polypeptides of the present invention may be employed to stimulate growth and differentiation of hematopoietic cells and bone marrow cells when used in combination with other cytokines.

The polypeptide of the invention may also be employed to maintain organs  
20       before transplantation or for supporting cell culture of primary tissues.

The polypeptide of the present invention may also be employed for inducing tissue of mesodermal origin to differentiate in early embryos.

The polypeptide or polynucleotides and/or agonist or antagonists of the  
25       present invention may also increase or decrease the differentiation or proliferation of embryonic stem cells, besides, as discussed above, hematopoietic lineage.

The polypeptide or polynucleotides and/or agonist or antagonists of the present invention may also be used to modulate mammalian characteristics, such as body height, weight, hair color, eye color, skin, percentage of adipose tissue,  
30       pigmentation, size, and shape (e.g., cosmetic surgery). Similarly, polypeptides or polynucleotides and/or agonist or antagonists of the present invention may be used to

modulate mammalian metabolism affecting catabolism, anabolism, processing, utilization, and storage of energy.

Polypeptide or polynucleotides and/or agonist or antagonists of the present invention may be used to change a mammal's mental state or physical state by  
5 influencing biorhythms, cardiac rhythms, depression (including depressive disorders), tendency for violence, tolerance for pain, reproductive capabilities (preferably by Activin or Inhibin-like activity), hormonal or endocrine levels, appetite, libido, memory, stress, or other cognitive qualities.

Polypeptide or polynucleotides and/or agonist or antagonists of the present  
10 invention may also be used as a food additive or preservative, such as to increase or decrease storage capabilities, fat content, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional components.

### **Other Preferred Embodiments**

15 Other preferred embodiments of the claimed invention include an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 50 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1.

Also preferred is a nucleic acid molecule wherein said sequence of contiguous  
20 nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the Clone Sequence and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Also preferred is a nucleic acid molecule wherein said sequence of contiguous  
25 nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the Start Codon and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Similarly preferred is a nucleic acid molecule wherein said sequence of  
30 contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5'

Nucleotide of the First Amino Acid of the Signal Peptide and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide  
5 sequence which is at least 95% identical to a sequence of at least about 150 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X.

Further preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 500 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X.

10 A further preferred embodiment is a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the nucleotide sequence of SEQ ID NO:X beginning with the nucleotide at about the position of the 5' Nucleotide of the First Amino Acid of the Signal Peptide and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X  
15 in Table 1.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence of SEQ ID NO:X.

Also preferred is an isolated nucleic acid molecule which hybridizes under  
20 stringent hybridization conditions to a nucleic acid molecule, wherein said nucleic acid molecule which hybridizes does not hybridize under stringent hybridization conditions to a nucleic acid molecule having a nucleotide sequence consisting of only A residues or of only T residues.

Also preferred is a composition of matter comprising a DNA molecule which  
25 comprises a human cDNA clone identified by a cDNA Clone Identifier in Table 1, which DNA molecule is contained in the material deposited with the American Type Culture Collection and given the ATCC Deposit Number shown in Table 1 for said cDNA Clone Identifier.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide  
30 sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in the nucleotide sequence of a human cDNA clone identified by a cDNA

Clone Identifier in Table 1, which DNA molecule is contained in the deposit given the ATCC Deposit Number shown in Table 1.

Also preferred is an isolated nucleic acid molecule, wherein said sequence of at least 50 contiguous nucleotides is included in the nucleotide sequence of the  
5 complete open reading frame sequence encoded by said human cDNA clone.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 150 contiguous nucleotides in the nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is an isolated nucleic acid molecule  
10 comprising a nucleotide sequence which is at least 95% identical to sequence of at least 500 contiguous nucleotides in the nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete  
15 nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is a method for detecting in a biological sample a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X  
20 wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1; which method comprises a step of comparing a nucleotide sequence of at least one nucleic acid molecule in said sample with a sequence selected from said group and  
25 determining whether the sequence of said nucleic acid molecule in said sample is at least 95% identical to said selected sequence.

Also preferred is the above method wherein said step of comparing sequences comprises determining the extent of nucleic acid hybridization between nucleic acid molecules in said sample and a nucleic acid molecule comprising said sequence  
30 selected from said group. Similarly, also preferred is the above method wherein said step of comparing sequences is performed by comparing the nucleotide sequence determined from a nucleic acid molecule in said sample with said sequence selected

from said group. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

A further preferred embodiment is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting nucleic acid molecules in said sample, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

The method for identifying the species, tissue or cell type of a biological sample can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a gene encoding a secreted protein identified in Table 1, which method comprises a step of detecting in a biological sample obtained from said subject nucleic acid molecules, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

The method for diagnosing a pathological condition can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

Also preferred is a composition of matter comprising isolated nucleic acid molecules wherein the nucleotide sequences of said nucleic acid molecules comprise a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1.

Also preferred is a polypeptide, wherein said sequence of contiguous amino acids is included in the amino acid sequence of SEQ ID NO:Y in the range of positions beginning with the residue at about the position of the First Amino Acid of the Secreted Portion and ending with the residue at about the Last Amino Acid of the Open Reading Frame as set forth for SEQ ID NO:Y in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the complete amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is a polypeptide wherein said sequence of contiguous amino acids is included in the amino acid sequence of a secreted portion of the secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is an isolated antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is a method for detecting in a biological sample a polypeptide comprising an amino acid sequence which is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as

defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1; which method comprises a step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group and determining whether the sequence of said polypeptide molecule in said sample is at least 90% identical to said sequence of at least 10 contiguous amino acids.

Also preferred is the above method wherein said step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group comprises determining the extent of specific binding of polypeptides in said sample to an antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is the above method wherein said step of comparing sequences is performed by comparing the amino acid sequence determined from a polypeptide molecule in said sample with said sequence selected from said group.

Also preferred is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting polypeptide molecules in said sample, if any, comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is the above method for identifying the species, tissue or cell type of a biological sample, which method comprises a step of detecting polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid



sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the above group.

Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a gene encoding a secreted protein identified in Table 1, which method comprises a step of detecting in a biological sample obtained from said subject polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

In any of these methods, the step of detecting said polypeptide molecules includes using an antibody.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a nucleotide sequence encoding a polypeptide wherein said polypeptide comprises an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated nucleic acid molecule, wherein said nucleotide sequence encoding a polypeptide has been optimized for expression of said polypeptide in a prokaryotic host.

Also preferred is an isolated nucleic acid molecule, wherein said polypeptide comprises an amino acid sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone

identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is a method of making a recombinant vector comprising inserting any of the above isolated nucleic acid molecule into a vector. Also preferred is the recombinant vector produced by this method. Also preferred is a method of making a recombinant host cell comprising introducing the vector into a host cell, as well as the recombinant host cell produced by this method.

Also preferred is a method of making an isolated polypeptide comprising culturing this recombinant host cell under conditions such that said polypeptide is expressed and recovering said polypeptide. Also preferred is this method of making an isolated polypeptide, wherein said recombinant host cell is a eukaryotic cell and said polypeptide is a secreted portion of a human secreted protein comprising an amino acid sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y beginning with the residue at the position of the First Amino Acid of the Secreted Portion of SEQ ID NO:Y wherein Y is an integer set forth in Table 1 and said position of the First Amino Acid of the Secreted Portion of SEQ ID NO:Y is defined in Table 1; and an amino acid sequence of a secreted portion of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1. The isolated polypeptide produced by this method is also preferred.

Also preferred is a method of treatment of an individual in need of an increased level of a secreted protein activity, which method comprises administering to such an individual a pharmaceutical composition comprising an amount of an isolated polypeptide, polynucleotide, or antibody of the claimed invention effective to increase the level of said protein activity in said individual.

The above-recited applications have uses in a wide variety of hosts. Such hosts include, but are not limited to, human, murine, rabbit, goat, guinea pig, camel, horse, mouse, rat, hamster, pig, micro-pig, chicken, goat, cow, sheep, dog, cat, non-human primate, and human. In specific embodiments, the host is a mouse, rabbit, goat, guinea pig, chicken, rat, hamster, pig, sheep, dog or cat. In preferred embodiments, the host is a mammal. In most preferred embodiments, the host is a human.

In specific embodiments of the invention, for each "Contig ID" listed in the fourth column of Table 2, preferably excluded are one or more polynucleotides comprising, or alternatively consisting of, a nucleotide sequence referenced in the fifth column of Table 2 and described by the general formula of a-b, whereas a and b are uniquely determined for the corresponding SEQ ID NO:X referred to in column 3 of Table 2. Further specific embodiments are directed to polynucleotide sequences excluding one, two, three, four, or more of the specific polynucleotide sequences referred to in the fifth column of Table 2. In no way is this listing meant to encompass all of the sequences which may be excluded by the general formula, it is just a representative example. All references available through these accessions are hereby incorporated by reference in their entirety.

TABLE 2

Gene No.	cDNA Clone ID	NT SEQ ID NO: X	Contig ID	Public Accession Numbers
13	HADGD93	23	826467	T89808, T89904
14	HADMA77	24	783049	T57670, T57710, T59256, R17479, R18081, R25021, R42975, R43779, R51909, R54297, R42975, R43779, R61184, R61185, H42535, H42534, H37934, H55771, H55864, H86756, N62115, N78346, W16551, AA001440, AA019981, AA253150, AA253149
16	HAFBL14	26	832502	R56815, R56814, H08346, H08347, H11971, W72908, W76134, AA055620, AA081637, AA084593, AA196285, AA830560, AA887798, D81504, D81671
22	HAGBC57	32	823117	R81779, R81877, H06499, H11720, H20563, H88250, H92573, H88250, N21594, N26496, N32318, N67614, W23526, AA039921, AA041544, AA127470, AA227465
24	H2CBH91	34	826669	H19982, H30276, H30341, W96424, AA010016, AA057192, AA514234, AA515071, AA527326
28	HAGBV25	38	838174	N46789, N50686, N50770, N72448, W60706, W60767, AA533514, AA573600, AA573975, W25815, W26314, W27386, AA248947, AA669692
30	HAGCC87	40	638587	R17880, R18189, R22638, R22639, N55064
34	HAGCZ70	44	747697	T62720
35	HAGDC73	45	724860	T66524, T78052, R15898, AA085512, AA098929, AA173780, AA190979, AA460343, AA460342
42	HAGDO70	52	812393	T83656, R20556, R20556, N31693, W02905, W61082, W63670, W78032, AA011180, AA464238, AA464346, AA428656

45	HAGDW68	55	835631	N59867, N62902, W01382, AA575925
46	HAGDX84	56	638158	R02692
47	HAGEG10	57	823543	T62744, T62894, T64529, T64535, T65953, T65958, T92713, T92790, R00209, R05403, R05404, R06985, R06986, R18149, R41696, R41696, R63842, R64456, R66071, R67671, H04551, H53471, H53846, H62712, H62797, H86336, H86337, N20405, N31919, N36423, N37081, N42704, N44298, N46397, N48830, W02787, W30927, W42709, W42902, W58350, W58475, W69500, W69501, W72259, W76476, W79810, W79591, W88556, W88638, W94007, W93952, W92367, W92368, W95398, W95447, AA013224, AA013319, AA019898, AA019911, AA022548, AA022549, AA046083, AA046189, AA053669, AA053771, AA070849, AA074726, AA074901, AA079889, AA079890, AA129509, AA131379, AA131497, AA136559, AA149019, AA167708, AA166764, AA166945, AA188783, AA188773, AA243403, AA251232, AA252615, AA252802, AA262264, AA262875, AA428587, AA429541
49	HAGEK37	59	793464	R08008, R08057, R23711, R25596, R26665, R52506, R52507, R67408, R68255, R68549, R78654, H06746, H06796, R95064, H60309, H60308, N47339, N58656, N93971, W40340, AA044394, AA042845, AA173408, AA173463
50	HAGEK86	60	748222	None

Having generally described the invention, the same will be more readily understood by reference to the following examples, which are provided by way of illustration and are not intended as limiting.

5

### Examples

#### Example 1: Isolation of a Selected cDNA Clone From the Deposited Sample

Each cDNA clone in a cited ATCC deposit is contained in a plasmid vector. Table 1 identifies the vectors used to construct the cDNA library from which each clone was isolated. In many cases, the vector used to construct the library is a phage vector from which a plasmid has been excised. The table immediately below correlates the related plasmid for each phage vector used in constructing the cDNA library. For example, where a particular clone is identified in Table 1 as being isolated in the vector "Lambda Zap," the corresponding deposited clone is in "pBluescript."

	Vector Used to Construct Library	Corresponding Deposited
	Plasmid	
	Lambda Zap	pBluescript (pBS)
20	Uni-Zap XR	pBluescript (pBS)
	Zap Express	pBK
	lafmid BA	plafmid BA
	pSport1	pSport1
	pCMVSPORT 2.0	pCMVSPORT 2.0
25	pCMVSPORT 3.0	pCMVSPORT 3.0
	pCR®2.1	pCR®2.1
	Vectors Lambda Zap (U.S. Patent Nos. 5,128,256 and 5,286,636), Uni-Zap XR (U.S. Patent Nos. 5,128, 256 and 5,286,636), Zap Express (U.S. Patent Nos. 5,128,256 and 5,286,636), pBluescript (pBS) (Short, J. M. et al., Nucleic Acids Res. 16:7583-7600 (1988); Altting-Mees, M. A. and Short, J. M., Nucleic Acids Res. 17:9494 (1989)) and pBK (Altting-Mees, M. A. et al., Strategies 5:58-61 (1992)) are commercially available from Stratagene Cloning Systems, Inc., 11011 N. Torrey	

Pines Road, La Jolla, CA, 92037. pBS contains an ampicillin resistance gene and pBK contains a neomycin resistance gene. Both can be transformed into E. coli strain XL-1 Blue, also available from Stratagene. pBS comes in 4 forms SK+, SK-, KS+ and KS-. The S and K refers to the orientation of the polylinker to the T7 and T3 primer sequences which flank the polylinker region ("S" is for SacI and "K" is for KpnI which are the first sites on each respective end of the linker). "+" or "-" refer to the orientation of the f1 origin of replication ("ori"), such that in one orientation, single stranded rescue initiated from the f1 ori generates sense strand DNA and in the other, antisense.

10 Vectors pSport1, pCMVSPORT 2.0 and pCMVSPORT 3.0, were obtained from Life Technologies, Inc., P. O. Box 6009, Gaithersburg, MD 20897. All Sport vectors contain an ampicillin resistance gene and may be transformed into E. coli strain DH10B, also available from Life Technologies. (See, for instance, Gruber, C. E., et al., Focus 15:59 (1993).) Vector lafmid BA (Bento Soares, Columbia University, NY) contains an ampicillin resistance gene and can be transformed into E. coli strain XL-1 Blue. Vector pCR@2.1, which is available from Invitrogen, 1600 Faraday Avenue, Carlsbad, CA 92008, contains an ampicillin resistance gene and may be transformed into E. coli strain DH10B, available from Life Technologies. (See, for instance, Clark, J. M., Nuc. Acids Res. 16:9677-9686 (1988) and Mead, D. et al., Bio/Technology 9: (1991).) Preferably, a polynucleotide of the present invention does not comprise the phage vector sequences identified for the particular clone in Table 1, as well as the corresponding plasmid vector sequences designated above.

The deposited material in the sample assigned the ATCC Deposit Number cited in Table 1 for any given cDNA clone also may contain one or more additional plasmids, each comprising a cDNA clone different from that given clone. Thus, deposits sharing the same ATCC Deposit Number contain at least a plasmid for each cDNA clone identified in Table 1. Typically, each ATCC deposit sample cited in Table 1 comprises a mixture of approximately equal amounts (by weight) of about 50 plasmid DNAs, each containing a different cDNA clone; but such a deposit sample may include plasmids for more or less than 50 cDNA clones, up to about 500 cDNA clones.

Two approaches can be used to isolate a particular clone from the deposited sample of plasmid DNAs cited for that clone in Table 1. First, a plasmid is directly isolated by screening the clones using a polynucleotide probe corresponding to SEQ ID NO:X.

- 5            Particularly, a specific polynucleotide with 30-40 nucleotides is synthesized using an Applied Biosystems DNA synthesizer according to the sequence reported. The oligonucleotide is labeled, for instance, with  $^{32}\text{P}$ -(-ATP using T4 polynucleotide kinase and purified according to routine methods. (E.g., Maniatis et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Press, Cold Spring, NY (1982).)
- 10          The plasmid mixture is transformed into a suitable host, as indicated above (such as XL-1 Blue (Stratagene)) using techniques known to those of skill in the art, such as those provided by the vector supplier or in related publications or patents cited above. The transformants are plated on 1.5% agar plates (containing the appropriate selection agent, e.g., ampicillin) to a density of about 150 transformants (colonies) per plate.
- 15          These plates are screened using Nylon membranes according to routine methods for bacterial colony screening (e.g., Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd Edit., (1989), Cold Spring Harbor Laboratory Press, pages 1.93 to 1.104), or other techniques known to those of skill in the art.

- Alternatively, two primers of 17-20 nucleotides derived from both ends of the
- 20          SEQ ID NO:X (i.e., within the region of SEQ ID NO:X bounded by the 5' NT and the 3' NT of the clone defined in Table 1) are synthesized and used to amplify the desired cDNA using the deposited cDNA plasmid as a template. The polymerase chain reaction is carried out under routine conditions, for instance, in 25  $\mu\text{l}$  of reaction mixture with 0.5  $\mu\text{g}$  of the above cDNA template. A convenient reaction mixture is
- 25          1.5-5 mM  $\text{MgCl}_2$ , 0.01% (w/v) gelatin, 20  $\mu\text{M}$  each of dATP, dCTP, dGTP, dTTP, 25 pmol of each primer and 0.25 Unit of Taq polymerase. Thirty five cycles of PCR (denaturation at 94 degree C for 1 min; annealing at 55 degree C for 1 min; elongation at 72 degree C for 1 min) are performed with a Perkin-Elmer Cetus automated thermal cycler. The amplified product is analyzed by agarose gel electrophoresis and
- 30          the DNA band with expected molecular weight is excised and purified. The PCR product is verified to be the selected sequence by subcloning and sequencing the DNA product.

Several methods are available for the identification of the 5' or 3' non-coding portions of a gene which may not be present in the deposited clone. These methods include but are not limited to, filter probing, clone enrichment using specific probes, and protocols similar or identical to 5' and 3' "RACE" protocols which are well known in the art. For instance, a method similar to 5' RACE is available for generating the missing 5' end of a desired full-length transcript. (Fromont-Racine et al., Nucleic Acids Res. 21(7):1683-1684 (1993).)

Briefly, a specific RNA oligonucleotide is ligated to the 5' ends of a population of RNA presumably containing full-length gene RNA transcripts. A primer set containing a primer specific to the ligated RNA oligonucleotide and a primer specific to a known sequence of the gene of interest is used to PCR amplify the 5' portion of the desired full-length gene. This amplified product may then be sequenced and used to generate the full length gene.

This above method starts with total RNA isolated from the desired source, although poly-A+ RNA can be used. The RNA preparation can then be treated with phosphatase if necessary to eliminate 5' phosphate groups on degraded or damaged RNA which may interfere with the later RNA ligase step. The phosphatase should then be inactivated and the RNA treated with tobacco acid pyrophosphatase in order to remove the cap structure present at the 5' ends of messenger RNAs. This reaction leaves a 5' phosphate group at the 5' end of the cap cleaved RNA which can then be ligated to an RNA oligonucleotide using T4 RNA ligase.

This modified RNA preparation is used as a template for first strand cDNA synthesis using a gene specific oligonucleotide. The first strand synthesis reaction is used as a template for PCR amplification of the desired 5' end using a primer specific to the ligated RNA oligonucleotide and a primer specific to the known sequence of the gene of interest. The resultant product is then sequenced and analyzed to confirm that the 5' end sequence belongs to the desired gene.

#### Example 2: Isolation of Genomic Clones Corresponding to a Polynucleotide

A human genomic P1 library (Genomic Systems, Inc.) is screened by PCR using primers selected for the cDNA sequence corresponding to SEQ ID NO:X., according to the method described in Example 1. (See also, Sambrook.)



### Example 3: Tissue Distribution of Polypeptide

Tissue distribution of mRNA expression of polynucleotides of the present invention is determined using protocols for Northern blot analysis, described by, among others, Sambrook et al. For example, a cDNA probe produced by the method described in Example 1 is labeled with P32 using the rediprime™ DNA labeling system (Amersham Life Science), according to manufacturer's instructions. After labeling, the probe is purified using CHROMA SPIN-100™ column (Clontech Laboratories, Inc.), according to manufacturer's protocol number PT1200-1. The purified labeled probe is then used to examine various human tissues for mRNA expression.

Multiple Tissue Northern (MTN) blots containing various human tissues (H) or human immune system tissues (IM) (Clontech) are examined with the labeled probe using ExpressHyb™ hybridization solution (Clontech) according to manufacturer's protocol number PT1190-1. Following hybridization and washing, the blots are mounted and exposed to film at -70 degree C overnight, and the films developed according to standard procedures.

### Example 4: Chromosomal Mapping of the Polynucleotides

An oligonucleotide primer set is designed according to the sequence at the 5' end of SEQ ID NO:X. This primer preferably spans about 100 nucleotides. This primer set is then used in a polymerase chain reaction under the following set of conditions : 30 seconds, 95 degree C; 1 minute, 56 degree C; 1 minute, 70 degree C. This cycle is repeated 32 times followed by one 5 minute cycle at 70 degree C. Human, mouse, and hamster DNA is used as template in addition to a somatic cell hybrid panel containing individual chromosomes or chromosome fragments (Bios, Inc). The reactions is analyzed on either 8% polyacrylamide gels or 3.5 % agarose gels. Chromosome mapping is determined by the presence of an approximately 100 bp PCR fragment in the particular somatic cell hybrid.

### Example 5: Bacterial Expression of a Polypeptide

A polynucleotide encoding a polypeptide of the present invention is amplified using PCR oligonucleotide primers corresponding to the 5' and 3' ends of the DNA sequence, as outlined in Example 1, to synthesize insertion fragments. The primers used to amplify the cDNA insert should preferably contain restriction sites, such as  
5 BamHI and XbaI, at the 5' end of the primers in order to clone the amplified product into the expression vector. For example, BamHI and XbaI correspond to the restriction enzyme sites on the bacterial expression vector pQE-9. (Qiagen, Inc., Chatsworth, CA). This plasmid vector encodes antibiotic resistance (Ampr), a bacterial origin of replication (ori), an IPTG-regulatable promoter/operator (P/O), a  
10 ribosome binding site (RBS), a 6-histidine tag (6-His), and restriction enzyme cloning sites.

The pQE-9 vector is digested with BamHI and XbaI and the amplified fragment is ligated into the pQE-9 vector maintaining the reading frame initiated at the bacterial RBS. The ligation mixture is then used to transform the E. coli strain  
15 M15/rep4 (Qiagen, Inc.) which contains multiple copies of the plasmid pREP4, which expresses the lacI repressor and also confers kanamycin resistance (Kanr). Transformants are identified by their ability to grow on LB plates and ampicillin/kanamycin resistant colonies are selected. Plasmid DNA is isolated and confirmed by restriction analysis.

20 Clones containing the desired constructs are grown overnight (O/N) in liquid culture in LB media supplemented with both Amp (100 ug/ml) and Kan (25 ug/ml). The O/N culture is used to inoculate a large culture at a ratio of 1:100 to 1:250. The cells are grown to an optical density 600 (O.D.600) of between 0.4 and 0.6. IPTG (Isopropyl-B-D-thiogalacto pyranoside) is then added to a final concentration of 1  
25 mM. IPTG induces by inactivating the lacI repressor, clearing the P/O leading to increased gene expression.

Cells are grown for an extra 3 to 4 hours. Cells are then harvested by centrifugation (20 mins at 6000Xg). The cell pellet is solubilized in the chaotropic agent 6 Molar Guanidine HCl by stirring for 3-4 hours at 4 degree C. The cell debris  
30 is removed by centrifugation, and the supernatant containing the polypeptide is loaded onto a nickel-nitrilo-tri-acetic acid ("Ni-NTA") affinity resin column (available from QIAGEN, Inc., supra). Proteins with a 6 x His tag bind to the Ni-NTA resin with

high affinity and can be purified in a simple one-step procedure (for details see: The QIAexpressionist (1995) QIAGEN, Inc., supra).

Briefly, the supernatant is loaded onto the column in 6 M guanidine-HCl, pH 8, the column is first washed with 10 volumes of 6 M guanidine-HCl, pH 8, then  
5 washed with 10 volumes of 6 M guanidine-HCl pH 6, and finally the polypeptide is eluted with 6 M guanidine-HCl, pH 5.

The purified protein is then renatured by dialyzing it against phosphate-buffered saline (PBS) or 50 mM Na-acetate, pH 6 buffer plus 200 mM NaCl. Alternatively, the protein can be successfully refolded while immobilized on the Ni-  
10 NTA column. The recommended conditions are as follows: renature using a linear 6M-1M urea gradient in 500 mM NaCl, 20% glycerol, 20 mM Tris/HCl pH 7.4, containing protease inhibitors. The renaturation should be performed over a period of 1.5 hours or more. After renaturation the proteins are eluted by the addition of 250 mM imidazole. Imidazole is removed by a final dialyzing step against PBS or 50  
15 mM sodium acetate pH 6 buffer plus 200 mM NaCl. The purified protein is stored at 4 degree C or frozen at -80 degree C.

In addition to the above expression vector, the present invention further includes an expression vector comprising phage operator and promoter elements operatively linked to a polynucleotide of the present invention, called pHE4a. (ATCC  
20 Accession Number 209645, deposited on February 25, 1998.) This vector contains: 1) a neomycinphosphotransferase gene as a selection marker, 2) an E. coli origin of replication, 3) a T5 phage promoter sequence, 4) two lac operator sequences, 5) a Shine-Delgarno sequence, and 6) the lactose operon repressor gene (lacIq). The origin of replication (oriC) is derived from pUC19 (LTI, Gaithersburg, MD). The  
25 promoter sequence and operator sequences are made synthetically.

DNA can be inserted into the pHEa by restricting the vector with NdeI and XbaI, BamHI, XhoI, or Asp718, running the restricted product on a gel, and isolating the larger fragment (the stuffer fragment should be about 310 base pairs). The DNA insert is generated according to the PCR protocol described in Example 1, using PCR  
30 primers having restriction sites for NdeI (5' primer) and XbaI, BamHI, XhoI, or Asp718 (3' primer). The PCR insert is gel purified and restricted with compatible enzymes. The insert and vector are ligated according to standard protocols.

The engineered vector could easily be substituted in the above protocol to express protein in a bacterial system.

#### Example 6: Purification of a Polypeptide from an Inclusion Body

5           The following alternative method can be used to purify a polypeptide expressed in E coli when it is present in the form of inclusion bodies. Unless otherwise specified, all of the following steps are conducted at 4-10 degree C.

          Upon completion of the production phase of the E. coli fermentation, the cell culture is cooled to 4-10 degree C and the cells harvested by continuous  
10   centrifugation at 15,000 rpm (Heraeus Sepatech). On the basis of the expected yield of protein per unit weight of cell paste and the amount of purified protein required, an appropriate amount of cell paste, by weight, is suspended in a buffer solution containing 100 mM Tris, 50 mM EDTA, pH 7.4. The cells are dispersed to a homogeneous suspension using a high shear mixer.

15           The cells are then lysed by passing the solution through a microfluidizer (Microfluidics, Corp. or APV Gaulin, Inc.) twice at 4000-6000 psi. The homogenate is then mixed with NaCl solution to a final concentration of 0.5 M NaCl, followed by centrifugation at 7000 xg for 15 min. The resultant pellet is washed again using 0.5M NaCl, 100 mM Tris, 50 mM EDTA, pH 7.4.

20           The resulting washed inclusion bodies are solubilized with 1.5 M guanidine hydrochloride (GuHCl) for 2-4 hours. After 7000 xg centrifugation for 15 min., the pellet is discarded and the polypeptide containing supernatant is incubated at 4 degree C overnight to allow further GuHCl extraction.

          Following high speed centrifugation (30,000 xg) to remove insoluble particles,  
25   the GuHCl solubilized protein is refolded by quickly mixing the GuHCl extract with 20 volumes of buffer containing 50 mM sodium, pH 4.5, 150 mM NaCl, 2 mM EDTA by vigorous stirring. The refolded diluted protein solution is kept at 4 degree C without mixing for 12 hours prior to further purification steps.

          To clarify the refolded polypeptide solution, a previously prepared tangential  
30   filtration unit equipped with 0.16 um membrane filter with appropriate surface area (e.g., Filtron), equilibrated with 40 mM sodium acetate, pH 6.0 is employed. The filtered sample is loaded onto a cation exchange resin (e.g., Poros HS-50, Perseptive

Biosystems). The column is washed with 40 mM sodium acetate, pH 6.0 and eluted with 250 mM, 500 mM, 1000 mM, and 1500 mM NaCl in the same buffer, in a stepwise manner. The absorbance at 280 nm of the effluent is continuously monitored. Fractions are collected and further analyzed by SDS-PAGE.

5 Fractions containing the polypeptide are then pooled and mixed with 4 volumes of water. The diluted sample is then loaded onto a previously prepared set of tandem columns of strong anion (Poros HQ-50, Perseptive Biosystems) and weak anion (Poros CM-20, Perseptive Biosystems) exchange resins. The columns are equilibrated with 40 mM sodium acetate, pH 6.0. Both columns are washed with 40  
10 mM sodium acetate, pH 6.0, 200 mM NaCl. The CM-20 column is then eluted using a 10 column volume linear gradient ranging from 0.2 M NaCl, 50 mM sodium acetate, pH 6.0 to 1.0 M NaCl, 50 mM sodium acetate, pH 6.5. Fractions are collected under constant A280 monitoring of the effluent. Fractions containing the polypeptide (determined, for instance, by 16% SDS-PAGE) are then pooled.

15 The resultant polypeptide should exhibit greater than 95% purity after the above refolding and purification steps. No major contaminant bands should be observed from Commassie blue stained 16% SDS-PAGE gel when 5 ug of purified protein is loaded. The purified protein can also be tested for endotoxin/LPS contamination, and typically the LPS content is less than 0.1 ng/ml according to LAL  
20 assays.

#### ***Example 7: Cloning and Expression of a Polypeptide in a Baculovirus Expression System***

In this example, the plasmid shuttle vector pA2 is used to insert a  
25 polynucleotide into a baculovirus to express a polypeptide. This expression vector contains the strong polyhedrin promoter of the Autographa californica nuclear polyhedrosis virus (AcMNPV) followed by convenient restriction sites such as BamHI, Xba I and Asp718. The polyadenylation site of the simian virus 40 ("SV40") is used for efficient polyadenylation. For easy selection of recombinant virus, the  
30 plasmid contains the beta-galactosidase gene from E. coli under control of a weak Drosophila promoter in the same orientation, followed by the polyadenylation signal

of the polyhedrin gene. The inserted genes are flanked on both sides by viral sequences for cell-mediated homologous recombination with wild-type viral DNA to generate a viable virus that express the cloned polynucleotide.

Many other baculovirus vectors can be used in place of the vector above, such as pAc373, pVL941, and pAcIM1, as one skilled in the art would readily appreciate, as long as the construct provides appropriately located signals for transcription, translation, secretion and the like, including a signal peptide and an in-frame AUG as required. Such vectors are described, for instance, in Luckow et al., *Virology* 170:31-39 (1989).

Specifically, the cDNA sequence contained in the deposited clone, including the AUG initiation codon and the naturally associated leader sequence identified in Table 1, is amplified using the PCR protocol described in Example 1. If the naturally occurring signal sequence is used to produce the secreted protein, the pA2 vector does not need a second signal peptide. Alternatively, the vector can be modified (pA2 GP) to include a baculovirus leader sequence, using the standard methods described in Summers et al., "A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures," Texas Agricultural Experimental Station Bulletin No. 1555 (1987).

The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("GeneClean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

The plasmid is digested with the corresponding restriction enzymes and optionally, can be dephosphorylated using calf intestinal phosphatase, using routine procedures known in the art. The DNA is then isolated from a 1% agarose gel using a commercially available kit ("GeneClean" BIO 101 Inc., La Jolla, Ca.).

The fragment and the dephosphorylated plasmid are ligated together with T4 DNA ligase. *E. coli* HB101 or other suitable *E. coli* hosts such as XL-1 Blue (Stratagene Cloning Systems, La Jolla, CA) cells are transformed with the ligation mixture and spread on culture plates. Bacteria containing the plasmid are identified by digesting DNA from individual colonies and analyzing the digestion product by

gel electrophoresis. The sequence of the cloned fragment is confirmed by DNA sequencing.

Five ug of a plasmid containing the polynucleotide is co-transfected with 1.0 ug of a commercially available linearized baculovirus DNA ("BaculoGold™ baculovirus DNA", Pharmingen, San Diego, CA), using the lipofection method described by Felgner et al., Proc. Natl. Acad. Sci. USA 84:7413-7417 (1987). One ug of BaculoGold™ virus DNA and 5 ug of the plasmid are mixed in a sterile well of a microtiter plate containing 50 ul of serum-free Grace's medium (Life Technologies Inc., Gaithersburg, MD). Afterwards, 10 ul Lipofectin plus 90 ul Grace's medium are added, mixed and incubated for 15 minutes at room temperature. Then the transfection mixture is added drop-wise to Sf9 insect cells (ATCC CRL 1711) seeded in a 35 mm tissue culture plate with 1 ml Grace's medium without serum. The plate is then incubated for 5 hours at 27 degrees C. The transfection solution is then removed from the plate and 1 ml of Grace's insect medium supplemented with 10% fetal calf serum is added. Cultivation is then continued at 27 degrees C for four days.

After four days the supernatant is collected and a plaque assay is performed, as described by Summers and Smith, supra. An agarose gel with "Blue Gal" (Life Technologies Inc., Gaithersburg) is used to allow easy identification and isolation of gal-expressing clones, which produce blue-stained plaques. (A detailed description of a "plaque assay" of this type can also be found in the user's guide for insect cell culture and baculovirology distributed by Life Technologies Inc., Gaithersburg, page 9-10.) After appropriate incubation, blue stained plaques are picked with the tip of a micropipettor (e.g., Eppendorf). The agar containing the recombinant viruses is then resuspended in a microcentrifuge tube containing 200 ul of Grace's medium and the suspension containing the recombinant baculovirus is used to infect Sf9 cells seeded in 35 mm dishes. Four days later the supernatants of these culture dishes are harvested and then they are stored at 4 degree C.

To verify the expression of the polypeptide, Sf9 cells are grown in Grace's medium supplemented with 10% heat-inactivated FBS. The cells are infected with the recombinant baculovirus containing the polynucleotide at a multiplicity of infection ("MOI") of about 2. If radiolabeled proteins are desired, 6 hours later the medium is removed and is replaced with SF900 II medium minus methionine and

cysteine (available from Life Technologies Inc., Rockville, MD). After 42 hours, 5 uCi of 35S-methionine and 5 uCi 35S-cysteine (available from Amersham) are added. The cells are further incubated for 16 hours and then are harvested by centrifugation. The proteins in the supernatant as well as the intracellular proteins are analyzed by  
5 SDS-PAGE followed by autoradiography (if radiolabeled).

Microsequencing of the amino acid sequence of the amino terminus of purified protein may be used to determine the amino terminal sequence of the produced protein.

#### **Example 8: Expression of a Polypeptide in Mammalian Cells**

10 The polypeptide of the present invention can be expressed in a mammalian cell. A typical mammalian expression vector contains a promoter element, which mediates the initiation of transcription of mRNA, a protein coding sequence, and signals required for the termination of transcription and polyadenylation of the transcript. Additional elements include enhancers, Kozak sequences and intervening  
15 sequences flanked by donor and acceptor sites for RNA splicing. Highly efficient transcription is achieved with the early and late promoters from SV40, the long terminal repeats (LTRs) from Retroviruses, e.g., RSV, HTLV I, HIV I and the early promoter of the cytomegalovirus (CMV). However, cellular elements can also be used (e.g., the human actin promoter).

20 Suitable expression vectors for use in practicing the present invention include, for example, vectors such as pSVL and pMSG (Pharmacia, Uppsala, Sweden), pRSVcat (ATCC 37152), pSV2dhfr (ATCC 37146), pBC12MI (ATCC 67109), pCMVSPORT 2.0, and pCMVSPORT 3.0. Mammalian host cells that could be used include, human HeLa, 293, H9 and Jurkat cells, mouse NIH3T3 and C127 cells, Cos 1,  
25 Cos 7 and CV1, quail QC1-3 cells, mouse L cells and Chinese hamster ovary (CHO) cells.

Alternatively, the polypeptide can be expressed in stable cell lines containing the polynucleotide integrated into a chromosome. The co-transfection with a selectable marker such as dhfr, gpt, neomycin, hygromycin allows the identification  
30 and isolation of the transfected cells.



The transfected gene can also be amplified to express large amounts of the encoded protein. The DHFR (dihydrofolate reductase) marker is useful in developing cell lines that carry several hundred or even several thousand copies of the gene of interest. (See, e.g., Alt, F. W., et al., J. Biol. Chem. 253:1357-1370 (1978); Hamlin, J. L. and Ma, C., Biochem. et Biophys. Acta, 1097:107-143 (1990); Page, M. J. and Sydenham, M. A., Biotechnology 9:64-68 (1991).) Another useful selection marker is the enzyme glutamine synthase (GS) (Murphy et al., Biochem J. 227:277-279 (1991); Bebbington et al., Bio/Technology 10:169-175 (1992). Using these markers, the mammalian cells are grown in selective medium and the cells with the highest resistance are selected. These cell lines contain the amplified gene(s) integrated into a chromosome. Chinese hamster ovary (CHO) and NSO cells are often used for the production of proteins.

Derivatives of the plasmid pSV2-dhfr (ATCC Accession No. 37146), the expression vectors pC4 (ATCC Accession No. 209646) and pC6 (ATCC Accession No. 209647) contain the strong promoter (LTR) of the Rous Sarcoma Virus (Cullen et al., Molecular and Cellular Biology, 438-447 (March, 1985)) plus a fragment of the CMV-enhancer (Boshart et al., Cell 41:521-530 (1985).) Multiple cloning sites, e.g., with the restriction enzyme cleavage sites BamHI, XbaI and Asp718, facilitate the cloning of the gene of interest. The vectors also contain the 3' intron, the polyadenylation and termination signal of the rat preproinsulin gene, and the mouse DHFR gene under control of the SV40 early promoter.

Specifically, the plasmid pC6, for example, is digested with appropriate restriction enzymes and then dephosphorylated using calf intestinal phosphates by procedures known in the art. The vector is then isolated from a 1% agarose gel.

A polynucleotide of the present invention is amplified according to the protocol outlined in Example 1. If the naturally occurring signal sequence is used to produce the secreted protein, the vector does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("GeneClean," BIO 101 Inc., La Jolla, Ca.). The fragment

then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

The amplified fragment is then digested with the same restriction enzyme and purified on a 1% agarose gel. The isolated fragment and the dephosphorylated vector  
5 are then ligated with T4 DNA ligase. *E. coli* HB101 or XL-1 Blue cells are then transformed and bacteria are identified that contain the fragment inserted into plasmid pC6 using, for instance, restriction enzyme analysis.

Chinese hamster ovary cells lacking an active DHFR gene is used for transfection. Five µg of the expression plasmid pC6 a pC4 is cotransfected with 0.5  
10 µg of the plasmid pSVneo using lipofectin (Felgner et al., *supra*). The plasmid pSV2-neo contains a dominant selectable marker, the *neo* gene from Tn5 encoding an enzyme that confers resistance to a group of antibiotics including G418. The cells are seeded in alpha minus MEM supplemented with 1 mg/ml G418. After 2 days, the cells are trypsinized and seeded in hybridoma cloning plates (Greiner, Germany) in  
15 alpha minus MEM supplemented with 10, 25, or 50 ng/ml of methotrexate plus 1 mg/ml G418. After about 10-14 days single clones are trypsinized and then seeded in 6-well petri dishes or 10 ml flasks using different concentrations of methotrexate (50 nM, 100 nM, 200 nM, 400 nM, 800 nM). Clones growing at the highest concentrations of methotrexate are then transferred to new 6-well plates containing  
20 even higher concentrations of methotrexate (1 µM, 2 µM, 5 µM, 10 mM, 20 mM). The same procedure is repeated until clones are obtained which grow at a concentration of 100 - 200 µM. Expression of the desired gene product is analyzed, for instance, by SDS-PAGE and Western blot or by reversed phase HPLC analysis.

### 25 **Example 9: Protein Fusions**

The polypeptides of the present invention are preferably fused to other proteins. These fusion proteins can be used for a variety of applications. For example, fusion of the present polypeptides to His-tag, HA-tag, protein A, IgG domains, and maltose binding protein facilitates purification. (See Example 5; see  
30 also EP A 394,827; Traunecker, et al., Nature 331:84-86 (1988).) Similarly, fusion to IgG-1, IgG-3, and albumin increases the halflife time in vivo. Nuclear localization signals fused to the polypeptides of the present invention can target the protein to a

specific subcellular localization, while covalent heterodimer or homodimers can increase or decrease the activity of a fusion protein. Fusion proteins can also create chimeric molecules having more than one function. Finally, fusion proteins can increase solubility and/or stability of the fused protein compared to the non-fused protein. All of the types of fusion proteins described above can be made by modifying the following protocol, which outlines the fusion of a polypeptide to an IgG molecule, or the protocol described in Example 5.

Briefly, the human Fc portion of the IgG molecule can be PCR amplified, using primers that span the 5' and 3' ends of the sequence described below. These primers also should have convenient restriction enzyme sites that will facilitate cloning into an expression vector, preferably a mammalian expression vector.

For example, if pC4 (Accession No. 209646) is used, the human Fc portion can be ligated into the BamHI cloning site. Note that the 3' BamHI site should be destroyed. Next, the vector containing the human Fc portion is re-restricted with BamHI, linearizing the vector, and a polynucleotide of the present invention, isolated by the PCR protocol described in Example 1, is ligated into this BamHI site. Note that the polynucleotide is cloned without a stop codon, otherwise a fusion protein will not be produced.

If the naturally occurring signal sequence is used to produce the secreted protein, pC4 does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

Human IgG Fc region:

```
GGGATCCGGAGCCCAAATCTTCTGACAAACTCACACATGCCCACCGTGC
CCAGCACCTGAATTGAGGGTGCACCGTCAGTCTTCCTCTTCCCCCAAAA
CCCAAGGACACCCTCATGATCTCCCGGACTCCTGAGGTCACATGCGTGGT
GGTGGACGTAAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGG
ACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTA
CAACAGCACGTACCGTGTGGTCAGCGTCCTACCGTCCTGCACCAGGACT
GGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCA
ACCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAAC
```

CACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAG  
GTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCAAGCGACATCGCCGT  
GGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACACTACAAGACCACGCCT  
CCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTG  
5 GACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCA  
TGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGG  
GTAAATGAGTGCGACGGCCGCGACTCTAGAGGAT (SEQ ID NO:1)

**Example 10: Production of an Antibody from a Polypeptide**

10 The antibodies of the present invention can be prepared by a variety of  
methods. (See, Current Protocols, Chapter 2.) As one example of such methods, cells  
expressing a polypeptide of the present invention is administered to an animal to  
induce the production of sera containing polyclonal antibodies. In a preferred  
method, a preparation of the secreted protein is prepared and purified to render it  
15 substantially free of natural contaminants. Such a preparation is then introduced into  
an animal in order to produce polyclonal antisera of greater specific activity.

In the most preferred method, the antibodies of the present invention are  
monoclonal antibodies (or protein binding fragments thereof). Such monoclonal  
antibodies can be prepared using hybridoma technology. (Köhler et al., Nature  
20 256:495 (1975); Köhler et al., Eur. J. Immunol. 6:511 (1976); Köhler et al., Eur. J.  
Immunol. 6:292 (1976); Hammerling et al., in: Monoclonal Antibodies and T-Cell  
Hybridomas, Elsevier, N.Y., pp. 563-681 (1981).) In general, such procedures  
involve immunizing an animal (preferably a mouse) with polypeptide or, more  
preferably, with a secreted polypeptide-expressing cell. Such cells may be cultured in  
25 any suitable tissue culture medium; however, it is preferable to culture cells in Earle's  
modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at  
about 56 degrees C), and supplemented with about 10 g/l of nonessential amino acids,  
about 1,000 U/ml of penicillin, and about 100 ug/ml of streptomycin.

The splenocytes of such mice are extracted and fused with a suitable myeloma  
30 cell line. Any suitable myeloma cell line may be employed in accordance with the  
present invention; however, it is preferable to employ the parent myeloma cell line  
(SP2O), available from the ATCC. After fusion, the resulting hybridoma cells are

selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands et al. (Gastroenterology 80:225-232 (1981).) The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the polypeptide.

5           Alternatively, additional antibodies capable of binding to the polypeptide can be produced in a two-step procedure using anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is possible to obtain an antibody which binds to a second antibody. In accordance with this method, protein specific antibodies are used to immunize an animal, preferably a  
10   mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the protein-specific antibody can be blocked by the polypeptide. Such antibodies comprise anti-idiotypic antibodies to the protein-specific antibody and can be used to immunize an animal to induce formation of  
15   further protein-specific antibodies.

          It will be appreciated that Fab and F(ab')<sub>2</sub> and other fragments of the antibodies of the present invention may be used according to the methods disclosed herein. Such fragments are typically produced by proteolytic cleavage, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')<sub>2</sub>  
20   fragments). Alternatively, secreted protein-binding fragments can be produced through the application of recombinant DNA technology or through synthetic chemistry.

          For in vivo use of antibodies in humans, it may be preferable to use "humanized" chimeric monoclonal antibodies. Such antibodies can be produced  
25   using genetic constructs derived from hybridoma cells producing the monoclonal antibodies described above. Methods for producing chimeric antibodies are known in the art. (See, for review, Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Cabilly et al., U.S. Patent No. 4,816,567; Taniguchi et al., EP 171496; Morrison et al., EP 173494; Neuberger et al., WO 8601533; Robinson  
30   et al., WO 8702671; Boulianne et al., Nature 312:643 (1984); Neuberger et al., Nature 314:268 (1985).)

**Example 11: Production Of Secreted Protein For High-Throughput Screening Assays**

The following protocol produces a supernatant containing a polypeptide to be tested. This supernatant can then be used in the Screening Assays described in Examples 13-20.

First, dilute Poly-D-Lysine (644 587 Boehringer-Mannheim) stock solution (1mg/ml in PBS) 1:20 in PBS (w/o calcium or magnesium 17-516F Biowhittaker) for a working solution of 50ug/ml. Add 200 ul of this solution to each well (24 well plates) and incubate at RT for 20 minutes. Be sure to distribute the solution over each well (note: a 12-channel pipetter may be used with tips on every other channel). Aspirate off the Poly-D-Lysine solution and rinse with 1ml PBS (Phosphate Buffered Saline). The PBS should remain in the well until just prior to plating the cells and plates may be poly-lysine coated in advance for up to two weeks.

Plate 293T cells (do not carry cells past P+20) at  $2 \times 10^5$  cells/well in .5ml DMEM(Dulbecco's Modified Eagle Medium)(with 4.5 G/L glucose and L-glutamine (12-604F Biowhittaker))/10% heat inactivated FBS(14-503F Biowhittaker)/1x Penstrep(17-602E Biowhittaker). Let the cells grow overnight.

The next day, mix together in a sterile solution basin: 300 ul Lipofectamine (18324-012 Gibco/BRL) and 5ml Optimem I (31985070 Gibco/BRL)/96-well plate. With a small volume multi-channel pipetter, aliquot approximately 2ug of an expression vector containing a polynucleotide insert, produced by the methods described in Examples 8 or 9, into an appropriately labeled 96-well round bottom plate. With a multi-channel pipetter, add 50ul of the Lipofectamine/Optimem I mixture to each well. Pipette up and down gently to mix. Incubate at RT 15-45 minutes. After about 20 minutes, use a multi-channel pipetter to add 150ul Optimem I to each well. As a control, one plate of vector DNA lacking an insert should be transfected with each set of transfections.

Preferably, the transfection should be performed by tag-teaming the following tasks. By tag-teaming, hands on time is cut in half, and the cells do not spend too much time on PBS. First, person A aspirates off the media from four 24-well plates of cells, and then person B rinses each well with .5-1ml PBS. Person A then aspirates off PBS rinse, and person B, using a 12-channel pipetter with tips on every other

channel, adds the 200ul of DNA/Lipofectamine/Optimem I complex to the odd wells first, then to the even wells, to each row on the 24-well plates. Incubate at 37 degrees C for 6 hours.

While cells are incubating, prepare appropriate media, either 1%BSA in

5 DMEM with 1x penstrep, or CHO-5 media (116.6 mg/L of  $\text{CaCl}_2$  (anhyd); 0.00130 mg/L  $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ ; 0.050 mg/L of  $\text{Fe}(\text{NO}_3)_3 \cdot 9\text{H}_2\text{O}$ ; 0.417 mg/L of  $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$ ; 311.80 mg/L of Kcl; 28.64 mg/L of  $\text{MgCl}_2$ ; 48.84 mg/L of  $\text{MgSO}_4$ ; 6995.50 mg/L of NaCl; 2400.0 mg/L of  $\text{NaHCO}_3$ ; 62.50 mg/L of  $\text{NaH}_2\text{PO}_4 \cdot \text{H}_2\text{O}$ ; 71.02 mg/L of  $\text{Na}_2\text{HPO}_4$ ; .4320 mg/L of  $\text{ZnSO}_4 \cdot 7\text{H}_2\text{O}$ ; .002 mg/L of Arachidonic Acid ; 1.022 mg/L

10 of Cholesterol; .070 mg/L of DL-alpha-Tocopherol-Acetate; 0.0520 mg/L of Linoleic Acid; 0.010 mg/L of Linolenic Acid; 0.010 mg/L of Myristic Acid; 0.010 mg/L of Oleic Acid; 0.010 mg/L of Palmitric Acid; 0.010 mg/L of Palmitic Acid; 100 mg/L of Pluronic F-68; 0.010 mg/L of Stearic Acid; 2.20 mg/L of Tween 80; 4551 mg/L of D-Glucose; 130.85 mg/ml of L- Alanine; 147.50 mg/ml of L-Arginine-HCL; 7.50 mg/ml

15 of L-Asparagine- $\text{H}_2\text{O}$ ; 6.65 mg/ml of L-Aspartic Acid; 29.56 mg/ml of L-Cystine-2HCL- $\text{H}_2\text{O}$ ; 31.29 mg/ml of L-Cystine-2HCL; 7.35 mg/ml of L-Glutamic Acid; 365.0 mg/ml of L-Glutamine; 18.75 mg/ml of Glycine; 52.48 mg/ml of L-Histidine-HCL- $\text{H}_2\text{O}$ ; 106.97 mg/ml of L-Isoleucine; 111.45 mg/ml of L-Leucine; 163.75 mg/ml of L-Lysine HCL; 32.34 mg/ml of L-Methionine; 68.48 mg/ml of L-Phenylalanine; 40.0

20 mg/ml of L-Proline; 26.25 mg/ml of L-Serine; 101.05 mg/ml of L-Threonine; 19.22 mg/ml of L-Tryptophan; 91.79 mg/ml of L-Tyrosine-2Na-2 $\text{H}_2\text{O}$ ; 99.65 mg/ml of L-Valine; 0.0035 mg/L of Biotin; 3.24 mg/L of D-Ca Pantothenate; 11.78 mg/L of Choline Chloride; 4.65 mg/L of Folic Acid; 15.60 mg/L of i-Inositol; 3.02 mg/L of Niacinamide; 3.00 mg/L of Pyridoxal HCL; 0.031 mg/L of Pyridoxine HCL; 0.319

25 mg/L of Riboflavin; 3.17 mg/L of Thiamine HCL; 0.365 mg/L of Thymidine; and 0.680 mg/L of Vitamin B<sub>12</sub>; 25 mM of HEPES Buffer; 2.39 mg/L of Na Hypoxanthine; 0.105 mg/L of Lipoic Acid; 0.081 mg/L of Sodium Putrescine-2HCL; 55.0 mg/L of Sodium Pyruvate; 0.0067 mg/L of Sodium Selenite; 20uM of Ethanolamine; 0.122 mg/L of Ferric Citrate; 41.70 mg/L of Methyl-B-Cyclodextrin

30 complexed with Linoleic Acid; 33.33 mg/L of Methyl-B-Cyclodextrin complexed with Oleic Acid; and 10 mg/L of Methyl-B-Cyclodextrin complexed with Retinal) with 2mm glutamine and 1x penstrep. (BSA (81-068-3 Bayer) 100gm dissolved in 1L

DMEM for a 10% BSA stock solution). Filter the media and collect 50 ul for endotoxin assay in 15ml polystyrene conical.

The transfection reaction is terminated, preferably by tag-teaming, at the end of the incubation period. Person A aspirates off the transfection media, while person  
5 B adds 1.5ml appropriate media to each well. Incubate at 37 degrees C for 45 or 72 hours depending on the media used: 1%BSA for 45 hours or CHO-5 for 72 hours.

On day four, using a 300ul multichannel pipetter, aliquot 600ul in one 1ml deep well plate and the remaining supernatant into a 2ml deep well. The supernatants from each well can then be used in the assays described in Examples 13-20.

10 It is specifically understood that when activity is obtained in any of the assays described below using a supernatant, the activity originates from either the polypeptide directly (e.g., as a secreted protein) or by the polypeptide inducing expression of other proteins, which are then secreted into the supernatant. Thus, the invention further provides a method of identifying the protein in the supernatant  
15 characterized by an activity in a particular assay.

### **Example 12: Construction of GAS Reporter Construct**

One signal transduction pathway involved in the differentiation and proliferation of cells is called the Jaks-STATs pathway. Activated proteins in the  
20 Jaks-STATs pathway bind to gamma activation site "GAS" elements or interferon-sensitive responsive element ("ISRE"), located in the promoter of many genes. The binding of a protein to these elements alter the expression of the associated gene.

GAS and ISRE elements are recognized by a class of transcription factors called Signal Transducers and Activators of Transcription, or "STATs." There are six  
25 members of the STATs family. Stat1 and Stat3 are present in many cell types, as is Stat2 (as response to IFN-alpha is widespread). Stat4 is more restricted and is not in many cell types though it has been found in T helper class I, cells after treatment with IL-12. Stat5 was originally called mammary growth factor, but has been found at higher concentrations in other cells including myeloid cells. It can be activated in  
30 tissue culture cells by many cytokines.



The STATs are activated to translocate from the cytoplasm to the nucleus upon tyrosine phosphorylation by a set of kinases known as the Janus Kinase ("Jaks") family. Jaks represent a distinct family of soluble tyrosine kinases and include Tyk2, Jak1, Jak2, and Jak3. These kinases display significant sequence similarity and are  
5 generally catalytically inactive in resting cells.

The Jaks are activated by a wide range of receptors summarized in the Table below. (Adapted from review by Schidler and Darnell, *Ann. Rev. Biochem.* 64:621-51 (1995).) A cytokine receptor family, capable of activating Jaks, is divided into two groups: (a) Class 1 includes receptors for IL-2, IL-3, IL-4, IL-6, IL-7, IL-9, IL-11, IL-  
10 12, IL-15, Epo, PRL, GH, G-CSF, GM-CSF, LIF, CNTF, and thrombopoietin; and (b) Class 2 includes IFN- $\alpha$ , IFN- $\gamma$ , and IL-10. The Class 1 receptors share a conserved cysteine motif (a set of four conserved cysteines and one tryptophan) and a WSXWS motif (a membrane proximal region encoding Trp-Ser-Xxx-Trp-Ser (SEQ ID NO:2)).

Thus, on binding of a ligand to a receptor, Jaks are activated, which in turn  
15 activate STATs, which then translocate and bind to GAS elements. This entire process is encompassed in the Jaks-STATs signal transduction pathway.

Therefore, activation of the Jaks-STATs pathway, reflected by the binding of the GAS or the ISRE element, can be used to indicate proteins involved in the proliferation and differentiation of cells. For example, growth factors and cytokines  
20 are known to activate the Jaks-STATs pathway. (See Table below.) Thus, by using GAS elements linked to reporter molecules, activators of the Jaks-STATs pathway can be identified.

	<u>Ligand</u>	<u>tyk2</u>	<u>JAKs</u> <u>Jak1</u>	<u>Jak2</u>	<u>Jak3</u>	<u>STATS</u>	<u>GAS(elements) or ISRE</u>
	<u>IFN family</u>						
5	IFN-a/B	+	+	-	-	1,2,3	ISRE
	IFN-g		+	+	-	1	GAS (IRF1>Lys6>IFP)
	Il-10	+	?	?	-	1,3	
	<u>gp130 family</u>						
10	IL-6 (Pleiotrophic)	+	+	+	?	1,3	GAS (IRF1>Lys6>IFP)
	Il-11(Pleiotrophic)	?	+	?	?	1,3	
	OnM(Pleiotrophic)	?	+	+	?	1,3	
	LIF(Pleiotrophic)	?	+	+	?	1,3	
	CNTF(Pleiotrophic)	-/+	+	+	?	1,3	
15	G-CSF(Pleiotrophic)	?	+	?	?	1,3	
	IL-12(Pleiotrophic)	+	-	+	+	1,3	
	<u>g-C family</u>						
	IL-2 (lymphocytes)	-	+	-	+	1,3,5	GAS
20	IL-4 (lymph/myeloid)	-	+	-	+	6	GAS (IRF1 = IFP >>Ly6)(IgH)
	IL-7 (lymphocytes)	-	+	-	+	5	GAS
	IL-9 (lymphocytes)	-	+	-	+	5	GAS
	IL-13 (lymphocyte)	-	+	?	?	6	GAS
	IL-15	?	+	?	+	5	GAS
25	<u>gp140 family</u>						
	IL-3 (myeloid)	-	-	+	-	5	GAS (IRF1>IFP>>Ly6)
	IL-5 (myeloid)	-	-	+	-	5	GAS
	GM-CSF (myeloid)	-	-	+	-	5	GAS
30	<u>Growth hormone family</u>						
	GH	?	-	+	-	5	
	PRL	?	+/-	+	-	1,3,5	
	EPO	?	-	+	-	5	GAS(B-CAS>IRF1=IFP>>Ly6)
35	<u>Receptor Tyrosine Kinases</u>						
	EGF	?	+	+	-	1,3	GAS (IRF1)
	PDGF	?	+	+	-	1,3	
	CSF-1	?	+	+	-	1,3	GAS (not IRF1)
40							

To construct a synthetic GAS containing promoter element, which is used in the Biological Assays described in Examples 13-14, a PCR based strategy is employed to generate a GAS-SV40 promoter sequence. The 5' primer contains four tandem copies of the GAS binding site found in the IRF1 promoter and previously demonstrated to bind STATs upon induction with a range of cytokines (Rothman et al., Immunity 1:457-468 (1994).), although other GAS or ISRE elements can be used instead. The 5' primer also contains 18bp of sequence complementary to the SV40 early promoter sequence and is flanked with an XhoI site. The sequence of the 5' primer is:

5':GCGCCTCGAGATTTCCCCGAAATCTAGATTTCCCCGAAATGATTTCCCC  
GAAATGATTTCCCCGAAATATCTGCCATCTCAATTAG:3' (SEQ ID NO:3)

The downstream primer is complementary to the SV40 promoter and is flanked with a Hind III site: 5':GCGGCAAGCTTTTTGCAAAGCCTAGGC:3' (SEQ ID NO:4)

PCR amplification is performed using the SV40 promoter template present in the B-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI/Hind III and subcloned into BLSK2-. (Stratagene.) Sequencing with forward and reverse primers confirms that the insert contains the following sequence:

5':CTCGAGATTTCCCCGAAATCTAGATTTCCCCGAAATGATTTCCCCGAAA  
TGATTTCCCCGAAATATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCC  
CCCCTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCT  
CCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCC  
TCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTTGGAGGCCT  
AGGCTTTTGCAAAAAAGCTT:3' (SEQ ID NO:5)

With this GAS promoter element linked to the SV40 promoter, a GAS:SEAP2 reporter construct is next engineered. Here, the reporter molecule is a secreted alkaline phosphatase, or "SEAP." Clearly, however, any reporter molecule can be instead of SEAP, in this or in any of the other Examples. Well known reporter molecules that can be used instead of SEAP include chloramphenicol acetyltransferase (CAT), luciferase, alkaline phosphatase, B-galactosidase, green fluorescent protein (GFP), or any protein detectable by an antibody.

The above sequence confirmed synthetic GAS-SV40 promoter element is subcloned into the pSEAP-Promoter vector obtained from Clontech using HindIII and XhoI, effectively replacing the SV40 promoter with the amplified GAS:SV40 promoter element, to create the GAS-SEAP vector. However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

Thus, in order to generate mammalian stable cell lines expressing the GAS-SEAP reporter, the GAS-SEAP cassette is removed from the GAS-SEAP vector using SalI and NotI, and inserted into a backbone vector containing the neomycin resistance gene, such as pGFP-1 (Clontech), using these restriction sites in the multiple cloning site, to create the GAS-SEAP/Neo vector. Once this vector is transfected into mammalian cells, this vector can then be used as a reporter molecule for GAS binding as described in Examples 13-14.

Other constructs can be made using the above description and replacing GAS with a different promoter sequence. For example, construction of reporter molecules containing NFK-B and EGR promoter sequences are described in Examples 15 and 16. However, many other promoters can be substituted using the protocols described in these Examples. For instance, SRE, IL-2, NFAT, or Osteocalcin promoters can be substituted, alone or in combination (e.g., GAS/NF-KB/EGR, GAS/NF-KB, IL-2/NFAT, or NF-KB/GAS). Similarly, other cell lines can be used to test reporter construct activity, such as HELA (epithelial), HUVEC (endothelial), Reh (B-cell), Saos-2 (osteoblast), HUVAC (aortic), or Cardiomyocyte.

#### **Example 13: High-Throughput Screening Assay for T-cell Activity.**

The following protocol is used to assess T-cell activity by identifying factors, and determining whether supernate containing a polypeptide of the invention proliferates and/or differentiates T-cells. T-cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 12. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The T-cell used in this assay is Jurkat T-cells (ATCC Accession No. TIB-152), although Molt-3 cells (ATCC Accession No. CRL-1552) and Molt-4 cells (ATCC Accession No. CRL-1582) cells can also be used.

Jurkat T-cells are lymphoblastic CD4+ Th1 helper cells. In order to generate stable cell lines, approximately 2 million Jurkat cells are transfected with the GAS-SEAP/neo vector using DMRIE-C (Life Technologies)(transfection procedure described below). The transfected cells are seeded to a density of approximately  
5 20,000 cells per well and transfectants resistant to 1 mg/ml gentamicin selected. Resistant colonies are expanded and then tested for their response to increasing concentrations of interferon gamma. The dose response of a selected clone is demonstrated.

Specifically, the following protocol will yield sufficient cells for 75 wells  
10 containing 200 ul of cells. Thus, it is either scaled up, or performed in multiple to generate sufficient cells for multiple 96 well plates. Jurkat cells are maintained in RPMI + 10% serum with 1% Pen-Strep. Combine 2.5 mls of OPTI-MEM (Life Technologies) with 10 ug of plasmid DNA in a T25 flask. Add 2.5 ml OPTI-MEM containing 50 ul of DMRIE-C and incubate at room temperature for 15-45 mins.

15 During the incubation period, count cell concentration, spin down the required number of cells ( $10^7$  per transfection), and resuspend in OPTI-MEM to a final concentration of  $10^7$  cells/ml. Then add 1ml of  $1 \times 10^7$  cells in OPTI-MEM to T25 flask and incubate at 37 degrees C for 6 hrs. After the incubation, add 10 ml of RPMI + 15% serum.

20 The Jurkat:GAS-SEAP stable reporter lines are maintained in RPMI + 10% serum, 1 mg/ml Gentamicin, and 1% Pen-Strep. These cells are treated with supernatants containing polypeptides of the invention and/or induced polypeptides of the invention as produced by the protocol described in Example 11.

On the day of treatment with the supernatant, the cells should be washed and  
25 resuspended in fresh RPMI + 10% serum to a density of 500,000 cells per ml. The exact number of cells required will depend on the number of supernatants being screened. For one 96 well plate, approximately 10 million cells (for 10 plates, 100 million cells) are required.

Transfer the cells to a triangular reservoir boat, in order to dispense the cells  
30 into a 96 well dish, using a 12 channel pipette. Using a 12 channel pipette, transfer 200 ul of cells into each well (therefore adding 100, 000 cells per well).

After all the plates have been seeded, 50 ul of the supernatants are transferred directly from the 96 well plate containing the supernatants into each well using a 12 channel pipette. In addition, a dose of exogenous interferon gamma (0.1, 1.0, 10 ng) is added to wells H9, H10, and H11 to serve as additional positive controls for the  
5 assay.

The 96 well dishes containing Jurkat cells treated with supernatants are placed in an incubator for 48 hrs (note: this time is variable between 48-72 hrs). 35 ul samples from each well are then transferred to an opaque 96 well plate using a 12 channel pipette. The opaque plates should be covered (using sellophene covers) and  
10 stored at -20 degrees C until SEAP assays are performed according to Example 17. The plates containing the remaining treated cells are placed at 4 degrees C and serve as a source of material for repeating the assay on a specific well if desired.

As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate Jurkat T cells. Over 30 fold induction is typically observed in the  
15 positive control wells.

The above protocol may be used in the generation of both transient, as well as, stable transfected cells, which would be apparent to those of skill in the art.

#### **Example 14: High-Throughput Screening Assay Identifying Myeloid Activity**

20 The following protocol is used to assess myeloid activity by determining whether polypeptides of the invention proliferates and/or differentiates myeloid cells. Myeloid cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 12. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The myeloid cell used in this assay is  
25 U937, a pre-monocyte cell line, although TF-1, HL60, or KG1 can be used.

To transiently transfect U937 cells with the GAS/SEAP/Neo construct produced in Example 12, a DEAE-Dextran method (Kharbanda et. al., 1994, Cell Growth & Differentiation, 5:259-265) is used. First, harvest  $2 \times 10^7$  U937 cells and wash with PBS. The U937 cells are usually grown in RPMI 1640 medium containing  
30 10% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 mg/ml streptomycin.

Next, suspend the cells in 1 ml of 20 mM Tris-HCl (pH 7.4) buffer containing 0.5 mg/ml DEAE-Dextran, 8 ug GAS-SEAP2 plasmid DNA, 140 mM NaCl, 5 mM KCl, 375 uM Na<sub>2</sub>HPO<sub>4</sub>·7H<sub>2</sub>O, 1 mM MgCl<sub>2</sub>, and 675 uM CaCl<sub>2</sub>. Incubate at 37 degrees C for 45 min.

- 5 Wash the cells with RPMI 1640 medium containing 10% FBS and then resuspend in 10 ml complete medium and incubate at 37 degrees C for 36 hr.

The GAS-SEAP/U937 stable cells are obtained by growing the cells in 400 ug/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 400 ug/ml G418 for couple of passages.

- 10 These cells are tested by harvesting  $1 \times 10^8$  cells (this is enough for ten 96-well plates assay) and wash with PBS. Suspend the cells in 200 ml above described growth medium, with a final density of  $5 \times 10^5$  cells/ml. Plate 200 ul cells per well in the 96-well plate (or  $1 \times 10^5$  cells/well).

- Add 50 ul of the supernatant prepared by the protocol described in Example 11. Incubate at 37 degrees C for 48 to 72 hr. As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate U937 cells. Over 30 fold induction is typically observed in the positive control wells. SEAP assay the supernatant according to the protocol described in Example 17.

20 **Example 15: High-Throughput Screening Assay Identifying Neuronal Activity.**

- When cells undergo differentiation and proliferation, a group of genes are activated through many different signal transduction pathways. One of these genes, EGR1 (early growth response gene 1), is induced in various tissues and cell types upon activation. The promoter of EGR1 is responsible for such induction. Using the EGR1 promoter linked to reporter molecules, activation of cells can be assessed.

- Particularly, the following protocol is used to assess neuronal activity in PC12 cell lines. PC12 cells (rat pheochromocytoma cells) are known to proliferate and/or differentiate by activation with a number of mitogens, such as TPA (tetradecanoyl phorbol acetate), NGF (nerve growth factor), and EGF (epidermal growth factor). The EGR1 gene expression is activated during this treatment. Thus, by stably

transfecting PC12 cells with a construct containing an EGR promoter linked to SEAP reporter, activation of PC12 cells can be assessed.

The EGR/SEAP reporter construct can be assembled by the following protocol. The EGR-1 promoter sequence (-633 to +1)(Sakamoto K et al., Oncogene  
5 6:867-871 (1991)) can be PCR amplified from human genomic DNA using the following primers:

5' GCGCTCGAGGGATGACAGCGATAGAACCCCGG -3' (SEQ ID NO:6)

5' GCGAAGCTTCGCGACTCCCCGGATCCGCCTC-3' (SEQ ID NO:7)

Using the GAS:SEAP/Neo vector produced in Example 12, EGR1 amplified  
10 product can then be inserted into this vector. Linearize the GAS:SEAP/Neo vector using restriction enzymes XhoI/HindIII, removing the GAS/SV40 stuffer. Restrict the EGR1 amplified product with these same enzymes. Ligate the vector and the EGR1 promoter.

To prepare 96 well-plates for cell culture, two mls of a coating solution (1:30  
15 dilution of collagen type I (Upstate Biotech Inc. Cat#08-115) in 30% ethanol (filter sterilized)) is added per one 10 cm plate or 50 ml per well of the 96-well plate, and allowed to air dry for 2 hr.

PC12 cells are routinely grown in RPMI-1640 medium (Bio Whittaker) containing 10% horse serum (JRH BIOSCIENCES, Cat. # 12449-78P), 5% heat-  
20 inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 ug/ml streptomycin on a precoated 10 cm tissue culture dish. One to four split is done every three to four days. Cells are removed from the plates by scraping and resuspended with pipetting up and down for more than 15 times.

Transfect the EGR/SEAP/Neo construct into PC12 using the Lipofectamine  
25 protocol described in Example 11. EGR-SEAP/PC12 stable cells are obtained by growing the cells in 300 ug/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 300 ug/ml G418 for couple of passages.

To assay for neuronal activity, a 10 cm plate with cells around 70 to 80%  
30 confluent is screened by removing the old medium. Wash the cells once with PBS (Phosphate buffered saline). Then starve the cells in low serum medium (RPMI-1640 containing 1% horse serum and 0.5% FBS with antibiotics) overnight.



The next morning, remove the medium and wash the cells with PBS. Scrape off the cells from the plate, suspend the cells well in 2 ml low serum medium. Count the cell number and add more low serum medium to reach final cell density as  $5 \times 10^5$  cells/ml.

- 5           Add 200  $\mu$ l of the cell suspension to each well of 96-well plate (equivalent to  $1 \times 10^5$  cells/well). Add 50  $\mu$ l supernatant produced by Example 11, 37°C for 48 to 72 hr. As a positive control, a growth factor known to activate PC12 cells through EGR can be used, such as 50 ng/ $\mu$ l of Neuronal Growth Factor (NGF). Over fifty-fold induction of SEAP is typically seen in the positive control wells. SEAP assay the  
10           supernatant according to Example 17.

**Example 16: High-Throughput Screening Assay for T-cell Activity**

- NF-KB (Nuclear Factor KB) is a transcription factor activated by a wide variety of agents including the inflammatory cytokines IL-1 and TNF, CD30 and  
15           CD40, lymphotoxin-alpha and lymphotoxin-beta, by exposure to LPS or thrombin, and by expression of certain viral gene products. As a transcription factor, NF-KB regulates the expression of genes involved in immune cell activation, control of apoptosis (NF- KB appears to shield cells from apoptosis), B and T-cell development, anti-viral and antimicrobial responses, and multiple stress responses.

- 20           In non-stimulated conditions, NF- KB is retained in the cytoplasm with I-KB (Inhibitor KB). However, upon stimulation, I- KB is phosphorylated and degraded, causing NF- KB to shuttle to the nucleus, thereby activating transcription of target genes. Target genes activated by NF- KB include IL-2, IL-6, GM-CSF, ICAM-1 and class 1 MHC.

- 25           Due to its central role and ability to respond to a range of stimuli, reporter constructs utilizing the NF-KB promoter element are used to screen the supernatants produced in Example 11. Activators or inhibitors of NF-KB would be useful in treating diseases. For example, inhibitors of NF-KB could be used to treat those diseases related to the acute or chronic activation of NF-KB, such as rheumatoid  
30           arthritis.

To construct a vector containing the NF-KB promoter element, a PCR based strategy is employed. The upstream primer contains four tandem copies of the NF-KB binding site (GGGGACTTTCCC) (SEQ ID NO:8), 18 bp of sequence complementary to the 5' end of the SV40 early promoter sequence, and is flanked with an XhoI site:

5':GCGGCCTCGAGGGGACTTTCCCGGGGACTTTCCGGGGACTTTCCGGGAC  
TTTCCATCCTGCCATCTCAATTAG:3' (SEQ ID NO:9)

The downstream primer is complementary to the 3' end of the SV40 promoter and is flanked with a Hind III site:

10 5':GCGGCAAGCTTTTTTGCAAAGCCTAGGC:3' (SEQ ID NO:4)

PCR amplification is performed using the SV40 promoter template present in the pB-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI and Hind III and subcloned into BLSK2-. (Stratagene)

Sequencing with the T7 and T3 primers confirms the insert contains the following sequence:

5':CTCGAGGGGACTTTCCCGGGGACTTTCCGGGGACTTTCCGGGGACTTTCC  
ATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCCTAACTCCGCCC  
ATCCCGCCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGA  
20 CTAATTTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTA  
TTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAA  
GCTT:3' (SEQ ID NO:10)

Next, replace the SV40 minimal promoter element present in the pSEAP2- promoter plasmid (Clontech) with this NF-KB/SV40 fragment using XhoI and HindIII. However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

In order to generate stable mammalian cell lines, the NF-KB/SV40/SEAP cassette is removed from the above NF-KB/SEAP vector using restriction enzymes SalI and NotI, and inserted into a vector containing neomycin resistance. Particularly, the NF-KB/SV40/SEAP cassette was inserted into pGFP-1 (Clontech), replacing the GFP gene, after restricting pGFP-1 with SalI and NotI.

Once NF-KB/SV40/SEAP/Neo vector is created, stable Jurkat T-cells are created and maintained according to the protocol described in Example 13. Similarly, the method for assaying supernatants with these stable Jurkat T-cells is also described in Example 13. As a positive control, exogenous TNF alpha (0.1, 1, 10 ng) is added to wells H9, H10, and H11, with a 5-10 fold activation typically observed.

#### **Example 17: Assay for SEAP Activity**

As a reporter molecule for the assays described in Examples 13-16, SEAP activity is assayed using the Tropix Phospho-light Kit (Cat. BP-400) according to the following general procedure. The Tropix Phospho-light Kit supplies the Dilution, Assay, and Reaction Buffers used below.

Prime a dispenser with the 2.5x Dilution Buffer and dispense 15 ul of 2.5x dilution buffer into Optiplates containing 35 ul of a supernatant. Seal the plates with a plastic sealer and incubate at 65 degree C for 30 min. Separate the Optiplates to avoid uneven heating.

Cool the samples to room temperature for 15 minutes. Empty the dispenser and prime with the Assay Buffer. Add 50 ml Assay Buffer and incubate at room temperature 5 min. Empty the dispenser and prime with the Reaction Buffer (see the table below). Add 50 ul Reaction Buffer and incubate at room temperature for 20 minutes. Since the intensity of the chemiluminescent signal is time dependent, and it takes about 10 minutes to read 5 plates on luminometer, one should treat 5 plates at each time and start the second set 10 minutes later.

Read the relative light unit in the luminometer. Set H12 as blank, and print the results. An increase in chemiluminescence indicates reporter activity.

**Reaction Buffer Formulation:**

# of plates	Rxn buffer diluent (ml)	CSPD (ml)
10	60	3
11	65	3.25
12	70	3.5
13	75	3.75
14	80	4
15	85	4.25
16	90	4.5
17	95	4.75
18	100	5
19	105	5.25
20	110	5.5
21	115	5.75
22	120	6
23	125	6.25
24	130	6.5
25	135	6.75
26	140	7
27	145	7.25
28	150	7.5
29	155	7.75
30	160	8
31	165	8.25
32	170	8.5
33	175	8.75
34	180	9
35	185	9.25
36	190	9.5
37	195	9.75
38	200	10
39	205	10.25
40	210	10.5
41	215	10.75
42	220	11
43	225	11.25
44	230	11.5
45	235	11.75
46	240	12
47	245	12.25
48	250	12.5
49	255	12.75
50	260	13

**Example 18: High-Throughput Screening Assay Identifying Changes in Small Molecule Concentration and Membrane Permeability**

- 5 Binding of a ligand to a receptor is known to alter intracellular levels of small molecules, such as calcium, potassium, sodium, and pH, as well as alter membrane potential. These alterations can be measured in an assay to identify supernatants which bind to receptors of a particular cell. Although the following protocol describes an assay for calcium, this protocol can easily be modified to detect changes

in potassium, sodium, pH, membrane potential, or any other small molecule which is detectable by a fluorescent probe.

The following assay uses Fluorometric Imaging Plate Reader ("FLIPR") to measure changes in fluorescent molecules (Molecular Probes) that bind small  
5 molecules. Clearly, any fluorescent molecule detecting a small molecule can be used instead of the calcium fluorescent molecule, fluo-4 (Molecular Probes, Inc.; catalog no. F-14202), used here.

For adherent cells, seed the cells at 10,000 -20,000 cells/well in a Co-star black 96-well plate with clear bottom. The plate is incubated in a CO<sub>2</sub> incubator for  
10 20 hours. The adherent cells are washed two times in Biotek washer with 200 ul of HBSS (Hank's Balanced Salt Solution) leaving 100 ul of buffer after the final wash.

A stock solution of 1 mg/ml fluo-4 is made in 10% pluronic acid DMSO. To load the cells with fluo-4, 50 ul of 12 ug/ml fluo-4 is added to each well. The plate is incubated at 37 degrees C in a CO<sub>2</sub> incubator for 60 min. The plate is washed four  
15 times in the Biotek washer with HBSS leaving 100 ul of buffer.

For non-adherent cells, the cells are spun down from culture media. Cells are re-suspended to 2-5x10<sup>6</sup> cells/ml with HBSS in a 50-ml conical tube. 4 ul of 1 mg/ml fluo-4 solution in 10% pluronic acid DMSO is added to each ml of cell suspension. The tube is then placed in a 37 degrees C water bath for 30-60 min. The cells are  
20 washed twice with HBSS, resuspended to 1x10<sup>6</sup> cells/ml, and dispensed into a microplate, 100 ul/well. The plate is centrifuged at 1000 rpm for 5 min. The plate is then washed once in Denley CellWash with 200 ul, followed by an aspiration step to 100 ul final volume.

For a non-cell based assay, each well contains a fluorescent molecule, such as  
25 fluo-4. The supernatant is added to the well, and a change in fluorescence is detected.

To measure the fluorescence of intracellular calcium, the FLIPR is set for the following parameters: (1) System gain is 300-800 mW; (2) Exposure time is 0.4 second; (3) Camera F/stop is F/2; (4) Excitation is 488 nm; (5) Emission is 530 nm;  
30 and (6) Sample addition is 50 ul. Increased emission at 530 nm indicates an extracellular signaling event which has resulted in an increase in the intracellular Ca<sup>++</sup> concentration.

**Example 19: High-Throughput Screening Assay Identifying Tyrosine Kinase Activity**

The Protein Tyrosine Kinases (PTK) represent a diverse group of  
5 transmembrane and cytoplasmic kinases. Within the Receptor Protein Tyrosine  
Kinase (RPTK) group are receptors for a range of mitogenic and metabolic growth  
factors including the PDGF, FGF, EGF, NGF, HGF and Insulin receptor subfamilies.  
In addition there are a large family of RPTKs for which the corresponding ligand is  
unknown. Ligands for RPTKs include mainly secreted small proteins, but also  
10 membrane-bound and extracellular matrix proteins.

Activation of RPTK by ligands involves ligand-mediated receptor  
dimerization, resulting in transphosphorylation of the receptor subunits and activation  
of the cytoplasmic tyrosine kinases. The cytoplasmic tyrosine kinases include  
receptor associated tyrosine kinases of the src-family (e.g., src, yes, lck, lyn, fyn) and  
15 non-receptor linked and cytosolic protein tyrosine kinases, such as the Jak family,  
members of which mediate signal transduction triggered by the cytokine superfamily  
of receptors (e.g., the Interleukins, Interferons, GM-CSF, and Leptin).

Because of the wide range of known factors capable of stimulating tyrosine  
kinase activity, the identification of novel human secreted proteins capable of  
20 activating tyrosine kinase signal transduction pathways are of interest. Therefore, the  
following protocol is designed to identify those novel human secreted proteins  
capable of activating the tyrosine kinase signal transduction pathways.

Seed target cells (e.g., primary keratinocytes) at a density of approximately  
25,000 cells per well in a 96 well Loprodyne Silent Screen Plates purchased from  
25 Nalge Nunc (Naperville, IL). The plates are sterilized with two 30 minute rinses with  
100% ethanol, rinsed with water and dried overnight. Some plates are coated for 2 hr  
with 100 ml of cell culture grade type I collagen (50 mg/ml), gelatin (2%) or  
polylysine (50 mg/ml), all of which can be purchased from Sigma Chemicals (St.  
Louis, MO) or 10% Matrigel purchased from Becton Dickinson (Bedford, MA), or  
30 calf serum, rinsed with PBS and stored at 4 degree C. Cell growth on these plates is  
assayed by seeding 5,000 cells/well in growth medium and indirect quantitation of  
cell number through use of alamarBlue as described by the manufacturer Alamar

Biosciences, Inc. (Sacramento, CA) after 48 hr. Falcon plate covers #3071 from Becton Dickinson (Bedford, MA) are used to cover the Loprodyne Silent Screen Plates. Falcon Microtest III cell culture plates can also be used in some proliferation experiments.

5           To prepare extracts, A431 cells are seeded onto the nylon membranes of Loprodyne plates (20,000/200ml/well) and cultured overnight in complete medium. Cells are quiesced by incubation in serum-free basal medium for 24 hr. After 5-20 minutes treatment with EGF (60ng/ml) or 50 ul of the supernatant produced in Example 11, the medium was removed and 100 ml of extraction buffer ((20 mM  
10   HEPES pH 7.5, 0.15 M NaCl, 1% Triton X-100, 0.1% SDS, 2 mM Na<sub>3</sub>VO<sub>4</sub>, 2 mM Na<sub>4</sub>P<sub>2</sub>O<sub>7</sub> and a cocktail of protease inhibitors (# 1836170) obtained from Boehrerger Mannheim (Indianapolis, IN) is added to each well and the plate is shaken on a rotating shaker for 5 minutes at 4 degrees C. The plate is then placed in a vacuum transfer manifold and the extract filtered through the 0.45 mm membrane  
15   bottoms of each well using house vacuum. Extracts are collected in a 96-well catch/assay plate in the bottom of the vacuum manifold and immediately placed on ice. To obtain extracts clarified by centrifugation, the content of each well, after detergent solubilization for 5 minutes, is removed and centrifuged for 15 minutes at 4 degrees C at 16,000 x g.

20           Test the filtered extracts for levels of tyrosine kinase activity. Although many methods of detecting tyrosine kinase activity are known, one method is described here.

          Generally, the tyrosine kinase activity of a supernatant is evaluated by determining its ability to phosphorylate a tyrosine residue on a specific substrate (a  
25   biotinylated peptide). Biotinylated peptides that can be used for this purpose include PSK1 (corresponding to amino acids 6-20 of the cell division kinase cdc2-p34) and PSK2 (corresponding to amino acids 1-17 of gastrin). Both peptides are substrates for a range of tyrosine kinases and are available from Boehringer Mannheim.

          The tyrosine kinase reaction is set up by adding the following components in  
30   order. First, add 10ul of 5uM Biotinylated Peptide, then 10ul ATP/Mg<sub>2+</sub> (5mM ATP/50mM MgCl<sub>2</sub>), then 10ul of 5x Assay Buffer (40mM imidazole hydrochloride,

pH7.3, 40 mM beta-glycerophosphate, 1mM EGTA, 100mM MgCl<sub>2</sub>, 5 mM MnCl<sub>2</sub>, 0.5 mg/ml BSA), then 5ul of Sodium Vanadate(1mM), and then 5ul of water. Mix the components gently and preincubate the reaction mix at 30 degrees C for 2 min. Initial the reaction by adding 10ul of the control enzyme or the filtered supernatant.

- 5           The tyrosine kinase assay reaction is then terminated by adding 10 ul of 120mM EDTA and place the reactions on ice.

- Tyrosine kinase activity is determined by transferring 50 ul aliquot of reaction mixture to a microtiter plate (MTP) module and incubating at 37 degrees C for 20 min. This allows the streptavidin coated 96 well plate to associate with the  
10   biotinylated peptide. Wash the MTP module with 300ul/well of PBS four times. Next add 75 ul of anti-phosphotyrosine antibody conjugated to horse radish peroxidase(anti-P-Tyr-POD(0.5u/ml)) to each well and incubate at 37 degrees C for one hour. Wash the well as above.

- Next add 100ul of peroxidase substrate solution (Boehringer Mannheim) and  
15   incubate at room temperature for at least 5 mins (up to 30 min). Measure the absorbance of the sample at 405 nm by using ELISA reader. The level of bound peroxidase activity is quantitated using an ELISA reader and reflects the level of tyrosine kinase activity.

20   **Example 20: High-Throughput Screening Assay Identifying Phosphorylation Activity**

- As a potential alternative and/or compliment to the assay of protein tyrosine kinase activity described in Example 19, an assay which detects activation (phosphorylation) of major intracellular signal transduction intermediates can also be  
25   used. For example, as described below one particular assay can detect tyrosine phosphorylation of the Erk-1 and Erk-2 kinases. However, phosphorylation of other molecules, such as Raf, JNK, p38 MAP, Map kinase kinase (MEK), MEK kinase, Src, Muscle specific kinase (MuSK), IRAK, Tec, and Janus, as well as any other phosphoserine, phosphotyrosine, or phosphothreonine molecule, can be detected by  
30   substituting these molecules for Erk-1 or Erk-2 in the following assay.

          Specifically, assay plates are made by coating the wells of a 96-well ELISA plate with 0.1 ml of protein G (1ug/ml) for 2 hr at room temp, (RT). The plates are



then rinsed with PBS and blocked with 3% BSA/PBS for 1 hr at RT. The protein G plates are then treated with 2 commercial monoclonal antibodies (100ng/well) against Erk-1 and Erk-2 (1 hr at RT) (Santa Cruz Biotechnology). (To detect other molecules, this step can easily be modified by substituting a monoclonal antibody detecting any of the above described molecules.) After 3-5 rinses with PBS, the plates are stored at 4 degrees C until use.

A431 cells are seeded at 20,000/well in a 96-well Loprodyne filterplate and cultured overnight in growth medium. The cells are then starved for 48 hr in basal medium (DMEM) and then treated with EGF (6ng/well) or 50 ul of the supernatants obtained in Example 11 for 5-20 minutes. The cells are then solubilized and extracts filtered directly into the assay plate.

After incubation with the extract for 1 hr at RT, the wells are again rinsed. As a positive control, a commercial preparation of MAP kinase (10ng/well) is used in place of A431 extract. Plates are then treated with a commercial polyclonal (rabbit) antibody (1ug/ml) which specifically recognizes the phosphorylated epitope of the Erk-1 and Erk-2 kinases (1 hr at RT). This antibody is biotinylated by standard procedures. The bound polyclonal antibody is then quantitated by successive incubations with Europium-streptavidin and Europium fluorescence enhancing reagent in the Wallac DELFIA instrument (time-resolved fluorescence). An increased fluorescent signal over background indicates a phosphorylation.

#### **Example 21: Method of Determining Alterations in a Gene Corresponding to a Polynucleotide**

RNA isolated from entire families or individual patients presenting with a phenotype of interest (such as a disease) is isolated. cDNA is then generated from these RNA samples using protocols known in the art. (See, Sambrook.) The cDNA is then used as a template for PCR, employing primers surrounding regions of interest in SEQ ID NO:X. Suggested PCR conditions consist of 35 cycles at 95 degrees C for 30 seconds; 60-120 seconds at 52-58 degrees C; and 60-120 seconds at 70 degrees C, using buffer solutions described in Sidransky et al., Science 252:706 (1991).

PCR products are then sequenced using primers labeled at their 5' end with T4 polynucleotide kinase, employing SequiTherm Polymerase. (Epicentre

Technologies). The intron-exon borders of selected exons is also determined and genomic PCR products analyzed to confirm the results. PCR products harboring suspected mutations is then cloned and sequenced to validate the results of the direct sequencing.

5           PCR products is cloned into T-tailed vectors as described in Holton et al., Nucleic Acids Research, 19:1156 (1991) and sequenced with T7 polymerase (United States Biochemical). Affected individuals are identified by mutations not present in unaffected individuals.

          Genomic rearrangements are also observed as a method of determining  
10 alterations in a gene corresponding to a polynucleotide. Genomic clones isolated according to Example 2 are nick-translated with digoxigenindeoxy-uridine 5'-triphosphate (Boehringer Mannheim), and FISH performed as described in Johnson et al., Methods Cell Biol. 35:73-99 (1991). Hybridization with the labeled probe is carried out using a vast excess of human cot-1 DNA for specific hybridization to the  
15 corresponding genomic locus.

          Chromosomes are counterstained with 4,6-diamino-2-phenylidole and propidium iodide, producing a combination of C- and R-bands. Aligned images for precise mapping are obtained using a triple-band filter set (Chroma Technology, Brattleboro, VT) in combination with a cooled charge-coupled device camera  
20 (Photometrics, Tucson, AZ) and variable excitation wavelength filters. (Johnson et al., Genet. Anal. Tech. Appl., 8:75 (1991).) Image collection, analysis and chromosomal fractional length measurements are performed using the ISee Graphical Program System. (Inovision Corporation, Durham, NC.) Chromosome alterations of the genomic region hybridized by the probe are identified as insertions, deletions, and  
25 translocations. These alterations are used as a diagnostic marker for an associated disease.

#### **Example 22: Method of Detecting Abnormal Levels of a Polypeptide in a Biological Sample**

30           A polypeptide of the present invention can be detected in a biological sample, and if an increased or decreased level of the polypeptide is detected, this polypeptide is a marker for a particular phenotype. Methods of detection are numerous, and thus,

it is understood that one skilled in the art can modify the following assay to fit their particular needs.

For example, antibody-sandwich ELISAs are used to detect polypeptides in a sample, preferably a biological sample. Wells of a microtiter plate are coated with specific antibodies, at a final concentration of 0.2 to 10 ug/ml. The antibodies are either monoclonal or polyclonal and are produced by the method described in Example 10. The wells are blocked so that non-specific binding of the polypeptide to the well is reduced.

The coated wells are then incubated for > 2 hours at RT with a sample containing the polypeptide. Preferably, serial dilutions of the sample should be used to validate results. The plates are then washed three times with deionized or distilled water to remove unbounded polypeptide.

Next, 50 ul of specific antibody-alkaline phosphatase conjugate, at a concentration of 25-400 ng, is added and incubated for 2 hours at room temperature. The plates are again washed three times with deionized or distilled water to remove unbounded conjugate.

Add 75 ul of 4-methylumbelliferyl phosphate (MUP) or p-nitrophenyl phosphate (NPP) substrate solution to each well and incubate 1 hour at room temperature. Measure the reaction by a microtiter plate reader. Prepare a standard curve, using serial dilutions of a control sample, and plot polypeptide concentration on the X-axis (log scale) and fluorescence or absorbance of the Y-axis (linear scale). Interpolate the concentration of the polypeptide in the sample using the standard curve.

### **Example 23: Formulation**

The invention also provides methods of treatment and/or prevention of diseases or disorders (such as, for example, any one or more of the diseases or disorders disclosed herein) by administration to a subject of an effective amount of a Therapeutic. By therapeutic is meant a polynucleotides or polypeptides of the invention (including fragments and variants), agonists or antagonists thereof, and/or antibodies thereto, in combination with a pharmaceutically acceptable carrier type (e.g., a sterile carrier).

The Therapeutic will be formulated and dosed in a fashion consistent with good medical practice, taking into account the clinical condition of the individual patient (especially the side effects of treatment with the Therapeutic alone), the site of delivery, the method of administration, the scheduling of administration, and other factors known to practitioners. The "effective amount" for purposes herein is thus determined by such considerations.

As a general proposition, the total pharmaceutically effective amount of the Therapeutic administered parenterally per dose will be in the range of about 1 ug/kg/day to 10 mg/kg/day of patient body weight, although, as noted above, this will be subject to therapeutic discretion. More preferably, this dose is at least 0.01 mg/kg/day, and most preferably for humans between about 0.01 and 1 mg/kg/day for the hormone. If given continuously, the Therapeutic is typically administered at a dose rate of about 1 ug/kg/hour to about 50 ug/kg/hour, either by 1-4 injections per day or by continuous subcutaneous infusions, for example, using a mini-pump. An intravenous bag solution may also be employed. The length of treatment needed to observe changes and the interval following treatment for responses to occur appears to vary depending on the desired effect.

Therapeutics can be administered orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), buccally, or as an oral or nasal spray. "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

Therapeutics of the invention are also suitably administered by sustained-release systems. Suitable examples of sustained-release Therapeutics are administered orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), buccally, or as an oral or nasal spray. "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. The term "parenteral" as used herein refers to

modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

Therapeutics of the invention are also suitably administered by sustained-release systems. Suitable examples of sustained-release Therapeutics include suitable  
5 polymeric materials (such as, for example, semi-permeable polymer matrices in the form of shaped articles, e.g., films, or microcapsules), suitable hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, and sparingly soluble derivatives (such as, for example, a sparingly soluble salt).

Sustained-release matrices include polylactides (U.S. Pat. No. 3,773,919, EP  
10 58,481), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman et al., Biopolymers 22:547-556 (1983)), poly (2- hydroxyethyl methacrylate) (Langer et al., J. Biomed. Mater. Res. 15:167-277 (1981), and Langer, Chem. Tech. 12:98-105 (1982)), ethylene vinyl acetate (Langer et al., Id.) or poly-D- (-)-3-hydroxybutyric acid (EP 133,988).

15 Sustained-release Therapeutics also include liposomally entrapped Therapeutics of the invention (*see* generally, Langer, *Science* 249:1527-1533 (1990); Treat et al., in *Liposomes in the Therapy of Infectious Disease and Cancer*, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 317 -327 and 353-365 (1989)). Liposomes containing the Therapeutic are prepared by methods known per se: DE  
20 3,218,121; Epstein et al., Proc. Natl. Acad. Sci. (USA) 82:3688-3692 (1985); Hwang et al., Proc. Natl. Acad. Sci.(USA) 77:4030-4034 (1980); EP 52,322; EP 36,676; EP 88,046; EP 143,949; EP 142,641; Japanese Pat. Appl. 83-118008; U.S. Pat. Nos. 4,485,045 and 4,544,545; and EP 102,324. Ordinarily, the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than  
25 about 30 mol. percent cholesterol, the selected proportion being adjusted for the optimal Therapeutic.

In yet an additional embodiment, the Therapeutics of the invention are delivered by way of a pump (*see* Langer, *supra*; Sefton, CRC Crit. Ref. Biomed. Eng. 14:201 (1987); Buchwald et al., Surgery 88:507 (1980); Saudek et al., N. Engl. J.  
30 Med. 321:574 (1989)).

Other controlled release systems are discussed in the review by Langer (*Science* 249:1527-1533 (1990)).

For parenteral administration, in one embodiment, the Therapeutic is formulated generally by mixing it at the desired degree of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a pharmaceutically acceptable carrier, i.e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation. For example, the formulation preferably does not include oxidizing agents and other compounds that are known to be deleterious to the Therapeutic.

Generally, the formulations are prepared by contacting the Therapeutic uniformly and intimately with liquid carriers or finely divided solid carriers or both. Then, if necessary, the product is shaped into the desired formulation. Preferably the carrier is a parenteral carrier, more preferably a solution that is isotonic with the blood of the recipient. Examples of such carrier vehicles include water, saline, Ringer's solution, and dextrose solution. Non-aqueous vehicles such as fixed oils and ethyl oleate are also useful herein, as well as liposomes.

The carrier suitably contains minor amounts of additives such as substances that enhance isotonicity and chemical stability. Such materials are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, succinate, acetic acid, and other organic acids or their salts; antioxidants such as ascorbic acid; low molecular weight (less than about ten residues) polypeptides, e.g., polyarginine or tripeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids, such as glycine, glutamic acid, aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, manose, or dextrans; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; counterions such as sodium; and/or nonionic surfactants such as polysorbates, poloxamers, or PEG.

The Therapeutic is typically formulated in such vehicles at a concentration of about 0.1 mg/ml to 100 mg/ml, preferably 1-10 mg/ml, at a pH of about 3 to 8. It will be understood that the use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of polypeptide salts.

Any pharmaceutical used for therapeutic administration can be sterile. Sterility is readily accomplished by filtration through sterile filtration membranes

(e.g., 0.2 micron membranes). Therapeutics generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

Therapeutics ordinarily will be stored in unit or multi-dose containers, for example, sealed ampoules or vials, as an aqueous solution or as a lyophilized formulation for reconstitution. As an example of a lyophilized formulation, 10-ml vials are filled with 5 ml of sterile-filtered 1% (w/v) aqueous Therapeutic solution, and the resulting mixture is lyophilized. The infusion solution is prepared by reconstituting the lyophilized Therapeutic using bacteriostatic Water-for-Injection.

The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the Therapeutics of the invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. In addition, the Therapeutics may be employed in conjunction with other therapeutic compounds.

The Therapeutics of the invention may be administered alone or in combination with adjuvants. Adjuvants that may be administered with the Therapeutics of the invention include, but are not limited to, alum, alum plus deoxycholate (ImmunoAg), MTP-PE (Biocine Corp.), QS21 (Genentech, Inc.), BCG, and MPL. In a specific embodiment, Therapeutics of the invention are administered in combination with alum. In another specific embodiment, Therapeutics of the invention are administered in combination with QS-21. Further adjuvants that may be administered with the Therapeutics of the invention include, but are not limited to, Monophosphoryl lipid immunomodulator, AdjuVax 100a, QS-21, QS-18, CRL1005, Aluminum salts, MF-59, and Virosomal adjuvant technology. Vaccines that may be administered with the Therapeutics of the invention include, but are not limited to, vaccines directed toward protection against MMR (measles, mumps, rubella), polio, varicella, tetanus/diphtheria, hepatitis A, hepatitis B, haemophilus influenzae B, whooping cough, pneumonia, influenza, Lyme's Disease, rotavirus, cholera, yellow fever, Japanese encephalitis, poliomyelitis, rabies, typhoid fever, and pertussis. Combinations may be administered either concomitantly, e.g., as an admixture,

separately but simultaneously or concurrently; or sequentially. This includes presentations in which the combined agents are administered together as a therapeutic mixture, and also procedures in which the combined agents are administered separately but simultaneously, e.g., as through separate intravenous lines into the same individual. Administration "in combination" further includes the separate administration of one of the compounds or agents given first, followed by the second.

The Therapeutics of the invention may be administered alone or in combination with other therapeutic agents. Therapeutic agents that may be administered in combination with the Therapeutics of the invention, include but not limited to, other members of the TNF family, chemotherapeutic agents, antibiotics, steroidal and non-steroidal anti-inflammatories, conventional immunotherapeutic agents, cytokines and/or growth factors. Combinations may be administered either concomitantly, e.g., as an admixture, separately but simultaneously or concurrently; or sequentially. This includes presentations in which the combined agents are administered together as a therapeutic mixture, and also procedures in which the combined agents are administered separately but simultaneously, e.g., as through separate intravenous lines into the same individual. Administration "in combination" further includes the separate administration of one of the compounds or agents given first, followed by the second.

In one embodiment, the Therapeutics of the invention are administered in combination with members of the TNF family. TNF, TNF-related or TNF-like molecules that may be administered with the Therapeutics of the invention include, but are not limited to, soluble forms of TNF-alpha, lymphotoxin-alpha (LT-alpha, also known as TNF-beta), LT-beta (found in complex heterotrimer LT-alpha2-beta), OPGL, FasL, CD27L, CD30L, CD40L, 4-1BBL, DcR3, OX40L, TNF-gamma (International Publication No. WO 96/14328), AIM-I (International Publication No. WO 97/33899), endokine-alpha (International Publication No. WO 98/07880), TR6 (International Publication No. WO 98/30694), OPG, and neutrokin-alpha (International Publication No. WO 98/18921, OX40, and nerve growth factor (NGF), and soluble forms of Fas, CD30, CD27, CD40 and 4-1BB, TR2 (International Publication No. WO 96/34095), DR3 (International Publication No. WO 97/33904), DR4 (International Publication No. WO 98/32856), TR5 (International Publication



No. WO 98/30693), TR6 (International Publication No. WO 98/30694), TR7 (International Publication No. WO 98/41629), TRANK, TR9 (International Publication No. WO 98/56892), TR10 (International Publication No. WO 98/54202), 312C2 (International Publication No. WO 98/06842), and TR12, and soluble forms  
5 CD154, CD70, and CD153.

In certain embodiments, Therapeutics of the invention are administered in combination with antiretroviral agents, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and/or protease inhibitors. Nucleoside reverse transcriptase inhibitors that may be administered in combination  
10 with the Therapeutics of the invention, include, but are not limited to, RETROVIR™ (zidovudine/AZT), VIDEX™ (didanosine/ddI), HIVID™ (zalcitabine/ddC), ZERIT™ (stavudine/d4T), EPIVIR™ (lamivudine/3TC), and COMBIVIR™ (zidovudine/lamivudine). Non-nucleoside reverse transcriptase inhibitors that may be administered in combination with the Therapeutics of the invention, include, but  
15 are not limited to, VIRAMUNE™ (nevirapine), RESCRIPTOR™ (delavirdine), and SUSTIVA™ (efavirenz). Protease inhibitors that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, CRIXIVAN™ (indinavir), NORVIR™ (ritonavir), INVIRASE™ (saquinavir), and VIRACEPT™ (nelfinavir). In a specific embodiment, antiretroviral agents,  
20 nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and/or protease inhibitors may be used in any combination with Therapeutics of the invention to treat AIDS and/or to prevent or treat HIV infection.

In other embodiments, Therapeutics of the invention may be administered in combination with anti-opportunistic infection agents. Anti-opportunistic agents that  
25 may be administered in combination with the Therapeutics of the invention, include, but are not limited to, TRIMETHOPRIM-SULFAMETHOXAZOLE™, DAPSONE™, PENTAMIDINE™, ATOVAQUONE™, ISONIAZID™, RIFAMPIN™, PYRAZINAMIDE™, ETHAMBUTOL™, RIFABUTIN™, CLARITHROMYCIN™, AZITHROMYCIN™, GANCICLOVIR™,  
30 FOSCARNET™, CIDOFOVIR™, FLUCONAZOLE™, ITRACONAZOLE™, KETOCONAZOLE™, ACYCLOVIR™, FAMCICOLVIR™, PYRIMETHAMINE™,

LEUCOVORIN™, NEUPOGEN™ (filgrastim/G-CSF), and LEUKINE™ (sargramostim/GM-CSF). In a specific embodiment, Therapeutics of the invention are used in any combination with TRIMETHOPRIM-SULFAMETHOXAZOLE™, DAPSONE™, PENTAMIDINE™, and/or ATOVAQUONE™ to prophylactically

5 treat or prevent an opportunistic *Pneumocystis carinii* pneumonia infection. In another specific embodiment, Therapeutics of the invention are used in any combination with ISONIAZID™, RIFAMPIN™, PYRAZINAMIDE™, and/or ETHAMBUTOL™ to prophylactically treat or prevent an opportunistic *Mycobacterium avium* complex infection. In another specific embodiment,

10 Therapeutics of the invention are used in any combination with RIFABUTIN™, CLARITHROMYCIN™, and/or AZITHROMYCIN™ to prophylactically treat or prevent an opportunistic *Mycobacterium tuberculosis* infection. In another specific embodiment, Therapeutics of the invention are used in any combination with GANCICLOVIR™, FOSCARNET™, and/or CIDOFOVIR™ to prophylactically treat

15 or prevent an opportunistic cytomegalovirus infection. In another specific embodiment, Therapeutics of the invention are used in any combination with FLUCONAZOLE™, ITRACONAZOLE™, and/or KETOCONAZOLE™ to prophylactically treat or prevent an opportunistic fungal infection. In another specific embodiment, Therapeutics of the invention are used in any combination with

20 ACYCLOVIR™ and/or FAMCICOLVIR™ to prophylactically treat or prevent an opportunistic herpes simplex virus type I and/or type II infection. In another specific embodiment, Therapeutics of the invention are used in any combination with PYRIMETHAMINE™ and/or LEUCOVORIN™ to prophylactically treat or prevent an opportunistic *Toxoplasma gondii* infection. In another specific embodiment,

25 Therapeutics of the invention are used in any combination with LEUCOVORIN™ and/or NEUPOGEN™ to prophylactically treat or prevent an opportunistic bacterial infection.

In a further embodiment, the Therapeutics of the invention are administered in combination with an antiviral agent. Antiviral agents that may be administered

30 with the Therapeutics of the invention include, but are not limited to, acyclovir, ribavirin, amantadine, and remantidine.

In a further embodiment, the Therapeutics of the invention are administered in combination with an antibiotic agent. Antibiotic agents that may be administered with the Therapeutics of the invention include, but are not limited to, amoxicillin, beta-lactamases, aminoglycosides, beta-lactam (glycopeptide), beta-lactamases, Clindamycin, chloramphenicol, cephalosporins, ciprofloxacin, ciprofloxacin, erythromycin, fluoroquinolones, macrolides, metronidazole, penicillins, quinolones, rifampin, streptomycin, sulfonamide, tetracyclines, trimethoprim, trimethoprim-sulfamthoxazole, and vancomycin.

Conventional nonspecific immunosuppressive agents, that may be administered in combination with the Therapeutics of the invention include, but are not limited to, steroids, cyclosporine, cyclosporine analogs, cyclophosphamide methylprednisone, prednisone, azathioprine, FK-506, 15-deoxyspergualin, and other immunosuppressive agents that act by suppressing the function of responding T cells.

In specific embodiments, Therapeutics of the invention are administered in combination with immunosuppressants. Immunosuppressants preparations that may be administered with the Therapeutics of the invention include, but are not limited to, ORTHOCLONE™ (OKT3), SANDIMMUNE™/NEORAL™/SANGDYA™ (cyclosporin), PROGRAF™ (tacrolimus), CELLCEPT™ (mycophenolate), Azathioprine, glucocorticosteroids, and RAPAMUNE™ (sirolimus). In a specific embodiment, immunosuppressants may be used to prevent rejection of organ or bone marrow transplantation.

In an additional embodiment, Therapeutics of the invention are administered alone or in combination with one or more intravenous immune globulin preparations. Intravenous immune globulin preparations that may be administered with the Therapeutics of the invention include, but not limited to, GAMMAR™, IVEEGAM™, SANDOGLOBULIN™, GAMMAGARD S/D™, and GAMIMUNE™. In a specific embodiment, Therapeutics of the invention are administered in combination with intravenous immune globulin preparations in transplantation therapy (e.g., bone marrow transplant).

In an additional embodiment, the Therapeutics of the invention are administered alone or in combination with an anti-inflammatory agent. Anti-inflammatory agents that may be administered with the Therapeutics of the invention

include, but are not limited to, glucocorticoids and the nonsteroidal anti-inflammatory, aminoarylcarboxylic acid derivatives, arylacetic acid derivatives, arylbutyric acid derivatives, arylcarboxylic acids, arylpropionic acid derivatives, pyrazoles, pyrazolones, salicylic acid derivatives, thiazinecarboxamides, e-  
5 acetamidocaproic acid, S-adenosylmethionine, 3-amino-4-hydroxybutyric acid, amixetrine, bendazac, benzydamine, bucolome, difenpiramide, ditazol, emorfazone, guaiazulene, nabumetone, nimesulide, orgotein, oxaceprol, paranyline, perisoxal, pifoxime, proquazone, proxazole, and tenidap.

In another embodiment, compositions of the invention are administered in  
10 combination with a chemotherapeutic agent. Chemotherapeutic agents that may be administered with the Therapeutics of the invention include, but are not limited to, antibiotic derivatives (e.g., doxorubicin, bleomycin, daunorubicin, and dactinomycin); antiestrogens (e.g., tamoxifen); antimetabolites (e.g., fluorouracil, 5-FU, methotrexate, floxuridine, interferon alpha-2b, glutamic acid, plicamycin,  
15 mercaptopurine, and 6-thioguanine); cytotoxic agents (e.g., carmustine, BCNU, lomustine, CCNU, cytosine arabinoside, cyclophosphamide, estramustine, hydroxyurea, procarbazine, mitomycin, busulfan, cis-platin, and vincristine sulfate); hormones (e.g., medroxyprogesterone, estramustine phosphate sodium, ethinyl estradiol, estradiol, megestrol acetate, methyltestosterone, diethylstilbestrol  
20 diphosphate, chlorotrianisene, and testolactone); nitrogen mustard derivatives (e.g., mephallen, chorambucil, mechlorethamine (nitrogen mustard) and thiotepa); steroids and combinations (e.g., bethamethasone sodium phosphate); and others (e.g., dicarbazine, asparaginase, mitotane, vincristine sulfate, vinblastine sulfate, and etoposide).

25 In a specific embodiment, Therapeutics of the invention are administered in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or any combination of the components of CHOP. In another embodiment, Therapeutics of the invention are administered in combination with Rituximab. In a further embodiment, Therapeutics of the invention are administered  
30 with Rituxmab and CHOP, or Rituxmab and any combination of the components of CHOP.

In an additional embodiment, the Therapeutics of the invention are administered in combination with cytokines. Cytokines that may be administered with the Therapeutics of the invention include, but are not limited to, IL2, IL3, IL4, IL5, IL6, IL7, IL10, IL12, IL13, IL15, anti-CD40, CD40L, IFN-gamma and TNF-alpha. In another embodiment, Therapeutics of the invention may be administered with any interleukin, including, but not limited to, IL-1alpha, IL-1beta, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, and IL-21.

In an additional embodiment, the Therapeutics of the invention are administered in combination with angiogenic proteins. Angiogenic proteins that may be administered with the Therapeutics of the invention include, but are not limited to, Glioma Derived Growth Factor (GDGF), as disclosed in European Patent Number EP-399816; Platelet Derived Growth Factor-A (PDGF-A), as disclosed in European Patent Number EP-682110; Platelet Derived Growth Factor-B (PDGF-B), as disclosed in European Patent Number EP-282317; Placental Growth Factor (PIGF), as disclosed in International Publication Number WO 92/06194; Placental Growth Factor-2 (PIGF-2), as disclosed in Hauser et al., Growth Factors, 4:259-268 (1993); Vascular Endothelial Growth Factor (VEGF), as disclosed in International Publication Number WO 90/13649; Vascular Endothelial Growth Factor-A (VEGF-A), as disclosed in European Patent Number EP-506477; Vascular Endothelial Growth Factor-2 (VEGF-2), as disclosed in International Publication Number WO 96/39515; Vascular Endothelial Growth Factor B (VEGF-3); Vascular Endothelial Growth Factor B-186 (VEGF-B186), as disclosed in International Publication Number WO 96/26736; Vascular Endothelial Growth Factor-D (VEGF-D), as disclosed in International Publication Number WO 98/02543; Vascular Endothelial Growth Factor-D (VEGF-D), as disclosed in International Publication Number WO 98/07832; and Vascular Endothelial Growth Factor-E (VEGF-E), as disclosed in German Patent Number DE19639601. The above mentioned references are incorporated herein by reference herein.

In an additional embodiment, the Therapeutics of the invention are administered in combination with hematopoietic growth factors. Hematopoietic growth factors that may be administered with the Therapeutics of the invention

include, but are not limited to, LEUKINE™ (SARGRAMOSTIM™) and NEUPOGEN™ (FILGRASTIM™).

In an additional embodiment, the Therapeutics of the invention are administered in combination with Fibroblast Growth Factors. Fibroblast Growth

5 Factors that may be administered with the Therapeutics of the invention include, but are not limited to, FGF-1, FGF-2, FGF-3, FGF-4, FGF-5, FGF-6, FGF-7, FGF-8, FGF-9, FGF-10, FGF-11, FGF-12, FGF-13, FGF-14, and FGF-15.

In additional embodiments, the Therapeutics of the invention are administered in combination with other therapeutic or prophylactic regimens, such as, for example,  
10 radiation therapy.

#### **Example 24: Method of Treating Decreased Levels of the Polypeptide**

The present invention relates to a method for treating an individual in need of an increased level of a polypeptide of the invention in the body comprising  
15 administering to such an individual a composition comprising a therapeutically effective amount of an agonist of the invention (including polypeptides of the invention). Moreover, it will be appreciated that conditions caused by a decrease in the standard or normal expression level of a secreted protein in an individual can be treated by administering the polypeptide of the present invention, preferably in the  
20 secreted form. Thus, the invention also provides a method of treatment of an individual in need of an increased level of the polypeptide comprising administering to such an individual a Therapeutic comprising an amount of the polypeptide to increase the activity level of the polypeptide in such an individual.

For example, a patient with decreased levels of a polypeptide receives a daily  
25 dose 0.1-100 ug/kg of the polypeptide for six consecutive days. Preferably, the polypeptide is in the secreted form. The exact details of the dosing scheme, based on administration and formulation, are provided in Example 23.

#### **Example 25: Method of Treating Increased Levels of the Polypeptide**

30 The present invention also relates to a method of treating an individual in need of a decreased level of a polypeptide of the invention in the body comprising

administering to such an individual a composition comprising a therapeutically effective amount of an antagonist of the invention (including polypeptides and antibodies of the invention).

In one example, antisense technology is used to inhibit production of a polypeptide of the present invention. This technology is one example of a method of decreasing levels of a polypeptide, preferably a secreted form, due to a variety of etiologies, such as cancer. For example, a patient diagnosed with abnormally increased levels of a polypeptide is administered intravenously antisense polynucleotides at 0.5, 1.0, 1.5, 2.0 and 3.0 mg/kg day for 21 days. This treatment is repeated after a 7-day rest period if the treatment was well tolerated. The formulation of the antisense polynucleotide is provided in Example 23.

#### **Example 26: Method of Treatment Using Gene Therapy-Ex Vivo**

One method of gene therapy transplants fibroblasts, which are capable of expressing a polypeptide, onto a patient. Generally, fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in tissue-culture medium and separated into small pieces. Small chunks of the tissue are placed on a wet surface of a tissue culture flask, approximately ten pieces are placed in each flask. The flask is turned upside down, closed tight and left at room temperature over night. After 24 hours at room temperature, the flask is inverted and the chunks of tissue remain fixed to the bottom of the flask and fresh media (e.g., Ham's F12 media, with 10% FBS, penicillin and streptomycin) is added. The flasks are then incubated at 37 degree C for approximately one week.

At this time, fresh media is added and subsequently changed every several days. After an additional two weeks in culture, a monolayer of fibroblasts emerge. The monolayer is trypsinized and scaled into larger flasks.

pMV-7 (Kirschmeier, P.T. et al., DNA, 7:219-25 (1988)), flanked by the long terminal repeats of the Moloney murine sarcoma virus, is digested with EcoRI and HindIII and subsequently treated with calf intestinal phosphatase. The linear vector is fractionated on agarose gel and purified, using glass beads.

The cDNA encoding a polypeptide of the present invention can be amplified using PCR primers which correspond to the 5' and 3' end sequences respectively as set

forth in Example 1 using primers and having appropriate restriction sites and initiation/stop codons, if necessary. Preferably, the 5' primer contains an EcoRI site and the 3' primer includes a HindIII site. Equal quantities of the Moloney murine sarcoma virus linear backbone and the amplified EcoRI and HindIII fragment are added together, in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The ligation mixture is then used to transform bacteria HB101, which are then plated onto agar containing kanamycin for the purpose of confirming that the vector has the gene of interest properly inserted.

10 The amphotropic pA317 or GP+am12 packaging cells are grown in tissue culture to confluent density in Dulbecco's Modified Eagles Medium (DMEM) with 10% calf serum (CS), penicillin and streptomycin. The MSV vector containing the gene is then added to the media and the packaging cells transduced with the vector. The packaging cells now produce infectious viral particles containing the gene (the packaging cells are now referred to as producer cells).

15 Fresh media is added to the transduced producer cells, and subsequently, the media is harvested from a 10 cm plate of confluent producer cells. The spent media, containing the infectious viral particles, is filtered through a millipore filter to remove detached producer cells and this media is then used to infect fibroblast cells. Media is removed from a sub-confluent plate of fibroblasts and quickly replaced with the media from the producer cells. This media is removed and replaced with fresh media. If the titer of virus is high, then virtually all fibroblasts will be infected and no selection is required. If the titer is very low, then it is necessary to use a retroviral vector that has a selectable marker, such as neo or his. Once the fibroblasts have been efficiently infected, the fibroblasts are analyzed to determine whether protein is produced.

The engineered fibroblasts are then transplanted onto the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads.

30 **Example 27: Gene Therapy Using Endogenous Genes Corresponding To Polynucleotides of the Invention**



Another method of gene therapy according to the present invention involves operably associating the endogenous polynucleotide sequence of the invention with a promoter via homologous recombination as described, for example, in U.S. Patent NO: 5,641,670, issued June 24, 1997; International Publication NO: WO 96/29411, published September 26, 1996; International Publication NO: WO 94/12650, published August 4, 1994; Koller et al., *Proc. Natl. Acad. Sci. USA*, 86:8932-8935 (1989); and Zijlstra et al., *Nature*, 342:435-438 (1989). This method involves the activation of a gene which is present in the target cells, but which is not expressed in the cells, or is expressed at a lower level than desired.

Polynucleotide constructs are made which contain a promoter and targeting sequences, which are homologous to the 5' non-coding sequence of endogenous polynucleotide sequence, flanking the promoter. The targeting sequence will be sufficiently near the 5' end of the polynucleotide sequence so the promoter will be operably linked to the endogenous sequence upon homologous recombination. The promoter and the targeting sequences can be amplified using PCR. Preferably, the amplified promoter contains distinct restriction enzyme sites on the 5' and 3' ends. Preferably, the 3' end of the first targeting sequence contains the same restriction enzyme site as the 5' end of the amplified promoter and the 5' end of the second targeting sequence contains the same restriction site as the 3' end of the amplified promoter.

The amplified promoter and the amplified targeting sequences are digested with the appropriate restriction enzymes and subsequently treated with calf intestinal phosphatase. The digested promoter and digested targeting sequences are added together in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The construct is size fractionated on an agarose gel then purified by phenol extraction and ethanol precipitation.

In this Example, the polynucleotide constructs are administered as naked polynucleotides via electroporation. However, the polynucleotide constructs may also be administered with transfection-facilitating agents, such as liposomes, viral sequences, viral particles, precipitating agents, etc. Such methods of delivery are known in the art.

Once the cells are transfected, homologous recombination will take place which results in the promoter being operably linked to the endogenous polynucleotide sequence. This results in the expression of polynucleotide corresponding to the polynucleotide in the cell. Expression may be detected by immunological staining, or  
5 any other method known in the art.

Fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in DMEM + 10% fetal calf serum. Exponentially growing or early stationary phase fibroblasts are trypsinized and rinsed from the plastic surface with nutrient medium. An aliquot of the cell suspension is removed for counting, and the remaining  
10 cells are subjected to centrifugation. The supernatant is aspirated and the pellet is resuspended in 5 ml of electroporation buffer (20 mM HEPES pH 7.3, 137 mM NaCl, 5 mM KCl, 0.7 mM Na<sub>2</sub> HPO<sub>4</sub>, 6 mM dextrose). The cells are recentrifuged, the supernatant aspirated, and the cells resuspended in electroporation buffer containing 1 mg/ml acetylated bovine serum albumin. The final cell suspension contains  
15 approximately 3X10<sup>6</sup> cells/ml. Electroporation should be performed immediately following resuspension.

Plasmid DNA is prepared according to standard techniques. For example, to construct a plasmid for targeting to the locus corresponding to the polynucleotide of the invention, plasmid pUC18 (MBI Fermentas, Amherst, NY) is digested with  
20 HindIII. The CMV promoter is amplified by PCR with an XbaI site on the 5' end and a BamHI site on the 3'end. Two non-coding sequences are amplified via PCR: one non-coding sequence (fragment 1) is amplified with a HindIII site at the 5' end and an Xba site at the 3'end; the other non-coding sequence (fragment 2) is amplified with a BamHI site at the 5'end and a HindIII site at the 3'end. The CMV promoter and the  
25 fragments (1 and 2) are digested with the appropriate enzymes (CMV promoter - XbaI and BamHI; fragment 1 - XbaI; fragment 2 - BamHI) and ligated together. The resulting ligation product is digested with HindIII, and ligated with the HindIII-digested pUC18 plasmid.

Plasmid DNA is added to a sterile cuvette with a 0.4 cm electrode gap  
30 (Bio-Rad). The final DNA concentration is generally at least 120 µg/ml. 0.5 ml of the cell suspension (containing approximately 1.5.X10<sup>6</sup> cells) is then added to the cuvette, and the cell suspension and DNA solutions are gently mixed. Electroporation is

performed with a Gene-Pulser apparatus (Bio-Rad). Capacitance and voltage are set at 960  $\mu$ F and 250-300 V, respectively. As voltage increases, cell survival decreases, but the percentage of surviving cells that stably incorporate the introduced DNA into their genome increases dramatically. Given these parameters, a pulse time of

5 approximately 14-20 mSec should be observed.

Electroporated cells are maintained at room temperature for approximately 5 min, and the contents of the cuvette are then gently removed with a sterile transfer pipette. The cells are added directly to 10 ml of prewarmed nutrient media (DMEM with 15% calf serum) in a 10 cm dish and incubated at 37 degree C. The following  
10 day, the media is aspirated and replaced with 10 ml of fresh media and incubated for a further 16-24 hours.

The engineered fibroblasts are then injected into the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads. The fibroblasts now produce the protein product. The fibroblasts can then be introduced into a  
15 patient as described above.

#### **Example 28: Method of Treatment Using Gene Therapy - In Vivo**

Another aspect of the present invention is using *in vivo* gene therapy methods to treat disorders, diseases and conditions. The gene therapy method relates to the  
20 introduction of naked nucleic acid (DNA, RNA, and antisense DNA or RNA) sequences into an animal to increase or decrease the expression of the polypeptide. The polynucleotide of the present invention may be operatively linked to a promoter or any other genetic elements necessary for the expression of the polypeptide by the target tissue. Such gene therapy and delivery techniques and methods are known in  
25 the art, see, for example, WO90/11092, WO98/11779; U.S. Patent NO. 5693622, 5705151, 5580859; Tabata et al., Cardiovasc. Res. 35(3):470-479 (1997); Chao et al., Pharmacol. Res. 35(6):517-522 (1997); Wolff, Neuromuscul. Disord. 7(5):314-318 (1997); Schwartz et al., Gene Ther. 3(5):405-411 (1996); Tsurumi et al., Circulation 94(12):3281-3290 (1996) (incorporated herein by reference).

30 The polynucleotide constructs may be delivered by any method that delivers injectable materials to the cells of an animal, such as, injection into the interstitial space of tissues (heart, muscle, skin, lung, liver, intestine and the like). The

polynucleotide constructs can be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

The term "naked" polynucleotide, DNA or RNA, refers to sequences that are free from any delivery vehicle that acts to assist, promote, or facilitate entry into the cell, including viral sequences, viral particles, liposome formulations, lipofectin or precipitating agents and the like. However, the polynucleotides of the present invention may also be delivered in liposome formulations (such as those taught in Felgner P.L. et al. (1995) Ann. NY Acad. Sci. 772:126-139 and Abdallah B. et al. (1995) Biol. Cell 85(1):1-7) which can be prepared by methods well known to those skilled in the art.

The polynucleotide vector constructs used in the gene therapy method are preferably constructs that will not integrate into the host genome nor will they contain sequences that allow for replication. Any strong promoter known to those skilled in the art can be used for driving the expression of DNA. Unlike other gene therapies techniques, one major advantage of introducing naked nucleic acid sequences into target cells is the transitory nature of the polynucleotide synthesis in the cells. Studies have shown that non-replicating DNA sequences can be introduced into cells to provide production of the desired polypeptide for periods of up to six months.

The polynucleotide construct can be delivered to the interstitial space of tissues within the an animal, including of muscle, skin, brain, lung, liver, spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, and connective tissue. Interstitial space of the tissues comprises the intercellular fluid, mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue ensheathing muscle cells or in the lacunae of bone. It is similarly the space occupied by the plasma of the circulation and the lymph fluid of the lymphatic channels. Delivery to the interstitial space of muscle tissue is preferred for the reasons discussed below. They may be conveniently delivered by injection into the tissues comprising these cells. They are preferably delivered to and expressed in persistent, non-dividing cells which are differentiated, although delivery and expression may be achieved in non-differentiated or less completely

differentiated cells, such as, for example, stem cells of blood or skin fibroblasts. *In vivo* muscle cells are particularly competent in their ability to take up and express polynucleotides.

For the naked polynucleotide injection, an effective dosage amount of DNA or  
5 RNA will be in the range of from about 0.05 g/kg body weight to about 50 mg/kg body weight. Preferably the dosage will be from about 0.005 mg/kg to about 20 mg/kg and more preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as the artisan of ordinary skill will appreciate, this dosage will vary according to the tissue site of injection. The appropriate and effective dosage of nucleic acid sequence  
10 can readily be determined by those of ordinary skill in the art and may depend on the condition being treated and the route of administration. The preferred route of administration is by the parenteral route of injection into the interstitial space of tissues. However, other parenteral routes may also be used, such as, inhalation of an aerosol formulation particularly for delivery to lungs or bronchial tissues, throat or  
15 mucous membranes of the nose. In addition, naked polynucleotide constructs can be delivered to arteries during angioplasty by the catheter used in the procedure.

The dose response effects of injected polynucleotide in muscle *in vivo* is determined as follows. Suitable template DNA for production of mRNA coding for polypeptide of the present invention is prepared in accordance with a standard  
20 recombinant DNA methodology. The template DNA, which may be either circular or linear, is either used as naked DNA or complexed with liposomes. The quadriceps muscles of mice are then injected with various amounts of the template DNA.

Five to six week old female and male Balb/C mice are anesthetized by intraperitoneal injection with 0.3 ml of 2.5% Avertin. A 1.5 cm incision is made on  
25 the anterior thigh, and the quadriceps muscle is directly visualized. The template DNA is injected in 0.1 ml of carrier in a 1 cc syringe through a 27 gauge needle over one minute, approximately 0.5 cm from the distal insertion site of the muscle into the knee and about 0.2 cm deep. A suture is placed over the injection site for future localization, and the skin is closed with stainless steel clips.

30 After an appropriate incubation time (e.g., 7 days) muscle extracts are prepared by excising the entire quadriceps. Every fifth 15  $\mu$ m cross-section of the individual quadriceps muscles is histochemically stained for protein expression. A

time course for protein expression may be done in a similar fashion except that quadriceps from different mice are harvested at different times. Persistence of DNA in muscle following injection may be determined by Southern blot analysis after preparing total cellular DNA and HIRT supernatants from injected and control mice.

- 5 The results of the above experimentation in mice can be use to extrapolate proper dosages and other treatment parameters in humans and other animals using naked DNA.

**Example 29: Transgenic Animals.**

- 10 The polypeptides of the invention can also be expressed in transgenic animals. Animals of any species, including, but not limited to, mice, rats, rabbits, hamsters, guinea pigs, pigs, micro-pigs, goats, sheep, cows and non-human primates, *e.g.*, baboons, monkeys, and chimpanzees may be used to generate transgenic animals. In a specific embodiment, techniques described herein or otherwise known in the art, are  
15 used to express polypeptides of the invention in humans, as part of a gene therapy protocol.

- Any technique known in the art may be used to introduce the transgene (i.e., polynucleotides of the invention) into animals to produce the founder lines of transgenic animals. Such techniques include, but are not limited to, pronuclear  
20 microinjection (Paterson et al., Appl. Microbiol. Biotechnol. 40:691-698 (1994); Carver et al., Biotechnology (NY) 11:1263-1270 (1993); Wright et al., Biotechnology (NY) 9:830-834 (1991); and Hoppe et al., U.S. Pat. No. 4,873,191 (1989)); retrovirus mediated gene transfer into germ lines (Van der Putten et al., Proc. Natl. Acad. Sci., USA 82:6148-6152 (1985)), blastocysts or embryos; gene targeting in embryonic  
25 stem cells (Thompson et al., Cell 56:313-321 (1989)); electroporation of cells or embryos (Lo, 1983, Mol Cell. Biol. 3:1803-1814 (1983)); introduction of the polynucleotides of the invention using a gene gun (see, *e.g.*, Ulmer et al., Science 259:1745 (1993); introducing nucleic acid constructs into embryonic pluripotent stem cells and transferring the stem cells back into the blastocyst; and sperm-  
30 mediated gene transfer (Lavitrano et al., Cell 57:717-723 (1989); etc. For a review of such techniques, see Gordon, "Transgenic Animals," Intl. Rev. Cytol. 115:171-229 (1989), which is incorporated by reference herein in its entirety.

Any technique known in the art may be used to produce transgenic clones containing polynucleotides of the invention, for example, nuclear transfer into enucleated oocytes of nuclei from cultured embryonic, fetal, or adult cells induced to quiescence (Campell et al., Nature 380:64-66 (1996); Wilmut et al., Nature 385:810-813 (1997)).

The present invention provides for transgenic animals that carry the transgene in all their cells, as well as animals which carry the transgene in some, but not all their cells, *i.e.*, mosaic animals or chimeric. The transgene may be integrated as a single transgene or as multiple copies such as in concatamers, *e.g.*, head-to-head tandems or head-to-tail tandems. The transgene may also be selectively introduced into and activated in a particular cell type by following, for example, the teaching of Lasko et al. (Lasko et al., Proc. Natl. Acad. Sci. USA 89:6232-6236 (1992)). The regulatory sequences required for such a cell-type specific activation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art. When it is desired that the polynucleotide transgene be integrated into the chromosomal site of the endogenous gene, gene targeting is preferred. Briefly, when such a technique is to be utilized, vectors containing some nucleotide sequences homologous to the endogenous gene are designed for the purpose of integrating, via homologous recombination with chromosomal sequences, into and disrupting the function of the nucleotide sequence of the endogenous gene. The transgene may also be selectively introduced into a particular cell type, thus inactivating the endogenous gene in only that cell type, by following, for example, the teaching of Gu et al. (Gu et al., Science 265:103-106 (1994)). The regulatory sequences required for such a cell-type specific inactivation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art.

Once transgenic animals have been generated, the expression of the recombinant gene may be assayed utilizing standard techniques. Initial screening may be accomplished by Southern blot analysis or PCR techniques to analyze animal tissues to verify that integration of the transgene has taken place. The level of mRNA expression of the transgene in the tissues of the transgenic animals may also be assessed using techniques which include, but are not limited to, Northern blot analysis of tissue samples obtained from the animal, *in situ* hybridization analysis, and reverse

transcriptase-PCR (rt-PCR). Samples of transgenic gene-expressing tissue may also be evaluated immunocytochemically or immunohistochemically using antibodies specific for the transgene product.

Once the founder animals are produced, they may be bred, inbred, outbred, or crossbred to produce colonies of the particular animal. Examples of such breeding strategies include, but are not limited to: outbreeding of founder animals with more than one integration site in order to establish separate lines; inbreeding of separate lines in order to produce compound transgenics that express the transgene at higher levels because of the effects of additive expression of each transgene; crossing of heterozygous transgenic animals to produce animals homozygous for a given integration site in order to both augment expression and eliminate the need for screening of animals by DNA analysis; crossing of separate homozygous lines to produce compound heterozygous or homozygous lines; and breeding to place the transgene on a distinct background that is appropriate for an experimental model of interest.

Transgenic animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying conditions and/or disorders associated with aberrant expression, and in screening for compounds effective in ameliorating such conditions and/or disorders.

### **Example 30: Knock-Out Animals.**

Endogenous gene expression can also be reduced by inactivating or "knocking out" the gene and/or its promoter using targeted homologous recombination. (E.g., see Smithies et al., Nature 317:230-234 (1985); Thomas & Capecchi, Cell 51:503-512 (1987); Thompson et al., Cell 5:313-321 (1989); each of which is incorporated by reference herein in its entirety). For example, a mutant, non-functional polynucleotide of the invention (or a completely unrelated DNA sequence) flanked by DNA homologous to the endogenous polynucleotide sequence (either the coding regions or regulatory regions of the gene) can be used, with or without a selectable marker and/or a negative selectable marker, to transfect cells that express polypeptides of the invention *in vivo*. In another embodiment, techniques known in



the art are used to generate knockouts in cells that contain, but do not express the gene of interest. Insertion of the DNA construct, via targeted homologous recombination, results in inactivation of the targeted gene. Such approaches are particularly suited in research and agricultural fields where modifications to embryonic stem cells can be used to generate animal offspring with an inactive targeted gene (*e.g.*, see Thomas & Capecchi 1987 and Thompson 1989, *supra*). However this approach can be routinely adapted for use in humans provided the recombinant DNA constructs are directly administered or targeted to the required site *in vivo* using appropriate viral vectors that will be apparent to those of skill in the art.

10 In further embodiments of the invention, cells that are genetically engineered to express the polypeptides of the invention, or alternatively, that are genetically engineered not to express the polypeptides of the invention (*e.g.*, knockouts) are administered to a patient *in vivo*. Such cells may be obtained from the patient (*i.e.*, animal, including human) or an MHC compatible donor and can include, but are not limited to fibroblasts, bone marrow cells, blood cells (*e.g.*, lymphocytes), adipocytes, muscle cells, endothelial cells etc. The cells are genetically engineered *in vitro* using recombinant DNA techniques to introduce the coding sequence of polypeptides of the invention into the cells, or alternatively, to disrupt the coding sequence and/or endogenous regulatory sequence associated with the polypeptides of the invention, *e.g.*, by transduction (using viral vectors, and preferably vectors that integrate the transgene into the cell genome) or transfection procedures, including, but not limited to, the use of plasmids, cosmids, YACs, naked DNA, electroporation, liposomes, etc. The coding sequence of the polypeptides of the invention can be placed under the control of a strong constitutive or inducible promoter or promoter/enhancer to achieve expression, and preferably secretion, of the polypeptides of the invention. The engineered cells which express and preferably secrete the polypeptides of the invention can be introduced into the patient systemically, *e.g.*, in the circulation, or intraperitoneally.

Alternatively, the cells can be incorporated into a matrix and implanted in the body, *e.g.*, genetically engineered fibroblasts can be implanted as part of a skin graft; genetically engineered endothelial cells can be implanted as part of a lymphatic or vascular graft. (See, for example, Anderson et al. U.S. Patent No. 5,399,349; and

Mulligan & Wilson, U.S. Patent No. 5,460,959 each of which is incorporated by reference herein in its entirety).

When the cells to be administered are non-autologous or non-MHC compatible cells, they can be administered using well known techniques which prevent the development of a host immune response against the introduced cells. For example, the cells may be introduced in an encapsulated form which, while allowing for an exchange of components with the immediate extracellular environment, does not allow the introduced cells to be recognized by the host immune system.

Transgenic and "knock-out" animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying conditions and/or disorders associated with aberrant expression, and in screening for compounds effective in ameliorating such conditions and/or disorders.

### **Example 31: Production of an Antibody**

#### **a) Hybridoma Technology**

The antibodies of the present invention can be prepared by a variety of methods. (See, Current Protocols, Chapter 2.) As one example of such methods, cells expressing polypeptide(s) of the invention are administered to an animal to induce the production of sera containing polyclonal antibodies. In a preferred method, a preparation of polypeptide(s) of the invention is prepared and purified to render it substantially free of natural contaminants. Such a preparation is then introduced into an animal in order to produce polyclonal antisera of greater specific activity.

Monoclonal antibodies specific for polypeptide(s) of the invention are prepared using hybridoma technology. (Kohler et al., Nature 256:495 (1975); Kohler et al., Eur. J. Immunol. 6:511 (1976); Kohler et al., Eur. J. Immunol. 6:292 (1976); Hammerling et al., in: Monoclonal Antibodies and T-Cell Hybridomas, Elsevier, N.Y., pp. 563-681 (1981)). In general, an animal (preferably a mouse) is immunized with polypeptide(s) of the invention or, more preferably, with a secreted polypeptide-expressing cell. Such polypeptide-expressing cells are cultured in any suitable tissue culture medium, preferably in Earle's modified Eagle's medium supplemented with 10% fetal bovine serum

(inactivated at about 56°C), and supplemented with about 10 g/l of nonessential amino acids, about 1,000 U/ml of penicillin, and about 100 µg/ml of streptomycin.

The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line (SP2O), available from the ATCC. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands et al. (Gastroenterology 80:225-232 (1981)). The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the polypeptide(s) of the invention.

Alternatively, additional antibodies capable of binding to polypeptide(s) of the invention can be produced in a two-step procedure using anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is possible to obtain an antibody which binds to a second antibody. In accordance with this method, protein specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the protein-specific antibody can be blocked by polypeptide(s) of the invention. Such antibodies comprise anti-idiotypic antibodies to the protein-specific antibody and are used to immunize an animal to induce formation of further protein-specific antibodies.

For in vivo use of antibodies in humans, an antibody is "humanized". Such antibodies can be produced using genetic constructs derived from hybridoma cells producing the monoclonal antibodies described above. Methods for producing chimeric and humanized antibodies are known in the art and are discussed herein. (See, for review, Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Cabilly et al., U.S. Patent No. 4,816,567; Taniguchi et al., EP 171496; Morrison et al., EP 173494; Neuberger et al., WO 8601533; Robinson et al., WO 8702671; Boulianne et al., Nature 312:643 (1984); Neuberger et al., Nature 314:268 (1985).)

b) Isolation Of Antibody Fragments Directed Against  
Polypeptide(s) of the Present Invention From A Library Of scFvs

Naturally occurring V-genes isolated from human PBLs are constructed into a library of antibody fragments which contain reactivities against polypeptide(s) of the invention to which the donor may or may not have been exposed (see e.g., U.S. Patent 5,885,793 incorporated herein by reference in its entirety).

5           Rescue of the Library.

A library of scFvs is constructed from the RNA of human PBLs as described in PCT publication WO 92/01047. To rescue phage displaying antibody fragments, approximately 109 E. coli harboring the phagemid are used to inoculate 50 ml of 2xTY containing 1% glucose and 100 µg/ml of ampicillin (2xTY-AMP-GLU) and grown to an  
10   O.D. of 0.8 with shaking. Five ml of this culture is used to inoculate 50 ml of 2xTY-AMP-GLU, 2 x 10<sup>8</sup> TU of delta gene 3 helper (M13 delta gene III, see PCT publication WO 92/01047) are added and the culture incubated at 37°C for 45 minutes without shaking and then at 37°C for 45 minutes with shaking. The culture is centrifuged at 4000 r.p.m. for 10 min. and the pellet resuspended in 2 liters of 2xTY containing 100 µg/ml  
15   ampicillin and 50 µg/ml kanamycin and grown overnight. Phage are prepared as described in PCT publication WO 92/01047.

M13 delta gene III is prepared as follows: M13 delta gene III helper phage does not encode gene III protein, hence the phage(mid) displaying antibody fragments have a greater avidity of binding to antigen. Infectious M13 delta gene III particles are made by  
20   growing the helper phage in cells harboring a pUC19 derivative supplying the wild type gene III protein during phage morphogenesis. The culture is incubated for 1 hour at 37°C without shaking and then for a further hour at 37°C with shaking. Cells are spun down (IEC-Centra 8,400 r.p.m. for 10 min), resuspended in 300 ml 2xTY broth containing 100 µg ampicillin/ml and 25 µg kanamycin/ml (2xTY-AMP-KAN) and grown overnight,  
25   shaking at 37°C. Phage particles are purified and concentrated from the culture medium by two PEG-precipitations (Sambrook et al., 1990), resuspended in 2 ml PBS and passed through a 0.45 µm filter (Minisart NML; Sartorius) to give a final concentration of approximately 10<sup>13</sup> transducing units/ml (ampicillin-resistant clones).

          Panning of the Library.

30           Immunotubes (Nunc) are coated overnight in PBS with 4 ml of either 100 µg/ml or 10 µg/ml of a polypeptide of the present invention. Tubes are blocked with 2% Marvel-PBS for 2 hours at 37°C and then washed 3 times in PBS. Approximately 10<sup>13</sup> TU of

phage is applied to the tube and incubated for 30 minutes at room temperature tumbling on an over and under turntable and then left to stand for another 1.5 hours. Tubes are washed 10 times with PBS 0.1% Tween-20 and 10 times with PBS. Phage are eluted by adding 1 ml of 100 mM triethylamine and rotating 15 minutes on an under and over  
5 turntable after which the solution is immediately neutralized with 0.5 ml of 1.0M Tris-HCl, pH 7.4. Phage are then used to infect 10 ml of mid-log E. coli TG1 by incubating eluted phage with bacteria for 30 minutes at 37°C. The E. coli are then plated on TYE plates containing 1% glucose and 100 µg/ml ampicillin. The resulting bacterial library is then rescued with delta gene 3 helper phage as described above to prepare phage for a  
10 subsequent round of selection. This process is then repeated for a total of 4 rounds of affinity purification with tube-washing increased to 20 times with PBS, 0.1% Tween-20 and 20 times with PBS for rounds 3 and 4.

#### Characterization of Binders.

Eluted phage from the 3rd and 4th rounds of selection are used to infect E. coli HB  
15 2151 and soluble scFv is produced (Marks, et al., 1991) from single colonies for assay. ELISAs are performed with microtitre plates coated with either 10 pg/ml of the polypeptide of the present invention in 50 mM bicarbonate pH 9.6. Clones positive in ELISA are further characterized by PCR fingerprinting (see, e.g., PCT publication WO 92/01047) and then by sequencing. These ELISA positive clones may also be further  
20 characterized by techniques known in the art, such as, for example, epitope mapping, binding affinity, receptor signal transduction, ability to block or competitively inhibit antibody/antigen binding, and competitive agonistic or antagonistic activity.

#### **Example 32: Assays Detecting Stimulation or Inhibition of B cell Proliferation and Differentiation**

25

Generation of functional humoral immune responses requires both soluble and cognate signaling between B-lineage cells and their microenvironment. Signals may impart a positive stimulus that allows a B-lineage cell to continue its programmed development, or a negative stimulus that instructs the cell to arrest its current  
30 developmental pathway. To date, numerous stimulatory and inhibitory signals have been found to influence B cell responsiveness including IL-2, IL-4, IL-5, IL-6, IL-7, IL10, IL-13, IL-14 and IL-15. Interestingly, these signals are by themselves weak effectors but can,

in combination with various co-stimulatory proteins, induce activation, proliferation, differentiation, homing, tolerance and death among B cell populations.

One of the best studied classes of B-cell co-stimulatory proteins is the TNF-superfamily. Within this family CD40, CD27, and CD30 along with their respective ligands CD154, CD70, and CD153 have been found to regulate a variety of immune responses. Assays which allow for the detection and/or observation of the proliferation and differentiation of these B-cell populations and their precursors are valuable tools in determining the effects various proteins may have on these B-cell populations in terms of proliferation and differentiation. Listed below are two assays designed to allow for the detection of the differentiation, proliferation, or inhibition of B-cell populations and their precursors.

In Vitro Assay- Purified polypeptides of the invention, or truncated forms thereof, is assessed for its ability to induce activation, proliferation, differentiation or inhibition and/or death in B-cell populations and their precursors. The activity of the polypeptides of the invention on purified human tonsillar B cells, measured qualitatively over the dose range from 0.1 to 10,000 ng/mL, is assessed in a standard B-lymphocyte co-stimulation assay in which purified tonsillar B cells are cultured in the presence of either formalin-fixed *Staphylococcus aureus* Cowan I (SAC) or immobilized anti-human IgM antibody as the priming agent. Second signals such as IL-2 and IL-15 synergize with SAC and IgM crosslinking to elicit B cell proliferation as measured by tritiated-thymidine incorporation. Novel synergizing agents can be readily identified using this assay. The assay involves isolating human tonsillar B cells by magnetic bead (MACS) depletion of CD3-positive cells. The resulting cell population is greater than 95% B cells as assessed by expression of CD45R(B220).

Various dilutions of each sample are placed into individual wells of a 96-well plate to which are added  $10^5$  B-cells suspended in culture medium (RPMI 1640 containing 10% FBS,  $5 \times 10^{-5}$  M 2ME, 100U/ml penicillin, 10ug/ml streptomycin, and  $10^{-5}$  dilution of SAC) in a total volume of 150ul. Proliferation or inhibition is quantitated by a 20h pulse (1uCi/well) with  $^3$ H-thymidine (6.7 Ci/mM) beginning 72h post factor addition. The positive and negative controls are IL2 and medium respectively.

In Vivo Assay- BALB/c mice are injected (i.p.) twice per day with buffer only, or 2 mg/Kg of a polypeptide of the invention, or truncated forms thereof. Mice receive this

treatment for 4 consecutive days, at which time they are sacrificed and various tissues and serum collected for analyses. Comparison of H&E sections from normal spleens and spleens treated with polypeptides of the invention identify the results of the activity of the polypeptides on spleen cells, such as the diffusion of peri-arterial lymphatic sheaths, and/or significant increases in the nucleated cellularity of the red pulp regions, which may indicate the activation of the differentiation and proliferation of B-cell populations. Immunohistochemical studies using a B cell marker, anti-CD45R(B220), are used to determine whether any physiological changes to splenic cells, such as splenic disorganization, are due to increased B-cell representation within loosely defined B-cell zones that infiltrate established T-cell regions.

Flow cytometric analyses of the spleens from mice treated with polypeptide is used to indicate whether the polypeptide specifically increases the proportion of ThB+, CD45R(B220)dull B cells over that which is observed in control mice.

Likewise, a predicted consequence of increased mature B-cell representation in vivo is a relative increase in serum Ig titers. Accordingly, serum IgM and IgA levels are compared between buffer and polypeptide-treated mice.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides of the invention (e.g., gene therapy), agonists, and/or antagonists of polynucleotides or polypeptides of the invention.

### **Example 33: T Cell Proliferation Assay**

A CD3-induced proliferation assay is performed on PBMCs and is measured by the uptake of <sup>3</sup>H-thymidine. The assay is performed as follows. Ninety-six well plates are coated with 100 µl/well of mAb to CD3 (HIT3a, Pharmingen) or isotype-matched control mAb (B33.1) overnight at 4 degrees C (1 µg/ml in .05M bicarbonate buffer, pH 9.5), then washed three times with PBS. PBMC are isolated by F/H gradient centrifugation from human peripheral blood and added to quadruplicate wells (5 x 10<sup>4</sup>/well) of mAb coated plates in RPMI containing 10% FCS and P/S in the presence of varying concentrations of polypeptides of the invention (total volume 200 ul). Relevant protein buffer and medium alone are controls. After 48 hr. culture at 37 degrees C, plates are spun for 2 min. at 1000

rpm and 100 µl of supernatant is removed and stored -20 degrees C for measurement of IL-2 (or other cytokines) if effect on proliferation is observed. Wells are supplemented with 100 ul of medium containing 0.5 uCi of <sup>3</sup>H-thymidine and cultured at 37 degrees C for 18-24 hr. Wells are harvested and incorporation of <sup>3</sup>H-thymidine used as a measure of proliferation. Anti-CD3 alone is the positive control for proliferation. IL-2 (100 U/ml) is also used as a control which enhances proliferation. Control antibody which does not induce proliferation of T cells is used as the negative controls for the effects of polypeptides of the invention.

The studies described in this example tested activity of polypeptides of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides of the invention (e.g., gene therapy), agonists, and/or antagonists of polynucleotides or polypeptides of the invention.

**Example 34: Effect of Polypeptides of the Invention on the Expression of MHC Class II, Costimulatory and Adhesion Molecules and Cell Differentiation of Monocytes and Monocyte-Derived Human Dendritic Cells**

Dendritic cells are generated by the expansion of proliferating precursors found in the peripheral blood: adherent PBMC or elutriated monocytic fractions are cultured for 7-10 days with GM-CSF (50 ng/ml) and IL-4 (20 ng/ml). These dendritic cells have the characteristic phenotype of immature cells (expression of CD1, CD80, CD86, CD40 and MHC class II antigens). Treatment with activating factors, such as TNF-α, causes a rapid change in surface phenotype (increased expression of MHC class I and II, costimulatory and adhesion molecules, downregulation of FCγRII, upregulation of CD83). These changes correlate with increased antigen-presenting capacity and with functional maturation of the dendritic cells.

FACS analysis of surface antigens is performed as follows. Cells are treated 1-3 days with increasing concentrations of polypeptides of the invention or LPS (positive control), washed with PBS containing 1% BSA and 0.02 mM sodium azide, and then incubated with 1:20 dilution of appropriate FITC- or PE-labeled monoclonal antibodies for 30 minutes at 4 degrees C. After an additional wash, the labeled cells are analyzed by flow cytometry on a FACScan (Becton Dickinson).



Effect on the production of cytokines. Cytokines generated by dendritic cells, in particular IL-12, are important in the initiation of T-cell dependent immune responses. IL-12 strongly influences the development of Th1 helper T-cell immune response, and induces cytotoxic T and NK cell function. An ELISA is used to measure the IL-12 release as follows. Dendritic cells ( $10^6$ /ml) are treated with increasing concentrations of polypeptides of the invention for 24 hours. LPS (100 ng/ml) is added to the cell culture as positive control. Supernatants from the cell cultures are then collected and analyzed for IL-12 content using commercial ELISA kit (e.g., R & D Systems (Minneapolis, MN)). The standard protocols provided with the kits are used.

Effect on the expression of MHC Class II, costimulatory and adhesion molecules. Three major families of cell surface antigens can be identified on monocytes: adhesion molecules, molecules involved in antigen presentation, and Fc receptor. Modulation of the expression of MHC class II antigens and other costimulatory molecules, such as B7 and ICAM-1, may result in changes in the antigen presenting capacity of monocytes and ability to induce T cell activation. Increase expression of Fc receptors may correlate with improved monocyte cytotoxic activity, cytokine release and phagocytosis.

FACS analysis is used to examine the surface antigens as follows. Monocytes are treated 1-5 days with increasing concentrations of polypeptides of the invention or LPS (positive control), washed with PBS containing 1% BSA and 0.02 mM sodium azide, and then incubated with 1:20 dilution of appropriate FITC- or PE-labeled monoclonal antibodies for 30 minutes at 4 degreesC. After an additional wash, the labeled cells are analyzed by flow cytometry on a FACScan (Becton Dickinson).

Monocyte activation and/or increased survival. Assays for molecules that activate (or alternatively, inactivate) monocytes and/or increase monocyte survival (or alternatively, decrease monocyte survival) are known in the art and may routinely be applied to determine whether a molecule of the invention functions as an inhibitor or activator of monocytes. Polypeptides, agonists, or antagonists of the invention can be screened using the three assays described below. For each of these assays, Peripheral blood mononuclear cells (PBMC) are purified from single donor leukopacks (American Red Cross, Baltimore, MD) by centrifugation through a Histopaque

gradient (Sigma). Monocytes are isolated from PBMC by counterflow centrifugal elutriation.

Monocyte Survival Assay. Human peripheral blood monocytes progressively lose viability when cultured in absence of serum or other stimuli. Their death results from internally regulated process (apoptosis). Addition to the culture of activating factors, such as TNF-alpha dramatically improves cell survival and prevents DNA fragmentation. Propidium iodide (PI) staining is used to measure apoptosis as follows. Monocytes are cultured for 48 hours in polypropylene tubes in serum-free medium (positive control), in the presence of 100 ng/ml TNF-alpha (negative control), and in the presence of varying concentrations of the compound to be tested. Cells are suspended at a concentration of  $2 \times 10^6$ /ml in PBS containing PI at a final concentration of 5  $\mu$ g/ml, and then incubated at room temperature for 5 minutes before FACSscan analysis. PI uptake has been demonstrated to correlate with DNA fragmentation in this experimental paradigm.

Effect on cytokine release. An important function of monocytes/macrophages is their regulatory activity on other cellular populations of the immune system through the release of cytokines after stimulation. An ELISA to measure cytokine release is performed as follows. Human monocytes are incubated at a density of  $5 \times 10^5$  cells/ml with increasing concentrations of the a polypeptide of the invention and under the same conditions, but in the absence of the polypeptide. For IL-12 production, the cells are primed overnight with IFN (100 U/ml) in presence of a polypeptide of the invention. LPS (10 ng/ml) is then added. Conditioned media are collected after 24h and kept frozen until use. Measurement of TNF-alpha, IL-10, MCP-1 and IL-8 is then performed using a commercially available ELISA kit (e.g, R & D Systems (Minneapolis, MN)) and applying the standard protocols provided with the kit.

Oxidative burst. Purified monocytes are plated in 96-w plate at  $2 \times 10^5$  cell/well. Increasing concentrations of polypeptides of the invention are added to the wells in a total volume of 0.2 ml culture medium (RPMI 1640 + 10% FCS, glutamine and antibiotics). After 3 days incubation, the plates are centrifuged and the medium is removed from the wells. To the macrophage monolayers, 0.2 ml per well of phenol red solution (140 mM NaCl, 10 mM potassium phosphate buffer pH 7.0, 5.5 mM dextrose, 0.56 mM phenol red and 19 U/ml of HRPO) is added, together with the

stimulant (200 nM PMA). The plates are incubated at 37°C for 2 hours and the reaction is stopped by adding 20 µl 1N NaOH per well. The absorbance is read at 610 nm. To calculate the amount of H<sub>2</sub>O<sub>2</sub> produced by the macrophages, a standard curve of a H<sub>2</sub>O<sub>2</sub> solution of known molarity is performed for each experiment.

- 5           The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polypeptides, polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

10       **Example 35: Biological Effects of Polypeptides of the Invention**

Astrocyte and Neuronal Assays:

- Recombinant polypeptides of the invention, expressed in *Escherichia coli* and purified as described above, can be tested for activity in promoting the survival, neurite outgrowth, or phenotypic differentiation of cortical neuronal cells and for inducing the proliferation of glial fibrillary acidic protein immunopositive cells, astrocytes. The selection of cortical cells for the bioassay is based on the prevalent expression of FGF-1 and FGF-2 in cortical structures and on the previously reported enhancement of cortical neuronal survival resulting from FGF-2 treatment. A thymidine incorporation assay, for example, can be used to elucidate a polypeptide of the invention's activity on these cells.

- 20           Moreover, previous reports describing the biological effects of FGF-2 (basic FGF) on cortical or hippocampal neurons *in vitro* have demonstrated increases in both neuron survival and neurite outgrowth (Walicke et al., "Fibroblast growth factor promotes survival of dissociated hippocampal neurons and enhances neurite extension." *Proc. Natl. Acad. Sci. USA* 83:3012-3016. (1986), assay herein incorporated by reference in its entirety). However, reports from experiments done on PC-12 cells suggest that these two responses are not necessarily synonymous and may depend on not only which FGF is being tested but also on which receptor(s) are expressed on the target cells. Using the primary cortical neuronal culture paradigm, the ability of a polypeptide of the invention to induce neurite outgrowth can be compared to the response achieved with FGF-2 using, for example, a thymidine incorporation assay.
- 30

#### Fibroblast and endothelial cell assays

Human lung fibroblasts are obtained from Clonetics (San Diego, CA) and maintained in growth media from Clonetics. Dermal microvascular endothelial cells are obtained from Cell Applications (San Diego, CA). For proliferation assays, the human  
5 lung fibroblasts and dermal microvascular endothelial cells can be cultured at 5,000 cells/well in a 96-well plate for one day in growth medium. The cells are then incubated for one day in 0.1% BSA basal medium. After replacing the medium with fresh 0.1% BSA medium, the cells are incubated with the test proteins for 3 days. Alamar Blue (Alamar Biosciences, Sacramento, CA) is added to each well to a final concentration of 10%. The  
10 cells are incubated for 4 hr. Cell viability is measured by reading in a CytoFluor fluorescence reader. For the PGE<sub>2</sub> assays, the human lung fibroblasts are cultured at 5,000 cells/well in a 96-well plate for one day. After a medium change to 0.1% BSA basal medium, the cells are incubated with FGF-2 or polypeptides of the invention with or without IL-1 $\alpha$  for 24 hours. The supernatants are collected and assayed for PGE<sub>2</sub> by EIA  
15 kit (Cayman, Ann Arbor, MI). For the IL-6 assays, the human lung fibroblasts are cultured at 5,000 cells/well in a 96-well plate for one day. After a medium change to 0.1% BSA basal medium, the cells are incubated with FGF-2 or with or without polypeptides of the invention IL-1 $\alpha$  for 24 hours. The supernatants are collected and assayed for IL-6 by ELISA kit (Endogen, Cambridge, MA).

20 Human lung fibroblasts are cultured with FGF-2 or polypeptides of the invention for 3 days in basal medium before the addition of Alamar Blue to assess effects on growth of the fibroblasts. FGF-2 should show a stimulation at 10 - 2500 ng/ml which can be used to compare stimulation with polypeptides of the invention.

#### Parkinson Models.

25 The loss of motor function in Parkinson's disease is attributed to a deficiency of striatal dopamine resulting from the degeneration of the nigrostriatal dopaminergic projection neurons. An animal model for Parkinson's that has been extensively characterized involves the systemic administration of 1-methyl-4 phenyl 1,2,3,6-tetrahydropyridine (MPTP). In the CNS, MPTP is taken-up by astrocytes and catabolized  
30 by monoamine oxidase B to 1-methyl-4-phenyl pyridine (MPP<sup>+</sup>) and released.

Subsequently, MPP<sup>+</sup> is actively accumulated in dopaminergic neurons by the high-affinity reuptake transporter for dopamine. MPP<sup>+</sup> is then concentrated in mitochondria by the electrochemical gradient and selectively inhibits nicotinamide adenine disphosphate: ubiquinone oxidoreductionase (complex I), thereby interfering with electron transport and  
5 eventually generating oxygen radicals.

It has been demonstrated in tissue culture paradigms that FGF-2 (basic FGF) has trophic activity towards nigral dopaminergic neurons (Ferrari et al., Dev. Biol. 1989). Recently, Dr. Unsicker's group has demonstrated that administering FGF-2 in gel foam implants in the striatum results in the near complete protection of nigral dopaminergic  
10 neurons from the toxicity associated with MPTP exposure (Otto and Unsicker, J. Neuroscience, 1990).

Based on the data with FGF-2, polypeptides of the invention can be evaluated to determine whether it has an action similar to that of FGF-2 in enhancing dopaminergic neuronal survival *in vitro* and it can also be tested *in vivo* for protection of dopaminergic  
15 neurons in the striatum from the damage associated with MPTP treatment. The potential effect of a polypeptide of the invention is first examined *in vitro* in a dopaminergic neuronal cell culture paradigm. The cultures are prepared by dissecting the midbrain floor plate from gestation day 14 Wistar rat embryos. The tissue is dissociated with trypsin and seeded at a density of 200,000 cells/cm<sup>2</sup> on polyorthinine-laminin coated glass coverslips.  
20 The cells are maintained in Dulbecco's Modified Eagle's medium and F12 medium containing hormonal supplements (N1). The cultures are fixed with paraformaldehyde after 8 days *in vitro* and are processed for tyrosine hydroxylase, a specific marker for dopaminergic neurons, immunohistochemical staining. Dissociated cell cultures are prepared from embryonic rats. The culture medium is changed every third day and the  
25 factors are also added at that time.

Since the dopaminergic neurons are isolated from animals at gestation day 14, a developmental time which is past the stage when the dopaminergic precursor cells are proliferating, an increase in the number of tyrosine hydroxylase immunopositive neurons would represent an increase in the number of dopaminergic neurons surviving *in vitro*.  
30 Therefore, if a polypeptide of the invention acts to prolong the survival of dopaminergic neurons, it would suggest that the polypeptide may be involved in Parkinson's Disease.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

5

**Example 36: The Effect of Polypeptides of the Invention on the Growth of Vascular Endothelial Cells**

On day 1, human umbilical vein endothelial cells (HUVEC) are seeded at  $2-5 \times 10^4$  cells/35 mm dish density in M199 medium containing 4% fetal bovine serum (FBS), 16 units/ml heparin, and 50 units/ml endothelial cell growth supplements (ECGS, Biotechnology, Inc.). On day 2, the medium is replaced with M199 containing 10% FBS, 8 units/ml heparin. A polypeptide having the amino acid sequence of SEQ ID NO:Y, and positive controls, such as VEGF and basic FGF (bFGF) are added, at varying concentrations. On days 4 and 6, the medium is replaced. On day 8, cell number is determined with a Coulter Counter.

15

An increase in the number of HUVEC cells indicates that the polypeptide of the invention may proliferate vascular endothelial cells.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

20

**Example 37: Stimulatory Effect of Polypeptides of the Invention on the Proliferation of Vascular Endothelial Cells**

For evaluation of mitogenic activity of growth factors, the colorimetric MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)2H-tetrazolium) assay with the electron coupling reagent PMS (phenazine methosulfate) was performed (CellTiter 96 AQ, Promega). Cells are seeded in a 96-well plate (5,000 cells/well) in 0.1 mL serum-supplemented medium and are allowed to attach overnight. After serum-starvation for 12 hours in 0.5% FBS, conditions (bFGF, VEGF<sub>165</sub> or a polypeptide of the invention in 0.5% FBS) with or without Heparin (8 U/ml) are added to wells for 48 hours. 20 mg of MTS/PMS mixture (1:0.05) are added per well and allowed

25

30

to incubate for 1 hour at 37°C before measuring the absorbance at 490 nm in an ELISA plate reader. Background absorbance from control wells (some media, no cells) is subtracted, and seven wells are performed in parallel for each condition. See, Leak *et al. In Vitro Cell. Dev. Biol.* 30A:512-518 (1994).

- 5           The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

10       **Example 38: Inhibition of PDGF-induced Vascular Smooth Muscle Cell Proliferation Stimulatory Effect**

- HAoSMC proliferation can be measured, for example, by BrdUrd incorporation. Briefly, subconfluent, quiescent cells grown on the 4-chamber slides are transfected with CRP or FITC-labeled AT2-3LP. Then, the cells are pulsed with 10% calf serum and 6  
15   mg/ml BrdUrd. After 24 h, immunocytochemistry is performed by using BrdUrd Staining Kit (Zymed Laboratories). In brief, the cells are incubated with the biotinylated mouse anti-BrdUrd antibody at 4 degrees C for 2 h after being exposed to denaturing solution and then incubated with the streptavidin-peroxidase and diaminobenzidine. After  
counterstaining with hematoxylin, the cells are mounted for microscopic examination, and  
20   the BrdUrd-positive cells are counted. The BrdUrd index is calculated as a percent of the BrdUrd-positive cells to the total cell number. In addition, the simultaneous detection of the BrdUrd staining (nucleus) and the FITC uptake (cytoplasm) is performed for individual cells by the concomitant use of bright field illumination and dark field-UV  
fluorescent illumination. See, Hayashida et al., J. Biol. Chem. 6:271(36):21985-21992  
25   (1996).

- The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

**Example 39: Stimulation of Endothelial Migration**

This example will be used to explore the possibility that a polypeptide of the invention may stimulate lymphatic endothelial cell migration.

Endothelial cell migration assays are performed using a 48 well microchemotaxis chamber (Neuroprobe Inc., Cabin John, MD; Falk, W., et al., J. Immunological Methods 1980;33:239-247). Polyvinylpyrrolidone-free polycarbonate filters with a pore size of 8  $\mu$ m (Nucleopore Corp. Cambridge, MA) are coated with 0.1% gelatin for at least 6 hours at room temperature and dried under sterile air. Test substances are diluted to appropriate concentrations in M199 supplemented with 0.25% bovine serum albumin (BSA), and 25  $\mu$ l of the final dilution is placed in the lower chamber of the modified Boyden apparatus. Subconfluent, early passage (2-6) HUVEC or BMEC cultures are washed and trypsinized for the minimum time required to achieve cell detachment. After placing the filter between lower and upper chamber,  $2.5 \times 10^5$  cells suspended in 50  $\mu$ l M199 containing 1% FBS are seeded in the upper compartment. The apparatus is then incubated for 5 hours at 37°C in a humidified chamber with 5% CO<sub>2</sub> to allow cell migration. After the incubation period, the filter is removed and the upper side of the filter with the non-migrated cells is scraped with a rubber policeman. The filters are fixed with methanol and stained with a Giemsa solution (Diff-Quick, Baxter, McGraw Park, IL). Migration is quantified by counting cells of three random high-power fields (40x) in each well, and all groups are performed in quadruplicate.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

**Example 40: Stimulation of Nitric Oxide Production by Endothelial Cells**


Nitric oxide released by the vascular endothelium is believed to be a mediator of vascular endothelium relaxation. Thus, activity of a polypeptide of the invention can be assayed by determining nitric oxide production by endothelial cells in response to the polypeptide.

Nitric oxide is measured in 96-well plates of confluent microvascular endothelial cells after 24 hours starvation and a subsequent 4 hr exposure to various levels of a



positive control (such as VEGF-1) and the polypeptide of the invention. Nitric oxide in the medium is determined by use of the Griess reagent to measure total nitrite after reduction of nitric oxide-derived nitrate by nitrate reductase. The effect of the polypeptide of the invention on nitric oxide release is examined on HUVEC.

- 5 Briefly, NO release from cultured HUVEC monolayer is measured with a NO-specific polarographic electrode connected to a NO meter (Iso-NO, World Precision Instruments Inc.) (1049). Calibration of the NO elements is performed according to the following equation:



- 10 The standard calibration curve is obtained by adding graded concentrations of  $\text{KNO}_2$  (0, 5, 10, 25, 50, 100, 250, and 500 nmol/L) into the calibration solution containing KI and  $\text{H}_2\text{SO}_4$ . The specificity of the Iso-NO electrode to NO is previously determined by measurement of NO from authentic NO gas (1050). The culture medium is removed and HUVECs are washed twice with Dulbecco's phosphate buffered saline. The cells are then  
15 bathed in 5 ml of filtered Krebs-Henseleit solution in 6-well plates, and the cell plates are kept on a slide warmer (Lab Line Instruments Inc.) To maintain the temperature at 37°C. The NO sensor probe is inserted vertically into the wells, keeping the tip of the electrode 2 mm under the surface of the solution, before addition of the different conditions. S-nitroso acetyl penicillamin (SNAP) is used as a positive control. The amount of  
20 released NO is expressed as picomoles per  $1 \times 10^6$  endothelial cells. All values reported are means of four to six measurements in each group (number of cell culture wells). See, Leak *et al. Biochem. and Biophys. Res. Comm.* 217:96-105 (1995).

- The studies described in this example tested activity of polypeptides of the invention. However, one skilled in the art could easily modify the exemplified studies to  
25 test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

#### **Example 41: Effect of Polypeptides of the Invention on Cord Formation in Angiogenesis**

- 30 Another step in angiogenesis is cord formation, marked by differentiation of endothelial cells. This bioassay measures the ability of microvascular endothelial cells to form capillary-like structures (hollow structures) when cultured *in vitro*.

CADMEC (microvascular endothelial cells) are purchased from Cell Applications, Inc. as proliferating (passage 2) cells and are cultured in Cell Applications' CADMEC Growth Medium and used at passage 5. For the *in vitro* angiogenesis assay, the wells of a 48-well cell culture plate are coated with Cell Applications' Attachment Factor Medium (200 ml/well) for 30 min. at 37°C. CADMEC are seeded onto the coated wells at 7,500 cells/well and cultured overnight in Growth Medium. The Growth Medium is then replaced with 300 mg Cell Applications' Chord Formation Medium containing control buffer or a polypeptide of the invention (0.1 to 100 ng/ml) and the cells are cultured for an additional 48 hr. The numbers and lengths of the capillary-like chords are quantitated through use of the Boeckeler VIA-170 video image analyzer. All assays are done in triplicate.

Commercial (R&D) VEGF (50 ng/ml) is used as a positive control. b-esteradiol (1 ng/ml) is used as a negative control. The appropriate buffer (without protein) is also utilized as a control.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

#### **Example 42: Angiogenic Effect on Chick Chorioallantoic Membrane**

Chick chorioallantoic membrane (CAM) is a well-established system to examine angiogenesis. Blood vessel formation on CAM is easily visible and quantifiable. The ability of polypeptides of the invention to stimulate angiogenesis in CAM can be examined.

Fertilized eggs of the White Leghorn chick (*Gallus gallus*) and the Japanese quail (*Coturnix coturnix*) are incubated at 37.8°C and 80% humidity. Differentiated CAM of 16-day-old chick and 13-day-old quail embryos is studied with the following methods.

On Day 4 of development, a window is made into the egg shell of chick eggs. The embryos are checked for normal development and the eggs sealed with cellotape. They are further incubated until Day 13. Thermanox coverslips (Nunc, Naperville, IL) are cut into disks of about 5 mm in diameter. Sterile and salt-free growth factors are dissolved in distilled water and about 3.3 mg/ 5 ml are pipetted on the disks. After air-drying, the

inverted disks are applied on CAM. After 3 days, the specimens are fixed in 3% glutaraldehyde and 2% formaldehyde and rinsed in 0.12 M sodium cacodylate buffer. They are photographed with a stereo microscope [Wild M8] and embedded for semi- and ultrathin sectioning as described above. Controls are performed with carrier disks alone.

- 5           The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

10    **Example 43: Angiogenesis Assay Using a Matrigel Implant in Mouse**

- In vivo* angiogenesis assay of a polypeptide of the invention measures the ability of an existing capillary network to form new vessels in an implanted capsule of murine extracellular matrix material (Matrigel). The protein is mixed with the liquid Matrigel at 4 degree C and the mixture is then injected subcutaneously in mice where it solidifies. After  
15   7 days, the solid “plug” of Matrigel is removed and examined for the presence of new blood vessels. Matrigel is purchased from Becton Dickinson Labware/Collaborative Biomedical Products.

- When thawed at 4 degree C the Matrigel material is a liquid. The Matrigel is mixed with a polypeptide of the invention at 150 ng/ml at 4 degrees C and drawn into cold  
20   3 ml syringes. Female C57Bl/6 mice approximately 8 weeks old are injected with the mixture of Matrigel and experimental protein at 2 sites at the midventral aspect of the abdomen (0.5 ml/site). After 7 days, the mice are sacrificed by cervical dislocation, the Matrigel plugs are removed and cleaned (i.e., all clinging membranes and fibrous tissue is removed). Replicate whole plugs are fixed in neutral buffered 10% formaldehyde,  
25   embedded in paraffin and used to produce sections for histological examination after staining with Masson’s Trichrome. Cross sections from 3 different regions of each plug are processed. Selected sections are stained for the presence of vWF. The positive control for this assay is bovine basic FGF (150 ng/ml). Matrigel alone is used to determine basal levels of angiogenesis.

- 30           The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to

test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

**Example 44: Rescue of Ischemia in Rabbit Lower Limb Model**

5           To study the in vivo effects of polynucleotides and polypeptides of the invention on ischemia, a rabbit hindlimb ischemia model is created by surgical removal of one femoral arteries as described previously (Takeshita *et al.*, *Am J. Pathol* 147:1649-1660 (1995)). The excision of the femoral artery results in retrograde propagation of thrombus and occlusion of the external iliac artery. Consequently, blood flow to the ischemic limb  
10 is dependent upon collateral vessels originating from the internal iliac artery (Takeshita *et al.* *Am J. Pathol* 147:1649-1660 (1995)). An interval of 10 days is allowed for post-operative recovery of rabbits and development of endogenous collateral vessels. At 10 day post-operatively (day 0), after performing a baseline angiogram, the internal iliac artery of the ischemic limb is transfected with 500 mg naked expression plasmid  
15 containing a polynucleotide of the invention by arterial gene transfer technology using a hydrogel-coated balloon catheter as described (Riessen *et al.* *Hum Gene Ther.* 4:749-758 (1993); Leclerc *et al.* *J. Clin. Invest.* 90: 936-944 (1992)). When a polypeptide of the invention is used in the treatment, a single bolus of 500 mg polypeptide of the invention or control is delivered into the internal iliac artery of the ischemic limb over a period of 1  
20 min. through an infusion catheter. On day 30, various parameters are measured in these rabbits: (a) BP ratio - The blood pressure ratio of systolic pressure of the ischemic limb to that of normal limb; (b) Blood Flow and Flow Reserve - Resting FL: the blood flow during undilated condition and Max FL: the blood flow during fully dilated condition (also an indirect measure of the blood vessel amount) and Flow Reserve is reflected by the ratio  
25 of max FL: resting FL; (c) Angiographic Score - This is measured by the angiogram of collateral vessels. A score is determined by the percentage of circles in an overlaying grid that with crossing opacified arteries divided by the total number in the rabbit thigh; (d) Capillary density - The number of collateral capillaries determined in light microscopic sections taken from hindlimbs.

30           The studies described in this example tested activity of polynucleotides and polypeptides of the invention. However, one skilled in the art could easily modify the exemplified studies to test the agonists, and/or antagonists of the invention.

**Example 45: Effect of Polypeptides of the Invention on Vasodilation**

Since dilation of vascular endothelium is important in reducing blood pressure, the ability of polypeptides of the invention to affect the blood pressure in spontaneously hypertensive rats (SHR) is examined. Increasing doses (0, 10, 30, 100, 300, and 900 mg/kg) of the polypeptides of the invention are administered to 13-14 week old spontaneously hypertensive rats (SHR). Data are expressed as the mean +/- SEM. Statistical analysis are performed with a paired t-test and statistical significance is defined as  $p < 0.05$  vs. the response to buffer alone.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

**Example 46: Rat Ischemic Skin Flap Model**

The evaluation parameters include skin blood flow, skin temperature, and factor VIII immunohistochemistry or endothelial alkaline phosphatase reaction. Expression of polypeptides of the invention, during the skin ischemia, is studied using in situ hybridization.

The study in this model is divided into three parts as follows:

- a) Ischemic skin
- b) Ischemic skin wounds
- c) Normal wounds

The experimental protocol includes:

- a) Raising a 3x4 cm, single pedicle full-thickness random skin flap (myocutaneous flap over the lower back of the animal).
- b) An excisional wounding (4-6 mm in diameter) in the ischemic skin (skin-flap).
- c) Topical treatment with a polypeptide of the invention of the excisional wounds (day 0, 1, 2, 3, 4 post-wounding) at the following various dosage ranges: 1mg to 100 mg.
- d) Harvesting the wound tissues at day 3, 5, 7, 10, 14 and 21 post-wounding for histological, immunohistochemical, and in situ studies.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

5

**Example 47: Peripheral Arterial Disease Model**

Angiogenic therapy using a polypeptide of the invention is a novel therapeutic strategy to obtain restoration of blood flow around the ischemia in case of peripheral arterial diseases. The experimental protocol includes:

- 10           a) One side of the femoral artery is ligated to create ischemic muscle of the hindlimb, the other side of hindlimb serves as a control.
- b) a polypeptide of the invention, in a dosage range of 20 mg - 500 mg, is delivered intravenously and/or intramuscularly 3 times (perhaps more) per week for 2-3 weeks.
- 15           c) The ischemic muscle tissue is collected after ligation of the femoral artery at 1, 2, and 3 weeks for the analysis of expression of a polypeptide of the invention and histology. Biopsy is also performed on the other side of normal muscle of the contralateral hindlimb.

20           The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

**Example 48: Ischemic Myocardial Disease Model**

25           A polypeptide of the invention is evaluated as a potent mitogen capable of stimulating the development of collateral vessels, and restructuring new vessels after coronary artery occlusion. Alteration of expression of the polypeptide is investigated in situ. The experimental protocol includes:

- 30           a) The heart is exposed through a left-side thoracotomy in the rat. Immediately, the left coronary artery is occluded with a thin suture (6-0) and the thorax is closed.

b) a polypeptide of the invention, in a dosage range of 20 mg - 500 mg, is delivered intravenously and/or intramuscularly 3 times (perhaps more) per week for 2-4 weeks.

5 c) Thirty days after the surgery, the heart is removed and cross-sectioned for morphometric and in situ analyzes.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

10

#### **Example 49: Rat Corneal Wound Healing Model**

This animal model shows the effect of a polypeptide of the invention on neovascularization. The experimental protocol includes:

- 15 a) Making a 1-1.5 mm long incision from the center of cornea into the stromal layer.
- b) Inserting a spatula below the lip of the incision facing the outer corner of the eye.
- c) Making a pocket (its base is 1-1.5 mm from the edge of the eye).
- d) Positioning a pellet, containing 50ng- 5ug of a polypeptide of the invention,
- 20 within the pocket.
- e) Treatment with a polypeptide of the invention can also be applied topically to the corneal wounds in a dosage range of 20mg - 500mg (daily treatment for five days).

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to

25 test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

#### **Example 50: Diabetic Mouse and Glucocorticoid-Impaired Wound Healing Models**

30 A. *Diabetic db+/db+ Mouse Model.*

To demonstrate that a polypeptide of the invention accelerates the healing process, the genetically diabetic mouse model of wound healing is used. The full thickness wound

healing model in the db+/db+ mouse is a well characterized, clinically relevant and reproducible model of impaired wound healing. Healing of the diabetic wound is dependent on formation of granulation tissue and re-epithelialization rather than contraction (Gartner, M.H. *et al.*, *J. Surg. Res.* 52:389 (1992); Greenhalgh, D.G. *et al.*,  
5 *Am. J. Pathol.* 136:1235 (1990)).

The diabetic animals have many of the characteristic features observed in Type II diabetes mellitus. Homozygous (db+/db+) mice are obese in comparison to their normal heterozygous (db+/+m) littermates. Mutant diabetic (db+/db+) mice have a single autosomal recessive mutation on chromosome 4 (db+) (Coleman *et al.* *Proc. Natl. Acad. Sci. USA* 77:283-293 (1982)). Animals show polyphagia, polydipsia and polyuria.  
10 Mutant diabetic mice (db+/db+) have elevated blood glucose, increased or normal insulin levels, and suppressed cell-mediated immunity (Mandel *et al.*, *J. Immunol.* 120:1375 (1978); Debray-Sachs, M. *et al.*, *Clin. Exp. Immunol.* 51(1):1-7 (1983); Leiter *et al.*, *Am. J. of Pathol.* 114:46-55 (1985)). Peripheral neuropathy, myocardial complications, and  
15 microvascular lesions, basement membrane thickening and glomerular filtration abnormalities have been described in these animals (Norido, F. *et al.*, *Exp. Neurol.* 83(2):221-232 (1984); Robertson *et al.*, *Diabetes* 29(1):60-67 (1980); Giacomelli *et al.*, *Lab Invest.* 40(4):460-473 (1979); Coleman, D.L., *Diabetes* 31 (Suppl):1-6 (1982)). These  
20 homozygous diabetic mice develop hyperglycemia that is resistant to insulin analogous to human type II diabetes (Mandel *et al.*, *J. Immunol.* 120:1375-1377 (1978)).

The characteristics observed in these animals suggests that healing in this model may be similar to the healing observed in human diabetes (Greenhalgh, *et al.*, *Am. J. of Pathol.* 136:1235-1246 (1990)).

Genetically diabetic female C57BL/KsJ (db+/db+) mice and their non-diabetic  
25 (db+/+m) heterozygous littermates are used in this study (Jackson Laboratories). The animals are purchased at 6 weeks of age and are 8 weeks old at the beginning of the study. Animals are individually housed and received food and water ad libitum. All manipulations are performed using aseptic techniques. The experiments are conducted according to the rules and guidelines of Human Genome Sciences, Inc. Institutional  
30 Animal Care and Use Committee and the Guidelines for the Care and Use of Laboratory Animals.



Wounding protocol is performed according to previously reported methods (Tsuboi, R. and Rifkin, D.B., *J. Exp. Med.* 172:245-251 (1990)). Briefly, on the day of wounding, animals are anesthetized with an intraperitoneal injection of Avertin (0.01 mg/mL), 2,2,2-tribromoethanol and 2-methyl-2-butanol dissolved in deionized water. The dorsal region of the animal is shaved and the skin washed with 70% ethanol solution and iodine. The surgical area is dried with sterile gauze prior to wounding. An 8 mm full-thickness wound is then created using a Keyes tissue punch. Immediately following wounding, the surrounding skin is gently stretched to eliminate wound expansion. The wounds are left open for the duration of the experiment. Application of the treatment is given topically for 5 consecutive days commencing on the day of wounding. Prior to treatment, wounds are gently cleansed with sterile saline and gauze sponges.

Wounds are visually examined and photographed at a fixed distance at the day of surgery and at two day intervals thereafter. Wound closure is determined by daily measurement on days 1-5 and on day 8. Wounds are measured horizontally and vertically using a calibrated Jameson caliper. Wounds are considered healed if granulation tissue is no longer visible and the wound is covered by a continuous epithelium.

A polypeptide of the invention is administered using at a range different doses, from 4mg to 500mg per wound per day for 8 days in vehicle. Vehicle control groups received 50mL of vehicle solution.

Animals are euthanized on day 8 with an intraperitoneal injection of sodium pentobarbital (300mg/kg). The wounds and surrounding skin are then harvested for histology and immunohistochemistry. Tissue specimens are placed in 10% neutral buffered formalin in tissue cassettes between biopsy sponges for further processing.

Three groups of 10 animals each (5 diabetic and 5 non-diabetic controls) are evaluated: 1) Vehicle placebo control, 2) untreated group, and 3) treated group.

Wound closure is analyzed by measuring the area in the vertical and horizontal axis and obtaining the total square area of the wound. Contraction is then estimated by establishing the differences between the initial wound area (day 0) and that of post treatment (day 8). The wound area on day 1 is 64mm<sup>2</sup>, the corresponding size of the dermal punch. Calculations are made using the following formula:

$$[\text{Open area on day 8}] - [\text{Open area on day 1}] / [\text{Open area on day 1}]$$

Specimens are fixed in 10% buffered formalin and paraffin embedded blocks are sectioned perpendicular to the wound surface (5mm) and cut using a Reichert-Jung microtome. Routine hematoxylin-eosin (H&E) staining is performed on cross-sections of bisected wounds. Histologic examination of the wounds are used to assess whether the healing process and the morphologic appearance of the repaired skin is altered by treatment with a polypeptide of the invention. This assessment included verification of the presence of cell accumulation, inflammatory cells, capillaries, fibroblasts, re-epithelialization and epidermal maturity (Greenhalgh, D.G. *et al.*, *Am. J. Pathol.* 136:1235 (1990)). A calibrated lens micrometer is used by a blinded observer.

Tissue sections are also stained immunohistochemically with a polyclonal rabbit anti-human keratin antibody using ABC Elite detection system. Human skin is used as a positive tissue control while non-immune IgG is used as a negative control. Keratinocyte growth is determined by evaluating the extent of reepithelialization of the wound using a calibrated lens micrometer.

Proliferating cell nuclear antigen/cyclin (PCNA) in skin specimens is demonstrated by using anti-PCNA antibody (1:50) with an ABC Elite detection system. Human colon cancer can serve as a positive tissue control and human brain tissue can be used as a negative tissue control. Each specimen includes a section with omission of the primary antibody and substitution with non-immune mouse IgG. Ranking of these sections is based on the extent of proliferation on a scale of 0-8, the lower side of the scale reflecting slight proliferation to the higher side reflecting intense proliferation.

Experimental data are analyzed using an unpaired t test. A p value of < 0.05 is considered significant.

### ***B. Steroid Impaired Rat Model***

The inhibition of wound healing by steroids has been well documented in various *in vitro* and *in vivo* systems (Wahl, Glucocorticoids and Wound healing. In: Anti-Inflammatory Steroid Action: Basic and Clinical Aspects. 280-302 (1989); Wahlet *et al.*, *J. Immunol.* 115: 476-481 (1975); Werb *et al.*, *J. Exp. Med.* 147:1684-1694 (1978)). Glucocorticoids retard wound healing by inhibiting angiogenesis, decreasing vascular permeability (Ebert *et al.*, *An. Intern. Med.* 37:701-705 (1952)), fibroblast proliferation,

and collagen synthesis (Beck *et al.*, *Growth Factors*. 5: 295-304 (1991); Haynes *et al.*, *J. Clin. Invest.* 61: 703-797 (1978)) and producing a transient reduction of circulating monocytes (Haynes *et al.*, *J. Clin. Invest.* 61: 703-797 (1978); Wahl, "Glucocorticoids and wound healing", *In: Antiinflammatory Steroid Action: Basic and Clinical Aspects*, Academic Press, New York, pp. 280-302 (1989)). The systemic administration of steroids to impaired wound healing is a well establish phenomenon in rats (Beck *et al.*, *Growth Factors*. 5: 295-304 (1991); Haynes *et al.*, *J. Clin. Invest.* 61: 703-797 (1978); Wahl, "Glucocorticoids and wound healing", *In: Antiinflammatory Steroid Action: Basic and Clinical Aspects*, Academic Press, New York, pp. 280-302 (1989); Pierce *et al.*, *Proc. Natl. Acad. Sci. USA* 86: 2229-2233 (1989)).

To demonstrate that a polypeptide of the invention can accelerate the healing process, the effects of multiple topical applications of the polypeptide on full thickness excisional skin wounds in rats in which healing has been impaired by the systemic administration of methylprednisolone is assessed.

Young adult male Sprague Dawley rats weighing 250-300 g (Charles River Laboratories) are used in this example. The animals are purchased at 8 weeks of age and are 9 weeks old at the beginning of the study. The healing response of rats is impaired by the systemic administration of methylprednisolone (17mg/kg/rat intramuscularly) at the time of wounding. Animals are individually housed and received food and water *ad libitum*. All manipulations are performed using aseptic techniques. This study is conducted according to the rules and guidelines of Human Genome Sciences, Inc. Institutional Animal Care and Use Committee and the Guidelines for the Care and Use of Laboratory Animals.

The wounding protocol is followed according to section A, above. On the day of wounding, animals are anesthetized with an intramuscular injection of ketamine (50 mg/kg) and xylazine (5 mg/kg). The dorsal region of the animal is shaved and the skin washed with 70% ethanol and iodine solutions. The surgical area is dried with sterile gauze prior to wounding. An 8 mm full-thickness wound is created using a Keyes tissue punch. The wounds are left open for the duration of the experiment. Applications of the testing materials are given topically once a day for 7 consecutive days commencing on the day of wounding and subsequent to methylprednisolone administration. Prior to treatment, wounds are gently cleansed with sterile saline and gauze sponges.

Wounds are visually examined and photographed at a fixed distance at the day of wounding and at the end of treatment. Wound closure is determined by daily measurement on days 1-5 and on day 8. Wounds are measured horizontally and vertically using a calibrated Jameson caliper. Wounds are considered healed if granulation tissue is no longer visible and the wound is covered by a continuous epithelium.

The polypeptide of the invention is administered using at a range different doses, from 4mg to 500mg per wound per day for 8 days in vehicle. Vehicle control groups received 50mL of vehicle solution.

Animals are euthanized on day 8 with an intraperitoneal injection of sodium pentobarbital (300mg/kg). The wounds and surrounding skin are then harvested for histology. Tissue specimens are placed in 10% neutral buffered formalin in tissue cassettes between biopsy sponges for further processing.

Four groups of 10 animals each (5 with methylprednisolone and 5 without glucocorticoid) are evaluated: 1) Untreated group 2) Vehicle placebo control 3) treated groups.

Wound closure is analyzed by measuring the area in the vertical and horizontal axis and obtaining the total area of the wound. Closure is then estimated by establishing the differences between the initial wound area (day 0) and that of post treatment (day 8). The wound area on day 1 is 64mm<sup>2</sup>, the corresponding size of the dermal punch. Calculations are made using the following formula:

$$[\text{Open area on day 8}] - [\text{Open area on day 1}] / [\text{Open area on day 1}]$$

Specimens are fixed in 10% buffered formalin and paraffin embedded blocks are sectioned perpendicular to the wound surface (5mm) and cut using an Olympus microtome. Routine hematoxylin-eosin (H&E) staining is performed on cross-sections of bisected wounds. Histologic examination of the wounds allows assessment of whether the healing process and the morphologic appearance of the repaired skin is improved by treatment with a polypeptide of the invention. A calibrated lens micrometer is used by a blinded observer to determine the distance of the wound gap.

Experimental data are analyzed using an unpaired t test. A p value of < 0.05 is considered significant.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

5

**Example 51: Lymphadema Animal Model**

The purpose of this experimental approach is to create an appropriate and consistent lymphedema model for testing the therapeutic effects of a polypeptide of the invention in lymphangiogenesis and re-establishment of the lymphatic circulatory system in the rat hind limb. Effectiveness is measured by swelling volume of the affected limb, quantification of the amount of lymphatic vasculature, total blood plasma protein, and histopathology. Acute lymphedema is observed for 7-10 days. Perhaps more importantly, the chronic progress of the edema is followed for up to 3-4 weeks.

Prior to beginning surgery, blood sample is drawn for protein concentration analysis. Male rats weighing approximately ~350g are dosed with Pentobarbital. Subsequently, the right legs are shaved from knee to hip. The shaved area is swabbed with gauze soaked in 70% EtOH. Blood is drawn for serum total protein testing. Circumference and volumetric measurements are made prior to injecting dye into paws after marking 2 measurement levels (0.5 cm above heel, at mid-pt of dorsal paw). The intradermal dorsum of both right and left paws are injected with 0.05 ml of 1% Evan's Blue. Circumference and volumetric measurements are then made following injection of dye into paws.

Using the knee joint as a landmark, a mid-leg inguinal incision is made circumferentially allowing the femoral vessels to be located. Forceps and hemostats are used to dissect and separate the skin flaps. After locating the femoral vessels, the lymphatic vessel that runs along side and underneath the vessel(s) is located. The main lymphatic vessels in this area are then electrically coagulated suture ligated.

Using a microscope, muscles in back of the leg (near the semitendinosus and adductors) are bluntly dissected. The popliteal lymph node is then located. The 2 proximal and 2 distal lymphatic vessels and distal blood supply of the popliteal node are then and ligated by suturing. The popliteal lymph node, and any accompanying adipose tissue, is then removed by cutting connective tissues.

Care is taken to control any mild bleeding resulting from this procedure. After lymphatics are occluded, the skin flaps are sealed by using liquid skin (Vetbond) (AJ Buck). The separated skin edges are sealed to the underlying muscle tissue while leaving a gap of ~0.5 cm around the leg. Skin also may be anchored by suturing to underlying muscle when necessary.

To avoid infection, animals are housed individually with mesh (no bedding). Recovering animals are checked daily through the optimal edematous peak, which typically occurred by day 5-7. The plateau edematous peak are then observed. To evaluate the intensity of the lymphedema, the circumference and volumes of 2 designated places on each paw before operation and daily for 7 days are measured. The effect plasma proteins on lymphedema is determined and whether protein analysis is a useful testing perimeter is also investigated. The weights of both control and edematous limbs are evaluated at 2 places. Analysis is performed in a blind manner.

Circumference Measurements: Under brief gas anesthetic to prevent limb movement, a cloth tape is used to measure limb circumference. Measurements are done at the ankle bone and dorsal paw by 2 different people then those 2 readings are averaged. Readings are taken from both control and edematous limbs.

Volumetric Measurements: On the day of surgery, animals are anesthetized with Pentobarbital and are tested prior to surgery. For daily volumetrics animals are under brief halothane anesthetic (rapid immobilization and quick recovery), both legs are shaved and equally marked using waterproof marker on legs. Legs are first dipped in water, then dipped into instrument to each marked level then measured by Buxco edema software(Chen/Victor). Data is recorded by one person, while the other is dipping the limb to marked area.

Blood-plasma protein measurements: Blood is drawn, spun, and serum separated prior to surgery and then at conclusion for total protein and Ca<sup>2+</sup> comparison.

Limb Weight Comparison: After drawing blood, the animal is prepared for tissue collection. The limbs are amputated using a quillitine, then both experimental and control legs are cut at the ligature and weighed. A second weighing is done as the tibio-cacaneal joint is disarticulated and the foot is weighed.

Histological Preparations: The transverse muscle located behind the knee (popliteal) area is dissected and arranged in a metal mold, filled with freezeGel, dipped

into cold methylbutane, placed into labeled sample bags at - 80EC until sectioning. Upon sectioning, the muscle is observed under fluorescent microscopy for lymphatics..

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to  
5 test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

**Example 52: Suppression of TNF alpha-induced adhesion molecule expression  
by a Polypeptide of the Invention**

10 The recruitment of lymphocytes to areas of inflammation and angiogenesis involves specific receptor-ligand interactions between cell surface adhesion molecules (CAMs) on lymphocytes and the vascular endothelium. The adhesion process, in both normal and pathological settings, follows a multi-step cascade that involves intercellular  
15 adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and endothelial leukocyte adhesion molecule-1 (E-selectin) expression on endothelial cells (EC). The expression of these molecules and others on the vascular endothelium determines the efficiency with which leukocytes may adhere to the local vasculature and  
20 extravasate into the local tissue during the development of an inflammatory response. The local concentration of cytokines and growth factor participate in the modulation of the expression of these CAMs.

Tumor necrosis factor alpha (TNF-a), a potent proinflammatory cytokine, is a stimulator of all three CAMs on endothelial cells and may be involved in a wide variety of inflammatory responses, often resulting in a pathological outcome.

The potential of a polypeptide of the invention to mediate a suppression of TNF-a  
25 induced CAM expression can be examined. A modified ELISA assay which uses ECs as a solid phase absorbent is employed to measure the amount of CAM expression on TNF-a treated ECs when co-stimulated with a member of the FGF family of proteins.

To perform the experiment, human umbilical vein endothelial cell (HUVEC)  
cultures are obtained from pooled cord harvests and maintained in growth medium (EGM-  
30 2; Clonetics, San Diego, CA) supplemented with 10% FCS and 1% penicillin/streptomycin in a 37 degree C humidified incubator containing 5% CO<sub>2</sub>. HUVECs are seeded in 96-well plates at concentrations of 1 x 10<sup>4</sup> cells/well in EGM

medium at 37 degree C for 18-24 hrs or until confluent. The monolayers are subsequently washed 3 times with a serum-free solution of RPMI-1640 supplemented with 100 U/ml penicillin and 100 mg/ml streptomycin, and treated with a given cytokine and/or growth factor(s) for 24 h at 37 degree C. Following incubation, the cells are then evaluated for CAM expression.

Human Umbilical Vein Endothelial cells (HUVECs) are grown in a standard 96 well plate to confluence. Growth medium is removed from the cells and replaced with 90 ul of 199 Medium (10% FBS). Samples for testing and positive or negative controls are added to the plate in triplicate (in 10 ul volumes). Plates are incubated at 37 degree C for either 5 h (selectin and integrin expression) or 24 h (integrin expression only). Plates are aspirated to remove medium and 100 µl of 0.1% paraformaldehyde-PBS(with Ca++ and Mg++) is added to each well. Plates are held at 4°C for 30 min.

Fixative is then removed from the wells and wells are washed 1X with PBS(+Ca,Mg)+0.5% BSA and drained. Do not allow the wells to dry. Add 10 µl of diluted primary antibody to the test and control wells. Anti-ICAM-1-Biotin, Anti-VCAM-1-Biotin and Anti-E-selectin-Biotin are used at a concentration of 10 µg/ml (1:10 dilution of 0.1 mg/ml stock antibody). Cells are incubated at 37°C for 30 min. in a humidified environment. Wells are washed X3 with PBS(+Ca,Mg)+0.5% BSA.

Then add 20 µl of diluted ExtrAvidin-Alkaline Phosphatase (1:5,000 dilution) to each well and incubated at 37°C for 30 min. Wells are washed X3 with PBS(+Ca,Mg)+0.5% BSA. 1 tablet of p-Nitrophenol Phosphate pNPP is dissolved in 5 ml of glycine buffer (pH 10.4). 100 µl of pNPP substrate in glycine buffer is added to each test well. Standard wells in triplicate are prepared from the working dilution of the ExtrAvidin-Alkaline Phosphatase in glycine buffer: 1:5,000 ( $10^0$ ) >  $10^{-0.5}$  >  $10^{-1}$  >  $10^{-1.5}$ . 5 µl of each dilution is added to triplicate wells and the resulting AP content in each well is 5.50 ng, 1.74 ng, 0.55 ng, 0.18 ng. 100 µl of pNPP reagent must then be added to each of the standard wells. The plate must be incubated at 37°C for 4h. A volume of 50 µl of 3M NaOH is added to all wells. The results are quantified on a plate reader at 405 nm. The background subtraction option is used on blank wells filled with glycine buffer only. The template is set up to indicate the concentration of AP-conjugate in each standard well [ 5.50 ng; 1.74 ng; 0.55 ng; 0.18 ng]. Results are indicated as amount of bound AP-conjugate in each sample.



The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

5           It will be clear that the invention may be practiced otherwise than as particularly described in the foregoing description and examples. Numerous modifications and variations of the present invention are possible in light of the above teachings and, therefore, are within the scope of the appended claims.

10           The entire disclosure of each document cited (including patents, patent applications, journal articles, abstracts, laboratory manuals, books, or other disclosures) in the Background of the Invention, Detailed Description, and Examples is hereby incorporated herein by reference. Further, the hard copy of the sequence listing submitted herewith and the corresponding computer readable form are both incorporated herein by reference in their entireties.

15

## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>52</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit 08 April 1999	Accession Number 203917
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
Europe In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

For receiving Office use only
<input checked="" type="checkbox"/> This sheet was received with the international application
Authorized officer <i>Yamamoto E. Chishima</i>

For International Bureau use only
<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer

**ATCC Deposit No.: 203917**

## **CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

## **NORWAY**

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

## **AUSTRALIA**

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

## **FINLAND**

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

## **UNITED KINGDOM**

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

**ATCC Deposit No.: 203917**

## **DENMARK**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

## **SWEDEN**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

## **NETHERLANDS**

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

***What Is Claimed Is:***

1. An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:
- 5 (a) a polynucleotide fragment of SEQ ID NO:X or a polynucleotide fragment of the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
- (b) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:Y or a polypeptide fragment encoded by the cDNA sequence included in ATCC Deposit
- 10 No:Z, which is hybridizable to SEQ ID NO:X;
- (c) a polynucleotide encoding a polypeptide domain of SEQ ID NO:Y or a polypeptide domain encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
- 15 (d) a polynucleotide encoding a polypeptide epitope of SEQ ID NO:Y or a polypeptide epitope encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
- (e) a polynucleotide encoding a polypeptide of SEQ ID NO:Y or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X,
- 20 having biological activity;
- (f) a polynucleotide which is a variant of SEQ ID NO:X;
- (g) a polynucleotide which is an allelic variant of SEQ ID NO:X;
- (h) a polynucleotide which encodes a species homologue of the SEQ ID NO:Y;
- 25 (i) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h), wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A residues or of only T residues.

2. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding a secreted protein.

3. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding the sequence identified as SEQ ID NO:Y or the polypeptide encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.

4. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises the entire nucleotide sequence of SEQ ID NO:X or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.

5. The isolated nucleic acid molecule of claim 2, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.

6. The isolated nucleic acid molecule of claim 3, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.

7. A recombinant vector comprising the isolated nucleic acid molecule of claim 1.

8. A method of making a recombinant host cell comprising the isolated nucleic acid molecule of claim 1.

9. A recombinant host cell produced by the method of claim 8.

10. The recombinant host cell of claim 9 comprising vector sequences.

11. An isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence selected from the group consisting of:

(a) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

5 (b) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z, having biological activity;

(c) a polypeptide domain of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

(d) a polypeptide epitope of SEQ ID NO:Y or the encoded sequence included  
10 in ATCC Deposit No:Z;

(e) a secreted form of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

(f) a full length protein of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

15 (g) a variant of SEQ ID NO:Y;

(h) an allelic variant of SEQ ID NO:Y; or

(i) a species homologue of the SEQ ID NO:Y.

12. The isolated polypeptide of claim 11, wherein the secreted form or the full length protein comprises sequential amino acid deletions from either the C-  
20 terminus or the N-terminus.

13. An isolated antibody that binds specifically to the isolated polypeptide of claim 11.

25 14. A recombinant host cell that expresses the isolated polypeptide of claim 11.

15. A method of making an isolated polypeptide comprising:

(a) culturing the recombinant host cell of claim 14 under conditions such that  
30 said polypeptide is expressed; and

(b) recovering said polypeptide.

16. The polypeptide produced by claim 15.

17. A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount  
5 of the polypeptide of claim 11 or the polynucleotide of claim 1.

18. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

(a) determining the presence or absence of a mutation in the polynucleotide of  
10 claim 1; and

(b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of said mutation.

19. A method of diagnosing a pathological condition or a susceptibility to  
15 a pathological condition in a subject comprising:

(a) determining the presence or amount of expression of the polypeptide of claim 11 in a biological sample; and

(b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.  
20

20. A method for identifying a binding partner to the polypeptide of claim 11 comprising:

(a) contacting the polypeptide of claim 11 with a binding partner; and

(b) determining whether the binding partner effects an activity of the  
25 polypeptide.

21. The gene corresponding to the cDNA sequence of SEQ ID NO:Y.

22. A method of identifying an activity in a biological assay, wherein the  
30 method comprises:

(a) expressing SEQ ID NO:X in a cell;

(b) isolating the supernatant;



- (c) detecting an activity in a biological assay; and
- (d) identifying the protein in the supernatant having the activity.

23. The product produced by the method of claim 20.

## 1

<110> Rosen et al.

<120> 50 Human Secreted Proteins

<130> PS502PCT

<140> Unassigned

<141> 2000-03-09

<150> 60/124,093

<151> 1999-03-12

<150> 60/166,989

<151> 1999-11-23

<160> 142

<170> PatentIn Ver. 2.0

<210> 1

<211> 733

<212> DNA

<213> Homo sapiens

<400> 1

gggatccgga	gccc aaatct	tctgacaaaa	ctcacacatg	cccaccgtgc	ccagcacctg	60
aattcgaggg	tgcaccgtca	gtcttcctct	tcccccaaaa	acccaaggac	accctcatga	120
tctcccgga	tcctgaggtc	acatgcgtgg	tggtggacgt	aagccacgaa	gacctgagg	180
tcaagttcaa	ctggtacgtg	gacggcgtgg	aggtgcataa	tgccaagaca	aagccgcggg	240
aggagcagta	caacagcacg	taccgtgtgg	tcagcgtcct	caccgtcctg	caccaggact	300
ggctgaatgg	caaggagtac	aagtgcgaag	tctccaacaa	agccctccca	accccatcg	360
agaaaacat	ctccaaagcc	aaagggcagc	cccagagaacc	acaggtgtac	accctgcccc	420
catcccggga	tgagctgacc	aagaaccagg	tcagcctgac	ctgcctggtc	aaaggcttct	480
atccaagcga	catcgccgtg	gagtgggaga	gcaatgggca	gccggagaac	aactacaaga	540
ccacgcctcc	cgtgctggac	tccgacggct	ccttcttcct	ctacagcaag	ctcaccgtgg	600
acaagagcag	gtggcagcag	gggaacgtct	tctcatgctc	cgtgatgcat	gaggctctgc	660
acaaccacta	cacgcagaag	agcctctccc	tgtctccggg	taaatgagtg	cgacggccgc	720
gactctagag	gat					733

<210> 2

<211> 5

<212> PRT

<213> Homo sapiens

<220>

<221> Site

<222> (3)

<223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 2

Trp	Ser	Xaa	Trp	Ser
1				5

<210> 3  
 <211> 86  
 <212> DNA  
 <213> Homo sapiens

<400> 3  
 gcgcctcgag atttccccga aatctagatt tccccgaaat gatttccccg aaatgatttc 60  
 cccgaaatat ctgccatctc aattag 86

<210> 4  
 <211> 27  
 <212> DNA  
 <213> Homo sapiens

<400> 4  
 gcggcaagct ttttgcaaag cctaggc 27

<210> 5  
 <211> 271  
 <212> DNA  
 <213> Homo sapiens

<400> 5  
 ctcgagattt ccccgaaatc tagatttccc cgaaatgatt tccccgaaat gatttccccg 60  
 aaatatctgc catctcaatt agtcagcaac catagtcccg cccctaactc cgcccatccc 120  
 gccctaact ccgcccagtt ccgcccattc tccgccccat ggctgactaa ttttttttat 180  
 ttatgcagag gccgaggccg cctcggcctc tgagctattc cagaagtagt gaggaggctt 240  
 ttttgagggc ctaggctttt gcaaaaagct t 271

<210> 6  
 <211> 32  
 <212> DNA  
 <213> Homo sapiens

<400> 6  
 gcgctcgagg gatgacagcg atagaacccc gg 32

<210> 7  
 <211> 31  
 <212> DNA  
 <213> Homo sapiens

<400> 7  
 gcgaagcttc gcgactcccc ggatccgcct c 31

<210> 8  
 <211> 12  
 <212> DNA  
 <213> Homo sapiens

<400> 8  
ggggactttc cc

12

<210> 9  
<211> 73  
<212> DNA  
<213> Homo sapiens

<400> 9  
gcggcctcga ggggactttc ccggggactt tccggggact ttccgggact ttccatcctg 60  
ccatctcaat tag 73

<210> 10  
<211> 256  
<212> DNA  
<213> Homo sapiens

<400> 10  
ctcgagggga ctttcccggg gactttccgg ggactttccg ggactttcca tctgccatct 60  
caattagtca gcaaccatag tcccgccctt aactccgccc atcccgcctc taactccgcc 120  
cagttccgcc cattctccgc cccatggctg actaattttt tttatttatg cagaggccga 180  
ggccgcctcg gcctctgagc tattccagaa gtagtgagga ggcttttttg gaggcctagg 240  
cttttgcaaa aagctt 256

<210> 11  
<211> 2318  
<212> DNA  
<213> Homo sapiens

<400> 11  
ccacgcgtcc gccc aaagtt ctggggtgac aggcgtgagt cactgtgcct ggccacttcc 60  
tggttcttag atgctgtctt tttccctgtg tcttcccata gttaaagggg agacaagctc 120  
ccctgggtgt cttataaagg cactgatgtc actcacaagg cttctatgcc caataactaa 180  
tcacctccca aaagcctcct aataaaacca ctttgggggt taggatttca acataggaat 240  
tttggggagg gacacgaaca tttagtcctt aacagtgatg tatttatttc ccattgttga 300  
aaggattggg catggcttat tttttgtcac atttgttctt tattacatgc taatgatggg 360  
aaccctgggtg ttgatattac tacatgatgt tattgtcaca tttactgagt ttataaatgc 420  
tcagaattta aaatgggtgat taatatTTTT gcaggtaatt catgaatatt gtactTTTT 480  
tctgaaccct tattcagaaa aggggctctg ccaagtggaa aaaaattatt tttcatcatt 540  
aaattttgag gtagtacttt tgtgaatgta tggttttaat aagtaggact atagacatac 600  
agccccctt tttttaacct ttacagctgg taggtatttt cctatttttg ttaatatggg 660  
ctttgttget tgattatagc acactgcttt gccgtgttta actttgaggg tgtgttgtgt 720  
tgttgaacag aaactgacct ttccagatat ttcttctttg gtgaagatca gacagttgaa 780  
gttgaagtat tcttcccatc aaattatcct gagggaggac tacagagcca gtttagtgag 840  
gattaaaaag gaaaaaaaaa ataggtgaac ctttgtaa at gccatcctgg actctgccaa 900  
ctgcttttcc ggggaatact gtggtggtct gtggccttgt cacaatcagg gatattgggtg 960  
aaaggcattc cctgaactgg gggccgacag caggctgact tttgagcagt cctgccacca 1020  
ctttgatttt ttatcttctt cctgtgccat gacttttatg cattgtttat ccagctccaa 1080  
ccagggggag acccactcga aagggtcctc cagaatgaat ggagactttc catgaggagt 1140  
ccctgtcatg acagtgacct ggtgtgtgca agctctcccc acttactgat ggctggaagg 1200  
cagtagtgcc tgcaggtttg cccttgccga acagtatgat gtcagtgtga atcgggacca 1260  
ggcctcatcc aggcctta at cttttttttt tttttttttt tttttgagac tgagcctggg 1320

tgacagagtg	agactccatc	tcaaaaaaaaa	aaaaaaaaaaa	aaaaagtaaa	tagcttttatt	1380
gagatagaaa	tcgagtcaca	cacttggtgta	tccatcacca	caatcaattt	cagaatatatt	1440
tcagcacccc	aaggggaagaa	gccttttagcg	atcgcaatcc	ctccctattc	tctccttccc	1500
caacccccgg	caaccactac	tgtattggac	tctctgtctc	catgggttca	cctattccgg	1560
atatttcata	tgagtggaa	catacaacat	gtgttcattt	cttatccggc	ttctttcact	1620
gaggatgttt	tcaaggatca	tccatggtgc	agcacgtgtc	ggttcttttt	atggccaaat	1680
aatatttcatt	tgtatggcta	gaccacattt	tcttgattga	tgcacagct	gatagacatt	1740
tgaactgggt	ccaccttttg	gctagtatga	agaatgctgc	tgtgaacagt	caggcacaca	1800
tttttggtg	gccatcggtt	ttcgcttatc	ttggttctat	aactagtgg	gaaattgctc	1860
agtcccatgg	gaattctgtt	tgttgagtgg	acaaggattc	cacttgtttc	taggatttgg	1920
agtgtgagga	aattgggaga	aaaggcacat	tgttaaaagg	tacataaatg	tgttctgtga	1980
aggagggtt	tgttgagcta	ggtcctaata	ataactgctt	tccattacta	ttttttcttt	2040
attttctttt	tagaaggaag	agattgttgt	gactctctta	ccagctgggc	actgtccggg	2100
atcagttatg	taaggggggc	atattttttg	tcatttttatt	atatgtagac	acataattgta	2160
ttttagtaaaa	taaattttta	gggtctaaaa	ttaatagggg	gctgggtgca	gtggcacatg	2220
tctgtaatcc	cagtgccttg	ggaggctgac	gcgggaggat	tgcttgagct	tgggagttgg	2280
aggctgcagt	gagttttttt	ttaaaaaaaa	aaaaaaaaa			2318

&lt;210&gt; 12

&lt;211&gt; 620

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 12

ccacgcgtcc	gcggaagctt	gggtggccac	cactcactcc	cacaacacag	ccaccatttc	60
ccaccagaa	tttctgtga	aatgtgtca	ttttaaaaca	gcacacatcc	tgagaattgc	120
aaagttgggc	atagagatca	atacaaatta	gacttctttt	tagatacgct	ctacgctctg	180
cagagccctc	tggggctctc	aagggctggg	acctgctgga	taaaactgga	tgaaactaag	240
ttgctgcttc	tttgggtgcc	ttgaatggac	tttcttggct	gcagtgcagt	taggtccgct	300
tcctagccgc	gtgctgctct	gccatcgggg	atgctaaagt	cggggagggc	caggaagcct	360
ttctttgctt	ggaagttttt	gtttctcctt	cgcctgctag	gttgggataa	tccgttggga	420
agtctctgag	cgtctttaaa	cataaaatct	agtttcaaag	gtttaaattc	ccaagttgcc	480
ccctaagtta	catgttgctt	aggcttgggt	gctatctgta	tgttataaat	aattccattt	540
agaaattaag	aaattatggg	ctgcattttt	gatgccagtg	gctctgtagt	atcccccaac	600
caccaaaaaa	aaaaaaaaaa					620

&lt;210&gt; 13

&lt;211&gt; 830

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (814)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 13

gagcttctac	tcctactccc	aaactctagc	aaaccactga	tttgtttttt	gtacctatag	60
ttttgctaaa	atatcataca	aatgaaatca	aacagcatgt	agccttttta	gtatggcttc	120
tttcacttgk	tataaaataa	taaaaattca	tttatgttgc	tatgtgtttt	aatagttcat	180
tgttttctat	ttctgaatag	tcttgcattg	tatggatgtc	ctacggttgt	ttatccatta	240
gccagttgaa	gaacatttgg	ttgttgccag	tttgggtgat	tataaaccca	ctctaaacat	300
tcatattcaa	gtttttgtat	gagcatttaa	gttttcattt	ctttgatgta	aaatcctagg	360

aatgggatcg	tgggctctat	atgataagtt	tatttttaact	ttataattaa	ccaccaaatt	420
tttccaaagt	gaaatattat	cttgtagtgc	cattgacaat	gtatgagagt	ccttactgct	480
ccacatcttt	gttagtactt	agtattgtca	gtttttgttt	tgctttttaga	cattttaata	540
gatgtctggt	attaactcat	ttgcactttc	ttaatgacta	ataatggtga	atatgtgctt	600
atltaccatc	catacgtctt	ctttttataaa	atatctattc	aactcttttg	accattttta	660
actgtatttg	ttttcttatt	gttgagtttt	gagagtttgg	atatgtccta	gatatgagtc	720
ctttgtcaga	aatgtgtttt	gtaaatattt	tctgccaggc	tgtagcttgc	attttcagtc	780
tcttaacagt	gtcttttcaca	gaacaaaaaa	aaanaaaaaa	gggcggccgc		830

&lt;210&gt; 14

&lt;211&gt; 4054

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 14

acgcgtccga	gagggtagag	gaggagaggg	aggaggagga	gggaggtggc	ggctcctgct	60
cctccaggcg	ctgcccagcc	ccttgtcagc	cagggctgaa	ccccgcagg	ataaggaagc	120
ctgtgtgggt	accaacaatc	aaagctacat	ctgtgacaca	ggacactgct	gtggacagtc	180
tcagtgtctg	aactactact	atgaactctg	gtggttctgg	ctggtgtgga	ccatcatcat	240
catcctgagc	tgctgctgtg	tttgccacca	ccgccgagcc	aagcaccgcc	ttcaggccca	300
gcagcggcaa	catgaaatca	acctgatcgc	ttaccgagaa	gccacaatt	actcagcgct	360
gccattttat	ttcaggtttt	tgccaaacta	tttactacct	cctttatgag	gaagtgggtga	420
accgacctcc	aactcctccc	ccaccataca	gtgccttcca	gctacagcag	cagcagctgc	480
tgctccaca	gtgtggccct	gcaggtggca	gtccccggg	catcgatccc	accaggggat	540
cccagggggc	acagagcagc	cccttgctctg	agcccagcag	aagcagcaca	agacccccaa	600
gcatcgctga	ccctgatecc	tctgacctac	cagttgaccg	agcagccacc	aaagccccag	660
ggatggagcc	cagtggctct	gtggctggcc	tgggggagct	ggacccgggg	gccttctctg	720
acaaagatgc	agaatgtagg	gaggagctgc	tgaaagatga	cagctctgaa	cacggcgcac	780
ccgacagcaa	agagaagacg	cctgggagac	atcgccgctt	cacaggtgac	tcgggcattg	840
aagtgtgtgt	gtgcaaccgg	ggccaccatg	acgatgacct	caaagagttc	aacacactca	900
tcgatgatgc	tctggatggg	cccctggact	tctgcgacag	ctgccatgtg	cggeccccctg	960
gtgatgagga	ggaaggcctc	tgctcagtcct	ctgaggagca	ggctcgagag	cctgggcacc	1020
cggacctgcc	acggccgccc	gcatgcctgc	tgctgaacac	catcaacgag	caggactctc	1080
ccaactccca	gagcagcagc	tccccagct	agagcaggtc	ctgccagcac	ccagcaactt	1140
ggcaaagcaa	ccagggtagg	ggagaaccac	gagagaagca	ttaagtgact	ttcaaagact	1200
ttcagagtac	agccacttgg	ttcctttttg	tttgttttcc	ttctcctctc	ctgcattttc	1260
ctccatctcc	aggtacagtt	cgggggtgtg	atgcctcttc	ctccacaagg	gcacagtgtt	1320
gtggagggct	aagtgtgttc	tgtgactcat	tctcatacc	ctaactccat	ctcctttctt	1380
taaagtcaaa	tctcacctac	ctgtttgggt	cagagagatg	tgttttaaaa	gcccccaagg	1440
aaggaggctg	ggactgtgcc	ctgacatgat	tcttggtgat	ggaatagggt	tgtgctctga	1500
ttctagttta	agagaacggt	gctgtatctc	agtccaggag	aggcagccca	tcttgccctt	1560
ggatgaagaa	ggaaaccac	agaggccag	ggcttgctcat	tgggctgcca	gtgtctgcca	1620
agccagcatt	gagctaattc	tgtgggagga	tgagagctac	tgggccgttg	tatgatagg	1680
tggtagggct	tgttgatctg	tcaaattcca	ggtgacaaga	tctatgcacc	ccatgcgtcc	1740
ttgaggggcc	ttttccccgc	aggctctggc	tggccgcagg	ctggttctgg	tgtgaaaggt	1800
tatactgcct	tttctttgtt	tgtttggttt	tttctctaaa	aacaaacagc	aaaagacagc	1860
tgaaaacaag	aacttcaccg	gtgggcaggc	aagaattctc	ttctggaaaa	tgacgtttgt	1920
ggctctttcc	caagttggcc	ttcaaagagc	ctgcctgctg	ttgagccaga	agatgtctcg	1980
tgtgaaggct	ggggtggcgg	ctgtcttgga	acctctgtga	gcaggaggcc	ctaagccgca	2040
ccagtggata	gaggtgcagc	tctctgcctc	tctgcccttt	ggctctgtgt	cacagggtgac	2100
cccgtgtcag	cctgcacgc	aagcacacac	cctgcggggc	ttcaagtctc	actgttccgt	2160
atgaggaacc	agacagcggg	ctgaggaagc	gatggcccca	gagaaagggc	ccctgtagcc	2220
tggctctcac	acagtatttt	atctttgatt	ctgaataaat	attttttgtg	gggttttttt	2280
tttttttttg	gtggcagttg	tttgttttta	actgaccact	tggaagaaac	accttggtta	2340

tctgtggttt	tcatgccttg	tccctgcctc	tacccccacc	cctttttgagt	cgggtgactc	2400
atTTTTtctgt	gtagagactc	ggtggcccgag	gcaggaggtg	aaagcagcca	tccggaaggc	2460
cctgggggacc	cttgtgcctg	ttgctcgcct	tcaggtcacc	agctgagctg	cgataggaaa	2520
atctgaatgg	aggcagcaaa	cagccaaaac	aaacattccc	cacccggccc	tgtgcatatg	2580
aagtctttct	tcccccaact	cttgaacgat	gatgatattc	agacgaagca	ttgatgttat	2640
ggaagaaaaga	aagaaacaaa	caaaatatat	atatatatgt	ccaaaaacag	acaaatccaa	2700
gggtgtgagg	taaacgagtg	tctgcattta	gattccacaa	aaccaaaatc	catgttgaac	2760
aaagttaaagt	ccgtacacag	tgactttttg	ggtgagccgt	gtgtgtctgt	ctgttgtgtg	2820
tgtgcctcaa	gccctgtttt	cctgtgaaga	tactttgagt	ggcagccatt	ctctccacgt	2880
gaaccacacg	tctggagcac	agacaggcct	ctcaagggtca	ttgatcttac	gcatttactg	2940
tttaccgaac	aaatgtctga	ctgtgtactc	gggtgtactc	cgcagcattg	tcgactgcag	3000
tccctgtgt	ttgccagaga	tactgtgctc	gaagtagagg	ttttactcta	ctcatcactg	3060
cgatttgcac	attgctccgt	ggacactcgg	aggcctgcgt	tctgttccct	ataaatggaa	3120
gcgtgctctg	agcctgtctg	cctccctcgg	ctgctgctgg	tcctcagtac	cagcgcccg	3180
gggtgtccac	aaccacttgg	gacagaagaa	ggtggaattt	cagacagaag	cttgactggg	3240
tcttcaatga	caggcttggg	ctagctgtgg	cccagacatc	ggccctgccc	agaattgcca	3300
ggaggagggt	ttgcaggctc	tagaggagcc	gcagggcctg	cctgcctctg	gtgagtccaa	3360
caggcacaag	caagctggcg	tgtggccaga	ggtagccgga	gtgtgtcaca	gccctcaga	3420
tgcctttcct	tccacctttt	tttatttttt	aagaatccca	aataactcac	tgaagtgtct	3480
caaaggcgaa	caagttttac	caaaatgaat	cctttttcag	ttaacagatc	aatggatga	3540
gttctgagcc	tctcaagttc	ctttccccag	ttagagtggg	gaactgggca	agtgttaact	3600
gtgggactca	ctgcagcgtc	ctatcctaaa	ggcacgaaaa	gacggaaatg	caacctgcgg	3660
agctgggctt	ggttccccag	gtcacagttt	ggcccccgct	acaggatgct	gccctgctca	3720
gagagagatt	taataggagg	ctgaagggaat	cgttaggggg	ccagggagat	gtgactgagg	3780
ctggcctttcc	acgtgaatga	gacggggctg	gtggagggtt	tggtgctaca	gccagtcaga	3840
agatttgcaa	atgcgaacac	attcctgtgt	gaggcacgtt	accctttgtc	agttattgtg	3900
aatatgtgta	ttttaagcaa	taagattcag	ctggtcagac	ttttctgggc	agtctcagtg	3960
acgcatttcc	tgtgctgtga	ttgttctgaa	gacagagtgg	ctctaaccac	tgtgagaagc	4020
ccaaataaaa	attgatccca	aaaaaaaaaa	aaaa			4054

&lt;210&gt; 15

&lt;211&gt; 452

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 15

gataaaataa	gattttcata	cattaaacaa	ggtaggattt	ttctatctgg	gacggaactt	60
tcaacacttg	gaggggttgt	agttatttct	cctcaaagat	ggcaaacatg	agtgtcccca	120
gttatccctc	ctctctgttc	aagttcgtta	actaatcacc	cagtatccat	gctatcgctg	180
gcccttctgt	ggcctatttt	tatactgttc	actgttcagt	gtcacttggt	tggtaacact	240
caacatcaac	gtgtgctacc	aaattgacac	cagaggacaa	aaaagaatca	agatatgtac	300
agcctgcttt	gtactgagcc	agctgccact	agatgttttt	tgtgataatg	aacacgtgag	360
gccatgtgga	cgcgagagat	ggctccgggt	tccctcagac	ggctcacagc	cagctgggtct	420
gcagtgcggy	tttagayycc	gatgtgggaa	cc			452

&lt;210&gt; 16

&lt;211&gt; 1193

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 16

aagctcta	acgactcact	atagggaag	ctggtaacgc	tgcagggtacc	gggtccggaat	60
tcccggtc	acccacgcgt	ccggttttc	tacatgaact	tttttctagg	actttgggtta	120

ctatacatat	tgtatatttt	aagaattctt	tatacaattt	taatatactg	caatactgca	180
gtttttgaca	atttggattc	catttgggat	atgaattttt	gcattcatta	ttgaataact	240
cttttaatat	ttttgagcaa	tgattatact	gctttacctt	gtgtcacttt	tttttttttt	300
aggaaaaact	catgttccag	tatattttct	ttacagagtg	aagtcattac	agcactgtat	360
ttctgtgttg	acatttgttg	gcagtgtgct	aagtaatgtt	ttttaaaagca	caggcttgag	420
gactatgggt	tacatcctgt	tggaaacatt	ccaaatggga	cttgtgtatt	ataccagga	480
ggctctcata	tataccatct	tggcatctgt	actgatgaat	aagttataat	gaacagttaa	540
aaatgctcat	tgaaaattaa	ataaaacaaa	aaggcagtta	tttcatgctt	ggtcaaaaac	600
atcaatacct	ttccaattaa	cactgagaaa	ttaaggttaa	gattctcctt	ttgtactggg	660
aaacaggctg	gaggactatg	gtcctcaagt	ttagaccaag	aggactatgg	tctcaagggt	720
caccatgaga	aatgtgttga	acatttttagt	atgctctatt	gtataatttt	tttggagggg	780
gggatggagt	ttcgctgttg	ttgccagggc	tggagtgcac	tagcaccatc	ttggctcacc	840
gcaacctctg	cctaccgggt	tcaagtaatt	cttgtgcctc	agcctcctga	gtagctggga	900
ttatagggcat	gcaccaccat	gccagctaa	ttttgtattt	ttattagaga	cagggtttct	960
ccgtgttggt	caggctgggc	tcaaactcct	gacctcaggt	gatctgcctg	tcttgcctcc	1020
ggcgtaaacac	tttttaagac	cagtgtaac	gaaagagaat	gtagccattc	tagccaccgt	1080
taaaagatac	acagtgaggt	gttgtgtttt	gtttttttta	tgatgaaaag	ttacacattt	1140
tttggagaga	aaagtcttag	ctgaaggtaa	atcaatggaa	aaaaaaaaaa	aaa	1193

&lt;210&gt; 17

&lt;211&gt; 1594

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 17

gctcccagag	tgtgccgggg	aggagatgag	gcagagaaga	cagctggctc	atctcctccc	60
agagtgtgcc	ggggcaggta	acttagttgt	tctgagagag	gtgacccctc	ctcagtgtcc	120
atgagtccca	gatgaattgg	ccaagtccta	gaaatagagg	ggctgcagag	cggrgaggaa	180
gaggtcccaa	tgaccagccc	ttgactgcca	ccgtttgtca	ctggcccccct	ggccctgttc	240
ccgtgatccc	agtcagatgc	cacattttta	taataaaact	agggctgagc	aggaargcgc	300
tggcarragt	tcattacctt	gcttattttc	aaactcttcc	taacccttct	gtcctgggtg	360
ttgtttgacc	tgaagatga	agagaacact	gctgtcttct	gtcatctgtc	tttctgtctc	420
acctgcacag	ggccaagccc	cgtggcagtg	cccagcgggc	actggggaca	gtgctgaggt	480
tacttatact	gagaaaccct	tgcacggcct	gtcccgcaga	gaaaagacag	cccttcgggg	540
tccttggttt	ggtctgmgtc	gtgggaaagg	accctagggc	atcacaatcg	cagccatgta	600
ccctgcagct	cacagagtca	atcagtttgg	ttttatttgc	atttgaacag	aaaccttgag	660
aaaaagaaa	ccaatttgtt	tatcttctag	gggataaaaa	taggcaagtg	tggcagccct	720
gtggccacgc	aggtcagaca	ctgcagcagt	gacactgggg	ttttattaat	caataggatg	780
tagctcactt	gttctgtcct	tttaaaaaaa	aaagcccacc	ctggagaaga	gatgcttggc	840
ccagctccta	cacaagggca	gcagtcactc	ccgggtccagg	gagctcttct	ggaggttttt	900
gcaagtagat	tctagagaac	tgagagaaca	agaagtcttc	cccactctgg	gcacatggaa	960
tcttcattca	aagagtttgg	tttgaattga	gagctctcag	ttttgcatat	caggtaacta	1020
tgatgtgaaa	agatgaagcg	gcctctttac	ctctcagagt	cagcccagac	cctcttcgcc	1080
tccctctctc	tcagagaagc	tcctctgtcc	ctttctcctc	cttttgacta	gagctagtgg	1140
gtggagagag	taactgaacg	ggaatttctt	agtgttatct	tctatcaata	atattttaat	1200
tgtcagtgtc	atagactggg	tggctggggg	ttgggagctg	gtggctcttg	aaaatcacca	1260
agtggcagaa	aggaagtatt	aggaagaaca	taaaggctta	gtgccagtgg	tgtcaggtaa	1320
tgcatattga	tacctcaact	aaaagaacat	ttggggcttt	attaaaattg	actaattctt	1380
ccaaagatag	cagctaaagg	aggacttaga	tgaatagagg	agggaggagg	cttgcaggac	1440
ggtgaagccc	tttgcttcca	gctctctgcc	tgctcagcca	ttgctccgtc	cctctgcagt	1500
tagattattc	cttgcagata	gcaatcaact	ggaaggaagt	gtctgtgtct	aatttgcagt	1560
agattattta	aaacaacaaa	aaaagggcgg	ccgc			1594



<210> 18  
 <211> 1042  
 <212> DNA  
 <213> Homo sapiens

<400> 18  
 ccacgcgtcc gtaagaccaa cacatgggac tgctatacat gggtcttctc aaatccattg 60  
 ttttcttttc tgggtgtaagt gaagaattga aggcttatgg ggtcgggtcta cagaccgtta 120  
 ttgagttcct acagaatacc cggttctggg cttggcgctg gatcagtcag gccctggttg 180  
 gtcttgcaact caaatgacaa acgtacaagg cttacaccgt gtgtcagatg gcaatggtga 240  
 agcagcatca gggagttggg gaggagaggt ggactgcttt ttttattgga gggaggtcaa 300  
 gaaggatgcc tgaataaggt aacatttgag cagagtccta aagacagtga ggggacaatc 360  
 atcagactag caggggaaaa agaactccag gtggggggaa cagcaacggc aaaggctgtg 420  
 aggtagaaac gcaataacgt gtttgaggaa taaggaggcc aggtggctgg aatggaggtt 480  
 agcaagggaa tgaggtaggg gcagttctgc gggctttgtt aggattctct tggaggaaag 540  
 cttattacca cagcgactga gagtgcctgc attagcctat gacctcagc tgtcagcttg 600  
 ttcagaggtg gcttagctgc agatggctgg cttcccacat ccgatgactg accacagtag 660  
 ggatatgagg gtctgacatc ttctgcccac tgctgtccaa ctctgatggg ccattccagt 720  
 tccaaggctc ctgcgggact gatggaggct gttcatggga ctgtatccct ccctggcttc 780  
 tccctctgcc cagttctcat gcctttcctt cctttccact ggtattgatc ccaagggtac 840  
 atgcttagtg ccatctcagg actcagtttc tccatttagt gtgattgaac tacgtgcatt 900  
 tgccagccct gtagtcccag ctactaaaga ggattgcttg agcccaggag ttcgaggctg 960  
 gaatgagcta tgattgcacc actggactcc agcctgggca acatagcaag actccgtctc 1020  
 tctaaaaaaaa aaaaaaaaaa aa 1042

<210> 19  
 <211> 855  
 <212> DNA  
 <213> Homo sapiens

<400> 19  
 ggcacgagct caggcatacc aggttatagc tccaagttcc acaggctctg taccacaggc 60  
 catcaaaaata taagtttcca ggctttgcag aagaccttgt ctcccttagaa atgccccaga 120  
 aattttccac accctcctcg gtatccatgg agagcctggg gccagatata tggctcatct 180  
 ctggcattgc ttctctcctt tccttcctgc atgtgttggg ggtgggttggt gtgggggaat 240  
 gtggatgggg gatgtcctgg ctgatgctg ccaaaatttc atcccacct ccttgcttat 300  
 cgtccctgtt ttgagggcta wgacttgagt ttttgtttcc catgttctct atagacttgg 360  
 gaccttctg aacttggggc ctatcactcc ccacagtgga tgccttagaa gggagaggga 420  
 aggagggagg caggcatagc atctgaacct agtgtggggg cattcactag aatcttcaat 480  
 caacctgggg tctccccacc ccacccaga taacctctc agttccctag ggtctcttct 540  
 tgcttgactc aatctaccca gagatgcccc ttagcacacc tagagggcag ggaccatagg 600  
 acccagggtc caaccccatc gtcagcacc cagccatgag gccaccctt agcacacctg 660  
 ctctgccccat ttagcttacc ctcccagttg gccagaatct gaggggagag cccccagaga 720  
 gcccccttcc ccatcagaag actgttgact gctttgcatt ttgggctctt ctatatat 780  
 tgtaaaagtaa gaaatatacc agatctaata aaacacaatg gctatgcaaa aaaaaaaaaa 840  
 aaaaaacctc gtgcc 855

<210> 20  
 <211> 1120  
 <212> DNA  
 <213> Homo sapiens

<400> 20

cccacgcgctc	cggatttttg	acactgccgt	gattaatttg	aaaggacgat	actttgcctg	60
gacttggttaa	aagaaaaatgt	gaatttataa	gatgtttaa	tttaattaag	gttggtttta	120
attgttttga	agcaacatag	tcttcattaa	taataaaatt	gctggacaga	atgattttta	180
aaagacagcc	tatcagtttt	aatgaagtat	ctagttttta	aaatgggtgc	gttagtagag	240
cttttatata	tttttccctt	cctccttcct	tcctttcttt	ctgaaaagtt	actagaaaag	300
aaataatagt	gaacaaaact	gatctagaag	aaaagatgga	aggacataaa	acactaggaa	360
tgaaataagg	cataattata	actatgccag	gagctcgtgt	atcacaagaa	caggtgcagc	420
tttagtgcac	taagtttgaa	aagctgaatg	aagcttacta	tagtaaaata	ccagttatta	480
aaattggctt	gcagaaattc	gtccaatata	agtaaacaac	caatagcaac	caggtgtaaa	540
tagttttata	ggctaatact	accaaactt	taaggaaacat	ataatttctg	tgttctagaa	600
cttgggaaaa	gatggagagt	tcaaaaactca	caccgtatgc	ctagtataac	ctcaatgcca	660
aaccagacgt	ggcagcgaca	gaaaaataaa	atcagaccaa	agtcatttga	aaaaaaaaatt	720
cctatatatta	tgattcaaaa	ctcagttatt	ttataaaata	ataatattaa	gtggataaag	780
aaacgccagt	tgtactatca	gctaaacatt	agaaaccttc	tcatcaggcc	aggtgaggtg	840
gctcatgcct	gtaatcccag	cactttggga	ggccaaggcg	ggcggatcac	ctgaggttgg	900
gagttcaaga	ccagcctggc	caacatggag	aaaccctgtc	tctactaaaa	atacaaaatt	960
agccaggcat	ggtggcacat	gtctgtaaac	ccagctactc	aggaaggctc	aggcaggaga	1020
attgcttgaa	cccgggaaggc	ggaggttgcg	gtgagccgag	atcacgccat	tgcactgggc	1080
aacaagagcg	aaactccgtc	tcaaaaaaaaa	aaaaaaaaaaa			1120

&lt;210&gt; 21

&lt;211&gt; 1278

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (20)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 21

gcctcaaggt	cccgggtccgn	aattcccggg	tcgacccacg	cgtccggccg	cagccacagc	60
ttgcacgttg	cgccgggtgt	gtctgtgcgt	gccagctgca	tctttgcgtr	ccatgtgtgc	120
aaggctgtgt	ttggctgagt	gttcatgttg	scctgtgattg	tgggcatgtt	tctgagtgtc	180
tgagtgatgc	ctgctgggtg	gggctgggtg	gtgtgtctgc	atgtgcgtgt	gtgtctgggg	240
agtttcaaag	gagaaagagg	gactcaccat	cacgctggct	cagccttaaa	aaggtaggac	300
atcctgacac	gtgctgcaac	atggatggac	cttaaggaca	ttgtgctgag	tgaaacaagc	360
cagaggcaaa	ggaacaaaca	tgtgatttct	cccagatgag	gtttctggag	gaggcagatc	420
tgtatggaca	gaaggtagca	tggtgggttg	cggggcaggg	ggaggagaga	atggagaatt	480
agtgtttaat	ggggacagag	tttcagttgg	ggaaggtgaa	aaggttctgg	agctggatga	540
tggtgatggt	tggacaacac	tgtgcatgca	cttaataccm	ctgagctgga	cacctaaaaa	600
tgcttacaat	ggtaaatttc	akgtatatatt	tactacaatt	tttaaaaaat	tggtctggcg	660
tggtggctta	tgctgtaat	cccaacactt	tgggaggcca	aggcgggagg	attgcttgag	720
ctcaggagtt	caacaccagc	ctgggcaata	tggtgaaacc	ccgactctac	gaaatataca	780
aaaattagcc	tggtgtggtg	gcttgcaact	ctaateccac	ctactcagta	ggctaaggca	840
caagaatctc	ttgaacctgg	gaggtggagg	ttgcagtaag	ccgagatcat	gccactgcaa	900
cccagtctgg	gcgacagagc	aagactctgt	ctcaaaaaat	aaaagataaa	taaaaaaatt	960
agaggccagg	tgtggctcac	acctgtactc	tcaacacttt	gggaggctga	ggtgggagga	1020
tcgcttgaag	tcaggcattt	aagacatgcc	taggcaacat	agtgagacct	tgactctaca	1080
aaaaaattca	aaagttaatg	agacatggtg	gtgcacacct	gtactaacag	ctacgagaga	1140
ggctaagggtg	ggaggatcac	ctgagcccgg	gaggttgagg	ctgcagttag	ccatgattgc	1200
accactgcac	tctagcctgg	gcgatacagc	aagaccctat	ctcaaaaaaaaa	aaaaaaaaaaa	1260
aaaaaaaaagg	gcggccgc					1278

<210> 22  
<211> 742  
<212> DNA  
<213> Homo sapiens

<400> 22  
ccacgcgtcc gggatcaaca actgcgtggg aagccggaat tattggttct tcttcagcac 60  
tgtggcctcg gccacagctg gcatgctctg cctgatcgcc atcctgctgt atgtcctcgt 120  
ccagtacctc gtgaaccccg ggggtgctccg cacggacccc aggtatgaag cagcgccagg 180  
accctgacca ggaggacctg ggccagagaa gccctcggg gtgcaggaca agactgccag 240  
tctcagcccc aggcattggct gcacccgcac tgacacagc ccgggtggcg agacagggag 300  
gacttgctcg cccttggttc agaacattcc ggagccaaca cgggtgtgaca tttttttcaa 360  
ggatgagctt tgccagctcc acgtggaagt ccctaaagct cctccttcca cttcgaagcg 420  
tgactgatgc ctccagggcc tcacagccgc ttctgaagca cttcctgaaa gccagctcca 480  
ccctggcgag gccctgacct cagcggaccc aagcccagga cgatgcctgt tgcgttcttc 540  
tccccagta gcaagtcacc tccccagca gcctccatgt tgtctgggct ctccctgtgg 600  
gggatgccag gggagagtga gagagcagag gtggccaaga tggcatgtgc tgcttctct 660  
cctggaacat gctgcttcca cagggcaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 720  
aaaaaaaaaa aaaaaaaaaa aa 742

<210> 23  
<211> 1033  
<212> DNA  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (928)  
<223> n equals a,t,g, or c

<220>  
<221> SITE  
<222> (958)  
<223> n equals a,t,g, or c

<220>  
<221> SITE  
<222> (977)  
<223> n equals a,t,g, or c

<220>  
<221> SITE  
<222> (1005)  
<223> n equals a,t,g, or c

<400> 23  
ggcaagtgca gtagagaaat gggccaagtt ctctggacac gtgtggatgt gtatatattgtg 60  
ttatacacaa ggccccaat tcctgcaact atttatacat gcaattgttc tgttggttgc 120  
tgagatggaa atcatataca cagagttaca aattcctgaa atgttccatc tatatttgat 180  
ataaacagac atacagtagc tgagaaagta acacagcttg actattgctc tgtttacctt 240  
ctattggaaa aaataattgt atccagaaca ccatatcagc cttatagcac gactgaatat 300  
catgttgcaa ttaattaaca acctgatatc tatttgggag caaatttaag ggaagactgg 360  
aggcctagga aatagaatac aaaatctcaa aactttttta aaagaagtaa ttcttgaaag 420

aacaaagcaa	actcattcct	tcataccatg	cttctgaaag	ctattccagc	agcccytccc	480
ccaaacaggc	atgtaattta	tggatctttt	acaaggtaat	aaaccacagt	aattacctcc	540
ctgcatccca	aactaagagg	acaaattaag	tcagaacttg	aaaataattt	aaaagagttt	600
tcccttgttt	caaataggaa	aaggaaacgc	caagacatag	aaaaccacgc	ttttcccgtg	660
ggaagaaccg	atgatgagcc	ctgatgaaag	aaggaagaag	acccgctgtc	tgccaaggcc	720
taaaggttag	aaatacagca	atTTTTctca	tgccgaagga	aaggcaaaat	ggtctaagaa	780
actgcaagag	tgtgatacaa	gttttcttca	acagcgagct	gggactggcg	acaatttctt	840
aactcacagc	ctccgcagtc	gccttagtcg	acaaagagag	cagcccacgc	agcgggccgc	900
ggcccgttgc	ccgtggcctt	tttatttnct	ttttgccctg	aaagtttcag	ttttagtngg	960
tttttttttg	gggtttncag	ggaaggaaac	aaacacattt	ccctntttga	tttttccaaa	1020
accctttttt	tgc					1033

&lt;210&gt; 24

&lt;211&gt; 1913

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (12)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (14)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (398)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 24

ctcgcaagag	antntttgtg	tttctaatac	aggatctgga	agtagtgctt	tctaatectc	60
atttctctgta	ggatgttcct	gcactataac	aagattatgt	tttcttccct	ctgcagcagc	120
tttctgcttc	ttgggtacta	ctagctattg	ttcaattcag	gtgaggcctg	tgatgacata	180
tatgtagcat	gtgctctgcg	ctccctgcaa	gctgagcaga	tacaaccaat	gcactactgt	240
atactcttgc	tgagaatgtg	gatgcagcct	cacagatctt	tgcaacactc	caaccagcca	300
ggaccagtgg	atcagaactg	atcttattgg	tctgataacc	aatcttattt	gtgaactgat	360
tcatatctgt	ctttccactc	ttggttctct	tgcctganga	acaaaaacag	tttaggaagc	420
ataattacga	acatttagga	accaatatgt	ataagtaatt	cggagactcc	aattcacctg	480
ccccccccc	atcccagggt	gtggaggctc	gaggaagctg	acttcttagg	ctaaaggaca	540
aaaaaatctc	tttacctcct	tggccatttt	catgttctct	gccaaatact	ataggcagtc	600
ttcattttgc	agagggtgagg	taagacttca	tcttattctt	catgtaatcc	caccttctaa	660
caaaaaataa	ataaatattt	aaattccaag	gagaagtgtt	ctttgtgtat	ttctagcaga	720
aaacagatgc	ttaagcctaa	gaaggaagat	ccgtccatga	caaaggaaaag	tggaaaactg	780
aaccagtatt	ctgaataactt	catgccagga	cagttgctat	tagcaactgt	tttgacacct	840
cagggcttta	aaatgggctc	tgcagacagc	atttgcatat	gcaagactca	gtagccaagc	900
ctccactgcc	aattgttgaa	ggcagtttca	gacgccacc	ttttgaggta	catttcttta	960
agcacaagag	aagtagaaat	ggcctttgcc	ttgtctccag	tggtttgtcc	ctctgggtgcc	1020
tcagcagata	ccagagctta	ttcttatgac	catttggaag	tagtccctcaa	agtaaagatc	1080
aagaaaaaat	tggattcttt	ttccattttc	tcataatagt	agcctagtca	acacaagact	1140
cccataaaat	atgactcact	attgggagcc	atactatttt	ataagcttac	ttctgtctga	1200
caaaactagc	tttcttcaag	gaaatataaa	ggaggggaaa	gtcacatagt	gttaggaaaa	1260

cattcctgtg	ttttgaatac	gatgaatcca	taggatagag	aaaaatctgc	ttgttctatt	1320
ctgagagttc	tctgagatat	cccttcactc	tgcttggcat	ttggccattg	atattcaaca	1380
ggtcactgac	caagcttttc	taaatttttc	agagagagtt	acttaccaat	aaggctctgtt	1440
cttaaaccta	cctagttgat	tttcatatct	ttccataaag	tgatcatgatt	ctatcataga	1500
ccctgactta	acattgtaag	gactatgagt	cctcccattt	tttaattaat	tttttttttag	1560
caaattagga	cttcggcagg	ttttcctctc	ctaaactcat	tctttcctcc	acaggattgc	1620
tttgtccatc	tcttgctttc	atttcaagtg	cataaacaaa	acctcaaagg	gcctgggaag	1680
gtgaggcagg	ccagagtctg	tgttctgtgt	tgagtgtcaa	gctatttggt	aagaaggctc	1740
gcaacaggcc	tttggtgtgg	ctctgccaga	gactgttctg	aacactttgc	ttgagatccg	1800
tgccctgtaa	aatggatatg	atgttttact	gatgtctgta	atacatattgt	aaacttccaa	1860
taaaatttga	ataaaaaaaaa	aaaaaaaaaaa	aaaaaaaaaaa	aaaaaaactc	gag	1913

&lt;210&gt; 25

&lt;211&gt; 1733

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (893)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 25

ggcaccgagga	gatccgggat	ttgtatgtta	acatccagcc	tgttcaagaa	cctaaagacc	60
aagcatttgg	caatggaaat	ggaataataa	ttattgctga	gacctccact	ggctgtttgt	120
ttgctggatc	atcgcttggg	aaacgagggt	taaatgcaga	caaagttgga	attgaagctg	180
ccgaaatgct	attagcaaat	cttagacatg	gtgggtactgt	ggatgagtat	ctgcaagacc	240
agctgattgt	tttcatggca	ttagccaatg	gagtttccag	aataaaaaaca	ggaccagtta	300
cactccatac	gcaaacccgc	atacattttg	ctgaacaaat	agcaaaggct	aaattttattg	360
tgaagaaatc	agaagatgaa	gaagacgccg	ctaaagatac	ttatattatt	gaatgccaag	420
gaattgggat	gacaaatcca	aatctataga	gtatttgcct	cttaaattgat	acctcattga	480
tatattgcac	tatttcataa	atactataaa	ataatgacta	ggaagtaact	tattaaaggc	540
tatgacttaa	atttgaagat	gaagtacagt	gttctagggt	tgctgagaag	gctcattaaa	600
ttaatctcac	tttgaatatc	tcctgagaga	tggacaatga	aatatcagtt	gggtggatatg	660
tgtgatagct	gatttcaata	ttgaagtatt	gaaataaaaat	attcctttaca	cctgaagtaa	720
atacattttt	cttttttatg	taattaatta	aatcagggat	atagatttga	tctgtaattt	780
gggtataatt	ctaacttttg	ctgaaatcac	atctcaagta	taatgaggca	acttttatgca	840
aatgtacttg	ttgtgacaac	aataacattt	tctttttttt	tttttttttt	ganacagtct	900
cgttctgtca	cccaggctgg	ggtgctgtgg	tgtgatcttg	gctcactgca	acctctgcct	960
cccgggttca	agcaattcta	ctgcctcagc	ttcctgagta	gttggtatta	caccaccatg	1020
cccagctaat	ttttgtattt	ttagtaaaga	cagggtttca	ccatattggg	caggctgggt	1080
tcgaactcct	gacctcgtga	tctgcccggc	tcggcctccc	aaagtgggtg	gattacaggc	1140
gtgagccagc	gcacccggca	acaataacat	ttaataggca	ttgtctcatt	ctaattgat	1200
ataccttcta	cctagtgggc	actttgtaca	tattttattt	ttattttatt	tattcatttt	1260
ttttgagaca	gagtctcact	ctgtcaccaa	gttggagtgc	agtggcacia	tctcagctca	1320
ctgcaacctc	cgccttccag	gttgaagtga	ttctccagcc	tcagcctccc	gagtagctgg	1380
gactccaggc	acgtaccacc	ataccagat	aattttttgca	tttttagtag	agacgggggt	1440
tcaccatgtt	ggctaggatg	gtctccatct	cctgacctcg	tgatccgccc	accttggcct	1500
cccaaagtgc	tgggattaca	ggcatgagcc	accacagctg	gccgtaaaata	ttttttgaat	1560
ttgaatctgt	tttggaagcc	aaatatgttt	tgggaagcaa	acaattaaga	gaagtaaaat	1620
tttaacccta	gtagggtttcg	cagattcatc	cccagatatg	tttttgtttg	gcttgtgtta	1680
ttaacaaata	aatgagtgtc	tttcaaattg	aaaaaaaaaa	aaaaaaaaaa	aaa	1733

<210> 26  
 <211> 2722  
 <212> DNA  
 <213> Homo sapiens

<400> 26  
 tttgaaaaaa aagatgctta ctgtatactt gttttcaagc atcctctaaa atcaaagggtt 60  
 ttgatcacia tatgcagatt tctcttgata gatacttaaa taggctatct ctctcctctt 120  
 cttgggcaat gccttggttt ctctctgaa tatttgcatt tgaaaggatt gcttcctggt 180  
 ctgctcattg atcaaaggta gggccaatta aggattctaa ccctaaccga gcaccacaaa 240  
 gccccctgg agcatcttcc cggctggcag gaccatgcca tctctgtgga gaagggtgctg 300  
 gggaggggaag tccttccagt gccacatgga gtgaggccct gcccatgctg gggactttgg 360  
 ggaggaattt ggtattctgg tggccttgct cagctctcat tgagatcttt tcctatcaga 420  
 atgttagtga atatacttcg cagctctttg ttcagcaata aggaatattc tttcaattcc 480  
 tgctcttcaa gccaatctac tacaccagc tgtctttcca gaagttcatc ccagcggtaa 540  
 tatgttggtg tttgttcttc tttggatttc acatctgttt tctggtagaa gtgagcactg 600  
 ttcacttggt cagtcgtctt attttctctc ttcctagatg actcagctct ttgtaaatgt 660  
 tgtgctcaac ttctaggggc cagttctaga ctttggagat gcagtgtctc ccagggtgtgc 720  
 acggacacct ggtccgtgga aacagggtgt atgggcacag gctgctgccc ttctgtctgg 780  
 tcgggggatt cctcttcttc aagctgctca gctaaccag aagaggggag agagtactcc 840  
 ggtggttccc agagcccctc ccgttggtgc gcttcgacct gacacctgct cgatgctgac 900  
 ttaggcttcc tgccaccaag caggaaacta gaaagagaac atttcagtgt aagggtctgtt 960  
 cccgacagca tggattagct tccgtgttct gaagttgttc ttttcatggt gtctgacacc 1020  
 gagggcggtg ttcgtccatc aggcgggatt ggatggagtc ttggtgtttt gccttctcag 1080  
 ggacaaaaaa tgtatcattg actccttaac agtgacctc ctcccaagga catatccgtg 1140  
 ttcatttttc ataggtttta ctcatttca taggtagatt ctgttaatgt gagtggaaa 1200  
 gaaaagacca atttgtacac cagtcacacc acaagacagt ttatcatata aaatacctca 1260  
 attttttgta ttcctcattt ccacctcaca attgtactgg tgatgaattt taagggtctg 1320  
 tccttttagct tataggtgat gtttcacatc tggccagatt cttatactc cattgtatac 1380  
 ttgaaaaggc tcagaattac aggaacagca gtgagaattt ggccactac cactgactcat 1440  
 ttgtttcatt cacattctc acgtgcaaca acataattat attttaagaa aatgtaactt 1500  
 tgttacatca aaatatgttg tctagtaaaa agttgatatt cagtagaaca aggatcatgt 1560  
 aaataaacat ctatttcaca tgtacccaaa agcattttaa aagcagaatc cagggcccag 1620  
 agcatgagcc agggaggagg atgtttttct tcytttctct atttttccct aaattgtgca 1680  
 aacatagggtg agtctcttaa cctttctgtg cctcagtttt tctacctcta aaggggtggg 1740  
 atggttcttc aaattgtttc taaaacaccg gcactttcag cagtgttctg gtggcctgag 1800  
 atgagagcac cgtgttcaga agtgccctgg agtggcacag tggaaactcc gcttgacagg 1860  
 accatggagt ctgctcagga ccattgctga ggacacacag cctcatgccc tgagaaagca 1920  
 aaggaagtgc tgggtgtaaa gtttgcata tcccatgaag ctttagtttt cctttttttg 1980  
 ttttaaaaga aagggtttta tatgttctat tgtaaaatat ggaaattaaa cagggacttc 2040  
 agaaagccgc acagaaagat caccttcyga tgggtgtgat tgctcctgac attcggccga 2100  
 ggtctgtatt ctgaaaaaga tttaatggcc tgtgaaacac gtggattctg ttgcactgga 2160  
 tttgtaataa atgacgctga acttctctg tccaagcagc tcaaccctga tgctgaactg 2220  
 acaccaggcg aatgtcaggg ctcccaaacc actagtcca aagggtcatg ttgaaaagt 2280  
 cagaatatct atttgtcaga atataataat tgccccccac cttagtattt ttgacttta 2340  
 cagaaattta gatactgttt ttcagtggct tgagcgtttt gccttttcaa aggataacta 2400  
 ttattttctt gaaaatggaa tataatcatg agaggaagaa gatgtaaaaa atgtcaaatg 2460  
 ttgattgggt gtgtaaaagt tttgtcatag acatgtattg gggagcttcc aattagcata 2520  
 catagacaca tgtgtcagtg gccaaagacct gcttatattt tgctttatag atgtagtcac 2580  
 agcatgttgt tattgcctca tgtaaaataa aaggctatta agttttccag taatatattat 2640  
 taatctgtat gtgtttttaa ataaaataac ttatttctag ctgaaaaaaa aaaaaaaaaa 2700  
 aaaaaaaaaa aaaaaactcg ta 2722

<210> 27

<211> 1094  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (470)  
 <223> n equals a,t,g, or c

<400> 27

ggcagcagta	cttgcataatg	gtgaattact	actgttgaca	gtttccgcag	aaatcctatt	60
tcagtggacc	aacattgttg	catggcagca	aatgccaaaca	ttttgtggaa	tagcagcaaa	120
tctacaagag	accctgggtg	gtttttcggt	ttgttttctt	tgttttttcc	cccttctcct	180
gaatcagcag	ggatggaagg	agggtaggga	agttacgaat	tactccttcc	aatagtagct	240
ctgaagtgtc	acatttaata	tcagtttttt	ttaaacatga	ttctagttaa	atgtagaaga	300
gagaagaaag	aggaagtgtt	cactttttta	atacactgat	ttagaaattt	gatgtcttat	360
atcaagtagt	tctgaggtat	tgatagcttg	ctttatttct	gcctttacgt	tgacagtgtt	420
gaagcagggg	gaataactag	ggcatatatt	tttttttttt	gtaagctgtt	tcatgatgtt	480
ttctttggaa	tttccggata	agttcaggaa	aacattctgc	atgttgatc	tagtctgatg	540
tacttatcca	tctcattaca	aacaaaaaca	cacagactgc	attttagact	ctgtaatcct	600
tgaatacggg	agtaaatttt	cttctttcct	gactttgaca	ttgtagctat	actgtttcca	660
tttttgtttt	tacaaatcct	ttgggtctaa	ttctgtgagc	ctacctatag	cactggatta	720
aaatgtctgc	atcatttctt	tagttatcca	gttaacttta	aaactgttgt	aaaagtgtaa	780
accagcccat	gacaggtttt	tgtacatgtt	aaagaacttc	attgttcagt	tttcatgatt	840
attgtgtaag	gaagactgat	gtagatgttc	tgtgctgtcc	tggaacctgt	taattacact	900
tacgacgtat	tttagttcca	catcacaatg	atttgtcccc	agtgaccctt	ttatcctttc	960
taggcacatt	tcttgttgtt	gttgttgttg	cagttccccct	ttgcattgta	ttgctttgac	1020
aactgtaatt	tgaatcagat	ctgaaagagg	tccagaataa	aatatatattt	gatattaaaa	1080
aaaaaaaaaa	aaaa					1094

<210> 28  
 <211> 1839  
 <212> DNA  
 <213> Homo sapiens

<400> 28

aattcggcac	gagtgggcag	tgaaatctag	ctagatgacc	ataatatgtc	tgcttttctt	60
gactttatta	ttattacttt	ttaagggcat	tgttcaatcc	tcgattttgt	atctatggca	120
gcaggtgaag	gtctctagat	gagcgttcac	atacacgatg	acaaatgggt	aaggaatttt	180
gaggctaata	tctttactgc	ttagatgtca	tgtactttat	aggcatagca	tttctagatt	240
taataggaag	gatctctgct	ctgtatgtgc	ttttatgtga	cttgcaaagg	aactattcca	300
tttaaataga	tttcaattag	gataatgggt	ttgagacatt	tcacaatggg	atattttcta	360
gactcttaag	atagaattgt	caaattatag	caaatagagt	tagaaattat	tttgcaattt	420
tctcagcaga	ttgtaatttc	tcttgccata	catgtagtca	ttgtaaaaat	aatagtgtaa	480
gggtaccttt	tataaaaactg	attattttcc	aaatagactg	gtaccttttg	gtttagaaaa	540
aaaatgatgg	aagaagattg	tagttcagga	gagcaagcag	aaagcagtca	tttttcagcc	600
tttcatttta	ttgtaccttt	ggtcacattt	ttgaagaaag	gccccaaaat	gccatattga	660
tgaaagaata	ttggtaattg	ggtagagttg	gaatgaaagt	gagattttca	gagtaacaag	720
gtcactttct	tctgtggctt	gtagaaacag	atatgtgatc	acaacagggtc	cagcagccag	780
ggttgggggg	agtagagagt	tcatgttaatt	tgtatcatgc	ttaaatttcc	atatttgaaa	840
aagcaactag	agaacaggat	tttgtcaaaa	caaagagaaa	aaaataattt	ttttaaacag	900
gagggggaaa	tgtacgtgtt	attcttacag	gatgttgaaa	aatgtttaaa	tagctgcgat	960
acagtttgtt	gagggggcag	gggacagtgg	gaacagtgc	taaaggggta	cattttgatg	1020
tagaaatgcc	tagttgaaga	aaaaagcttg	cctggggagga	aagtttctgt	ggagatgtac	1080

cctgcatttg	gagtgatgta	ctgaagcatc	aaagactcag	cattaatttt	gatctttctt	1140
gggaagctgg	agaaaataat	gcattttctga	gaaaaaatag	taacttatga	aatgtcaaag	1200
cctgctctgg	acaatgtcaa	catccatgag	tgcgaggcaa	attcaagaat	ccaaacccta	1260
agtgaagacc	ttcctgacct	gctgtctaga	cgtcaggggc	tgtttgagcg	gtgagggtcca	1320
gcgggttagg	cattccaaag	atacgagagg	cccacaccca	catcaggatt	gtgtgttagt	1380
tctcaggctt	cctaggattt	ttcttgggaa	aagggttttg	accccaagtg	gtcctccagct	1440
tgacagaaat	ctttagaggc	agctcagaaa	aactttgggt	tcccaaaata	atccaaaggc	1500
taaagttctg	ccacccttta	aaagagtagt	gttttggctg	ggcgcggtgg	ttcacacttg	1560
taatcccagc	actttgggaa	accgaggcgg	gcggatcacg	aggtcaggag	ttcgagacca	1620
acctggccaa	catggtgaaa	ccccgtctct	actgaaaata	caaaagttag	ctgagcatgg	1680
tggtgcatgc	ctgtagtccc	agctacttgg	gaggctgagg	caggagaatc	gcttgaaccc	1740
gggaggtgga	ggttgtagtg	agccgagatc	ccaccactgc	actccaacct	gggcagcaga	1800
gtgagactcc	atctcaaaaa	aaaaaaaaaa	aaactcgag			1839

&lt;210&gt; 29

&lt;211&gt; 1330

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 29

ggcacgagcc	tgcagctatc	attcatccag	ttaagaattt	gaagaagtgt	gtgcacaaag	60
tatcacagcc	accggaaaaat	atgcacatga	tgctggagca	ttagaatgca	acagaaagag	120
ccctgggctt	ggagtatgca	gaactgggtc	ttgttacaac	tcctcttact	agtgggctct	180
ggaagaaaac	acattgaatt	catgatcatg	gttaaccttt	ggagagagag	aggagaccag	240
gatgaaggag	ccagtcgaag	atcctgttca	agtgtacact	gagccagcag	gttcaccaga	300
aagctattga	gcgtttgctg	gaacacatta	tgcagggtga	atcttctctg	gaatgttgcc	360
aaggattttt	tatgcttctg	tggcaggcat	ttcttgaaca	ttgtcattta	gccaaagcaa	420
gaagattttc	ttaaaggata	gaaaatgttt	aaaaattttt	gtttgtttga	agataggtta	480
aatggctata	tgatctcagg	ataagacaga	gaaaatcact	tatttctcta	agtgatctga	540
ttagggttagt	gatgttttgc	ctttaaacag	attcatcatt	attcctaaag	tattgctgta	600
ttaatactgt	ctctagaaaag	tatccaccag	tgccctactt	tcttcgatat	cattagctgt	660
ttttcgaaaac	tgaattttgct	cttcagagat	ttctcatatg	tttgcgata	agggaactact	720
ggtaatatgcc	aagaaaattt	ggagggtgcag	agaacatgct	gaaacagaat	ttcacttttca	780
attctagaac	tatgccataa	aaaaaaaggga	aaatgtaaaa	atgtctttat	attagagcag	840
atatttttaa	agtattgcaa	attcaatgat	aaattctaag	gttaaaattg	gacacataaa	900
aaatacaata	tataaatatc	tcccagaaa	ttattatcta	atgaatagta	aaagctgact	960
acaaacctatg	tcattttaac	aagggtttta	atagtaccaa	gattctcatc	atatgctctg	1020
ggataccag	tgatgtacaa	gggttctctc	taaacatggg	gaggaaaaat	ttcaaatata	1080
aagatttgaa	tcttgtcttt	gccattcact	agctgtgtga	tcttgggtta	gttacctggg	1140
ttctctgagc	ttcagtggtca	tctgtaaaaac	aggaataata	atacctagct	cagagggtggg	1200
tgtggtggct	cacgcctgta	atcccagcac	tttgggaggc	caaggcaggt	ggatcactag	1260
gtcaggagtt	tgagaccagc	ctggccaaga	tggtgaaatc	ctgtctctac	ttaaaaaaa	1320
aaaaaaaaaa						1330

&lt;210&gt; 30

&lt;211&gt; 1504

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1120)

&lt;223&gt; n equals a,t,g, or c



&lt;400&gt; 30

gctcctctga	tccaggagca	ttggcagggt	tgtgttggga	ctgctgggta	agttggagct	60
gtgtaactac	ttagtTTTTg	gtagccaatc	agaacgcag	ccccacatat	tccagctcgg	120
tacatgttga	taaacagact	catccaaact	ttcaaaatgg	attcgtacta	aacatgctca	180
ggTTTTaaat	tttggtttgc	ttttgagctt	ttcctcttta	tgtggctctt	aataataagt	240
agttagaatg	aaccaagcca	tcccagttat	tccaagcagg	ctctcaaagt	acctttgagc	300
accttccacc	tggctgggtc	ccagkccagg	gtccacagcc	ctgctccctt	ctcagcaagg	360
aggggtggcct	gtctgacagt	gcagttgaac	cTTTgctccc	tactctgcaa	cttttgaaga	420
cttcaggcta	atcaaaatta	cttataatta	gaatcaagt	cctttattct	tgttttttat	480
ttttatttta	tttattttat	tttttagatg	gagttttgcc	cttgttgccc	aggctggagt	540
gcaatggcat	gatctcagct	cactgcaacc	tctgcctccc	gggttcaagc	gattctcctg	600
cctcagcctg	ctgggtagct	gggattacag	gcattctgcca	ccacgcccgg	ctaattttgt	660
gtgtgtgtat	atgtctatgt	gtgtgtgtgt	atgtatatat	cttttttttt	tttttttagt	720
agagatgggtg	tttcaccata	ttggccaggc	tgggtctcaa	ctcctgaact	catgtgatcc	780
gcctgccttg	gcccctcaaa	gtgctgggat	tacaggcatg	agccaccaca	cccggcctat	840
tcttggtatt	ctttattctt	ggttttctag	ccttttagaaa	aaaaaaatct	agtcttggtg	900
aagaaaatgt	tcattttaat	caagctccag	tacagcttgt	gtcaagacct	agtaagacca	960
cctttaatgt	gttcctggat	atgacattaa	aaactaactt	gaaaattggt	aggatatattc	1020
cttgttccct	acttttattg	taaaatctac	tacattctta	agaattaaaa	aatgccattt	1080
cagaagagat	gatagtttta	tcttggccaa	ggaattatcn	ttcttagtag	cctatatattg	1140
cttattccaa	aaaaggcggt	aacctccatc	aaaacatctt	ctgcgcctct	ctctcagcat	1200
atgctttgat	atttgaagt	tgtaatagat	tggagctatc	agtcacttat	ttctaaaaaa	1260
tgtattcttt	tttcttcata	gctgtgaaga	gggataccaa	ggaaagttct	ttctgtgtgc	1320
tttctctttg	gtaatgctta	tcttatgaac	actcaactga	aaaaaacactc	cacctaaag	1380
caggaaagat	ggcaattcta	aatagcagct	attatccccg	ggtataaaact	atttttgttg	1440
ttggccttggg	gctttgctgc	aggtattaat	agtttaaaaa	aaaaaaaaaa	aaaaaaaaact	1500
cgag						1504

&lt;210&gt; 31

&lt;211&gt; 1280

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (893)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 31

gaattcggca	cgagctcctg	tggaggaatt	tctccctttg	gaactaagac	ctctaagcca	60
gtggggcata	aaattatgag	aacaggaaga	ataaattttg	ctagtgggtc	accagggtta	120
ataatgcag	gtgccacttt	tgtttctacc	ccttgattcc	tggctatgga	gggaaaaaaa	180
gtaccattta	ttggatgctg	attcagagcr	tatatatagc	cctctggaga	actctgccct	240
ccctgcmagt	wattgccacc	tagctgggtc	tataactgaa	tcttcaaaag	gccatcccat	300
catcctatta	ggccagcttc	tttagcatga	taaggaacat	agaccagtga	attccaggag	360
caatgactca	tactgaaatt	yttttgctgt	gaykgaktct	tgatcasaag	caatggtgta	420
tggaaatatga	caatgggtaa	agcattccat	gagaccatgg	atgacaattt	tggcagaatt	480
ttgtatgagg	aagcaaactc	gtatcgaggg	tctgttctag	taagaacaaa	atgctacccc	540
ttccatgatg	gaagtagttc	aatgtaatca	actacaaagc	tgactgagca	cccagaggaa	600
tagtgccata	cttgaggtca	gtgtygttkt	cwgctgctsa	ctggttgggc	cctcagcagt	660
ggcatccagg	ttggccttgg	atagtggaaa	tccatattgc	tgagcctatg	tatgamctcc	720
attcttgcca	ctgtggccac	tttgttcatg	agccatgaac	aaagaggata	ccagttagcc	780
tctttcccca	gccctgttct	gacaggggtg	gctggaatag	agactgactg	gtttccacag	840

acttgattat	cctatatcca	cttcattatt	aaaatcctcc	tctgctaaga	tcncctttgg	900
tgagaatttt	atggcataca	tccttctttt	cttttcttct	tttctttttt	ttcccattga	960
gagaggctctg	tcctgggtgg	gtgtgatggc	tcatgcctgt	aatcccaccg	ctttgggagg	1020
ttgaggcgag	tggatcgctt	gagcccaaga	gtttgagacc	agcctgggca	acattgtcaa	1080
accatctctt	caaaaaaata	cagaaattag	ccagggtgtg	tgggtgcactc	ctgtggttcc	1140
agctactttg	gaggctgagg	tgggaggatc	acctgagccc	gaggagggtg	aagctgcagt	1200
gggctgtgat	cgcgccactg	cactgcagcc	tgagcaatag	agtgagatcc	tgtctcaaaa	1260
aaaaaaaaa	aaaaactcga					1280

&lt;210&gt; 32

&lt;211&gt; 1528

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 32

aattcggcac	gaggtttgtg	gaaacaaccc	ttagaatcct	attatTTTTT	aagaaggaaa	60
aattggacag	cctcctgagc	cagagtaggc	tcggagactc	ctgttgTTTT	taactgaaat	120
agtaaataat	gtatttccac	cattttaccca	gagtaggctc	agagactcct	gttgTTTTcta	180
attgaaacag	taaataatgt	atttccacca	tttagtagct	tttcaagagt	ccttaaaaaat	240
ttttggacag	cacagaaaca	tggattactt	agccctttag	ttctcagatt	gagttatata	300
cttcccagca	atttctgtta	tttaagattg	ctatctcatt	tctgggtgtaa	tacttacatg	360
gaagtctttc	tctatttggg	ggtgggtggg	ttctggcaca	taggaatttc	ttaatggcag	420
aatattctga	aattctcggc	attaaagtat	acttgataat	tagttcactt	aatattaaag	480
catgttcatt	cttttcttcc	caggctcgcta	ttaaagcatg	aagactttct	gaaacctgcc	540
ctagagctgg	gatattgttt	gtgggcaata	ttttttattg	tctcttgttt	aaaaagtgaa	600
cagtgcctag	tgaagttagg	tgacttttac	accttttacg	atgactactt	ttgggtggagt	660
tgaaatgctg	ttttcattct	gcatttgtgt	agtttggtgc	tttgttccaa	gttaagtgtt	720
ttcagaaaag	tatgttttgc	atgtattttt	ttacagtcta	aattttgact	gctgagaagt	780
ttctattgta	caaaacttca	tttaaaagg	ttttctactg	aatccagggt	attctgaaga	840
tcgaagcctg	tgtaaaatgc	taccaaattg	caaaaagcaa	caataaacag	tttgattttt	900
acttttcttt	ctaacatatc	aatgcttagc	agaactattc	agattgtcag	tagtaaattt	960
aaagacaaat	gcccgttttc	ctccagtcga	tgaaacatac	catacttata	tacctgcaac	1020
taagtgttta	aaattatgct	ctgtaactct	gtactgctag	tattagaact	aaaaatctta	1080
aaatacagcc	agtgcctaat	gcttatatca	atgtggattt	gtcggctttt	atgtaatctg	1140
taatatgtat	agcaggaaat	acgaagagtt	acacagtgtg	tgcttataaa	ggctgtttct	1200
taaagggtgt	acaaggggat	aatgggtatt	caactagtta	tcagcaagtg	acaatacatt	1260
ccaccacaaa	tacactcttg	ttcttctagc	ttttagacta	tatgaaaaaa	cggggtgctt	1320
caaagtacat	gataagggaa	cactatacct	gtcatggatg	aactgaagac	tttgccgtgtt	1380
catttttttaa	atattatttt	caggtccttt	gcttaccaaa	ggaggcccaa	tttcaactcaa	1440
atgtttttgag	aactgtgttt	aaataaacgc	aaatgaaaag	aaaaatgttg	gtgcagctgt	1500
tcacaaaaaa	aaaaaaaaaa	aactcgag				1528

&lt;210&gt; 33

&lt;211&gt; 1458

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 33

gaaaaaatga	tctctgattc	atcagcatga	atttccaagt	ttgggggtaca	gggcaatgca	60
ctttcctcag	tttatttata	ttattgtttt	taaaaatttg	caatacttac	caaagataaa	120
ggatttgtaa	gaaacagctt	ttggaagagg	agcagtgtata	taggtttatt	ttactaatga	180
taatagtaaag	taaattataa	agaaccttta	atgttttctg	agaaagtaaa	gcctattctt	240
ggagtttata	atcattttaag	tggttctgga	caaaacttac	caaattcttt	actgttatta	300

ctaaaaagra	tgtaacaat	tttaagaaaa	caaaaaaatt	atTTTTtaag	aattttgttt	360
atcggttgat	atactcattg	ccaaaccaga	ttaaagtaat	attccaattg	gattggcttc	420
ttctaagctc	tacttctaag	gaaattgttt	ggattgattt	gctgtctgtg	ctttgagaat	480
gacttttttc	ccctcctcct	tttttttaaa	gcaaactttg	cgtaacttat	tgagcaaggt	540
ttcccccttc	ttttctgccg	aacttaaaaca	actaaatcaa	cagtatgaaa	aattatttca	600
taaatggatg	ctgcaattac	agtaagtatt	atcattacaa	acccttgtaa	aataaagaat	660
aatattttaca	tgaatcttta	tgtaaaagta	agttaacatt	tttcttttta	cagtgaagtt	720
cagatatTTta	gtcatatata	aaaataaatg	taaaaataga	cattatgact	cagatataga	780
aatgtcactt	tattgtatga	ctcttcccag	aaattctaca	gtttttaaga	aattttgtgtt	840
tatcagactt	gacagccatt	gataagataa	atagcatttc	ttagaattat	gttattgggtt	900
taaaaaactt	gaatatttcc	tttgtcaaga	tttaataaata	taacaattag	aaaaaaaaaat	960
tataaagttt	tccacagcat	agttctttta	atgaaaggat	aatattttact	ttaatcttat	1020
gtatgtgtac	tacagacttt	cagaatttta	tgaacagatt	tgttctataa	gcattatttt	1080
actatttttaa	cattatttcc	tagaatrttt	tttctactgt	attatttttca	cacacctcag	1140
attaaattttt	aaatttccat	taaaacacct	agaagaatga	ttgaaatcaa	aacataatac	1200
tttctttttta	tgataattac	ttttatcctt	gcagttaaaa	agacttgaac	ataaggaagt	1260
gcttaaaatg	tacactaatg	tgaatataca	tgcacactca	cagttacatt	gtcactgagg	1320
taaataagaa	ggtagagcca	tggaccaggc	acttggcctc	ccataatccc	agtgttttgg	1380
gaggccaagg	caggaggatt	gcttgagccc	aggggtttga	gagactctgt	cttaaaaaaaa	1440
aaaaaaaaaaa	aactcgag					1458

&lt;210&gt; 34

&lt;211&gt; 1760

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (129)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (132)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (179)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 34

tggtgaacag	cctgtttgct	ggaatggacc	tgacgagcct	tcagaatctc	cagaatctcc	60
agtcgctcca	gctggcaggc	ctcatgggct	tccctccagg	actggcaaca	gctgccaccg	120
ccggagtgnC	gnaagaaccc	tgctgctgtg	ctgcccctga	tgctgccagg	aatggcgng	180
cctgcccac	gtgttgggct	tgggctgggct	gttgaataac	cctctgtcag	ctgctactgg	240
aaacaccact	actgcttcta	gtcaaggaga	accggaagac	agcacttcaa	aaggagagga	300
gaaaggaaat	gagaatgaag	acgagaacaa	agactctgag	aaaagcacag	atgctgtttc	360
ggctgctgac	tctgcgaatg	gatctgttgg	tgctgctact	gccccggctg	gattgccctc	420
aaaccgccta	gccttcaacc	ctttcctcct	gtccacaatg	gccccggggc	tcttctaccc	480
atccatgttt	ctacctccag	gactgggggg	attgacgctg	cctgggttcc	cagcattggc	540
aggacttcag	aatgccgtgg	gtccagcgga	agaaaaggct	gctgacaagg	ctgagggagg	600
accctttaaa	gatggagaga	cccttgaagg	cagcgatgcc	gagggagagc	ctggataaga	660
ctgcagagtc	ctccctctta	gaagacgaaa	tagcacaggg	tgaagagcta	gactcacttg	720

atggggggga	tgaaatagaa	aacaatgaaa	atgatgaata	accagtacca	gttccagttc	780
aagtgtttta	aacttttgac	aagtggtagt	cctactgttt	acactcacag	ttaatgttca	840
tacctagttt	tataagctgt	tctgtaacat	agtgtagcaa	aaaaaaaaag	tcaagtcattg	900
ttatacaggt	gtgtcaaaaag	gtatcttggg	cattaagtat	tgtgcagtcg	attatattat	960
atccctagga	gagatgraat	ttgagagggtg	atcatgtytt	tttaagggraa	cttamataat	1020
gctctgcttt	tttttttytc	ttggtaccat	tggtattata	ataaagagca	atttgtaact	1080
gagtggcact	aatggaagaa	agtgtctgtc	aaaggaagta	tgaagttata	tattttaattt	1140
tttaattttta	atttttaatt	tttttgctgt	gaaggccaag	ctgaaattta	ccatacatat	1200
catacttgct	catttgtttc	cctttttgac	tgtatggggg	ttcccacact	cgtgcataca	1260
cacacatcca	tacactctga	caatctccac	gctagtgtga	acgcctctgt	cccaggcgcc	1320
agcaataata	aggcagctgt	tgaatgtgaa	gggtcccttt	ggaaaattta	cctactggga	1380
gggttcttgc	cagacagaac	tacagttcca	ttgtctcgtg	gtcttgtaat	gcactggtaa	1440
aaacaaaata	aatagatgaa	taaaataaga	gtgagagaag	agagaatcag	gtaccttttt	1500
taaattaaag	gactttgtta	ctttagccac	aaagctaaaa	cagcattacc	tcagctctaa	1560
actagccttg	aagtttacag	acatgacttt	gtaaatgtat	tgtttttctt	tgttgtgatg	1620
tcctttttatt	tttttctttg	aaaactgcta	tcattgtaaga	taaaatgtaa	attgctgcca	1680
actgtagtaa	tgatgctttt	aataaaaagt	acccatgata	aaaaaaaaaa	aaaaaaaaaa	1740
aaaaaaaaaa	aaactcgkag					1760

&lt;210&gt; 35

&lt;211&gt; 1568

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 35

ggcacgagtt	ttaaattaaa	tggaatgcc	actgacgtga	tgtcgtttgc	actgcaggat	60
gacagaactg	ttgtgtgaat	accattgtat	ttgccaaatg	gtccactcgt	catttcagaa	120
caaacaaatg	gatgggtgtc	gtaagtcggc	aaacactggg	gacatttagc	cttgtttatg	180
ttcctttcct	tttgctgcat	atttttggct	ccaaaagcta	ctggctgaat	caacagggcc	240
tctgaatcag	gagagaagtc	tggtagcatt	aatttttagt	gctatgtcca	tattctcttc	300
agactgcatg	aatcctactg	ctcaggacca	agtctagggt	agaggagagg	gcaatcaacc	360
tcttttggtt	cggatgttgt	gtgcaaagcc	cagggttcaa	ataagcagta	attatctcct	420
attacttagt	gctgatcaac	agcacctcta	cgtctaattg	ccaacctgcc	ctaactcatg	480
tgactattct	tgttttagcc	agagacagaa	ggaccaaat	ttataaataa	cactttattg	540
tcattattcc	attaaacgat	taggggatgt	ggccctgccc	ttgctttcaa	atgcctctag	600
ccctgatggg	ttctggatta	tttaataaat	ctgcacattt	tcttgccagg	aagtgcact	660
ccctgtccta	gtcgggtctat	ctggacttgc	ccttgctcgt	tcgtggctct	cgggtggtat	720
ctgcagcttg	ttaatcgtgt	aaagtcaaga	gaagaatgta	tacacatatg	tgtgttgaat	780
aattactatt	ggcataggta	tgtgtatata	cacggtgcac	caatctacag	tatatatagc	840
agagaatcag	aggctaaaaa	tattacccca	tatgttccag	tattagtcac	ggattgcaaa	900
ggcttagtaa	cttgagcagg	agagaaaact	ccctcaaagt	cataaatcct	gagtgcacaac	960
tgtctgtgga	tgacagatcc	cttcacctgt	ggacaacctg	gctgggggtg	gggggctgtt	1020
ccaccagctc	acctgagcat	gtagagggtg	gtcctgcagt	ggtctcgtgg	gtattactgc	1080
ttgtgtctga	ttgtcctgta	ttttgtaaca	ctttagaaga	atacagaaaa	gtgcagtaat	1140
tctctttctc	catagtattt	aagcagaaat	attgctagtt	taatattgtg	tcaggctcgtc	1200
ctattaacca	ggagcagatg	acagtaaaat	ttcagtgaat	agcaccttga	catctacaac	1260
ttaaaaatgg	tgattgaagc	aaaatatgta	aacttgtacg	gggtgatcgt	gtgctttgga	1320
acagagtatt	gttgaagtaa	ttagaagata	tattaagggtg	ttcctggtaa	tgaaggcatg	1380
taagttataa	taattgtagc	tttctgaata	agtgtcaaac	tatatcttta	agtgtgctgt	1440
atgctgagtt	acaagttagg	tcattttatga	atggaatgta	aaataatact	aaaaatgctt	1500
caataactta	tcttggtatt	gctaataaaa	aaaaaaaagct	gtgaaacatt	aaaaaaaaaa	1560
aaaaaaaaaa						1568

<210> 36  
 <211> 743  
 <212> DNA  
 <213> Homo sapiens

<400> 36  
 gattggtcag atttgccttt ttccagaatc tgaagtcatt ccgtactgta tgtacacatt 60  
 tgtgtctggc ttggctccag ataaagtttt tgggattcat gaatgttgtt gcacgtatta 120  
 ggagagactc ctttgtattg ctgagtagta ttccctctg tggtagacc atgatttatt 180  
 tatccatcta cctgttgggtg aacatttttg ctgtttctaa ttcttggcca tcatgaataa 240  
 aactgctgtg aatgttccta caataataat tgtctaaaca tatgttttta tttcttttgt 300  
 gtcttagtcc gtcgggctgc tataactaag aaccacagcc tgggtggctt ataaacaaca 360  
 gaaatttatt tttcatggtt ctggaggctg ggaagtccaa gatcaagggtg ccagtggatt 420  
 cagtgtctgt tgagggccca tgtcttgatt catagatggc ggtcttcttg ctgtgttctc 480  
 ctagacatgg cagaaggggc aaggagctc tctggggtct cttttataag ggcaccaatc 540  
 ccattcatgc aggctctgcc ctcatgacct aatcacctcc gaggaggccc aaaggcccta 600  
 cctccaagta ccatcatatg agggattagg tttcaaggta tgaacctggg gaggacataa 660  
 acagtcagtc tagctttttg ggtaaataaa ttgctgggct taataataaa tgtatatatta 720  
 actgtaaaaa aaaaaaaaaa aaa 743

<210> 37  
 <211> 1715  
 <212> DNA  
 <213> Homo sapiens

<400> 37  
 ggcacgagat catggccttg ttttttacag gcccaacgaa ggaaccactt ctgggaactc 60  
 attgaggaaa gagagaacag caaccctttt gacaacgatg aagaagaggt tgtcaccttt 120  
 gagctgggag agatgttgct tatgcttttg gctgcagggtg gggacgacga actaacagac 180  
 tctgaagatg agtgggactt gtttcatgat gagctggaag atttttatga cttggatcta 240  
 tagcaacctt gcgtggcgtg tgaactggtc tgcgtacctc agacagcaga tgtcccctgt 300  
 ggtggtgtgg cagtgcctgt gttctctcct aggcaggcct ctcaactcca ggtgctgtcc 360  
 taagaatttt taccagggc tgtttctcaa cccctcacct ttccctgagg agtgtgttgt 420  
 tttccctgtt gaaaaaagt acaaaaataa atcttaaagt tagttttttg taacacgaat 480  
 ttaactgtca gacagttagt gtaggtgtgt tgcgtcatct gttttcaacc agattgcatt 540  
 tatggacttt tcacacactc attttgagga cccaggttc aaaagtaaaa gcagtggccc 600  
 tgctttgggg tccaagaata ggagtgatgg gtgaaggagc ctaagctggc caatagccct 660  
 ctgccccaga catgggatgt ggatccttga ggtttctggt gaaatctgca catctgtgtt 720  
 tttatatctg ttccctaccc tgtaatccct accagtgca cttgttctgt ggttttggtc 780  
 tcttgtttaa ttgcacacaa gtaatactac tgggtaacca gaatcagggtg tgaatgtgtt 840  
 gagatttttt actgttttgc atgataggaa aattgagaaa gaatacgtat aaaagataga 900  
 gaggcataac atcaatgcag agttggaagt tggctcccaa gggctgacat ggtgtgagtg 960  
 tgtgggtgtg tgataagctt ctcatccctg catagatgca gtattcttag ccttagtaga 1020  
 aaaacctggt ttagtggttt aagccttggtg tggcagatag atcttaaagg gcaaagcagt 1080  
 atattggtag ttgtcaatat agcagtgcta gctctgtcta tataaataga gaaatggggt 1140  
 tagccataga ggttaaaact acctggttat cccatataat aacacaaact gggctcttga 1200  
 tacacagttg tatttaatgt tttacgatct agcctttcca gtacaggcac tttctgagaa 1260  
 acctttgtcc tcacttgagg cattttggtg tcgggttttt gtgtttgttt ttgtgggtat 1320  
 ttgcctcatt ccaccctga gctttcaggt agacagacgt gattcaaaac tctgttctaa 1380  
 ggtgtttatt gtagtgaggt aatgggtttg cagtgataag tcatactttt ccaccgaaag 1440  
 ggagggtctg ggaatccctg agattagcta aagttaagtt gttggaagaa ttcccttgatt 1500  
 ggaaattgta cctttgtgtt ttgttgctct gtttcctgaa aataactcgg ggatgctcct 1560  
 ggtttgtcca tctactgctt tgattccttg gatccaccc attctttcac ttttaagaaaa 1620  
 aacaaataat tgttcagag gtctctgtat tttgcgtctg ctttttgtaa gaagcacttt 1680

tcccaaataa aacaattaaa aaaaaaaaaa aaaaa

1715

&lt;210&gt; 38

&lt;211&gt; 1896

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1871)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1884)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 38

gaaaggtgta	agaaactagg	aaacaatgcc	ttgctgttga	attctgtgat	gtctgccttc	60
cgggctgagt	tcatcgccac	aaggtctatg	gatttcattg	gcatgattaa	agagtgtgat	120
gaatctgggt	tccccaagca	tcttcttttt	cgatcactgg	gattaaactt	ggccttggt	180
gacctctctg	agagtgaccg	acttcagatt	ctcaacgaag	cttggaaggt	catcactaag	240
ctgaagaacc	cacaggacta	cattaattgt	gccgaagtgt	gggtggaata	cacctgcaag	300
catttcacga	aacgagaggt	gaataccgtt	ttggcagatg	tcatcaagca	catgactcca	360
gacgtgcat	ttgaagattc	ctacccccag	cttcagttaa	taattaagaa	agttattgcc	420
cacttccatg	acttctcagt	tcttttctca	gtggrraaat	ttctgccgtt	tctggacatg	480
ttccaaaaag	agagtgtgcg	ggtggaggtt	tgcaaatgca	tcatggacgc	ctttatcaag	540
catcaacaag	agccacacaa	ggacccggtc	atcttgaatg	cccttttgca	tgtttgcaag	600
accatgcatg	actctgtgaa	tgcactcact	cttgaggatg	agaaaagaat	gctgtcatat	660
ttgattaatg	gatttataaa	aatggtttcc	tttggccgtg	atthtgaaca	acagctgagt	720
ttttatgttg	agtccaggtc	gatgttttgc	aatctggagc	ctgttcttgt	gcagttgatt	780
catagtgtga	accggttggc	aatggagaca	agaaaagtaa	tgaaaggaaa	tcattccaga	840
aagacagctg	catttgtccg	ggcctgtgtt	gcctactgct	tcatcaccat	ccccctccctg	900
gcgggcatct	tcacacgtct	caatctctac	ctgcattctg	gtcaggtggc	cttggccaac	960
cagtgcctct	cccaagctga	tgtttttttc	aaagccgcta	taagccttgt	tccggaagtt	1020
ccaaagatga	ttaatattga	ygggaagatg	cggccatcgg	aatcgttcct	tctggaattc	1080
ctctgcaatt	tcttttctac	tttattaata	gttccggatc	atcctgaaca	tggggctctg	1140
tttcttggtc	gagagcttct	caacgtgatc	caggactaca	cctgggagga	caacagcgat	1200
gagaaaatcc	gcatctacac	ctgcgtcctg	catctcctct	ccgcatgag	ccaggagacg	1260
tacctttacc	acatagacaa	agtggactcc	aacgacagcc	tctacggggg	agactccaag	1320
ttcctggcag	aaaacaacaa	gctgtgtgag	acggtgatgg	ctcagatcct	agagcatctg	1380
aaaaccctgg	ccaaggacga	ggccctgaag	cgccagagct	cgttgggcct	ttccttcttt	1440
aacagcatct	tggcccatgg	ggacctacgc	aacaacaagc	tcaaccagct	ctcgtcaac	1500
ctgtggcacc	tggcacagag	gcacggctgt	gcagacacca	ggaccatggt	gaaaacgcta	1560
gaatacatca	agaagcaaag	caaacaacca	gacatgactc	atctgacgga	gctggccctc	1620
agactccctc	tgcaacaag	gacctgacct	ccgggcccct	ccccaggctc	agggactctg	1680
gtgccaaatc	cagaaagatc	tgtctgtgctg	ccctgaactc	ttacggcaat	ttaggtttct	1740
catttttctt	ttctttttac	atatgtacaa	attgttttaa	gctttggcct	ctatccaggt	1800
tattctgaca	atgaagaaat	gggagttgtc	agagcattaa	aatgcaatct	tcactaaaaa	1860
aaawaaaaaa	naaaatgctg	gagnatgagg	aaaaaa			1896

&lt;210&gt; 39

&lt;211&gt; 2075

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 39

ggcacgaggt	gtttgatgcc	attttggatt	ctccacatg	ttgattgtt	gtgtgtatgt	60
atgtttggag	tgaggatgtg	tgaaacattg	ctatggttct	gggagtcaga	gctgtacaga	120
acggtttaca	aaatgtcact	ccctcatcac	ccctacagt	cccttctcac	tctctttttt	180
ccaccatctt	cccactcaca	ctctagtttc	tagtttatcc	ttgctgtatt	tcttcacaaa	240
tgagcagata	cagtacatgt	atatattctt	ttatctccct	tttttgtttg	tctgtttctg	300
tgtttttttg	gtttgatattg	ttttttgagg	ctagaaggca	gtggcgtgat	ctcggctcac	360
tgcagccttc	acctccctgg	ctcaagcaat	tctcatgctg	aagcttcccg	aatagctggg	420
actacaggtg	tgtgccacca	cccggtggcta	atttttgtat	ttctagtaga	gatgggggtt	480
cgtcatgttg	gccgggctgg	tctcaaaactc	ctgagctcag	gtgatctgcc	catctcagcc	540
tcccaaagtg	ctgggataac	acgtgtgagc	cactgcgccc	agccttatct	ccttttttat	600
acatgaatag	cagcgtgcta	tatatatagt	ctttgctcca	tgcaatwatt	ttawtttawt	660
twatttttta	gaaagggttcy	tgttctgtca	cccaggctgg	agtgcaatgg	tgcaatctca	720
gctcactgca	gcttcgactt	cctggctcaa	gcaatcttcc	catcttagcc	tcccaggtag	780
ctgggactac	aggcacacat	cactgcaccc	agctaaat	taattat	tttagggaca	840
aagtctcctt	cactgtgttg	cccaggatgg	tcttgaactc	ctgacctcag	gtgacctac	900
ttccttggcc	tcccaaagtg	ctgggattat	aggcatgggc	cattgcatct	ggcctcattg	960
tttatttgtt	tgttttcaag	atgggggtctc	actctgccac	ccaggctgga	gtgcagtggg	1020
gtaatcatgg	ctcactgcag	cctcaacctt	tctgtttaa	atcagcctgc	aaagcctcga	1080
aattctctcc	caccttttgc	cattttttct	ttctgtggaa	gtcatggggg	tctccctga	1140
ttatttagat	tgctccctta	tctcacataa	tggcctggta	ataaagtaag	attcaaacca	1200
tatgcagagg	tagagagatg	aattacagt	aatacctgtc	ttagtccctt	tgkgttgcta	1260
ctaaggagga	cttgaggctg	ggtaatttgt	aaagaaaaga	ggtttat	gctaaaagaa	1320
gcatggcacc	agcgcttgct	tctggtgagg	atcccaggca	tgtccagtca	tggtagaagg	1380
caaagcggag	caggcgttag	atggcaagag	aggaagcaag	acagggaggg	aggtgccagg	1440
ctctttttta	caaccagctc	mwcagaaact	aatagagtga	aaactcactc	acatccccac	1500
attccgcatt	aatctgctct	tgaggatatct	gccctcctga	cccaaacc	tcccatcaga	1560
ccacacctcc	aacattgtga	tcaaatttca	acctgcactt	agggtc aaat	acccaaacta	1620
tagcgatacc	ttgtacactt	ttcaccacaga	ttttaacagt	tcaagatttt	gccatgtttg	1680
ctttatctgt	ttatttcttt	ttctttttct	gaattawtta	watataatata	tcaccctatg	1740
tacactaaaa	actatgcata	tcttttaaaaa	tgcggctatt	ggggccaggc	acagtggctc	1800
acgcctgtgg	tcccagcact	ttgggagggt	gaggcggggtg	gatcacctga	ggtcggggagt	1860
tcaagaccag	cctgaccgtc	atgaggaagc	cccttctctg	ctaaagatac	aaaattgcgg	1920
gcctggtggg	aatcccagct	actcgggagg	ctgagacagg	agagtctctt	cagcctgggg	1980
ggcggagggt	gcagtgaacc	gaggtcgcgy	cgttgcactc	cagcctgggg	gacaagagt	2040
aaactccatc	tcaaaaaaaa	aaaaaaaaaa	ctcga			2075

&lt;210&gt; 40

&lt;211&gt; 1592

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (5)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (805)

&lt;223&gt; n equals a,t,g, or c

<220>  
<221> SITE  
<222> (857)  
<223> n equals a,t,g, or c

<220>  
<221> SITE  
<222> (1587)  
<223> n equals a,t,g, or c

<220>  
<221> SITE  
<222> (1588)  
<223> n equals a,t,g, or c

<220>  
<221> SITE  
<222> (1589)  
<223> n equals a,t,g, or c

<400> 40

cccnataac	aatgcataag	ttatagatta	cataccattc	agtgtagcat	gatgaaatct	60
cttgccaate	tgttccatcc	acctgggatg	tgaatcatcc	ctctctctgg	tgtattcaya	120
ctgtatgtgc	tagccgtctc	tgttacgaga	tcagctgtcg	tggaatcagt	gctagtgttc	180
aggtaactct	tatttaataa	ttgcctcaaa	gtgcattgtg	ctgtgcctaa	tttataaaat	240
aaacgggtatc	ataggtatgt	atgtatacga	aaaacatagt	atatgcaggg	ttgggtacta	300
tccacagttt	caggcatcta	ctgggggggtc	ttggaatata	tccccagagg	taaggggtga	360
ctactgtata	cagccatgcc	aacatgctgg	ttctcagaga	gttataagag	agattaaaaa	420
tacatgcagc	tgtttgggca	ctttcttccc	aaataaaaata	cccagtaaaa	tgtaacatac	480
tacctatagc	ttgataatct	atctgaggat	gtttatgatg	tctgtctata	tactttaatt	540
tggccttagc	ttctttgtag	gtatcaagtt	atcacttgca	aattttatctt	caaaaagcat	600
agtttcttgt	acatttttaga	agattagttt	ttcttatctt	gggacacctt	caccaatgtt	660
ttaaatgtgg	ataaatttta	atgtggaatt	tcttttaaaa	ataatcctct	tcataagagca	720
atacaacaaa	aatgtgttgt	atcttggaga	tttacattat	aaatgtagta	acattttatga	780
gcttaaattt	aatgaaacct	ttttnttttt	ttgagacagt	cttgcaactgt	cgcccagggt	840
agagtgcagg	gcatganctc	agctcaactgc	aacctccgtc	tcccgggttc	aagcaattct	900
cgtgcctcag	cctcctcagt	aactggcatt	ataggtgtgc	accaccacac	ctggctaatt	960
twrgtatttw	tcataaagac	gggggtttca	ccatgttggc	caggctgggtc	tcaaactcct	1020
gacctcaggt	gacagcctc	cctcggscct	ccaaagtgtc	gggattacag	gcatgagcca	1080
tggtgcctgg	ccaaacgttt	ttattacaaa	tattacatta	aactaaagct	cacaactgtt	1140
actatgcctc	aggaattaac	agtcatttct	catttgtgtt	atycycwat	tkgatamcat	1200
atagtgacta	tctctttatg	ggttaaatat	cagtttcttg	gccagaattc	aagatctgcc	1260
cctaactaat	cctacttctc	ccagtacctt	tacagcactc	ctaccctact	agtaactctg	1320
atatctcata	gtcctcagat	ttatcaagca	aacgaaactg	aatgagcact	actataaggt	1380
accacaaact	acaaaaggag	acagttttgc	ccttggttgc	ttcagttaaa	ttattgtgct	1440
attttttget	taatttctag	gttttttttg	cgtgtttatc	atgtctccgt	aggtaaagtg	1500
gccagaaaac	tttttctact	ttacatttcc	tgtaagtgtc	gtttgtttga	ataaagttaa	1560
tgtgtgaggt	taaaaaaaaa	aaaaagnnna	ga			1592

<210> 41  
<211> 1324  
<212> DNA  
<213> Homo sapiens



&lt;400&gt; 41

ggcacgagaa	gaacagaaaa	aagctaatag	aggaaggtaa	atctctaaat	gagttaaata	60
aggcttaaat	aaagtttgca	tggtatatc	tctaaaagtt	gattggcgtg	gaggaggctg	120
tatgtgtttg	tgtgtgtatg	cacatgggca	tgtctatgtg	taaggtcaga	agggggagcc	180
tgaattatct	actgcttttt	tggttaacta	gtcctatttt	taaaactttg	tctaactccc	240
aaaacttatt	aatgcgacat	gtagtactga	attagaagtt	attgttaaac	tcaggacagc	300
tctgtggaga	ttcacaaagt	aatttcacga	aaacttatga	ggaagttgtt	cagtactgtc	360
actaattaac	gcgcacaaaa	aaaaaacttg	ttgtgagtaa	ttatgggtga	tttcgctgca	420
aaacaaatta	gtatacgaat	tattattttt	cctcaaattg	taaaggtttt	gtttctatta	480
agtctctaac	atctccaga	ttaaaaatac	caaaactatt	tttaaaactta	aggaataaaag	540
tatcaaaaatt	aaccattaaa	ttaatagtc	ttaaagttgc	tatgtatatg	gtaagtaaaa	600
caattcctat	tctaagttat	acatgggtat	aaattctagg	tacagtcgca	tgaagcatta	660
ttgactttta	ttaactcagt	gtttttaaag	gtttcatact	aatctatgaa	tgctctgaat	720
gctgcaggga	aaaagaagca	caatcagtat	ttcattatct	atgaattctc	aatggaatta	780
tcctatccgg	tccacacaca	taatagcatt	agcatttctt	cttataccat	gttgaaatac	840
tttaatacaa	actctcaata	gaagcttaaa	cataagtgg	taagtctgtt	gtctagtctc	900
attcacctgc	ctcaacatgc	tttctttcat	tctatttgca	tacaaaatgt	tcttattttca	960
gttttgtaga	caggatatga	gttagcatac	tcgtgtttgt	tcagctgtcc	atcctgcatc	1020
gttactacaa	tgcccttttc	tgccatttaa	tggtgtttgt	atcaatgttc	ccatattttgc	1080
tgcattttta	ctccataaaa	aggaaatgtg	atctcgtatt	aatagttttg	ttgatcaact	1140
caatattttct	gcaccaatca	gcatacctat	atgcatgtag	tagtctgtac	aattgttcaa	1200
catcaaaaata	cttggtttact	ttatgtcaaa	atgtctataa	aattgctggc	attgttctcc	1260
atctcagctc	ggtagaataa	gcgagataga	aaataaatgt	gtaaatgaaa	aaaaaaaaaa	1320
aaaa						1324

&lt;210&gt; 42

&lt;211&gt; 1214

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 42

ggagaatatt	aaaataaatg	cagaatgcgt	tggtcccgct	tctgggtgtg	gttctctttca	60
tgttctcaac	ttggccttgg	acttccaaag	aggtggatta	gtgtctccac	aaagatccag	120
cagataatca	ctgtttctcc	ctttaatcct	tttagagaca	aagtaagaat	aatatacaat	180
ggtaccttgg	ccctccaggg	gttatttacc	tggtacctca	gttattacta	acccagctga	240
gaagcaggaa	ggaaggagat	gggcctctga	acagccaaaa	cagatgtcta	aagttcaagc	300
tcacctggat	catttattct	taatttagac	aacaaaatga	ggtttttcca	gctttggcac	360
gtagtgagg	atgctatggc	aggttccttg	agagcagcca	gaagtgatag	cctggtttga	420
gctgaggggt	ctgtggaata	ctgatactca	aacacaatag	ctcaagaagc	cggatggtct	480
gggcccacac	tcggttttca	cagttagtaa	ctgctgttcg	taatgacagt	gctgcattat	540
tagagagaaa	ttaattcatt	cttcatataa	tcttgcaaag	gctcttagag	tatgatatca	600
tttagggagg	attaccacca	gatatgatta	aactccctca	gtttttctgc	taagttttgt	660
tttcatatca	gtgccagaat	ttaacagtgg	tctctatcct	acgagggaaa	gatagagtag	720
ctgccttttag	ttagaaatat	acataaccaa	aagtgcagca	cattaggaat	tgttcaaaaa	780
ggatcttaac	ctggaacagt	ggaatgattt	cctacaagtg	cattatttgc	cttttgartw	840
aaataaggtc	cactatcatc	catctttgsg	gcctgatgar	ttttagaatt	cararctttt	900
cagatttttt	gaaaggaaat	atgtatgtat	acaaaaccac	acatcacata	aaagccctgg	960
cagggtctaa	ggtaacacac	tatgataaag	cattaatatt	tctgcagtga	aatgtacgaa	1020
gaactaatta	ggacaaactc	tgtagtttat	ttaaataata	aaccagtaga	ctgggtgctg	1080
tggtcacgc	ctgtaatccc	agcacttttg	gaggccaagg	ttggcagatc	acgaggtcaa	1140
gtgattgaga	ccattttggc	tgatacgggtg	aaaccctgtc	tctactaaaa	aaaaaaaaaa	1200
aaaaaaactc	gtag					1214

<210> 43  
 <211> 1338  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (266)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (327)  
 <223> n equals a,t,g, or c

<400> 43  
 gaattcgcca cgagctatac agggcttatg tgcatactct gatgggggct tcccagtgcc 60  
 ctttcgcagc ggccctccgg cctctacact tctcctctg ggtagcagct ctccttggtc 120  
 tccagcagcc actccagagg ctgcagctca gaaatgccta ggtaccagtg accagcctgc 180  
 tctcaacct ccctggccag ctagtcttg ttgccctgtt ttctgaaacg tacctccaca 240  
 tcamaggcca ctcttggtg cttrantgct actgtragta agttgtttctg cttstgtgctc 300  
 tgtgcacagt cgattttctgt gacgggnaag gcctgctgct gtgtgtctct actgacactc 360  
 accacgaaga gcactttctga tgtcagcagc aagcaccctt catgctcctg gcctgagccc 420  
 ctcaccagaa ccacgtccag ggccatgtgg acttctggct tggccagaga ctgaagcatt 480  
 ttctgtttta aaaggagaaa agtgaggcca ggggccagct gtgaaaagat ggtcacttat 540  
 cagtgtcat tatttacc aa tggggcaacc tccacaaggg caaaggggcc tcaccaatcc 600  
 agttacccat tttagcttga aatgtaattg tcagtctctca gactgattct gattaacaga 660  
 acctgcttcc tcttgggaac aaagatttcc cttgggtttg cttattagct ctttttctcc 720  
 ccattagaaa tagcacctct aattagagtg ctggttccac agggaatctc aggcctctca 780  
 gcaagactgg gtttctctgc caatgtatga cttccttga gtggttaggt acggaacaga 840  
 ggagttgtgc agccagcccc aaacctggca acagcagcct cttcctgtcc ctctacagtg 900  
 ctcttggtgct gcctgagatg ccagtgccaa caatggctac tcttgggcty cctggaagca 960  
 tggccatta gcttgagagc aagccaggag ctattracat acmatatgga tgtaaagtgt 1020  
 agcacgtatc tcaataattt taccagacat atttgacatg gctgtttgga gcctggctcag 1080  
 catgtagatc acttggtgta tggcgctgtt tgggaagctg agaaagtcca gctccatgta 1140  
 aaatacctgt ggtaagagaa gtaagggagt ttactactt gttttctgga aaacagtttc 1200  
 atgctgcaat gatgtcatct gttcagagcc atccataaaa tgttacagat ccaaaatgat 1260  
 gtcacatctt tgggaagcaag cgtatagata atcattaaac attacaatgc tcttaaaaaa 1320  
 aaaaaaaaaa aactcgag 1338

<210> 44  
 <211> 1686  
 <212> DNA  
 <213> Homo sapiens

<400> 44  
 ttaaaaacaa agaaatatag ctagtaagtc caaaatggga aacaaaatca aatcactgtg 60  
 cccagccatt tgtttatttt cttaggaaaa atgtctattc aaattatttg ctgcctttgg 120  
 ttcttctctt atcttattac gtgccagaaa ccctccttgc cccttgactt ttctattctt 180  
 ccctcttcgg aggtataata taaccattgt acagtgggtt agagtttagg ctactgtgat 240  
 gtggcaccta tttctacctc ttattgtacc aactattgta tcttgggcta gttacttaat 300  
 cctgcagagc ctcagttttc ttgtctgtaa aacaaagata tcagtacttc cctcacaact 360  
 ttgttgtttt gaatgagatg ttgtatgtaa catgggttaga ataggacctg acaccacca 420

ggtattccat	aaatgttagc	tgctagagta	ttctgcacct	gcccatgaaa	gattaactgt	480
cacaggaatt	gccctcctgc	cataaacaat	gagaaaacta	gataaaatat	atgaaaccac	540
agtttttgac	attgaacaac	aggcaacatg	ggactgttat	ctctaagaga	agggaaaaaa	600
ccaaggtgat	ccctacagtt	gccctggctt	actgcttagg	cacagtttct	aggctacagc	660
aaggaaagag	aacccaaaaac	tgraactggc	aaccttactt	gactagagmc	agagatgaca	720
gtctgagaag	agtaaggcaa	agtgtctgaa	aggctggaac	tctctacaga	gmcakccctt	780
tggttttttg	tatatatagt	aatctgtgca	tgaatgagat	gaagttcctc	aaagcccaag	840
atggaacctt	cagaaagcaa	ttgactgaat	aattcacaaa	attcatgatt	tgtattccca	900
ccagccagtg	tgaagagtag	tgggactaat	ttagtctcag	aataaaaact	attctggagy	960
ttccataacw	aagtgtagag	caagccttgg	aagaagcaaa	ctgattagca	ggttacataa	1020
ttgtgcacca	cactaacacc	aaataccctt	taaaggaata	tttaaaggag	cacccttcaa	1080
acaaaaccca	ctaccagaa	aagtcacaac	cttgcatтта	atcagtaatt	atcgagtgtg	1140
caaaaataacc	aacttacatg	accagtaagc	tgaggaggga	taatcaatca	ataggtaaaa	1200
accccagaat	gacggtgata	atagaataga	aaagaaccag	cctggcacag	tggctcatgc	1260
ctgtaatctc	agcacttttg	gaggcccagg	caggtggact	gctgaggtc	aggagtttga	1320
gaccagcctg	gccaacatgt	tgaacccccg	tctgcatgaa	aaatagaaaa	aattagccag	1380
gcatggtggc	gggtgcctgt	aatcccagct	actcgggaag	ctgaggcagg	agaatcactt	1440
gaacccgga	ggcagagctt	gcagtgcagc	aagatcgtgc	cattgcactc	cagcctgggc	1500
aacaagagcg	aaactctgtc	tcaaaaaaaaa	aaaaaaaaaga	atagaaaaga	accttaagcc	1560
aggtatgatg	gctcacacct	gcaatcccag	cactttggga	ggctgaggca	ggaggatcac	1620
ttaagccgag	gagttcaatt	ccagcctagg	caatatagca	agaccccatc	tcaacaaaa	1680
aaaaaa						1686

&lt;210&gt; 45

&lt;211&gt; 1634

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (311)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (567)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 45

tcggttgggc	atgctgctta	ccgcagatga	tggaagcgac	ggcccgtaca	aagacagaag	60
cgttggtttc	actgagtcag	tgctgattct	ctcaaataga	gcttgaagga	taaatcttca	120
tttttgtttc	aacaaaactt	cgaacaaaaa	tggaagaaaa	taatctacag	tgcatgagt	180
tggttgacgg	taattttgaa	gaagttccca	gggagacggc	aattcagttt	aaacctccac	240
tatacagaca	gcggtaccag	ttcgttaaaa	atttagtggg	tcaacatgag	cctaagaagg	300
ttgcagacct	ngggatgtgg	tgatacttca	ctcttaaggc	tgctaaaagt	caatccatgc	360
attgaattgc	ttgtttggag	agatattaat	gaggataaat	tacgatggag	aggggattcg	420
ttagctcett	tcctggggga	ttttctgaaa	yctcgggata	tgaatttgaa	ccatcacatt	480
gtatcatggc	tccgttgttg	agagagactc	tcgtttgctt	gggatttgga	cttgataaac	540
gtgtattgaa	ttaatagaac	atltgggnatt	caggtggatc	tggccagatt	tcctggaagt	600
ggtatttggg	tacctgtctc	catccatgat	tgtcatcagc	acacccaaact	ctgaattcaa	660
tcccctgttt	ccatcagtga	ccttaagaga	ttcagatcat	aaatttgagt	ggaccagaat	720
ggagtttcag	acctgggctt	tatatgtggc	aaatcgctat	gattactctg	tggagtttac	780
tgggtgtcgg	gaaccaccag	ctggagctga	gaatgttgga	tactgtaccc	agataggaat	840
cttcgggaaa	aatggaggaa	aggcaacaga	atcatgtctt	tcagagcagc	atgatcagca	900

tgtttataaa	gctgttttta	ccacctcata	cccaagctta	cagcaggaaa	ggttcttttaa	960
acttgtgttg	gttaatgagg	tgtcccaaca	agtggaaagc	ttaagagtga	gccacctgcc	1020
aaggcggaaa	gaacaggctg	gggaacgggg	tgataagycc	aaagacawtg	gtggctcaaa	1080
ggccccgtgc	ccatgctttg	gaccagtctt	cacagagggt	gagaaggcca	agatagagaa	1140
ctctcccaca	cccttctgtg	ttggagataa	atthtttcgt	cctctgcaga	gactccttgc	1200
gtatcccaag	ttgaaccgct	tatgtgctra	tgaagagatg	atgagatcag	tcattgctga	1260
ctcaattcct	ctgagcagtg	atggttctgc	agtgggtggc	gacctgcgta	attatttttg	1320
tgaacagttt	gagttttgaa	ccatgtttat	ttcctgaaat	ttcaggggtc	cagcgatagt	1380
tgtgctcact	tagaatttag	ttttttttgt	gtaatcctaa	ttcaagtaat	gtttttaaag	1440
tttctactga	aaagtctatg	ttccaagcca	ttggacagac	ctgcttgaga	tatggccaga	1500
ctgcagtgag	ccctgagaaa	gatatgaggg	tttaaaacgg	gtgctttcct	ttgatttttg	1560
acttttttgt	tttctcaaga	ataaagaagt	tggatgtggt	aatatgttaa	aaaaaaaaaa	1620
aaaaaaaaact	cgag					1634

&lt;210&gt; 46

&lt;211&gt; 2012

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 46

tatgcaagct	cgaaattaac	cctcactaaa	gggaacaaaa	gctggagctc	caccgcgggtg	60
gcggccgctc	tagaactagt	ggatcccccg	ggctgcagga	attcggcacg	agtgtagagc	120
tcaaagaaat	ctgccaacat	gtatgtggac	tcttgagagg	tgggctttcc	cagtacatgc	180
taaacagact	tgttatgcca	agaggaagtg	aatagaaatg	atagcatcaa	atatccaaac	240
tgacaggaag	tttcttttgc	atagcataga	acatggttgt	cctctgagtt	ccactaatgt	300
tccaggatat	cttgcccttc	tgcctctggc	tgctccctgg	tgtttggcac	catagcgttg	360
tcactttaca	ccattgcctt	gggacacaca	gagtgaaactg	tttgagtgat	aagtaattta	420
ggtagaaaact	ttacccttaa	tttcaaatga	taccaaacag	ctcattacta	ccccaaagga	480
cgctctccgt	agcttcttga	ttccccagtt	tccttctaga	aacaaggact	ccaatagcac	540
tataacccta	aacaggccct	aaccacagaag	aatacaccac	aaaatgcgat	tgattttctc	600
aaaatatcac	agtcttagac	actatacaaa	taattcaaga	aaattcttct	taccctgcag	660
tggatatagt	attctattat	attctccagc	aaaactttta	ggacttttca	aaactcatttc	720
taagccaaat	agtttagata	aatatattacc	cttatatttg	gggggaattc	aggctcacca	780
tttgccgagg	caagcccatc	aacagtctag	aggcatattc	tgtgtcattc	cttcccgtct	840
ccttcataga	atactacttt	ttcctttttg	ctcctggcca	ttctccatca	tctgctgatt	900
attgctaacc	acaggatgct	ggcaaagctt	acagtgatag	gcacatgtgt	tcagtgatgt	960
ccaatacact	cttatcacag	tggttattgc	ttcttactct	tttcaaatgc	attattctac	1020
ccctcaacct	atatccaatc	attagaacta	tacctgactg	gagcccagaa	cttgggacca	1080
atacttaatt	caaatagcag	gggcttgctc	acaaacatta	agcccaaaaa	gaagcacagc	1140
actttgaaaa	gtcaaatagg	cctttggtag	ctctgtacat	ttgcaatttt	acatttggtta	1200
ttagttttata	gcactaataa	cacttcagtc	gtgaatctac	agtctcaata	tgataagtct	1260
tagaacatgt	tctagaaata	gtggtacctt	gctgctatta	tacttagtaa	cttatacccc	1320
aatataataa	taagtattaa	atacagattg	tgtatgcatt	ctttgtgtgt	atatgccaac	1380
tgtactactt	aacctcactg	atgagcaatt	agaaaaatac	acaaattgtc	atagtgaata	1440
taagtcttgg	tcaattcaga	tgatacgtga	acctgataaa	tgctctaata	gatatgctat	1500
tttgctctgt	attgcttggt	ttacagtatg	gtgcatgttg	tttgctaaat	aaaatgataa	1560
taataataaa	gtataccaat	tttaagggtta	gaattaaaat	tttgcacata	tgcttcttga	1620
tattctgaaa	tgtattctgt	ggcttaatta	tcttattcat	acacatttca	ctttggcttt	1680
ttaccccctag	gaaataactg	tccaagtata	tatctcgtct	tctttcttgt	aactttgatt	1740
aaactgctta	cttcaactta	caacattgta	aagccagaat	acctcatttt	aacagtgaata	1800
aaaaatatga	tgacctgatg	tgttctcttg	tatttgattt	gaactacctt	aataggctta	1860
actgtaataa	taaatatata	atthttggcag	gcattttttc	ctttgttttg	atgaacattt	1920
tgttattggg	ccacttctaa	ttttgtctta	aagagttata	aactcagtgt	caataaaaca	1980
tcttggtata	taaaaaaaaa	aaaaaaaaaa	aa			2012

<210> 47  
 <211> 1322  
 <212> DNA  
 <213> Homo sapiens

<400> 47  
 ggcacgaggt ggggctagct ggaacttagt ttccaactgc tggaatggat tatttccttc 60  
 tggctagggc tgatccaaat gctcttccat gggaacctgc tgaattctgt cctgtgttgc 120  
 ttttggctgt gacagggcag cactgagttc caatgcaaag tttcacaatt acttcactct 180  
 tcctcctcca aacacacgga ctctctcagc accacaaggt actgctggag aatggcggat 240  
 gagtgggtga gacaactcaa gaccatcttt tctacgctct tcagtgcctc tttccttggg 300  
 aggatgttaa aactaagtac tgtgatcact cacctgattt ttggttctta tgaagggtgt 360  
 ttcttgtgtg gatagttgtt caattttggg gttcctgcag tagagacaat caatggaggg 420  
 ttctgttcaa ctctcttggg ccaccttctc caatcctgtt ctacttaatg tatcttggca 480  
 aactttccat atcagtacag agaaagcttc ttcattctga ctgctgcata gtatcccagt 540  
 gcttgaaggt agcatgatta atttagccat ccaattcata ggcacagggt atttgggttg 600  
 ctttctatta cttgtaatta caaacagtgc tattctgtta tatcttgaa atatatTTTT 660  
 gtgcacatta tagaaaatgt caaagtgatt ttcattgtagg ttgttccagt gaatgagagt 720  
 tcttattttg tcacatactt ggcaaccctg agattatcaa tacgatttaa atctgtctgc 780  
 caaacagata ggtttgtaaa aatgtacttt attgttttaa tgtgaatttc tttgattata 840  
 agtaacaatt aagaatattt ccaaataatt gtgaaccatt tttctttttt tgtgagctgc 900  
 cttttcttgt cctttgttca ttttaaactg ggttgtttta gcctctttta aattgatttt 960  
 taaaacttgt atataatta gatatgattt agttgtgtcc ccactcaaat ctcatgtcga 1020  
 attgtaatcc ccaatgttgg aggaggggtc tgggtgggag tgattggatc ataggggcag 1080  
 atttccccct tgctgttctc atgctagtga atgagttctc acaagatttg gttgtttaaa 1140  
 agtgtagcac ctcccacttt gctctcttcc tcttctcttg gccatgtaag atgtgcctgc 1200  
 ttcccccttg ccttctgcca tgattctaag tctcctgagg cctccccagc catgcttctc 1260  
 gtacagcctg taaactgtga gccaatataa cctcttttat ttataaaaaa aaaaaaaaaa 1320  
 aa 1322

<210> 48  
 <211> 941  
 <212> DNA  
 <213> Homo sapiens

<400> 48  
 ggcacgagga aaaacagaaa gagcatctgg ggagcgagtg aaaattcctt aggtgattcc 60  
 taagatttcc ttgggtatct ggtttttgtt ttcataattg agtgtgtgca tgtgtgcatg 120  
 actttaatga cttttttaat ggggtgggag gtggctgggg tgctgggggt gaaggaagtt 180  
 tgggttgatt ttgtggtgt tttgtttaat agagaatttt ttttttctg ttcccctgtc 240  
 agctggtctg acagatttaa gaactctcat tcttaaaaga ctttggactt aaatctagca 300  
 tttagactag gactgttcta ctgtgaagaa agttctgtct ccttttagccc ggtttgtttc 360  
 tcccgtctca ggtctagaat cccaagcagt gttcttttct ggtgaacact gtgagccgca 420  
 gatgtgactt tttttttaaa gtcactctct cagcaatcca gaggttcctt gacctcatta 480  
 tttgtcctat ctctccctta tagtcctaag ccaagacatt tgacctttga catttgacct 540  
 ttgcagtgtc atgtgagggc gtcagtatag aggcctttgc atctgggcct ggcaccgct 600  
 ctctgcctct ggaggctaaa ccctgtctgg atttctcttg ggatctaacg tgggatcttc 660  
 tggacagaca accgtgacat cagcagtgtt ggtgctgctg tgtgtggact gaacacctgc 720  
 actttgtcag aggacacgct gcatgggccc cgcttgcggt tcatcaggc ctgctgcagg 780  
 agctctgaga acaagaaaga gtggacaccc gttccccctg atcatctgta ttgcgtgcta 840  
 tttcagagtg gggaaagtgt aaactatttg ccttctggag ctctttgtga aaaaataaaa 900  
 aaaaacttag ctcaaaaaaa aaaaaaaaaa aaaaaaaaaa a 941

<210> 49  
 <211> 1874  
 <212> DNA  
 <213> Homo sapiens

<400> 49  
 gatgacttat atttcaggcc tttgttttgtt tctctgttagg tctcattttt tgatatgctc 60  
 tttctcatta gagaagataa gatgtttttat ttttattaga aatcaggaat cattttaact 120  
 cacattacca tgatctggag cattgtttaca tgttggtattt gtgtgtgcac tgggtgtgtt 180  
 atgcaagggga gactgaattc acaagtcaga ggtgaatctg agcctcatta ggcagaatat 240  
 tcaaccagc agaaaattga atttgtcgca caaagcactt aaacctacaa cccattgcaa 300  
 gaattgaaat cagatcaggg ataagtata tcagaatctg ggaaagccgg aggtgagggg 360  
 ggaggggaag aagctgaaag tctcaaagca agcatcggtt tcaccttggg ggggtgaaat 420  
 ttcaggacag gattttacct gaatgccaca gctgaggagg aaggtcagtt gcagcttttag 480  
 gcgatttacc agctttgaga aactagtcag tttaggaaat gattagggta ttaaagctaa 540  
 ggtttaagat aaagaaagaa aaggccacct agttgagatc caactgggtg gacttgggtt 600  
 tatgggaaag agagacagtg gttatggttg ctgtgggaca aggtctggaa acagattcct 660  
 gagggacata gcagctggca gtgggcatag atggaaatcc caaatgcctc tttcttctga 720  
 cccctctgtc ttaaacaggg tagtgtggct gatttttaggt catgtgcctg atagcagtgc 780  
 aagagaatat acaagaggta attgggagat aaaactctgg tgcagttgtt actgggggca 840  
 ctcatagtgt acacaggaga aaaatgtcat ggaatgtttc attagctgca tcttggatt 900  
 agagaaaaca cctttccaga gcctccttcc tctgcccgt taggttacct gggcatcgac 960  
 tcccctgtct ttgagatagt cagctccctg aggccaagga tgctggcttg agttgggttc 1020  
 ttcacagcat ttaacatagt gcctgacaca taatagtctc tctatttatg ctaaaataat 1080  
 acaatcctca agacttgaca tcagctctgg aatagtagag tgggaatgct gcagaaaaga 1140  
 tccagagagg aaagaaggca ccgagatgtt aaaatgcggc ttgttgacag aatacttggg 1200  
 attgtgcagt gctgctatct ctatttttca cttttggcag gtatttatta tttcactgat 1260  
 aggagacatc aagttccagc attttaatcc tgtacttgaa acctacattt acaagcactt 1320  
 cagcgccact ttggcatatg tgtaagtatg atctgaagga actacatgtt gttggatctt 1380  
 tggatttgta ctcttaggac tggattgttg agaaacgaga cggacctatt actattcagt 1440  
 aaatacgctt gttaaggcag aactcttatt ctaagcttcc ggggtggaaa aggggaacct 1500  
 ctaagtattc taactctgaa agggggctaa gatcagggcc ttcattctgg atcaggcgaa 1560  
 atttccttaa ggatccagaa taggccaggc gtggttgctc atacctgcaa ttccagcact 1620  
 ttgtggggag gattgcttga ggccaggaat tcaagaccag cctaggcaac ataacaagaa 1680  
 cctatcttta caaaaaatta aaaagttagc caggtgtggt gacacacacc tgtagtccta 1740  
 gctactcgag aggtcttagg gagaggattg cttaagccca gggaagtcaa ggctgcagtg 1800  
 agctgtgatc atgccattgc actccagcct aagtgcacaga gcaagactta gtatctaaaa 1860  
 aaaaaaaaaa aaaa 1874

<210> 50  
 <211> 643  
 <212> DNA  
 <213> Homo sapiens

<400> 50  
 ggcacgagcc ccagaccctc taaaaactct gtacctctcg gtgcgcggca gcctcttgct 60  
 gtagttcttc ttttctggat atgactgtca gtttcgtcat gagatttctt gctctcattt 120  
 cgaactcttt ctttcttcca ctttcttttg gggcgacccc cgatccatgc caggctcttc 180  
 tgtgaagacc gttccaacct cgtttccatt tcttgaatgt tgagtattac aacatcactg 240  
 cgctaggggtg cttcatgggt ctgttctcga agaggccagt tgggctgaat ctcttctctc 300  
 ccactggctc ctgatattct gctgtatttt gtcttcttct tgatttttcc ctaggggttt 360  
 ggggtgggtg acttaggggc ggcttttgtg ttctccctct ctctctcttt ctttcttgta 420

tgtatgtatg	gactgggttaa	agtgagtttg	ggcagctgac	tttatgggat	gggttggtctg	480
acttttgttc	aacattaaag	acaaaccaac	aaattgtaca	gctgcacaca	gaacaccttt	540
gagtgtgaac	ttgaatggca	actagaggct	tactttttga	acttcaggta	tgtaactcaa	600
aagtaaataa	aaacactatt	ttttcaaaaa	aaaaaaaaaa	aaa		643

&lt;210&gt; 51

&lt;211&gt; 1669

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1601)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 51

aggaaccact	tgagcccggc	aggtagaggt	tgcagtgagc	tgagatcaca	tcactgtact	60
ccagcttggg	cgacagagcg	agactccatc	tcgaaaagaa	aaagaaaaag	aaaagtctgt	120
ttcatcagaa	caggtttctg	tgttgacagg	atttaccttt	caggccatta	attgtgttgc	180
tctgctctct	tcctgacttc	atattgcttc	agaagagatg	tctgcttcca	ttctttgttc	240
ctttgtacat	agtgtttttt	tcactctctg	ctgcttttca	gtggttttta	ggaaaatgat	300
tatcacatta	tttatgtagt	tttttgcaca	ttattttgct	ggagttgttt	gaacttcttg	360
gctctgtgtg	tttatactgt	ttattgaatt	ggataaacag	ttgtacaccc	atacagtgaa	420
tactgaacaa	caaaaagtaa	tgaagtattt	atacacgcaa	caacacgggt	gaactgtaaa	480
tcattgacctg	agttaaagaa	gcccgggaaa	ataggtgcca	tatggattca	tttatataaa	540
acttgaagat	gcaaaactgat	ctacagacaa	agatttgtgg	ttgcctgggg	atggtggaca	600
gatggatcga	tcacaaaggg	gcatagagac	ttttggtgaa	aaaggaaatg	tttttatctc	660
gattgtcatg	ttttcactga	caaatatgtc	agaactcaac	aaattatata	ttataaatat	720
gtgcagggtta	ttcttcgcca	attatgtatg	tcaataaagt	tgtaaaggga	taaaaaatga	780
agggtttggc	ctgcactttt	gggaatctgt	agttctctta	gtgacccatg	tatacaaaaa	840
ttcttaagtg	taggttatgg	tgtttttaac	aattttataat	actgatgaag	tttaattagc	900
aattcagaag	tacactttta	ttaatttgat	gcatacaaaa	gtgtgcaatt	ataggtctaa	960
tgctatgcta	ttgattgttc	agttttgctg	tagtgaatgt	gaatttttat	tttagagatg	1020
aggtctcact	ctgtcgtctca	ggctggagtg	cagtggtgcc	atcagagctt	actcaacctc	1080
ccaggtcaag	tgatccttcc	gcctgagcct	cccaagtagc	tgagactaca	ggctgaatgt	1140
gaatgttgaa	tgaatgaatg	aattgggtgt	aaacaggcta	aactgtctca	gaacttgtgg	1200
attgtgctga	aagcagtatg	gcctctggca	gtgaagtaaa	ccttgggcca	gatactgcca	1260
tgaggtggct	atctagctga	acattttagt	acaattctga	gacttgcata	tttattctct	1320
catttcctag	aaaataccgg	ccaaaaaaag	tatgaggtct	ataaggagga	ggaaaaacat	1380
gaagtttaac	atgcctatag	aaaaattttac	atcccatgaa	tgtatataat	ttgctgctgt	1440
tttacacagc	aaaagcaccc	ctgtgactag	caccagatc	aagaaataga	acaccacctc	1500
gctctggcag	cttttaacaa	ttttattctg	gccgggcgtg	gtggctcaca	cctgtgatec	1560
cagtgccttg	cgaggctgtg	gtgggaagat	tgcttgcgtt	ncaggagttc	aagaccagcc	1620
tgggtaacat	agcaagacct	cgtctctact	gaaaaaaaaa	aaaaaaaaaa		1669

&lt;210&gt; 52

&lt;211&gt; 948

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 52

ggcacgaggc	ggcctgggag	tcagcggccc	gagcgggaag	cgccggggcg	gcccactgtg	60
cggccgtcgt	gggggaagcg	aaggttcctg	attccacctc	cctcctaagt	gaaggcttcc	120

gtccctggag	aggaggcggc	gccctgtatc	ggccttcgtc	ctccgcggga	gctgcgggcg	180
caagatgagt	ggagaggaga	acccagccag	caagcccacg	ccggtgcagg	acgtacaggg	240
cgacggggcg	tggatgtccc	tgcaccatcg	gttcgtggct	gacagcaaag	ataaggaacc	300
cgaagtcgtc	ttcctcgggg	actccttggg	ccagctcatg	caccagtgcg	agatctggcg	360
cgagctcttc	tctcctctgc	atgcacttaa	ctttggcatt	ggtggtgacg	gcacacagca	420
tgtactgtgg	cggtcgaga	atggggagct	ggaacacatc	cggcccaaga	ttgtgggtggt	480
ctgggtgggc	accaacaacc	acggacacac	agcagagcag	gtgactgggtg	gcacaaaggc	540
cattgtgcaa	ctggtgaatg	agcgacagcc	cgagggcccg	gttgtggtgc	tgggacctgct	600
tccgcgaggg	caacatccca	acccacttcg	ggagaagaac	cgacaggtga	acgagctggg	660
acgggcgggc	ctggctggcc	accctcgggc	ccacttccta	gatgccgacc	ctggctttgt	720
gcactcagat	ggcaccatca	gccatcatga	catgtatgat	tacctgcac	tgagccgctt	780
gggctacaca	cctgtttgcc	gggctctgca	ctccctgctt	ctgcgtctgc	tggcccaaga	840
ccagggccaa	ggtgtctccc	tgttgagacc	cgcaccttaa	gcacctgct	gccttccac	900
aacattaaac	tctccttctt	cagaaaaaaa	aaaaaaaaaa	actcgtag		948

&lt;210&gt; 53

&lt;211&gt; 2007

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 53

ggcagcagct	aaccttagag	gtatcccaat	tggaatgta	gttctgggaa	acaaagtcaa	60
agcagtggga	gaggtaacca	attctgaagg	gacatgggtg	caactggatc	agaacagcat	120
ggtagagtct	tgtgagagtg	atgaaggaga	ggcatgggtc	ttagctagag	acagaggcgg	180
aaaccagtac	ctccgacatg	aagatgaaca	agctcttctg	gatcagaatt	ctcaaactcc	240
tcttccaagc	cctttctcag	tgcaagcttt	taataaaggg	caagttgcag	tgcccaagga	300
tttgattatg	gactcggaaa	tagcaaagtt	ttgactgttt	tacctactgc	aggtgaccaa	360
ctgagtgcc	tattgaattc	cattcagtc	cgacccaatc	tcccagctcc	ttccatcttt	420
gatcaagctg	caaaacctcc	ctcttcccta	gtacacagcc	catttgtgtt	cggacagccc	480
ctttccttcc	agcagcctca	gcttcagagt	gatcgaggaa	acatctcaac	atcttctaaa	540
ccagcctcta	catcaggaaa	atcagagctg	tcctctaaac	acagcagatc	gcttaaacct	600
gatggacgta	tgagccggac	tactgctgat	cagaagaagc	caagggggac	agaaagttaa	660
tctgctagt	aatccctcat	cttaaaatct	gatgctgcaa	agttgagggtc	agattcccac	720
agtaggtcat	tatcccccaa	ccataacacc	ttgcagacat	tgaaatctga	tgggaggatg	780
ccttctagct	ccagagctga	atccccagga	ccaggttctc	ggttgctcatc	tcctaagcca	840
aagactctcc	cagccaatag	gtctagccca	tcgggtgcta	gttctccacg	ctcctcctca	900
ccacatgata	aaaatctacc	tcaaaaaagt	actgctcctg	ttaagacaaa	gcttgatcct	960
cctcgggaac	gttctaaatc	agactcttac	acacttgatc	cagataacct	ccgaagaag	1020
aaaatgcccc	tcacagaacc	tttgagagga	cggccaacgt	cacaaaaacc	aaaatcagta	1080
ccaaaggatt	ctacagattc	ccctggatct	gaaaaatagag	ctcctctccc	catgtggtac	1140
aggaaaacct	ccacagttag	gtgggtcgaa	tctgcacctc	aagtacttta	aaaacaaata	1200
gtctaacaga	cagcacctgc	gatgacagca	gtgaatttaa	gagtgtggat	gaaggttcaa	1260
ataaagttca	tttttagcatt	ggaaaagcac	cactgaaaga	tgaacaggaa	atgagagcat	1320
ctcccaaaat	aagtcgaaaa	tgtgctaata	gacacaccag	gccccaaaaa	gaaaaatcga	1380
gttttctttt	caaaggagat	ggatccaagc	cttttagagcc	agccaagcaa	gccatgtctc	1440
cttctgtggc	cgaatgtgcc	agagctgtgt	ttgcttccct	cctctggcat	gaaggcatag	1500
tacatgatgc	aatggcttgt	tcttctttcc	taaagtttca	tcctgaactt	tccaaagaac	1560
atgctcctat	aaggagtagt	ttaaatagcc	aacaacctac	agaggaaaaa	gaaaccaagt	1620
taaaaaatag	acattcatta	gaaatatcat	ctgcactgaa	tatgtttaat	attgcacccc	1680
atggaccaga	tatatctaag	atgggttagca	tcaacaaaaa	caaggtattg	tctatgctta	1740
aggaaccacc	tctgcatgaa	aaatgtgagg	atgggaaaac	cgagaccact	tttgaaatgt	1800
ccatgcataa	cacaatgaag	tctaagtctc	ctcttccctt	aactttacaa	catttagtgg	1860
ctttttggga	agacatctct	ttggctacta	tcaaagctgc	ttcccagaat	atgatttttc	1920
caagtctctg	ttcctgtgca	gttcttaaaa	agaaagagtg	tgagaaagag	aataagaagt	1980



ccaaaaagga aaaaaaaaaa aaaaaaa

2007

&lt;210&gt; 54

&lt;211&gt; 1284

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 54

gagctggccc	tatctgtctc	cgtccttgct	acacacagct	actgggagga	tcattccaaa	60
acacaaatct	gagagagtct	tcccttgccc	tcaacataaa	gactagactc	cagccaggcc	120
taggaagccc	tgctcaagcc	agagtccacc	tacctgggcc	ctctctccta	tttcccattc	180
tgctactctg	cttaacacac	atggaattta	tgccaaacta	cttggtgctc	tcaaaacatg	240
ccatgggtgc	ttttgectct	gtgtcttcac	atattgtgtg	tctctgcctg	aaatgctttt	300
ccccgccttg	ataacctggg	gaacttccag	tcattccttg	ctgatgcaga	cagatgggtg	360
agtgactgta	caccttcctc	tcccttgcta	ccttccatca	gagaggctgg	gaagcaaacc	420
ctctacttcc	ccagcctccc	ttgcagttag	gggtgcccac	atgagagaca	ttgtctggca	480
ccagcccttc	cccactgctt	tctgtcttga	acccagatgt	gatgcctggg	gcagctgcag	540
ccatctcatg	accatgtcac	aacaaacacc	acaccaccca	agtgacaaga	tgaacagtgc	600
ctggatgcct	gatgacatgg	ttcagctgcc	aggccaaccc	caagcagcca	acctccggaa	660
ttctcatgag	ataattaaac	attgttaaga	ctgaagacac	tgtgaatcaa	attgcctgtc	720
acttgcaact	aaaagcactc	ctgattgaca	ctgggcctca	cctcaagcac	ccactactca	780
ctgaagtcct	tctggatccc	tgctcctagt	acaccttgca	caagcccatc	tcagcacttg	840
tctgtttcac	tatattagat	ttgctcattg	tctccctccc	ccattatact	gagacctttt	900
agaggaaaaga	gactgagtct	ttccacttta	atcttttagta	cctagcccag	cccctagcac	960
acagcaagtc	tttagtaggt	agattttgtag	aatatagggtc	tattttccag	ccttatattg	1020
taattttata	cttacagtat	ttttattaca	agctgcctcc	attccttatt	ttaaaaaggc	1080
caagagaaac	ctagatgtcc	atcaataatg	gactggataa	agaaaatgta	ttatggccgg	1140
gtacagtggg	tcacatctgt	aatactagca	ctttaggaag	ctgaggcagg	aggattgttt	1200
gagcgcagga	gttcaagaca	agcctgggca	gcacagttag	accctatctc	taccaaaaaa	1260
aaaaaaaaaa	aaaaaaaaaa	aaaaa				1284

&lt;210&gt; 55

&lt;211&gt; 1687

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (380)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 55

gtttaagaaa	atgtttggat	ggggcgattt	tcattccaac	atcaaaacag	tgaagctgaa	60
cctgttgata	actgggaaaa	ttgtagatca	tggcaatggg	acatttagtg	tttatttcag	120
gcataattca	actgggtcaag	ggaatgtatc	tgctcagcttg	gtacccccta	caaaaatcgt	180
ggaatttgac	ttggcacaac	aaaccgtgat	tgatgccaaa	gattccaagt	cttttaattg	240
tcgcattgaa	tatgaaaagg	ttgacaaggc	taccaagaac	acactctgca	actatgaccc	300
ttcaaaaacc	tgttaccagg	agcaaaccce	aagtcattgta	tcctggctct	gctccaagcc	360
ctttaagggt	atctgtattn	acatttcctt	atagtacaga	ttataaaactg	gtacagaaag	420
tgtgccctga	ctacaactac	cayagtgcac	caccttactt	tccctcggga	tgaagggtgaa	480
catgggggtg	agactgaagc	ctgaggaatt	aaaggtcata	tgacagggct	gttacctcaa	540
agaagaaggt	cacatctgtt	gcctggaatg	tgtctacact	gctgctcttg	tyaactggct	600
gcaaaatmca	ctagtggaaa	mcactctgat	gtaatttctg	cccagtcagc	ttcatccctc	660

agtataattg	taaatcatca	cagattttga	attcacacct	gaagacatgc	tctcacatat	720
agagggtacac	aaacacaccg	tcatgcacat	ttcagcttgc	gtctatcatg	attcctgttg	780
agagggcttt	cattgtctga	ctcataatgg	ttcaggatca	actatcatca	aacggaagga	840
ttaactagac	agagaatgtt	tctaacagtt	gctgttatgg	aaatctcttt	taaagtcttg	900
agtacatgct	aatcaataat	ctycaactcat	gcattcctac	tgcttggagt	agctgtactg	960
gtaaatacta	ctgtaggagt	atctgcttgt	taaaatggaa	aaatgtgtct	ttagagctca	1020
gtattctttaa	ttttacaaac	acaacaaaat	gtagtaactt	ttttccagca	tacagtaggc	1080
acattcaaag	tggtccaaga	tggtctcttt	ttctttgaaa	ggggcctgtt	ctcagtaaag	1140
atgagcaaac	atgttgaatt	tacatgtggg	cagacattgg	gataacaact	ttcatcacca	1200
atcattggac	ttttgtgaag	tcgacaccag	ctaaggctgc	ttaaaataag	ttctgatcat	1260
tatataagaa	gggaaatgcc	tggcagacac	catgtaagtt	ataagtgtct	gtcttatctt	1320
tactacacat	attgtaacaa	attcaatatc	ctagtcttca	tttgtatgaa	tggtttgtat	1380
tgtacatagt	ttaaccaagt	gttattttgag	ctgcttatta	atattaactt	gtacttgtct	1440
ctctgcttgt	tattggttaa	gaaaaaagga	tatgaggaat	tcattttatc	aatgtagctg	1500
tgaaggccat	taaaaagaca	aacttaatgt	acagagcatt	tattcagatc	aagtattgtt	1560
gaaagctata	catatacaac	attacagtct	gtctgtatct	agatatttta	tttctggaaa	1620
aatgaaatg	tacataaaaa	taaaacactt	aaagttgagt	ttcaaaaaaa	aaaaaaaaaa	1680
actcgag						1687

&lt;210&gt; 56

&lt;211&gt; 952

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 56

ggcagcagct	tattttctgg	tgaggagct	tagtaagtgg	tgctacaatt	gctgtgcaaa	60
gaaattccag	aggggagaag	aatgtaaaag	tttgggtggg	ggtggcttgg	cattgccctt	120
ttttcccacc	gattcgggtg	ctgggtgaagg	tgaggagatg	gaactccaat	taagggaactg	180
gagagaggtg	aagaattttg	caggtggggag	atttggattt	gaatgtggac	ttgtaaatga	240
cttgaccttg	ccatctgtgt	tcaaggctac	ggtttgctgt	ggggttcctg	ggagagctta	300
ctcaccctgg	agtcttttct	ttctcttgc	ccaagaagag	ccctgttggg	gctttaccac	360
cgcttggagt	ctcccagagga	cacaaacagg	cagagagggg	cgtgtaggga	gagttctttc	420
ctgttttctg	tgctttcctt	tttacaggac	tcccgggaagg	ccactcatgg	ccatgccagg	480
agcttttctca	gaaacagtca	taaacgatct	cttgagtctc	tttcttgtcc	tcccagctga	540
gcttttcttat	tccacccttt	ctgggtgtct	taggaatgca	tgagagacct	ggacgttttt	600
ctgctctctt	ctggcctcca	tgagagccatg	ggctcggctc	ggcggtctct	cacctcacia	660
tttatttctt	cctcccgtgc	cagcccttct	tttgtgtctg	aaaccgggtt	taaaatgtga	720
ctctcccaga	gaagaagccg	ctggctgtat	gaaacttgac	ggcgcttttg	taaggtgcca	780
cccccaaact	ttaaggtagc	taaaccaatt	tttaaaagat	tcaatggctt	gttcaccttc	840
cagatgtagc	tattgatgta	cacttcgcaa	cggagtgtct	gaaattgtgg	tggtcctgat	900
ttataggatt	tcataattaa	aatgtctgct	gaataaaaaa	aaaaaaaaaa	aa	952

&lt;210&gt; 57

&lt;211&gt; 5684

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (706)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (755)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 57

aatttttggga	ctgttgacct	tgctgtgaga	aaagagacaa	cgactgagca	agcactacca	60
ccagcactgt	tactgggaat	tagaagacct	gagtttctgt	ccagaccctc	agtgc aaact	120
gaggatgctc	catccaaagt	gaattatggg	acttgccatt	ttccaaaatg	ccttatcctt	180
taccatctct	gcacttttgt	tcatactctc	attctacttt	ggaactgctg	ctctgtggct	240
tttcatctgt	caaaactgcc	attttctcag	tatccaactc	ttatgccctc	ttttccatga	300
gtctcctaac	tagccagaat	agagctttta	agttttatga	catttcgtta	tgtatcctct	360
atctgtatac	aaaatcctgt	aaaatagtta	cttgccctgca	tttactgtct	ttgcagatag	420
cagactcctt	gaaagcaggg	tccttgttta	gtgcactctt	gcccacatac	accacaactt	480
atcaagatgc	atttattagg	aaggaggagt	ttagagagca	ggctatcaga	ataaccactc	540
agtaagtgtt	ttcttaattg	ctatgtgata	acttacatta	ctcttaatga	ggagaaaagt	600
cgctagatat	ggatcatgtt	tatgttttaa	tggtttttta	ttctaaattt	kgatctaggg	660
agccctcaga	cataaggaga	aaccaatatg	ttgaakgatg	gggtantaca	tacagaagga	720
ccaagacctt	attttctccy	acttaagagg	aatcntgkya	agatgmmmgg	acagcttttt	780
aaaaggagaa	ggtcataaga	cagtttgagg	aaggcattgg	aagaggaaga	rgggcaatgt	840
ctccttttkt	ttattgttgg	tatataaact	taaaatctca	gttcttttta	tggcacttgt	900
ggagccactt	cctctcctca	ccaaaaaatg	cccagtaccc	tgaatccgat	caaatctctc	960
tcctaaagta	taaggcttag	tttctgtgtg	ctgcttcgcg	agacagttcc	cacaaatcga	1020
gagtgttaat	cagacttttg	tggtttcttt	tttggtttgc	tggtgtttgt	tttcatthtt	1080
catttgtctt	tgccaaagcc	aggctcatca	agaatttaaca	gccatcaggc	tgccgatgtg	1140
ctgacagcag	accacttag	agtcctgtgt	ttgtaattcc	atgcattkgt	tattttacct	1200
gttttgkccc	tgcccttctt	agtcctgtgc	ctcctgattg	ctgagtgttc	acctggacct	1260
tctgactacc	ttccctgtgc	tattccatca	gcctacagac	ctgggtacctg	gattttttgcc	1320
cgagatgatt	cctaccacct	tactactgac	gaagacaccc	attccagtgg	accactgtga	1380
cccaggaggc	attcagccat	catgatgtgg	cctttacctc	cactcctgtc	ttgttctacc	1440
cagattcagc	acagcccttt	atagtgaagt	cagagtcctc	aagccaaata	gctaaagctg	1500
ttttatcaca	acaaaggcct	agtttgttcc	atgagtgtgc	atthcatttc	ttcagttaaa	1560
gccttcagag	acacacaata	aatttggacc	aggggatttt	ttagttatta	atgctctctg	1620
aagaaaggca	acatcttttt	gagagcagca	ttggaccaca	ccccacaatc	tcaaatgatt	1680
gaaattcatg	aacatctagg	atcccatgaa	ggctactgga	ccctgttttt	tctacttcaa	1740
atcctgtagt	agcctactga	atgagaaaac	atattctgac	ccattgggat	caaatcaaag	1800
gcacagtga	ctcctcatag	catcttcttt	ggaattactc	aggaaccaga	actttttaca	1860
caaatgtaag	aaattctacc	aaggagtccc	cttacctaac	agcatctcac	aaggctgcac	1920
cagattccag	aaaaggcttc	tcttgataca	tcaaggtaga	accwctatgc	atthtgtgac	1980
cgacttattc	ttagatcatt	ggttttccaa	aggctttgtg	gccatgaagc	cctttgagtg	2040
aaaactgtgc	agaagcccag	agtaaaaagt	aagctgctct	ggatgaagta	gtgaagcaag	2100
agtaggggct	tgaatcctgc	tacaactatc	ttcctttacc	accgtgggtg	cacctaaggg	2160
gacttcctta	caacaccttg	aactcttccg	aacacagttt	gaaaaccact	gccccagaca	2220
gcaatatgtt	tgacctgaat	ggcattccaa	tcttttctgt	acctccactc	agcacagttc	2280
atgttcagta	gatgctgaac	attcttagaa	atactgtgtg	tgaacttaga	aaagtgcaag	2340
aagacaggca	tgtctttgac	cccaggaatg	atcatttgct	gaagatgggtg	tcaagtgaac	2400
ctagattaac	agccctccac	tccagatgga	tatccagtga	ttcctagaat	gggatatagc	2460
cagagaacaa	ttctatgcac	cctacactga	cagactccct	taagcaacac	cagatgctct	2520
actgggtactt	gaagtacatg	actttgaagt	cttgaccctc	catgaatacc	tgaattatca	2580
gcaagcgggt	tttgaagctg	gtgcctcatt	gaggccatat	tagagcaact	tgtacatttg	2640
acctcttggt	atcagccatg	gtactctact	tcgtgtgcaa	gagataacta	tgaaagccaa	2700
attcaaatac	tggaacatt	tcctaaaggg	gctcaatata	tatcatctgt	cttcttttcc	2760
aaactacaca	tactgtatg	actcaaccag	tagcagttat	attgccccct	ggtttttatt	2820
cagtttaact	actgtttcca	agataaatga	gctaataagc	tttaaaaaaa	aaaaaaaaaa	2880
aggctgaatt	cttttttctt	catcactggc	atatctgcct	attctccaga	attattatga	2940
ctattcagct	cactttaaca	gttgaacttc	aagcgacaat	ctttgaacac	cccttctcat	3000

gtgatttaaa	atgaaacccat	ttggaaaagt	ttcttctagc	cagtaataga	tttttttttt	3060
aattgtctctg	ccttgtgccc	agagatgttc	ttttaagatg	aatcttttga	tgtctgatac	3120
caccaaatat	aggtggtagg	gagagttgga	ggctggccct	ttgagcaggc	cattagctta	3180
cttgcctgggc	atttccgata	gcttattgcc	tacctttttg	ctggaaacaa	actgatttga	3240
aaaacaaaat	ctatgaagac	tgcagctaag	gattttatcg	gtagacttaa	gagcttttgt	3300
ccttgtggat	atttttagtg	aaccacatca	gtctcaatac	tgtcatttta	cactgactca	3360
gagcagctga	cttcattcct	tgccatgata	tatatattaag	gcaggcattg	taacagacat	3420
aaagacaact	tatctgtttc	agcaggaagg	attcagttta	tgaactctca	gaccagatca	3480
tgttgaacaa	ggagactttg	atgtgtgtca	tgagaaaact	cattctttac	ttcccagtca	3540
atttaaaggc	cagctatcct	gagctactcg	aatgaatgca	ctggttaaac	attggaaata	3600
gtttgtttat	atccttgtct	ctctctaggc	caattgtgat	tacatgactc	gactctacat	3660
ctcgtcaaac	aaggcctagg	tctggttgct	gtagactgct	cgccctcaac	aaataaaaatc	3720
tggttgacta	gctccttgt	atatacaact	attatttgtt	aagaagaaat	tatcgtcaat	3780
tttctactac	cttccaattg	tcagctcttt	ttttcctctc	tggtttttcc	tatactttac	3840
agaaaaagac	attgatctat	actgccattc	cctctaatec	tgccatactc	agtcaaaaagg	3900
aatgacttaa	gatgaagatg	atcatctgct	cgagtctaaa	atatacattg	tatataagaa	3960
ttggtgatta	gaaaagcaaa	aaacctaaaa	cttaaatcta	ggagtctgta	tactgtctcc	4020
atgtctccat	gcctcagatc	tcatctaaat	ctttgaacag	caccattcaa	ccaatctgag	4080
gccttgactt	gcttgtaaga	tgattctcag	agatcggctg	agttaaaaaa	gatgacgact	4140
tgattaccaa	agaaagtagg	gccaactttg	acaaatctgg	ctctgctgac	cctgtcactc	4200
ccagatgtag	catagactcc	taaacagaa	ctcaagtctg	attgaggata	aggccttctc	4260
ctgagctgaa	agttcttttg	cagatgagca	agaaactgaa	agctgatgta	cctgactggc	4320
tctgtaagat	cagaaaactg	tatccagaat	aagccctatg	gattaacccc	tgagtaccca	4380
gagtaaaaa	taattttacag	aacttcctta	ttgatctgct	ggttcttcca	gatcatatcc	4440
tggtctattg	tatggctggc	ctttctgaag	gtacctgct	tgtctatttt	cctgactcag	4500
ctcttgccctg	cctttttcac	atgttgctgc	aattagactc	accgtgagga	ctacagtcaa	4560
tttcagtcta	tcttgtgccc	aatacaacaa	ggatttttaa	tagtaacaac	ccacacctca	4620
cccactagga	ctcaatgttc	acaacaggaa	ggaccattgc	tgcatactcc	ttgaccagca	4680
acttttttga	agatattttt	aagtgcagag	taggcctcta	ttcctgtatg	taattgttca	4740
ttttcagcac	ctggaacctc	atctatcggg	tctggaagga	atacagcagt	tcgaaagccg	4800
cgtccatttc	tctccttcag	tagtgcagaa	atgagtcoga	ttcaccagta	cacacagaac	4860
tgtaccagtt	caacctagca	aaagaagaaa	agtttccact	gtacttaaaa	tttacagctg	4920
actcaaattg	cctcacagaa	ttatttgatg	tagaaggcta	gttgtcttac	ttcagatcag	4980
caggacagtt	gggtctcag	actcatgacc	actgagtttg	cttgtgttga	aactgtgggt	5040
tcatccaaca	tatgctattg	gacatgatta	ttattccatt	caaattggatt	acagacttct	5100
tgaggacagg	acaaacttat	ctctcatggt	gttttttttag	aatactttta	taaccaagga	5160
agaaacctatg	ccagctgtta	ccattcaact	tcttaagcag	agattaagct	ttttcatatc	5220
tgttcttata	ctggacatca	gtagttttta	attgcccagc	atccgttcca	tcttgtaaca	5280
actccctgat	gtttcttaaa	accacctctt	cctattttca	gtctgtgggt	tggacagtct	5340
gacccaacct	tgagctttgt	gggtgaacat	gtaattcaga	cctcatcaat	cagcaaattcc	5400
atctgaactg	tggaggagaa	gctctcttta	ctgagggtgc	tttagctttg	taggatgaaa	5460
acctcaaact	aacagggcct	accatgtaga	gaatgaagcc	agtgcagggg	aaagcagagc	5520
caaaatatgg	agagacttga	atcctgatga	cagcgtttgt	gcccctggat	ccaaccgtgc	5580
ctgaagctag	aatatccctt	ggacttttca	gttatgtgaa	ccaataaata	cccttttttg	5640
cttaaaaaaa	aaaaaaaaaa	aaaaaawaaa	aaaaaaaaaa	aaaa		5684

&lt;210&gt; 58

&lt;211&gt; 557

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 58

gaattcggca	cgagtctgag	gcctcacaca	aatcaccct	taaccctcta	tttatggctt	60
tacaggcttt	ttctagcctg	ctcctccata	ttctttcaac	ctctacccat	taccagttc	120

caaagccact	tccacat	ttt	caggcattat	agcaacaacc	ccattcttgg	caccaatctt	180
cttagtccat	ttcgcgtac	tataacaata	tttgagactg	ggtaatttgt	aaagaacaga		240
gatttttaggc	taggcgcagt	ggctcacaca	tgtaatccca	gcgctttggg	aggccaaggc		300
gggaggattg	cttgagggtca	ggagttcaag	actagcctgg	ccaacatggt	gaaactgcat		360
ctctactaaa	aatacaaaaa	ttagctgggc	atcctggtgg	caggccctg	tagtcccagc		420
tacttgggag	gctgaggcac	aaaaatcact	tgaaaccggg	aggcagaggt	tcagacaagc		480
ctagatcatg	ccactgcact	ccagcctggg	tgacagagca	agactctgtc	tcaaaaaaaa		540
aaaaaaaaaa	ctcgagg						557

&lt;210&gt; 59

&lt;211&gt; 1410

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 59

agggaaaaat	aacacagcta	ctcctcactg	caaaaacata	tccatgcgta	gaatcaacaa	60
ctccagtcac	gggaccagga	ggagctctgg	gacgcagaca	cattccttgg	atgttgattt	120
tttttatgat	ctagtaaagg	aataggtaaa	gtctttgatg	tcagtgaagt	ggcaacatag	180
ccaaaaagtt	gggtaccttt	taggaaatga	tggtgtaagt	ctccttaatg	tatcctgagg	240
taagtttccct	actggcagca	gattttgtaa	gaattacttt	taagaatttc	attctttttg	300
tatgggtcatg	gagctccaac	catttttaat	aggaaagtct	tttgtaaatt	gttgctggtt	360
taatgtcatt	tctgtcttta	taacttgatc	aagaatgatt	ggaaggcaaa	caggtttaca	420
aatcaattct	gtgactttta	aaaagttgac	aatgttgtca	gattttaaacc	agtgtggcta	480
gtaaaaagca	gctcactcaa	tgtgggtggc	tccctattcc	tttacgctcc	ccctatccct	540
accccaacaag	cctttcgatt	ataaaatact	accaatcttg	ttataagatt	actgtggagt	600
agtcaagtac	tccccgggac	ttctgagctg	gtggaatatt	ttatttcaga	ctgaaaacag	660
agagcactct	ccttggaag	ggaaagcgga	gcttgctgag	tgagagatgg	agcctcatgg	720
tgtacaactg	agggtagtta	actcatcact	tctcccaagc	actcgatccc	agcttcaccc	780
actgggtgttg	ctttgcttga	actgttcaag	ccttttatag	ccttaccata	agtatttaga	840
tatgggtgtcc	ttttctgttt	ttgggggggg	agttttgttg	tgttttttta	aagtaagtgc	900
ttaagtatta	actttgggtt	gtccctctctg	tatgtttcga	aggggttttg	gttctttttg	960
cttctgtttt	cttaaacatg	ttttccactc	ccacttgggc	atthttggaag	ctgggtcagct	1020
agcagggtttt	ctgggatgtc	gggagacctc	gatgacctta	tccgggtgcaa	tactagctaa	1080
ggtaaagcta	gaaacctaca	ctgtcacttt	actgagattt	ctgagtatac	ttttcatatt	1140
gccttaatgt	agcagtaatg	tggtttatgca	tttggttctt	tgacacagaca	ttttgtcaaa	1200
tattaaaact	ctactttttt	atggcacata	ttagcatata	agcctttatt	ccaagaggtta	1260
tttatttttt	cacttgataa	aaaataatgt	ttccacgtaa	agaactctgt	tatatcctag	1320
aggactctgt	cttttatatt	cgggataata	aagactttta	agcaaaaaaa	aaaaaaaaaa	1380
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaag				1410

&lt;210&gt; 60

&lt;211&gt; 1759

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 60

ggcacgagca	caagccctgt	gagaggtgtg	tttggaatca	cttggtatcc	aatcacatg	60
tcacccctag	gagcaaggag	accggttggg	tttggggctg	gtctggaatg	aagaagcatc	120
tctcagcttc	cgaaggctgc	atggctcagc	gcagtatctc	aatcatgccc	tgcccgtttg	180
cacatttggg	cctgttggta	gttacctctc	tggtgactgg	caaagtcagc	aaggatattg	240
gggtggagca	ccctggctaa	gcacctctct	gattatagag	ctatggagta	gaagacagat	300
ggagaatgag	aggcctgtga	gaacaatcag	tcagttgcca	tctttcagag	ctgctcgagt	360
tcaaaagtgt	gtcatacagg	gtattttacc	attgctacct	ttaagggtatt	caggtgggaa	420

```

cctaggctgt ggcttcacat aatggaactt gggtgccatc ctaccctgtg atgttgagct 480
ggccagcact ggtgtaggaa cctcaaggac tctgtgcttc tctggtttgg ggcctaggat 540
aaacacaggc cctgcttgcc ccttggttct aggacacatc ttcccatgcc agcaaagtta 600
atgaaccagt ctacaagata actgttgaaa gaattcttag agaaacaacc cacaggaggg 660
gagccatgtc agagcccaag aaaaccatcc catcctgagc tctgccttct gtgctgctct 720
ctgcatccta ttctctgtcg gaacaggacc ccaactgtgtc cttgctcttc taggcagagt 780
tgtgggagag tgctaaatgc ttttgagtgg ggcagcctgt ggaatgggat ctcatactgg 840
ctccttagac cttgggcca tgaactcagt atggagcagg acctgcgatg ttctgatgga 900
ttatacccac agtgatattt ggcacatctg ccaaaagcta caaacaaccc ccaacaacta 960
cacactatat cttgtgagaa gtgtcctacc caggagtcct gaatgtgatc tgagtatgct 1020
ctaaggcagc cccaggaaaa gcaattcagt ccctctctct ttgcctttag acctgcaggc 1080
tgggacaatg aaaagaaaa atgtatttta catgaaaatt ttacaaccgt gaagccggaa 1140
gatgcatatg aagactttat tgtgaaacct cccgtgagaa agctgggtcca cgacaaagag 1200
ttggcagcag aagatgagca ggtgttccta atgaagcaac agtcactcct tgccaagcaa 1260
ccagccactc ccacgagagt ttttgaattt cctgcaagag gaccttctgg ttctccaagg 1320
accagggtc ggggagggcc agccagtgtg cctagtctct ccccaggcac gtcagtaaaa 1380
aaccgggacc caaacatcaa aaataatgca gcaagtgaag ggggtgtgcc cagcttcttc 1440
aacagtctgt tgagtaaaaa gacagtctct cctggaagtc ctggtgctgg tggggtgcag 1500
agcacagcca agaagtcagg acaaaagact gtgttgtcaa atgttcagga agaactggat 1560
agaatgactc gaaagccaga ctctatggta acaaactctt caacagaaaa tgaagcctga 1620
acctccttaa aaagtgcata tgtcgaatga ccaaataact atgtatattg atctgctaag 1680
accaggattt ttctgatatg gcacatgcta tcagtttttt ggggcagggg agatgaactt 1740
taaaaaaaaa aaaaaaaaaa

```

&lt;210&gt; 61

&lt;211&gt; 31

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (31)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 61

```

Met Leu Met Met Gly Thr Leu Val Leu Ile Leu Leu His Asp Val Ile
  1                      5                      10                      15

```

```

Val Thr Phe Thr Glu Phe Tyr Asn Ala Gln Asn Leu Lys Trp Xaa
          20                      25                      30

```

&lt;210&gt; 62

&lt;211&gt; 36

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (36)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 62

```

Met Lys Leu Ser Cys Cys Phe Phe Gly Ala Leu Glu Trp Thr Phe Leu

```

38

1 5 10 15  
Ala Ala Val Thr Leu Gly Pro Leu Pro Ser Arg Val Leu Leu Cys His  
20 25 30  
Arg Gly Cys Xaa  
35

<210> 63  
<211> 32  
<212> PRT  
<213> Homo sapiens  
  
<220>  
<221> SITE  
<222> (32)  
<223> Xaa equals stop translation

<400> 63  
Met Leu Leu Cys Val Leu Ile Val His Cys Phe Leu Phe Leu Asn Ser  
1 5 10 15  
Leu Ala Leu Tyr Gly Cys Pro Thr Val Val Tyr Pro Leu Ala Ser Xaa  
20 25 30

<210> 64  
<211> 16  
<212> PRT  
<213> Homo sapiens  
  
<220>  
<221> SITE  
<222> (16)  
<223> Xaa equals stop translation

<400> 64  
Met Asn Ser Gly Gly Ser Gly Trp Cys Gly Pro Ser Ser Ser Ser Xaa  
1 5 10 15

<210> 65  
<211> 33  
<212> PRT  
<213> Homo sapiens  
  
<220>  
<221> SITE

&lt;222&gt; (33)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 65

Met	Leu	Ser	Leu	Ala	Leu	Leu	Trp	Pro	Ile	Phe	Ile	Leu	Phe	Thr	Val
1				5					10					15	

Gln	Cys	His	Leu	Phe	Gly	Asn	Thr	Gln	His	Gln	Arg	Val	Leu	Pro	Asn
			20				25						30		

Xaa

&lt;210&gt; 66

&lt;211&gt; 47

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (47)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 66

Met	Asn	Phe	Phe	Leu	Gly	Leu	Trp	Leu	Leu	Tyr	Ile	Leu	Tyr	Ile	Leu
1				5					10					15	

Arg	Ile	Leu	Tyr	Thr	Ile	Leu	Ile	Tyr	Cys	Asn	Thr	Ala	Val	Phe	Asp
			20					25					30		

Asn	Leu	Asp	Ser	Ile	Trp	Tyr	Met	Asn	Phe	Cys	Ile	His	Tyr	Xaa
		35					40					45		

&lt;210&gt; 67

&lt;211&gt; 67

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (61)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (67)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 67

Met	Lys	Arg	Thr	Leu	Leu	Ser	Ser	Val	Ile	Cys	Leu	Ser	Ala	Ser	Pro
1				5					10					15	

Ala	Gln	Gly	Gln	Ala	Pro	Trp	Gln	Cys	Pro	Ala	Val	Thr	Gly	Asp	Ser
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----



40

20 25 30

Ala Glu Val Thr Tyr Pro Glu Lys Pro Leu His Gly Leu Ser Arg Arg  
35 40 45

Glu Lys Thr Ala Leu Pro Gly Pro Trp Phe Gly Leu Xaa Arg Gly Lys  
50 55 60

Gly Pro Xaa  
65

<210> 68  
<211> 58  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (58)  
<223> Xaa equals stop translation

<400> 68  
Met Gly Leu Leu Tyr Met Val Leu Leu Lys Ser Ile Val Phe Phe Ser  
1 5 10 15

Gly Val Ser Glu Glu Leu Lys Ala Tyr Gly Val Gly Leu Gln Thr Val  
20 25 30

Ile Glu Phe Leu Gln Asn Thr Arg Phe Trp Ala Trp Arg Trp Ile Ser  
35 40 45

Gln Ala Leu Leu Gly Leu Ala Leu Lys Xaa  
50 55

<210> 69  
<211> 56  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (56)  
<223> Xaa equals stop translation

<400> 69  
Met Glu Ser Leu Gly Pro Asp Ile Trp Leu Ile Ser Gly Ile Ala Ser  
1 5 10 15

Ser Pro Ser Phe Leu His Val Leu Val Val Val Val Gly Glu Cys  
20 25 30

Gly Trp Gly Met Ser Trp Leu Met Pro Ala Lys Ile Ser Ser His Pro  
35 40 45

Pro Cys Leu Ser Ser Leu Phe Xaa  
50 55

<210> 70  
<211> 28  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (28)  
<223> Xaa equals stop translation

<400> 70  
Met Gly Ala Leu Val Glu Leu Leu Tyr Ile Phe Pro Phe Leu Leu Pro  
1 5 10 15

Ser Phe Leu Ser Glu Lys Leu Leu Glu Lys Lys Xaa  
20 25

<210> 71  
<211> 37  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (37)  
<223> Xaa equals stop translation

<400> 71  
Met Pro Ala Gly Val Gly Trp Trp Val Cys Leu His Val Arg Val Cys  
1 5 10 15

Leu Gly Ser Phe Lys Gly Glu Arg Gly Thr His His His Ala Gly Ser  
20 25 30

Ala Leu Lys Arg Xaa  
35

<210> 72  
<211> 35  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (35)  
<223> Xaa equals stop translation

<400> 72

Met Leu Cys Leu Ile Ala Ile Leu Leu Tyr Val Leu Val Gln Tyr Leu  
1 5 10 15  
Val Asn Pro Gly Val Leu Arg Thr Asp Pro Arg Tyr Glu Ala Ala Pro  
20 25 30  
Gly Pro Xaa  
35

<210> 73  
<211> 46  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (46)  
<223> Xaa equals stop translation

<400> 73  
Met Cys Ile Leu Cys Tyr Thr Gln Gly Pro Lys Phe Leu Gln Leu Phe  
1 5 10 15  
Ile His Ala Ile Val Leu Leu Phe Ala Glu Met Glu Ile Ile Tyr Thr  
20 25 30  
Glu Leu Gln Ile Pro Glu Met Phe His Leu Tyr Leu Ile Xaa  
35 40 45

<210> 74  
<211> 24  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (24)  
<223> Xaa equals stop translation

<400> 74  
Cys Leu Gln Trp Phe Val Pro Leu Val Pro Gln Gln Ile Pro Glu Leu  
1 5 10 15  
Ile Leu Met Thr Ile Trp Lys Xaa  
20

<210> 75  
<211> 88  
<212> PRT  
<213> Homo sapiens

<220>

<221> SITE

<222> (88)

<223> Xaa equals stop translation

<400> 75

Met	Leu	Leu	Ala	Asn	Leu	Arg	His	Gly	Gly	Thr	Val	Asp	Glu	Tyr	Leu
1				5				10					15		

Gln	Asp	Gln	Leu	Ile	Val	Phe	Met	Ala	Leu	Ala	Asn	Gly	Val	Ser	Arg
	20							25					30		

Ile	Lys	Thr	Gly	Pro	Val	Thr	Leu	His	Thr	Gln	Thr	Ala	Ile	His	Phe
	35						40					45			

Ala	Glu	Gln	Ile	Ala	Lys	Ala	Lys	Phe	Ile	Val	Lys	Lys	Ser	Glu	Asp
	50					55					60				

Glu	Glu	Asp	Ala	Ala	Lys	Asp	Thr	Tyr	Ile	Ile	Glu	Cys	Gln	Gly	Ile
65					70					75					80

Gly	Met	Thr	Asn	Pro	Asn	Leu	Xaa
					85		

<210> 76

<211> 32

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (32)

<223> Xaa equals stop translation

<400> 76

Met	Leu	Val	Phe	Val	Leu	Leu	Trp	Ile	Ser	His	Leu	Phe	Ser	Gly	Arg
1				5					10					15	

Ser	Glu	His	Cys	Ser	Leu	Val	Gln	Ser	Ser	Tyr	Phe	Pro	Ser	Ser	Xaa
		20						25					30		

<210> 77

<211> 42

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (42)

<223> Xaa equals stop translation

&lt;400&gt; 77

Met Ala Ala Asn Ala Asn Ile Leu Trp Asn Ser Ser Lys Ser Thr Arg  
1 5 10 15

Asp Pro Gly Trp Phe Phe Val Leu Phe Ser Leu Phe Phe Pro Pro Ser  
20 25 30

Pro Glu Ser Ala Gly Met Glu Gly Gly Xaa  
35 40

&lt;210&gt; 78

&lt;211&gt; 36

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (36)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 78

Met Thr Ile Ile Cys Leu Leu Phe Leu Thr Leu Leu Leu Leu Leu Phe  
1 5 10 15

Lys Gly Ile Val Gln Ser Ser Ile Leu Tyr Leu Trp Gln Gln Val Lys  
20 25 30

Val Ser Arg Xaa  
35

&lt;210&gt; 79

&lt;211&gt; 59

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (59)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 79

Met Gln Gln Lys Glu Pro Trp Ala Trp Ser Met Gln Asn Trp Phe Leu  
1 5 10 15

Leu Gln Leu Leu Leu Leu Val Gly Ser Gly Arg Lys His Ile Glu Phe  
20 25 30

Met Ile Met Val Asn Leu Trp Arg Glu Arg Gly Asp Gln Asp Glu Gly  
35 40 45

Ala Ser Arg Arg Ser Cys Ser Ser Val His Xaa  
50 55

<210> 80  
<211> 20  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (20)  
<223> Xaa equals stop translation

<400> 80  
Lys Phe Trp Phe Ala Phe Glu Leu Phe Leu Phe Met Trp Leu Leu Ile  
1 5 10 15  
Ile Ser Ser Xaa  
20

<210> 81  
<211> 66  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (28)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (42)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (66)  
<223> Xaa equals stop translation

<400> 81  
Met Val Pro Leu Leu Phe Leu Pro Leu Asp Ser Trp Leu Trp Arg Glu  
1 5 10 15  
Lys Lys Tyr His Leu Leu Asp Ala Asp Ser Glu Xaa Ile Tyr Ser Pro  
20 25 30  
Leu Glu Asn Ser Ala Leu Pro Ala Ser Xaa Cys His Leu Ala Gly Ala  
35 40 45  
Ile Thr Glu Ser Ser Lys Gly His Pro Ile Ile Leu Leu Gly Gln Leu  
50 55 60  
Leu Xaa  
65

<210> 82  
<211> 19  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (19)  
<223> Xaa equals stop translation

<400> 82  
Met Glu Val Phe Leu Tyr Leu Gly Val Val Gly Phe Trp His Ile Gly  
1 5 10 15

Ile Ser Xaa

<210> 83  
<211> 31  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (31)  
<223> Xaa equals stop translation

<400> 83  
Met Asn Phe Gln Val Trp Gly Thr Gly Gln Cys Thr Phe Leu Ser Leu  
1 5 10 15

Phe Ile Leu Leu Phe Leu Lys Ile Cys Asn Thr Tyr Gln Arg Xaa  
20 25 30

<210> 84  
<211> 41  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (41)  
<223> Xaa equals stop translation

<400> 84  
Met Arg Met Lys Thr Arg Thr Lys Thr Leu Arg Lys Ala Gln Met Leu  
1 5 10 15

Phe Arg Leu Leu Thr Leu Arg Met Asp Leu Leu Val Leu Leu Leu Pro  
20 25 30

Arg Leu Asp Cys Pro Gln Thr Arg Xaa

35

40

<210> 85  
<211> 38  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (38)  
<223> Xaa equals stop translation

<400> 85  
Met Val Ser Val Ser Arg Gln Thr Leu Val Thr Phe Ser Leu Val Tyr  
1 5 10 15

Val Pro Phe Leu Leu His Ile Phe Gly Ser Lys Ser Tyr Trp Leu  
20 25 30

Asn Gln Gln Gly Leu Xaa  
35

<210> 86  
<211> 22  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (22)  
<223> Xaa equals stop translation

<400> 86  
Met Ile Tyr Leu Ser Ile Tyr Leu Leu Val Asn Ile Leu Ala Val Ser  
1 5 10 15

Asn Ser Trp Pro Ser Xaa  
20

<210> 87  
<211> 26  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (26)  
<223> Xaa equals stop translation

<400> 87  
Met Lys Lys Arg Leu Ser Pro Leu Ser Trp Ala Arg Cys Cys Leu Cys  
1 5 10 15



Phe Trp Leu Gln Val Gly Thr Thr Asn Xaa  
20 25

<210> 88

<211> 18

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (18)

<223> Xaa equals stop translation

<400> 88

Met Leu Ser Pro Gly Arg Cys Phe Ala Ile Trp Ser Leu Phe Leu Cys  
1 5 10 15

Ser Xaa

<210> 89

<211> 66

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (66)

<223> Xaa equals stop translation

<400> 89

Met Pro Phe Trp Ile Leu Pro His Val Asp Cys Leu Cys Val Cys Met  
1 5 10 15

Phe Gly Val Arg Met Cys Glu Thr Leu Leu Trp Phe Trp Glu Ser Glu  
20 25 30

Leu Tyr Arg Thr Val Tyr Lys Met Ser Leu Pro His His Pro Tyr Ser  
35 40 45

Ala Leu Leu Thr Leu Phe Phe Pro Pro Ser Ser His Ser His Ser Ser  
50 55 60

Phe Xaa  
65

<210> 90

<211> 10

<212> PRT

<213> Homo sapiens

<220>  
<221> SITE  
<222> (10)  
<223> Xaa equals stop translation

<400> 90  
Met Phe Met Met Ser Val Tyr Ile Leu Xaa  
1 5 10

<210> 91  
<211> 42  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (42)  
<223> Xaa equals stop translation

<400> 91  
Met Ser Met Cys Lys Val Arg Arg Gly Ser Leu Asn Tyr Leu Leu Leu  
1 5 10 15  
Phe Trp Leu Thr Ser Pro Ile Phe Lys Thr Leu Ser Asn Ser Gln Asn  
20 25 30  
Leu Leu Met Arg His Val Val Leu Asn Xaa  
35 40

<210> 92  
<211> 67  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (67)  
<223> Xaa equals stop translation

<400> 92  
Trp Leu Arg Phe Trp Cys Val Phe Ser Ser Cys Ser Gln Leu Gly Leu  
1 5 10 15  
Gly Leu Pro Lys Arg Trp Ile Ser Val Ser Thr Lys Ile Gln Gln Ile  
20 25 30  
Ile Thr Val Ser Pro Phe Asn Pro Phe Arg Asp Lys Val Arg Ile Ile  
35 40 45  
Tyr Asn Gly Thr Leu Ala Leu Gln Gly Leu Phe Thr Trp Tyr Leu Ser  
50 55 60  
Tyr Tyr Xaa

65

<210> 93  
<211> 40  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (40)  
<223> Xaa equals stop translation

<400> 93  
Met Gly Ala Ser Gln Cys Pro Phe Ala Ala Ala Leu Arg Pro Leu His  
1 5 10 15

Phe Leu Leu Trp Val Ala Ala Leu Leu Gly Leu Gln Gln Pro Leu Gln  
20 25 30

Arg Leu Gln Leu Arg Asn Ala Xaa  
35 40

<210> 94  
<211> 36  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (36)  
<223> Xaa equals stop translation

<400> 94  
Met Ser Ile Gln Ile Ile Cys Cys Leu Trp Phe Phe Leu Tyr Leu Ile  
1 5 10 15

Thr Cys Gln Lys Pro Ser Leu Pro Leu Asp Phe Phe Ile Leu Pro Ser  
20 25 30

Ser Glu Val Xaa  
35

<210> 95  
<211> 31  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (31)  
<223> Xaa equals stop translation

&lt;400&gt; 95

Met Trp Gln Ile Ala Met Ile Thr Leu Trp Ser Leu Leu Val Ser Gly  
1 5 10 15

Asn His Gln Leu Glu Leu Arg Met Leu Asp Thr Val Pro Arg Xaa  
20 25 30

&lt;210&gt; 96

&lt;211&gt; 40

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (40)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 96

Met Phe Gln Asp Ile Leu Ala Leu Cys Leu Trp Leu Leu Pro Gly Val  
1 5 10 15

Trp His His Ser Val Val Thr Tyr Asn His Cys Leu Gly Thr His Arg  
20 25 30

Val Asn Cys Leu Ser Asp Lys Xaa  
35 40

&lt;210&gt; 97

&lt;211&gt; 34

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (34)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 97

Met Asp Tyr Phe Leu Leu Ala Arg Ala Asp Pro Asn Ala Leu Pro Trp  
1 5 10 15

Glu Pro Ala Glu Phe Cys Pro Val Leu Leu Leu Ala Val Thr Gly Gln  
20 25 30

His Xaa

&lt;210&gt; 98

&lt;211&gt; 4

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

<220>  
<221> SITE  
<222> (4)  
<223> Xaa equals stop translation

<400> 98  
Met Cys Ala Xaa  
1

<210> 99  
<211> 34  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (34)  
<223> Xaa equals stop translation

<400> 99  
Met Ile Trp Ser Ile Val Thr Cys Trp Ile Cys Val Cys Thr Gly Val  
1 5 10 15

Phe Met Gln Gly Arg Leu Asn Ser Gln Val Arg Gly Glu Ser Glu Pro  
20 25 30

His Xaa

<210> 100  
<211> 35  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (35)  
<223> Xaa equals stop translation

<400> 100  
Met Thr Val Ser Phe Val Met Arg Phe Leu Ala Leu Ile Ser Asn Ser  
1 5 10 15

Phe Phe Leu Pro Leu Ser Leu Gly Ala Thr Pro Asp Pro Cys Gln Val  
20 25 30

Phe Leu Xaa  
35

<210> 101  
<211> 34  
<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (34)

<223> Xaa equals stop translation

<400> 101

Met Ser Ala Ser Ile Leu Cys Ser Phe Val His Ser Val Phe Phe Ile  
1 5 10 15

Ser Gly Cys Phe Ser Val Val Phe Arg Lys Met Ile Ile Thr Leu Phe  
20 25 30

Met Xaa

<210> 102

<211> 181

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (181)

<223> Xaa equals stop translation

<400> 102

Met His Gln Cys Glu Ile Trp Arg Glu Leu Phe Ser Pro Leu His Ala  
1 5 10 15

Leu Asn Phe Gly Ile Gly Gly Asp Gly Thr Gln His Val Leu Trp Arg  
20 25 30

Leu Glu Asn Gly Glu Leu Glu His Ile Arg Pro Lys Ile Val Val Val  
35 40 45

Trp Val Gly Thr Asn Asn His Gly His Thr Ala Glu Gln Val Thr Gly  
50 55 60

Gly Ile Lys Ala Ile Val Gln Leu Val Asn Glu Arg Gln Pro Gln Ala  
65 70 75 80

Arg Val Val Val Leu Gly Leu Leu Pro Arg Gly Gln His Pro Asn Pro  
85 90 95

Leu Arg Glu Lys Asn Arg Gln Val Asn Glu Leu Val Arg Ala Ala Leu  
100 105 110

Ala Gly His Pro Arg Ala His Phe Leu Asp Ala Asp Pro Gly Phe Val  
115 120 125

His Ser Asp Gly Thr Ile Ser His His Asp Met Tyr Asp Tyr Leu His  
130 135 140

Leu Ser Arg Leu Gly Tyr Thr Pro Val Cys Arg Ala Leu His Ser Leu  
145 150 155 160

Leu Leu Arg Leu Leu Ala Gln Asp Gln Gly Gln Gly Ala Pro Leu Leu  
165 170 175

Glu Pro Ala Pro Xaa  
180

<210> 103

<211> 36

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (36)

<223> Xaa equals stop translation

<400> 103

Met Lys Met Asn Lys Leu Phe Trp Ile Arg Ile Leu Lys Leu Leu Leu  
1 5 10 15

Gln Ala Leu Ser Gln Cys Lys Leu Leu Ile Lys Gly Lys Leu Gln Cys  
20 25 30

Pro Arg Ile Xaa  
35

<210> 104

<211> 18

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (18)

<223> Xaa equals stop translation

<400> 104

Met Pro Trp Cys Leu Leu Pro Leu Cys Leu His Ile Leu Cys Val Ser  
1 5 10 15

Ala Xaa

<210> 105

<211> 40

<212> PRT

<213> Homo sapiens

<220>  
<221> SITE  
<222> (40)  
<223> Xaa equals stop translation

<400> 105  
Met Ala Met Gly His Leu Val Phe Ile Ser Gly Ile Ile Gln Leu Val  
1 5 10 15  
Lys Gly Met Tyr Leu Ser Ala Trp Tyr Pro Leu Gln Lys Ser Trp Asn  
20 25 30  
Leu Thr Trp His Asn Lys Pro Xaa  
35 40

<210> 106  
<211> 6  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (6)  
<223> Xaa equals stop translation

<400> 106  
Met Trp Thr Cys Lys Xaa  
1 5

<210> 107  
<211> 56  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (56)  
<223> Xaa equals stop translation

<400> 107  
Met Val Leu Ala Ile Phe Gln Asn Ala Leu Ser Phe Thr Ile Ser Ala  
1 5 10 15  
Leu Leu Phe Ile Leu Ser Phe Tyr Phe Gly Thr Ala Ala Leu Trp Leu  
20 25 30  
Phe Ile Cys Gln Asn Cys His Phe Leu Ser Ile Gln Leu Leu Cys Pro  
35 40 45  
Leu Phe His Glu Ser Pro Asn Xaa  
50 55



<210> 108  
<211> 33  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (33)  
<223> Xaa equals stop translation

<400> 108  
Met Ala Leu Gln Ala Phe Ser Ser Leu Leu Leu His Ile Leu Ser Thr  
1 5 10 15  
Ser Thr His Tyr Pro Val Pro Lys Pro Leu Pro His Phe Gln Ala Leu  
20 25 30

Xaa

<210> 109  
<211> 40  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (40)  
<223> Xaa equals stop translation

<400> 109  
Met Phe Arg Arg Gly Phe Gly Ser Phe Cys Phe Cys Phe Leu Lys His  
1 5 10 15  
Val Phe His Ser His Leu Gly Ile Leu Glu Ala Gly Gln Leu Ala Gly  
20 25 30

Phe Leu Gly Cys Arg Glu Thr Xaa  
35 40

<210> 110  
<211> 32  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (32)  
<223> Xaa equals stop translation

<400> 110  
Met Pro Cys Pro Phe Ala His Leu Val Leu Leu Val Val Thr Ser Leu  
1 5 10 15

Val Thr Gly Lys Val Ser Lys Asp Ile Gly Val Glu His Pro Gly Xaa  
20 25 30

<210> 111  
<211> 53  
<212> PRT  
<213> Homo sapiens

<400> 111  
Phe Cys Thr Ala Lys Gln Thr Thr Ile Arg Val Asn Arg Gln Ala Thr  
1 5 10 15  
Glu Trp Glu Lys Ile Phe Ala Thr Tyr Leu Ser Asp Lys Gly Leu Leu  
20 25 30  
Ser Gly Ile Cys Asn Glu Leu Lys Gln Ile Tyr Lys Lys Lys Thr Asn  
35 40 45  
Asn Pro Ile Lys Lys  
50

<210> 112  
<211> 46  
<212> PRT  
<213> Homo sapiens

<400> 112  
Phe Cys Ser Val Lys Asp Thr Val Lys Arg Leu Lys Met Gln Ala Thr  
1 5 10 15  
Ala Trp Gln Lys Ile Phe Thr Lys His Ile Ser Asp Lys Gly Leu Ile  
20 25 30  
Ser Arg Thr Tyr Pro Asn Ser Gln Asn Ser Thr Ile Arg Lys  
35 40 45

<210> 113  
<211> 85  
<212> PRT  
<213> Homo sapiens

<400> 113  
Arg Glu Leu Cys Pro Gly Val Asn Thr Gln Pro Tyr Leu Cys Glu Thr  
1 5 10 15  
Gly His Cys Cys Gly Glu Thr Gly Cys Cys Thr Tyr Tyr Tyr Glu Leu  
20 25 30

Trp Trp Phe Trp Leu Leu Trp Thr Val Leu Ile Leu Phe Ser Cys Cys  
                   35                                  40                                  45

Cys Ala Phe Arg His Arg Arg Ala Lys Leu Arg Leu Gln Gln Gln Gln  
           50                                  55                                  60

Arg Gln Arg Glu Ile Asn Leu Leu Ala Tyr His Gly Ala Cys His Gly  
       65                                  70                                  75                                  80

Ala Gly Pro Val Pro  
                                   85

<210> 114  
 <211> 84  
 <212> PRT  
 <213> Homo sapiens

<400> 114  
 Lys Glu Ala Cys Val Gly Thr Asn Asn Gln Ser Tyr Ile Cys Asp Thr  
       1                                  5                                  10                                  15

Gly His Cys Cys Gly Gln Ser Gln Cys Cys Asn Tyr Tyr Tyr Glu Leu  
                                   20                                  25                                  30

Trp Trp Phe Trp Leu Val Trp Thr Ile Ile Ile Ile Leu Ser Cys Cys  
                   35                                  40                                  45

Cys Val Cys His His Arg Arg Ala Lys His Arg Leu Gln Ala Gln Gln  
       50                                  55                                  60

Arg Gln His Glu Ile Asn Leu Ile Ala Tyr Arg Glu Ala His Asn Tyr  
       65                                  70                                  75                                  80

Ser Ala Leu Pro

<210> 115  
 <211> 71  
 <212> PRT  
 <213> Homo sapiens

<400> 115  
 Pro Gly Phe Lys Arg Phe Ser Cys Leu Ser Leu Pro Arg Ser Trp Asp  
       1                                  5                                  10                                  15

Tyr Arg His Pro Pro Pro Arg Pro Ala Asn Phe Glu Phe Leu Val Glu  
                   20                                  25                                  30

Thr Gly Phe Leu His Val Gly Gln Ala Gly Leu Glu Leu Leu Thr Ser  
           35                                  40                                  45

Gly Asp Leu Pro Ala Ser Ala Ser Gln Ser Ala Arg Ile Thr Gly Val  
       50                                  55                                  60

Ser His Arg Ala Arg Pro Glu  
65 70

<210> 116

<211> 71

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (9)

<223> Xaa equals stop translation

<400> 116

Pro Gly Ser Ser Asn Ser Pro Ala Xaa Ala Phe Leu Ser Ser Trp Val  
1 5 10 15

Tyr Arg His Val Pro Pro Cys Leu Ala Asn Phe Val Phe Leu Val Glu  
20 25 30

Thr Gly Phe Leu His Val Gly Gln Ala Gly Leu Glu Leu Pro Thr Ser  
35 40 45

Gly Asp Pro Pro Ala Leu Ala Ser Gln Ser Ala Gly Ile Thr Gly Met  
50 55 60

Ser His Leu Thr Trp Pro Asp  
65 70

<210> 117

<211> 25

<212> PRT

<213> Homo sapiens

<400> 117

Val Gln Trp His Asp Phe Gly Ser Leu Gln Pro Leu Pro Pro Gly Phe  
1 5 10 15

Lys Arg Phe Ser Cys Leu Ser Leu Pro  
20 25

<210> 118

<211> 25

<212> PRT

<213> Homo sapiens

<400> 118

Val Gln Trp Arg Asp Leu Gly Ser Pro Gln Pro Pro Pro Ser Gly Phe  
1 5 10 15

Lys Gln Phe Ser Cys Leu Ser Leu Pro

60

20

25

&lt;210&gt; 119

&lt;211&gt; 85

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 119

His His Ala Arg Leu Ile Phe Asn Phe Cys Leu Phe Glu Met Glu Ser  
 1 5 10 15

His Ser Val Thr Gln Ala Gly Val Gln Trp Pro Asn Leu Gly Ser Leu  
 20 25 30

Gln Pro Leu Pro Pro Gly Leu Lys Arg Phe Ser Cys Leu Ser Leu Pro  
 35 40 45

Ser Ser Trp Asp Tyr Gly His Leu Pro Pro His Pro Ala Asn Phe Cys  
 50 55 60

Ile Phe Ile Arg Gly Gly Val Ser Pro Tyr Leu Ser Gly Trp Ser Gln  
 65 70 75 80

Thr Pro Asp Leu Arg  
 85

&lt;210&gt; 120

&lt;211&gt; 86

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (54)

&lt;223&gt; Xaa equals stop translation

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (81)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 120

His Leu Ala Ser Asn Phe Phe Ile Tyr Leu Leu Phe Phe Glu Thr Glu  
 1 5 10 15

Ser Cys Ser Val Ala Gln Thr Gly Leu Gln Trp His Asp Leu Gly Leu  
 20 25 30

Leu Gln Pro Pro Pro Pro Arg Phe Lys Arg Phe Leu Cys Leu Ser Leu  
 35 40 45

Leu Ser Arg Trp Asp Xaa Arg Cys Lys Pro Pro His Gln Ala Asn Phe  
 50 55 60

Cys Ile Phe Arg Arg Val Gly Val Ser Pro Tyr Cys Pro Gly Trp Cys  
 65 70 75 80

Xaa Thr Pro Glu Leu Lys  
 85

<210> 121  
 <211> 147  
 <212> PRT  
 <213> Homo sapiens

<400> 121  
 Lys Glu Ile Arg Asp Leu Tyr Val Asn Ile Gln Pro Val Gln Glu Pro  
 1 5 10 15

Lys Asp Gln Ala Phe Gly Asn Gly Asn Gly Ile Ile Ile Ile Ala Glu  
 20 25 30

Thr Ser Thr Gly Cys Leu Phe Ala Gly Ser Ser Leu Gly Lys Arg Gly  
 35 40 45

Val Asn Ala Asp Lys Val Gly Ile Glu Ala Ala Glu Met Leu Leu Ala  
 50 55 60

Asn Leu Arg His Gly Gly Thr Val Asp Glu Tyr Leu Gln Asp Gln Leu  
 65 70 75 80

Ile Val Phe Met Ala Leu Ala Asn Gly Val Ser Arg Ile Lys Thr Gly  
 85 90 95

Pro Val Thr Leu His Thr Gln Thr Ala Ile His Phe Ala Glu Gln Ile  
 100 105 110

Ala Lys Ala Lys Phe Ile Val Lys Lys Ser Glu Asp Glu Glu Asp Ala  
 115 120 125

Ala Lys Asp Thr Tyr Ile Ile Glu Cys Gln Gly Ile Gly Met Thr Asn  
 130 135 140

Pro Asn Leu  
 145

<210> 122  
 <211> 147  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (22)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (23)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (24)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (25)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (26)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (27)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (28)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (29)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (30)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 122  
 Glu Glu Ile Arg Asp Leu Tyr Val Asn Ile Gln Pro Val Gln Glu Pro  
 1 5 10 15  
 Lys Asp Gln Ala Phe Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Ala Glu  
 20 25 30  
 Thr Ser Thr Gly Cys Leu Phe Ala Gly Ser Ser Leu Gly Lys Arg Gly  
 35 40 45  
 Val Asn Ala Asp Lys Val Gly Ile Glu Ala Ala Glu Met Leu Leu Ala  
 50 55 60  
 Asn Leu Arg His Gly Gly Thr Val Asp Glu Tyr Leu Gln Asp Gln Leu  
 65 70 75 80

Ile Val Phe Met Ala Leu Ala Asn Gly Val Ser Arg Ile Lys Thr Gly  
                             85                            90                            95

Pro Val Thr Leu His Thr Gln Thr Ala Ile His Phe Ala Glu Gln Ile  
                             100                            105                            110

Ala Lys Ala Lys Phe Ile Val Lys Lys Ser Glu Asp Glu Glu Asp Ala  
                             115                            120                            125

Ala Lys Asp Thr Tyr Ile Ile Glu Cys Gln Gly Ile Gly Met Thr Asn  
                             130                            135                            140

Pro Asn Leu  
 145

<210> 123

<211> 193

<212> PRT

<213> Homo sapiens

<400> 123

Val Asp Tyr Val Gly Pro Leu Pro Ser Trp Lys Gly Gln Arg Phe Val  
   1                            5                            10                            15

Leu Thr Gly Val Asp Thr Tyr Ser Gly Tyr Gly Phe Ala Phe Pro Ala  
                             20                            25                            30

Arg Asn Ala Ser Ala Lys Thr Thr Ile His Gly Leu Thr Glu Cys Leu  
                             35                            40                            45

Ile Tyr Arg His Gly Ile Pro His Ser Ile Ala Ser Asp Gln Gly Thr  
                             50                            55                            60

His Phe Thr Ala Arg Glu Val Arg Gln Trp Ala His Asp His Gly Ile  
   65                            70                            75                            80

His Trp Ser Tyr His Val Pro His His Pro Glu Ala Ala Gly Leu Ile  
                             85                            90                            95

Glu Arg Trp Asn Gly Leu Leu Lys Met Gln Leu Gln His Gln Leu Gly  
                             100                            105                            110

Gly Asn Ser Leu Glu Gly Trp Gly Arg Val Leu Gln Lys Ala Val Tyr  
                             115                            120                            125

Ala Leu Asn Gln Arg Ser Ile Tyr Gly Thr Val Ser Pro Ile Ala Arg  
                             130                            135                            140

Ile His Gly Ser Arg Asn Gln Gly Val Glu Lys Gly Ile Val Pro Leu  
   145                            150                            155                            160

Thr Ile Thr His Ser Asp Pro Leu Gly Lys Phe Leu Leu Pro Val Pro  
                             165                            170                            175



Ile Thr Leu Gly Ser Ala Gly Leu Glu Val Leu Ala Pro Glu Ala Gly  
                  180                                  185                                  190

Val

<210> 124  
<211> 182  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (13)  
<223> Xaa equals stop translation

<220>  
<221> SITE  
<222> (56)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (59)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (60)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (91)  
<223> Xaa equals stop translation

<220>  
<221> SITE  
<222> (99)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (100)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (101)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE

<222> (102)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (103)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (104)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (105)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (106)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (107)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (108)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (109)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (110)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (111)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (112)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE

&lt;222&gt; (113)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 124

Val	Asp	Tyr	Ile	Glu	Leu	Leu	Pro	Ser	Trp	Lys	Gly	Xaa	His	Phe	Val
1				5					10					15	

Leu	Thr	Arg	Thr	Asp	Pro	Arg	Tyr	Arg	Phe	Ala	Ser	Ser	Tyr	Lys	Ile
			20				25						30		

Leu	Pro	Lys	Leu	Ser	Ser	Met	Val	Ser	Trp	Asn	Ala	Leu	Pro	Ile	Val
		35					40					45			

Ile	Phe	His	Thr	Thr	Leu	Leu	Xaa	Ile	Lys	Xaa	Xaa	Ser	Gln	Gln	Lys
	50					55					60				

Asn	Phe	Ser	Met	Ser	His	Cys	Ser	Trp	Asn	Ser	Leu	Val	Tyr	Val	Pro
65					70					75					80

Tyr	His	Ala	Lys	Glu	Ala	Gly	Leu	Ile	Gly	Xaa	Trp	Asp	Gly	Leu	Leu
				85					90					95	

Lys	Ile	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa
			100					105					110		

Xaa	Ser	Ser	Pro	Glu	Gly	Tyr	Ile	Tyr	Ala	Leu	Asn	Gln	His	Pro	Ile
		115					120					125			

Asn	Gly	Thr	Phe	Phe	Pro	Ser	Ile	Ala	Arg	Asn	Gln	Gly	Val	Glu	Thr
	130						135					140			

Lys	Val	Ala	Pro	Cys	Ile	Ile	Asn	Pro	Gly	Asp	Pro	Leu	Ala	Lys	Phe
145					150					155					160

Ile	Leu	Pro	Val	Leu	Ile	Ile	Leu	Cys	Pro	Thr	Gly	Leu	Glu	Val	Leu
				165					170					175	

Val	Pro	Lys	Gly	Glu	Ile
				180	

&lt;210&gt; 125

&lt;211&gt; 34

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 125

Gln	Gln	Thr	Leu	Arg	Asn	Leu	Leu	Ser	Lys	Val	Ser	Pro	Ser	Phe	Ser
1				5					10					15	

Ala	Glu	Leu	Lys	Gln	Leu	Asn	Gln	Gln	Tyr	Glu	Lys	Leu	Phe	His	Lys
			20					25					30		

Trp Met

<210> 126  
 <211> 34  
 <212> PRT  
 <213> Homo sapiens

<400> 126  
 Lys Gln Thr Leu Arg Asn Leu Leu Ser Lys Val Ser Pro Ser Phe Ser  
 1 5 10 15  
 Ala Glu Leu Lys Gln Leu Asn Gln Gln Tyr Glu Lys Leu Phe His Lys  
 20 25 30

Trp Met

<210> 127  
 <211> 206  
 <212> PRT  
 <213> Homo sapiens

<400> 127  
 Met Ile Asn Ile Asp Gly Lys Met Arg Pro Ser Glu Ser Phe Leu Leu  
 1 5 10 15  
 Glu Phe Leu Cys Asn Phe Phe Ser Thr Leu Leu Ile Val Pro Asp His  
 20 25 30  
 Pro Glu His Gly Val Leu Phe Leu Val Arg Glu Leu Leu Asn Val Ile  
 35 40 45  
 Gln Asp Tyr Thr Trp Glu Asp Asn Ser Asp Glu Lys Ile Arg Ile Tyr  
 50 55 60  
 Thr Cys Val Leu His Leu Leu Ser Ala Met Ser Gln Glu Thr Tyr Leu  
 65 70 75 80  
 Tyr His Ile Asp Lys Val Asp Ser Asn Asp Ser Leu Tyr Gly Gly Asp  
 85 90 95  
 Ser Lys Phe Leu Ala Glu Asn Asn Lys Leu Cys Glu Thr Val Met Ala  
 100 105 110  
 Gln Ile Leu Glu His Leu Lys Thr Leu Ala Lys Asp Glu Ala Leu Lys  
 115 120 125  
 Arg Gln Ser Ser Leu Gly Leu Ser Phe Phe Asn Ser Ile Leu Ala His  
 130 135 140  
 Gly Asp Leu Arg Asn Asn Lys Leu Asn Gln Leu Ser Val Asn Leu Trp  
 145 150 155 160  
 His Leu Ala Gln Arg His Gly Cys Ala Asp Thr Arg Thr Met Val Lys

165 170 175  
 Thr Leu Glu Tyr Ile Lys Lys Gln Ser Lys Gln Pro Asp Met Thr His  
 180 185 190  
 Leu Thr Glu Leu Ala Leu Arg Leu Pro Leu Gln Thr Arg Thr  
 195 200 205  
  
 <210> 128  
 <211> 206  
 <212> PRT  
 <213> Homo sapiens  
  
 <400> 128  
 Met Ile Asn Ile Asp Gly Lys Met Arg Pro Ser Glu Ser Phe Leu Leu  
 1 5 10 15  
 Glu Phe Leu Cys Asn Phe Phe Ser Thr Leu Leu Ile Val Pro Asp His  
 20 25 30  
 Pro Glu His Gly Val Leu Phe Leu Val Arg Glu Leu Leu Asn Val Ile  
 35 40 45  
 Gln Asp Tyr Thr Trp Glu Asp Asn Ser Asp Glu Lys Ile Arg Ile Tyr  
 50 55 60  
 Thr Cys Val Leu His Leu Leu Ser Ala Met Ser Gln Glu Thr Tyr Leu  
 65 70 75 80  
 Tyr His Ile Asp Lys Val Asp Ser Asn Asp Ser Leu Tyr Gly Gly Asp  
 85 90 95  
 Ser Lys Phe Leu Ala Glu Asn Asn Lys Leu Cys Glu Thr Val Met Ala  
 100 105 110  
 Gln Ile Leu Glu His Leu Lys Thr Leu Ala Lys Asp Glu Ala Leu Lys  
 115 120 125  
 Arg Gln Ser Ser Leu Gly Leu Ser Phe Phe Asn Ser Ile Leu Ala His  
 130 135 140  
 Gly Asp Leu Arg Asn Asn Lys Leu Asn Gln Leu Ser Val Asn Leu Trp  
 145 150 155 160  
 His Leu Ala Gln Arg His Gly Cys Ala Asp Thr Arg Thr Met Val Lys  
 165 170 175  
 Thr Leu Glu Tyr Ile Lys Lys Gln Ser Lys Gln Pro Asp Met Thr His  
 180 185 190  
 Leu Thr Glu Leu Ala Leu Arg Leu Pro Leu Gln Thr Arg Thr  
 195 200 205

<210> 129  
<211> 84  
<212> PRT  
<213> Homo sapiens

<400> 129  
Lys Met Leu Gln Ser Leu Gly Arg Pro Glu Val His Met Ala Leu Asp  
1 5 10 15  
Val Val Leu Val Arg Gly Ser Gly Gln Glu His Glu Gly Cys Leu Leu  
20 25 30  
Leu Thr Ser Glu Val Leu Phe Val Val Ser Val Ser Glu Asp Thr Gln  
35 40 45  
Gln Gln Ala Phe Pro Val Thr Glu Ile Asp Cys Ala Gln Asp Ser Lys  
50 55 60  
Gln Asn Asn Leu Leu Thr Val Gln Leu Lys Gln Pro Arg Val Ala Cys  
65 70 75 80  
Asp Val Glu Val

<210> 130  
<211> 84  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (52)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (63)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (73)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (80)  
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 130  
Lys Met Leu Gln Ser Leu Gly Arg Pro Glu Val His Met Ala Leu Asp  
1 5 10 15  
Val Val Leu Val Arg Gly Ser Gly Gln Glu His Glu Gly Cys Leu Leu

20                      25                      30  
 Leu Thr Ser Glu Val Leu Phe Val Val Ser Val Ser Glu Asp Thr Gln  
                     35                      40                      45  
 Gln Gln Ala Xaa Pro Val Thr Glu Ile Asp Cys Ala Gln Asp Xaa Lys  
                     50                      55                      60  
 Gln Asn Asn Leu Leu Thr Val Gln Xaa Lys Gln Pro Arg Val Ala Xaa  
                     65                      70                      75                      80  
 Asp Val Glu Val

<210> 131  
 <211> 35  
 <212> PRT  
 <213> Homo sapiens

<400> 131  
 Gly Ile Leu His Gly Ala Gly Leu Ser Gln Leu Pro Lys Gln Arg His  
                     1                      5                      10                      15  
 Gln Pro Ser Asp Leu His Ala Asp Gln Ala Pro Asn Ser His Val Lys  
                     20                      25                      30  
 Tyr Val Trp  
                     35

<210> 132  
 <211> 35  
 <212> PRT  
 <213> Homo sapiens

<400> 132  
 Gly Ile Leu His Gly Ala Gly Leu Ser Gln Leu Pro Lys Gln Arg His  
                     1                      5                      10                      15  
 Gln Pro Ser Asp Leu His Ala Asp Gln Ala Pro Asn Ser His Val Lys  
                     20                      25                      30  
 Tyr Val Trp  
                     35

<210> 133  
 <211> 231  
 <212> PRT  
 <213> Homo sapiens

<400> 133  
 Met Ser Gly Glu Glu Asn Pro Ala Ser Lys Pro Thr Pro Val Gln Asp  
                     1                      5                      10                      15

Val Gln Gly Asp Gly Arg Trp Met Ser Leu His His Arg Phe Val Ala  
                   20                                  25                                  30  
 Asp Ser Lys Asp Lys Glu Pro Glu Val Val Phe Ile Gly Asp Ser Leu  
                   35                                  40                                  45  
 Val Gln Leu Met His Gln Cys Glu Ile Trp Arg Glu Leu Phe Ser Pro  
                   50                                  55                                  60  
 Leu His Ala Leu Asn Phe Gly Ile Gly Gly Asp Gly Thr Gln His Val  
                   65                                  70                                  75                                  80  
 Leu Trp Arg Leu Glu Asn Gly Glu Leu Glu His Ile Arg Pro Lys Ile  
                                   85                                  90                                  95  
 Val Val Val Trp Val Gly Thr Asn Asn His Gly His Thr Ala Glu Gln  
                                   100                                  105                                  110  
 Val Thr Gly Gly Ile Lys Ala Ile Val Gln Leu Val Asn Glu Arg Gln  
                   115                                  120                                  125  
 Pro Gln Ala Arg Val Val Val Leu Gly Leu Leu Pro Arg Gly Gln His  
                   130                                  135                                  140  
 Pro Asn Pro Leu Arg Glu Lys Asn Arg Gln Val Asn Glu Leu Val Arg  
                   145                                  150                                  155                                  160  
 Ala Ala Leu Ala Gly His Pro Arg Ala His Phe Leu Asp Ala Asp Pro  
                                   165                                  170                                  175  
 Gly Phe Val His Ser Asp Gly Thr Ile Ser His His Asp Met Tyr Asp  
                   180                                  185                                  190  
 Tyr Leu His Leu Ser Arg Leu Gly Tyr Thr Pro Val Cys Arg Ala Leu  
                   195                                  200                                  205  
 His Ser Leu Leu Leu Arg Leu Leu Ala Gln Asp Gln Gly Gln Gly Ala  
                   210                                  215                                  220  
 Pro Leu Leu Glu Pro Ala Pro  
                   225                                  230

&lt;210&gt; 134

&lt;211&gt; 231

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (206)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;



<221> SITE  
<222> (207)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (208)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (209)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (210)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (211)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (212)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (213)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (214)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (215)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (216)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (217)  
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 134

```

Met Ser Gly Glu Glu Asn Pro Ala Ser Lys Pro Thr Pro Val Gln Asp
 1              5              10              15

Val Gln Gly Asp Gly Arg Trp Met Ser Leu His His Arg Phe Val Ala
              20              25              30

Asp Ser Lys Asp Lys Glu Pro Glu Val Val Phe Ile Gly Asp Ser Leu
              35              40              45

Val Gln Leu Met His Gln Cys Glu Ile Trp Arg Glu Leu Phe Ser Pro
 50              55              60

Leu His Ala Leu Asn Phe Gly Ile Gly Gly Asp Gly Thr Gln His Val
 65              70              75              80

Leu Trp Arg Leu Glu Asn Gly Glu Leu Glu His Ile Arg Pro Lys Ile
              85              90              95

Val Val Val Trp Val Gly Thr Asn Asn His Gly His Thr Ala Glu Gln
              100              105              110

Val Thr Gly Gly Ile Lys Ala Ile Val Gln Leu Val Asn Glu Arg Gln
              115              120              125

Pro Gln Ala Arg Val Val Val Leu Gly Leu Leu Pro Arg Gly Gln His
              130              135              140

Pro Asn Pro Leu Arg Glu Lys Asn Arg Gln Val Asn Glu Leu Val Arg
              145              150              155              160

Ala Ala Leu Ala Gly His Pro Arg Ala His Phe Leu Asp Ala Asp Pro
              165              170              175

Gly Phe Val His Ser Asp Gly Thr Ile Ser His His Asp Met Tyr Asp
              180              185              190

Tyr Leu His Leu Ser Arg Leu Gly Tyr Thr Pro Val Cys Xaa Xaa Xaa
              195              200              205

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gln Asp Gln Gly Gln Gly Ala
              210              215              220

Pro Leu Leu Glu Pro Ala Pro
              225              230

```

&lt;210&gt; 135

&lt;211&gt; 72

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 135

```

Pro Ser Ser Glu Thr Ser Leu Ser Phe Ser Thr Asn Gly Asn Asp Glu
 1              5              10              15

```

Glu Asp Leu Glu Arg Pro Ile Glu Arg Lys Lys Thr Arg Leu Pro Asn  
                             20                            25                            30

Ala Leu Thr Pro Ser Val Ala Asp Cys Ile Arg Ala Val Phe Ala Ala  
                             35                            40                            45

Phe Val Trp His Glu His Leu Val Lys Asp Leu Met Ala Ala Ala Ala  
                             50                            55                            60

Tyr Leu Arg Phe His Gln Asn Leu  
                             65                            70

<210> 136

<211> 63

<212> PRT

<213> Homo sapiens

<400> 136

Pro Lys Lys Glu Lys Ser Ser Phe Leu Phe Lys Gly Asp Gly Ser Lys  
                             1                            5                            10                            15

Pro Leu Glu Pro Ala Lys Gln Ala Met Ser Pro Ser Val Ala Glu Cys  
                             20                            25                            30

Ala Arg Ala Val Phe Ala Ser Phe Leu Trp His Glu Gly Ile Val His  
                             35                            40                            45

Asp Ala Met Ala Cys Ser Ser Phe Leu Lys Phe His Pro Glu Leu  
                             50                            55                            60

<210> 137

<211> 128

<212> PRT

<213> Homo sapiens

<400> 137

Phe Lys Lys Met Phe Gly Trp Gly Asp Phe His Ser Asn Ile Lys Thr  
                             1                            5                            10                            15

Val Lys Leu Asn Leu Leu Ile Thr Gly Lys Ile Val Asp His Gly Asn  
                             20                            25                            30

Gly Thr Phe Ser Val Tyr Phe Arg His Asn Ser Thr Gly Gln Gly Asn  
                             35                            40                            45

Val Ser Val Ser Leu Val Pro Pro Thr Lys Ile Val Glu Phe Asp Leu  
                             50                            55                            60

Ala Gln Gln Thr Val Ile Asp Ala Lys Asp Ser Lys Ser Phe Asn Cys  
                             65                            70                            75                            80

Arg Ile Glu Tyr Glu Lys Val Asp Lys Ala Thr Lys Asn Thr Leu Cys  
                             85                            90                            95

Asn Tyr Asp Pro Ser Lys Thr Cys Tyr Gln Glu Gln Thr Gln Ser His  
 100 105 110

Val Ser Trp Leu Cys Ser Lys Pro Phe Lys Val Ile Cys Ile Tyr Ile  
 115 120 125

<210> 138

<211> 128

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (127)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 138

Phe Lys Lys Met Phe Gly Trp Gly Asp Phe His Ser Asn Ile Lys Thr  
 1 5 10 15

Val Lys Leu Asn Leu Leu Ile Thr Gly Lys Ile Val Asp His Gly Asn  
 20 25 30

Gly Thr Phe Ser Val Tyr Phe Arg His Asn Ser Thr Gly Gln Gly Asn  
 35 40 45

Val Ser Val Ser Leu Val Pro Pro Thr Lys Ile Val Glu Phe Asp Leu  
 50 55 60

Ala Gln Gln Thr Val Ile Asp Ala Lys Asp Ser Lys Ser Phe Asn Cys  
 65 70 75 80

Arg Ile Glu Tyr Glu Lys Val Asp Lys Ala Thr Lys Asn Thr Leu Cys  
 85 90 95

Asn Tyr Asp Pro Ser Lys Thr Cys Tyr Gln Glu Gln Thr Gln Ser His  
 100 105 110

Val Ser Trp Leu Cys Ser Lys Pro Phe Lys Val Ile Cys Ile Xaa Ile  
 115 120 125

<210> 139

<211> 27

<212> PRT

<213> Homo sapiens

&lt;400&gt; 139

Tyr Ser Thr Asp Tyr Lys Leu Val Gln Lys Val Cys Pro Asp Tyr Asn  
 1 5 10 15

Tyr His Ser Asp Thr Pro Tyr Phe Pro Ser Gly  
 20 25

&lt;210&gt; 140

&lt;211&gt; 27

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 140

Tyr Ser Thr Asp Tyr Lys Leu Val Gln Lys Val Cys Pro Asp Tyr Asn  
 1 5 10 15

Tyr His Ser Asp Thr Pro Tyr Phe Pro Ser Gly  
 20 25

&lt;210&gt; 141

&lt;211&gt; 184

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 141

Phe Ile Pro Ala Gly Trp Asp Asn Glu Lys Lys Ile Ala Ile Leu His  
 1 5 10 15

Glu Asn Phe Thr Thr Val Lys Pro Glu Asp Ala Tyr Glu Asp Phe Ile  
 20 25 30

Val Lys Pro Pro Val Arg Lys Leu Val His Asp Lys Glu Leu Ala Ala  
 35 40 45

Glu Asp Glu Gln Val Phe Leu Met Lys Gln Gln Ser Leu Leu Ala Lys  
 50 55 60

Gln Pro Ala Thr Pro Thr Arg Ala Ser Glu Ser Pro Ala Arg Gly Pro  
 65 70 75 80

Ser Gly Ser Pro Arg Thr Gln Gly Arg Gly Gly Pro Ala Ser Val Pro  
 85 90 95

Ser Ser Ser Pro Gly Thr Ser Val Lys Lys Pro Asp Pro Asn Ile Lys  
 100 105 110

Asn Asn Ala Ala Ser Glu Gly Val Leu Ala Ser Phe Phe Asn Ser Leu  
 115 120 125

Leu Ser Lys Lys Thr Gly Ser Pro Gly Ser Pro Gly Ala Gly Gly Val  
 130 135 140

Gln Ser Thr Ala Lys Lys Ser Gly Gln Lys Thr Val Leu Ser Asn Val

145		150		155		160									
Gln	Glu	Glu	Leu	Asp	Arg	Met	Thr	Arg	Lys	Pro	Asp	Ser	Met	Val	Thr
				165					170					175	
Asn	Ser	Ser	Thr	Glu	Asn	Glu	Ala								
				180											

<210> 142  
 <211> 184  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (90)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (91)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (92)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (93)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (94)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (95)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (96)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (97)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE  
 <222> (98)  
 <223> Xaa equals any of the naturally occurring L-amino acids  
  
 <220>  
 <221> SITE  
 <222> (99)  
 <223> Xaa equals any of the naturally occurring L-amino acids  
  
 <220>  
 <221> SITE  
 <222> (100)  
 <223> Xaa equals any of the naturally occurring L-amino acids  
  
 <220>  
 <221> SITE  
 <222> (101)  
 <223> Xaa equals any of the naturally occurring L-amino acids  
  
 <220>  
 <221> SITE  
 <222> (102)  
 <223> Xaa equals any of the naturally occurring L-amino acids  
  
 <220>  
 <221> SITE  
 <222> (103)  
 <223> Xaa equals any of the naturally occurring L-amino acids  
  
 <400> 142  
 Phe Arg Pro Ala Gly Trp Asp Asn Glu Lys Lys Ile Ala Ile Leu His  
   1                  5                  10                  15  
 Glu Asn Phe Thr Thr Val Lys Pro Glu Asp Ala Tyr Glu Asp Phe Ile  
                   20                  25                  30  
 Val Lys Pro Pro Val Arg Lys Leu Val His Asp Lys Glu Leu Ala Ala  
                   35                  40                  45  
 Glu Asp Glu Gln Val Phe Leu Met Lys Gln Gln Ser Leu Leu Ala Lys  
   50                  55                  60  
 Gln Pro Ala Thr Pro Thr Arg Val Phe Glu Phe Pro Ala Arg Gly Pro  
   65                  70                  75                  80  
 Ser Gly Ser Pro Arg Thr Gln Gly Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa  
                   85                  90                  95  
 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Val Lys Asn Pro Asp Pro Asn Ile Lys  
                   100                  105                  110  
 Asn Asn Ala Ala Ser Glu Gly Val Leu Pro Ser Phe Phe Asn Ser Leu  
   115                  120                  125  
 Leu Ser Lys Lys Thr Val Ser Pro Gly Ser Pro Gly Ala Gly Gly Val

130 135 140

Gln Ser Thr Ala Lys Lys Ser Gly Gln Lys Thr Val Leu Ser Asn Val  
145 150 155 160

Gln Glu Glu Leu Asp Arg Met Thr Arg Lys Pro Asp Ser Met Val Thr  
165 170 175

Asn Ser Ser Thr Glu Asn Glu Ala  
180

1

73

PS502PP2



## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US00/06012

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) :C07K 14/47; C12N 5/10, 5/16, 15/12, 15/63, 15/64

US CL :Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 530/350; 536/23.1, 23.5, 24.3, 24.31; 435/69.1, 71.1, 71.2, 471.325, 252.3, 254.11, 320.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  
NONEElectronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
WEST, CAS ONLINE, MEDLINE, CAPLUS

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X ---- A	WO 92/05256 A1 (GENETICS INSTITUTE, INC.; THE WISTAR INSTITUTE) 02 April 1992 (02/04/92), see entire document, especially pages 17-21.	1-3, 7-11, 14-16 ----- 4-6, 12, 21

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z* document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

24 JULY 2000

Date of mailing of the international search report

09 AUG 2000

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

PREMA MERTZ

Telephone No. (703) 308-0196

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/06012

**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
1-12, 14-16, 21 (SEQ ID NO:11, 61)

Remark on Protest

☐

The additional search fees were accompanied by the applicant's protest.

☐

No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US00/06012

## A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

530/350; 536/23.1, 23.5, 24.3, 24.31; 435/69.1, 71.1, 71.2, 471, 325, 252.3, 254.11, 320.1

## BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claims 1-12, 14-16, 21, drawn to a nucleic acid of SEQ ID NO:11 encoding a protein of SEQ ID NO:61, a vector, a host cell, a method of making the protein and the protein of SEQ ID NO:61.

Group II, claim 13, drawn to an antibody that binds the protein of SEQ ID NO:61.

Group III, claim 17, drawn to a method of treating a condition comprising administering the protein of SEQ ID NO:61.

Group IV, claim 18, drawn to a method of diagnosing a pathological condition using the polynucleotide encoding a protein of SEQ ID NO:61.

Group V, claim 19, drawn to a method of diagnosing a pathological condition by determining the amount of protein of SEQ ID NO:61.

Group VI, claim 20, drawn to a method of identifying a binding partner of the protein of SEQ ID NO:61.

Group VII, claims 22-23, drawn to a method of identifying an activity in a biological assay.

Group VIII, claim 17, drawn to a method for treating a condition comprising administering the nucleic acid of SEQ ID NO:11.

The inventions listed as Groups I-VIII do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Pursuant to 37 C.F.R. § 1.475 (d), the ISA/US considers that where multiple products and processes are claimed, the main invention shall consist of the first invention of the category first mentioned in the claims and the first recited invention of each of the other categories related thereto. Accordingly, the main invention (Group I) comprises the first-recited product, a nucleic acid encoding a protein of SEQ ID NO:61, a vector, a host cell, a method of making the protein of SEQ ID NO:61, and the protein of SEQ ID NO:61. Further pursuant to 37 C.F.R. § 1.475 (d), the ISA/US considers that any feature which the subsequently recited products and methods share with the main invention does not constitute a special technical feature within the meaning of PCT Rule 13.2 and that each of such products and methods accordingly defines a separate invention.

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack Unity of Invention because they are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for more than one species to be searched, the appropriate additional search fees must be paid. The species are as follows:

the polynucleotides set forth in SEQ ID NO:11-60 encoding the polypeptides set forth in SEQ ID NO:61-110.

**THIS PAGE BLANK (USPTO)**